Presidential Greeting - American Society for Laser Medicine and ...

Presidential Greeting 

As a former resident of the Lone Star State, it is my pleasure to welcome y’all to 

Texas and to the 31 st Annual Conference of the American Society for Laser 

Medicine and Surgery. The ASLMS Program Committee led by Dr. Serge Mordon has 

assembled an excellent program of educational sessions to stimulate thought and 

to generate idea sharing. 

The ASLMS organization and therefore its Annual Conference are unique in their 

multi-disciplinary nature. The fundamental purpose of the ASLMS and its Annual 

Conference is to provide a forum at which a multi-disciplinary array of scientists, 

clinicians, students, health care professionals and industry representatives can 

learn, share, investigate and create ideas, the outcomes of which are clinical 

applications that can and have changed the world of patient care. 

Whether this is your first or thirty-first Annual Conference, you have the opportunity to participate in the 

exciting exchanges of information and ideas which will challenge you to grow professionally. I encourage 

you to both gather and share information, as the success of the Annual Conference can only be fully 

realized through the sharing of ideas and expertise by all conference attendees. 

Take advantage of all the activities described in this program. It’s a short 3-day conference; you can catch 

up on your sleep on the flight home. ASLMS conducts ongoing participant evaluation surveys during and 

after the conference to gather feedback. We encourage your completion of these surveys and look forward 

to your feedback as that is how we will improve future conferences. 

Saddle up and get ready to participate in three days of exciting professional growth. 

E. Duco Jansen, Ph.D. 

President 

2011 Member-Get-A-Member Program Deadline 

July 31, 2011 

2012 Abstract and Travel Grant Deadline 

October 17, 2011 

ASLMS Research Grant Application Deadline 

January 9, 2012 

Dr. Horace Furumoto Innovations Professional 

Development Award Deadline 

January 31, 2012 

Important Dates & Deadlines 


2012 ASLMS Annual Conference 

April 18 – April 22, 2012 

Gaylord Palms TM Resort & Convention Center 

Kissimmee, FL 

2013 ASLMS Annual Conference 

April 3-7, 2013 

Sheraton Boston Hotel/Hynes Convention Center 

Boston, MA

2 

Program Chair Greeting 

Welcome to the ASLMS 31 th Annual Conference. Each Annual Conference provides 

an opportunity for sharing the new scientific developments and clinical 

applications in light based and related technologies. 

This year’s conference has labored to keep the best of past conferences while 

incorporating new courses, new sessions and new expert panels. 

2011 Annual Conference 

Pre-Conference Courses: March 30-31, 2011 

Annual Conference: April 1-3, 2011 

Gaylord Texan TM Resort and Convention Center 

Grapevine, TX 

The 2011 Annual Conference, with more than 250 scientific presentations, 

addresses experimental and translational research, cutaneous laser surgery, Serge R. Mordon, Ph.D. 

photobiomodulation, surgical applications and interstitial laser therapy. Further, 

course content reflects multiple specialty areas, including oncology, dermatology, 

plastic surgery, otolaryngology, urology, nursing and allied health, among others. Lastly, a session is 

dedicated to international experiences in order to open the ASLMS to medical laser societies outside the 

United States. 

We are also excited to announce that our Keynote Speaker is Neil R. Ogden, Chief, General Surgery Devices 

Branch, Division of Surgery, Orthopedic, and Restorative Devices at the Office of Device Evaluation, Food 

and Drug Administration. His expertise encompasses light based devices, and particularly surgical laser 

systems. Mr. Ogden’s lecture will discuss how FDA relates to practicing physicians, researchers and 

industry in terms of current light device issues. 

The variety of learning opportunities we’ve put together for you this year are intended to foster a spirit of 

collaboration while demonstrating the ASLMS’s extraordinary commitment to excellence. 

Another goal of this Annual Conference is to bring to clinicians, scientists, health care professionals, laser 

technicians, students and industry representatives a unique occasion to grow professionally and connect 

with colleagues from around the world. 

We do hope that you will enjoy your time at this Annual Conference and we strongly encourage you to 

contribute your expertise and perspective to the sharing. 

Thank You 

The ASLMS would like to thank Dr. Howard Schlossberg, Program Manager at the Air 

Force Office for Scientific Research for the grant to the Society which allows the ASLMS to 

support graduate student and postdoctoral fellow attendance at our Annual Conference.

What’s New for 2011! 





Grapevine, TX 

ASLMS is the leading medical Society in the field of laser and energy-based treatment, and the only one 

that is truly multidisciplinary. We are a diverse organization, with much to teach and learn from each 

other. 

Keynote Speaker. Neil R. Ogden, Chief, General Surgery Devices Branch, Division of Surgery, Orthopedic 

and Restorative Devices, Office of Device Evaluation, Food and Drug Administration. Plan to attend the 

Plenary Session on Friday, April 1, 2011 to hear Mr. Ogden's lecture on "Light, Science, Medicine, and the 

FDA”. 

Complimentary lunch Friday and Saturday with ticket in the Exhibit Hall with Paid Conference 

Registration. 

Course On-Site Registration yields an e-link to electronic course materials. IKON Office Solutions (Business 

Center at the Gaylord Texan TM ) has computers and printing available at the attendees’ expense. 

Optional Knowledge Based Exam following the Fundamentals of Lasers in Health Care Course will be 

offered FREE to individuals attending the full two-day Fundamentals Course. 

Scar Revision luncheon will provide an understanding of the options for the management of scars utilizing 

lasers and related energy devices. 

Acne Treatment luncheon experts will discuss the different light therapies used for acne treatment. 

Interstitial Laser Therapy Session combined with the Surgical Applications session will be focused on ILT 

which is becoming a very attractive procedure with lower rates of infection than open surgery and more 

acceptable aesthetic results have been reported. 

PDT: Principle and Clinical Role Course will address therapy fundamentals/basic science, rationale, 

clinical outcomes, morbidities, treatment procedure and clinical data collected from peer-reviewed 

publications. 

ILT: Principle and Clinical Role Course will address ILT and laser ablation or tissue destruction methods, 

best use and application practices and reviews existing and recent evidence regarding clinical practice. 

International Experience in Lasers in Dermatology sessions will promote clinical and fundamental studies 

on laser applications and related technologies. 

Endovenous Laser Ablation Expert Panel will focus on ELA which is now the most widely accepted and 

used treatment option for insufficient great and short saphenous veins. 

PDT in Dermatology Expert Panel clinicians will share their extensive experience in photodynamic therapy 

treatments for actinic keratoses, non-melanoma skin cancer, acne and other disorders. 

Burns and Trauma Expert Panel clinicians will discuss how we can leverage multispecialty expertise to 

provide trauma and burn survivor’s optimal functional and cosmetic care. 

Cutting Edge “Translational Medicine” Session will continue the tradition of presenting high quality, 

unbiased academic investigations into the development and application of lasers and related technology. 

Cutting Edge “Laser and Skin” Session will stimulate the course attendees to question dogma and to 

challenge our laser engineers to shatter conventional approaches. Although it might be difficult to predict 

what changes will occur within the next several years, it is absolutely true that future directions and 

discoveries will derive from our efforts to improve patient outcomes. 

3

4 

Dr. Horace Furumoto 

Innovations Professional 

Development Award 

ASLMS is very pleased to administer the Dr. Horace Furumoto 

Innovations Professional Development Award which memorializes 

and honors Dr Furumoto’s genius and leadership in the development of 

laser technology. 

Through his excellent leadership and creativity, Dr. Furumoto 

endeavored to develop laser technology for use in health care. This 

award is designed to inspire others to enter the field, and continue the 

development of laser technologies which promote excellence in 

patient care by advancing biomedical applications of lasers worldwide. 

Throughout Dr. Furumoto’s outstanding career, he was highly regarded 

for his dedication to and innovation in the development of laser 

technologies. The criteria used to select the annual Innovations 

Professional Development Award in Dr. Furumoto’s honor are based 

upon those personal characteristics which he exhibited. 

The annual Dr. Horace Furumoto Innovations Professional Development 

Award recognizes individuals who demonstrate a potential for 

contributing to and the dedication and creativity required to expand 

the development of lasers in the health care enterprise. 

In 2011, up to $5,000 may be awarded to an individual who is 

identified as having the potential to substantially contribute to the 

development and application of laser and related technologies in 

health care. The award is provided to assist the recipient with 

continuing their professional development. 

The ASLMS Awards Committee is charged with selecting an individual 

to receive the Dr. Horace Furumoto Innovations Award. The award will 

be made available each year; however, the Awards Committee has the 

discretion to determine if an appropriate recipient has been identified. 

The Awards Committee will make its selection using criteria which has 

been developed by ASLMS in consultation with the award sponsors. The 

Dr. Horace Furumoto Innovations Award recipient will be announced at 

the ASLMS Annual Conference. 

Nominations and applications for the Dr. Horace Furumoto Innovations 

Professional Development Award will be solicited from the membership 

of ASLMS and other individuals and organizations which are involved in 

and/or support the continued development of laser and related 

technology in healthcare. The nomination/application deadline is 

January 31, 2012. The nomination/application form and supporting 

instructions are available on the ASLMS Web site, www.aslms.org. 





Grapevine, TX 

Horace Furumoto, Ph.D. was born in 

Hawaii in 1933. Dr. Furumoto began his 

career in the sixties at AVCO in the laser 

weapons division, and then moved to 

NASA. He is credited with developing 

the worlds first practical dye laser. 

In 1971, he founded Candela Laser 

Corporation and developed the 

extremely versatile flashlamp – excited 

dye laser (FEDL). 

In 1992 in collaboration with Wellman 

Laboratories at Massachusetts General 

Hospital, Dr. Furumoto developed 

selective photothermolysis. Using this 

technology, he created devices that 

were used to treat birthmarks, kidney 

stones and glaucoma. 

In 1991, Dr. Furumoto founded 

Cynosure, Inc. He introduced what 

became the Photo-Genica series of 

lasers, and spearheaded the use of the 

long pulse alexandrite lasers for hair 

removal. Dr. Furumoto retired in 2003. 

Physics was Dr. Furumoto’s passion. He 

loved the process of thinking, 

calculating, designing, drawing, 

building, and testing ideas. During his 

career, Dr. Furumoto was awarded 

twenty-six U.S. patents and twenty-one 

international patents. He is considered 

a pioneer in medical laser technology 

innovation. 

In multi million dollar contracts and 

individual promises, Dr. Furumoto 

always delivered, contributing to his 

lasting reputation as a faithful, sincere, 

and trustworthy colleague, mentor and 

partner. 

Biographical information provided by Cynosure.

AWARD CRITERIA 





Grapevine, TX 

The purpose of this award is to recognize individuals early in their career and to provide the recipient with 

resources to continue their professional development. The award selection criterion focuses on the 

individual’s demonstrated potential for leadership, innovation and desire for continued professional 

growth. Evidence of the individual’s commitment and ability to participate in the continued development 

of innovations in the areas of laser and related technologies are also important. 

Consistent with the characteristics exhibited by Dr. Horace Furumoto throughout his career, candidates for 

the Dr. Horace Furumoto Innovations Professional Development Award will exhibit one or more of the 

following: 

• Clearly defined professional development goals. 

• Demonstrated interest, ability and/or evidence of having participated in the development of laser 

and related technologies for health care applications. 

• Demonstrated commitment to the discipline of lasers and related technologies. 

• Obtained appropriate professional education upon which to build additional professional 

development. 

• Demonstrated ability to be an innovative leader. 

• Demonstrated innovative approaches to clinical practice. 

Candidates will be regarded by supervisors and/or colleagues as having the potential to be a “leader of 

innovation” in the development of laser and related technology. Examples of evidence of high regard by 

supervisors or colleagues include but are not limited to: 

• Selection to be a presenter at national or international conferences. 

• A history of having been awarded research grants to conduct laser and related technology 

development research, etc. 

• Letters of recommendation supporting the individual’s potential for continued development. 

• Acceptance into an organized continuing education program. 

Recipients will be selected based upon evidence of one or more of these criterions. 

The ASLMS would like to acknowledge and thank the following 

companies who have provided financial support for this award. 

The recipient of the Fourth Annual Dr. Horace Furumoto 

Innovations Professional Development Award will be 

announced during the Plenary Session on 

Saturday, April 2, 2011. 

5

ASLMS Keynote Speaker 

Neil R. Ogden, Chief 

General Surgery Devices Branch, Division of 

Surgery, Orthopedic and Restorative Devices, 

Office of Device Evaluation, Food and Drug 

Administration 

“Light, Science, Medicine, and the FDA” 

6 





Grapevine, TX 

Neil R. Ogden 

The ASLMS is pleased to announce that Neil R. Ogden, Chief of the General Surgery Devices, from the FDA 

Office of Device Evaluation has agreed to serve as the keynote speaker at our 31 st ASLMS Annual 

Conference. Mr. Ogden’s lecture entitled “Light, Science, Medicine, and the FDA” is scheduled during the 

Plenary Session in Longhorn F on Friday, April 1, 2011 at 11:00 am – 11:59 am. Mr. Ogden’s keynote 

lecture will discuss how FDA relates to practicing physicians, researchers, and industry in terms of current 

light device issues. 

Mr. Ogden completed his undergraduate studies in biomedical engineering at Tulane University in New 

Orleans in 1980. While working at Tulane University Medical School, he earned his Master’s degree in 

biomedical engineering at Tulane University in 1985. 

He became Peace Corps Volunteer with his wife Ellyn in Papua, New Guinea, New Ireland Province, 1987- 

1989. Mr. Ogden enjoys international travel with his family having visited Australia, Belgium, Canada, 

Germany, France, Greece, Guatemala, Italy, India, Mexico, South Africa, Switzerland, and Zimbabwe. 

He worked briefly at the National Institutes of Health before joining the Food and Drug Administration in 

1990 as a new scientific reviewer in the General Surgery Devices Branch, in the Office of Device Evaluation 

in the Center for Devices and Radiologic Health. As a scientific reviewer, one of his areas of expertise was 

light based device reviews with emphasis on surgical laser systems. 

Mr. Ogden was selected as the Branch Chief for the General Surgery Devices Branch in December, 1998. As 

Branch Chief, he has supervised hundreds of light based device reviews and final recommendations for 

marketing which includes reviews of surgical lasers, IPLs, visible spectrum diagnostic devices (Melafind), 

biostimulation lights, OCT systems, surgical lights, and other optical devices. During this period he has 

received numerous awards for excellent job performance including the 2010 FDA Human Capital Investment 

Award. He has written articles about device regulation which has been published in FDA Consumer, FDA 

Today, and Seminars in Laparoscopic Surgery. He has also co-authored a chapter on FDA regulation in the 

book, Cancer Principles and Practices of Oncology, 7th Edition. 

He has broadened his professional experience over the past six years by working as Acting Deputy Division 

Director in the Division of Cardiovascular Devices, the Division of Anesthesiology, General Hospital, 

Infection Control, and Dental Devices, the Division of Surgery and Orthopedic Devices each in the Office of 

Device Evaluation, and most recently the Division of Biology in the Office of Science and Engineering 

Laboratories.

6:30 am – 5:00 pm Registration – Texas Ballroom Prefunction 

6:30 am – 8:00 am Continental Breakfast – Texas A 

FUNDAMENTALS OF LASERS IN HEALTH CARE COURSE – Texas A 

Two Day Fundamentals Course #001 

Day One Only #002 

(Fee required to attend) 





Grapevine, TX 

This course is intended for physicians and other clinicians, scientists, researchers, and laser and related technology industry 

personnel who are considering entering or who have minimal background and experience in the field of laser and other lightbased 

technology and their application in health care. 

8:00 am – 8:29 am Introduction/Pre-Test 

8:30 am – 9:29 am Biophysics Principles 

9:30 am – 9:44 am Break 

9:45 am – 10:44 am Interaction of Tissue With Light Energy 

10:45 am – 11:44 am Laser and Light Energy Device Applications 

11:45 am – 12:29 pm CASH LUNCH - On Your Own 

12:30 pm – 1:44 pm Basic Laser Safety 

1:45 pm – 2:29 pm Treating Vascular Lesions and Port Wine Stains 

2:30 pm – 2:44 pm Break 

Wednesday, March 30, 2011 

A separate registration fee must be paid in order to attend courses 

2:45 pm – 3:44 pm Hair Removal 

3:45 pm – 4:44 pm Fractional Ablative Skin Rejuvenation 

4:45 pm – 5:00 pm Q&A/Post-Test/Adjourn 

7

6:00 am – 6:00 pm Registration – Texas Ballroom Prefunction 

6:30 am – 8:00 am Continental Breakfast – Texas Ballroom Prefunction 

7:30 am – 7:44 am 

7:45 am – 8:44 am 

8:45 am – 9:29 am 

9:30 am – 9:44 am 

9:45 am – 10:29 am 

8 

FUNDAMENTALS OF LASERS IN HEALTH 

CARE COURSE – Texas A 

(Day Two Only #003) 

Introduction/Pre-Test 


Fractional Non-Ablative Rejuvenation 

Tattoos, Pigmented Lesions, Melasma 

Break 

Treatment Complications Including Darker Skin 

10:30 am – 11:29 am Body Sculpting Fundamentals 

11:30 am – 11:44 am Q&A (Morning Session) 

11:45 am – 12:30 pm CASH LUNCH – On Your Own 

12:00 pm – 1:15 pm CASH LUNCH – On Your Own 

12:15 pm – 1:15 pm 






Grapevine, TX 

Thursday, March 31, 2011 

A separate registration fee must be paid in order to attend courses and luncheons 

Luncheon With 

the Experts 

CLINICAL 

APPLICATION 

COURSE 

(Intermediate/ 

Advanced) 

(Fee required to 

attend) 

Resurfacing and 

Contouring #005 

Texas C 

8:00 am–12:00 pm 

NURSING/ALLIED 

HEALTH COURSE 

(All-Day Program) 

(Fee required to 

attend) 

Nursing/Allied Health 

#004 

Texas 1&2 

7:30 am – 4:30 pm 

Business Meeting 

4:30 pm – 5:00 pm 

• My Approach to Fractional Resurfacing #018 – Dallas 5-6 

• My Approach to Skin Tightening Technologies #019 – San Antonio 5-6 

• Practical Pearls to Optimize Clinical Outcomes – Laser/Light-Based Procedures #020 – Texas 6 

• Non-Invasive and Invasive Fat Removal #021 – Texas 5 

• Difficult Cases and Complications #022 – Grapevine 3 

• NEW – Scar Revision #023 – Texas 4 

• NEW – Acne Treatment #024 – Texas 3 

FUNDAMENTALS OF LASERS IN HEALTH 

CARE COURSE 

CLINICAL APPLICATION COURSES 

(Intermediate/Advanced) 


12:30 – 1:44 pm 

Lasers With Non-Device Skin Treatment Interventions Laser Treatment of Vascular Lesions #006 

Texas C 

1:45 pm – 2:44 pm Patient Selection/Relationship Building 

1:30 pm – 5:30 pm 

2:45 pm – 2:59 pm Post-Test/Adjourn 

3:00 pm – 5:00 pm Knowledge-Based Exam 

Hair and Pigment Removal #007 

Texas D 

1:30 pm – 5:30 pm

6:00 am – 6:00 pm 

6:30 am – 8:00 am 

7:00 am - 10:00 am 

Registration – Texas Ballroom Prefunction 

Continental Breakfast – Texas Ballroom Prefunction 

Exhibits Open – 9:00 am – 7:00 pm 

Laser Treatment of Patients 

of Color #008 

Longhorn F 

10:00 am – 10:30 am BREAK/View ePosters – Longhorn D&E 

10:30 am – 12:00 pm 

12:00 pm – 1:30 pm 

1:00 pm – 2:45 pm 

2:45 pm – 3:45 pm 




Complications, Controversies, and 

Legal Issues #009 

Texas C 





Grapevine, TX 

Friday, April 1, 2011 

A separate registration fee must be paid in order to attend courses. 

NEW: PDT: Principle and 

Clinical Role #011 

Texas 2-3 

Plenary Session – Longhorn F (3-day conference begins) 

Welcome & Introduction – Serge R. Mordon, Ph.D. 

Presidential Address & Citations – E. Duco Jansen, Ph.D. 

Keynote Speaker 

Neil R. Ogden, Chief of the General Surgery Devices, Food and Drug Administration 

Complimentary Lunch with Ticket in Exhibit Hall/View ePosters – Longhorn D&E 

Experimental and 

Translational 

Research Session 

Texas C 

Cutaneous 

Laser Surgery 

Session 

Longhorn F 

BREAK/View ePosters – Longhorn D&E 

BREAKOUT SESSIONS 

Photobiomodulation 

Session 

Texas 4-6 

Surgical Applications 

and Interstitial Laser 

Therapy Session 

Texas 2-3 

3:00 pm – 3:15 pm EXPERT IN THE EXHIBIT HALL – Laser Safety – Merete Haedersdal, M.D. – Longhorn D&E 

NEW- 

Photodynamic 

Therapy 

Session 

Texas D 

3:15 pm – 3:30 pm EXPERT IN THE EXHIBIT HALL – The Cosmetic Consultation – Elizabeth L. Tanzi, M.D. – Longhorn D&E 

3:45 pm – 6:00 pm Experimental and 

Translational 


Texas C 

Cutaneous 


Session 

Longhorn F 



Session 

Texas 4-6 

Surgical Applications 

and Interstitial Laser 


Texas 2-3 

NEW- 

Photodynamic 

Therapy 

Session 

Texas D 

9

6:00 am – 7:30 pm 

6:30 am – 8:00 am 

7:00 am - 9:00 am 

10 



Exhibits Open – 9:00 am – 7:30 pm 

Student/Post- 

Doc/Resident 

Opportunities 

#012 

Texas 2-3 




Technologies for 

Fat Related 

Disorders #013 

Longhorn F 

Periorbital 

Therapies 

#014 

Texas C 





Grapevine, TX 

Photography, 

Treatment 

Documentation 

and Oversight 

#015 

Texas D 

How to Use Optical 

Diagnostics in Clinical 

Laser Medicine #016 

Texas 1 

9:15 am - 10:10 am NEW - Cutting Edge “Translational Medicine” Session – Longhorn F (2 nd day of conference begins) 

10:05 am – 10:30 am 

10:30 am – 11:30 am 

11:30 am – 12:00 pm 

12:00 pm – 1:30 pm 

1:00 pm – 2:45 pm 

2:45 pm – 3:45 pm 


Plenary Session – Longhorn F 

Presentation of Horace Furumoto Innovations Professional Development Award - TBA 

Caroline and William Mark Memorial Award – Franz Hillenkamp, Ph.D. 

Ellet H. Drake Memorial Award – Dieter Manstein, M.D. 

Leon Goldman Memorial Award – Stephen G. Bown, M.D., F.R.C.P. 

Nursing/Allied Health Excellence Award – Faye M. Jenkins, R.N., B.S.N. 

ASLMS Business Meeting (Members Only) – Longhorn F 

Complimentary Lunch with Ticket in Exhibit Hall/View ePosters – Longhorn D&E 

NEW – Cutting Edge “Laser and Skin” Session – Longhorn F 


3:00 pm – 3:15 pm EXPERT IN THE EXHIBIT HALL – How to Thrive in a Difficult Economy – Paul M. Friedman, M.D. – 

Longhorn D&E 

3:15 pm – 3:30 pm EXPERT IN THE EXHIBIT HALL – Laser and the Law – Mathew M. Avram, M.D., J.D. – Longhorn D&E 

3:45 pm – 6:00 pm 

Saturday, April 2, 2011 



Translational Research 

Session 

Texas C 

Cutaneous Laser Surgery 

Session 

Longhorn F 

6:00 pm – 7:30 pm Exhibitor Reception / Silent Auction 



Session 

Texas 4-6 

NEW - International 

Experience in Lasers 

in Dermatology 

Session 

Texas D

6:30 am – 12:30 pm 

6:30 am – 8:00 am 


7:00 am - 7:45 am NEW - Endovenous Laser 

Ablation 

Longhorn F 

8:00 am – 10:00 am 

10:00 am – 10:30 am 

10:30 am – 12:00 pm 

Sunday, April 3, 2011 



Exhibits Closed 

Exhibits Closed 

Experimental 

and 

Translational 

Research 

Session 

Texas C 

EXPERT PANELS 

(No additional fee required to attend) 

Cutaneous 

Laser 

Surgery 

Session 

Longhorn F 

NEW - PDT in 

Dermatology 

Texas D 


BREAK – Texas Ballroom Prefunction 



Session 

Texas C 

NEW - 

International 

Experience in 

Lasers in 

Dermatology 

Session 

Texas D 






Grapevine, TX 

NEW – Burns and 

Trauma 

Texas 4-6 


Session 

Texas 4-6 

Cutaneous Laser Surgery Session 

Longhorn F 

CLINICAL 

APPLICATION 

COURSE 


(Additional fee required) 

NEW - ILT: Principle 

and Clinical Role 

Course #017 

7:00 am – 10:00 am 

Texas 2-3 

11

12 

ePosters/Exhibits 





Grapevine, TX 

Exhibit Hall/ePoster Viewing Hours: Longhorn D&E 

Friday, April 1, 2011 ........................................................................................ 9:00 am – 7:00 pm 

Saturday, April 2, 2011 ..................................................................................... 9:00 am – 7:30 pm 

Sunday, April 3, 2011 ............................................................................................ Exhibits Closed 

Directors: Gregory T. Absten, B.Sc., M.B.A., C.L.R.T. (Exhibit Chair); Emil A. Tanghetti, M.D. (ePoster Chair) 

Disclosures 

Gregory T. Absten – No disclosure 

Emil A. Tanghetti received equipment and a discount from Cynosure and Palomar 

ePosters 

Twenty viewing stations will be located in the Exhibit Hall. We have extended the lunch hour and breaks to 

allow additional time for viewing ePosters and visiting with the exhibitors. No hard copy posters will be on 

display. A maximum of 4 CME credits will be offered for viewing the ePosters. 

ePoster Q&A 

Each ePoster will include a tab labeled “Questions and Answers”. When the conference attendee clicks on 

the Q&A tab, they will view a running list of questions along with each question’s corresponding answer 

from the author. Additionally, there will be a button labeled “Submit a Question”. When the conference 

attendee clicks this button, they will be provided with a form which has a blank area for them to type and 

submit their question to the author. The system will update every morning at 6:00 am local time. All 

questions and answers from the previous day will be posted to each ePoster. Also, the Q&A log will be 

viewable in the post-conference online version, but the ability to ask questions will not be available in the 

post-conference online version. 

A REMINDER FOR CONFERENCE ATTENDEES TO PLEASE VIEW THE ePOSTERS AND PARTICIPATE IN THE 

ASK eQUESTIONS AND RECEIVE eANSWERS PROGRAM. 

Experts in the Hall 

Experts in the Exhibit Hall will give a five minute presentation followed by 10 minutes of questions and 

answers. Following is a schedule of speakers, topics, and dates/times of presentations. 

Date Time Speaker Topic 

Friday, April 1, 2011 3:00 pm – 3:15 pm Merete Haedersdal, M.D. Laser Safety 

Friday, April 1, 2011 3:15 pm – 3:30 pm Elizabeth L. Tanzi, M.D. The Cosmetic Consultation 

Saturday, April 2, 2011 3:00 pm – 3:15 pm Paul M. Friedman, M.D. How to Thrive in a 

Difficult Economy 

Saturday, April 2, 2011 3:15 pm – 3:30 pm Mathew M. Avram, M.D., 

J.D. 

Laser and the Law





Grapevine, TX 

Annual Conference attendees can receive great deals on new medical laser equipment and supplies at the 

31st Annual Conference. All net proceeds from the Silent Auction will be designated to fund research 

projects designed to foster the development and use of lasers and other related technologies in medical 

and surgical applications. Minimum bids start at 50% of total value. 

Jason N. Pozner, M.D. Chair, ASLMS Silent Auction Task Force 

6 th Annual Silent Auction Schedule 

March 31, 2011 

Online bidding closes at 11:59 pm. 

April 1, 2011 

Annual Conference bidding opens in exhibition hall at 9:00 am to all conference attendees. 

April 2, 2011 

Annual Conference bidding closes at 7:00 pm. The names of winners will be announced at 7:15 pm. Items 

that do not receive minimum bids will be available online for members on April 6, 2011. 

Company Item Donated to Date Estimated 

Value 

Allergan Juvederm XC Ulta and XC Ultra Plus $ 3,350.00 

R. Rox Anderson, M.D. Four hours of Stimulating Discussion with Dr. R. Rox 

Anderson 

Mathew Avram, M.D. Engage in a One-day Observational Preceptorship with 

Dr. Mathew Avram 

7,500.00 

2,500.00 

Buffalo Filter Surgical Smoke Evacuation System 1,500.00 

Canfield Imaging Systems PhotoFile Software 825.00 

CoolTouch, Inc. Two-Year Warranty for any CoolTouch Laser System 10,000.00 

Cynosure, Inc. Affirm Tips 9,000.00 

DEKA Medical, Inc. Bottles of Wine 795.00 

DermaNetwork.org DermaNetwork.org – Connecting Patients with Physicians 3,600.00 

Ellman International $1,500 of Ellman International Products 1,500.00 

FotoFinder Systems, Inc. FotoFinder Handyscope 1,490.00 

David J. Goldberg, M.D., J.D. One Day On-Site Observational Preceptorship 2,500.00 

Green Bay Packers/Milwaukee 

Brewers 

Silent Auction for Research 

Packer Autographed Football/Milwaukee Brewers – Two 

Club Level Seat Tickets 

750.00 

HOYA ConBio RevLite Q-Switched Nd:YAG One Year Laser Lease 48,000.00 

Incredible Marketing One Custom Complete Web site 8,995.00 

Int’l Aes. and Laser Association IALA Membership and Aesthetic Laser Procedures 

Training 

1,745.00 

13

14 





Grapevine, TX 

Company Item Donated to Date Estimated 

Value 

Lumenis, Inc. Dinner for Six at Quince www.quincerestaurant.com 

Including Tip Tier Wine 

Private dinner at Dough Room of Flour and Water 

Hotel Voucher 

2,000.00 

2,000.00 

1,000.00 

5,000.00 

MedCo Data, LLC Charty Ready Scanning Solution 5,200.00 

MedCo Data, LLC Workflow Centric Analysis 6,000.00 

MJD Patient Communications MJD Gift Certificate 1,000.00 

NexTech Systems, Inc. iPad 64GB with wi-fi 750.00 

Oculo-Plastik, Inc. One pr Durette® II External Laser Shield with OPSoft 

Laser Mouthguard (bag of 10) 

One pair Durette® III External Laser Shields with mobile 

plastic attachments, with OPSoft Laser Mouthguard (bag 

of 10) 

One pair Durette® IV External Laser Shields with Mobile 

Metal Attachments, with OPSoft Laser Mouthguard (bag 

of 10) 

Palomar Medical Technologies, Inc. Palomar® Artisan Pulsed-light and Laser System 

Including Pulsed Light MaxG Handpiece 

339.00 

339.00 

339.00 

1,017.00 

90,000.00 

PCA Skin PCA Skin In-Office Training Seminar 1,500.00 

PhotoMedex Neova Skincare Basket 1,000.00 

Quality Medical Publishing (QMP) Four Book Collection 900.00 

Quantum BioMedical, Inc. Quantum WARP 10 750.00 

Rockwell Laser Industries Medical Laser Safety Officer Course 895.00 

Sciton, Inc. iPad wi-fi 32 GB from Apple with iTunes Gift Certificate 1,000.00 

Ava Shamban, M.D. One-day On-Site Observational Preceptorship 2,500.00 

Solta Medical VIP Visit to Solta Medical 3,500.00 

Surgeon’s Advisor In-depth Web Site, Social Media, Reputation, and 

Internet Strategy Analysis 

Syneron/Candela eMatrix Sublative Rejuvenation System and a Paul Reed 

Smith 513 Guitar 

1,500.00 

53,900.00 

Syris Scientific Syris v600 Vision Enhancement System 2,035.00 

THE Aesthetic Guide Certified Aesthetic Consultant (CAC) Program (Practice) 3,500.00 

The Patient’s Guide Patient’s Guide Calls 5,000.00 

Ulthera, Inc. Ulthera DeepSEE Transducers 10,000.00 

Zeltiq Aesthetics, Inc. CoolSculpting eZ App 8 and 8 Cycle eZ Card 16,500.00 

Zimmer MedizinSystems Zimmer Cryo 6 8,995.00 

Total Estimated Value of 2011 Silent Auction Donations To Date $326,492.00





Grapevine, TX 

Fundamentals of Lasers in Health Care Course 

Wednesday, March 30 – Thursday, March 31, 2011 

A separate registration fee must be paid in order to attend courses. CME credits and CE contact hours 

available. 

Fundamentals of Lasers in Health Care – Texas A 

Directors: J. Stuart Nelson, M.D., Ph.D., David M. Verebelyi, M.D. 

March 30 - 8:00 am – 5:00 pm 

March 31 – 7:30 am – 3:00 pm 

Optional Knowledge Based Exam* 

3:00 pm – 5:00 pm 

Faculty: Gregory T. Absten, B.Sc., M.B.A., C.L.R.T., R. Rox Anderson, M.D., A. Jay Burns, M.D., Jason N. 

Pozner, M.D., E. Victor Ross, M.D., Emil A. Tanghetti, M.D., Elizabeth L. Tanzi, M.D. 

ACCME Accreditation Statement 

The American Society for Laser Medicine and Surgery, Inc. is accredited by the Accreditation Council for 

Continuing Medical Education to provide continuing medical education for physicians. 

Continuing Medical Education Credit 

The American Society for Laser Medicine and Surgery, Inc. designates this live activity for a maximum of 18.25 

AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their 

participation in the activity. 

You will receive a statement of CME credit hours after the Annual Conference. 

Continuing Education Credit 

This offering by the ASLMS, in conjunction with Professional Medical Education Association is accredited for a 

maximum of 19.5 contact hours. Professional Medical Education Association is approved by the California 

Board of Registered Nursing, Provider # CEP 12386. Note: Most State Boards of Nursing accept another State 

Board’s approval for granting credits. Check with the Board of Nursing in your state for clarification. 

Certificates of Attendance will be provided. You will receive a statement of CE contact hours after the 

Annual Conference. 

Optional Knowledge Based Exam 

Individuals who score a minimum of 80% will receive a statement from ASLMS acknowledging their 

comprehension of the information provided in the course. All examination participants will receive their score. 

This exam is offered at no additional cost to course participants*. 

*Exam available only for those who register and attend both days. Previous Fundamentals or Irvine Aesthetics 

course attendees have the exam only option available for a fee of $250.00. 

• Prerequisite - Individuals who wish to take the exam only must have taken ANY previous 2-Day 

Fundamentals Course offering or attended the Aesthetics Laser Course held November 6-7, 2010 at the 

Beckman Laser Institute in Irvine, California. 

• Pre-Registration Only. No walk-in's will be accepted for the exam only option. 

15

Fundamentals of Lasers in Health Care continued – Texas A 

16 





Grapevine, TX 

Objectives: This course is intended for physicians and other clinicians, scientists, researchers, and laser and 

related technology industry personnel who are considering entering or who have minimal background and 

experience in the field of laser and other light-based technology and their application in health care. At the 

conclusion of the course, participants will: 

1. Understand the biophysics pertinent to the application of lasers and other light-based energy devices and 

related technology, and will be prepared to apply this same understanding related to the provision of 

patient care. 

2. Understand the working parts of a laser and other light-based devices. 

3. Understand the interaction and implications of using lasers and other light-based devices and related 

technologies on human tissues and be capable of using this knowledge in the provision of patient care. 

4. Be familiar with a broad array of lasers and light-based devices used in the provision of health care 

procedures and be capable of determining which laser and/or light-based technology is most appropriately 

used for particular clinical procedures. 

5. Be introduced to the interactions of lasers and other light emitting devices and popular non device skin 

interventions (i.e., muscle relaxers and fillers, etc). 

6. Understand the legal issues associated with the use of lasers and related technology in patient care, and 

will be capable of using this knowledge to avoid any legal ramifications for themselves, their organization, 

and the patients for which they care. 

7. Understand the safety risks to providers and patients associated with the use of lasers and related 

technology, and understand and be capable of using this knowledge to practice the safety necessary to 

provide a safe environment for all providers and patients. 

8. Be capable of practicing good patient selection and properly preparing patients for treatment with lightbased 

devices. 

9. Have sufficient exposure to a cross-section of clinical applications such that they are capable of using this 

knowledge to discern the clinical applications for which they may or may not choose to develop specific 

laser application skills. 

WEDNESDAY MARCH 30, 2011 – Session Moderator: J. Stuart Nelson 

8:00 am - 8:29 am Introduction/Orientation/Pre-Test 

8:30 am - 9:29 am UNIT I - Biophysics Principles Pertinent to the Use of Lasers and Other Light Energy 

Devices - J. Stuart Nelson 

9:30 am - 9:44 am Refreshment Break 

9:45 am - 10:44 am UNIT II - The Interaction of Tissue with Light Energy - J. Stuart Nelson 

10:45 am - 11:44 am UNIT III - Lasers and Other Light Energy Devices and Their Preferred Applications - 

R. Rox Anderson 

11:45 am - 12:29 pm Cash Lunch – On Your Own 

12:30 pm - 1:44 pm UNIT IV – Basic Laser Safety Principles and Practices - Gregory T. Absten 

1:45 pm - 2:29 pm UNIT V – Treating Vascular Lesions and Port Wine Stains Using Laser and Other Light 

Energy Technology - J. Stuart Nelson 

2:30 pm - 2:44 pm Refreshment Break 

2:45 pm - 3:44 pm UNIT VI – Application of Lasers and Other Devices for Hair Removal - David M. 

Verebelyi 

3:45 pm - 4:44 pm UNIT VII – Fractional Ablative Skin Rejuvenation – A. Jay Burns 

4:45 pm – 5:00 pm Q&A/Post-Test/Adjourn

Fundamentals of Lasers in Health Care continued – Texas A 

THURSDAY, MARCH 31, 2011 - Session Moderator: David M. Verebelyi 

7:30 am - 7:44 am Introduction/Orientation/Pre-Test 





Grapevine, TX 

7:45 am - 8:44 am UNIT VIII – Fractional Non-Ablative Skin Rejuvenation - E. Victor Ross 

8:45 am - 9:29 am UNIT IX – Laser Treatment of Tattoos, Pigmented Lesions, Melasma - E. Victor Ross 

9:30 am - 9:44 am Refreshment Break 

9:45 am - 10:29 am UNIT X – Light Energy Based Treatment Complications Including Those for Patients With 

Darker Skin Photo Types - E. Victor Ross 

10:30 am - 11:29 am UNIT XI – Non-Invasive and Invasive Body Sculpting Fundamentals - Jason N. Pozner 

11:30 am - 11:44 am Q&A – (Morning Session) 

11:45 am - 12:29 pm Cash Lunch – On Your Own 

12:30 pm - 1:44 pm Unit XII – Implications and Opportunities of Using Light Based Energy Technologies in 

Combination With Non-Device Skin Treatment Interventions - Emil A. Tanghetti 

1:45 pm - 2:44 pm UNIT XIII – Patient Selection and Relationship Building Opportunities to Avert Legal 

Issues –Elizabeth L. Tanzi 

2:45 pm - 2:59 pm Post-Test/Adjourn 

3:00 pm - 5:00 pm Administration of Knowledge Based Exam 

Disclosures 


R. Rox Anderson received royalties from Massachusetts General Hospital which owns and licenses patents on laser hair removal, fractional A. 

Jay Burns received discount from Cutera, Cynosure, Palomar, Sciton, Zeltiq, and Zimmer; stockholder with Skin Medica and Zeltiq; research 

grant from Solta, Uthera, and Zeltiq; honoraria from Sciton, Solta, Ulthera, and Zeltiq; medical advisory board for Ulthera and Zeltiq 

laser treatments, and cryolipolysis; serves on scientific advisory boards for PhotoMedex and Ulthera 

J. Stuart Nelson received equipment from Cynosure, Fotona, and Genentech; research grant from Syneron/Candela, New Star, Wyeth-Pfizer; 

royalties from Syneron/Candela and New Star; honoraria/speaker from Syneron/Candela 

Jason N. Pozner received equipment from DEKA, Elemé, Sciton, Syneron; consulting fees from Sciton, Syneron, and Ulthera; discount from 

Alma and Zeltiq; stockholder with Sciton; research grant from Aesthera, Continuum Biomedical, Sciton, and Syneron; honoraria from Sciton, 

Syneron, Ulthera, and Zeltiq 

E. Victor Ross received financial grant and consulting fees from Palomar and Syneron; equipment from Cutera, Lumenis, Palomar, and Sciton; 

research grant from Cutera, Palomar, and Syneron; honoraria from Cutera, Lumenis, Palomar, and Syneron 


Elizabeth L. Tanzi received equipment from Cynosure, Lumenis, Palomar, Solta, and Syneron; consulting fees from Medicis, Myoscience, and 

Zeltiq 

David M. Verebelyi – No disclosure 

17

18 





Grapevine, TX 

A separate registration fee must be paid in order to attend courses. CE contact hours available. 

Nursing/Allied Health – Merging Lasers and Technology Design in 2011– 

Texas 1&2 

Directors: Faye M. Jenkins, R.N., B.S.N. (Section Chair), Krystie P. Lennox, PA-C (Education Chair) 

7:30 am – 4:30 pm 

Faculty: Eric F. Bernstein, M.D., Donna C. Gabriel, L.P.N., David J. Goldberg, M.D., J.D., Penny J. Smalley, 

R.N., C.M.L.S.O., Jill Waibel, M.D., Andrea Willey, M.D. 


This offering by the ASLMS, in conjunction with Professional Medical Education Association is accredited for 8.4 

contact hours. Professional Medical Education Association is approved by the California Board of Registered 

Nursing, Provider # CEP 12386. Note: Most State Boards of Nursing accept another State Board’s approval for 

granting credits. Check with the Board of Nursing in your state for clarification. Certificates of Attendance will 

be provided. You will receive a statement of CE contact hours after the Annual Conference. 

Educational Needs 

The 2011 Nursing/Allied Health course is designed to develop awareness of available education for the variety 

of providers using lasers. The program will also offer a forum for discussion to explore the educational needs of 

the attendees during roundtable discussions with experienced providers and educators. 

Participants 

The participants are nurses and allied health professionals seeking information and education necessary to be 

safe and effective in the roles they play in the delivery of laser treatment. 

Background Requirements 

The nursing and allied professionals attending the course should have a basic knowledge of laser function, 

science, applications, and safety. 

Instructional Content and/or Expected Learning Outcomes 

The goal of this year’s Nursing/Allied Health course is to create an awareness of the broad scope of life 

changing applications that laser treatments have. Attendees will have educational options addressed for 

further understanding of the use of lasers in their field. We will provide an all encompassing review of laser 

safety, addressing any new changes in the Standards of Laser Safety, if any. Attendees will be introduced to 

laser applications and the importance of patient preparation and follow-up. Attendees will meet colleagues 

and share valuable experiences that can impact your practice today, tomorrow, and into the future. 

7:30 am – 8:45 am Laser Safety – Penny J. Smalley 

8:46 am – 9:00 am Break 

9:01 am – 9:16 am 283 Evaluation of the Thulium Fiber 1927nm Wavelength for Off-Face Treatment of 

Photodamaged Skin with Actinic Lesions 

Rebecca Sprague�, Suzanne Kilmer 1 , Laser & Skin Surgery Center of Northern 

California, Sacramento, CA 

1 

Research grant from Candela, CoolTouch, Cutera, Cynosure, Ellipse, HOYA ConBio, Iriderm, 

Lumenis, Palomar, Primaeva, Reliant, Sciton, Thermage, Ulthera, and Zeltiq; serves on medical 

advisory boards for Candela, Cutera, Ellipse, HOYA ConBio, Lumenis, Primaeva, Ulthera, and Zeltiq 

•Content discusses non-FDA approved device or off-label use 

�Peggy Nowell RN Travel Grant Recipient. 

Nursing/Allied 

Health Course 

Thursday, March 31, 2011





Grapevine, TX 

Nursing/Allied Health – Merging Lasers and Technology Design in 2011 Cont. – Texas 1&2 

9:17 am – 9:37 am Lasers in the Treatment of Tubular Sclerosis – Donna C. Gabriel 

9:38 am – 9:59 am Laser/Light Treatment of Photoaging – Eric F. Bernstein 

10:00 am – 10:14 am Break 

10:15 am – 10:44 am Before the “Laser Incident”, Be Prepared – David J. Goldberg 

10:45 am – 10:59 am 281 Sun + Laser = Disaster! 

Trudy Fleming 1 , Fleming Institute, Melbourne, Australia 

1 Stockholder in Fleming Institute 

Content discusses non-FDA approved device or off-label use 

11:00 am – 11:29 am Laser Correction, Post Burn Injuries – Jill S. Waibel 

11:30 am – 11:44 am 282 Development of Combination Therapy Strategies 

Patricia A. Owens 1 , James Brazil 2 , Sharon Olson, Olympic Dermatology and 

Laser Clinic, Olympia, WA 

11:45 am – 11:59 am Q&A 

Nursing/Allied 

Health Course 


1 Consulting fees from Lumenis and Rockwell Laser Industries 

2 Consulting fees from Lumenis 


12:00 pm – 1:29 pm Cash Lunch – On Your Own 

1:30 pm – 1:44 pm 280 Treatment of Subcutaneous Fat Using a Novel Non-Invasive Cooling Device – 

CoolSculpting by ZELTIQ 

Holly Bryan, Tina Alster, Elizabeth Tanzi, Washington Institute of Dermatologic 

Laser Surgery, Washington, DC 

1:45 pm – 2:14 pm CoolSculpting by ZELTIQ - Andrea Willey 

2:15 pm – 4:29 pm Round Table Breakout Discussions 

1) Education: What Do We Need, How Do We Get It? – Holly Bryan 

2) The Role of ANSI and OSHA in a Laser Setting – Penny J. Smalley 

3) Treating Skin of Color – Debi Cordi 

4) Documentation – Donna C. Gabriel 

5) Treating Photodamage/Prevention – Rebecca Sprague 

6) Multiple Approaches to Skin Tightening – Patricia A. Owens 

4:30 pm – 5:00 pm Nursing/Allied Health Business Meeting 

Disclosures 

Eric F. Bernstein received equipment from Candela, Cynosure, DEKA, Lumenis, and Reliant; consulting fees from TRIA Beauty; discount from 

Zeltiq 

Donna C. Gabriel – No disclosure 

David J. Goldberg received consulting fees from Ultrashape; research grant from Alma and Viora 

Faye M. Jenkins – No disclosure 

Krystie P. Lennox – No disclosure 

Penny J. Smalley – received consulting fees from Rockwell Laser Industries and Buffalo Filter 

Jill S. Waibel received consulting fees from Allergan and Medicis; research grant from Sciton; honoraria from Candela and Syneron 

Andrea Willey – No disclosure 

19

20 

Clinical 

Application 

Courses 







Grapevine, TX 


available. 

Resurfacing and Contouring – Texas C 8:00 am – 12:00 pm 

Directors: Richard E. Fitzpatrick, M.D., Paul M. Friedman, M.D. 

Faculty: Tina S. Alster, M.D., A. Jay Burns, M.D., Jeffrey S. Dover, M.D., Roy G. Geronemus, M.D., 

Suzanne L. Kilmer, M.D., Robert A. Weiss, M.D., Christopher B. Zachary, M.B.B.S., F.R.C.P. 





The American Society for Laser Medicine and Surgery, Inc. designates this live activity for a maximum of 

3.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the 

extent of their participation in the activity. 


This offering by the ASLMS, in conjunction with Professional Medical Education Association is accredited for 

4.5 contact hours. Professional Medical Education Association is approved by the California Board of 

Registered Nursing, Provider # CEP 12386. Note: Most State Boards of Nursing accept another State Board’s 

approval for granting credits. Check with the Board of Nursing in your state for clarification. Certificates 

of Attendance will be provided. You will receive a statement of CE contact hours after the Annual 

Conference. 


This course will present improved and new techniques, treatments, and technologies in order to promote 

optimal patient outcomes. Lectures will focus on the most recent advances for photo-damaged, scarred 

and in lax skin utilizing a broad spectrum of state-of-the-art devices. It is anticipated that the attendees 

will familiarize themselves with the various technologies prior to attending this course as the speakers will 

focus on advanced applications rather than introductory concepts. 

Participants 

This course is designed for dermatologists, plastic surgeons, and physicians that have an interest in skin 

rejuvenation and body contouring through the use of lasers, light sources, and radio-frequency devices. 


This course is NOT intended as an introductory course. Physics of the various technologies will be 

presented at an advanced level. 


This course will provide an opportunity to gain perspective on the role of ablative, non-ablative resurfacing, 

rejuvenation techniques, and effective therapy alternatives for their patients. Newer therapeutic options 

in ablative and non-ablative fractional resurfacing, radio-frequency and ultrasound, as well as facial/body 

recontouring techniques will also be reviewed. 

8:00 am – 8:10 am Discussion and Pre-Test – Richard E. Fitzpatrick, Paul M. Friedman 

8:11 am – 8:27 am Non-Ablative Fractional Photothermolysis – Paul M. Friedman 

8:28 am – 8:44 am Ablative Fractional Resurfacing – Richard E. Fitzpatrick

Clinical 

Application 

Courses 







Grapevine, TX 


available. 

Resurfacing and Contouring Continued – Texas C 8:00 am – 12:00 pm 

8:45 am – 9:01 am Facial Rejuvenation “My Approach” – Tina S. Alster 

9:02 am – 9:18 am Facial Rejuvenation “My Approach” – Christopher B. Zachary 

9:19 am – 9:35 am Ancillary Laser Treatments to Enhance Facial Rejuvenation - Roy G. Geronemus 

9:36 am - 9:59 am Questions and Answers 

10:00 am – 10:15 am Break 

10:16 am – 10:32 am Update Non-invasive Facial and Body Shaping – Robert A. Weiss 

10:33 am – 10:49 am Update on New Emerging Body Shaping Technology – Jeffrey S. Dover 

10:50 am – 11:06 am Resurfacing and Contouring: Combining the Concepts – A. Jay Burns 

11:07 am – 11:23 am Combining Technology for Facial Rejuvenation – Suzanne L. Kilmer 

11:24 am – 11:49 am Question and Answers 

11:50 am – 12:00 pm Post Test - Richard E. Fitzpatrick, Paul M. Friedman 

Disclosures 

Tina S. Alster – No disclosure 

A. Jay Burns received discount from Cutera, Cynosure, Palomar, Sciton, Zeltiq, and Zimmer; stockholder with Skin Medica and Zeltiq; 

research grant from Solta, Uthera, and Zeltiq; honoraria from Sciton, Solta, Ulthera, and Zeltiq; medical advisory board for Ulthera and 

Zeltiq 

Jeffrey S. Dover received consulting fees from Lumenis, and Solta; research grant from Cutera, Lumenis, and Solta 

Richard E. Fitzpatrick received financial grant and honoraria from Solta; consulting fees from Candela, SkinMedica, and Solta; discount from 

Candela; stockholder with SkinMedica and Solta; equity position with SkinMedica; serves on scientific advisory board for Zeltiq 

Paul M. Friedman received honoraria from Candela, DUSA, and Solta 

Roy G. Geronemus is an investigator for Cynosure, DUSA, Invasix, Palomar, Solta, and Syneron; stockholder with Solta; serves on Medical 

Advisory Board for Candela, Lumenis, PhotoMedex, Syneron, and Zeltiq 

Suzanne L. Kilmer serves on medical advisory boards for Candela, Cutera, Ellipse, HOYA ConBio, Lumenis, Primaeva, Ulthera, and Zeltiq; 

research grant from Candela, CoolTouch, Cutera, Cynosure, Ellipse, HOYA ConBio, Iriderm, Lumenis, Palomar, Primaeva, Reliant, Sciton, 

Thermage, Ulthera, and Zeltiq 

Robert A. Weiss received financial grant, equipment, and honoraria from Lumenis, Palomar, and Solta; research grant from Lumenis and 

Palomar 

Christopher B. Zachary received discounted equipment from Cutera and Solta (UCI); honoraria from Sciton and Solta 

21

22 

Clinical 

Application 

Courses 







Grapevine, TX 


available. 

Laser Treatment of Vascular Lesions – Texas C 1:30 pm – 5:30 pm 

Directors: Kristen M. Kelly, M.D., Thomas E. Rohrer, M.D. 

Faculty: R. Rox Anderson, M.D., Kenneth A. Arndt, M.D., Melissa A. Bogle, M.D., Bernard Choi, Ph.D., 

Christine C. Dierickx, M.D., Roy G. Geronemus, M.D., Arielle N.B. Kauvar, M.D., Suzanne L. Kilmer, M.D., J. 

Stuart Nelson, M.D., Ph.D., Elizabeth L. Tanzi, M.D., Robert A. Weiss, M.D. 






AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of 

their participation in the activity. 





approval for granting credits. Check with the Board of Nursing in your state for clarification. Certificates of 

Attendance will be provided. You will receive a statement of CE contact hours after the Annual 

Conference. 


The course is designed to enhance the participant’s understanding of lasers and light sources in the 

treatment of vascular lesions. 

Participants 

The course is designed for dermatologists, plastic surgeons, vascular surgeons, and all physicians performing 

cutaneous laser surgery or treating vascular abnormalities. 


Attendees should have some knowledge of laser physics, tissue interaction and the practical use of vascular 

devices. 


This course will enhance the participants understanding of lasers and non-coherent light sources in the 

treatment of vascular abnormalities and telangiectasias and will increase knowledge about light based 

treatment approaches to unwanted vascular lesions. Attendees will be informed about current research 

related to development and enhancement of light based treatment of vascular lesions. 

1:30 pm – 1:34 pm Discussion and Pre-Test – Kristen M. Kelly, Thomas E. Rohrer 

1:35 pm – 1:49 pm Understanding Laser and Light Treatments of Vascular Lesions – Thomas E. Rohrer 

1:50 pm – 1:59 pm The Importance of Cooling – Melissa A. Bogle 

2:00 pm – 2:14 pm Use of Alexandrite Lasers for Treatment of Vascular Lesions - Suzanne L. Kilmer

Clinical 

Application 

Courses 







Grapevine, TX 


available. 

Laser Treatment of Vascular Lesions Continued – Texas C 1:30 pm – 5:30 pm 

2:15 pm – 2:29 pm Treatment of Facial Telangiectases - Kenneth A. Arndt 

2:30 pm – 2:44 pm Complications - Roy G. Geronemus 

2:45 pm – 2:59 pm Questions for First Half Faculty 

3:00 pm – 3:29 pm Break 

3:30 pm – 3:44 pm Treatment of Leg Telangiectases - Robert A. Weiss 

3:45 pm – 3:59 pm Treatment of Port Wine Stains and Hemangiomas – Kristen M. Kelly 

4:00 pm – 4:09 pm How I Approach my Vascular Lesion Patient – Christine C. Dierickx 

4:10 pm – 4:19 pm How I Approach my Vascular Lesion Patient – Arielle N.B. Kauvar 

4:20 pm – 4:29 pm Update of Vascular Lesion Treatment Research – Bernard Choi 

4:30 pm – 5:14 pm Panel Discussion of Case Presentations: R. Rox Anderson, J. Stuart Nelson, Elizabeth 

Tanzi 

5:15 pm – 5:30 pm Conclusion and Post-Test – Kristen M. Kelly, Thomas E. Rohrer 

Disclosures 

R. Rox Anderson received royalties from Massachusetts General Hospital which owns and licenses patents on laser hair removal, 

fractional laser treatments, and cryolipolysis; serves on scientific advisory boards for PhotoMedex and Ulthera 

Kenneth A. Arndt – No disclosure 

Melissa A. Bogle – No disclosure 

Bernard Choi – No disclosure 

Christine C. Dierickx received equipment from Candela, Cutera, Lumenis, Palomar, and Ulthera; research grant from Palomar 

Roy G. Geronemus is an investigator for Cynosure, DUSA, Invasix, Palomar, Solta, and Syneron; stockholder with Solta; serves on 

Medical Advisory Board for Candela, Lumenis, Photomedex, Syneron, and Zeltiq 

Arielle N.B. Kauvar – No disclosure 

Kristen M. Kelly received equipment from Candela, DUSA, and Solta; consulting fees from Lumenis and Ulthera; research grant from 

Candela, DUSA, Graceway 

Suzanne L. Kilmer serves on medical advisory boards for Candela, Cutera, Ellipse, HOYA ConBio, Lumenis, Primaeva, Ulthera, and 

Zeltiq; research grant from Candela, CoolTouch, Cutera, Cynosure, Ellipse, HOYA ConBio, Iriderm, Lumenis, Palomar, Primaeva, Reliant, 

Sciton, Thermage, Ulthera, and Zeltiq 

J. Stuart Nelson received equipment from Cynosure, Fotona, and Genentech; research grant from Syneron/Candela, New Star, Wyeth- 

Pfizer; royalties from Syneron/Candela and New Star; honoraria/speaker from Syneron/Candela 

Thomas E. Rohrer received research grant from Syneron/Candela, Julia Therapeutics, and Radiancy; honoraria from Syneron/Candela 

and Radiancy; serves on medical advisory board for Syneron/Candela and Julia Therapeutics 

Elizabeth L. Tanzi received equipment from Cynosure, Lumenis, Palomar, Solta, and Syneron; consulting fees from Medicis, Myoscience, 

and Zeltiq 

Robert A. Weiss received financial grant, equipment, honoraria from Cynosure, Lumenis, and Palomar; consulting fees from Cynosure 

23

24 

Clinical 

Application 

Courses 







Grapevine, TX 


available. 

Hair and Pigment Removal – Texas D 1:30 pm – 5:30 pm 

Directors: Eric F. Bernstein, M.D., Henry H.L. Chan, M.D., Ph.D., F.R.C.P. 

Faculty: Mathew M. Avram, M.D., J.D., Suzanne L. Kilmer, M.D., Dieter Manstein, M.D., E. Victor Ross, 

M.D., Brian D. Zelickson, M.D. 














Conference. 


This course will teach basic laser physics and biology of tissue interaction, basic safety tips, and optimal 

laser usage for pigmented lesions and hair removal. 

Participants 

This course is geared toward all physicians performing laser surgery. 


Participants should have a basic understanding of the fundamentals of skin biology, laser physics, and laser 

tissue interaction. 


Upon completion of the course, the participant will advance their knowledge base and acquire an up-to-date 

understanding of complications and how to avoid them with laser hair removal, basic physics biology for 

laser hair removal, and selecting the correct device. 

1:30 pm - 1:39 pm Discussion and Pre-Test - Eric F. Bernstein, Henry H.L. Chan 

1:40 pm - 1:59 pm Laser Physics, Hair and Pigmented Lesions - Henry H.L. Chan 

2:00 pm - 2:19 pm Laser Treatment of Pigmented Lesions - E. Victor Ross 

2:20 pm - 2:39 pm Hair and Tattoo Removal in Skin of Color - Henry H.L. Chan 

2:40 pm - 2:49 pm Q&A

Clinical 

Application 

Courses 







Grapevine, TX 


available. 

Hair and Pigment Removal Continued – Texas D 1:30 pm – 5:30 pm 

2:50 pm - 3:09 pm Avoiding Complications in Tattoo Removal - Eric F. Bernstein 

3:10 pm - 3:24 pm Break 

3:25 pm - 3:44 pm Laser Hair Removal - Eric F. Bernstein 

3:45 pm - 4:04 pm Avoiding Complications in Hair Removal - Suzanne Kilmer 

4:05 pm - 4:24 pm Laser Treatment of Tattoos - Brian D. Zelickson 

4:25 pm - 4:34 pm Q&A 

4:35 pm - 4:54 pm Medical Legal Aspects of Hair/Pigmented Lesion/Tattoo Removal - Mathew M. Avram 

4:55 pm - 5:14 pm Future of Hair, Pigment, Tattoo Lasers - Dieter Manstein 

5:15 pm - 5:30 pm Q&A and Post-Test - All Faculty 

Disclosures 

Mathew M. Avram is a stockholder with Zeltiq 

Eric F. Bernstein received equipment from Candela, Cynosure, DEKA, Lumenis, and Reliant; consulting fees from TRIA Beauty; discount 

from Zeltiq 

Henry H.L. Chan received financial grant from Lumenis; equipment from Candela, Elemé, Lumenis, Palomar, Solta, Syneron, Zeltiq; 

discount from Candela; stockholder with Lumenis, Solta 

Suzanne L. Kilmer serves on medical advisory boards for Candela, Cutera, Ellipse, HOYA ConBio, Lumenis, Primaeva, Ulthera, and 

Zeltiq; research grant from Candela, CoolTouch, Cutera, Cynosure, Ellipse, HOYA ConBio, Iriderm, Lumenis, Palomar, Primaeva, Reliant, 

Sciton, Thermage, Ulthera, and Zeltiq 

Dieter Manstein, received equipment from Quantel Derma and Solta; consulting fees from Elemé, Quantel Derma and Zeltiq; research 

grant from Candela and Lumenis; stockholder with Zeltiq, royalties from Massachusetts General Hospital due to licensing contracts with 

Candela, Elemé, Palomar, Solta, Zeltiq and Zimmer 

E. Victor Ross received financial grant and consulting fees from Palomar and Syneron; equipment from Cutera, Lumenis, Palomar, and 

Sciton; research grant from Cutera, Palomar, and Syneron; honoraria from Cutera, Lumenis, Palomar, and Syneron 

Brian D. Zelickson received equipment from Candela, Lumenis, and Syneron; consulting fees from Medicis; discount from Lumenis and 

Syneron; research grant from Cutera, Lumenis, Palomar, Solta, Syneron, Ulthera, and Zeltiq; honoraria from Zeltiq; intellectual 

property rights with Candela 

25

26 





Grapevine, TX

Clinical 

Application 

Course 







Grapevine, TX 


available. 

Laser Treatment of Patients of Color – Longhorn F 7:00 am – 10:00 am 

Directors: Paul J. Carniol, M.D., Jennifer Kim, M.D., Ph.D. 

Faculty: Andrew F. Alexis, M.D., Kei Negishi, M.D., Mario A. Trelles, M.D., Ph.D. 





The American Society for Laser Medicine and Surgery, Inc. designates this live activity for a maximum of 3 AMA 

PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their 









This course will address avoiding adverse events and improving efficacy of laser treatment of patients with skin 

of color. 

Participants 

This course is geared toward clinical laser practitioners. 


Participants should have basic clinical laser skills and training. 


This course will address discussion of appropriate treatment parameters, pre- and post-operative care, patient 

selection, and management of adverse events. 

7:00 am – 7:29 am Discussion, History, Physics, Concept of Ethnicity, Pre-Test – Paul J. Carniol 

7:30 am – 7:59 am Laser Treatments of Pigmentary Concerns – Mario A. Trelles 

8:00 am – 8:29 am Laser and Light Based Skin Rejuvenation and Toning Techniques for Asian Patients – Kei 

Negishi 

8:30 am – 8:59 am Managing Acne and Acne Scars – Jennifer Kim 

9:00 am – 9:29 am Lasers for Hair Removal and Hair Disorders – Andrew F. Alexis 

9:30 am – 10:00 am Discussion and Post-Test - Paul J. Carniol, Jennifer Kim 

Disclosures 

Andrew F. Alexis – No disclosure 

Paul Carniol – No disclosure 

Jennifer Kim received consulting fees from Allergan, Galderma, and Steifel/GSK; stockholder with Allergan; research grant from Dong Sung 

Pharmaceuticals 

Kei Negishi received equipment from Cutera, Sciton, and Lumenis 

Mario A. Trelles – No disclosure 

27

28 

Clinical 

Application 

Courses 







Grapevine, TX 


available. 

Complications, Controversies, and Legal Issues – Texas C 7:00 am – 10:00 am 

Directors: Mathew A. Avram, M.D., J.D., Suzanne L. Kilmer, M.D. 

Faculty: Eric F. Bernstein, M.D., Henry H.L. Chan, M.D., Ph.D., F.R.C.P., Christine C. Dierickx, M.D., Jeffrey S. 

Dover, M.D., Roy G. Geronemus, M.D., David J. Goldberg, M.D., J.D., Merete Haedersdal, M.D., Ph.D., Zeina 

Tannous, M.D., Robert A. Weiss, M.D., Christopher B. Zachary, M.B.B.S., F.R.C.P., Brian D. Zelickson, M.D. 





The American Society for Laser Medicine and Surgery, Inc. designates this live activity for a maximum of 2.75 AMA 










This course is designed to address all common complications of a host of laser and light source treatments. 

Participants 

Participants include any physicians or allied health professionals involved in the operation of lasers in surgery. 


Participants should have experience with the basics of laser. 


It is expected that at the conclusion of this course, participants will be able to identify gaps in their knowledge 

which will aid in their safe treatment of patients in order to limit potential side effects. 

7:00 am – 7:05 am Discussion and Pre-Test – Mathew M. Avram, Suzanne L. Kilmer 

7:06 am - 7:14 am Vascular Lasers/IPL - Brian D. Zelickson 

7:15 am - 7:19 am Laser Complications in Pediatric Patients – Zeina Tannous 

7:20 am – 7:28 am Pigment Lasers/Tattoo Lasers - Eric F. Bernstein 

7:29 am - 7:37 am Hair Removal Lasers - David J. Goldberg 

7:38 am - 7:46 am Photodynamic Therapy - Merete Haedersdal 

7:47 am - 7:55 am Non-Invasive Fat Removal, Tissue Tightening - Christine C. Dierickx 

7:56 am - 8:04 am Laser Lipolysis - Robert A. Weiss 

8:05 am - 8:28 am Questions and Answers 

8:29 am - 8:39 am Break 

8:40 am - 8:48 am Laser Treatment of Darker Skin Types - Henry H.L. Chan 

8:49 am - 8:57 am Non-Ablative Fractional - Jeffrey S. Dover 

8:58 am - 9:06 am Ablative Fractional - Christopher B. Zachary 

9:07 am - 9:15 am Ablative Laser - Suzanne L. Kilmer

Clinical 

Application 

Courses 







Grapevine, TX 


available. 

Complications, Controversies, and Legal Issues Continued – Texas C 7:00 am – 10:00 am 

9:16 am - 9:24 am Complications of Unskilled Laser Operators - Roy G. Geronemus 

9:25 am - 9:33 am Legal Issues - Mathew M. Avram 

9:34 am - 10:00 am Questions and Answers and Post Test – Mathew M. Avram, Suzanne L. Kilmer 

Disclosures 


Eric F. Bernstein received equipment from Cynosure, DEKA, HOYA ConBio, and Syneron; consulting fees from TRIA Beauty; discount from 

Candela, Cynosure, HOYA ConBio, Solta, and Zeltiq; research grant from Candela, Cynosure, and Solta 

Henry H.L. Chan received financial grant from Lumenis; equipment from Candela, Elemé, Lumenis, Palomar, Solta, Syneron, Zeltiq; discount 

from Candela; stockholder with Lumenis, Solta 

Christine C. Dierickx received equipment from Candela, Cutera, Lumenis, Palomar, Ulthera; research grant from Palomar and Medicis 

Jeffrey S. Dover received consulting fees from Lumenis, and Solta; research grant from Cutera, Lumenis, and Solta 

Roy G. Geronemus received consulting fees from Cynosure, DUSA, Invasix, Palomar, Solta, and Syneron; stockholder with Solta; serves on 

Medical Advisory Board for Candela, Lumenis, Photomedex, Syneron, and Zeltiq 


Merete Haedersdal – No disclosure 

Suzanne L. Kilmer serves on medical advisory boards for Candela, Cutera, Ellipse, HOYA ConBio, Lumenis, Primaeva, Ulthera, and Zeltiq; 

research grant from Candela, CoolTouch, Cutera, Cynosure, Ellipse, HOYA ConBio, Iriderm, Lumenis, Palomar, Primaeva, Reliant, Sciton, 

Thermage, Ulthera, and Zeltiq 

Zeina Tannous – No disclosure 

Robert A. Weiss received financial grant, equipment, and honoraria from Cynosure, Lumenis, and Palomar; consulting fees from Cynosure 

Christopher B. Zachary received discounted equipment from Cutera and Solta (UCI); honoraria and educational support from Sciton and Solta 


Syneron; research grant from Cutera, Lumenis, Palomar, Solta, Syneron, Ulthera, and Zeltiq; honoraria from Zeltiq; intellectual property 

rights with Candela 

29

Ron R. Allison – No disclosure 

Keith A. Cengel – No disclosure 

Gordon H. Downie – No disclosure 

M. Sam Eljamel – No disclosure 

Colin Hopper – No disclosure 

Herbert C. Wolfsen – No disclosure 

30 





Grapevine, TX 


available. 

PDT: Principle and Clinical Role – Texas 2-3 7:00 am – 10:00 am 

Director: Ron R. Allison, M.D. 

Faculty: Keith A. Cengel, M.D., Ph.D., Gordon H. Downie, M.D., Ph.D., M. Sam Eljamel, M.D., Colin Hopper, 

B.D.S., M.B.B.S., M.D., F.D.S., F.R.C.S., Herbert C. Wolfsen, M.D. 















This course will address the fundamentals of PDT in terms of the basic science behind this therapy, the rationale 

for this treatment, the clinical outcomes and morbidities expected, the actual treatment procedure, and the data 

collected clinically from peer-reviewed publications. 

Participants 

This course is designed for oncologists, dermatologists, surgeons, pulmonologists, and gastroenterologists involved 

with photodynamic therapy. 


Although it is not a prerequisite, attendees would ideally have some basic understanding of laser tissue 

interactions. Individual attendees do not need to have significant experience or expertise in laser medicine or 

surgery. 


At the conclusion of the course, attendees will have a clinical history and overview of photodynamic therapy. 

They will understand the basic science of PDT (photosensitizers, light source, photodynamic reaction), understand 

clinical treatment calculations, and treatment outcomes and morbidity of clinical PDT. 

7:00 am – 7:29 am Introduction, Fundamentals of PDT, and Pre-Test – Ron R. Allison 

7:30 am – 7:59 am Clinical PDT – Cutaneous and Head and Neck – Colin Hopper 

8:00 am – 8:29 am Clinical PDT – Neurooncology – M. Sam Eljamel 

8:30 am – 8:59 am Clinical PDT - Pulmonary Indications – Gordon H. Downie 

9:00 am – 9:29 am Clinical PDT – Gastrointestinal – Herbert C. Wolfsen 

9:30 am – 9:54 am Clinical PDT – Genitourinary – Keith A. Cengel 

9:55 am – 10:00 am Conclusion and Post Test – Ron R. Allison 

Disclosures 

Clinical 

Application 

Courses 


Friday, April 1, 2011

Conference 

Plenary Session 






Grapevine, TX 

Conference Plenary Session – Longhorn F 10:30 am – 12:00 pm 

10:30 am – 10:39 am WELCOME & INTRODUCTION 

Serge R. Mordon, Ph.D.*, Program Chair 

INSERM U703, Lille, France 

*Stockholder with Ekkyo 

E. Duco Jansen, Ph.D.*, President 

Vanderbilt University, Nashville, TN 

*Received a salary, research grant, and intellectual property rights from Vanderbilt University; research 

grant from NIH, DOD, HFSP, and Lockheed-Martin \ 

10:40 am – 10:59 am PRESIDENTIAL ADDRESS AND ANNOUNCEMENT OF AWARDS/CITATIONS 

E. Duco Jansen, Ph.D., President 

Presidential Citations 

Ken Day, Ph.D. 

Raymond J. Lanzafame, M.D., M.B.A. 

J. Stuart Nelson, M.D., Ph.D. 

Jason N. Pozner, M.D. 

Best Overall Awards 

Robert Anolik Dr. Richard E. Fitzpatrick Clinical Research 

and Innovations Award 

Xingjia Wu Best Overall Experimental and Translational 

Research 

Best Student/Resident Awards 

Vivian Laquer Best Student/Resident Cutaneous 


Mehmet Kosoglu Best Student/Resident Experimental and 


Tianyi Wang Best Student/Resident Photobiomodulation 

Liyi Huang Best Student/Resident Photodynamic 

Therapy 

Edward C. Wu Best Student/Resident Surgical 

Applications/Interstitial Laser Therapy 

Recipients of the best ePoster awards will be announced at the Annual Conference. 

2011 Research Grant Recipients To Be Announced 

31

11:00 am – 11:59 am KEYNOTE SPEAKER 

32 

Conference 



LIGHT, SCIENCE, MEDICINE, AND THE FDA 

Neil R. Ogden, Chief, General Surgery Devices Branch, 

Division of Surgery, Orthopedic, and Restorative 

Devices, Office of Device Evaluation, Food and Drug 

Administration, Silver Spring, MD 





Grapevine, TX 

Mr. Ogden completed his undergraduate studies in biomedical engineering at Tulane 

University in New Orleans in 1980. While working at Tulane University Medical 

School, he earned his Master’s degree in biomedical engineering at Tulane University 

in 1985. 

He became Peace Corps Volunteer with his wife Ellyn in Papua, New Guinea, New 

Ireland Province, 1987-1989. Mr. Ogden enjoys international travel with his family 

having visited Australia, Belgium, Canada, Germany, France, Greece, Guatemala, 

Italy, India, Mexico, South Africa, Switzerland, and Zimbabwe. 

He worked briefly at the National Institutes of Health before joining the Food and 

Drug Administration in 1990 as a new scientific reviewer in the General Surgery 

Devices Branch, in the Office of Device Evaluation in the Center for Devices and 

Radiologic Health. As a scientific reviewer, one of his areas of expertise was light 

based device reviews with emphasis on surgical laser systems. 

Mr. Ogden was selected as the Branch Chief for the General Surgery Devices Branch 

in December, 1998. As Branch Chief, he has supervised hundreds of light based 

device reviews and final recommendations for marketing which includes reviews of 

surgical lasers, IPLs, visible spectrum diagnostic devices (Melafind), biostimulation 

lights, OCT systems, surgical lights, and other optical devices. During this period he 

has received numerous awards for excellent job performance including the 2010 FDA 

Human Capital Investment Award. He has written articles about device regulation 

which has been published in FDA Consumer, FDA Today, and Seminars in 

Laparoscopic Surgery. He has also co-authored a chapter on FDA regulation in the 

book, Cancer Principles and Practices of Oncology, 7th Edition. 

He has broadened his professional experience over the past six years by working as 

Acting Deputy Division Director in the Division of Cardiovascular Devices, the Division 

of Anesthesiology, General Hospital, Infection Control, and Dental Devices, the 

Division of Surgery and Orthopedic Devices each in the Office of Device Evaluation, 

and most recently the Division of Biology in the Office of Science and Engineering 

Laboratories. 

12:00 pm – 1:30 pm COMPLIMENTARY LUNCH WITH TICKET IN EXHIBIT HALL (View ePosters)





Grapevine, TX 

Experimental and Translational Research – Texas C 1:00 pm – 5:45 pm 

Directors: Jennifer K. Barton, Ph.D., Bernard Choi, Ph.D. 

Disclosures 


Jennifer K. Barton – No disclosure 


These sessions promote understanding of basic processes of light interaction with tissues and cells, design of 

light-based diagnostic and therapeutic devices and techniques, and early translation of this knowledge to 

clinical application. 

Participants 

Scientists, engineers, medical practitioners as well as other health care professionals involved in biomedical 

applications of lasers are invited to attend. 


Participants should have a basic understanding or experience of how light interacts with tissues. 


These sessions will provide attendees knowledge of cutting-edge advances in optical diagnostics and 

therapeutics, and their early translation to the clinical management of patients. Novel results are presented 

that will impact the development of new and more efficacious, light-based therapeutic and diagnostic devices 

and applications. Characterization of light sources and safety issues are also considered. 

Hot Topics 

• Lasers plus drugs: Towards more effective blood vessel treatments 

• Safety and efficacy of laser nerve stimulation in humans 

• Novel microneedles for interstitial light and fluid delivery 

• Photoacoustic detection of melanoma 

1:00 pm – 1:11 pm 

(ePoster available) 


Translational 



PHOTOBIOMODULATION 

INVITED SPEAKER 

1 SAFETY AND EFFICACY OF INFRARED NEURAL STIMULATION IN HUMANS 

Jonathan Cayce 1 , Jonathan Wells 2 , Jonathan Malphrus, Chris Kao, Sharon 

Thomsen, Noel Tulipan, Peter Konrad 3 , E. Duco Jansen 4 , Anita Mahadevan- 

Jansen 4 , Vanderbilt University, Nashville, TN, Lockheed Martin Aculight, 

Bothel, WA, University of Texas at Austin, Austin, TX 

1 

Research grant from NIH/HFSP 

2 

Stockholder with Lockheed Martin Aculight, intellectual property rights with Vanderbilt 

University and Lockheed Martin Aculight 

3 

Intellectual property rights with Vanderbilt University 

4 

Research grant from NIH/HFSP; royalties from Lockheed Martin Aculight; intellectual property 

rights with Vanderbilt University 

1:12 pm – 1:23 pm 2 TREATING TRACHEAL STENOSIS USING LOW LEVEL LASER THERAPY: AS A 

POTENTIAL TOOL IN AN EXPERIMENTAL STUDY IN RAT MODEL 

Claudia Silva, Nathali Pinto, Raduan Hage, Neila Garcia, Emilia Arisawa, M. 

Cristina Chavantes, UNIVAP, USP, São José dos Campos, São Paulo, Brazil 


33

34 


Translational 







Grapevine, TX 

1:24 pm – 1:35 pm 3 NOVEL APPROACH FOR HEALING LEG ULCERS: CASE STUDY INVOLVING 

COMBINED EFFECT OF LOW LEVEL LASER THERAPY AND BIOCERAMICS 

Supriya Babu, Bheemsain Rao, Veena P. Waiker, Jaisri Goturu, Vasanthi 

Ananthakrishnan, G. Dayananda, Arun Kumar, M.S. Ramaiah Institute of 

Technology, Medical College and Hospital, Bangalore, Karnataka, India 


NANOPARTICLES 

1:36 pm – 1:47 pm 4 EFFECT OF POLYETHYLENE GLYCOL COATING ON BIODISTRIBUTION OF 

ICG-LOADED POLYMERIC NANOCAPSULES IN MICE 

Baharak Bahmani�, Sharad Gupta, Bahman Anvari, University of California, 

Riverside, CA 


2009 ASLMS STUDENT RESEARCH GRANT RECIPIENT 

1:48 pm – 1:59 pm 5 NARROWBAND IMAGING OF TARGETED GOLD NANORODS IN TUMORS 

Priyaveena Puvanakrishnan 1 , Parameswaran Diagaradjane, Glenn Goodrich, 

Jon Schwartz, Sunil Krishnan, James Tunnell 1 , University of Texas at Austin, 

Austin, TX, University of Texas/MD Anderson Cancer Center, Nanospectra 

Biosciences, Inc., Houston, TX 

1 

Royalties from the University of Texas through Nanospectra Biosciences 


PRECLINICAL THERAPEUTICS I 

2:00 pm – 2:11 pm 6 INDUCTION OF LIPOLYSIS IN HUMAN ADIPOCYTES BY HYPERTHERMIA 

ALONE AND IN COMBINATION WITH PHOTODYNAMIC TREATMENT 

Valery Tuchin 1 , Irina Yanina, Georgy Simonenko, Andrey Belikov, David 

Tabatadze, Ilya Yaroslavsky, Gregory Altshuler, Institute of Optics and 

Biophotonics, Saratov State University, Saratov, Russian Federation, Laser 

Center, SPITMO, St. Petersburg, Russia, Palomar Medical Technologies, Inc., 

Burlington, MA 

1 

Equipment, consulting fees, and travel expenses from Palomar 


2:12 pm – 2:23 pm 7 HEAT SHOCK PROTEIN EXPRESSION IN TISSUES AFTER SHORT PULSE LASER- 

INDUCED DAMAGE 

Amir Sajjadi�, Kunal Mitra, Michael Grace, Melbourne, FL 



2:24 pm – 2:44 pm 8 MOBILIZATION OF ENDOTHELIAL PROGENITOR CELLS FOLLOWING 

PHOTODYNAMIC THERAPY 

Charles Gomer, Angela Ferrario, Marian Luna, University of Southern 

California, Children’s Hospital, Los Angeles, CA 


2:45 pm – 3:44 pm Break – Visit the Exhibits and ePosters 

�Recipient of U.S. Air Force Office of Scientific Research travel grant.





Grapevine, TX 

3:45 pm – 3:56 pm 9 COMPARISON OF ANTIANGIOGENIC AGENTS FOR INHIBITING REPERFUSION 

OF PHOTOCOAGULATED BLOOD VESSELS IN AN ANIMAL MODEL 

Wangcun Jia, Victor Sun, Tom Liu 1 , Bernard Choi, J. Stuart Nelson 2 , 

Beckman Laser Institute and Medical Clinic, University of California, Irvine, 

CA, Conrex Pharmaceuticals, Newtown Square, PA 

1 

Salary from Conrex Pharmaceuticals 

2 

Research grant from Wyeth Pharmaceuticals 


3:57 pm – 4:08 pm VIRUS-BASED OPTICAL NANO-CONSTRUCTS FOR POTENTIAL OPTICAL 

IMAGING AND LASER THERAPY APPLICATIONS 

Bongsu Jung, Yadir Guerrero, Rao Ayala, Bahman Anvari, UC Riverside, 

Riverside, CA 


4:09 pm – 4:20 pm 



Translational 



12 OPTIMAL WAVELENGTH SELECTION FOR LASH TREATMENT OF SKIN 

PHOTOTYPES I TO VI 

Sylvain Giraud 1 , Sonia Saai 2 , Cecile Philandrianos, Alain Cornil 3 , Guy 

Magalon, Ekkyo, Aix-en-Provence, Paca, France, APHM Hospital La 

Conception, Marseille, Paca, France 

1 

Travel expenses from Ekkyo 

2 

Salary expenses from Ekkyo 

3 

Equity position with Ekkyo 


4:21 pm – 4:32 pm 13 TISSUE EFFECTS INDUCED BY Er,Cr:YSGG LASER PULSES DELIVERED 

THROUGH A RADIAL EMITTING FIBER STUDIED WITH HIGH SPEED OPTICAL 

THERMOGRAPHY 

Rudolf Verdaasdonk 1 , Vladimir Lemberg 2 , Albert Veen van der 1 , Stefan 

Been 3 , Dmitri Boutoussov 4 , Werner Landgraf 4 , VU University Medical Center, 

Amsterdam, The Netherlands, Optomix, Santa Clara, CA, Biolase, Irvine, CA, 

Biolase, Floss, Germany 

1 

Research grant from Biolase 

2 

Consulting fees from Biolase 

3 

Research grant from FP7 MIRSURG 

4 

Salary from Biolase 


4:33 pm – 4:44 pm 14 IS IT POSSIBLE TO PERFORM LASER RESHAPING WITHOUT DRAMATIC 

EFFECT ON CHONDROCYTES? 

Emil Sobol 1 , Natalia Vorobieva 2 , Olga Baum 3 , Anatoly Shekhter 4 , Anna 

Guller 4 , Institute on Laser and Information Technologies, Medical Academy of 

Moscow, Troitsk, Moscow Region, Russia 

1 

Equipment and stockholder with Arcuo Medical 

2 

Equipment from Arcuo Medical 

3 

Stockholder with Arcuo Medical 

4 

Salary from Arcuo Medical 


35

4:45 pm – 4:56 pm 


36 


Translational 







Grapevine, TX 

15 FLUID CHARACTERIZATION OF A NOVEL HOLLOW-CORE MICRONEEDLE 

DESIGN 

Robert Hood�, Mehmet Kosoglu, Matthew Parker, Christopher Rylander, 

Virginia Tech, Blacksburg, VA 


4:57 pm – 5:08 pm 16 USING TRIPHASIC THEORY TO EVALUATE CARTILAGE MECHANICAL 

RESPONSE TO LASER RESHAPING 

Dmitry Protsenko, Brian Wong, Beckman Laser Institute and Medical Clinic, 

University of California, Irvine, CA 


5:09 pm – 5:20 pm 17 COMPARISON OF THERMAL AND MECHANICAL CHARACTERISTICS DURING 

TISSUE ABLATION OF Er:YAG, Er,Cr:YSGG AND CO2 IN THE MICROSECOND 

TO MILLISECONDS PULSE RANGE IN VIEW OF SOFT TISSUE APPLICATIONS IN 

SURGERY 

Rudolf Verdaasdonk 1 , Vladimir Lemberg 2 , Albert Veen van der 1 , Stefan 

Been 3 , Dmitri Boutoussov 4 , Werner Landgraf 4 , VU University Medical Center, 

Amsterdam, The Netherlands, Optomix, Santa Clara, CA, Biolase, Irvine, CA, 

Biolase, Floss, Germany, University Medical Center, Utrecht, The 

Netherlands 

1 

Research grant from Biolase 

2 

Consulting fees from Biolase 

3 

Research grant from FP7 MIRSURG 

4 

Salary from Biolase 


LATE-BREAKING ABSTRACT / 2008 AND 2009 ASLMS RESEARCH GRANT 

RECIPIENT 

5:21 pm – 5:32 pm IN VIVO TUMOR-TARGETING OF GOLD NANOPARTICLES: EFFECT OF 

PARTICLE TYPE AND DOSING STRATEGY 

Jaesook Park, Parameshwaran Diagaradjane, Glenn Goodrich, Jon Schwartz, 

Sunil Krishnan, James Tunnell, University of Texas at Austin, Austin, TX, MD 

Anderson Cancer Center, Nanospectra Biosciences, Houston, TX 


LATE-BREAKING ABSTRACT 

5:33pm – 5:45 pm INTRAVITAL IMAGING OF ABNORMAL VASCULATURE IN PRENEOPLASTIC 

ORAL MUCOSA BY TWO-PHOTON LUMINESCENCE OF GOLD NANORODS 

Saam Motamedi, Tuya Shilagard, Kert Edward, Luke Koong, Suimin Qui, 

Gracie Vargas, University of Texas Medical Branch, Galveston, TX 






Gaylord Texan TM 2011 Annual Conference 



Gaylord Texan Resort and Convention Center 

Grapevine, TX 

TM Resort and Convention Center 

Grapevine, TX 

Cutaneous Laser Surgery – Longhorn F 1:00 pm – 6:10 pm 

Directors: Directors: Mathew Mathew M. Avram, M.D., J.D., Paul M. Friedman, M.D. 

Disclosures 


Paul M. Friedman received honoraria from Candela, DUSA and Solta 

LASER LASER AND LIGHT THERAPY FOR THE TREATMENT OF VASCULAR LESIONS AND SCARS 


This session focuses on the use of lasers lasers and light sources for the treatment of cutaneous vascular lesions and 

scars. The topics of new therapeutic techniques and optimized treatment approaches for targeting vascular 

lesions and scars will be addressed in this session. Participants will develop an understanding of the present 

treatment indications, therapeutic techniques, and new and innovative technologies. 

Participants 

This session will benefit physicians and health care personnel who treat vascular cutaneous disorders in the 

disciplines of dermatology, plastic surgery, otolaryngology, facial plastic surgery, and vascular surgery. It will 

also benefit those engineers and medical medical device personnel who actively work to develop devices for the 

treatment of cutaneous disorders. 





Attendees will gain knowledge of cutting edge laser and light sources and their clinical applications in the 

area of cutaneous vascular lesions and scars. 

Hot Topics 

�� Laser speckle imaging during treatment 

�� Histologic change of burn scars after fractional ablative treatment 

1:00 pm – 1:01 pm Introduction – Mathew M. Avram, Paul M. Friedman 

1:02 pm – 1:07 pm 


46 INVESTIGATION INTO SAFE AND EFFECTIVE TREATMENT INTERVALS OF 

PORT WINE STAINS USING THE PULSED DYE LASER 

Robert Anolik, Tracey Newlove, Elliot T. Weiss, Anne Chapas, Lori 

Brightman, Elizabeth K. Hale, Julie K. Karen, Leonard Bernstein, Roy G. 

Geronemus 1 46 INVESTIGATION INTO SAFE AND EFFECTIVE TREATMENT INTERVALS OF 

PORT WINE STAINS USING THE PULSED DYE LASER 

Robert Anolik, Tracey Newlove, Elliot T. Weiss, Anne Chapas, Lori 

Brightman, Elizabeth K. Hale, Julie K. Karen, Leonard Bernstein, Roy G. 

Geronemus , Laser and Skin Surgery Center of New York, New York University 

School of Medicine, New York, NY 

1 , Laser and Skin Surgery Center of New York, New York University 

School of Medicine, New York, NY 

1 

Equity Equity position with Solta 

1:08 pm – 1:13 pm 47 REAL-TIME LASER SPECKLE IMAGING AS AN INTRAOPERATIVE DIAGNOSTIC 

TOOL DURING TREATMENT OF PORT WINE STAIN BIRTHMARKS 

Bruce Yang, Owen Yang, Kristen Kelly, J. Stuart Nelson, Bernard Choi, 

Beckman Laser Institute and Medical Clinic, University of California, Irvine, 

CA 

1:14 pm – 1:19 pm 


�Recipient �Recipient of ASLMS travel grant. 

Cutaneous Laser 

Surgery Session 


48 THE USE OF LONG PULSED Nd:YAG LASER IN THE TREATMENT OF 

PEDIATRIC VENOUS MALFORMATION 

Stratos Sofos�, Sofos�, Se Hwang Liew, Liverpool, United Kingdom 

37

38 






Grapevine, TX 

1:20 pm – 1:25 pm TREATMENT OF PORT WINE STAIN USING AN INTENSE PULSE LIGHT DEVICE 

WITH A NEW OPTIMIZED LIGHT HANDPIECE 

E. Victor Ross, Emily Yu, Chad Tingey, Scripps Clinic, San Diego, CA 

1:26 pm – 1:31 pm 


50 OPTIMIZED SPECTRAL OUTPUT AND PULSE SHAPES FOR VASCULAR 

TREATMENTS 

Robert Weiss 1 , E. Victor Ross 2 , Emil Tanghetti 3 , David B. Vasily 3 , James 

Childs 4 , Mikhail Smirnov 4 , Gregory Altshuler 4 , Maryland Laser, Skin and Vein 

Institute, Baltimore, MD, Scripps Clinic, San Diego, CA, Center for 

Dermatology and Laser Surgery, Sacramento, CA, Aesthetica Cosmetic & 

Laser Surgery Center, Bethlehem, PA, Palomar Medical Technologies, 

Burlington, MA 

1 

Equipment and research grant from Palomar 

2 

Equipment, consulting fees, research grant from Palomar 

3 

Equipment from Palomar 

4 

Salary from Palomar 

1:32 pm – 1:37 pm 51 SPLIT-FACE RANDOMIZED TREATMENT OF FACIAL TELANGIECTASIA 

COMPARING PULSED DYE LASER AND A NEW OPTIMIZED LIGHT HANDPIECE 

Emil Tanghetti 1 , Center for Dermatology and Laser Surgery, Sacramento, CA 

1 


1:38 pm – 1:43 pm 


1:44 pm – 2:02 pm Q&A 

2:03 pm – 2:08 pm 


52 ANGIOGENESIS MEDIATOR ALTERATIONS IN ANGIOMAS AFTER PULSED DYE 

LASER TREATMENT 

Kristen Kelly, Belinda Dao, Janelle Marshall, Amy Nguyen, Vivian Laquer��, 

Elizabeth Rugg, Ronald Harris, Tina Chen, Beckman Laser Institute and 

Medical Clinic, University of California, Irvine, CA 


53 NON-ABLATIVE FRACTIONAL LASER RESURFACING FOR THE TREATMENT OF 

SCARS AND GRAFTS AFTER MOHS MICROGRAPHIC SURGERY: A RANDOMIZED 

CONTROLLED TRIAL 

Evelien Verhaeghe, Katia Ongenae, Jessica Bostoen, Jo Lambert, University 

Hospital Ghent, Ghent, Belgium 

2:09 pm – 2:14 pm 54 HISTOLOGIC CHARACTERISTICS OF MATURE BURN SCARS BEFORE AND 

AFTER THREE TREATMENTS WITH FRACTIONAL CO2 LASER 

David Ozog 1 , Marsha Chaffins 1 , Ronald Moy 1 , Elizabeth Farhat 1 , Henry Ford 

Hospital, Detroit, MI, University of California, Los Angeles, CA 

1 

Study funded by Lumenis 


2:15 pm – 2:20 pm 





55 SUCCESSFUL TREATMENT OF POST BURN SCARS WITH FRACTIONAL CO2 

LASER IN INDIAN SKIN 

Ashok Naik, Sahil Dhavan, Shilpa Shah, Niteen Dhepe, Pune, India 

�Recipient of U.S. Air Force Office of Scientific Research travel grant. 

�Best Student/Resident Cutaneous Laser Surgery Award Recipient.






Grapevine, TX 

2:21 pm – 2:26 pm GENE EXPRESSION ANALYSIS OF IN VIVO WOUND HEALING POST NON 

INVASIVE MONOPOLAR RADIOFREQUENCY TREATMENT: EVIDENCE OF 

NEOCOLLAGENESIS 

Erica Lee Elford, Rachana Soni, Kerrie Jiang, Sherry Alandt, Steven K. 

Struck, Vikramaditya P. Bedi, Christopher B. Zachary, Solta Medical Inc., 

Hayward, CA, Struck Plastic Surgery, Atherton, CA, University of California, 

Irvine, CA 

2:27 pm – 2:32 pm 57 TREATMENT OF SCARS USING LASER AND LASER ASSISTED 

CORTICOSTEROID DELIVERY 

Jill Waibel, Stephen Davis, Emmy Graber, Nathan Uebelhoer, Miami 

Dermatology and Laser Institute, University of Miami Miller School of 

Medicine Miami, FL, Boston University School of Medicine and Boston Medical 

Center, Boston, MA, Naval Medical Center, San Diego, CA 

2:33 pm – 2:44 pm Q&A 


RADIOFREQUENCY, NON-ABLATIVE FRACTIONAL, AND BODY CONTOURING 


This session focuses on the use of radiofrequency and non-ablative fractional lasers for the treatment of a 

variety of conditions. Additionally, each of the topics of laser-assisted liposuction, techniques for non-invasive 

fat removal, assessment of techniques to evaluate treatment outcomes, and potential complications will be 

addressed. Participants will develop an understanding of the present treatment indications, therapeutic 

techniques, and new and innovative technologies. 

Participants 

This session will benefit physicians and health care personnel who treat cutaneous disorders in the disciplines 

of dermatology, plastic surgery, and facial plastic surgery. It will also benefit those engineers and medical 

device personnel who actively work to develop devices for the treatment of cutaneous disorders. 





Attendees will gain knowledge of cutting edge laser treatments and their clinical applications in the 

treatment of cutaneous conditions. 

Hot Topics 

� Radiofrequency laser treatments for a variety of conditions 

� Side effects and risks from cryolipolysis 

3:45 pm – 3:50 pm 





58 FRACTIONAL ABLATIVE RADIOFREQUENCY TREATMENT FOR SKIN TYPES V- 

VI: RISK-BENEFIT ANALYSIS 

Jennifer Chwalek, Mussarrat Hussain, David Goldberg, Skin Laser & Surgery 

Specialists of NY and NJ, New York, NY 

39

3:51 pm – 3:56 pm 


3:57 pm – 4:02 pm 


4:03 pm – 4:08 pm 


40 





Grapevine, TX 

59 THE EFFECTS OF FRACTIONAL RADIOFREQUENCY MICRONEEDLE ON 

PERIORBITAL WRINKLES OF KOREAN PATIENTS 

Won-Serk Kim 1 , Ga-young Lee 1 , Kangbuk Samsung Hospital, Sungkyunkwan 

University School of Medicine, Seoul, Korea 

1 

Equipment from Jeisys 


60 BIPOLAR PARALLEL RADIOFREQUENCY FOR REDUCTION DEPTH OF 

WRINKLES: A PROSPECTIVE STUDY VISUALIZED BY COLORED 3D IMAGING 

SYSTEM 

Katharina Russe-Wilflingseder 1 , Elisabeth Russe 1 , Plastische Chirurgie und 

Laserzentrum, Innsbruck, Austria 

1 

Equipment from Asclepion Laser Technologies 


61 A NOVEL ENERGY ASSISTED LIPOLYSIS APPROACH USING COMBINED RF AND 

LASER TECHNOLOGY 

Jason Pozner 1 , Haim Epstein 2 , Boris Vaynberg 2 , Ruthie Amir 2 , Cleveland 

Clinic, Weston, FL, Syneron, Yokneam Illit, Israel 

1 

Equipment and research grant from Syneron 

2 

Salary from Syneron 


4:09 pm – 4:14 pm 62 FRACTIONAL BIPOLAR RADIOFREQUENCY DELIVERED THROUGH A VACUUM- 

ASSISTED, MICRONEEDLE ARRAY FOR THE TREATMENT OF ACNE SCARRING: 

A PILOT STUDY 

Girish Munavalli 1 , Robert Anderson 2 , Dermatology Laser and Vein Specialists, 

Charlotte, NC, Theravant Corporation, Pleasanton, CA 

1 

Equipment and equity position with Theravant 

2 

Salary, equity position, intellectual property rights with Theravant 


4:15 pm – 4:20 pm TREATMENT OF BURN SCAR DEFORMITIES IN FITZPATRICK SKIN TYPES IV-V 

WITH NON-ABLATIVE FRACTIONAL PHOTOTHERMOLYSIS: A REPORT OF 7 

CASES 

Sean Boutros, Houston Plastic & Craniofacial Surgery, Houston, TX 

4:21 pm – 4:36 pm Q&A 

4:37 pm – 4:42 pm 





64 1550nm and 1927 FRACTIONAL LASER RESURFACING FOR THE TREATMENT 

OF ACTINIC KERATOSIS AND PHOTODAMAGE: A COMPARATIVE STUDY 

Paul M. Friedman, Jennifer M. Landau, Megan N. Moody, Denise Marquez, 

Jennifer Peterson, Leonard H. Goldberg 1 , Irene J. Vergilis-Kalner, 

DermSurgery Associates, Houston, TX, Goldman Butterwick & Associates, 

Cosmetic Laser Dermatology, San Diego, CA 

1 

Research grant from Solta





Grapevine, TX 

4:43 pm – 4:48 pm 65 LONG-TERM FOLLOW-UP OF 1927nm FRACTIONAL RESURFACING FOR 

ACTINIC KERATOSES ON THE FACE 

Elliot Weiss, Robert Anolik, Lori Brightman, Anne Chapas, Elizabeth Hale, 

Julie Karen, Leonard Bernstein, Roy Geronemus 1 , Laser & Skin Surgery 

Center of New York, New York, NY 

1 

Stockholder with Solta 

4:49 pm – 4:54 pm 


4:55 pm – 5:03 pm Q&A 

5:04 pm – 5:09 pm 


66 NON-ABLATIVE FRACTIONAL RESURFACING WITH THE 1927nm THULIUM 

LASER IS AN EFFECTIVE, WELL-TOLERATED TREATMENT FOR ACTINIC 

CHEILITIS 

Robert Anolik, Elliot T. Weiss, Abdul K. El Tal, Anne Chapas, Lori Brightman, 

Elizabeth K. Hale, Julie K. Karen, Leonard Bernstein, Leonard H. Goldberg, 

Paul M. Friedman, Roy G. Geronemus 1 , Laser and Skin Surgery Center of New 

York, New York, NY, MD Anderson Cancer Center, DermSurgery Associates, 

Houston, TX 

1 

Equity position with Solta 

67 MULTIPLE TREATMENT, NON-INVASIVE CRYOLIPOLYSIS FOR BODY 

CONTOURING IN CHINESE PATIENTS 

Samantha Y. Shek, Nicola P.Y. Chan, C.K. Yeung, Henry H.L. Chan, The 

University of Hong Kong, Hong Kong, China 

5:10 pm – 5:15 pm 68 TREATMENT OF THE DERMIS AND HYPODERMIS JUNCTION WITH WATER 

AND FAT SELECTIVE LASER WAVELENGTHS USING OPTICAL COMPRESSION 

PINS 

Brian Zelickson 1 , Susan Walgrave, Irmina Wallander, James Childs 2 , David 

Tabatadze 2 , Mikhail Smirnov 2 , Gregory Altshuler 2 , Zel Skin and Laser 

Specialists, Edina, MN, Marshfield Clinic, Marshfield, WI, Palomar Medical 

Technologies, Inc., Burlington, MA 

1 


2 



5:16 pm – 5:21 pm 


5:22 pm – 5:27 pm 





69 SIDE EFFECTS AND RISKS ASSOCIATED WITH CRYOLIPOLYSIS 

Jeffrey Dover 1 , Nazanin Saedi, Michael Kaminer 1 , Christopher Zachary 2 , 

SkinCare Physicians, Chestnut Hill, MA, University of California, Irvine, CA 

1 

Travel expenses, research grant, honoraria, serves on scientific advisory board for Zeltiq 

2 

Travel expenses and honoraria from Zeltiq 

70 COMPARISON OF LASER-ASSISTED LIPOLYSIS AND LIPOSUCTION: 

HISTOLOGY AND SPLIT-BODY CLINICAL RESULTS 

Robert Weiss 1 , Jeffrey Angobaldo 2 , Sean Doherty 3 , Brooke Seckel 1 , Maryland 

Laser, Skin and Vein Institute, Baltimore, MD, Renaissance Plastic Surgery, 

Plano, TX, Boston Plastic Surgery Associates, Concord, MA 

1 


2 


3 


41

42 





Grapevine, TX 

5:28 pm – 5:33 pm 71 A 24-WEEK CONTROLLED TRIAL TO ASSESS THE EFFECTS OF AN INTENSE 

ULTRASOUND TREATMENT ON LOWER FACE SKIN LAXITY USING A NOVEL 3- 

D SELF-POSITIONING LASER SCANNER 

Daniel Barolet 1 , Mathieu Auclair 2 , Francois Barolet 2 , Virginie C. Barolet 2 , 

Isabelle Lussier 3 , McGill University, RoseLab Skin Optics Research Laboratory, 

Montreal, Canada 

1 Equipment from Northern Optotronics and Ulthera 

2 Salary from RoseLab Skin Optics Research Laboratory 

3 Consulting fees from RoseLab Skin Optics Research Laboratory 


5:34 pm - 5:39 pm 72 A NOVEL METHOD FOR OBJECTIVELY ASSESSING LIPOSUCTION OUTCOMES: 

3-DIMENSIONAL SURFACE IMAGING 

Elliot Weiss, Lori Brightman, Roy Geronemus, Laser & Skin Surgery Center of 

New York, New York, NY 


5:40 pm – 5:45 pm 73 HIGH-INTENSITY FOCUSED ULTRASOUND DEVICE FOR NON-INVASIVE BODY 

CONTOURING: AGREEMENT OF OBJECTIVE AND SUBJECTIVE AESTHETIC 

OUTCOMES 

Jeffrey Dover 1 , Patrick Martin 2 , Ira Lawrence 2 , The Sculpt Group, Skin Care 

Physicians, Chestnut Hill, MA, Medicis Technologies Corporation, Scottsdale, 

AZ 

1 Consulting fees from Iridex, Lumenis, Medicis, Shaser, Solta, Zeltiq; stockholder with CVS/Skin 

Effects and Shaser; research grant from Allergan, Cynosure, Lumenis, Medicis, Merz Pharma, 

OpusMed, Palomar, Shaser, Solta, and Syneron 

2 Salary from Medicis 



5:46 pm – 5:51 pm EFFICACY OF A NOVEL BI-DIRECTIONAL SIDELIGHT OPTICAL FIBER AND 

1440nm Nd:YAG LASER IN THE TREATMENT OF CELLULITE AS MEASURED 

BY 3-DIMENSIONAL SURFACE IMAGING 

Bruce Katz, Juva Skin & Laser Center, New York, NY 

5:52 pm – 6:10 pm Q&A 



Friday, April 1, 2011





Grapevine, TX 

Photobiomodulation – Texas 4-6 1:00 pm – 6:15 pm 

Directors: Juanita J. Anders, Ph.D., Michael Hamblin, M.D. 

Disclosures 

Juanita J. Anders received equipment from Irradia Laser Therapy Systems, Lite Cure, LLC and PhotoThera 

Michael Hamblin – No disclosure 


The purpose of this session is to present and discuss the latest findings in pre-clinical (in vitro and in vivo 

experiments) and clinical investigations on the critical parameters, mechanism, and effectiveness of light as a 

therapy for a broad range of clinical applications. Light and its photonic effects and photo-medicine in 

general have gained recognition as an area of innovative and novel research with significant clinical 

implications. 

Participants 

Any scientist, engineer, medical practitioner, individual in industry, as well as other health care professionals 

involved in biomedical applications of lasers are invited to participate in these sessions. 


Participants should have an understanding of light interaction with biological tissues and basic and clinical 

research. 


This session will provide the latest data on basic science and clinical application of low intensity light in a 

wide spectrum of applications. The participants will increase their knowledge in this area and hopefully be 

stimulated to formulate new ideas to identify the mechanisms involved and the critical parameters needed 

for successful clinical application of light. 

"Hot Topics" 

• New techniques for delivering laser energy deeper into tissues 

• New clinical applications for photobiomodulation including: 

• Treatment of depression 

• Treatment of severe tracheal stenosis 

• Light therapy as a promising treatment for traumatic brain injury, spinal cord injury and peripheral 

nerve injury 

• Photoactivated antimicrobial collagen for wound care 

• Transcutaneous light treatment for reduction of subcutaneous fat 

1:00 pm – 1:34 pm 

1:35 pm – 1:44 pm 

1:45 pm – 1:54 pm 

1:55 pm – 1:59 pm 


Session 


PHOTOBIOMODULATION: BASIC SCIENCE AND PRE-CLINICAL STUDIES 


THE EFFECT OF LOW LEVEL LASER THERAPY ON OTOTOXICITY AND NOISE 

INDUCED HEARING LOSS 

Chung-Ku Rhee, Dankook University, College of Medicine, Medical Laser 

Research Center, Cheonan, Korea 

Discussion 

145 NEW TECHNIQUE FOR DELIVERING LASER ENERGY DEEPER INTO TISSUE 

Sean Wang, Qun Li, Kerith Wang, B&W TEK, Inc., Newark, DE 


Discussion 

43

2:00 pm – 2:09 pm 

2:10 pm – 2:14 pm 

2:15 pm – 2:24 pm 


2:25 pm – 2:29 pm 

2:30 pm – 2:39 pm 


2:40 pm – 2:44 pm 

44 





Grapevine, TX 

EFFECTIVE POWER AND ENERGY DENSITIES DIFFER WITH WAVELENGTH IN 

VIVO AND IN VITRO 

Juanita J. Anders, Uniformed Services University of the Health Sciences, 

Bethesda, MD 

Discussion 

147 EFFECTS OF VEGF MIMICKING PEPTIDES AND PHOTORADIATION ON WOUND 

HEALING IN A MURINE PRESSURE ULCER MODEL 

Istvan Stadler 1 , Raymond Lanzafame 2 , Rochester General Hospital, 

Rochester, NY 

1 

Equipment from Quantum Devices 

2 

Equipment from Quantum Devices; consulting fees from Duetchebank, GLG Councils and 

Leerink Swan; editor-in-chief of Photomedicine and Laser Surgery; editorial board of General 

Surgery News, Journal of Laparoendoscopic Surgery, Journal of the Society of Laparoscopic 

Surgeons, and Lasers in Medical Sciences 


Discussion 

148 PHOTOACTIVATED ANTIMICROBIAL COLLAGEN REDUCES BIOBURDEN IN A 

MURINE PRESSURE ULCER MODEL 

Raymond Lanzafame 1 , Istvan Stadler 2 , Ryan Cunningham 3 , Robert Soltz 4 , 

Barbara Soltz 3 , Rochester General Hospital, Rochester, NY, Conversion 

Energy Enterprises, Spring Valley, NY 

1 

Equipment and intellectual property rights with Conversion Energy Enterprises; research grant 

from NIH NIGM Grant #1R43GM087753-01; editor-in-chief of Photomedicine and Laser Surgery; 

editorial board of General Surgery News, Journal of Laparoendoscopic Surgery, Journal of the 

Society of Laparoscopic Surgeons, and Lasers in Medical Sciences 

2 

Equipment from Conversion Energy Enterprises; research grant from NIH NIGM Grant 

#1R43GM087753-01 

3 

Equipment from Conversion Energy Enterprises 

4 

Equipment, stockholder, equity position, intellectual property rights with Conversion Energy 

Enterprises; research grant from NIH NIGM Grant #1R43GM087753-01 


Discussion 


3:45 pm – 4:19 pm 


4:20 pm – 4:29 pm 


Session 


149 IN VITRO AND IN VIVO STUDIES OF LLLT FOR TRAUMATIC BRAIN INJURY 

Michael Hamblin 1 , Weijun Xuan 1 , Qiuhe Wu 1 , Ying-Ying Huang 1 , Sulbha K. 

Sharma 1 , Gitika B. Kharkwal 1 , Wellman Center for Photomedicine, 

Massachusetts General Hospital, Harvard Medical School, Boston, MA, MIT 

Division of Health Sciences and Technology, Cambridge, MA 

1 

Equipment and research grant from PhotoThera 


Discussion

4:30 pm – 4:39 pm 


4:40 pm – 4:44 pm 

4:45 pm – 4:54 pm 

4:55 pm – 4:59 pm 

5:00 pm – 5:09 pm 


5:10 pm – 5:14 pm 

5:15 pm – 5:24 pm 

5:25 pm - 5:29 pm 


Session 






Grapevine, TX 

150 PULSE LIGHT IRRADIATION IMPROVES BEHAVIORAL OUTCOME IN A RAT 

MODEL OF CHRONIC MILD STRESS 

Xingjia Wu�, Stephanie Alberico, Helina Moges, Ruchir Sehra, Luis 

DeTaboada, Juanita Anders 1 , Uniformed Services University of the Health 

Sciences, Bethesda, MD, PhotoThera, Inc., Carlsbad, CA 

1 

Equipment from Photothera 


Discussion 

151 980nm LASER IRRADIATION IMPROVED FUNCTIONAL RECOVERY AFTER 

PERONEAL NERVE INJURY IN RABBITS 

Helina Moges, Xingjia Wu, Brian Pryor, Jason Smith, Juanita Anders 1 , 

Uniformed Services University of the Health Sciences, Bethesda, MD, 

LiteCure, Newark, NJ 

1 

Equipment from LiteCure 


Discussion 

152 COMBINED OCT AND MULTI-PHOTON LUMINESCENCE MICROSCOPY FOR 

MACROPHAGE DETECTION IN ATHEROSCLEROTIC PLAQUES USING 

PLASMONIC GOLD NANOROSE 

Tianyi Wang��, S.M. Shams Kazmi, Jordan Dwelle, Veronika Sapozhnikova, 

Jake Mancuso, Brian Willsey, Keith Johnston, Marc Feldman, Andrew Dunn, 

Thomas Milner, University of Texas at Austin, Austin, TX, University of Texas 

Health Science Center at San Antonio, San Antonio, TX 


Discussion 


�Best Overall Basic Science Award Recipient. 

�Best Student/Resident Photobiomodulation Award Recipient. 


810nm LOW LEVEL LASER THERAPY PENETRATION: THE EFFECTS OF 

DIFFERENT BEAM PROFILES IN REACHING DEEP ANATOMICAL TARGETS 

James Carroll 1 , THOR Photomedicine, Chesham, Bucks, United Kingdom 

1 

Equipment, travel expenses, salary, stockholder, equity position and intellectual property 

rights with THOR Photomedicine 


Discussion 

45

5:30 pm – 5:39 pm 

5:40 pm - 5:44 pm 

5:45 pm – 5:54 pm 


5:55 pm – 5:59 pm 

6:00 pm – 6:09 pm 


6:10 pm – 6:15 pm 

46 


Session 







Grapevine, TX 

PRELIMINARY ASSESSMENT OF MULTIPLE PHOTOACTIVATED 

ANTIMICROBIAL COLLAGEN TREATMENTS ON BIOBURDEN IN INFECTED 

MURINE PRESSURE ULCERS 

Istvan Stadler 1 , Raymond Lanzafame 2 , Aaron Muhlbauer, Jacob Griggs, 

Robert Soltz 3 , Barbara Soltz 3 , Rochester General Hospital, Rochester, NY, 

Conversion Energy Enterprises, Spring Valley, NY 

1 

Equipment from Conversion Energy Enterprises, Carestream Health, PathoLase; research grant 

from NIH NIGM Grant #1R43GM087753-01 

2 

Equipment from Conversion Energy Enterprises, Carestream Health, PathoLase; research grant 

from NIH NIGM Grant #1R43GM087753-01; intellectual property rights with conversion Energy 

3 

Equipment, stockholder, equity position, and intellectual property rights with Conversion 

Energy Enterprises; research grant NIH NIGM Grant #1R43GM087753-01 


Discussion 

155 THE EFFECTS OF RED LIGHT ON HIGH GLUCOSE INDUCED DYSFUNCTIONAL 

MYOBLASTS AND THEIR MECHANISM 

Fang-Hui Li, En-Xiu Wei, Yan-Ying Liu, Timon Cheng-Yi Liu, Laboratory of 

Laser Sports Medicine, South China Normal University, Guangzhou, China 


Discussion 

156 SIRTUIN1-MEDIATED PHOTOPROMOTION ON TNF-ALPHA INHIBITED 

EXPRESSION OF CIRCADIAN CLOCK GENES IN CULTURED NIH3T3 

FIBROBLASTS 

De-Feng Wu, Ling Zhu, Timon Cheng-Yi Liu, Laboratory of Laser Sports 

Medicine, South China Normal University, Guangzhou, China 


Discussion





Grapevine, TX 

Photodynamic Therapy – Texas D 1:00 pm – 6:00 pm 

Director: Ron R. Allison, M.D. 

Invited Speakers: Keith A. Cengal, M.D., Ph.D., Rosa Cuenca, M.D., Gordon H. Downie, M.D., Ph.D., M. Sam 

Eljamel, M.D., Colin Hopper, B.D.S., M.B.B.S., M.D., F.D.S., F.R.C.S., Thomas S. Mang, Ph.D., Herbert C. 

Wolfsen, M.D. 


The PDT mini-symposium will include competitively chosen abstracts and invited expert lectures. Topics 

include: oncologic photodynamic therapy for skin, neurologic, head and neck, pulmonary, GI and GU cancers 

as well as non-oncologic therapy for cutaneous and non-cutaneous lesions and infections. The future 

indications and innovations in PDT will also be discussed. 

Participants 

This session is designed for scientists, dermatologists, surgeons, pulmonologists, gastroenterologists, and 

urologists interested in photodynamic therapy. 


Although it is not a prerequisite, attendees would ideally have some basic understanding of laser tissue 

interactions. Individual attendees do not need to have significant experience or expertise in laser medicine or 

surgery. 


At the conclusion of the session, attendees will have an overview of the current status and future endeavors 

in oncologic and non-oncologic photodynamic therapy. 

Hot Topics 

• Nanoparticles in PDT 

• PDT of infections 

• Improved PDT for skin cancers 

• The use of PDT in lung cancers 

• The use of PDT in GI cancers 

• The use of PDT in GU cancers 

• The future of PDT 

• Photodynamic therapy uses light to treat cancer and non-cancerous lesions and infections. Technological 

innovation has allowed PDT to achieve lesion ablation with excellent cosmetic and functional outcome. 

This session will highlight these achievements. 

1:00 pm – 1:09 pm 


Photodynamic 



MINI SYMPOSIA: NEURO AND HEAD AND NECK PRESENTATIONS AND ABSTRACTS 

M. Sam Eljamel, Colin Hopper 

168 IN VITRO STUDY OF THE PHOTODYNAMIC THERAPY OF NANO- 

PHOTOSENSITIZER ON HUMAN ORAL TONGUE CANCER CAL-27 CELLS 

Pingping Li, Guolin Li, Yan Pang, Lingyue Sheb, Qing Xu, Jizhong Gu, Guoyu 

Zhou, Xinyuan Zhu, Michael Hamblin, Ninth People’s Hospital, Shanghai Jiao 

Tong University School of Medicine, Shanghai Research Institute of 

Stomatology, Shanghai Key Laboratory of Stomatology, College of Chemistry 

and Chemical Technology, Shanghai, China, First Affiliated Hospital of 

Haerbin Medical University, Haerbin, China, Wellman Center for 

Photomedicine, Massachusetts General Hospital, Boston, MA 


47

48 





Grapevine, TX 

1:10 pm – 1:19 pm 169 PDT DISINFECTION OF ORAL BIOFILM 

Thomas Mang, Lynn Mikulshi, Dharam Tayal, Robert Baier, SUNY at Buffalo 

School of Dental Medicine, Buffalo, NY 


1:20 pm – 1:29 pm 


170 MECHANISMS OF ANTIMICROBIAL PHOTODYNAMIC THERAPY: AN IN VITRO 

STUDY ON GRAM NEGATIVE AND GRAM POSITIVE BACTERIA 

Liyi Huang��, Michael Hamblin, Wellman Center for Photomedicine, 

Massachusetts General Hospital, Boston, MA 


1:30 pm – 1:39 pm 171 MECHANISM OF PROPIONIBACTERIUM ACNE DESTRUCTION BY INITIATION 

OF REACTIVE OXYGEN SPECIES BY 414nm ABSORPTION 

Caerwyn Ash 1 , Llinos Harris 2 , Thierry Maffeis, Marc Clement 3 , Gareth 

Stockman, Michael Kiernan 3 , Godfrey Town 3 , Swansea University, University 

of Wales, Global Academy, Swansea, United Kingdom 

1 

Equipment and salary from CyDen; travel expenses from Swansea University 

2 

Equipment from CyDen 

3 

Consulting fees from CyDen 


1:40 pm – 1:44 pm Co-Chair Critique of Abstracts 

MINI SYMPOSIA: PULMONARY PRESENTATIONS AND ABSTRACTS 

Gordon H. Downie 

1:45 pm – 2:04 pm PDT AS PART OF MULTIDISCIPLINARY THORACIC ONCOLOCY 

Gordon H. Downie, Northeast Texas Interventional Medicine, Mt. Pleasant, 

TX 

2:05 pm – 2:29 pm PDT FOR THE TREATMENT OF PERIPHERAL LUNG CANCERS 

Gordon H. Downie, Northeast Texas Interventional Medicine, Mt. Pleasant, 

TX 

2:30 pm – 2:44 pm Q&A 

Photodynamic 



2:45 pm – 3:44 pm Break - Visit the Exhibits and ePosters 

MINI SYMPOSIA: GI/GU PRESENTATIONS AND ABSTRACTS 

Herbert C. Wolfsen, Keith A. Cengal 

3:45 pm – 4:04 pm PDT IN GASTROENTEROLOGY: A LOST DECADE 

Herbert C. Wolfsen, Mayo Clinic, Jacksonville, FL 

4:05 pm – 4:29 pm MOLECULARLY TARGETED APPROACHES TO PDT 

Keith A. Cengal, University of Pennsylvania, Philadelphia, PA 


�Best Student/Resident Photodynamic Therapy Award Recipient.

MINI SYMPOSIA: TECHNOLOGY AND TREATMENT 

Thomas S. Mang, Rosa Cuenca 





Grapevine, TX 

4:30 pm – 4:39 pm 176 TEMPERATURE MODULATED PHOTODYNAMIC THERAPY FOR THE 

TREATMENT OF ACTINIC KERATOSES ON THE EXTREMITIES 

Andrea Willey 1 , Fernanda Sakamoto, Solano Dermatology, Laser & Skin 

Surgery Center, UC Davis, Sacramento, CA, Wellman Center for 

Photomedicine, Boston, MA 

1 

Equipment and research grant from DUSA Pharmaceuticals 


4:40 pm – 4:49 pm 177 FRACTIONAL CO2 LASER IMPROVES TREATMENT OF NBCC WITH ALA-PDT 

Roman Smucler, Jan Lippert, Marek Vlk, Charles University, Prague, Czech 

Republic 


4:50 pm – 4:59 pm 178 NEW TOPICAL PHOTODYNAMIC THERAPY FOR MANAGEMENT OF PRIMARY 

AXILLARY HYPERHIDROSIS 

Manal Salah, Abeer Attia�, Maha Fadel, Shahira Almenshawy, National 

Institute of Enhanced Laser Sciences, Cairo, Egypt 


5:00 pm – 5:09 pm 


179 INVESTIGATION OF THE EFFECTIVENESS OF NON-COHERENT BLUE LIGHT IN 

INTRALESIONAL PHOTODYNAMIC THERAPY OF BASAL CELL CARCINOMA 

Robert Anolik�, Elliot T. Weiss, Anne Chapas, Leonard Bernstein, Lori 

Brightman, Elizabeth K. Hale, Julie K. Karen, Roy Geronemus 1 , Laser and 

Skin Surgery Center of New York, New York, NY 

1 



5:10 pm – 5:14 pm Co-Chair Critique of Abstracts 

5:15 pm – 5:29 pm Q&A 

Photodynamic 



5:30 pm – 6:00 pm FUTURE OF PDT AND PROGRAM SUMMARY 

Ron R. Allison 

Disclosures 

Ron R. Allison – No disclosure 

Keith A. Cengel – No disclosure 

Rosa Cuenca - No disclosure 

Gordan H. Downie - No disclosure 

M. Sam Eljamel – No disclosure 

Colin Hopper – No disclosure 

Thomas S. Mang - No disclosure 

Herbert C. Wolfsen – No disclosure 

�Recipient of Richard E. Fitzpatrick Clinical Research and Innovations Award. 


49

50 

Surgical/ILT 

Session 






Grapevine, TX 

Surgical Applications and Interstitial Laser Therapy – Texas 2-3 1:00 pm – 6:00 pm 

Directors: Raymond J. Lanzafame, M.D., M.B.A., Roger J. McNichols, Ph.D., Karl-G. Tranberg, M.D., Ph.D., 

Carson Wong, M.D., F.R.C.S.C., F.A.C.S. 

Disclosures 

Raymond J. Lanzafame received consulting fees from Deutsche Bank, Gerson Lehman, GLG Councils, ATRMUS, and medical device start 

ups on a contract/fee for service basis. Also note that I am an SGE appointee to FDA CDRH ODE General and Plastic Surgery Devices and 

other medical advisory panels 

Roger McNichols received travel expenses from Bio Tex, Inc.; salary, stockholder, equity position, and intellectual property rights with 

Bio Tex, Inc. and Visualase, Inc. 

Karl-G.Tranberg received travel expenses, consulting fees, stockholder, equity position, and intellectual property rights with Clinical 

Laserthermia Systems AB 

Carson Wong received consulting fees from American Medical Systems, Inc. 


This session will present and discuss topical surgical applications in a variety of disciplines including general 

surgery, ophthalmology, plastic surgery, urology, vascular surgery and surgical research. These combined 

disciplines will report relevant clinical and laboratory investigations in a diverse cross section of biomedicine. 

It is expected that interdisciplinary interaction and dialogue regarding laser tissue interaction, clinical and 

basic research results will provide new insights and meet the educational need of participants attending these 

sessions. 

Participants 

Any scientist, student, engineer, medical practitioner, and personnel involved in other aspects of health care, 

and/or industries, as well as all with an interest in these topical areas are invited to attend. 


Individuals who participate in the sessions should have a basic interest in laser medicine and surgery and the 

potential applications of these technologies. Although it is not a prerequisite, attendees would ideally have 

some basic understanding of laser tissue interactions. Individual attendees do not need to have significant 

experience or expertise in laser medicine or surgery. 


These sessions will provide cutting-edge information on surgical applications and interstitial laser therapy. 

Participants will sample a menu of scientific presentations and have the opportunity to discuss findings with 

presenters, colleagues, and peers. Participants are expected to increase their knowledge regarding basic 

science and clinical applications. Various ablation or tissue destruction methods including lasers and ILT will 

be presented, with reference to clinical practice and current applications. After engaging in this educational 

activity participants will be able to describe current clinical techniques for focal/local tumor control or lesion 

production and other applications. It is hoped that dialogue and didactic material will enable the participants 

to formulate new ideas and apply new techniques and principles to solve clinical and basic science problems 

relevant to their scope of practice. 

"Hot Topics" 

• Use of gold-based nanoparticles to direct laser interstitial photothermal cancer therapy 

• MR-guided laser ablation of liver and kidney tumors 

• Laser interstitial thermotherapy and focal laser ablation for prostate cancer 

• Treatment planning optimization of photodynamic therapy of prostate cancer 

• Greenlight laser photoselective vaporization prostatectomy for symptomatic benign prostatic hyperplasia 

• Photochemical tissue bonding: A potential strategy for treating limbal stem cell deficiency 

• Surface temperature distributions in rabbit auricular cartilage following laser cartilage reshaping with 

carbon dioxide spray cooling 

• Laser assisted facial rhytidectomy and facial rejuvenation 

• Treatment of cellulite using a 1440nm pulsed laser 

• High definition body contouring using laser assisted liposculpture

1:00 pm - 1:09 pm 

1:10 pm – 1:14 pm 

1:15 pm - 1:24 pm 

1:25 pm – 1:29 pm 

1:30 pm - 1:39 pm 


1:40 pm – 1:44 pm 

1:45 pm – 1:54 pm 


1:55 pm – 1:59 pm 

2:00 pm - 2:09 pm 


2:10 pm – 2:14 pm 

Surgical/ILT 

Session 


GENERAL APPLICATIONS OF ILT 





Grapevine, TX 

181 USE OF GOLD-BASED NANOPARTICLES TO DIRECT LASER INTERSTITIAL 

PHOTOTHERMAL CANCER THERAPY 

Jon Schwartz 1 , Glenn Goodrich 2 , Kelly Gill-Sharp 2 , J. Donald Payne 3 , 

Nanospectra Biosciences, Inc., Houston, TX 

1 

Equipment, travel expenses, salary, stockholder, and intellectual property rights with 

Nanospectra 

2 

Equipment, salary, stockholder, and intellectual property rights with Nanospectra 

3 

Equipment, stockholder, equity position and intellectual property rights with Nanospectra 


Discussion 

182 MR-GUIDED LASER ABLATION OF LIVER AND KIDNEY TUMORS 

Ashok Gowda 1 , Eric Walser, Visualase, Inc., Houston, TX, Mayo Clinic, 

Jacksonville, FL 

1 

Travel expenses, salary, stockholder, and equity position with Visualase 

Discussion 

PROSTATE APPLICATIONS OF ILT 


183 LASER INTERSTITIAL THERMOTHERAPY FOR PROSTATE CANCER: ANIMAL 

MODEL AND NUMERICAL SIMULATION OF TEMPERATURE AND DAMAGE 

DISTRIBUTION 

Mohamad-Feras Marqa�, Pierre Colin, Pierre Nevoux, Serge Mordon, Nacim 

Betrouni, CHRU Lille and Inserm, U703, Université Lille Nord de France, 

Lille, France 


Discussion 

184 A PHANTOM FOR INTERSTITIAL LASER THERMOTHERAPY OF PROSTATE 

CANCER TRAINING 

Pierre Nevoux, Pierre Colin, Serge Mordon, Bertrand Leroux, Nasr Makni, 

Mohamad Feras Marqa, Philippe Puech, Arnauld Villers, Nacim Betrouni, 

CHRU Lille and Inserm, U703, Université Lille Nord de France, Lille, France 


Discussion 

185 MINIMALLY INVASIVE FOCAL LASER ABLATION FOR PROSTATE TUMORS 

Anil Shetty 1 , Ashok Gowda 2 , Roger McNichols 2 , Visualase, Inc., Houston, TX 

1 

Travel expenses and salary from Visualase 

2 

Travel expenses, salary, stockholder, equity position, and intellectual property rights with 

Visualase 

Discussion 

2:15 pm - 2:24 pm 186 COMPARISON OF TISSUE EFFECTS AFTER PAL, WAL, SAL, UAL AND LAL 

Afschin Fatemi, S-thetic Clinic, Duesseldorf, Germany 


2:25 pm – 2:29 pm 

Discussion 


51

2:30 pm - 2:39 pm 


2:40 pm – 2:44 pm 

52 





Grapevine, TX 

187 TREATMENT PLANNING OPTIMIZATION OF PHOTODYNAMIC THERAPY OF 

PROSTATE CANCER USING WST11-TOOKAD SOLUBLE 

Nacim Betrouni, Renaud Lopes, Marqa Mohamad-Feras, Pierre Colin, Pierre 

Nevoux, Serge Mordon, CHRU Lille and Inserm, U703, Université Lille Nord de 

France, Lille, France 


Discussion 


3:45 pm – 3:54 pm 

3:55 pm – 3:59 pm 

4:00 pm - 4:09 pm 

4:10 pm – 4:14 pm 

4:15 pm – 4:24 pm 


4:25 pm - 4:29 pm 

4:30 pm – 4:39 pm 


4:40 pm - 4:44 pm 

Surgical/ILT 

Session 


UROLOGIC SURGERY 

188 THE 180W GREENLIGHT XPS - LASER PHOTOSELECTIVE VAPORIZATION 

PROSTATECTOMY FOR SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA: 

PRELIMINARY RESULTS 

Kurt Strom, Xiao Gu, Massimiliano Spaliviero, Carson Wong 1 , The University 

of Oklahoma Health Sciences Center, Oklahoma City, OK 

1 

Consulting fees from American Medical Systems 

Discussion 

189 INCIDENCE OF URETHERAL STRICTURES FOLLOWING LASER ABLATION OF 

TCC 

Kelly Healy�, Arturo Colon-Herdman, Nicholas Leone, Scott Hubosky, 

Demetrius Bagley, Thomas Jefferson, Philadelphia, PA 

Discussion 

OPHTHALMOLOGIC SURGERY 

2008/2009 RESEARCH GRANT RECIPIENT 

190 PHOTOCHEMICAL TISSUE BONDING: A POTENTIAL STRATEGY FOR 

TREATING LIMBAL STEM CELL DEFICIENCY 

Chuan Gu�, Robert Redmond, Irene Kochevar, Ying Wang, Min Yao, Wellman 

Center for Photomedicine, Massachusetts General Hospital, Harvard Medical 

School, Boston, MA 


Discussion 

PLASTIC SURGERY 

191 EX VIVO EVALUATION OF LASER AURICULAR CARTILAGE RESHAPING WITH 

CARBON DIOXIDE SPRAY COOLING IN A RABBIT MODEL 

Edward C. Wu 1 �, Victor Sun, Wangcun Jia, Dmitriy E. Protsenko, Cyrus T. 

Manuel, Brian J.F. Wong, J. Stuart Nelson, Beckman Laser Institute and 

Medical Clinic, University of California, Irvine, CA 

1 

Financial grant from ASLMS Student/Research grant 


Discussion 


�Recipient of ASLMS travel grant. 

�Best Student/Resident Surgical Applications/Interstitial Laser Therapy Award Recipient.

4:45 pm – 4:54 pm 

4:55 pm - 4:59 pm 

5:00 pm – 5:09 pm 

5:10 pm - 5:14 pm 

5:15 pm – 5:24 pm 


5:25 pm - 5:29 pm 

5:30 pm – 5:39 pm 


5:40 pm – 5:44 pm 

5:45 pm – 5:54 pm 


5:55 pm - 6:00 pm 

192 





Grapevine, TX 

LASER ASSISTED FACIAL RHYTIDECTOMY AND FACIAL REJUVENATION: A 

REVIEW OF THE FIRST 500 PROCEDURES 

Richard Gentile 1 , Northeastern Ohio College of Medicine, Youngstown, OH 

1 

Equipment, travel expenses, honoraria from Cynosure 

Discussion 

193 TREATMENT OF CELLULITE WITH 1-YEAR FOLLOW-UP USING A 1440nm 

PULSED LASER: PRELIMINARY REPORT 

Barry DiBernardo 1 , University of Medicine and Dentistry of New Jersey, 

Newark, NJ 

1 

Equipment, consulting fees, research grant from Cynosure 


Discussion 

194 

Surgical/ILT 

Session 


HIGH DEFINITION BODY CONTOURING USING LASER ASSISTED 

LIPOSCULPTURE 

Jamal Jomah, Med Art Clinics, Riyadh, Saudi Arabia 


Discussion 

195 A CONCEPT OF BODY CONTOURING BY COMBINING MINIMAL INVASIVE AND 

NON-INVASIVE PROCEDURES: LASER LIPOLYSIS, RADIOFREQUENCY AND 

ACOUSTIC WAVES 

Katharina Russe-Wilflingseder, Manfred Herold, Elisabeth Russe, Plastische 

Chirurgie und Laserzentrum, Innsbruck, Austria 

Discussion 

GENERAL SURGERY 

196 LASER HEMORRHOIDECTOMY: RETROSPECTIVE STUDY OF AN EFFECTIVE 

AND AMBULATORY HEMORRHOIDECTOMY 

Manish Khandelwal, M. Hemadri, E. Ewart, P.J. Moore, Scunthorpe, United 

Kingdom 

Discussion 

53

54 





Grapevine, TX

Clinical 

Application 

Courses 







Grapevine, TX 

No CME credits and CE contact hours for the Student/Post-Doc/Resident Opportunities course are available. 

Student/Post-Doc/Resident Opportunities – Texas 2-3 7:30 am – 9:00 am 

Director: Jennifer K. Barton, Ph.D., Thomas E. Milner, Ph.D. 

Faculty: R. Rox Anderson, M.D., Bernard Choi, Ph.D., E. Duco Jansen, Ph.D. 


Pre-career professionals will learn about examples of successful scientist/physician careers. They will also 

learn about funding opportunities available to them. 

Participants 

The course is designed for all future physicians, residents, and fellows. 


There are no special background requirements. 


The course will include information on career progression, including the importance of publishing, how to find 

training fellowships, and information about research funding. 

7:30 am - 7:34 am Welcome and Introductions - Jennifer K. Barton, Thomas E. Milner 

7:35 am - 7:44 am Publications - How Your Published Work Impacts Your Career Options - Jennifer K. 

Barton 

7:45 am - 7:54 am Pre- and Post-Doctoral Fellowship Opportunities - Thomas E. Milner 

7:55 am - 8:14 am Supporting Your Research – Building Collaborations – R. Rox Anderson 

8:15 am - 8:29 am Supporting Your Research - How to Find Research Funding Opportunities – Bernard Choi 

8:30 am - 8:49 am Supporting Your Research – Tips for Writing Proposals – E. Duco Jansen 

8:50 am - 9:00 am Discussion and Wrap-Up – All Faculty 

Disclosures 

R. Rox Anderson received royalties from Massachusetts General Hospital which owns and licenses patents on laser hair removal, fractional 


Jennifer K. Barton – No disclosure 


E. Duco Jansen received a salary, royalties, research grant, and intellectual property rights from Vanderbilt University; research grant 

from NIH, DOD, HFSP, and Lockheed-Martin 

Thomas E. Milner – No disclosure 

55

56 

Clinical 

Application 

Courses 







Grapevine, TX 


available. 

Technologies for Fat Related Disorders – Longhorn F 7:00 am – 9:00 am 

Directors: Neil S. Sadick, M.D., F.A.A.D., F.A.A.C.S., F.A.C.P., F.A.C.Ph., Brian D. Zelickson, M.D. 

Faculty: Mathew M. Avram, M.D., J.D., Lori Brightman, M.D., A. Jay Burns, M.D., Henry H.L. Chan, M.D., 

Ph.D., F.R.C.P., Barry E. DiBernardo, M.D., Misbah H. Khan, M.D., Dieter Manstein, M.D., Jason N. Pozner, 

M.D. 





The American Society for Laser Medicine and Surgery, Inc. designates this live activity for a maximum of 2 









Conference. 


This course will provide information on new technologies, indications for cellulite, non-invasive lipolysis and 

technology associated liposuction. 

Participants 

This course is designed for medical doctors utilizing these technologies. 


Participants should have an understanding of the treatment of cellulite, fat deposits, and liposuction in 

clinical practice. 


It is expected that participants will understand the appropriate use of these technologies, identify new 

treatment paradigms, understand integration of multiple technologies, and to be able to recognize and 

manage complications. 

7:00 am - 7:05 am Discussion and Pre-Test - Neil S. Sadick, Brian D. Zelickson 

7:06 am - 7:16 am Basic Science Advances in Adipocyte Structure and Function - Misbah H. Khan 

7:17 am - 7:27 am Cellulite Technologies - Controversies in Technology - Why is Cellulite so Difficult to 

Treat? - Mathew M. Avram 

7:28 am - 7:38 am Cellulite Technologies - Proven Effective Techniques - New Generational Approaches 

Lori Brightman 

7:39 am - 7:49 am RF Ultrasound and Laser Assisted Liposuction Approaches - Barry E. DiBernardo 

7:50 am - 8:00 am RF Ultrasound and Laser Assisted Liposuction Approaches - Jason N. Pozner 

8:01 am - 8:11 am Non-Invasive Lipolyctic Technologies - Henry H.L. Chan 

8:12 am - 8:22 am Non-Invasive Lipolyctic Technologies - A. Jay Burns





Grapevine, TX 


available. 

Technologies for Fat Related Disorders Continued – Longhorn F 7:00 am – 9:00 am 

8:23 am - 8:33 am New Technologies on the Horizon - Dieter Manstein 

8:34 am - 8:54 am Q&A - All Faculty 

8:55 am - 9:00 am Conclusion and Post Test - Neil S. Sadick, Brian D. Zelickson 

Disclosures 


Lori Brightman received equipment from and is a clinical investigator for Candela, DUSA, Invasix, Lutronics, Lythera, Palomar, Solta, 

Syneron, and Zeltiq; travel expenses and honoraria from Candela, DUSA, Lutronics, Solta, and Syneron; stockholder with Invasix; 

A. Jay Burns received discount from Cutera, Cynosure, Palomar, Sciton, Zeltiq, and Zimmer; stockholder with SkinMedica and Zeltiq; 

research grant from Solta, Uthera, and Zeltiq; honoraria from Sciton, Solta, Ulthera, and Zeltiq; medical advisory board for Ulthera and 

Zeltiq 

Henry H.L. Chan received financial grant from Lumenis; equipment from Candela, Elemé, Lumenis, Palomar, Solta, Syneron, Zeltiq; 

discount from Candela; stockholder with Lumenis, Solta 

Barry E. DiBernardo received royalties from Elsevier; consulting fees from Canfield, Cutera, Cynosure, Human Med, and Obagi; honoraria 

from Cutera, Cynosure, and Zeltiq; research grant from Ethicon and Obagi; serves on clinical advisory board for Merz; clinical studies for 

Lithera 

Misbah H. Khan – No disclosure 

Dieter Manstein received equipment from Quantel Derma and Solta; consulting fees from Elemé, Quantel Derma and Zeltiq; research 

grant from Candela and Lumenis; stockholder with Zeltiq, royalties from Massachusetts General Hospital due to licensing contracts with 

Candela, Elemé, Palomar, Solta, Zeltiq and Zimmer 

Jason N. Pozner received equipment from DEKA, Elemé, Sciton, Syneron; consulting fees from Sciton, Syneron, and Ulthera; discount 

from Alma and Zeltiq; stockholder with Sciton; research grant from Aesthera, Continuum Biomedical, Sciton, and Syneron; honoraria from 

Sciton, Syneron, Ulthera, and Zeltiq 

Neil S. Sadick received equipment from Osyris, SmoothShapes; research grant from Cynosure and Osyris 


Syneron; research grant from Cutera, Lumenis, Palomar, Solta, Syneron, Ulthera, and Zeltiq; honoraria from Zeltiq; intellectual property 

rights with Candela 

Periorbital Therapies – Texas C 7:00 am – 9:00 am 

Directors: Brian S. Biesman, M.D., F.A.C.S., Howard Conn, M.D. 

Faculty: Jane Olson, M.D. 

Clinical 

Application 

Courses 







The American Society for Laser Medicine and Surgery, Inc. designates this live activity for a maximum of 2 









Conference. 

57

58 

Clinical 

Application 

Courses 







Grapevine, TX 


available. 

Periorbital Therapies Continued – Texas C 7:00 am – 9:00 am 


This course will help attendees understand the role of surgery, injectables, and lasers and other devices in 

periorbital rejuvenation. 

Participants 

This course is designed for anyone with an interest in periorbital rejuvenation. 


This is a moderately advanced course for the individual who already has a working knowledge of the anatomy 

and physiology of the periorbital region and who also has a working knowledge of the concepts of skin 

resurfacing, skin tightening, botulinum toxins, and soft tissue fillers. 


It is expected that participants will learn the following: 

• Anatomy of the periorbital region as pertains to aesthetics 

• Role of botulinum toxins in the periorbital region 

• Role of injectable fillers in the periorbital region 

• Role of ablative skin resurfacing in the periorbital region 

• Role of coagulative and ablative skin resurfacing in the periorbital region 

• Role of surgery in periorbital rejuvenation 

• Pitfalls of treatment and patient assessment in periorbital rejuvenation 

• The role of combination therapy in periorbital rejuvenation 

7:00 am - 7:04 am Discussion and Pre-Test - Brian S. Biesman 

7:05 am - 7:19 am Surgical Anatomy of the Periorbital Region – Jane Olson 

7:20 am - 7:29 am Ablative Resurfacing of the Eyelids - Brian S. Biesman 

7:30 am - 7:44 am Fractional Resurfacing of the Eyelids - Brian S. Biesman 

7:45 am - 7:59 am Fractional Resurfacing of the Eyelids, Ablative - Howard Conn 

8:00 am - 8:09 am Non-Invasive Eyelid Skin Tightening - Brian S. Biesman 

8:10 am - 8:19 am Denervation Agents in the Periorbital Region – Jane Olson 

8:20 am - 8:29 am Periorbital Use of Soft Tissue Fillers - Howard Conn 

8:30 am - 8:39 am Surgical Rejuvenation of the Periorbital Region – Jane Olson 

8:40 am - 8:54 am Combination Therapies, Case Discussions, Emerging Technologies - Q&A – All Faculty 

8:55 am - 9:00 am Conclusion and Post-Test - Brian S. Biesman 

Disclosures 

Brian S. Biesman received consulting fees from Cutera; research grant from Lumenis, Syneron, and TRIA Beauty; honoraria from Allergan, 

Medicis, and Ulthera 

Howard Conn – No disclosure 

Jane Olson is a faculty trainer and speaker for Medicis

Clinical 

Application 

Courses 







Grapevine, TX 


available. 

Photography, Treatment Documentation, and Oversight – Texas D 7:00 am – 9:00 am 

Directors: Murad Alam, M.D., George J. Hruza, M.D., M.B.A. 

Faculty: Eric F. Bernstein, M.D., Ashish Bhatia, M.D., David J. Goldberg, M.D., J.D., Freddy Jones, E. Victor 

Ross, M.D. 












granting credits. Check with the Board of Nursing in your state for clarification. Certificates of Attendance 

will be provided. You will receive a statement of CE contact hours after the Annual Conference. 


There is a need to obtain optimal and reproducible clinical photographs that can be used in patient care and 

for potential liability situations. There is a need for accurate documentation of procedures for patient care and 

liability reasons. There is a need for proper oversight of personnel performing laser procedures for optimal 

patient care. There is a need for using the Internet for ethical and effective communications about one’s 

practice. 

Participants 

This course is designed for practicing physicians with an interest in laser and energy surgery in the ambulatory 

setting as well as physicians entering the field. 


Basic understanding of digital photography in medical practice will help make the course more relevant for the 

participants. 


The course will consist of a series of presentations and panel discussions focusing on the optimal way to take 

digital clinical photographs; to properly integrate them into the practice electronic database; electronic 

marketing of the practice; to correctly and reproducibly document laser and energy procedures performed; to 

know the correct level of supervision of the laser and energy operators in the practice; and to know the 

liability implications of proper documentation and information retrieval. After attending this course, the 

participants will be able to 1) discuss the optimal techniques for taking clinical photographs, 2) market the 

practice through electronic media, 3) more accurately document laser and energy-based procedures, 4) 

understand the correct degree of oversight required when performing laser and energy-based procedures, and 

5) integrate digital photographs into digital databases and digital retrieval systems. 

59

60 

Clinical 

Application 

Courses 







Grapevine, TX 


available. 

Photography, Treatment Documentation, and Oversight Continued – 

Texas D 

7:00 am – 9:00 am 

7:00 am - 7:01 am Discussion - George J. Hruza, Murad Alam 

7:02 am - 7:05 am Pre-Test 

7:06 am - 7:25 am Achieving Optimal and Reproducible Photographs – Freddy Jones 

7:26 am - 7:45 am Effective Integration of Photographs into EMR's - Ashish Bhatia 

7:46 am - 8:05 am Practice Marketing Through Electronic Media (Internet) – Eric F. Bernstein 

8:06 am - 8:25 am Effective Documentation for Patient Care and Liability Protection – E. Victor Ross 

8:26 am - 8:45 am Legal and Liability Implications of Laser Operator Supervision – David J. Goldberg 

8:46 am – 8:55 am Panel Discussion - Q&A 

8:56 am - 9:00 am Post-Test 

Disclosures 

Murad Alam – No disclosure 

Eric F. Bernstein received equipment from Candela, Cynosure, DEKA, Lumenis, and Reliant; consulting fees from TRIA Beauty; discount 

from Zeltiq 

Ashish Bhatia received honoraria from Bioform Medical, Galderma, OrthoDermatologics, and Ranbaxy 


George J. Hruza – No disclosure 

Freddy Jones is a stockholder and holds an equity position with Profect Medical Technologies, LLC 

E. Victor Ross received financial grant and consulting fees from Palomar and Syneron; equipment from Cutera, Lumenis, Palomar, and 

Sciton; research grant from Cutera, Palomar, and Syneron; honoraria from Cutera, Lumenis, Palomar, and Syneron 

How to Use Optical Diagnostics in Clinical Laser Medicine – Texas 1 7:00 am – 9:00 am 

Directors: Brian S. Sorg, Ph.D., James W. Tunnell, Ph.D. 

Faculty: Marc Feldman, M.D., Kishwer S. Nehal, M.D. 






AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their 






granting credits. Check with the Board of Nursing in your state for clarification. Certificates of Attendance 

will be provided. You will receive a statement of CE contact hours after the Annual Conference.

Clinical 

Application 

Courses 







Grapevine, TX 


available. 

How to Use Optical Diagnostics in Clinical Laser Medicine Continued – 

Texas 1 

7:00 am – 9:00 am 


This course is designed to inform clinicians on the following educational needs: 1) confocal microscopy 

mechanisms and imaging of skin, with a review of clinical applications of confocal microscopy in dermatology 

for diagnosis, margin mapping, and treatment monitoring of skin cancers, and 2) optical coherence tomography 

mechanisms and imaging of blood vessels, with a review of clinical applications in cardiology for imaging of 

arteries, diagnosis of arterial disease, and monitoring of therapies. 

Participants 

This course is designed for any physician who is interested in learning more modern in vivo clinical microscopy 

imaging techniques, specifically confocal microscopy and optical coherence tomography. 


Participants should have a basic understanding of how light interacts with tissues. 


At the conclusion of the course, attendees will be informed of current modern emerging in vivo clinical 

microscopy techniques, and the added value of the capabilities of these techniques to clinical practice. 

7:00 am - 7:04 am Discussion and Pre-Test - Brian S. Sorg, James W. Tunnell 

7:05 am - 7:39 am Fundamentals of Confocal Microscopy and Optical Coherence Tomography - Brian S. 

Sorg, James W. Tunnell 

7:40 am - 7:44 am Break 

7:45 am - 8:14 am Confocal Microscopy in Clinical Dermatology - Kishwer S. Nehal 

8:15 am - 8:19 am Break 

8:20 am - 8:49 am Optical Coherence Tomography in Clinical Cardiology - Marc Feldman 

8:50 am - 9:00 am Q&A and Post-Test - Brian S. Sorg, James W. Tunnell 

Disclosures 

Marc Feldman – Received royalties from Volcano Corporation related to their OCT program 

Kishwer S. Nehal - No disclosure 

Brian S. Sorg - No disclosure 

James W. Tunnell received research grant from ASLMS and NIH; royalties and intellectual property rights with the University of Texas 

61

62 





Grapevine, TX 

The Cutting Edge: “Translational Medicine” – Longhorn F 9:15 am – 10:05 am 

Directors: R. Rox Anderson, M.D., E. Duco Jansen, Ph.D. 

Faculty: Anita Mahadevan-Jansen, Ph.D., J. Stuart Nelson, M.D., Ph.D., Claus-Peter Richter, M.D., Ph.D. 


Clinicians, health professional representatives, scientists, engineers, and industry representatives need big-picture 

understanding of the success and limitations of current laser and light-based treatment for challenging medical 

conditions, and of the cutting-edge research that may someday lead to an improvement in the standard of care. 

Participants 

All attendees of the ASLMS Annual Conference. 


Attendees are not required to have any prior knowledge of laser medicine or basic science. 


Leading clinicians and scientific researchers will discuss state-of-the-art and future care for patients with 

challenging medical conditions. This knowledge may lead to increased cooperation among conference attendees 

and new research directions. 

9:15 am – 9:16 am INTRODUCTION - R. Rox Anderson, E. Duco Jansen 

GUIDING THERAPY WITH OPTICAL SPECTROSCOPY/IMAGING 

9:17 am – 9:26 am INTRAOPERATIVE GUIDANCE OF TUMOR/SURGICAL RESECTION 

Anita Mahadevan-Jansen, Vanderbilt University, Nashville, TN 

9:27 am – 9:32 am Discussion 

NOVEL THERAPEUTIC USE OF LASERS 

9:33 am – 9:42 am DEVELOPMENT OF A LASER-BASED COCHLEAR IMPLANT 

Claus-Peter Richter, Northwestern University, Chicago, IL 


TRANSLATING NEW DISCOVERIES IN TREATMENT OF VASCULAR LESIONS 

9:49 am – 9:58 am GAME CHANGING STRATEGIES FOR LASER TREATMENT OF VASCULAR SKIN LESIONS 

J. Stuart Nelson, Beckman Laser Institute and Medical Clinic, University of California, 

Irvine, CA 


Cutting Edge 

“Translational 

Medicine” Session 


Disclosures 

R. Rox Anderson received royalties from Massachusetts General Hospital which owns and licenses patents on laser hair removal, fractional laser 

treatments, and cryolipolysis; serves on scientific advisory boards for PhotoMedex and Ulthera 

E. Duco Jansen received a salary, research grant, and intellectual property rights from Vanderbilt University; research grant from NIH, DOD, 

HFSP, and Lockheed-Martin 

Anita Mahadevan-Jansen received a salary, research grant, and intellectual property rights from Vanderbilt University; research grant from NIH 

and DOD 

Claus-Peter Richter - No disclosure





Grapevine, TX 

Plenary Session – Longhorn F 10:30 am – 12:00 pm 

10:30 am – 10:34 am Presentation of Dr. Horace Furumoto Innovations Award 

RECIPIENT TBA 

10:35 am – 10:49 am Caroline and William Mark Memorial Award 

FROM THE EARLY DAYS OF MEDICAL LASER APPLICATIONS TO A ROUTINE CLINICAL USE 

TODAY: PERSONAL ENCOUNTERS 

Franz Hillenkamp, Ph.D.*, Institute for Medical Physics & Biophysics, Muenster, 

Germany 

*No disclosure 

� 

10:50 am – 11:04 am Ellet H. Drake Memorial Award 

THE EGG OF COLUMBUS: OVERCOMING BARRIERS TO INNOVATION 

Dieter Manstein, M.D.*, Wellman Center for Photomedicine, Boston, MA 

*Equipment from Quantel Derma and Solta; consulting fees from Elemé, Quantel Derma and Zeltiq; research 

grant from Candela and Lumenis; stockholder with Zeltiq; royalties from Massachusetts General Hospital 

due to licensing contracts with Candela, Elemé, Palomar, Solta, Zeltiq and Zimmer 

11:05 am – 11:19 am Leon Goldman Memorial Award 

FINDING THE RIGHT INDICATIONS FOR PHOTODYNAMIC THERAPY 

Stephen G. Bown, M.D., F.R.C.P.*, University College, London, United Kingdom 

*Research grants from Hamamatsu Photonics, PCI Biotech, and QLT 

11:20 am – 11:29 am Nursing/Allied Health Excellence Award 

THE ROLE OF ALLIED NURSES AND HEALTH CARE PROFESSIONALS: "PRICELESS” 

Faye M. Jenkins, R.N., B.S.N., Wilmington, MA 

*No disclosure 

Conference 



11:30 am – 12:00 pm ASLMS BUSINESS MEETING (Members Only) – Longhorn F 

CALL BUSINESS MEETING TO ORDER – E. Duco Jansen, Ph.D., President 

ADDITIONS TO THE AGENDA (Address questions from the Members in Attendance) 

APPROVAL OF MINUTES OF APRIL 17, 2010 BUSINESS MEETING – E. Duco Jansen, Ph.D. 

TREASURER'S REPORT – Mathew M. Avram, M.D., J.D., Treasurer 

ELECTION RESULTS – E. Duco Jansen, Ph.D. 

NEW BUSINESS – E. Duco Jansen, Ph.D. 

SECRETARY'S REPORT – J. Stuart Nelson, M.D., Ph.D. 

INTRODUCTION OF BRIAN D. ZELICKSON, M.D., PRESIDENT-ELECT 

12:00 pm – 1:30 pm COMPLIMENTARY LUNCH WITH TICKET IN EXHIBIT HALL (View ePosters) 

63

64 





Grapevine, TX 

The Cutting Edge: “Laser and Skin” – Longhorn F 1:00 pm – 2:45 pm 

Directors: Mathew M. Avram, M.D., J.D., Christopher B. Zachary, M.B.B.S., F.R.C.P. 

Faculty: R. Rox Anderson, M.D., Marc R. Avram, M.D., Henry H.L. Chan, M.D., Ph.D., F.R.C.P., Michael Hamblin, 

M.D., Christopher Hughes, Ph.D., Kristen M. Kelly, M.D., Jennifer Y. Lin, M.D., E. Victor Ross, M.D., Fernanda 

Sakamoto, Ph.D., Zeina S. Tannous, M.D., Ben J. Vakoc, Ph.D., Jill S. Waibel, M.D. 


Clinicians, health professional representatives, scientists, engineers, and industry representatives need bigpicture 

understanding of the success and limitations of current laser and light-based treatment for challenging 

medical conditions, and of the cutting-edge research that may someday lead to an improvement in the standard 

of care. 

Participants 

All attendees of the ASLMS Annual Conference. 


Attendees are not required to have any prior knowledge of laser medicine or basic science. 


Leading clinicians and scientific researchers will discuss state-of-the-art and future care for patients with 

challenging medical conditions. This knowledge may lead to increased cooperation among conference attendees 

and new research directions. 

1:00 pm – 1:02 pm INTRODUCTION - Mathew M. Avram, Christopher B. Zachary 

1:03 pm – 1:07 pm 

1:08 pm – 1:12 pm 

1:13 pm – 1:17 pm 

1:18 pm – 1:22 pm 

1:23 pm – 1:27 pm 

1:28 pm – 1:32 pm 

1:33 pm – 1:37 pm 

1:38 pm – 1:42 pm 

1:43 pm – 1:47 pm 

Cutting Edge 

“Laser and Skin” 

Session 


IMAGING AND LASER THERAPY: HOW MIGHT THIS WORK? POSSIBILITIES AND 

PRACTICAL LIMITS OF TARGETING THE SKIN WITH CURRENT TECHNOLOGIES 

Christopher B. Zachary, University of California, Irvine, CA 

Ben J. Vakoc, Wellman Center for Photomedicine, Massachusetts General Hospital, 

Boston, MA 

Q&A 

VASCULAR MALFORMATIONS: WHAT’S AVAILABLE IN 2011, AND HOW MIGHT WE 

PREVENT REVASCULARIZATION? 

Kristen M. Kelly, Beckman Laser Institute and Medical Clinic, University of California, 

Irvine, CA 

Christopher Hughes, University of California, Irvine, CA 

Q&A 

CASUALTIES OF WAR: HOW DO WE TREAT BURN AND TRAUMATIC SCARS? 

Jill S. Waibel, Dr. Jill Waibel Laser Center, Miami, FL 

R. Rox Anderson, Massachusetts General Hospital, Boston, MA 

Q&A

1:48 pm – 1:52 pm 

1:53 pm – 1:57 pm 

1:58 pm – 2:02 pm 

2:03 pm – 2:07 pm 

2:08 pm – 2:12 pm 

2:13 pm – 2:17 pm 

2:18 pm – 2:22 pm 

2:23 pm – 2:27 pm 

2:28 pm – 2:32 pm 

Cutting Edge 

“Laser and Skin” 

Session 






Grapevine, TX 

CONGENITAL NEVI: EASY TO DIAGNOSE; DIFFICULT TO TREAT. EARLY vs LATE 

TREATMENT, AND WITH WHAT? 

Henry H.L. Chan, University of Hong Kong, Hong Kong 

Jennifer Y. Lin*, Brigham & Women’s Hospital, Boston, MA 

Q&A 

*Content may discuss non-FDA approved device or off-label use 

LASER TREATMENT OF ACNE: WHY CAN’T WE DO BETTER? 

E. Victor Ross, Scripps Clinic, San Diego, CA 

Fernanda Sakamoto, Wellman Center for Photomedicine, Boston, MA 

Q&A 

REGROWING HAIR WITH LASER AND LIGHT SOURCES. IS THIS PRACTICAL? 

Marc R. Avram, Clinical Professor of Dermatology, Weill Cornell Medical School, New 

York, NY 

Michael Hamblin, Wellman Center for Photomedicine, Boston, MA 

Q&A 

2:33 pm – 2:45 pm PANEL DISCUSSION - Mathew M. Avram, Christopher B. Zachary 

Disclosures 

R. Rox Anderson received royalties from Massachusetts General Hospital which owns and licenses patents on laser hair removal, fractional 


Marc R. Avram – No disclosure 


Henry H.L. Chan received financial grant from Lumenis; equipment from Candela, Elemé, Lumenis, Palomar, Solta, Syneron, Zeltiq; discount 

from Candela; stockholder with Lumenis, Solta 

Michael Hamblin – No disclosure 

Christopher Hughes – Pending 

Kristen M. Kelly received equipment from Candela and Solta; consulting fees from Lumenis; research grant from Candela, DUSA, Graceway 

Jennifer Y. Lin – No disclosure 



Fernanda Sakamoto – No disclosure 

Zeina S. Tannous – No disclosure 

Ben J. Vakoc – No disclosure 


Christopher B. Zachary - No disclosure 

65

66 





Grapevine, TX 

Experimental and Translational Research – Texas C 3:45 pm – 6:00 pm 


OPTICAL IMAGING 


3:45 pm – 4:05 pm 20 REGULATORY PERSPECTIVE OF OPTICAL IMAGING DEVICES: TECHNOLOGY, 

INDICATIONS, AND FUTURE CHALLENGES 

Kejing Chen, Richard Felten, Long Chen, Neil Ogden, Office of Device 

Evaluation, Food and Drug Administration, Silver Spring, MD 


4:06 pm – 4:17 pm 21 IN VIVO IMAGING OF KIDNEY MICROVASCULATURE USING DOPPLER OPTICAL 

COHERENCE TOMOGRAPHY 

Jeremiah Wierwille�, Peter Andrews, Maristela Onozato, Yu Chen, College 

Park, MD, Washington, DC 


4:18 pm – 4:29 pm 22 MULTIMODAL OPTICAL IMAGING FOR DETECTING BREAST CANCER 

Rakesh Patel�, Ashraf Khan, Robert Quinlan, Anna Yaroslavsky, University of 

Massachusetts, Lowell, MA, UMass Memorial Healthcare, Inc., Worcester, MA 


4:30 pm – 4:41 pm DYE-ENHANCED MULTIMODAL CONFOCAL IMAGING OF BRAIN CANCERS 

Dennis Wirth�, Matija Snuderl, Sameer Sheth, William Curry, Anna 

Yaroskavsky, University of Massachusetts, Lowell, MA, Harvard Medical School, 



OPTICAL DIAGNOSTICS 


4:42 pm – 5:02 pm 24 FROM LASER TISSUE INTERACTION TO MALDI MASS SPECTROMETRY 

Franz Hillenkamp, University of Muenster, Muenster, Germany 


5:03 pm – 5:14 pm 



Translational 

Research 


25 MECHANICAL TISSUE OPTICAL CLEARING TECHNIQUE INCREASES RESOLUTION 

AND CONTRAST OF A TARGET IMAGE BENEATH EX VIVO PORCINE SKIN 

Alondra Izquierdo-Roman�, William Vogt, Christopher Rylander, Virginia Tech, 

Blacksburg, VA 


5:15 pm – 5:26 pm 26 HIGH-RESOLUTION, THICK-TISSUE OPTICAL HISTOLOGY OF TISSUE 

MICROVASCULATURE 

Austin Moy�, Bernard Choi, Beckman Laser Institute and Medical Clinic, 




5:27 pm – 5:38 pm 


5:39 pm – 5:50 pm 


5:51 pm – 6:02 pm 



Translational 

Research 






Grapevine, TX 

27 PHOTOACOUSTIC DETECTION OF MELANOMA AND MICROSPHERES IN VITRO 

USING A MICE MODEL 

Sagar Gupta�, Kirby Campbell, Adam Daily, Kiran Bhattacharya, Luis Parada, 

John Viator, University of Missouri, Columbia, MO 


28 MULTIDOMAIN SIMULATION OF MECHANICAL TISSUE OPTICAL CLEARING 

DEVICES: A PLATFORM FOR DEVICE OPTIMIZATION 

William Vogt�, Alondra Izquierdo-Roman, Christopher Rylander, Virginia Tech, 



29 SIGNAL VARIATION OF FLUORESCEIN DYE IN ANTERIOR CHAMBER AND 

VITREOUS EYE 

Raiyan Zaman�, Jeffrey Oliver, Ashley Welch, James Tunnell, Henry Rylander, 

University of Texas at Austin, Austin, TX 



67

68 





Grapevine, TX 

Cutaneous Laser Surgery – Longhorn F 3:45 pm – 6:15 pm 

Directors: Mathew M. Avram, M.D., J.D., Paul M. Friedman, M.D. 

HOT TOPICS: NEW LASERS AND NEW INDICATIONS 


This session focuses on the use of novel lasers, new indications, and innovative therapeutic techniques. Each of 

the topics of laser-assisted vehicle delivery, new technologies for in-office and home-use devices, and 

optimized treatment parameters for tattoo removal will be addressed. Participants will develop an 

understanding of the present treatment indications, therapeutic techniques, and new and innovative 

technologies. 

Participants 

This session will benefit physicians and health care personnel who treat cutaneous disorders in the disciplines of 

dermatology, plastic surgery, and facial plastic surgery. It will also benefit those engineers and medical device 

personnel who actively work to develop devices for the treatment of cutaneous disorders. 





Attendees will gain knowledge of cutting edge laser treatments and their clinical applications in the treatment 

of a variety of cutaneous conditions. 

Hot Topics 

• Laser-assisted vehicle delivery 

• Optimized techniques for tattoo removal 

3:45 pm – 3:46 pm Introduction – Mathew M. Avram, Paul M. Friedman 

3:47 pm – 3:52 pm 74 MELANIN OPTICAL DENSITY AS A PREDICTOR OF MAXIMUM TOLERATED 

FLUENCE FOR PHOTODERMATOLOGY 

Ilya Yaroslavsky 1 , Gregory Altshuler 1 , Guangming Wang 2 , Felicia Whitney 2 , 

Henry Zenzie 2 , Palomar Medical Technologies, Inc., Burlington, MA 

1 

Travel expenses, salary, stockholder, equity position with Palomar 

2 

Salary, stockholder, equity position with Palomar 


3:53 pm – 3:58 pm 


3:59 pm – 4:04 pm 






75 QUALITY CONTROL AND THE PULSED DYE LASER: WHEN NOT TO TREAT 

Joshua Shofner, Zeina Tannous, Mathew Avram, Massachusetts General 

Hospital, Boston, MA 


76 OPTIMAL TATTOO REMOVAL IN ONE TREATMENT SESSION WITH 

NANOSECOND-DOMAIN LASER PULSES 

Theodora Kossida�, Dimitrios Rigopoulos, Andreas Katsambas, R. Rox 

Anderson, A. Syggros Skin Disease Hospital, National and Kapodistrian 

University of Athens Medical School, Athens, Greece, Wellman Center for 

Photomedicine, Massachusetts General Hospital, Harvard Medical School, 

Boston, MA





Grapevine, TX 

4:05 pm – 4:10 pm 77 COMBINATION OF MULTIPLE Q-SWITCHED WAVELENGTHS IMPROVES TATTOO 

CLEARANCE COMPARED TO SINGLE WAVELENGTH TREATMENT 

Arielle Kauvar 1 , New York Laser & Skin Care, New York, NY 

1 

Equipment from Candela 

4:11 pm – 4:16 pm 78 REDISTRIBUTION OF INK FOLLOWING LASER TATTOO REMOVAL 

Arisa Ortiz�, Mathew Avram, University of California, Irvine, CA, 


4:17 pm – 4:22 pm 


4:23 pm – 4:37 pm Q&A 

79 A MULTI-CENTER EVALUATION OF THE MIRADRY SYSTEM TO TREAT 

SUBJECTS WITH AXILLARY HYPERHIDROSIS 

Mark Lupin, H. Chih-Ho Hong, Kathryn F. O’Shaughnessy, University of British 

Columbia, Victoria, Canada, Vancouver, Canada, Miramar Labs, Sunnyvale, CA 


4:38 pm – 4:43 pm 80 A PILOT STUDY OF LASER ASSISTED DELIVERY OF ALLOGENIC MESENCHYMAL 

STEM CELLS 

Evangelos Badiavas, Stephen Davis, Jill Waibel, Miller School of Medicine, 

University of Miami, Cutaneous Surgery Wound Healing Research Laboratory, 

Miami Dermatology and Laser Institute, Miami, FL 


4:44 pm – 4:49 pm 


81 A SPLIT-FACE STUDY INVESTIGATING ALLUMERA COMBINED WITH MULTIPLE 

LASER AND LIGHT SOURCES FOR PHOTOREJUVENATION 

Sabrina Fabi 1 , Jennifer Peterson 2 , Mitchel Goldman 3 , Goldman Butterwick & 

Associates, Cosmetic Laser Surgery, San Diego, CA 

1 

Research grant from Photocure 

1 

Consultant for SkinMedica, performed work for Lumenis; educational grants from Allergan 

3 

Serves on advisory board for Aesthera, Allergan (Global Alliance Council), Bio Med Sciences, 

Galderma, Lumenis, Merz Pharmaceutical, Sanofi-Aventis, and Theraplex; consultant for Bioniche 

Pharmaceuticals, Johnson & Johnson, Lithera, Lumenis, Medicis Pharmaceuticals, Mentor, New 

Star Lasers, Ortho Dermatologics, Quinova Pharmaceuticals, and Veinacare; medical director and 

stockholder with Lumenis, stockholder with New Star Lasers, medical director for Obagi Medical 

Products 


4:50 pm – 4:55 pm 82 COMPARISON STUDY OF NON-ABLATIVE FRACTIONAL TREATMENT WITH AND 

WITHOUT ADVANCED SKIN COMPRESSION TECHNIQUE 

Taro Kono 1 , Motoko Nakata, Hiroyuki Sakurai, Henry Chan, Tokyo Women's 

Medical University, Tokyo, Japan, University of Hong Kong, Hong Kong, China 

1 


4:56 pm – 5:01 pm 83 DEEP HEATING OF DERMIS USING NON-ABLATIVE FRACTIONAL TECHNIQUE 

WITH MICRO-COMPRESSION OPTICS 

Christine Dierickx 1 , Sean Doherty 2 , Laser Clinic Boom, Boom, Belgium, Boston 

Plastic Surgery Associates, Concord, MA 

1 

Equipment, travel expenses, research grant from Palomar 

2 

Travel expenses, salary, equity position with Palomar 





69

70 






Grapevine, TX 

5:02 pm – 5:07 pm PULSE STACKING WITH A 1450nm LASER CAN INCREASE DEPTH OF 

TREATMENT 

Arisa Ortiz, William Lewis, R. Rox Anderson, University of California, Irvine, 

CA, Wellman Center for Photomedicine, Boston, MA 


5:08 pm – 5:21 pm Q&A 

5:22 pm – 5:27 pm 85 HISTOLOGICAL EVALUATION OF A NON-ABLATIVE 1940nm FRACTIONAL 

LASER 

E. Victor Ross 1 , Chad Tingey, Yacov Domankevitz 2 , Kevin Schomacker 2 , James 

Hsia 2 , Scripps Clinic, San Diego, CA, Candela, Wayland, MA 

1 

Financial grant, equipment, and honoraria from Candela 

2 

Salary from Candela 


5:28 pm – 5:33 pm 





86 CLINICAL RESULTS OF NON-ABLATIVE FRACTIONAL PHOTOTHERMOLYSIS 

FOR HOME-USE TREATMENT OF PHOTODAMAGED SKIN 

Christopher Zachary 1 , Marieke van Grootel, Tom Nuijs, Kerrie Jiang, Steven 

Struck, University of California, Irvine, CA, Philips Research, Eindhoven, The 

Netherlands, Solta Medical, Hayward, CA, The Struck Clinic, Palo Alto, CA 

1 

Travel expenses and educational support from Solta 


5:34 pm – 5:39 pm 87 EFFECTS OF DEVIATION FROM FOCAL PLANE ON LESION DEPTH AND 

DIAMETER FOR ABLATIVE FRACTIONAL PHOTOTHERMOLYSIS 

Garuna Kositrana 1 , Henry Chan 2 , Dieter Manstein 3 , Wellman Center for 


1 

Research grant from Lumenis 

2 

Consulting fees and equity position with Lumenis 

3 

Consulting fees from Eleme, Quantel, Zeltiq; research grant from Lumenis; royalties from 

Candela, Elemé, Solta, Zeltiq, Zimmer; equity position with Zeltiq 


5:40 pm – 5:45 pm 88 PSEUDOMELANOMA FOLLOWING FRACTIONAL CO2 LASER RESURFACING 

Deborah Sarnoff 1 , Robert Gotkin 1 , Ritu Saini, NYU Medical Center, New York, 

NY 

1 

Equipment from Cynosure and DEKA 

5:46 pm- 5:51 pm 89 ULCERATION OF MATURE SURGICAL SCARS FROM NON-ABLATIVE 1550nm 

FRACTIONAL LASER TREATMENTS ASSOCIATED WITH INTRA-LESIONAL 

LIDOCAINE INJECTIONS 

Gary Chuang�, Zeina Tannous, Mathew Avram, Wellman Laboratories of 

Photomedicine, Massachusetts General Hospital, Harvard Medical School, 

Boston, MA 

5:52 pm – 5:57 pm 227 ABLATIVE FRACTIONAL RESURFACING FOR TATTOO REMOVAL 

Omar Ibrahimi, Fernanda Sakamoto, Mathew Avram, R. Rox Anderson, 

Wellman Center for Photomedicine, Boston, MA 


5:58 pm – 6:15 pm Q&A 

�Recipient of ASLMS travel grant.





Grapevine, TX 

Photobiomodulation – Texas 4-6 3:45 pm – 5:30 pm 


3:45 pm – 4:19 pm 

4:20 pm – 4:29 pm 

4:30 pm – 4:39 pm 


4:40 pm – 4:44 pm 

4:45 pm – 4:54 pm 


4:55 pm – 4:59 pm 

5:00 pm – 5:09 pm 

5:10 pm – 5:14 pm 

5:15 pm – 5:24 pm 

5:25 pm – 5:30 pm 



Session 


PHOTOBIOMODULATION: CLINICAL STUDIES 


TRANSCRANIAL LASER THERAPY IN THE TREATMENT OF ALZHEIMER’S 

DISEASE: A TRANSGENIC MOUSE MODEL 

Luis De Taboada, PhotoThera, Inc., Carlsbad, CA 

Discussion 

158 A NEW POSSIBILITY TO TREAT SEVERE TRACHEAL STENOSIS APPLYING LOW 

LEVEL LASER THERAPY: PILOT STUDY 

Nathali Pinto, Tatiana Magacho, Mara Pereira, M. Cristina Chavantes, 

University of São Paulo, São Paulo, Brazil, Pitagoras University, Vila Velha, 

Brazil 


Discussion 

160 INNOVATIVE METHOD TO IMPROVE EFFICACY AND TOLERABILITY OF PDT 

TREATMENTS 

Carl Thornfeldt 1 , CT Derm, Fruitland, ID 

1 

Stockholder with CT Derm; salary from Episciences 


Discussion 

161 A PROSPECTIVE SPLIT-FACE DOUBLE-BLIND RANDOMIZED PLACEBO- 

CONTROLLED TRIAL TO ASSESS THE EFFICACY OF LIGHT-EMITTING DIODE 

POSTFRACTIONAL ABLATIVE LASER FOR SKIN REJUVENATION 

Valeria Campos, Juliana Jordao�, Tatiana Cordero, Clinica Valeria Campos, 

Jundiai, Brazil, Curitiba, Brazil, Campinas, São Paulo, Brazil 


Discussion 

162 SAFETY AND EFFICACY OF FOOTLASER TREATMENT OF ONYCHOMYCOSIS IN 

PRIVATE PRACTICE 

Michael Uro, Laura Uro, Michael Abrahams, Martine Abrahams, Robert 

Grzywacz, Foot Doctor Laser Center, Sacramento, CA, The London Nail Laser 

Clinic, London, England, Las Vegas, NV 

Discussion 

71

72 





Grapevine, TX 

International Experience in Lasers in Dermatology - Texas D 3:45 pm – 6:00 pm 

Director: Thierry Passeron, M.D., Ph.D. 

Disclosure 

Thierry Passeron – No disclosure 


These sessions are directed towards sharing international expertise in lasers in the field of cutaneous 

conditions. Attendees will develop an understanding of the present treatment indications, therapeutic 


Participants 

These sessions will benefit physicians and health care personnel who treat cutaneous disorders in the disciplines 

of dermatology, plastic surgery, and facial plastic surgery. It will also benefit those engineers and medical 

device personnel who actively work to develop devices for the treatment of cutaneous disorders. 





These sessions will provide attendees an opportunity to learn more about the international expertise of cutting 

edge laser treatments and their clinical applications in the area of cutaneous conditions. Interactions between 

participants and sharing experiences will be encouraged. Novel results are presented that will impact the 

development of new and more efficacious, light-based therapies and diagnostics. Safety issues are also 

considered. 

Hot Topics 

• Home devices 

• Treatment of axillary hyperhidrosis 

• Cellulite 

• Melasma 

HOME DEVICES 

Christine C. Dierickx, Thierry Passeron 

3:45 pm – 3:50 pm 

3:51 pm – 3:52 pm 

International 

Experience in 


Dermatology 


113 GUIDELINES ON THE SAFETY OF LIGHT-BASED HOME-USE DEVICES FROM THE 

EUROPEAN SOCIETY FOR LASER DERMATOLOGY 

Godfrey Town 1 , Caerwyn Ash 2 , Christine Dierickx, Merete Haedersdal, Klaus 

Fritz, University of Wales, Global Academy, Swansea Metropolitan University, 

Swansea, United Kingdom, University Hospital Ghent, Ghent, East Flanders, 

Belgium, Massachusetts General Hospital, Boston, MA, Copenhagen, Denmark, 

European Society of Laser Dermatology, Landau, Rheinland-Pfalz, Germany 

1 

Consulting fees from CyDen and Unilever; travel expenses from CyDen 

2 

Equipment and equity position with CyDen; travel expenses from Swansea University; salary from 

Global Academy and University of Wales 


Discussion

3:53 pm – 3:58 pm 


3:59 pm – 4:00 pm 

4:01 pm – 4:06 pm 


4:07 pm – 4:08 pm 

4:09 pm – 4:14 pm 

4:15 pm – 4:16 pm 

4:17 pm – 4:22 pm 

4:23 pm – 4:24 pm 


International 

Experience in 


Dermatology 






Grapevine, TX 

114 INVESTIGATION AND DEVELOPMENT OF A MEASUREMENT TECHNIQUE FOR 

THE SPATIAL ENERGY DISTRIBUTION OF HOME-USE INTENSE PULSED LIGHT 

SYSTEMS 

Gareth Thomas, Caerwyn Ash 1 , Richard Hugtenburg, Michael Kiernan 2 , Godfrey 

Town 2 , Swansea University, University of Wales, Global Academy, Swansea, 

United Kingdom 

1 


2 



Discussion 

115 OPTIMUM CHOICE OF IRRADIATION WAVELENGTH FOR SKIN COLOR 

DETERMINATION USING SKIN REFLECTANCE MEASUREMENTS 

Caerwyn Ash 1 , Stuart Jones 2 , Godfrey Town 3 , Marc Clement 3 , Peter Bjerring, 

Michael Kiernan 3 , Swansea University, CyDen, University of Wales, Global 

Academy, Swansea, United Kingdom, Molholm Hospital, Vejle, Denmark 

1 


2 

Equipment and salary from CyDen 

3 



Discussion 

OTHER 

116 CONCOMMITANT USE OF LASER AND ISOTRETINOIN, HOW SAFE? 

Ahmed Alissa, National Center for Vitiligo and Psoriasis, Riyadh, Saudi Arabia 

Discussion 

MEDICAL USE OF LASER 

117 A PROSPECTIVE PILOT STUDY OF THE ALEXANDRITE LASER ON BASAL CELL 

CARCINOMAS 

Daniel I. Wasserman 1 �, Zeina Tannous, Gary D. Monheit 2 , Total Skin & Beauty 

Dermatology Center, Birmingham, AL, Harvard Medical School, Boston, MA 

1 

Equipment from Candela 

2 

Equipment from Candela; consulting fees from Allergan, Electro-optical Sciences, Galderma, 

Genzyme, J&J, Medicis, Mentor, Merz and Revance; research grant from Electro-optical Sciences, 

Galderma, Kythera, Medicis, Mentor, Neocutis and Revance; honoraria from Allergan, Galderma 

and Medicis 


Discussion 

73

4:25 pm – 4:30 pm 


4:31 pm – 4:32 pm 

4:33 pm – 4:38 pm 


4:39 pm – 4:40 pm 

4:41 pm – 4:46 pm 

4:47 pm – 4:48 pm 

4:49 pm – 4:54 pm 


4:55 pm – 4:56 pm 

4:57 pm – 5:02 pm 

5:03 pm – 5:04 pm 

5:05 pm – 5:10 pm 

5:11 pm – 5:12 pm 


74 

International 

Experience in 


Dermatology 






Grapevine, TX 

118 PROPOSING CONCEPT OF SELECTIVE PHOTOTHERMOCOAGULATION AND 

VARIOUS DERMATOLOGIC INDICATIONS BY USING 1444nm Nd:YAG LASER 

Kyung Goo Lee�, Sang Geun Lee, Sang Min Yi, Jae Hwan Kim, Jae Eun Choi, Il- 

Hwan Kim, Korea University Hospital, An-San Si, Kyunggi Do, Korea 


Discussion 

119 ERBIUM LASER DERMABRASION FOR TREATING VITILIGO: A COMBINATION 

APPROACH 

Wedd Bayoumi, Florence Le Duff, Laura Sillard, Jean-Philippe Lacour, Jean- 

Paul Ortonne, Thierry Passeron, University Hospital of Nice, Nice, Alpes- 

Maritimes, France 


Discussion 

120 STUDY ABOUT EFFICACY AND SAFETY IN LASER ASSISTED SWEAT GLAND 

REDUCTION FOR AXILLARY HYPERHIDROSIS 

Afschin Fatemi, s-thetic Clinic, Duesseldorf, Germany 

Discussion 

ACNE 

121 TREATMENT OF SEVERE OR REFRACTORY ACNE WITH NON-ABLATIVE 

1450nm DIODE LASER 

Rosalind Hughes, Katerina Tsilika, Jean-Paul Ortonne, Jean-Philippe Lacour, 

Thierry Passeron 1 , University Hospital of Nice, Nice, Alpes-Maritimes, France 

1 

Research grant from Candela 

Discussion 

SCARS 

122 FRACTIONAL Er:YAG LASER FOR ACNE SCARS IN SKIN OF COLOR 

Mukta Sachdev�, Sunaina Hameed, Manipal Hospital, MS Skin Clinic, 

Bangalore, Karnataka, India 

Discussion 

123 THE CLINICAL EFFICACY AND STATISTICAL EVALUATION OF 150 ACNE SCARS 

BY INSULATED MICRO-NEEDLING FRACTIONAL RF TECHNOLOGY 

Takashi Takahashi 1 , Shibuya-ku, Tokyo, Japan 

1 

Equipment from Jeisys 


Discussion

5:13 pm – 5:18 pm 

5:19 pm – 5:20 pm 

5:21 pm – 5:26 pm 

5:27 pm – 5:28 pm 

5:29 pm – 5:34 pm 

5:35 pm – 5:36 pm 

5:37 pm – 5:42 pm 

5:43 pm – 5:44 pm 

5:45 pm – 5:50 pm 

5:51 pm - 5:52 pm 

International 

Experience in 


Dermatology 


HAIR AND PIGMENT REMOVAL 





Grapevine, TX 

124 LONG-TERM RESULTS OF AXILLARY HAIR REMOVAL WITH A CONTINUOUSLY 

SCANNED DIODE LASER AND A SPOT-TO-SPOT SCANNED ALEXANDRITE LASER 

(EPICON STUDY) 

Sonja Grunewald 1 , Marc Oliver Bodendorf 2 , Alexander Zygouris 2 , Jan Christoph 

Simon 2 , Uwe Paasch 2 , University of Leipzig, Leipzig, Saxony, Germany 

1 

Equipment from Quantel-Derma 

2 

Equipment and research grant from Quantel-Derma 


Discussion 

125 INCREASED FORMATION OF FIBROSIS AFTER TREATMENT WITH ABLATIVE vs 

NON-ABLATIVE FRACTIONAL LASER THERAPY 

Bas S. Wind, Arne A. Meesters, Marije W. Kroon, Johan F. Beek, J.P. Wietze 

Van der Veen, Allard C. Van der Wal, Jan D. Bos, Albert Wolkerstorfer, 

Netherlands Institute for Pigment Disorders, Academic Medical Center, 

University of Amsterdam, Amsterdam, The Netherlands 


Discussion 

126 FRACTIONAL RADIOFREQUENCY FOLLOWED BY HYDROQUINONE FOR 

TREATMENT OF MELASMA 

Moshe Lapidoth, Shlomit Halachmi, Rabin Medical Center, Petach, Tikva, Israel 

Discussion 


SEVERE RHINOPHYMA: FRACTIONAL CO2 LASER – A NEW TREATMENT OPTION 

Rafael Nunes, Daniela Nunes, Luciana Camara, Fabiana Wanick, Guilherme 

Nunes, Ana Paula Martins, Thiara Lenzi, Slim Clinique Laser Center and 

Bonsuesso Dermatology Hospital, Rio De Janeiro, Brazil 

Discussion 


STRIAE IMPROVEMENT WITH A NOVEL APPROACH BY SUBLATIVE 

REJUVENATION: A PRELIMINARY REPORT WITH OBJECTIVE MEASUREMENT 

Maurice Adatto 1 , Boris Vaynberg 2 , Ruthie Amir 2 , Hanit Brenner-Lavie 2 , Guido 

Mariotto 3 , Roman Kantor 3 , Skinpulse Laser Center, Geneva, Switzerland, 

Syneron Medical, Yokneam, Israel, Miravex Limited, Dublin, Ireland 

1 

Equipment from Syneron 

2 


3 

Salary from Miravex Limited 


Discussion 

75

5:53 pm – 5:58 pm 

5:59 pm – 6:00 pm 

76 

International 

Experience in 


Dermatology 







Grapevine, TX 

COMBINED ABLATIVE FRACTIONAL RADIOFREQUENCY AND ULTRASOUND IN 

SKIN REFINING 

Maria Angelo-Khattar 1 , Aesthetica Clinic, Dubai, United Arab Emirates 

1 

Equipment from Alma Lasers 


Discussion

Expert Panels 






Grapevine, TX 

Endovenous Laser Ablation Expert Panel – Longhorn F 7:00 am – 7:45 am 

Directors: Ethan A. Prince, M.D., Carson Wong, M.D., F.R.C.S.C., F.A.C.S. 

Faculty: Neil S. Sadick, M.D. 

Objectives: This session is intended for practicing physicians who have an interest in endovenous laser ablation. 

The panel will focus on ELA which is now the most widely accepted and used treatment option for insufficient great 

and saphenous veins. Panel topics include: 1) differences in clinical outcomes and safety between lasers of different 

wavelengths and power; 2) differences in clinical outcomes and safety between laser ablation, radiofrequency 

ablation, and surgery, and 3) differences in clinical outcomes and safety between EVLA and hook avulsion 

(phlebectomy) as a same day procedure or as separate staged procedures on different days. 

Disclosures 

Ethan A. Prince – No disclosure 

Neil S. Sadick received equipment from Osyris and SmoothShapes; research grant from Cynosure and Osyris 

Carson Wong received consulting fees from American Medical Systems, Inc. 

PDT in Dermatology – Texas D 7:00 am – 7:45 am 

Directors: Michael H. Gold, M.D., Arielle N.B. Kauvar, M.D. 

Faculty: Joel L. Cohen, M.D., Merete Haedersdal, M.D., Ph.D., Jason K. Rivers, M.D., E. Victor Ross, M.D., 

Fernanda Sakamoto, M.D. 

Objectives: This session is intended for practicing physicians who have an interest in the clinical application of 

photodynamic therapy to cutaneous disease. An expert panel of clinicians with extensive experience in photodynamic 

therapy will share their therapeutic approaches for the treatment of actinic keratoses, non-melanoma skin cancer, 

acne and other inflammatory disorders. At the conclusion of the session, attendees will be able to recognize the 

indications for photodynamic therapy and discuss various treatment regimens using available photosensitizers, lasers, 

and light sources. There will be an opportunity for questions and comments from the attendees. 

Disclosures 

Joel L. Cohen is currently a consultant for DUSA 

Michael H. Gold received travel expenses, research grant, honoraria, and is a stockholder with DUSA; consultant for Galderma and Photocure; 

honoraria and equity position with Galderma 

Merete Haedersdal – No disclosure 

Arielle N.B. Kauvar – No disclosure 

Jason K. Rivers – No disclosure 



Fernanda Sakamoto – No disclosure 

Burns and Trauma Expert Panel – Texas 4-6 7:00 am – 7:45 am 

Directors: Maj. (Dr.) Chad Hivnor, Jill S. Waibel, M.D. 

Faculty: R. Rox Anderson, M.D., Robert J. Spence, M.D. 

Objectives: Attendees of this panel should be individuals who have an interest in energy based and other innovative 

therapies for scar revision after severe injuries. Trauma and severe scars such as burn scars have both functional and 

cosmetic issues. There continues to be a rising number of trauma and burn survivors. The market and demand for 

surgery, laser and other innovative solutions for scars is growing dramatically as survival rates increase. An expert 

panel will discuss how we can leverage areas of multispecialty expertise to give optimal care. The panel will consist 

of burn reconstructive surgeons, laser experts from dermatology and plastic surgery as well as both military and 

civilian physicians. The panel discussions will include possible prevention of scars, early scar interventions with lasers 

as well as late reconstruction of mature scars with lasers. Other innovative research will also be shared. Different 

scar types as well as different laser types will be discussed. Timing of surgery and laser therapy will also be 

addressed. There will be an opportunity for questions and comments from the attendees. 

Disclosures 

R. Rox Anderson received royalties from Massachusetts General Hospital which owns and licenses patents on laser hair removal, fractional laser 

treatments, and cryolipolysis; serves on scientific advisory boards for PhotoMedex and Ulthera 

Chad Hivnor - No disclosure 

Robert J. Spence – No disclosure 


77

78 

Clinical 

Application 

Course 







Grapevine, TX 

A separate registration fee must be paid in order to attend courses. No CME credits and CE contact hours 

available for this course. 

ILT: Principal and Clinical Role – Texas 2-3 7:00 am – 10:00 am 

Director: Roger J. McNichols, Ph.D., Karl-G. Tranberg, M.D., Ph.D. 

Faculty: R. Jason Stafford, Ph.D., David Woodrum, M.D., Ph.D. 


This course will inform clinicians about features of various ablation or tissue destruction methods including lasers 

and ILT, and will instruct clinicians on the best practice in use and application of ILT in clinical applications. It 

will further educate clinicians on existing and recent evidence regarding clinical practice of ILT. 

Participants 

This course is designed for general surgeons, neurosurgeons, urologic surgeons, and interventional radiologists. 


Attendees should have some knowledge of laser physics, tissue interaction, and the application of ILT. 


After engaging in this educational activity physician participants will be able to: 1) describe the basic principles 

that govern laser-tissue interaction and laser thermotherapy; 2) describe current clinical techniques for 

focal/local tumor control or lesion production; 3) differentiate ILT from other local treatment methods based on 

advantages/disadvantages; 4) describe suitable applications for ILT and differentiate indications/ 

contraindications for particular treatment applications; 5) determine the applicability of lasers and ILT in their 

own clinical practices, and 6) demonstrate knowledge about various systems/devices available for ILT. 

7:00 am – 7:05 am Discussion and Pre-Test – Roger J. McNichols, Karl-G. Tranberg 

7:06 am – 7:15 am What is Interstitial Laser (Thermo) Therapy? – Roger J. McNichols 

• Definitions of ILT and Other Forms of (Laser-Mediated) Heat Treatment 

7:16 am – 7:30 am Laser Tissue Effects – Roger J. McNichols 

• Absorption, Scattering, Determinants of Tissue Effects 

7:31 am – 7:45 am Local Treatment of Cancer – Overview of Local and Systemic Effects – Karl-G. Tranberg 

• Surgical Resection, Local Chemotherapy (Regional Cytostatic Infusion, 

Chemoembolization, Regional Perfusion), Local Destruction Methods Such as RFA, 

Laser, Cryotherapy, Microwave Coagulation, PDT, HIFU, Ethanol Injection 

7:46 am – 7:55 am Why is ILT Attractive – Karl-G. Tranberg 

• Immunologic Aspects; Imaging Compatibility; Volumetric Thermal Generation 

7:56 am – 8:10 am Evaluation Before, During, and After Treatment – R. Jason Stafford 

• Real-Time Monitoring Imaging

Clinical 

Application 

Course 







Grapevine, TX 

A separate registration fee must be paid in order to attend courses. No CME credits and CE contact hours 

available for this course. 

ILT: Principal and Clinical Role Continued – Texas 2-3 7:00 am – 10:00 am 

8:11 am – 8:20 am Treatment Planning – David Woodrum 

• Indications/Contraindications to Ablation; Specific Considerations for ILT; Placement 

Approaches; Limitations 

8:21 am – 8:35 am ILT – Experimental Results – Karl-G. Tranberg 

• Rat Tumor Model 

8:36 am – 8:45 am Break 

8:46 am – 9:00 am ILT – Clinical Results – David Woodrum, Karl-G. Tranberg 

• The American Experience; The Swedish Experience 

9:01 am – 9:10 am Literature Survey and Clinical Experience – Roger J. McNichols, David Woodrum, Karl-G. 

Tranberg 

• Review of Published Results; Presentation of Clinical Experience 

9:11 am – 9:20 am Combinations With Other Local and Systemic Therapies – R. Jason Stafford, Roger J. 

McNichols 

9:21 am – 9:30 am Problems – Roger J. McNichols, Karl-G. Tranberg, R. Jason Stafford 

• Tissue Analysis; Real-Time Monitoring/Imaging; Pre- and Post-Therapy Evaluation 

9:31 am – 9:40 am Levels of Evidence for ILT – Karl-G. Tranberg 

• Comparison of Methods; Pros and Cons; Swedish Guidelines for Local Tumor 

Destruction 

9:41 am – 9:50 am ILT – Indications and Clinical Role – Roger J. McNichols, Karl-G. Tranberg 

• Present Status; Areas That Need to be Improved; Future Possibilities 

9:51 am – 10:00 am Discussion and Post-Test – Roger J. McNichols, Karl-G. Tranberg, David Woodrum, 

R. Jason Stafford 

Disclosures 

Roger McNichols received travel expenses from Bio Tex, Inc.; salary, stockholder, equity position, and intellectual property rights with Bio 

Tex, Inc. and Visualase, Inc. 

R. Jason Stafford received consulting fees from Visualase, Inc. 

Karl-G Tranberg received travel expenses, consulting fees, stockholder, equity position, and intellectual property rights with Clinical 

Laserthermia Systems AB 

David Woodrum – No disclosure 

79

80 





Grapevine, TX 

Experimental and Translational Research – Texas C 8:00 am – 12:00 pm 


8:00 am – 8:11 am 


8:12 am – 8:23 am 


8:24 am – 8:35 am 



Translational 

Research 


IMAGE-GUIDED SURGERY 

30 IS EXTERNAL SKIN TEMPERATURE AN ADEQUATE MODALITY TO SAFELY 

MONITOR PATIENTS DURING LASER LIPOLYSIS? 

Kenneth Rothaus 1 , New York Presbyterian Hospital Weill Cornell, New York, NY 

1 

Discount from Palomar 


31 PREDICTION OF THE MAXIMAL SAFE LASER RADIANT EXPOSURE ON AN 

INDIVIDUAL PATIENT BASIS BASED ON PHOTOTHERMAL TEMPERATURE 

PROFILING IN HUMAN SKIN 

Boris Majaron, Luka Vidovic, Matija Milanic, Wangcun Jia, J. Stuart Nelson, 

Jozef Stefan Institute, Ljubljana, Slovenia, Beckman Laser Institute and Medical 

Clinic, University of California, Irvine, CA 


32 A LED BASED IMAGING SYSTEM FOR OPTIMIZATION OF PHOTODYNAMIC 

THERAPY OF BASAL CELL CARCINOMA 

Rolf B. Saager�, David J. Cuccia, Steven Saggesse, Kristen M. Kelly, Anthony J. 

Durkin, Beckman Laser Institute and Medical Clinic, University of California, 

Modulated Imaging, Inc., Irvine, CA 


8:36 am – 8:47 am 33 REFLECTION MODALITY CONTINUOUS-WAVE TERAHERTZ IMAGER FOR CANCER 

DEMARCATION 

Cecil Joseph, Anna Yaroslavsky, Thomas Goyette, Robert Giles, University of 

Massachusetts, Lowell, MA 


CLINICAL THERAPEUTICS 

8:48 am – 8:59 am 34 TEST METHODOLOGIES FOR ESTABLISHING SAFETY OF HOME-USE LASER 

BASED DEVICES 

David Sliney 2 , Michail Smirnov 1 , Stewart Wilson 1 , Oldrich Laznicka 1 , Oksana 

Bradley 1 , Felicia Whitney 1 , Gregory Altshuler 1 , Ilya Yaroslavsky 1 , Fallston, MD, 

Palomar Medical Technologies, Burlington, MA 

1 


2 

Travel expenses and consultant for Palomar 








Grapevine, TX 

9:00 am – 9:11 am 35 COMBINATION THERAPY FOR THE TREATMENT OF 

ERYTHEMATOTELANGIECTATIC ROSACEA 

Jane Yoo�, Ryan Turner, Amy Lynne Frankel, Jinan Chaarani, Giselle Singer, 

Ellen Marmur, Mount Sinai Medical Center, New York, NY 


9:12 am – 9:23 am 36 EFFECTS ON ADIPOCYTES AND SEPTAL FIBERS AFTER HIGH INTENSE HIGH 

FREQUENCY ULTRASOUND 

Afschin Fatemi, S-thetic Clinic, Duesseldorf, Germany 


9:24 am – 9:35 am 37 LOW-FLUENCE 1064nm Q-SWITCHED Nd:YAG LASER 

Yuan-Hong Li, Tian-Hua Xu, Hong-Duo Chen, No. 1 Hospital of China Medical 

University, Shenyang, China 

9:36 am – 9:47 am 38 MICROSCOPIC OBSERVATION OF ULTRAPULSE-MODE vs SUPERPULSE-MODE 

FRACTIONAL CO2 LASER ON BACK SKIN 

Yuan-Hong Li 1 , Xue-Gang Xu 1 , Hong-Duo Chen 1 , No. 1 Hospital of China Medical 

University, Shenyang, China 

1 

Equipment from Lumenis 

9:48 am – 10:29 am Break 

PRECLINICAL THERAPEUTICS II 


10:30 am – 10:50 am 39 TRANEXAMIC ACID-CONTAINING LIPOSOMES FOR ANTIFIBRINOLYTIC SITE- 

SPECIFIC PHARMACO-LASER THERAPY OF PORT WINE STAINS 

Michal Heger 1 , Anton I.P.M. de Kroon, Academic Medical Center, University of 

Amsterdam, Amsterdam, The Netherlands, University of Utrecht, Utrecht, The 

Netherlands 

1 

Intellectual property rights with patent filing at EPO 


10:51 am – 11:02 am 


40 TOWARDS ENHANCEMENT OF PDT EFFICACY IN EXTRAHEPATIC 

CHOLANGIOCARCINOMAS USING LIPOSOMAL PHOTOSENSITIZATION 

Mans Broekgaarden, Anton I.P.M. de Kroon, J. Antoinette Killian, Thomas M. 

van Gulik, Michal Heger, Academic Medical Center, University of Amsterdam, 

Amsterdam, The Netherlands, Institute of Biomembranes, University of Utrecht, 

Utrecht, The Netherlands 


11:03 am – 11:14 am 41 IN VITRO TESTING OF DUAL-MODE THULIUM MICROSURGICAL LASER 

Matthew Keller, James Stafford, Jonathan Wells, Lockheed Martin Aculight, 

Bothell, WA 




Translational 

Research 


81

11:15 am – 11:26 am 


11:27 am – 11:38 am 


82 





Grapevine, TX 

42 HYPERTHERMIA ENHANCED IMAGE GUIDED LASER-ICG THERAPY 

Klressa Barnes�, Gal Shafirstein, Wolfgang Baumler, Ran Friedman, Leah 

Hennings, Mustafa Sarimollaoglu, Jessica Webber, Cassie Jackson, James Suen, 

Robert Griffin, University of Arkansas for Medical Sciences, Little Rock, AR, 

Regensberg University, Regensberg, Germany 


43 FIBEROPTIC MICRONEEDLES FOR MICROSCALE INTERSTITIAL DELIVERY OF 

THERAPEUTIC LIGHT 

Mehmet Kosoglu��, Robert Hood, Christopher Rylander, Virginia Tech, 




11:39 am – 11:50 am CAN A FRACTIONAL LASER ASSIST TRANSDERMAL ABSORPTION OF LIDOCAINE 

IN AN IN VIVO ANIMAL MODEL? 

Georgette Oni, Spencer Brown, Jeffrey Kenkel, UT Southwestern Medical 

Center, Dallas, TX 


11:51 am – 12:02 pm 


Translational 

Research 



CHARACTERIZING VARIABILITY IN RAMAN SPECTRA OF BENIGN LESIONS 

TOWARDS CANCER DETECTION IN SKIN 

Isaac Pence, Chetan Patil, Elizabeth Vargis, Alex Walsh, Matthew Keller, Harish 

Krishnamoorthi, Jonathan Cayce, Constantine Paras, Alex Makowski, Xiaohong 

Bi, Mark Mackanos, E. Duco Jansen, Darrell Ellis, Anita Mahadevan-Jansen, 

Vanderbilt University, Nashville, TN, Lockheed-Martin Aculight, Bothel, WA 



�Best Student/Resident Experimental and Translational Medicine Award Recipient.





Grapevine, TX 

Cutaneous Laser Surgery – Longhorn F 8:00 am – 11:40 am 

Directors: Mathew M. Avram, M.D., J.D., Paul M. Friedman, M.D. 

FRACTIONAL LASERS, BODY CONTOURING 


This session focuses on the use of fractional lasers for the treatment of dyspigmentation, photoaging, acne scars, 

and warts. Ultrasound and combination treatments for body contouring will also be addressed. Participants will 

develop an understanding of the present treatment indications, therapeutic techniques, and new and innovative 

technologies. 

Participants 





Participants should have a basic understanding of the fundamentals of skin biology, laser physics, and laser tissue 

interaction. 


Attendees will gain knowledge of cutting edge laser treatments and their clinical applications in the treatment of 

a variety of cutaneous conditions. 

Hot Topics 

• 1927nm thulium fiber laser for the treatment of melasma 

• Ultrasound devices for body contouring 

8:00 am – 8:01 am Introduction – Mathew M. Avram, Paul M. Friedman 

8:02 am – 8:07 am 


8:08 am – 8:13 am 


8:14 am – 8:19 am 





91 TREATMENT OF MELASMA IN FITZPATRICK SKIN TYPES IV-V WITH NON- 

ABLATIVE FRACTIONAL PHOTOTHERMOLYSIS: A REPORT OF 14 CASES WITH 

LONG-TERM FOLLOW-UP 

Paul M. Friedman, Jennifer M. Landau, Kristel D. Polder, Megan N. Moody, 

Leonard H. Goldberg, Irene J. Vergilis-Kalner, Denise Marquez, DermSurgery 

Associates, Houston, TX, Rodgers Dermatology, Dallas, TX 

92 TREATMENT OF MELASMA WITH A NOVEL FRACTIONATED 1927nm THULIUM 

FIBER LASER 

Kristel Polder 1 , Suzanne Bruce 2 , University of Texas, Suzanne Bruce and 

Associates, Houston, TX 

1 

Equipment and honoraria from Solta 

2 

Equipment from Solta 


93 EFFICACY OF 1927nm THULIUM FIBER LASER FOR THE TREATMENT OF 

MELASMA IN CHINESE PATIENTS 

Stephanie G.Y. Ho, N. Chan, C.K. Yeung, Samantha Y. Shek, Henry H.L. Chan 1 , 

The University of Hong Kong, Hong Kong, China 

1 


83

84 





Grapevine, TX 

8:20 am – 8:25 am 94 NON-ABLATIVE 1550nm FRACTIONAL LASER THERAPY NOT EFFECTIVE FOR 

ASHY DERMATOSIS AND POST-INFLAMMATORY HYPERPIGMENTATION: A PILOT 

STUDY 

Marije W. Kroon, Bas S. Wind, Arne A. Meesters, Albert Wolkerstorfer, J.P. 

Wietze Van der Veen, Jan D. Bos, Allard A. Van der Wal, Johan F. Beek, The 

Netherlands Institute for Pigment Disorders, Amsterdam, The Netherlands 



8:26 am – 8:31 am SUCCESSFUL TREATMENT OF FACIAL MELASMA WITH A COMBINATION OF 

MICRODERMABRASION AND Q-SWITCHED Nd:YAG LASER TREATMENT 

Arielle N.B. Kauvar, New York Laser & Skin Care, New York, NY 

8:32 am – 8:42 am Q&A 

8:43 am – 8:48 am 95 

ABLATIVE FRACTIONAL RESURFACING OF EYELIDS: A PROSPECTIVE 

EVALUATION 

Brian Biesman 1 , Nashville Centre for Laser and Facial Surgery, Nashville, TN 

1 

Research grant from Lumenis 

8:49 am – 8:54 am 96 COLD INDUCED MODULATION OF TARGETED FACIAL NERVES. A PILOT STUDY 

OF A MINIMALLY INVASIVE CRYOPROBE DEVICE FOR IMMEDIATE REDUCTION 

OF DYNAMIC WRINKLES 

Francis Palmer 1 , Vic Narurkar 1 , Thomas Munyon 2 , Kristine Tatsutani 3 , Los 

Angeles, CA, California Pacific Medical Center, San Francisco, CA, Munyon 

Dermatology, Myoscience, Redwood City, CA 

1 

Consulting fees and equity position with Myoscience 

2 

Consulting fees from Myoscience 

3 

Salary and equity position with Myoscience 


8:55 am – 9:00 am 97 ENHANCED SKIN REJUVENATION: A NOVEL COMBINED NON-ABLATIVE AND 

FRACTIONAL APPROACH 

Hanit Brenner-Lavie 1 , Yossi Adanny 1 , Avner Rozenberg 1 , Haim Epstein 1 , Genady 

Nahshon 1 , Ruthie Amir 1 , Ulrich Toft 1 , Tal Nachlieli 2 , Boris Vaynberg 1 , Syneron 

Medical, Ltd., Yokneam Illit, Israel, Assuta Medical Center, Haifa, Israel 

1 


1 

Equipment, consulting fees, honoraria from Syneron 

9:01 am – 9:06 am 





98 LONG-TERM EFFICACY AND SAFETY OF MICRO-FOCUSED ULTRASOUND FOR 

SKIN TIGHTENING AND LIFTING: RESULTS IN 183 KOREAN SUBJECTS 

Nark-Kyoung Rho, Chan-Woo Jeong, Deuk-Pyo Lee, Sangjin Park, Seung-Hui 

Kang, Jang-Hyun Shin, Byung-Soon Park, Leaders Aesthetic Laser & Cosmetic 

Surgery Center, Seoul, Korea 

9:07 am – 9:12 am 99 CLINICAL STUDY OF TRANSCUTANEOUS FOCUSED ULTRASOUND FOR LOWER 

FACIAL AND SUBMENTAL SKIN TIGHTENING IN ASIANS 

Nicola P.Y. Chan, Carol S. Yu, Johnny C.Y. Chan, Samantha S. Shek, Henry H.L. 

Chan 1 , The University of Hong Kong, Eye Institute, Hong Kong, China 

1 

Equipment from Ulthera





Grapevine, TX 

9:13 am – 9:18 am 100 CLINICAL AND HISTOPATHOLOGICAL EVALUATION OF A NEW NON-INVASIVE 

BODY CONTOURING DEVICE COMBINING HIGH POWER BIPOLAR 

RADIOFREQUENCY, INFRARED LIGHT, NEGATIVE PRESSURE AND MECHANICAL 

TISSUE MANIPULATION 

Hema Sundaram 1 , Jason N. Pozner 1 , Sundaram Dermatology, Cosmetic & Laser 

Surgery, Fairfax, VA, Sanctuary Plastic Surgery, Boca Raton, FL 

1 

Equipment from Syneron/Candela 

9:19 am – 9:36 am Q&A 

9:37 am – 9:42 am 


9:43 am – 9:48 am 


102 

9:49 am – 9:54 am 104 

9:55 am – 10:00 am 


COMPARISON OF FRACTIONAL Er:YAG AND CO2 LASERS IN RESURFACING OF 

ATROPHIC ACNE SCARS IN ASIANS 

Woraphong Manuskiatti, Thanawan Iamphonrat, Rungsima Wanitphakdeedecha, 

Sasima Eimpunth, Siriraj Hospital, Mahidol University, Bangkok, Thailand 

103 A PROSPECTIVE RANDOMIZED SPLIT-FACE COMPARISON STUDY OF NON- 

ABLATIVE FRACTIONAL LASER RESURFACING IN THE TREATMENT OF ACNE 

SCARRING IN FITZPATRICK SKIN PHOTOTYPES IV-VI 

Andrew Alexis, Marcy Coley, Janiene Luke, Sejal Shah, Yahya Argobi, Murad 

Alam, Skin of Color Center, St. Lukes Roosevelt Hospital, New York, NY, 

Downstate Medical Center, Brooklyn, NY, Northwestern University, Chicago, IL 

EVALUATION OF THE COMBINED TREATMENT WITH FRACTIONAL LASER AND 

FRACTIONAL RADIOFREQUENCY FOR ACNE SCARS IN ASIANS 

Chi Keung Yeung, Nicola P.Y. Chan, Carol S. Yu, Henry H.L. Chan 1 , The 

University of Hong Kong, Hong Kong, China 

1 

Equipment loan from Syneron 

105 THERMO-FRACTIONAL PDT FOR PERSISTENT WARTS 

Leonardo Marini, SDC-The Skin Doctors’, Center, Trieste, Italy 



10:01 am – 10:06 am 1064nm QS Nd:YAG LASER AND 1550nm ERBIUM-DOPED FRACTIONATED 

FIBER LASER FOR THE TREATMENT OF NEVUS OF OTA IN FITZPATRICK SKIN 

TYPE IV 

Paul Friedman, Irene Vergilis-Kalner, Jennifer Landau, Megan Moody, Leonard 

Goldberg, Denise Marques, DermSurgery Associates, Houston, TX 

10:07 am – 10:19 am Q&A 

10:20 am – 10:30 am Break 




85

86 

EXCIMER LASER AND HAIR REMOVAL 





Grapevine, TX 


This session focuses on the use of excimer lasers for the treatment of palmoplantar psoriasis and vitiligo. Each of 

the topics of innovative in-office and home-use devices and optimized treatment techniques for hair removal will 

also be addressed. Participants will develop an understanding of the present treatment indications, therapeutic 


Participants 





Participants should have a basic understanding of the fundamentals of skin biology, laser physics, and laser tissue 

interaction. 


Attendees will gain knowledge of cutting edge laser treatments and their clinical applications in the treatment of 

a variety of cutaneous conditions and hair removal. 

Hot Topics 

• Excimer laser for the treatment of palmoplantar psoriasis and vitiligo 

• Lasers with vacuum-assisted suction for hair removal 

10:31 am – 10:36 am 106 308nm EXCIMER LASER TREATMENT OF PALMOPLANTAR PSORIASIS 

David Goldberg, Nathalie Dietrich-Comte, Mussarrat Hussain, Skin Laser & 

Surgery Specialists of NY and NJ, New York, NY 

10:37 am – 10:42 am 





107 STUDY OF EFFICACY AND TOLERABILITY MONOCHROMATIC EXCIMER LIGHT IN 

TREATMENT OF VITILIGO 

Niteen Dhepe, Tushar Kshirsagar, Ashok Naik, Vaishali Phadke, Pune, India 

10:43 am – 10:48 am 108 USE OF COMBINATION LASERS FOR MORE EFFECTIVE HAIR REMOVAL 

Abnoeal Bakus, Dina Yaghmai, Jerome Garden, Northwestern Hospital, Chicago, 

IL 

10:49 am – 10:54 am 109 CLINICAL EVALUATION OF A 800nm LONG-PULSED DIODE LASER DEVICE WITH 

A LARGE SPOT SIZE AND VACUUM-ASSISTED SUCTION FOR HAIR REMOVAL 

Omar Ibrahimi, Suzanne Kilmer 1 , UC Davis Medical Center, Skin and Laser 

Center of Northern California, Sacramento, CA 

1 

Equipment, consulting fees and research grant from Lumenis 

10:55 am – 11:00 am 110 SAFETY AND EFFICACY OF A HAND-HELD DIODE LASER FOR UPPER LIP HAIR 

REMOVAL 

Brian Biesman 1 , Whitney Morris, Nashville Centre for Laser and Facial Surgery, 

Nashville, TN 

1 

Consulting fees and research grant from TRIA Beauty 

•Content discusses non-FDA approved device or off-label use





Grapevine, TX 

11:01 am – 11:06 am 111 BILATERAL AXILLA HAIR REMOVAL COMPARING A SINGLE WAVELENGTH 

ALEXANDRITE LASER WITH COMBINED MULTIPLEXED ALEXANDRITE AND 

Nd:YAG LASER TREATMENT FROM A SINGLE LASER PLATFORM 

Eric Bernstein 1 , University of Pennsylvania, Ardmore, PA 

1 

Equipment and research grant from Cynosure 

11:07 am – 11:12 am 


112 A SPLIT AXILLA COMPARISON STUDY OF AXILLARY HAIR REMOVAL WITH LOW 

FLUENCE HIGH REPETITION RATE 810nm DIODE LASER vs HIGH FLUENCE LOW 

REPETITION RATE 1064nm Nd:YAG LASER 

Rungsima Wanitphakdeedecha, Kanchalit Thanomkitti, Sasima Eimpunth, 

Woraphong Manuskiatti, Siriraj Hospital, Bangkok, Thailand 


11:13 am – 11:18 am A RANDOMIZED, BLINDED CLINICAL STUDY OF A MICROWAVE DEVICE FOR 

TREATMENT OF AXILLARY HYPERHIDROSIS 

Suzanne L. Kilmer, William Coleman III, Larry Fan, Dee Anna Glaser, Michael 

Kaminer, Robert Nossa, Stacy Smith, Laser & Skin Surgery Center of Northern 

California, Sacramento, CA, Coleman Center for Cosmetic Dermatologic 

Surgery, Metaire, LA, Bay Area Center for Plastic Surgery, Oakland, CA, St. Louis 

University, St. Louis, MO, SkinCare Physicians, Chestnut Hill, MA, The 

Dermatology Group of Northern New Jersey, Verona, NJ, Therapeutics Clinical 

Research, San Diego, CA 


11:19 am – 11:40 am Q&A 




87

88 





Grapevine, TX 

Photobiomodulation – Texas 4-6 8:00 am – 9:30 am 


8:00 am – 8:34 am 

8:35 am – 8:44 am 

8:45 am – 8:54 am 

8:55 am – 8:59 am 

9:00 am – 9:09 am 


9:10 am – 9:14 am 

9:15 am – 9:24 am 

9:25 am – 9:30 am 


Session 


PHOTOBIOMODULATION: CLINICAL APPLICATIONS 


164 REVIEW OF MECHANISMS BY WHICH THE SPONTANEOUS EFFECTS OF 

PHOTONS ARE AMPLIFIED IN VIVO: THE PASER PRINCIPLE 

Mary Dyson 1 , King's College, London, United Kingdom 

1 

Stockholder with Meditech-Bioflex International 


Discussion 

165 A 764 PATIENT RETROSPECTIVE STUDY REGARDING THE EFFICACY OF LOW- 

LEVEL LASER THERAPY FOR NON-INVASIVE BODY SLIMMING OF THE WAIST, 

HIPS, AND THIGHS 

Ryan Maloney 1 , Steven Shanks 2 , Jillian Maloney, Erchonia, McKinney, TX, 

University of Arizona, Gilbert, AZ 

1 

Consulting fees from Erchonia 

2 

Salary, stockholder, intellectual property rights with Erchonia 

Discussion 

166 LOW LEVEL LASER THERAPY FOR ADIPOSE REDUCTION IN 30 WOMEN 

Elizabeth VanderVeer, Carrie Anderson, VanderVeer Center, Portland, OR 


Discussion 

167 NOVEL NON-INVASIVE TECHNIQUE USING LOW LEVEL LASER FOR CHIN 

REJUVENATION 

Vinod Podichetty 1 , Jean-Claude Nerette, Research Practice Partners, Inc., 

Miramar, FL, Bellissimo Medical Center, Weston, FL 

1 

Consulting fees from Meridian Medical, Inc. 


Discussion





Grapevine, TX 

International Experience in Lasers in Dermatology - Texas D 8:00 am – 10:10 am 

Director: Thierry Passeron, M.D., Ph.D. 

8:00 am – 8:05 am 

8:06 am – 8:07 am 

8:08 am – 8:13 am 


8:14 am – 8:15 am 

8:16 am – 8:21 am 


8:22 am – 8:23 am 

8:24 am – 8:29 am 


8:30 am – 8:31 am 

International 

Experience in 


Dermatology 


FAT 

Maurice Adatto, Moshe Lapidoth 

A TWO-CENTER PROSPECTIVE CONTROLLED CLINICAL SAFETY AND EFFICACY 

OF 980nm DIODE LASER WITH NOVEL ENERGY REGULATION AND 

VISUALIZATION TECHNOLOGY FOR LASER ASSISTED LIPOSUCTION 

Neil Sadick 1 , Carmen Kavali, Theo Diktaban, Weill Cornell Medical College, New 

York, NY 

1 Funding and equipment from Osyris 

Discussion 

131 RADIAL ACOUSTIC WAVES FOR THE TREATMENT OF CELLULITE: A DOUBLE- 

BLINDED RANDOMIZED PROSPECTIVE STUDY VERUM vs PLACEBO 

Katharina Russe-Wilflingseder 1 , Elisabeth Russe, Plastische Chirurgie und 

Laserzentrum, Innsbruck, Austria 

1 Equipment from Storz Medical 


Discussion 

132 BODY SCULPTING WITH ACOUSTIC WAVE THERAPY: RANDOMIZED, 

CONTROLLED, STUDY ON 14 SUBJECTS 

Maurice Adatto 1 , R. Adatto-Neilson, P. Novak 2 , A. Krotz 2 , G. Haller 2 , SkinPulse 

Dermatology & Laser Center, Geneva, Switzerland, Storz Medical, Tagerwilen, 

Switzerland 

1 Equipment discount from Storz Medical 

2 Salary from Storz Medical 

Discussion 

133 REDUCTION IN ADIPOSE TISSUE VOLUME USING A NEW HIGH POWER 

RADIOFREQUENCY TECHNOLOGY COMBINED WITH INFRARED LIGHT AND 

MECHANICAL MANIPULATION FOR BODY CONTOURING 

Maurice Adatto 1 , Boris Vaynberg 2 , Ruthie Amir 2 , SkinPulse Dermatology & Laser 

Center, Geneva, Switzerland, Syneron Medical, Yokneam Illit, Israel 

1 Equipment discount from Syneron Medical 

2 Salary from Syneron Medical 

Discussion 

89

8:32 am – 8:37 am 

8:38 am – 8:39 am 

8:40 am – 8:45 am 

8:46 am – 8:47 am 

8:48 am – 8:53 am 

8:54 am – 8:55 am 

8:56 am – 9:01 am 


9:02 am – 9:03 am 

9:04 am – 9:09 am 


9:10 am – 9:11 am 

90 

International 

Experience in 


Dermatology 


SKIN TIGHTENING 





Grapevine, TX 

134 POST FACE LIFTING RF TREATMENT: CASE REPORTS AND FUTURE DIRECTIONS 

Tal Nachlieli 1 , Hanit Brenner-Lavie 2 , Ruthie Amir 2 , Eldad Moor 3 , Assuta Medical 

Center, Haifa, Israel, Syneron Medical, Yokneam Illit, Israel, Ramat Aviv Medical 

Center, Tel-Aviv, Israel 

1 

Equipment and salary from Syneron Medical 

2 

Salary from Syneron Medical 

3 

Equipment from Syneron Medical 

Discussion 

FRACTIONAL RESURFACING 

135 EFFICACY AND PATIENT SATISFACTION OF A NEW NON-ABLATIVE FRACTIONAL 

LASER 1340nm FOR THE FACIAL REJUVENATION IN BRAZILIAN PATIENTS 

Valeria Campos, Tatiana Cordero, Juliana Jordao, Jundiai, São Paulo, Brazil, 

Campinas, São Paulo, Brazil, Curitiba, São Paulo, Brazil 


Discussion 

136 A PILOT STUDY OF FRACTIONAL MICRO-PLASMA RADIOFREQUENCY FOR 

TREATMENT OF FACIAL SCARS AND RHYTIDS 

Shlomit Halachmi, Arie Orenstein 1 , Tania Meneghel, Moshe Lapidoth 1 , Rabin 

Medical Center, Petach, Tikva, Israel, Tel Hashomer Hospital, Tel Hashomer, 

Israel, Renaissance Medical Center, São Paulo, Brazil 

1 

Equipment from Alma 

Discussion 

137 TREATMENT OF DEPRESSED ACNE SCARS AND DEEP WRINKLES WITH A NOVEL 

MULTI-SOURCE FRACTIONAL RADIOFREQUENCY DEVICE – HISTOLOGICAL AND 

CLINICAL RESULTS ON 50 PATIENTS WITH LONG-TERM FOLLOW-UP 

Yoram Harth 1 , Klaus Fritz 2 , OR Medical Center, Herzlya, Israel, University 

Hospital, Bern, Switzerland 

1 

Travel expenses, salary, stockholder, equity position, intellectual property rights with EndyMed 

2 

Equipment from EndyMed 


Discussion 

138 SEQUENTIAL PHOTOTHERMAL 1064nm Nd:YAG AND 2940nm Er:YAG 

FRACTIONAL RESURFACING AND REMODELING vs 2940nm Er:YAG 

FRACTIONAL RESURFACING ALONE: A COMPARATIVE STUDY 

Leonardo Marini, SDC-The Skin Doctors’ Center, Trieste, Italy 

Discussion

9:12 am – 9:17 am 

9:18 am – 9:19 am 

9:20 am – 9:25 am 


9:26 am – 9:27 am 

9:28 am – 9:33 am 

9:34 am – 9:35 am 

9:36 am – 9:41 am 

9:42 am – 9:43 am 

9:44 am – 9:49 am 

9:50 am – 9:51 am 

International 

Experience in 


Dermatology 






Grapevine, TX 

139 COMBINED FRACTIONAL, NON-ABLATIVE TREATMENT OF STRIAE: CLINICAL 

AND HISTOLOGICAL OBSERVATIONS 

Vic Narurkar 1 , Christine Dierickx 1 , Carolyn Chang 1 , Ava Shamban 1 , Bay Area 

Laser Institute/CPMC, San Francisco, CA, Skin and Laser Center, Boom, Belgium, 

Laser Institute for Derm and European Skin Care, Santa Monica, CA 

1 


Discussion 

140 CLINICAL EFFICACY OF FRACTIONAL ERBIUM FIBER 1410nm LASER FOR 

TREATMENT OF DILATED PORES IN KOREANS 

JeeYoung Park, SangJun Lee, JiHo Rho, KyeKong Song, Arundaunnara 

Dermatologic Clinic, Chung-ang University, Seoul, Korea 

Discussion 


REJUVENATION OF THE NECK WITH THE E-MATRIX FRACTIONAL 

RADIOFREQUENCY DEVICE 

Sylvie Angel, Jean-Michel Mazer 1 , Paris, France 

1 

Honoraria from Syneron 

Discussion 


THE NEW FASHION VECTORIAL WAY TO IMPROVE FAT REMODELING AND 

SCULPTING THE FACE USING NON-INVASIVE IN MOTION SELECTIVE 

ULTRASOUND (ACCENT ULTRAFACE): 12 MONTH FOLLOW-UP 

Almeida Guiherme, Almeida Leticia, Elaine Marques, Rachel Queiroz, Hospital 

Sirio Libanes, São Paulo, Brazil 

Discussion 


COMBINED SHEAR WAVE ULTRASOUND AND UNIPOLAR RADIOFREQUENCY FOR 

NON-INVASIVE SELECTIVE LIPOLYSIS AND SKIN TIGHTENING: A PILOT STUDY 

Jong Min Park, ILOMYS Cosmetic Surgery and Laser Center, Seoul, Korea 


Discussion 

91

9:52 am – 9:57 am 

9:58 am – 9:59 am 

10:00 am – 10:05 am 

10:06 am – 10:10 am 

92 

International 

Experience in 


Dermatology 







Grapevine, TX 

924nm, 975nm LASER DEVICE: NEW APPROACH TO TREAT CELLULITE 

Rafael Nunes, Francisco Leite, Daniella Nunes, Luciana Camara, Ana Paula 

Martins, Monica Souza, Guilherme Nunes, Slim Clinique Laser Center and 

Bonsucesso Dermatology Hospital, Rio De Janeiro, Brazil, Centro De 

Dermatologia E Laser De Brasilia, Brasilia, Brazil 

Discussion 

130 A PILOT STUDY OF PULSED MAGNETIC THERAPY IN BODY CONTOURING 

Shlomit Halachmi, Maurice Adatto, Moshe Lapidoth, Rabin Medical Center, 

Petach, Tikva, Israel, SkinPulse Dermatology & Laser Center, Geneva, 



Discussion





Grapevine, TX 

ePoster Viewing Hours: Longhorn D&E 




ePoster Chair: Emil A. Tanghetti, M.D. 

ePosters 

Disclosure 


ePosters 

Twenty viewing stations will be located in the Exhibit Hall. We have extended the lunch hour and breaks to 

allow additional time for viewing ePosters and visiting with the exhibitors. No hard copy posters will be on 

display. A maximum of 4 CME credits will be offered for viewing the ePosters. In addition to the ePosters listed 

below, oral presentations listed throughout the program who also prepared and submitted an ePoster will be 

denoted with (ePoster available) next to their presentation time. 

ePoster Q&A 

Each ePoster will include a tab labeled “Questions and Answers”. When the conference attendee clicks on the 

Q&A tab, they will view a running list of questions along with each question’s corresponding answer from the 

author. Additionally, there will be a button labeled “Submit a Question”. When the conference attendee 

clicks this button, they will be provided with a form which has a blank area for them to type and submit their 

question to the author. The system will update every morning at 6:00 am local time. All questions and 

answers from the previous day will be posted to each ePoster. Also, the Q&A log will be viewable in the postconference 

online version, but the ability to ask questions will not be available in the post-conference online 

version. 

ACNE 

223 PURPURIC PULSE DYE LASER TREATMENTS OF ACNE REDUCE LESIONS – A CHART REVIEW 

Judith Hellman, Hadar Lev-Tov, Mount Sinai School of Medicine, New York, NY, SUNY Downstate 

College of Medicine, Brooklyn, NY 


250 FRACTIONAL CO2 LASER IN THE COMBINED TREATMENT OF PAPULOPUSTULAR ACNE VULGARIS 

Julia Pryaslova, Anastasia Tolstaya, Mikhail Golikov, Ksenia Krechko, Ekaterinburg, Russia 

DENTAL/ENT 

208 REVIEW OF THE LITERATURE: LOW LEVEL LASER THERAPY IN THE TREATMENT OF 

TEMPOROMANDIBULAR DISORDERS 

Hadi Daia, Heidi C. Crow, Thomas S. Mang, Buffalo, NY 


225 OCT vs CURRENT CLINICAL STANDARDS FOR EARLY-STAGE CARIES DETECTION 

Jennifer Holtzman, Kathryn Osann, Sandeep Potdar, Steven Duong, Yeh-chan Ahn, Zhongping Chen, 

Petra Wilder-Smith, Beckman Laser Institute and Medical Clinic, University of California, Irvine, CA 


93

94 

ePosters 





Grapevine, TX 

269 CLINICAL RESEARCH STUDY TO EVALUATE THE EFFECTS OF PROTOTYPE DENTIFRICES ON SOFT- 

TISSUE ARCHITECTURE 

Joseph Youssef, Steven Duong, Travis Tucker, Jun Zhang, Kathryn Osann, Petra Wilder-Smith, 

Beckman Laser Institute and Medical Clinic, University of California, Irvine, CA 


205 LOW FREQUENCY ULTRASOUND FOR NON-INVASIVE FAT CONTOURING 

Joseph Cervone 1 , UMDNJ, West Orange, NJ 

1 

Consulting fees, discount, and honoraria from Sound Surgical Technologies 


FAT 

212 PATIENT SATISFACTION AT 2 AND 6 MONTHS AFTER A SINGLE NON-INVASIVE CRYOLIPOLYSIS 

TREATMENT FOR SUBCUTANEOUS FAT LAYER REDUCTION 

Jeffrey Dover 1 , Michael Kaminer 1 , Maureen Teahan, Lauren Barrett, SkinCare Physicians, Chestnut 

Hill, MA 

1 

Consulting fees and research grant from Zeltiq 

232 LASER LIPOLYSIS WITH A 980nm DIODE LASER vs TRADITIONAL AND ULTRASOUND ASSISTED 

LIPOSUCTION: PERSONAL EXPERIENCE 

Tiziana Lazzari, Genova, Italy 

238 THE NEW FASHION VECTORIAL WAY TO IMPROVE FAT REMODELING AND SCULPTING THE FACE 

USING NON-INVASIVE IN MOTION SELECTIVE SHEAR WAVES ULTRASOUND (ACCENT ULTRA) 

Guilherme Almeida, Leticia Almeida, Elaine Marques, Rachel Queiroz, Hospital Sirio Libanes, São 

Paulo, Brazil 

255 IS SKIN TIGHTENING AN ADDED ADVANTAGE TO LASER LIPOLYSIS AS COMPARED TO CONVENTIONAL 

SUCTION ASSISTED LIPOSUCTION? A CONTROLLED STUDY 

Kenneth Rothaus 1 , New York Presbyterian Hospital Weill Cornell, New York, NY 

1 

Equipment, discount, research grant from Palomar 

266 A NOVEL THERAPY FOR EFFECTIVE CELLULITE TREATMENT IN WOMEN 

Carrie Anderson, Elizabeth VanderVeer, VanderVeer Center, Portland, OR 


FRACTIONAL RESURFACING 

206 TREATMENT WITH DUAL WAVELENGTH 1550nm and 1927nm FRACTIONAL LASER FOR FACIAL SKIN 

REJUVENATION IN ASIANS 

Nicola P.Y. Chan, Johnny C.Y. Chan, Mona L.S. Chiu, Henry H.L. Chan 1 The University of Hong Kong, 

Hong Kong, China 

1 

Stockholder with Solta

ePosters 





Grapevine, TX 

226 NEW TOTAL COMBINATION TECHNIQUES WITH PUNCH, FRACTIONAL AND LONG-PULSED Er:YAG 

LASER FOR THE TREATMENT OF ACNE SCARS COMPARED WITH THE CLASSIC SEQUENTIAL 

COMBINATION THERAPY 

Eun Ju Hwang, Jeanne Jung, Jong Hee Lee, Hun Suh Dae, Klaripa Clinic, Boramae Hospital, Seoul 

National Hospital, Seoul, Korea 

228 CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FRACTIONAL RADIOFREQUENCY 

SYSTEM 

Tae Woo Noh, Yoo Seok Kang, Un Ha Lee, Hyun Su Park, Sang Jai Jang, Bang Soon Kim 1 , Sanggye Paik 

Hospital, S&U Clinic, Seoul, Korea 

1 

Equipment from Syneron 

240 THE SAFETY AND EFFICACY OF MICRO ABLATIVE FRACTIONAL CO2 LASER IN THE TREATMENT OF 

NON-FACIAL SKIN PHOTODAMAGE, WRINKLES, PIGMENT DISORDERS AND LAXITY: A CASE SERIES OF 

480 BRAZILIAN PATIENTS 

Guilherme Almeida 1 , Elaine Marques, Leticia Almeida, Rachel Queiroz, Hospital Sirio Libanes, São 

Paulo, Brazil 

1 

Equipment from Ultrapulse 

247 CLINICAL EFFECTS OF GROWTH FACTOR BASED GEL vs VEHICLE IN PATIENTS TREATED WITH A 

NON-ABLATIVE, FRACTIONATED RESURFACING PROCEDURE 

Jennifer Peterson 1 , Sabrini Fabi, Mitchel Goldman 2 , Goldman Butterwick & Associates Cosmetic Laser 

Dermatology, San Diego, CA 

1 

Consulting fees from Skin Medica 

2 

Consulting fees from Skin Medica and Cynosure 

249 1927nm FRACTIONAL THULIUM FIBER LASER FOR THE TREATMENT OF NON-FACIAL 

PHOTODAMAGE: A PILOT STUDY 

Kristel Polder 1 , April Harrison, Leigh Ellen Eubanks, Suzanne Bruce 2 , University of Texas, Suzanne 

Bruce and Associates, Houston, TX 

1 

Equipment and honoraria from Solta 

2 

Equipment from Solta 


252 PRELIMINARY RESULTS OF A CLINICAL TRIAL USING A NOVEL INTRALESIONAL FRACTIONAL 

RADIOFREQUENCY DEVICE FOR DEEP DERMAL HEATING OF FACIAL SKIN 

Nark-Kyoung Rho, Jeong-Yeop Lee, Soohong Kim, Kyung-Ae Jang, Seok-Beom Park, Leaders Aesthetic 

Laser & Cosmetic Surgery Center, Seoul, Korea 


268 TREATMENT OF POST-INFLAMMATORY HYPERPIGMENTATION WITH 1927nm THULIUM FRACTIONAL 

LASER 

Jill Waibel, Dan Wasserman, Elizabeth Houshmand, Emily Tierney, Miami Dermatology and Laser 

Institute, Miami, FL, Total Skin and Beauty Dermatology Center, Birmingham, AL, Wright State 

University, Dayton, OH, South Shore Skin Center, Cohasset & Plymouth, MA 

95

96 

ePosters 

HAIR, PIGMENT AND TATTOO REMOVAL 





Grapevine, TX 

201 AGE OF TATTOO IS AN INDICATOR FOR THE RATE OF SUCCESS OF LASER-ASSISTED TATTOO 

REMOVAL 

Robert Anolik, Julie K. Karen, Elizabeth K. Hale, Leonard Bernstein, Roy G. Geronemus 1 , Laser and 

Skin Surgery Center of New York, New York, NY 

1 

Equity position with Solta 

203 HAIR REMOVAL WITH ALEXANDRITE LASER ON SKIN GRAFTS AFTER RECONSTRUCTIVE FACIAL 

SURGERY 

Cesar Arroyo, Antonio Diaz, Marcedes Martinez, Agustin De la Quintana, Patricia Homar, Madrid, 

Spain 

204 AGMINATED BLUE NEVI ARISING WITHIN A CONGENITAL MELANOCYTIC NEVUS: TREATMENT WITH 

755nm ALEXANDRITE LASER 

Portia Bradford, Corbin Petersen, Puja Puri, Claude Burton, Duke University Medical Center, Durham, 

NC 

207 HOME-USE HAIR REMOVAL DEVICES: DO THEY HAVE THE PARAMETERS DECLARED? 

Esther Cuerda, Jose Luis Lopez-Estebaranz, Jesus del Pozo-Losada, Rafael Linares, Maria Angustias 

Palomar, Universidad Rey Juan Carlos, Fundacion Universitaria Hospital Alcorcon, Hospital 

Universitario Juan Canalejo, Madrid, Spain 


210 TREATMENT OF BECKERS NEVUS WITH MODIFIED INTENSE PULSED LIGHT IN INDIAN SKIN 

Ashok Naik, Vaishali Phadke, Shubhangi Sundalam, Nirav Desai, Niteen Dhepe, Pune, Maharashtra, 

India 

211 USE OF A FRACTIONATED Q-SWITCHED RUBY LASER FOR TREATMENT OF FACIAL LENTIGINES 

Joseph Diehl, Lisa Chipps 1 , Ronald Moy 1 , David Geffen School of Medicine at UCLA, Los Angeles, CA 

1 

Equipment from Asclepion Laser Technologies 


231 URTICARIA INDUCED BY LASER EPILATION: STUDY OF 36 PATIENTS – BRIEF: A CLINICAL AND 

HISTOLOGICAL ASSESSMENT OF 36 PATIENTS 

Nerea Landa, Natalia Corrons, Inaki Zabalza, Jose Azpiazu, Dermitek Clinic, Sinpelo Clinics, Madrid, 

Spain, Galdakao Hospital, Bilbao, Bizkaia, Spain 

233 INTENSE PULSED LIGHT AND LOW-FLUENCE Q-SWITCHED Nd:YAG LASER ELICITS MORE RAPID 

CLINICAL IMPROVEMENT IN ASIAN PATIENTS WITH MELASMA 

Jong Hee Lee, Se Young Na, Soyun Cho, Seoul National University Boramae Hospital, Seoul, Korea 

245 PIGMENTATION SEQUELAE OF CUTANEOUS AIDS-RELATED KAPOSI’S SARCOMA SUCCESSFULLY 

TREATED BY Q-SWITCHED ALEXANDRITE AND Nd:YAG 532nm LASERS 

Rosalind Hughes, Jean-Philippe Lacour, Thierry Passeron, University Hospital of Nice, Nice, Alpes- 

Maritimes, France 


ePosters 





Grapevine, TX 

251 EVALUATION OF EFFICACY OF Q-SWITCHED Nd:YAG LASER FOR TATTOO REMOVAL IN INDIAN 

PATIENTS 

Srikantha Rathi, Niteen Dhepe, Ashok Naik, Dr. Dhepe’s Skin City, Solapur, Maharashtra, India 

262 MELASMA TREATMENT WITH A COMBINATION OF TOPICAL CREAMS AND PULSED CO2 FRACTIONAL 

ABLATIVE RESURFACING 

Mario Trelles, Mariano Velez, Instituto Medico Vilafortuny, Cambrils, Tarragona, Spain 

285 PERIORBITAL HYPERPIGMENTATION IN ASIANS: CAN A PROPOSED CLASSIFICATION IMPROVE 

TREATMENT OUTCOME? 

C.L. Goh, H. Ranu, S. Thng, B.K. Goh, A. Burger, National Skin Centre, Unilever, Singapore, Singapore 

IMAGING 

236 GUIDING PROSTATE CANCER PDT/LLLT THERAPIES USING AUTOMATIC WARPING OF MRI-BASED 

PLANNING DATA 

Nasr Makni, Philippe Puech, Mohamad-Feras Marqa, Serge Mordon, Nacim Betrouni, Inserm U703, 

CHU, Lille, France 


256 POLARIZED PHOTOGRAPHY OF THE SKIN 

Claudia Sa Guimaraes, Rio de Janeiro, Brazil 


264 EFFICACY OF A NOVEL NON-HYDROQUINONE FORMULATION IN THE TREATMENT OF MELASMA: A 

REFLECTANCE CONFOCAL MICROSCOPE STUDY 

Katerina Tsilika, Jean-Luc Levy, Hee-Yang Kang, Luc Duteil, Abdallah Khemis, Thierry Passeron, Jean- 

Paul Ortonne, Philippe Bahadoran, CHU of Nice, Nice, France, Center of Dermatological Lasers, 

Marseille, France 


284 DIAGNOSIS OF BASAL CELL CARCINOMA USING REFLEXIVE CONFOCAL LASER MICROSCOPY IN THE 

CLINICAL SETTING 

Steven Nelson, David Swanson 1 , Mayo Clinic, Scottsdale, AZ 

1 

Research grant from Mayo Clinic 


MEDICAL USE OF LASERS 

214 COMBINATION 15% AZELAIC ACID GEL AND INTENSE PULSE LIGHT THERAPY FOR MILD TO 

MODERATE ROSACEA 

Sabrina Fabi, Jennifer Peterson, Mitchel Goldman 1 , Goldman Butterwick & Associates Cosmetic Laser 

Surgery, San Diego, CA 

1 

Research grant from Intendis 

218 MULTIPLE SESSION LOW FLUENCE Q-SWITCHED Nd:YAG LASER TREATMENT OF MELASMA 

David Goldberg 1 , Nathalie Dietrich-Comte, Alia Brown, Mussarrat Hussain, Skin Laser & Surgery 

Specialists of NY and NJ, New York, NY 

1 

Research grant from Focus Medical 

97

98 

ePosters 





Grapevine, TX 

224 OPTICAL COHERENCE TOMOGRAPHY CAN DETECT AND QUANTIFY CHEMOTHERAPY-INDUCED ORAL 

MUCOSITIS 

Michael Hoang, Irvine, CA 


241 PULSED DYE LASER TREATMENT FOR JESSNER’S LYMPHOCYTIC INFILTRATION OF THE SKIN 

Jean-Loic Michel, Denis Perrin, Thierry Passeron, Laser Center, St-Etienne, Loire, France, Laser 

Center, Strasbourg, Bas-Rhin, France, University Hospital of Nice, Nice, Alpes-Maritimes, France 


OTHER 

200 STRIAE IMPROVEMENT WITH A NOVEL APPROACH BY SUBLATIVE REJUVENATION: A PRELIMINARY 

REPORT 

Maurice Adatto, Boris Vaynberg 1 , Ruthie Amir 1 , Hanit Brenner-Lavie 1 , Skinpulse Dermatology & Laser 

Center, Geneva, Switzerland, Syneron Medical, Yokneam, Illit, Israel 

1 

Salary from Syneron Medical 

267 BOTULINUM TOXIN A FOR THE EFFECTIVE TREATMENT OF TMJ AND BRUXISM 

Dianna Burget, Elizabeth VanderVeer, VanderVeer Center, Portland, OR 



163 LOW-LEVEL LASER THERAPY FOR ANDROGENIC ALOPECIA: A 24-WEEK RANDOMIZED DOUBLE-BLIND 

PLACEBO CONTROLLED TRIAL 

Jee Woong Choi, Jun Young Kim, Jung Bok Jung, Se Young Na, Seok-Jong Lee, Jung Im Na, Weon Ju 

Lee, Sang Woong Youn, Do Won Kim, Kyoung Chan Park, Chang Hun Huh, Seoul National University 

Bundang Hospital, Seongnam, Gyeonggi, Korea, Kyungpook National University School of Medicine, 

Dae-gu-Kyungsangpook, Korea 


235 SELF-ADAPTIVE EFFECTS OF LOW INTENSITY LASER IRRADIATION IN PROPHYLAXIS OF MUSCULAR 

FIBROSIS 

Li Luo, Lin Zhang, Timon Cheng-Yi Liu, School of Sports Science, Soochow University, Suzhou, Jiangsu, 

China, Laboratory of Laser Sports Medicine, South China Normal University, Guangzhou, Guangdong, 

China 


ePosters 

RESEARCH (BASIC SCIENCE) 





Grapevine, TX 

258 FLUENCE DEPENDENCY OF THE 400nm ABLATION RATES OF SUPRA- AND SUBGINGIVAL DENTAL 

CALCULUS 

Joshua Schoenly, Wolf Seka, Peter Rechmann, University of Rochester, Rochester, NY, School of 

Dentistry, University of California, San Francisco, CA 


RESURFACING 

217 CLINICAL EVALUATION OF 1550nm AND 1927nm LASER DELIVERED BY FRACTIONAL FOR ASIAN 

PATIENTS OF MELASMA AND ACNE SCARS 

Takahiro Fujimoto, Clinic F, Tokyo, Japan 

SKIN TIGHTENING 

239 THE NEW FASHION WAY TO IMPROVE THE APPEARANCE OF CELLULITE USING THE COMBINATION 

ON NON-INVASIVE SELECTIVE ULTRASOUND (ACCENT ULTRA) WITH IN MOTION UNIPOLAR 

RADIOFREQUENCY (ACCENT UNIFORM) 

Guilherme Almeida 1 , Elaine Marques, Leticia Almeida, Rachel Queiroz, Hospital Sirio Libanes, São 

Paulo, Brazil 

1 

Equipment from Accent 

SURGERY/INTERSTITIAL LASER THERAPY 

219 LASH WITH A 1210nm DIODE LASER IN SECONDARY KELOID SCAR PREVENTION, SAFETY RESULTS IN 

20 PATIENTS 

David Gonnelli, Sonia Saai 1 , Guy Magalon, APHM, Hospital Conception, Ekkyo, Aix-en-Provence, 

Marseille, Paca, France 

1 

Salary from Ekkyo 


THERAPY 

220 TRIAL OF LOW LEVEL LASER ACUPUNCTURE THERAPY FOR SMOKING CESSATION 

Anurag Gupta, Bonnie Treece, Michelle Kerr, Preet Kaur, Arun Gupta, New York, NY, Monroe, MI 


263 HISTOPATHOLOGY AND IMMUNOHISTOCHEMISTRY OF CUTANEOUS LUPUS ERYTHEMATOSUS AFTER 

PULSED DYE LASER TREATMENT 

Teresa Truchuelo, Pablo Boixeda, Carmen Moreno, Maria Luisa Zamorano, Javier Alcantara, Pedro 

Jaen, Ramon y Cajal Hospital, Madrid, Spain 

VASCULAR LESIONS 

209 PORT WINE STAINS PREVIOUSLY TREATED WITH AN INTENSE PULSED LIGHT SYSTEM. TREATMENT 

WITH A DUAL-WAVELENGTH LASER SYSTEM (595, 1064nm) IN 40 PATIENTS 

Jesus Del Pozo, Esther Cuerda, Lucia Perez-Varela, Laura Rosende, CHU A Coruna, A Coruna, Spain, 

University Rey Juan Carlos, Madrid, Spain 


99

100 

ePosters 





Grapevine, TX 

244 MULTI-WAVELENGTH LASER TREATMENT FOR CUTANEOUS VASCULAR LESIONS IN ASIANS 

Takafumi Ohshiro, Toshio Ohshiro, Katsumi Sasaki, Yuki Taniguchi, Ohshiro Clinic, Tokyo, Japan 

246 SUPERFICIAL LYMPHANGIOMA TREATED WITH FRACTIONAL ABLATIVE LASER: CLINICAL AND 

REFLECTANCE CONFOCAL MICROSCOPY EVALUATION 

Katerina Tsilika, Jean-Philippe Lacour, Philippe Bahadoran, Jean-Paul Ortonne, Thierry Passeron, 

University Hospital of Nice, Nice, Alpes-Maritimes, France 


253 TREATMENT OF PORT WINE STAIN USING A NEW OPTIMIZED PULSED LIGHT HANDPIECE 

E. Victor Ross 1 , Emily Yu, Scripps Clinic, San Diego, CA 

1 

Financial grant, equipment, consulting fees, research grant and honoraria from Palomar 

49 TREATMENT OF INFANTILE HEMANGIOMAS WITH THE 595nm PULSED DYE LASER USING DIFFERENT 

PULSE WIDTHS IN AN ASIAN POPULATION 

Yong-Kwang Tay, Changi General Hospital, Singapore





Grapevine, TX 

Exhibit Hall Hours: Longhorn D&E 




Exhibit Chair: Gregory T. Absten, B.Sc., M.B.A., C.L.R.T. (Exhibit Chair) 

Disclosure 


THE ASLMS CONFERENCE AND COURSES ARE INTENDED SOLELY FOR SCIENTIFIC AND EDUCATIONAL PURPOSES 

AND NOT TO PROMOTE OR ENDORSE PRODUCTS OR SERVICES. CHILDREN UNDER THE AGE OF 16 ARE NOT 

PERMITTED IN THE EXHIBIT HALL. THE SYMBOL � DENOTES THOSE COMPANIES WHO HAVE DONATED TO THE 6 TH 

ANNUAL SILENT AUCTION. 

NEW FOR 2011 - Exhibit Hall 

Exhibits 

• Located adjacent to largest scientific sessions. 

• All ePoster viewing stations, beverage breaks, internet pavilion, and the Silent Auction will be strategically 

located in the exhibit hall so conference attendees are encouraged to enter and move throughout the 

exhibit area. 

• Special “Exhibitor Breaks” will be scheduled from 2:45 pm - 3:45 pm on Friday and Saturday. Educational 

sessions on both Friday and Saturday will be adjourned during these times. 

• Free lunches for conference registrants on Friday and Saturday in the exhibit hall with tickets. 

• Two free drink tickets for conference registrants and exhibitors (based on booth size) during the exhibitor 

reception on Saturday. 

• Overhead announcements of scheduled activities will be made in the exhibit hall to inform and attract 

registrants to the exhibit area. 

• ASLMS will display announcements in all education session rooms prior to and after promoting attendance 

in the exhibit hall. 

Experts in the Hall 

Experts in the Exhibit Hall will give a five minute presentation followed by 10 minutes of questions and 

answers. Following is a schedule of speakers, topics, and dates/times of presentations. 

Date Time Speaker Topic 

Friday, April 1, 2011 3:00 pm – 3:15 pm Merete Haedersdal, M.D. Laser Safety 

Friday, April 1, 2011 3:15 pm – 3:30 pm Elizabeth L. Tanzi, M.D. The Cosmetic Consultation 

Saturday, April 2, 2011 3:00 pm – 3:15 pm Paul M. Friedman, M.D. How to Thrive in a Difficult 

Economy 

Saturday, April 2, 2011 3:15 pm – 3:30 pm Mathew M. Avram, M.D., J.D. Laser and the Law 

101

102 

Acuderm, Inc. ........................................ 528 

5370 NW 35 Terrace, Suite 106 

Ft. Lauderdale, FL 33309 

Since 1983, Acuderm has built its reputation as an 

innovator and supplier of high quality specialty 

medical products, disposable instruments, smoke 

evacuators and dermatologic supplies with eight 

patents across its product line (all made in the 

United States). Acuderm continues to be a leading 

edge manufacturer of products for the medical 

marketplace. 

ASLMS INDUSTRY ADVISORY COUNCIL MEMBER 

Aerolase ............................................... 801 

777 Old Saw Mill River Road 

Tarrytown, NY 10591 

Aerolase has developed innovative laser technology 

that enables treatment with shorter pulse 

durations, removing pain and discomfort from the 

treatments on all skin types while delivering bestin-class 

efficacy. Our LightPod lasers, which 

incorporate gold-standard 1064nm and 2940nm 

modalities, are used for permanent hair reduction, 

PFB, wrinkles, skin tightening, sun and age spots, 

vascular lesions, toenail fungus and many other 

conditions. LightPod lasers lead the industry in 

terms of providing the lowest total cost of 

ownership for aesthetic lasers. Aerolase has a 

reputation for exceptional customer service and 

support, providing training, upgrade options and 

materials for the marketing of your aesthetic 

services. 

VÉÑÑxÜ fÑÉÇáÉÜ 

�Allergan ............................................. 716 

2525 Dupont Drive 

Irvine, CA 92612 

Allergan Medical, a division of Allergan, Inc., offers 

the most comprehensive, science-based, aesthetic 

product offerings under its Total Facial 

Rejuvenation portfolio, including BOTOX® 

Cosmetic; hyaluronic acid and collagen-based 

dermal fillers; LATISSE (bimatoprost ophthalmic 

solution) 0.03%; and physician-dispensed skin care 

products. These products will be featured in our 

booth. 

�Donated to the ASLMS Silent Auction. 

Exhibits 





Grapevine, TX 

Alma Lasers, Ltd. ........................... Island 908 

485 Half Day Road, Suite100 

Buffalo Grove, IL 60089 

Alma Lasers is a global developer, manufacturer 

and provider of laser, light-based and 

radiofrequency equipment for cosmetic and 

medical applications. Alma Lasers' expertise lies in 

the winning combination of an ability to innovate 

bringing unique new technologies to the global 

aesthetic market, balanced by a strategic depth of 

clinical knowledge and industry experience. Each 

day, thousands of plastic surgeons, dermatologists, 

obstetricians, gynecologists and general physicians 

in 45 countries depend on Alma Lasers to deliver 

visible results that improve lives. 

American Society for Laser Medicine and Surgery 

(ASLMS) ................................................ 325 

2100 Stewart Avenue, Suite 240 

Wausau, WI 54401 

The American Society for Laser Medicine and 

Surgery is the world's largest scientific organization 

dedicated to facilitating research, education, and 

high standards of clinical care in the field of 

medical laser applications. It provides a forum for 

the exchange of scientific information and 

participates in communicating the latest 

developments in laser medicine and surgery to 

clinicians, research investigators, government, 

regulatory agencies, and the public. The Society 

has taken the lead in formulating standards and 

guidelines for establishing safe, effective laser 

programs in hospitals and other institutions, and 

has recommended standards for medical laser 

training programs. Stop by our booth, pick up a 

Society brochure, and complete an on-line 

membership application today. 

Anthony Products/Gio Pelle ....................... 206 

7740 Records Street 

Indianapolis, IN 46226 

For 40 years, Anthony Products has specialized in 

the manufacture and distribution of ENT, plastic 

surgery and dermatology instruments and 

equipment. As an authorized distributor for Welch 

Allyn and Midmark, we can meet all of your 

practice needs. Our sister company, Gio Pelle, 

specializes in customized skin care and 

microdermabrasion.

Astanza Laser ........................................ 233 

1770 Saint James Place, Suite 105 

Houston, TX 77056 

Astanza Laser is the global leader in tattoo removal 

technology. Our lasers are designed, manufactured, 

and used exclusively for laser tattoo removal by 

practitioners worldwide. Our flagship Trinity laser 

is the most useful Q-switched laser ever 

manufactured for tattoo removal – offering 

treatments with a 1 Joule Nd:YAG as well as a 1 

Joule Ruby laser. Astanza also shares expertise in 

tattoo removal treatments, patient care, and clinic 

operations. Our technology makes removing tattoos 

of all colors possible; our partnership with our 

customers helps make their practices thrive. 

Avo Photonics, Inc. ................................. 509 

700 Business Center Drive, Suite 125 

Horsham, PA 19044 

Avo Photonics, Inc. provides custom design and 

contract manufacturing of opto-electronic 

components and systems. Avo’s unique pure service 

model supports customers in the medical, military, 

communication, and commercial markets. From 

design thru production, Avo Photonics is a one-stop 

shop. Avo’s personnel and equipment are an 

extension of its customer’s business, providing 

transparent services at the volumes needed to 

advance from design to market dominance. From 

unique megawatt class lasers to high-volume 

automated manufacturing and environmental 

testing, Avo Photonics provides a cost effective 

outsourcing solution. Optical, mechanical, 

electrical, thermal, materials, and system 

engineering as well as all clean room production 

follow ISO certified quality procedures to assure 

consistent production. 






Grapevine, TX 

B&W Tek, Inc. ........................................ 215 

19 Shea Way 

Newark, DE 19713 

B&W Tek, Inc. is an advanced instrumentation 

company producing optical spectroscopy and laser 

instrumentation for biomedical, physical, chemical, 

and research communities. With a strong vertical 

integration capability, B&W Tek also provides 

custom product development, design, and 

manufacturing. With emphasis on low cost, high 

performance lasers and spectrometers, B&W Tek 

strives for versatility - innovating solutions. The 

ISO 9001 and ISO 13485 certified facility and the 

patented technologies ensure high quality 

products, consistently proven and growing every 

day. As a result, B&W Tek leads worldwide sales of 

Raman spectrometers. For more information go to 

www.bwtek.com. 

BTL Industries, Inc. ................................. 132 

312 Long Pointe Lane 

Columbia, SC 29229 

BTL Aesthetics introduces RF RedeFined with Exilis. 

A significant technological advance in 

radiofrequency aesthetic treatments. The exclusive 

Energy Flow Control system with variable surface 

cooling delivers precise volumetric heating of tissue 

for wrinkles, laxity and body contouring. Exilis 

patented applicators deliver maximum thermal 

effect without costly consumables, while ensuring 

total safety, comfort and control. 

Bank of America Practice Solutions ............. 328 

5 Park Plaza, Suite 350 


Bank of America Practice Solutions is your 

specialized practice lending source. Whether you 

want to purchase a single piece of equipment, 

remodel or expand your office, buy or start a new 

practice or purchase your office commercial real 

estate we have financing programs and options to 

make your goals a reality. See us at booth 328. 

�Buffalo Filter ....................................... 401 

595 Commerce Drive 

Buffalo, NY 14228 

Buffalo Filter ® is a medical device manufacturer 

with a primary focus on manufacturing and 

engineering products for the evacuation and 

filtration of hazardous smoke plume generated 

during laser/electrosurgical procedures. Products 

include: surgical smoke evacuators, ULPA/HEPA 

replacement filters, and accessories (tubes, 

adapters, and wands) for various medical 

specialties. 

103

104 

�Canfield Imaging Systems ....................... 601 

253 Passaic Avenue 

Fairfield, NJ 07004-2524 

Canfield Imaging Systems is the leading worldwide 

developer and provider of imaging software and 

photographic systems for the medical and skin care 

industries. Canfield products are utilized in medical 

and aesthetic practices, hospitals, skin care and 

wellness centers, spas, and medical spas. Product 

lines include industry-standard Mirror ® imaging 

software, VISIA ® complexion analysis, VECTRA ® 3D 

systems, Reveal ® facial imagers, customized 

photographic studio solutions and numerous 

specialized imaging devices and lighting systems for 

clinical photography. 

CareCredit ............................................ 628 

2995 Red Hill Avenue, Suite 100 

Costa Mesa, CA 92626-5923 

CareCredit ® , a part of GE Capital, is a revolving line 

of credit that offers patient financing programs. 

We offer convenient monthly payment plans to help 

you attract and schedule more patients. There is no 

cost to get started today. Call 866-247-3049 or visit 

www.carecredit.com. 

Celleration ............................................ 335 

6321 Bury Drive, Suite 15 

Eden Prairie, MN 55346 

Celleration ® manufactures and distributes MIST 

Ultrasound Healing Therapy ® . MIST ® reduces your 

patient’s recovery period by accelerating the 

body’s normal healing process. The painless, noncontact, 

low-frequency sound waves of MIST ® 

reduce inflammation, increase collagen deposition 

and reduce bacteria at and below the skin’s 

surface. 

Coherent, Inc. ....................................... 829 

5100 Patrick Henry Drive 

Santa Clara, CA 95054 

Coherent, Inc. is the World’s leading manufacturer 

of photonics-based products for a wide range of 

commercial and scientific applications; industry’s 

largest and most diverse selection of lasers and a 

wide range of laser test and measurement 

equipment. Highly reliable, high performance 

product lines include CO2, continuous-wave, diode, 

diode module, diode-pumped solid-state, optically 

pumped semiconductor lasers (OPSL), excimer, ion, 

tunable-dye, YAG, YLF, and ultrafast lasers. 






Grapevine, TX 

UÜÉÇéx fÑÉÇáÉÜ 

�CoolTouch, Inc. .................................... 224 

9085 Foothills Boulevard 

Roseville, CA 95747 

CoolTouch Inc. is a leading United States based 

developer and manufacturer of innovative, 

advanced laser products for medical professionals. 

Engineering and science-based, CoolTouch is 

considered a pioneer in the medical and aesthetics 

technology industry. CoolTouch introduced the 

first 1320nm wavelength laser to medical 

professionals for non-ablative wrinkle treatment. 

CoolTouch continued to set new standards in the 

industry with the launch of CoolTouch CTEV for 

varicose vein treatment and with CoolLipo for 

laser lipolysis and skin tightening. CoolTouch 

products are FDA-cleared and are manufactured in 

Roseville, California. For more information, please 

visit www.CoolTouch.com. 

Cosmeticsurgery.com ............................... 434 

8667 Haven Avenue, Suite 200 

Rancho Cucamonga, CA 91730 

At CosmeticSurgery.com, we provide total internet 

marketing solutions for cosmetic surgeons and 

dermatologists all over the country. Medical 

professionals have the opportunity to further 

increase their visibility on the Internet in regional 

and national markets. CosmeticSurgery.com is one 

of the most trusted and strongest brand names in 

the field of elective health care; we specialize in 

Web Design, Search Engine Optimization (SEO), 

Social Media, Directories, Blogs, and Video 

Marketing.

CuraMedix, LLC ...................................... 125 

500 East Washington Street, Suite 34 

North Attleboro, MA 02760 

CuraMedix, LLC is an emerging leader in medical 

technology focused on the development, 

distribution, utilization and commercialization of 

non-invasive biologic response activating devices in 

the regenerative medicine area for the repair of 

tissue, musculoskeletal and vascular structures. 

Extracorporeal Pulse Activation Technology (EPAT ® ) 

is proprietary technology based on several unique 

sets of acoustic pressure waves that activate 

biologic and angiogenic responses to include new 

vascularization and microcirculatory improvement, 

stimulation of collagen, increased metabolism, 

inducement of lipolysis and break down of fiberous 

tissue. EPAT ® is a breakthrough treatment which 

promotes healing and healthy tissue without 

invasive surgery. Fast, Safe, Effective, and 

Affordable! 

Cutera ......................................... Island 600 

3240 Bayshore Boulevard 

Brisbane, CA 94005 

Cutera is a leading provider of laser and other 

energy-based aesthetic systems for practitioners 

worldwide. Cutera is excited to launch two 

breakthrough systems, the Excel V and genesisplus 

lasers, at this year’s Annual Conference of the 

American Society for Laser Medicine and Surgery. In 

addition, Cutera’s multi-application Xeo platform 

combines the most versatile laser and light 

technologies in a single, upgradeable system. Since 

1998, Cutera has been developing innovative, easyto-use 

products that enable physicians and other 

qualified practitioners to offer safe and effective 

aesthetic treatments to their patients. For more 

information, call 1-888-4CUTERA or visit 

www.cutera.com. 






Grapevine, TX 



�Cynosure, Inc. ............................ Island 414 

5 Carlisle Road 

Westford, MA 01886-3601 

Cynosure, Inc. develops and markets premier 

cosmetic laser systems that are used by physicians 

and other practitioners to perform non-invasive and 

minimally invasive procedures to remove hair, treat 

vascular and pigmented lesions, rejuvenate the 

skin, liquefy and remove unwanted fat through 

laser lipolysis and temporarily reduce the 

appearance of cellulite. 



�DEKA Medical, Inc. ....................... Island 814 

665 Third Street, Suite 20 

San Francisco, CA 94107 

DEKA Medical, Inc., based in San Francisco, 

California, is the medical division of the El En 

Group, the world's largest manufacturer of lasers 

and pulsed light equipment for aesthetic and 

medical applications. DEKA offers a range of 

premium devices, including the highly acclaimed 

SmartXide DOT, Synchro FT, Excilite-μ, PhotoSilk 

and MiniSilk to the North American market. 

DermaSweep ......................................... 711 

3715 Atherton Road 

Rocklin, CA 95765 

DermaSweep MD, the latest evolution of microresurfacing 

skincare…from the sandblasting 

machines of the past to DermaSweep’s innovative 

combination of vacuum pressure, precision brush 

tips, and integrated topical delivery allows for the 

most personalized, targeted, and comfortable, 

particle-free system ever created. DermaSweep 

offers the pro-active practitioner the greatest 

possibility of overall skin health and benefits no 

matter what unique skin care needs are required. 

DermaSweep treatments can be completely 

personalized and combined with additional 

modalities to provide the most inclusive skin care 

program available. 

105

106 

DUSA Pharmaceuticals, Inc. ....................... 721 

25 Upton Drive 

Wilmington, MA 01887 

DUSA Pharmaceuticals, Inc. is an integrated, 

dermatology pharmaceutical company focused 

primarily on the development and marketing of its 

Levulan ® Photodynamic Therapy (PDT) technology 

platform. Levulan Kerastick ® plus blue light 

illumination using the BLU-U ® blue light 

photodynamic therapy illuminator is currently 

approved for the treatment of Grade 1 or II AKs of 

the face or scalp. 

Eclipse Aesthetics ........................... Island 200 

16850 Dallas Parkway 

Dallas, TX 75248 

With over 15 years experience in the aesthetic 

industry, Eclipse Aesthetics offers a wealth of 

practical insight and affordable aesthetic solutions 

to help build a successful practice. The Eclipse 

product portfolio includes: Equinox, a highly 

respected fractional CO2 laser system, EndyMed 

PRO with 3Deep RF technology, SmoothCool IPL 

system, the iPulse and the new RegenPlasma PRP 

program. Visit the Eclipse Aesthetics Island 200 to 

learn more about our equipment specials today! 

�Ellman International ............................. 227 

3333 Royal Avenue 

Oceanside, NY 11572 

Ellman International is a privately held 

manufacturer of medical devices used to perform a 

variety of aesthetic and surgical procedures. The 

Pellevé Wrinkle Reduction System is a key product 

used by physicians for skin tightening and to 

stimulate new collagen as a part of the skin 

rejuvenation process. 

Elsevier ................................................ 201 

5305 Burning Spring Court 

Arlington, TX 76017 






Grapevine, TX 

EltaMD Skincare ...................................... 720 

2055 Luna Road, Suite 126 

Carrollton, TX 75006 

EltaMD Skincare offers a variety of sunscreens, 

moisturizers, and post-procedure products, 

available to patients worldwide through approved, 

dispensing physicians. EltaMD is founded on the 

belief that the responsible and innovative 

application of medical expertise and science will 

change the way physician-dispensed skin care 

products treat people. EltaMD products are 

formulated using proven science, backed up by 

clinical testing designed to accomplish three goals: 

prevent damage, heal problems, and maintain skin 

health. Visit www.eltamd.com for more 

information. 

Energist NA ........................................... 913 

169 Main Street 

Nyack, NY 10960 

Energist Ltd, based is Swansea, South Wales, 

United Kingdom was founded in 1999. Energist 

Group designs, manufactures and markets a variety 

of light-based aesthetic devices, serving the 

medical, spa and beauty market segments. The 

Group’s MedArt facility in Copenhagen, Denmark, 

manufactures a range of fractional CO2 and diode 

lasers for medical, surgical, and aesthetic 

applications. With an installed base of over 8,000 

systems world-wide, Energist Group operates 

directly in both the United States and United 

Kingdom markets and in over 50 countries through 

a world class distribution network. 

Enhanced Image Technologies .................... 535 

15720 John J. Delaney Drive, Suite 300 

Charlotte, NC 28277 

Enhanced Image Technologies is your aesthetic 

solutions partner for imaging, laser and bodyshaping 

technologies, including: Image Pro skin 

imaging and Sellas True Fractional skin 

resurfacing. We help you enhance your image and 

your bottom line.

Envy Medical ......................................... 104 

31340 Via Colinas, Suite 101 

Westlake Village, CA 91362 

Envy Medical’s mission is to offer highly effective 

non-invasive skin rejuvenation therapies for 

patients suffering from either dermatologic or 

aesthetic conditions. The company's lead products 

include SilkPeel ® , a breakthrough system that 

combines precision non-invasive exfoliation with 

Dermalinfusion, deep delivery of a diverse set of 

skin-specific solutions, all designed to improve and 

revitalize the skin. The company has also 

introduced its first product line, under the brand 

name Lumixyl. Recent studies show that 

Lumixyl, incorporating a peptide chain of ten 

amino acids, treats hyperpigmentation more 

efficaciously than hydroquinone. 

Erchonia Corporation ............................... 220 

2021 Commerce Drive 

McKinney, TX 75069 

Stop by our booth 220 and experience what 

Erchonia’s laser health care can do for you. 

Proven, non-invasive, drug free solutions are in 

high demand as the public gets tired of hearing the 

negative side effects to prescription drugs. Try it 

for yourself; we will be conducting free 

demonstrations during exhibit hours. 

Fallene, Ltd. ......................................... 533 

2555 Industry Lane 

West Norritor, PA 19403 

Fallene, Ltd. is very excited to introduce our 

newest product, Tizo3 SPF40, into our physician 

dispensed line of products. Tizo3 is formulated 

with multiple physical particle sizes of titanium and 

zinc, yet dries to a clear, matte finish on any 

complexion. This unique formulation offers 

unparalleled protection, practically undetectable 

defense for the face that truly feels like silk on 

your skin, and can also used as a make-up primer. 

Tizo3 is paraben, paba, oil and fragrance free and 

is specially formulated without UV absorbing 

chemicals to offer superior, irritant free UVA/UVB 

light protection. No other sunscreen compares to 

Tizo3’s protective capability. 






Grapevine, TX 

FiberTech-RoMack .................................. 728 

P.O. Box 615 

Lightfoot, VA 23090 

LEONI Fiber Optics Inc. (LFOI) is a leading producer 

of high-end quartz/quartz multi-mode fibers and 

specialty fiber optic probes for medical 

applications. With its FiberTechR-Products, LFOI is 

a leading special fiber producer for medical fibers 

and for laser beam delivery. The optical fibers we 

produce are suitable for use with Nd:YAG, Ho:YAG, 

KTP, argon and diode lasers. We offer fibers for 

different wavelengths, with different numerical 

apertures (NA) and an Ultra low OH content in the 

size of 50 microns to 2,000 microns and configured 

with SMA 905 connectors or customized connector’s 

designs. Our fiber optics are used in Aesthetic, 

Vascular, Dermatology, General Surgery, Urology, 

Ophthalmology, Endoscopy and in all other laser 

medicine applications. We also produce fiber 

bundles and a very broad range of specialty fiber 

assemblies for many medical and industrial 

applications. 

Focus Medical ........................................ 824 

23 FJ Clarke Circle 

Bethel, CT 06801 

�FotoFinder Systems, Inc. ........................ 725 

9693 Gerwig Lane, Suite S 

Columbia, MD 21046-2837 

FotoFinder Mediscope is the imaging system for 

consistent before and after photo documentation of 

facial and body treatments. All camera settings 

are administered by computer and automatically 

adjusted for follow-ups. Outstanding before and 

after photos are taken every time by any user. 

SkinSpector quantifies vascular conditions (redness) 

and underlying sun damage (brown spots). The 

software Guided Photography assures user-friendly 

consistent body photography. 

107

108 

Fotona Lasers ............................... Island 708 

1415 1 st Street South, Suite 5 

Wilmar, MN 56201 

At Fotona we pride ourselves on our technical 

know-how, our experience in research and 

development and the unmatched clinical support 

and training provided to our owners. Fotona’s 

innovative laser system platforms allow 

practitioners to combine two effective treatment 

lasers in one system or acquire them individually. 

Fotona has a wide range of high-quality, highest 

performance systems to suit each particular 

practice’s needs. When additional applications are 

required, an upgrade will optimize any practice’s 

range of treatment services. When you own 

Fotona, you own the best made laser on the 

planet. 

HCG True Diet ........................................ 632 

5203 Heritage Avenue 

Colleyville, TX 76034 

The HCG True Diet is a medical weight loss 

program. We teach doctors how to add the HCG 

Diet to their practice and generate leads through 

online marketing. 

Hironic Co., Ltd. ..................................... 511 

913 Sicox Tower 

513-14 Sangdaewon-dong, Joonwon-gu 

Sungnam, Kyunggi 462-120 

Korea 

Hironic Co., Ltd. manufactures medical equipment. 

The new MIDAS RF machine with strong cooling 

system and infrared for face lifting and body 

shaping, the MIXEL dual focusing CO2 fractional 

laser with RF tube, the MIPL intense pulsed light 

with double filtering system, and Peltier cooling 

system and the MIDEPI 808nm diode laser for hair 

removal. 

Hopewell Pharmacy ................................. 123 

1 West Broad Street 

Hopewell, NJ 08525 

Hopewell Pharmacy is a full service compounding 

pharmacy located in central New Jersey. We 

specialize in custom prescriptions, from topical 

anesthetics, to injectables and other topical 

medications. We have a shipping department to 

ship directly to your office or to your patients. Stop 

by and see the latest in topical anesthetics offering 

the best combinations and most cost effective 

creams or ointments. Whatever laser or treatment 

you are doing, we have the solution! 






Grapevine, TX 

ZÉÄw fÑÉÇáÉÜ 


�HOYA ConBio ....................................... 415 

47733 Fremont Boulevard 

Fremont, CA 94538 

HOYA ConBio designs and manufactures 

sophisticated laser systems used in aesthetic 

medical practices worldwide. The company’s 

innovative technologies are highly versatile, 

clinically effective, and offer a rapid return on 

investment. The RevLite and MedLite Q-switched 

Nd:YAG lasers treats wrinkles, acne scars, 

pigmented lesions, unwanted tattoos and dark, 

vellus hair. The V-Raser 980 diode is FDA cleared 

for facial veins. HOYA ConBio’s newest laser, the 

DermaSculpt Er:YAG, is cleared for skin resurfacing 

and cutaneous lesions. 

Human Med, Inc. ..................................... 631 

1860 Crown Drive, Suite 1408 


An innovator and leader in water-jet surgery, 

human med ® is the world’s first and foremost 

manufacturer of water-jet assisted aesthetic 

devices. Human med’s innovative products, 

including the body-jet ® , harvest-jet ® , 

FillerCollector and LipoCollector II, have helped 

to usher in a fundamentally new approach to 

lipoplasty and natural fat harvesting. By continuing 

to explore and develop cutting-edge technologies, 

human med ® is dedicated to playing an integral 

role in the ongoing evolution of aesthetic medicine. 


�Incredible Marketing ............................. 332 

16441 Scientific Way, Suite 200 


Incredible Marketing, Inc. is a full service internet 

marketing firm with emphasis on custom Web site 

development and Search Engine Optimization 

(SEO). Our award winning custom work is 

specifically geared towards the medical and 

professional industry. We bring a unique one-onone 

approach to all clients, with an emphasis on 

developing a long term plan for success.

Innovative Optics, Inc. ............................. 217 

6812 Hemlock Lane 

Maple Grove, MN 55369 

Innovative Optics, Inc. is a manufacturer and 

distributor of laser eye protection for the clinician 

and the patient offering a complete selection of 

laser and IPL glasses. We offer three sizes of 

stainless steel patient intra-ocular shields as well 

as SmartShield disposable patient eye patches. Our 

new stainless steel patient laser goggle is designed 

for comfort and has a four way adjustment for a 

custom fit. Visit our website at 

www.InnovativeOptics.com. 

�International Aesthetic and Laser Assoc. .... 128 

P.O. Box 14629 

Tallahassee, FL 32317 

International Aesthetic and Laser Association is a 

non-profit association that is designed to bring 

stakeholders in the laser cosmetic industry 

together. The mandate for IALA is to enhance the 

image of the laser cosmetic services industry 

through the provision of standardized training and 

certification programs, promotion of safe and 

effective cosmetic procedures, proactively working 

with regulatory and legislative bodies to ensure the 

appropriate level of regulation, education programs 

for consumers and public awareness, and promote 

and/or develop research programs to further the 

effectiveness and safety of cosmetic laser services. 

Iredale Mineral Cosmetics ......................... 722 

28 Church Street 

Great Barrington, MA 01230 

Jane Iredale - The SKIN CARE MAKEUP ® is a 

comprehensive line of mineral cosmetics that 

provides products with the utmost integrity and the 

ability to enhance the lives of women through their 

effectiveness, simplicity and beauty. Founder and 

President, Jane Iredale, has worked with worldrenowned 

plastic surgeons and dermatologists in 

the development of her line because she believes 

makeup should be as good for the skin as it is 

aesthetically pleasing. 






Grapevine, TX 

Iridex Corporation ................................... 300 

1212 Terra Bella Avenue 

Mountain View, CA 94043 

Iridex Corporation is a leading worldwide provider 

of therapeutic based laser systems used to treat a 

variety of skin conditions. The VariLite system is 

the complete skin lesion laser solution for treating 

vascular lesions, benign pigmented lesions, 

cutaneous lesions, and acne vulgaris. Gemini ® gives 

you both a KTP laser and an Nd:YAG laser to treat a 

vast array of conditions including acne, wrinkles, 

redness diffusion, age spots, and unwanted hair. 

The Gemini, with its 1064nm Nd:YAG and 532nm 

KTP, stands out in an exploding non-invasive 

aesthetic laser market by pushing the envelope on 

versatility, speed and effectiveness, while 

maintaining a solid record of safety and reliability. 

With integrated contact cooling, dual wavelengths 

and dual handpieces, the Gemini gives you one of 

the most powerful aesthetic green lasers ever 

developed and treats a vast array of conditions 

including acne, wrinkles, redness diffusion, age 

spots, and unwanted hair. The VariLite, with its 

532nm KTP and 940nm diode wavelengths, offers 

dual-wavelength versatility in a single-system 

solution. It combines reliability with true 

portability, efficient performance, and clinical 

versatility for the precision treatment of vascular, 

pigmented, and cutaneous lesions. 

Jeisys Medical, Inc. ................................. 107 

307, Daerung Techno Tower 8 th , 481-11 

Gasan-Dong, Geumcheon-gu 

Seoul, Korea 

Jeisys Medical, Inc., a worldwide medical device 

manufacturer, produces high-end products for 

plastic surgeons, dermatologists, physicians, and 

health care professionals. Jeisys serves the 

industry as one of the leading companies with 

rigorous research and development level and 

valuable experience. Jeisys products are being 

globally marketed by overseas offices and 

worldwide distribution partners. For more 

information, go to www.jeisys.com. 

109

110 

Laser Concepts 

www.cosmeticlaserworld.com ................... 821 

11915 Quincy Lane 


Laser Concepts is the best value in the pre-owned 

laser business. With our ten years of successful 

sales in the business, Laser Concepts has proven to 

be the safest and most highly recognized company 

to invest in aesthetic equipment. Laser Concepts 

has established themselves as a leader in the 

industry with their knowledge, superior pre-owned 

equipment, service, and training. 

Laser Peripherals, LLC ............................. 106 

1000 Boone Avenue, Suite 300 

Golden Valley, MN 55427 

Laser Peripherals, LLC designs, manufactures, and 

distributes OEM's medical laser fibers for use in 

both hard and soft tissue surgical laser 

applications. We manufacture and market at least 

thirty different surgical fiber options for use with 

diode, holmium, KTP and Nd:YAG lasers. Fiber 

designs include free beam and contact and lateral 

emitting. Laser Peripherals has recently completed 

our ISO/CE certification and we are now actively 

looking for distribution partners in a variety of 

international markets. 

Laser Scientific ...................................... 516 

210A Commerce Boulevard 

Round Rock, TX 78664 

Laser Scientific specializes in designing, 

engineering, and manufacturing high performance 

laser components, replacement parts and 

accessories for a variety of cosmetic lasers. In 

addition, we provide nationwide service and global 

sales and support. Our customers include 

physicians, aestheticians, engineers, and medspa 

owners. Our development efforts are focused on 

re-engineering some of the laser parts known to 

have high failure rates. In addition to servicing and 

providing parts, Laser Scientific buys and sells both 

new and previously owned cosmetic lasers. 

Lasering s.r.l. ............................... Island 620 

Via Staffette Partigiane, 54 

Modena 41122, Italy 

The MiXto SX ® was the first Micro Fractional CO2 

Laser for skin resurfacing introducted in 2007. 

MiXto stands apart from all other fractional CO2 

lasers for many reasons. The laser energy is 

delivered in chopped CW mode. CW mode delivers 

more heat than any Ultra Pulse or Super Pulse 

system. The benefits include "no pin point" 

bleading and superior short and long term results. 





Grapevine, TX 

MiXto has a patent pending scanning algorithm that 

delivers the ablative spots in a "Z" pattern. This 

predetermined/reproducable scan pattern provides 

the greatest tissue relaxation time between strikes 

for greater patient comfort and lowers the risk of 

side effects. MiXto comes with two treatment spot 

sizes and adjustable treatment density gen. The 

180 micron spot is used for deeper penetration and 

skin tightening. The 300 micron spot is used to 

deliver superior heat energy for long term collagen 

production. MiXto is safe for all skin types. There 

are "NO" disposable costs with MiXto. MiXto is not 

just a fractional CO2 laser but can also be used in 

traditional resurfacing mode and as a surgical laser 

with cutting handpieces. Stop by our booth and ask 

about our "Show Special". 

Light Age, Inc. ........................................ 610 

500 Apgar Drive 

Somerset, NJ 08873 

Light Age, Inc. develops, manufactures and markets 

solid-state laser systems for aesthetic procedures 

and medical device research and development. 

Standard laser products, FDA approved, include our 

new ultra compact Q-Clear for treatment of age 

spots, pigmented lesions and tattoos, the Epicare 

for hair removal, and the Ta2Eraser for tattoo 

removal. 

Lippincott Williams & Wilkins .................... 311 

318 North Heartz Road 

Coppell, TX 75019 

Lippincott Williams & Wilkins will have on display 

the latest books and journals in aesthetic medicine, 

lasers, and dermatology. 

LocateADoc.com ..................................... 500 

1060 Woodcock Road 

Orlando, FL 32803 

LocateADoc.com powered by PracticeDock, our 

lead generation system delivers pre-qualified, 

quality patient leads to your practice. Transform 

quality prospects into business with PracticeDock, 

and its network of health-related Web sites and 

social media systems, including the award winning 

LocateADoc.com. Use real-time tools to track the 

success of your lead generation program down to 

your exact Return On Investment (ROI). With more 

than 650,000 unique Web site visitors per month 

and two million pages of educational content, 

LocateADoc.com has been named a Hitwise "Top 10 

Web site" since 2005 and is certified by Health On 

the Net Foundation (HON).



�Lumenis, Inc. ............................. Island 508 

5302 Betsy Ross Drive 

Santa Clara, CA 95054-1101 

Lumenis, Inc. is the leading developer, 

manufacturer and marketer of proprietary laser 

and intense pulsed light (IPL) systems. Lumenis 

aesthetic systems are reknown worldwide for 

advanced applications including scar reduction, 

fractional resurfacing, photorejuvenation, hair 

removal, improvement of vascular and pigmented 

lesions, and wrinkle reduction. Leading products 

include DeepFX and ActiveFX with UltraPulse, 

AcuPulse, LightSheer Duet, LumenisOne and M22. 

Lutronic, Inc. ................................ Island 320 

51 Everett Drive, A-50 

Princeton Junction, NJ 08550 

A global leader in aesthetic and medical laser 

systems, Lutronic is focused on providing advanced 

technology at an exceptional value. Our proven 

product portfolio reflects the company’s core 

competency of excellence in creating innovative, 

intuitive and versatile laser systems that deliver 

long-lasting results for clinicians and patients 

worldwide. Products include systems for fractional 

laser resurfacing, tattoo and pigmented lesion 

removal, non-ablative rejuvenation, laser surgery 

and facial contouring. 

MD-Ware Software .................................. 405 

1788 Drew Road, Suite A 

Mississauga, Ontario L5S 1L7 

Canada 

MD-Ware is the most powerful marketing and 

practice management software. MD-Ware offers an 

intuitive, easy touch screen design and flexibility. 

We are the obvious choice with our one-step 

QuickBooks Link, Credit Card Module, Online 

Booking, MD-EMR, the best technical support and 

the industry's first automated marketing. 






Grapevine, TX 


�MedCo Data, LLC .................................. 827 

1410 North Westshore Boulevard, Suite 710 

Tampa, FL 33607 

MedCo Data’s patent pending Workflow Centric 

Evaluation System is a tenured, proven 

methodology for matching an individual practice to 

the proper electronic record solution and then 

implementing with adoption standards exceeding 

“Meaningful Use” criteria. MedCo Data’s process is 

the most complete solution in the industry; 

covering budgeting, selection, negotiation, 

implementation, infrastructure and even long term 

support. 

MedEsthetics Magazine ............................ 709 

7628 Densmore Avenue 

Van Nuys, CA 91406-2042 

MedEsthetics Magazine provides up-to-date product 

information and covers service trends and business 

management issues for medical spa owners and 

physicians offering medical aesthetic procedures in 

specialized facilities. Each issue includes a business 

profile, an equipment update, marketing 

suggestions, management solutions and information 

on legal issues and training options. 

Medicis Aesthetics, Inc. ............................ 820 

7720 North Dobson Road 

Scottsdale, AZ 85256 

Medicis Aesthetics, Inc. is dedicated to helping 

patients attain a healthy and youthful appearance 

and self-image, and to help you redefine beauty in 

your patients. It’s at the heart of everything we do. 

Who’s better to bring you Perlane ® and the 

category’s sales leader in the United States and 

worldwide, Restylane ® . 

MedNet Technologies, Inc. ........................ 316 

1975 Linden Boulevard, Suite 407 

Elmont, NY 11003 

MedNet Technologies, Inc. designs, hosts and 

manages Web sites for medical practices, hospitals 

and other health care organizations. Clients range 

in size from small medical offices to teaching 

hospitals to medical societies. Developing and 

optimizing your Web presence on the internet is 

our goal. 

111

112 

MicroAire Surgical Instruments, LLC ............ 707 

1641 Edlich Drive 

Charlottesville, VA 22911 

MicroAire Aesthetics Instruments, LLC is a world 

leader in aesthetic plastic surgery through two 

groundbreaking products: the PAL ® LipoSculptor 

(power-assisted lipoplasty); and Endotine ® 

bioabsorbable multi-point fixation devices for 

cosmetic facial procedures. MicroAire Aesthetics 

also proudly makes EpiCut (epithelium tissue 

removal), SurgiWire and ReleaseWire 

(subcutaneous dissection). For more information, 

please visit microaire.com. 

Miramar Labs ......................................... 429 

445 Indio Way 

Sunnyvale, CA 94085 

Miramar Labs is a medical device company 

dedicated to bringing the next generation energy 

modality to dermatology. The company’s miraDry 

system is a revolutionary, non-invasive, quick 

outpatient treatment designed to provide a lasting 

solution for those suffering from excessive 

underarm sweat. miraDry utilizes a breakthrough 

microwave energy technology platform. 

�MJD Patient Communications .................. 408 

4915 Saint Elmo Avenue, Suite 306 

Bethesda, MD 20814-6093 

The new TopDocs.com is the physician’s portal with 

concierge service that provides up to 40% off on 

MJD’s Web site design, procedure brochures, 

looping DVD’s and MOH systems to give your 

cosmetic, plastic or laser practice a boost. Visit 

our booth to make sure you are listed in 

TopDocs.com. 

Neocutis, Inc. ........................................ 700 

512 East Eleven Mile Road 

Royal Oak, MI 48067 

Neocutis, a leader in innovative, effective skin care 

brings the precision of Swiss technology and 

cellular therapy research together for scientifically 

advanced breakthroughs in anti-aging and postprocedural 

recovery. PSP ® (Process Skin Cell 

Proteins), Neocutis’ proprietary skin care 

ingredient is derived from a biotechnology process 

that extracts rich proteins such as anti-oxidants, 

cytokines, and fibroblasts known to optimize wound 

healing and skin rejuvenation. 






Grapevine, TX 

NeoGraft ............................................... 904 

419 Southfork, Suite 103 

Lewisville, TX 75057 

The Follicular Unit Extraction (FUE) technique of 

the NeoGraft is the most advanced and minimally 

invasive hair transplant method to date. The 

NeoGraft system delivers automation of the FUE 

technique, the most advanced technique in the hair 

transplant industry. With the NeoGraft system 

procedure times are cut in half, with reduced 

patient discomfort and the most natural results of 

any hair transplant technology. NeoGraft is the 

leader in automated hair restoration with over 

10,000 hair transplant procedures performed 

worldwide. With a high return on investment, 

cutting edge technology, and rock solid 

dependability, the NeoGraft hair restoration system 

is the perfect fit for physicians searching for an 

exciting new revenue stream. 

�NexTech Systems, Inc. ........................... 619 

5550 West Executive Drive, Suite 350 

Tampa, FL 33609 

NexTech Practice 2011 is fully integrated Practice 

Management, Marketing, and (EMR/EHR) software 

designed specifically for dermatologists, cosmetic 

medical practices, and medical spas. With a client 

base of over 3,500 physician clients and 30,000 in 

staff worldwide, Practice 2011 is comprehensive, 

completely modular, and CCHIT 2011 certified. 

Main modules include Electronic Medical Records, 

Scheduling, Cosmetic Financial Accounting, E- 

Prescribing, Lab Integration, Insurance and 

Electronic Billing, Marketing, Inventory, Surgery 

Center Management, Spa Management, Contact 

Management, Patient and Prospect Tracking, 

Patient Education Forms, Skin Care Invoicing, 

Microsoft Word Mass Merge, Web site Integration, 

Photo Archiving, and Links to PDA’s and Smart 

Phones. 

OSA – The Optical Society ................. Tabletop 2 

2010 Massachusetts Avenue NW 

Washington, DC 20036 

The Optical Society brings together optics and 

photonics scientists, engineers, educators, and 

business leaders. OSA’s membership totals 15,500 

individuals from over 95 countries. Approximately 

47% of the Society’s members reside outside the 

United States. Visit www.osa.org for more 

information.

Obagi Medical Products ............................ 704 

3760 Kilroy Airport Way, Suite 500 

Long Beach, CA 90806 

Obagi Medical Products is the leader in providing 

therapeutic prescription-based skin care products 

in the physician-dispensed market. The products 

are designed to prevent, correct and improve the 

most common skin disorders in adult skin. The OMP 

product portfolio includes Nu-Derm, Condition and 

Enhance, CRx, CLENZIderm, ELASTIderm, Pro-C 

Serums and Rosaclear. 

�Oculo-Plastik, Inc. ................................ 403 

200 Suave West 

Montreal, Quebec H3L 1Y9 

Canada 

Oculo-Plastik, Inc. will have on display LaserSecure 

instruments and ocular shields (Cox and II H with 

offset handle and Durette II - III and IV external 

goggles). The Durette III and IV feature movable 

plastic or metal attachments, OPSoft mouthguard 

for hair removal, with laser IPL and RF systems, 

laser eyewear for the OR, cooling eye and face 

masks and disposable eye patches for laser IPL and 

LED. Not for laser: autoclavable yellow transparent 

or black plastic ocular shields, Jaeger and 

Desmarres, Durette plastic goggles (black) for PDT. 



�Palomar Medical Technologies, Inc. .. Island 400 

15 Network Drive 

Burlington, MA 01803 

Palomar Medical Technologies, Inc. develops the 

most advanced laser and pulsed-light systems for 

aesthetic applications including true laser body 

sculpting, permanent hair reduction, fractional skin 

resurfacing, and skin rejuvenation. Palomar's 

Starlux ® 500 and SlimLipo systems empower 

doctors to offer remarkable results with 

exceptional versatility, ease of use, and comfort. 

Discover "From Light Comes Beauty" at 

palomarmedical.com. 






Grapevine, TX 

PatientNOW ........................................... 100 

400 Inverness Parkway, Suite 200 

Englewood, CO 80112 

PatientNOW provides HHS-ONC Certified EMR and 

Practice Management software for aesthetic 

medical practices. Benefits of PatientNOW 

include: iPad application, The ONE EMR for your 

plastic surgery or aesthetic medical practice. 

Photocure ............................................. 127 

100 Overlook Center, 2 nd Floor 

Princeton, NJ 08540 

Photocure, the world leader in photodynamic 

technology, specializes in developing and 

commercializing highly selective and effective 

solutions for cancer and dermatology. Photocure is 

pleased to introduce their latest product, 

Allumera, a light-activated cosmetic treatment 

specially formulated to visibly reduce skin’s 

outward signs of aging while producing a more 

radiant and glowing complexion. 

�PhotoMedex ........................................ 606 

147 Keystone Drive 

Montgomeryville, PA 18936 

PhotoMedex offers innovative products including 

XTRAC ® excimer laser for dermatological 

applications, such as psoriasis, fiber-optic laser 

systems for surgical procedures, Neova ® line of 

products with patented Copper Peptide technology 

for skin, hair and wound care, and Omnilux line of 

LED products for acne, fine lines, and wrinkles. 

Photonics Media ..................................... 723 

2 South Street 

Pittsfield, MA 01201 

Photonics Media – the Pulse of the Industry – is 

Laurin Publishing Company’s international suite of 

media with more than 50 years of the industry’s 

leading publications. In print with Photonics 

Spectra and BioPhotonics magazines, the 

EuroPhotonics and AsiaPhotonics feature sections, 

the Photonics Showcase supplement and the 

Photonics Buyer’s Guide. Also online at 

www.photonics.com. 

113

114 

Pierre Fabre Dermo Cosmetique USA ........... 231 

9 Campus Drive, 2 nd Floor 

Parisippany, NJ 07054 

A global leader in dermatological skincare including 

brands Eau Thermale Avène, based on 

hydrotherapy, dedicated to sensitive skin; and 

Glytone®, offering the highest level of free glycolic 

acid through a systematic approach for skin 

rejuvenation and optimal skin health. 

www.glytone.com www.aveneusa.com 

Quantel Derma GmbH .............................. 732 

Am Wolfsmantel 46 

Erlangen 91058, Germany 

Quantel Derma GmbH develops and markets 

innovative dermatological laser and light-based 

systems for medical and aesthetic indications. The 

state-of-the-art technologies of the company based 

in Erlangen, Germany, are a worldwide synonym for 

certified quality and reliable benefits for the 

patient. At ASLMS 2011, Quantel Derma presents 

several highlights of its comprehensive product 

portfolio: The 308 EXCIMER SYSTEM, the handy, 

highly effective treatment solution for 

monochromatic UVB therapy with 308nm; and LEDA 

EPI the cutting edge diode laser system for high 

speed hair removal on all skin types. 

RPMC Lasers, Inc. ................................... 121 

203 Joseph Street 

O’Fallon, MO 63366 

Since 1996 RPMC has been offering high power 

single emitters in wavelengths from 622nm - 

2.3μm, laser diode bar products including 

unmounted bars, conductive packages, 

microchannel cooled stacks, and fiber coupled 

packages, laser diode modules, and laser diode 

accessories including laser diode drivers, TEC 

controllers, and heatsinks. 

Ra Medical Systems, Inc. ........................... 108 

2270 Camino Vida Roble 

Suite L 

Carlsbad, CA 92011 

Ra Medical Systems, Inc. markets the PHAROS EX- 

308, an advanced 308nm super narrowband UVB 

excimer laser for the treatment of psoriasis, 

vitiligo, atopic dermatitis, and leukoderma. 






Grapevine, TX 

Revision Skincare .................................... 911 

9019 Premier Row 


Revision Skincare makes the highest quality 

products with one overriding purpose: to solve a 

patient’s skin care problems. Based on the 

principal that cosmeceuticals must provide a 

targeted solution, their formulas are designed to 

correct each skin care condition through multiple 

pathways. They use only the purest, premium 

quality ingredients in their products and sell them 

exclusively to physicians in over 10 countries. The 

crown jewel of Revision Skincare is their worldrenowned 

staff of chemists who have developed 

many breakthrough formulas that combat acne, 

aging skin and other complex dermatological 

conditions. Highly effective products like 

Teamine ® , Nectifirm ® , Intellishade ® , Revox II and 

their Advanced Skincare Line. Every day, 

scientific advances in skin care are made at their 

Dallas, Texas facility, where they test, 

manufacture and distribute their own clinicallyproven, 

high-performing products. For more 

information call 800-385-6652 or visit 

www.revisionskincare.com. 

�Rockwell Laser Industries ....................... 805 

7754 Camargo Road 

Cincinnati, OH 43243 

Rockwell Laser Industries offers integrated laser 

safety services, consulting features FDA/CDRH/IEC 

compliance reporting assistance, testing and ANSI 

audits. Training institute offers in-depth laser 

safety courses with hands-on experience. Product 

line includes eyewear, barriers, interlock systems, 

signs/labels, windows, hazard analysis software, 

viewers, measurement equipment, 

manuals/standards and interactive training 

materials.

Sandstone Medical Technologies ......... Island 520 

105 Citation Court 

Homewood, AL 35209 

Sandstone Medical Technologies was founded with 

the goal of providing physicians state-of-the-art, 

easy to use, aesthetic lasers and light based 

technologies at an affordable price. Current 

products include: The Matrix LS-40 CO2 laser for 

fractional skin resurfacing, the Cheveux 810nm 

diode laser for permanent hair reduction, the 

Apollo IPL for the treatment of vascular and 

pigmented lesions and active acne, the UltraLight- 

Q, dual wavelength (1064/532nm) laser for the 

removal of tattoos and the Whisper-3G Er:YAG 

system for the famous, minimal downtime 

“Lunchtime laser peel.” All systems include a twoyear 

warranty and our unmatched “Buy-Back 

Guarantee.” 

�Sciton, Inc. ................................ Island 800 

925 Commercial Street 

Palo Alto, CA 94303 

Sciton provides best-in-class laser and light source 

solutions for medical professionals who want 

superior durability, performance and value. We 

offer high quality, expandable platforms with 

modules for fractional skin resurfacing, superficial 

and deep skin peeling, laser-assisted lipolysis, 

wrinkle reduction, hair removal, treatment of 

vascular and pigmented lesions, phototherapy, scar 

reduction, and treatment of varicose veins and 

acne. 

Skin & Aging .......................................... 630 

83 General Warren Boulevard, Suite 100 

Malvern, PA 19355 

Skin & Aging is an award-winning dermatology 

journal that provides practical advice to help 

dermatologists treat common conditions such as 

skin cancer, acne and psoriasis, as well as how to 

incorporate cosmetic procedures such as Botox and 

laser skin resurfacing into dermatology practice. 

Also provided are practice management topics such 

as managed care, legal issues and coding 

techniques. This monthly journal offers timely 

information presented by respected dermatologists 

in an attractive, easy-to-read format. 






Grapevine, TX 

SkinMedica, Inc. ..................................... 900 

5909 Sea Lion Place, Suite H 

Carlsbad, CA 92010 

An innovator in the area of skin health, SkinMedica 

develops and markets prescription and nonprescription 

products to physicians to treat 

dermatologic conditions and improve the 

appearance of skin. Our line of aesthetic skin care 

products enhance skin appearance and reduce signs 

of aging and include the revolutionary TNS Essential 

Serum and hallmark TNS Recovery Complex ® . 


�Solta Medical, Inc. ....................... Island 214 

25881 Industrial Boulevard 

Hayward, CA 94545 

Solta Medical, Inc. develops innovative products 

that meet and exceed needs of the growing 

aesthetic market. We engineer safe, effective 

solutions for patients and deliver compelling 

business opportunities for physicians. We are 

committed to superior innovation, research and 

development. Solta Medical is a collaboration of 

the industry’s two leading brands: Thermage, 

pioneer in non-invasive skin tightening and 

contouring, and Fraxel, premier solution for skin 

resurfacing. The Thermage and Fraxel systems, 

both delivering non-invasive treatments with 

minimal recovery time, enable physicians to offer 

more compelling solutions to the anti-aging 

market. For more information, call 1-877-782-2286 

or go to www.solta.com. 

Sound Surgical Technologies, LLC ............... 427 

357 South McCaslin Boulevard, Suite 100 

Louisville, CO 80027 

Sound Surgical Technologies is a leading 

manufacturer and distributor of ultrasonic body 

shaping technologies, including the VASER Lipo ® , 

VASER ® Shape MC1 and MedSculpt Systems. 

VASER Lipo ® effectively treats all areas of the body 

and is clinically proven to enhance skin retraction, 

reduce blood loss, and maintain the viability of fat 

cells for fat grafting procedures. The VASER Shape 

MC1 and MedSculpt Systems is an ideal 

companion to VASER Lipo ® , combining ultrasound 

and massage therapies to increase lymphatic and 

venous circulation, minimize postoperative pain 

and swelling, and temporarily improve the 

appearance of cellulite. All of the devices are FDAcleared 

for use in the United States. To learn more, 

visit www.vaser.com. 

115

116 

SPIE ........................................... Table Top 1 

1000 20 th Street 

P.O. Box 10 

Bellingham, WA 98227-0010 

SPIE is an international society advancing an 

interdisciplinary approach to the science and 

application of light. The SPIE Digital Library houses 

over 300,000 technical papers from the Society's 

conference proceedings and journals in cutting 

edge technologies such as biophotonics, 

nanotechnology, sensors, lasers, electro-optics, 

imaging, solar energy and communications. 

Founded in 1955, the Society has 164 Student 

Chapters around the world, and more than 16,000 

individual; 5,000 student; and 450 corporate 

Members in 84 countries. Visit SPIE.org. 

SPECTRUM Photomedicine ........................ 130 

7481 Warden Road 

Sherwood, AR 72120 

Providing the S cience, P ractice, E ducation, C 

reativity, T echnology, R esearch, U understanding 

and M arketing of Photomedicine. Display of RJ 

Laser products and integration with Electronic 

Health Record and Practice Management systems of 

Horizon Medical World. Physician will also provide 

tips on how to integrate photomedicine in clinical 

practice examples from United Pain Care and 

Medical Esthetique. 

Surgimedics ........................................... 808 

2950 Mechanic Street 

Lake City, PA 16423 

Smoke Evacuators are primarily used during ESU 

and laser procedures to remove smoke plume, 

reduce potential mutagens, and reduce odors near 

the site. Surgimedics' unique low cost removable 

pre-filter protects and extends the life of the 

primary 4-stage ULPA filter which is the leading 

cost of consumables in smoke evacuation systems. 

Get yours today! 






Grapevine, TX 


�Syneron/Candela .......................... Island 306 

530 Boston Post Road 

Wayland, MA 01778 

Syneron manufactures and distributes medical 

aesthetic devices that are powered by the 

proprietary elos technology that enable physicians 

to offer advanced solutions for a broad range of 

aesthetic applications. Syneron’s recent merger 

with Candela Corporation now creates the largest 

aesthetic medical device company with the 

broadest portfolio of products and an unrivaled 

pipeline of innovation. Together, our combined 

experience, financial strength and world-class 

customer service will provide the support our 

customers need to build their practice. 

�Syris Scientific ..................................... 507 

22 Shaker Road 

P.O. Box 127 

Gray, ME 04039 

Syris Scientifics' patented cross polarized 

visualization systems continue to allow health care 

providers to see vascular structures 1mm below the 

skin's surface. Laser, sclerotherapy and 

dermatologic procedures are enhanced by the 

reduced glare, magnification and illumination. The 

v300, v600 or the Vantage are defined as truly a 

"Light so unique it must be experienced." Ask about 

our 30-day no risk trial offer. Visit our Web site 

www.syrisscientific.com or call us at 800-714-1374 

for more information. 


�THE Aesthetic Guide ............................. 203 

120 Vantis, Suite 470 

Aliso Viejo, CA 92656 

THE Aesthetic Guide, which has a readership of 

20,000 medical aesthetic practices, is published by 

Medical Insight, Inc. We also publish THE European 

Aesthetic Guide. Free subscriptions are available to 

qualified medical aesthetic practices. Medical 

Insight, Inc. also conducts market research and 

publishes market studies. Visit www.miinews.com 

for a complete list of services.

The Laser Network, LLC ........................... 309 

19336 Goddard Ranch Court, Suite 201-203 

Morrison, CO 80465 

The Laser Network (TLN) was developed to service 

the redeployment needs of the medical community 

in the areas related to medical lasers and IPL 

systems. The members of TLN utilize a 

revolutionary Web driven service, 

TheLaserTrader.com, designed to insure both 

buyers and sellers receive the most professional 

services available. 

ThermoTek, Inc. ..................................... 810 

1200 Lakeside Parkway, Suite 200 

Flower Mound, TX 75028 

ThermoTek, Inc. has been a leader in the medical 

device industry for more than 15 years with 

innovative designs for precision thermal 

management solutions. Our newest introductions 

for the aesthetic and therapeutic market are the 

ArTek Spot and the ArTek Air which are effective 

dermal cooling devices for laser/light based 

treatments and injectables. 

TJ Sales Associates, Inc. ........................... 417 

3010 Route 10 

Denville, NJ 07834 

TJ Sales Associates, Inc. is a technical laser 

company supporting the medical, cosmetic, 

industrial and scientific laser markets worldwide 

since 1980. TJS also provides on-site service and 

repairs for many lasers including Lumenis, 

Cynosure, Candela, Alma, Cutera, Palomar, Sciton 

and many more. You will find we offer a 

comprehensive inventory containing such items as 

OEM flashlamps, optics, fibers, crystals, cavities, 

filters, safety glasses and diagnostic tools to name 

a few. 






Grapevine, TX 



�Ulthera, Inc. ....................................... 529 

2150 South Country Club Drive, Suite 21 

Mesa, AZ 85210 

The innovative Ulthera system platform utilizes 

focused ultrasound with visualization for noninvasive 

treatment of lax skin and its support 

structure. For the first time, practitioners can see 

and thermally coagulate not only the dermis, but 

the underlying fibro-muscular layer, resulting in 

significant, reliable outcomes, and the first-ever 

energy-based device to receive FDA clearance for 

non-invasive lift. 

UltraShape NA, Inc. ................................. 333 

2603 Camino Ramon, 2 nd Floor 

San Ramon, CA 94583 

UltraShape ® redefines aesthetic medicine by 

developing, manufacturing and marketing 

innovative non-invasive technologies for fat cell 

destruction and body sculpting. The company 

develops and markets clinically proven safe and 

effective solutions that enhance the lives of 

patients. The new V3 by UltraShape ® uses 

proprietary new Vertical Dynamic Focus (VDF) 

ultrasound technology that employs pulsed (nonthermal) 

focused ultrasound that instantly, 

selectively and permanently destroys fat cells 

without affecting surrounding structures and 

RFVac vacuum-assisted radiofrequency to create a 

synergistic effect and tighten tissue. The Contour I 

V3 system is not FDA cleared for sale in the United 

States. 

117

118 

Venus Concept Ltd. ................................. 432 

38 HaBarzel Street 

Tel Aviv 40591, Israel 

Venus Concept, Ltd. is a leading developer and 

manufacturer of innovative medical aesthetics 

devices. The company began its operations in 

November 2006, and reached profitability soon 

afterwards. Venus Concept's products represent the 

ultimate fusion in high-tech and aesthetics and are 

powered by patented technologies, with clinical 

efficacy proven in over one million successful 

treatments worldwide. With over 100 years of 

combined experience, the very seasoned senior 

management team of Venus Concept understands 

the new industry dynamic and has set out to 

develop an organization of top pedigree individuals 

committed to 100% customer satisfaction and 

success. 

WON Technology Co., LTD ........................ 627 

538 Yongsan-dong 

Yuseong-gu 

Daejeon 305-500, South Korea 

Yodle ................................................... 504 

50 West 23 rd Street, 4 th Floor 

New York, NY 10010 

Yodle, a leader in local online advertising and 

named fastest growing local online advertising 

company by industry analyst Borrell Associates, 

connects thousands of local businesses with 

consumers in a process so simple and cost-effective 

that business owners can't imagine any other way 

to advertise. Yodle has developed an integrated 

approach to signing up and serving local businesses 

that are transitioning their marketing budgets 

online. Yodle is headquartered in New York, New 

York with a presence in 25 major cities across the 

United States. 






Grapevine, TX 


�Zeltiq Aesthetic, Inc. ............................. 615 

4698 Willow Road 

Pleasanton, CA 94588 

Zeltiq Aesthetics, founded in 2005, is a sciencebased 

medical device company dedicated to the 

development of non-invasive procedures for the 

reduction of unwanted fat tissue. The Zeltiq 

approach utilizes a patented method called 

Cryolipolysis (the use of precisely controlled 

cooling to remove fat) that is designed to only kill 

fat cells and not harm the skin or other tissue. 



�Zimmer MedizinSystems ......................... 806 

172 Fallow Deer Road 

Franktown, CO 80116 

Zimmer MedizinSystems offers comfort solutions for 

your aesthetic practice. Our Cold Air devices are 

designed to cool the epidermis while distracting 

the patient. Zimmer Cold Air devices are used in a 

wide range of aesthetic procedures. Please come 

by our booth to see our adapters for many of the 

Candela laser devices.

Exhibitor Listing 

Acuderm, Inc. ................................................ 528 

Aerolase ....................................................... 801 

Allergan ........................................................ 716 

Alma Lasers, Ltd... ................................... Island 908 

American Society for Laser Medicine and Surgery ...... 325 

Anthony Products/Gio Pelle ................................ 206 

Astanza Laser ................................................. 233 

Avo Photonics, Inc. .......................................... 509 

B&W Tek, Inc. ................................................ 215 

BTL Industries, Inc. .......................................... 132 

Bank of America Practice Solutions ....................... 328 

Buffalo Filter ................................................. 401 

Canfield Imaging Systems. .................................. 601 

CareCredit .................................................... 628 

Celleration .................................................... 335 

Coherent, Inc. ................................................ 829 

CoolTouch, Inc. .............................................. 224 

Cosmeticsurgery.com ....................................... 434 

CuraMedex LLC ............................................... 125 

Cutera. ................................................. Island 600 

Cynosure, Inc. ......................................... Island 414 

DEKA Medical, Inc. .................................... Island 814 

DermaSweep .................................................. 711 

DUSA Pharmaceuticals, Inc. ................................ 721 

Eclipse Aesthetics ..................................... Island 200 

Ellman International ......................................... 227 

Elsevier ....................................................... 201 

EltaMD Skincare .............................................. 720 

Energist NA .................................................... 913 

Enhanced Image Technologies ............................. 535 

Envy Medical .................................................. 104 

Erchonia Corporation ........................................ 220 

Fallene, Ltd. .................................................. 533 

FiberTech-RoMack ........................................... 728 

Focus Medical ................................................. 824 

FotoFinder Systems, Inc. ................................... 725 

Fotona Lasers .......................................... Island 708 

HCG True Diet ................................................ 632 

Hironic Co., Ltd. ............................................. 511 

Hopewell Pharmacy .......................................... 123 

HOYA ConBio .................................................. 415 

Human Med, Inc. ............................................. 631 

Incredible Marketing ......................................... 332 

Innovative Optics, Inc. ...................................... 217 

International Aesthetic and Laser Association .......... 128 

Iredale Mineral Cosmetics .................................. 722 

Iridex Corporation ........................................... 300 

Jeisys Medical, Inc. .......................................... 107 

Laser Concepts – www.cosmeticlaserworld.com ........ 821 

Laser Peripherals, LLC ...................................... 106 

Laser Scientific .............................................. 516 

Lasering s.r.l. .......................................... Island 620 





Grapevine, TX 

Light Age, Inc. ................................................ 610 

Lippincott Williams & Wilkins .............................. 311 

LocateADoc.com ............................................. 500 

Lumenis, Inc. .......................................... Island 508 

Lutronic, Inc. ......................................... Island 320 

MD-Ware Software ........................................... 405 

MedCo Data, LLC ............................................. 827 

MedEsthetics Magazine ...................................... 709 

Medicis Aesthetics, Inc. ..................................... 820 

MedNet Technologies, Inc. .................................. 316 

MicroAire Surgical Instruments, LLC....................... 707 

Miramar Labs .................................................. 429 

MJD Patient Communications .............................. 408 

Neocutis, Inc. ................................................. 700 

NeoGraft ....................................................... 904 

NexTech Systems, Inc. ...................................... 619 

Obagi Medical Products ..................................... 704 

Oculo-Plastk, Inc. ............................................ 403 

OSA – The Optical Society .......................... Tabletop 2 

Palomar Medical Technologies, Inc. ............... Island 400 

PatientNOW ................................................... 100 

Photocure ...................................................... 127 

PhotoMedex ................................................... 606 

Photonics Media .............................................. 723 

Pierre Fabre Dermo Cosmetique USA ..................... 231 

Quantel Derma GmbH ....................................... 732 

RPMC Lasers, Inc. ............................................ 121 

Ra Medical Systems, Inc. .................................... 108 

Revision Skincare ............................................. 911 

Rockwell Laser Industries ................................... 805 

Sandstone Medical Technologies ................... Island 520 

Sciton, Inc. ............................................ Island 800 

Skin & Aging ................................................... 630 

SkinMedica, Inc. .............................................. 900 

Solta Medical ......................................... Island 214 

Sound Surgical Technologies LLC .......................... 427 

SPIE ................................................... Table Top 1 

SPECTRUM Photomedicine .................................. 130 

Surgimedics ................................................... 808 

Syneron/Candela .................................... Island 306 

Syris Scientific ................................................ 507 

THE Aesthetic Guide ......................................... 203 

The Laser Network, LLC ..................................... 309 

ThermoTek, Inc. .............................................. 810 

TJ Sales Associates, Inc. .................................... 417 

Ulthera, Inc. .................................................. 529 

UltraShape NA, Inc. .......................................... 333 

Venus Concept, Ltd. ......................................... 432 

WON Technology Co., LTD .................................. 627 

Yodle ........................................................... 504 

Zeltiq Aesthetics, Inc. ....................................... 615 

Zimmer MedizinSystems ..................................... 806 

119

120 





Grapevine, TX 

The American Society for Laser Medicine and Surgery would like to thank the following 

companies who have generously sponsored functions at the 31 st ASLMS Annual Conference. 

ZÉÄw fÑÉÇáÉÜá 

HOYA ConBio 

Palomar Medical Technologies, Inc. 

Syneron/Candela 

UÜÉÇéx fÑÉÇáÉÜá 

CoolTouch, Inc. 

Cynosure, Inc. 

MedCo Data, LLC 

Ulthera, Inc. 

Zeltiq Aesthetics, Inc. 

Zimmer MedizinSystems 


Allergan 

R. Rox Anderson, M.D. 

DEKA Medical, Inc. 

DermaNetwork.org 

Incredible Marketing 

Lumenis, Inc. 

Solta Medical 

THE Aesthetic Guide 

The Patient’s Guide





Grapevine, TX 

ASLMS and Industry Share in the Benefits 

of Continuing Development of Laser 

Applications 

Industry has played a critical role in the establishment and the growth of ASLMS and the use of lasers in medical 

and surgical applications. Through its 2005 strategic planning process, the ASLMS Board of Directors identified the 

opportunity to develop a mutually beneficial relationship with its industry partners to be a high priority. The 

Industry Advisory Council concept grew out of an interest, and a commitment by the Society, to incorporate greater 

interchange with industry. The Industry Advisory Council was created to provide a mutually beneficial relationship 

through which ASLMS and laser and related technology industries can work together to increase the value of an 

ASLMS membership, and to improve patient care by supporting research initiatives, and applications of laser and 

related technologies in medicine and surgery. 

Because both ASLMS and industry share in the benefits of the continuing development of laser applications, it was 

decided that the resources generated from Industry Advisory Council memberships and the net proceeds generated 

from the industry supported Silent Auction would be dedicated to the funding of laser application research. At the 

2010 Annual Conference, ASLMS awarded $157,000 to several scientists, medical researchers, and students who are 

working on important laser research projects that may be applied someday to the medical and surgical care of 

patients. This year, approximately $152,000 will be awarded for new research projects. ASLMS is especially 

pleased to announce that within the past five years; over $1 million in research has been awarded. 

We would also like to acknowledge and thank the following members of the ASLMS Industry Advisory Council. 

Aerolase Corporation Paul Efremkin, Ph.D. 

Cynosure, Inc. Michael Davin 

DEKA Medical, Inc. Dale Koop, Ph.D. 

HOYA ConBio Tim Gehlmann 

Lumenis, Inc. Robert Mann 

Palomar Medical Technologies, Inc. Richard Bankowski 

Ulthera, Inc. Teri Larsen 

Zimmer MedizinSystems Terry Schmidt 

121

122 





Grapevine, TX


ASLMS Employee Since 2006 





Grapevine, TX 

Presidential Citations and Awards 

In recognition of his dedication and service to ASLMS, his leadership and strategic 

vision for our Society. 

Raymond J. Lanzafame, M.D., M.B.A. 

ASLMS Member Since 1984 

For his long term dedication and service to ASLMS and for keeping our educational 

efforts compliant with the jungle of ACCME rules and our programs CME accredited. 

J. Stuart Nelson, M.D., Ph.D. 

ASLMS Member Since1987 

In recognition of his service as Editor-in-Chief of our “red” journal; for his service as 

Secretary of ASLMS; for his relentless pursuit of scientific and clinical excellence; for 

his continued efforts over many years to rebuild the Basic Science section of our 

Annual Conference; and for being a mentor and friend. 

Jason N. Pozner, M.D. 

ASLMS Member Since 1995 


10:40 am – 10:59 am 

Longhorn F 

2011 Presidential Citations are presented to: 

In recognition for his efforts to keep our silent auction vibrant in difficult economic 

times. 

123

124 





Grapevine, TX 



10:40 am – 10:59 am 

Longhorn F 

2011 Best Awards are presented to: 

DR. RICHARD E. FITZPATRICK CLINICAL RESEARCH AND INNOVATIONS AWARD 

Recipient: Robert Anolik 

Co-Authors: Elliot T. Weiss, Anne Chapas, Leonard Bernstein, Lori Brightman, Elizabeth K. Hale, 

Julie K. Karen, Roy Geronemus 

Location: Laser and Skin Surgery Center of New York, New York, NY 

Abstract Title: INVESTIGATION OF THE EFFECTIVENESS OF NON-COHERENT BLUE LIGHT IN 

INTRALESIONAL PHOTODYNAMIC THERAPY OF BASAL CELL CARCINOMA 

Presentation Date: Friday, April 1, 2011 – Texas D – 5:00 pm – 5:09 pm 

BEST OVERALL EXPERIMENTAL AND TRANSLATIONAL RESEARCH AWARD 

Recipient: Xingjia Wu 

Co-Authors: Stephanie Alberico, Helina Moges, Ruchir Sehra, Luis DeTaboada, Juanita Anders 

Location: Uniformed Services University of the Health Sciences, Bethesda, MD, PhotoThera, 

Inc., Carlsbad, CA 

Abstract Title: PULSE LIGHT IRRADIATION IMPROVES BEHAVIORAL OUTCOME IN A RAT MODEL OF 

CHRONIC MILD STRESS 

Presentation Date: Friday, April 1, 2011 – Texas 4-6 – 4:30 pm – 4:39 pm

BEST STUDENT/RESIDENT CUTANEOUS LASER SURGERY AWARD 





Grapevine, TX 



10:40 am – 10:59 am 

Longhorn F 


Recipient: Vivian Laquer 

Co-Authors: Kristen Kelly, Belinda Dao, Janelle Marshall, Amy Nguyen, Elizabeth Rugg, Ronald 

Harris, Tina Chen 

Location: Beckman Laser Institute and Medical Clinic, University of California, Irvine, CA 

Abstract Title: ANGIOGENESIS MEDIATOR ALTERATIONS IN ANGIOMAS AFTER PULSED DYE LASER 

TREATMENT 

Presentation Date: April 1, 2011 – Longhorn F – 1:38 pm – 1:43 pm 

BEST STUDENT/RESIDENT EXPERIMENTAL AND TRANSLATIONAL RESEARCH AWARD 

Recipient: Mehmet Kosoglu 

Co-Authors: Robert Hood, Christopher Rylander 

Location: Virginia Tech, Blacksburg, VA 

Abstract Title: FIBEROPTIC MICRONEEDLES FOR MICROSCALE INTERSTITIAL DELIVERY OF 


Presentation Date: April 3, 2011 – Texas C – 11:27 am – 11:38 am 

BEST STUDENT/RESIDENT PHOTOBIOMODULATION AWARD 

Recipient: Tianyi Wang 

Co-Authors: S.M. Shams Kazmi, Jordan Dwelle, Veronika Sapozhnikova, Jake Mancuso, Brian 

Willsey, Keith Johnston, Marc Feldman, Andrew Dunn, Thomas Milner 

Location: University of Texas at Austin, Austin, TX, University of Texas Health Science Center 

at San Antonio, San Antonio, TX 

Abstract Title: COMBINED OCT AND MULTI-PHOTON LUMINESCENCE MICROSCOPY FOR MACROPHAGE 

DETECTION IN ATHEROSCLEROTIC PLAQUES USING PLASMONIC GOLD NANOROSE 

Presentation Date: April 1, 2011 – Texas 4-6 – 5:00 pm – 5:09 pm 

125

126 

BEST STUDENT/RESIDENT PHOTODYNAMIC THERAPY THERAPY AWARD 





Grapevine, TX 



10:40 am – 10:59 am 

Longhorn F 


Recipient: Liyi Huang 

Co-Author: Michael Hamblin 

Location: Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 

Abstract Title: MECHANISMS OF ANTIMICROBIAL PHOTODYNAMIC THERAPY: AN IN VITRO STUDY ON 

GRAM NEGATIVE AND GRAM POSITIVE BACTERIA 

Presentation Date: April 1, 2011 – Texas D – 1:20 pm – 1:29 pm 

BEST STUDENT/RESIDENT SURGICAL APPLICATIONS/INTERSTITIAL LASER THERAPY AWARD 

Recipient: Edward C. Wu 

Co-Authors: Victor Sun, Wangcun Jia, Dmitriy E. Protsenko, Cyrus T. Manuel, Brian J.F. Wong, 

J.Stuart Nelson 

Location: Beckman Laser Institute and Medical Clinic, University of California, Irvine, CA 

Abstract Title: EX VIVO EVALUATION OF LASER AURICULAR CARTILAGE RESHAPING WITH CARBON 

DIOXIDE SPRAY COOLING IN A RABBIT MODEL 

Presentation Date: April 1, 2011 – Texas 2-3 – 4:30 pm – 4:39 pm





Grapevine, TX 

Caroline and William Mark Memorial Award 

Saturday, April 2, 2011 - 10:35 am – 10:49 am 

“From the Early Days of Medical Laser Applications to a Routine Clinical Use 

Today: Personal Encounters” 

Longhorn F 

William B. Mark was a design engineer who became involved with the utilization of lasers in medicine during the 

mid 1970's. After attending the Second International Medical Laser Congress in Detroit, he began working to 

establish an organization covering all medical specialties, an organization to allow and encourage physicians and 

scientists to exchange knowledge, explore uses of present equipment, and generate new medical lasers and 

accessories. At the Society's Annual Conference, the Caroline and William Mark Memorial Award is presented to a 

member selected for outstanding contributions to laser technology. 

Distinguished Recipients (to date) 

2011 Caroline and William Mark Memorial Award 

is presented to: 

Franz Hillenkamp, Ph.D. 

Institute for Medical Physics & Biophysics 

Muenster, Germany 

1982 Leon Goldman (deceased) 1997 R. Rox Anderson Boston, MA 

1983 Thomas J. Dougherty Buffalo, NY 1998 George S. Abela East Lansing, MI 

1984 Geza J. Jako Melrose, MA 1999 Richard O. Gregory Celebration, FL 

1985 Joseph H. Bellina (deceased) 2000 Isaac Kaplan Savyon, Israel 

1986 Francis A. L’Esperance New York, NY 2001 Raymond J. Lanzafame Rochester, NY 

1987 Leonard J. Cerullo Chicago, IL 2002 Ashley J. Welch Austin, TX 

1988 John A. Dixon (deceased) 2003 Martin J.C. van Gemert The Netherlands 

1989 Myron L. Wolbarsht Durham, NC 2004 Brian C. Wilson Toronto, Canada 

1990 Michael W. Berns Irvine, CA 2005 Lars O. Svaasand Trondheim, Norway 

1991 John A. Parrish Boston, MA 2006 Joseph T. Walsh, Jr. Evanston, IL 

1992 Robert H. Ossoff Nashville, TN 2007 Serge R. Mordon Lille, France 

1993 James S. McCaughan, Jr. Galena, OH 2008 Richard E. Fitzpatrick La Jolla, CA 

1994 Marvin P. Fried Bronx, NY 2009 J. Stuart Nelson Irvine, CA 

1995 Ronald G. Wheeland Columbia, MO 2010 E. Victor Ross San Diego, CA 

1996 Kenneth A. Arndt Chestnut Hill, MA 

127

128 

Ellet H. Drake Memorial Award 


“The Egg of Columbus: Overcoming Barriers to Innovation” 





Grapevine, TX 

The Ellet H. Drake Memorial Award was established in 1995 to recognize a practicing physician who has contributed 

to innovative laser procedures and/or laser products for medicine. The award is given in honor of Ellet Drake, 

M.D., co-founder of the American Society for Laser Medicine and Surgery. The award recipient must be a practicing 

physician with at least five years of practice; contributed to innovative laser procedures and/or laser products for 

medicine, contributed to literature, and has demonstrated excellence in teaching on a regional or greater level 

substantiating his/her laser activity during his/her career. 


Longhorn F 

2011 Ellet H. Drake Memorial Award 


Dieter Manstein, M.D. 

Wellman Center for Photomedicine 

Boston, MA 

1995 John A. Parrish Boston, MA 2003 Robert A. Weiss Hunt Valley, MD 

1996 R. Rox Anderson Boston, MA 2004 J. Stuart Nelson Irvine, CA 

1997 David B. Apfelberg Palo Alto, CA 2005 Richard E. Fitzpatrick La Jolla, CA 

1998 Ronald G. Wheeland Columbia, MO 2006 Kenneth A. Arndt Chestnut Hill, MA 

1999 Raymond J. Lanzafame Rochester, NY 2007 E. Victor Ross San Diego, CA 

2000 George S. Abela East Lansing, MI 2008 Jeffrey S. Dover Chestnut Hill, MA 

2001 Roy G. Geronemus New York, NY 2009 Suzanne L. Kilmer Sacamento, CA 

2002 Jerome M. Garden Chicago, IL 2010 Henry H.L. Chan Hong Kong

Leon Goldman Memorial Award 





Grapevine, TX 


“Finding the Right Indications for Photodynamic Therapy” 

Longhorn F 

The Leon Goldman Memorial Award was established in 1998 to recognize the many contributions in the areas of 

clinical laser research, laser patient care, and medical laser education of Leon Goldman, M.D., the "Father of Laser 

Medicine." The plenary session speaker must be a practicing physician who has demonstrated longitudinal 

excellence throughout their career in performing clinical laser research, providing high quality laser services to 

patients or educating others in medical laser applications. The individual must also share the characteristics of 

honesty, high ethical standards, and a dedication to patients that were possessed by its namesake. 


2011 Leon Goldman Memorial Award 


Stephen G. Bown, M.D., F.R.C.P. 

University College 

London, United Kingdom 

1999 David J. Goldberg Hackensack, NJ 2005 Ronald G. Wheeland Columbia, MO 

2000 Jeffrey S. Dover Chestnut Hill, MA 2006 Roy G. Geronemus New York, NY 

2001 Tina S. Alster Washington, DC 2007 J. Stuart Nelson Irvine, CA 

2002 R. Rox Anderson Boston, MA 2008 Jerome M. Garden Chicago, IL 

2003 Kenneth A. Arndt Chestnut Hill, MA 2009 Christopher B. Zachary Irvine, CA 

2004 Richard E. Fitzpatrick La Jolla, CA 2010 Brian S. Biesman Nashville, TN 

129

130 





Grapevine, TX 

Nursing/Allied Health Excellence Award 


“The Role of Allied Nurses and Health Care Professionals: “Priceless” 

Longhorn F 

The Nursing/Allied Health Excellence Award was established in 1991 to recognize outstanding nursing/allied health 

contributions to ASLMS and the advancement of joint practice in laser medicine and surgery. As an active member 

of ASLMS, the recipient of this award has promoted laser nursing/allied health in medicine through demonstrated 

expertise, consistent professional conduct, and exceptional standards of practice in nursing. 


2011 Nursing/Allied Health Excellence Award 


Faye M. Jenkins, R.N., B.S.N. 

Wilmington, MA 

1991 Sue E. Huether Sandy, UT 2001 Susan L. Olson Minneapolis, MN 

1992 Carolyn J. Mackety Holland, MI 2002 Mary E. Flor Edina, MN 

1993 Penny J. Smalley Chicago, IL 2003 Donna C. Gabriel Boston, MA 

1994 Patricia A. Hartwig Minneapolis, MN 2004 Deirdre A. O’Hare Waltham, MA 

1995 Mary A. Cayton Milwaukee, WI 2005 Judy A. Chamberlain Cincinnati, OH 

1996 Vangie Dennis Lawrenceville, GA 2006 Rebecca L. Sprague Sacramento, CA 

1997 Patricia A. Durgin West Columbia, SC 2007 Jeff T. Counters Edina, MN 

1998 Kay A. Ball Lewis Center, OH 2008 Sharon K. Olson Olympia, WA 

1999 Patricia A. Owens Olympia, WA 2009 Sue Terry McFarland, WI 

2000 Dale P. Goodwin McMeekin (deceased) 2010 Krystie P. Lennox Boca Raton, FL





Grapevine, TX 

Annual Conference Program Committee 

PROGRAM CHAIR 

Serge R. Mordon, Ph.D. 

Director, INSERM Laboratory 

#703, Photomedicine Center, 

Lille University Hospital, Lille, 

France 

PRESIDENT, CUTTING EDGE 

“TRANSLATIONAL MEDICINE” 

CO-DIRECTOR 


Professor of Biomedical 

Engineering and Neurosurgery, 

Vanderbilt University, 

Nashville, TN 

Thank you to the following outstanding group of Section Chairs and staff who voluntarily labored tirelessly this year 

to select the best abstracts for presentation at the Annual Conference. During this conference, they will continue 

to work hard to ensure that their sessions run on time and that the speakers provide appropriate disclosures of 

interest to maintain our current CME accreditation by the Accreditation Council of Continuing Medical Education. 

CUTANEOUS LASER SURGERY 

SECTION CHAIR, CUTTING EDGE 

“LASER AND SKIN” CO- 

DIRECTOR 

Mathew M. Avram, M.D., J.D. 

Director, Massachusetts General 

Hospital Dermatology Laser & 

Cosmetic Center, Wellman 

Center for Photomedicine, 

Harvard Medical School, Boston, 

MA 

CUTTING EDGE 

“TRANSLATIONAL MEDICINE” 

CO-DIRECTOR 

R. Rox Anderson, M.D. 

Professor at Harvard Medical 

School, Adjunct Professor at MIT, 

Director of the Wellman Center 

for Photomedicine at 

Massachusetts General Hospital, 

Boston, MA 

EXPERIMENTAL AND 

TRANSLATIONAL RESEARCH 

SECTION CO-CHAIR 

Jennifer K. Barton, Ph.D. 

Professor and Head of Biomedical 

Engineering, University of 

Arizona, Tucson, AZ 

CUTANEOUS LASER SURGERY 


Paul M. Friedman, M.D. 

Director of the DermSurgery Laser 

Center of Houston, Houston, TX 

CUTTING EDGE “LASER AND SKIN’ 

CO-DIRECTOR 

Christopher B. Zachary, M.B.B.S., 

F.R.C.P. 

Professor and Chair, Department of 

Dermatology, University of 

California, Irvine, CA 


TRANSLATIONAL RESEARCH 


Bernard Choi, Ph.D. 

Assistant Professor of Biomedical 

Engineering and Surgery at 


131

132 

NURSING/ALLIED HEALTH CO- 

CHAIR 

Faye M. Jenkins, R.N., B.S.N. 

Laser Nurse Consultants, 

Wilmington, MA 



Juanita J. Anders, Ph.D. 

Professor of Anatomy, Physiology 

and Genetics, Uniformed 

Services University of the Health 

Sciences, Bethesda, MD 



Ron R. Allison, M.D. 

Medical Director, 21st Century 

Oncology, Greenville NC 

SURGICAL APPLICATIONS/ 

INTERSTITIAL LASER THERAPY 


Raymond J. Lanzafame, M.D., 

M.B.A. 

Raymond J. Lanzafame, MD, 

PLLC, Rochester, NY 




Karl-G. Tranberg, M.D., Ph.D. 

Emeritus Professor of Surgery, 

Lund University Hospital, Medical 

Director, Clinical Laserthermia 

Systems, Lund, Sweden 





Grapevine, TX 

NURSING/ALLIED HEALTH CO- 

CHAIR 

Krystie P. Lennox, PA-C 

Sanctuary Medical Aesthetic 

Center, Boca Raton, FL 

PHOTOBIOMODULATION SECTION 

CO-CHAIR 

Michael R. Hamblin, M.D. 

Associate Professor, Harvard 

Medical School, Principal 

Investigator, Wellman Center for 




Keyvan Moghissi, B.Sc., M.D., 

F.R.C.S., F.E.T.C.S. 

Professor/Consultant 

Cardiothoracic Surgeon, The 

Yorkshire Laser Centre 

East Yorkshire, United Kingdom 




Roger J. McNichols, Ph.D. 

Chief Scientist, BioTex, Inc., 

Houston, TX 




Carson Wong, M.D., F.R.C.S.C., 

F.A.C.S. 

Medical Director, Center for 

Robotic Surgery, OU Medical 

Center, Associate Professor Chief, 

Endourologic, Minimally Invasive 

and Robotic Surgery, Urology, The 

University of Oklahoma Health 

Sciences Center, Oklahoma City, OK

ePOSTER SECTION CHAIR 

Emil A. Tanghetti, M.D. 

Center for Dermatology & Laser 

Surgery, Sacramento, CA 

ASLMS STAFF 

Dianne Dalsky 

Executive Director 

Wausau, WI 

ASLMS STAFF 

Barb Brown 

Program and Services 

Coordinator 

Wausau, WI 

ASLMS STAFF 

Diane Dodds 

Member and Customer Service 

Assistant 

Wausau, WI 

ASLMS STAFF 

Corri Marschall 

Conference Specialist 

Wausau, WI 





Grapevine, TX 

INTERNATIONAL EXPERIENCE IN 

LASERS IN DERMATOLOGY 

SECTION CHAIR 

Thierry Passeron, M.D., Ph.D. 

Department of Dermatology & 

INSERM U895 Team 1, University 

Hospital of Nice, Nice, France 

ASLMS STAFF 


Strategic Initiatives Director 

Wausau, WI 

ASLMS STAFF 

Paula Deffner 

Accounting Assistant 

Wausau, WI 

ASLMS STAFF 

Jane Frohm 

Industry Relations Specialist 

Wausau, WI 

ASLMS STAFF 

Michelle Theiler 

CME/Conference Coordinator 

Wausau, WI 

133

134 





Grapevine, TX 

General Conference Information 

ABSTRACTS 

Each presentation is listed with the corresponding abstract number and can be found in the back of your Final 

Program. 

CHILDCARE SERVICES 

Children under the age of 16 are not permitted in the Exhibit Hall or scientific sessions. The Gaylord Texan TM 

recommends the following childcare services: 

- Professional Sitter (Ms. Cris Waits) (972) 788-0022 / Cell (214) 477-0767 

- Nannies on the Go (817) 442-0225 

- Mom’s Best Friend (972) 446-0500 or (817) 226-2669 

CONTINENTAL BREAKFAST / COMPLIMENTARY LUNCH 

A continental breakfast will be provided to course attendees and a continental breakfast (Friday-Sunday) and a 

complimentary lunch with ticket (Exhibit Hall) will be provided to Annual Conference attendees on Friday and 

Saturday. 

DIGITAL MEDIA SALES 

If you would like to pre-order digitally and audio captured courses and sessions from the 31 st ASLMS Annual 

Conference, visit the Digital Media Sales desk located across from the ASLMS Registation Desk. We are offering an 

on-site special only – buy one get one of equal or lesser value for FREE (limit 2 free). 

Digital Medical Sales Desk Open Hours: 

Thursday, March 31, 2011 12:00 pm – 6:00 pm 

Friday, April 1, 2011 10:00 am – 6:00 pm 

Saturday, April 2, 2011 10:00 am – 6:00 pm 

Sunday, April 3, 2011 7:00 am – 1:00 pm 

DISASTER POLICY 

In the event of an emergency situation during the Annual Conference, information will be posted on the Society’s 

Web site, www.aslms.org. 

HOTEL INFORMATION 

Gaylord Texan TM Resort & Convention Center 

1501 Gaylord Trail 

Grapevine, TX 76051 

Main Hotel Number: (817) 778-1000 

Guest Fax: (817) 778-1001 

Check-in: 3:00 pm / Check-out 11:00 am





Grapevine, TX 


INTERNET PAVILION 

For the convenience of our conference attendees, an “Internet Pavilion” is located in the Exhibit Hall during open 

hours for conference attendees. Six internet stations are available. 

LITERATURE / PHOTOGRAPHY / VIDEOTAPING POLICY 

NO literature can be distributed during courses and scientific sessions. NO photography or videotaping is permitted 

in courses, scientific sessions, and exhibit hall. 

OFFICIAL LANGUAGE 

The official language at the 31 st ASLMS Annual Conference and Courses is English. No simultaneous translation is 

available. 

PHOTOGRAPHS 

The ASLMS reserves the right to take photos at the Annual Conference and to publish the photos in ASLMS marketing 

materials. Your attendance and registration authorizes the ASLMS to publish photos in our publications, marketing 

materials and on our Web site. If your photo appears on the Web site or in a publication, and you prefer that we 

discontinue using the image, please contact our office to identify the photo. 

PRESS 

The official ASLMS press room is located in San Antonio 3. Please feel free to contact Ms. Nadine Tosk who will be 

available throughout the Annual Conference. Press releases and background information will also be available in 

the Press Room. Members of the press are invited to all courses, and Annual Conference sessions (excludes 

luncheons); however they must adhere to the guidelines below: 

• Members of the press must wear badges identifying them as media representatives. 

• Members of the press are neither allowed to ask questions at the microphones during a session nor are they 

allowed to interview members of the Society except in controlled situations. We encourage media 

representatives to schedule interviews with Ms. Nadine Tosk in the press room so she can coordinate the 

interview with the speakers. After the Annual Conference, you can contact Ms. Tosk at (847) 920-9858, 

nadinepr@gmail.com. 

RESPONSIBLE DRINKING POLICY 

With alcohol served at the Annual Conference reception, the ASLMS encourages responsible drinking. In addition to 

alcoholic beverages, non-alcoholic options are provided. No alcohol is served to anyone under age 21. 

REFUND POLICY 

No refunds after March 15, 2011. 

RESEARCH EDUCATION FUND RIBBONS AND PINS 

You may note on attendee badges ribbons that signify a member who has given a contribution to the Research and 

Education Fund. Top research contributors will receive a pin to wear. 

SMOKING 

It is a policy of the ASLMS and Gaylord Texan that the use of tobacco products is strictly prohibited at the 

conference and in all areas of the exhibit hall (including setup and dismantle of exhibits). Thank you for not 

smoking. 

135

136 





Grapevine, TX 


SPEAKER READY ROOM: Dallas 1 

Hours of Operation: 

Wednesday, March 30, 2011 6:30 am - 5:00 pm 

Thursday, March 31, 2011 6:30 am - 6:00 pm 

Friday, April 1, 2011 6:30 am - 6:00 pm 

Saturday, April 2, 2011 6:30 am - 6:00 pm 

Sunday, April 3, 2011 6:30 am - 12:30 pm 

ATTENTION: INDIVIDUALS WITH DISABILITIES 

The ASLMS is committed to making its conference accessible to all individuals. If you have a disability, check the 

individual with disabilities line on the conference registration and hotel reservation forms. Advance notification of 

any special needs will help us better serve you. Most requests for auxiliary aids or services can be accommodated, 

if the ASLMS is notified prior to the Annual Conference. 

COPYRIGHT 

All of the proceedings of the Annual Conference, including the presentation of scientific papers, are intended solely 

for the benefit of the members of the American Society for Laser Medicine and Surgery, Inc. No statement of 

presentation made is to be regarded as dedicated to the public domain. Any statement or presentation is to be 

regarded as limited publication only and all property rights in the material presented, including common law 

copyright, are expressly reserved to the speaker or to the American Society for Laser Medicine and Surgery, Inc. 

Any sound reproduction, transcript, or other use of the material presented at the Annual Conference without the 

permission of the speaker or the ASLMS is prohibited to the full extent of common law copyright in such material. 

DISCLAIMER 

The views expressed and materials presented throughout the Annual Conference whether during scientific sessions, 

instructional courses, or otherwise, represent the personal views of the individual participants and do not represent 

the opinion of the American Society for Laser Medicine and Surgery, Inc. This organization assumes no 

responsibility for the content of the presentations made by an individual participant or group of participants.





Grapevine, TX 


DISCLOSURE OF FACULTY'S AND SPEAKER'S COMMERCIAL RELATIONSHIP(S) 

Consistent with the ASLMS policy, faculty and speakers for the conference are expected to disclose to you at the 

beginning of their presentation, any economic or other personal interests that create, or it may be perceived as 

creating, a conflict related to the material discussed. This policy is intended to make you aware of faculty's and 

speaker's interests, so you may form your own judgments about such material. Disclosure of faculty's and speaker's 

relationship(s) is indicated in the conference program. Please be advised that FDA approval is specific in regard to 

approved uses and labeling of drugs and devices. The presenter must disclose whether or not the device/treatment 

is approved by the FDA or if it is considered to be investigational, and must fully disclose any off-label use of 

devices, drugs or other materials that constitute the subject of the presentation. In order to meet the guidelines 

established by the Accreditation Council for Continuing Medical Education, the ASLMS Committee on Continuing 

Education has endorsed the policy that disclosure of all proprietary interests or other potential conflicts of interest 

must be provided to conference registrants of all speakers and spouses who have relationships with industry. 

GUIDELINES FOR REVIEW AND SELECTION OF ABSTRACTS 

The Program Chairperson performs an initial review of all abstract submissions. The Program Chairperson may at 

his/her discretion, re-categorize the abstracts. Abstracts are then submitted to the individual Section Chairpersons 

who review, rank, and select abstracts for presentation at the Annual Conference. Given the brevity of the 

abstracts, the Program and Section Chairpersons realize that the detail level obtained through this process cannot 

achieve the level of a full article in a peer-reviewed journal. However, the spirit of this Annual Conference is that 

full disclosure (in so far as conflicts of interest as well as details in methodology) will be expected at the time of 

presentation. Abstracts that cannot meet this criterion due to intellectual property concerns or withhold vital 

methodology specifics do not meet the criteria for acceptance and do not represent the spirit and intent of the 

Annual Conference should not be submitted. 

The Section Chairpersons also take into consideration the following criteria when reviewing abstracts: 

• Abstracts must not have been published or presented previously (clinical series updates are an exception). 

• All scientific research referred to, reported on, or used in the abstract must conform to the generally 

accepted standards of experimental design, data collection, and analysis. 

• Selection priority will be given to those abstracts that report already collected data. Abstracts should contain 

tangible factual information and should accurately reflect work that has actually been performed. 

Statements such as "results will be discussed' should be avoided. 

• Recommendations in the abstract involving clinical medicine must be based on evidence that is accepted 

within the profession of medicine as adequate justification for their indications and contraindications in the 

care of patients. 

• The abstract must not present recommendations, treatment, or manners of practicing medicine that are not 

within the definitions as noted above, are known to have risks or dangers that outweigh the benefits, or are 

known to be ineffective in the treatment of patients. 

• The number of patients in the study will be taken into consideration. Scientific, well-designed studies are 

given preference over anecdotal findings or single experiment or case. 

• High quality abstracts with no bias toward a specific company(ies). 

• Each author of an abstract submitted to ASLMS must have made a significant contribution to the research and 

must assume responsibility for the content of the abstract. 

• The number of abstracts submitted by an individual and/or institution will be taken into consideration. In 

order to provide diversity of input, we discourage any one author making more than two presentations in a 

session. The other submissions could be submitted for the poster session. 

• The purpose of our conference is to disseminate accurate, balanced and objective information regarding 

lasers and other optical sources in medicine and surgery. This purpose is best served by including 

presentations that are varied in terms of topics and presenters. 

• Abstracts should feature category-specific data with the expectation of full disclosure regarding methods and 

materials. 

137

138 





Grapevine, TX

(INSERT CME FORMS) 





Grapevine, TX 

139

140 





Grapevine, TX





Grapevine, TX 

141

142 





Grapevine, TX

Continuing Education Credits 





Grapevine, TX 

A statement of CME credit hours will be issued to you on-site and/or following the conference which you can 

forward to your specialty boards, specialty academies or to your State Medical Examining Boards to meet your 

continuing education requirements. 

ANNUAL CONFERENCE 

ACCME ACCREDITATION STATEMENT 

The American Society for Laser Medicine and Surgery, Inc. is accredited by the Accreditation Council for Continuing 

Medical Education to provide continuing medical education for physicians. 

CONTINUING MEDICAL EDUCATION CREDIT 


PRA Category 1 Credit(s) TM . Physicians should claim only the credit commensurate with the extent of their 


ASLMS COURSES AND LUNCHEONS 

EDUCATIONAL ACTIVITY CME CREDIT HOURS CE CONTACT HOURS* 

Fundamentals of Lasers in Health Care Course 16.25 credit hours 17.1 contact hours 

Fundamentals of Lasers in Health Care Course With Exam 18.25 credit hours 19.5 contact hours 

Units I – VII (Day One Only) 7.75 credit hours 9.3 contact hours 

Units VIII – XIII (Day Two Only) 6.5 credit hours 7.8 contact hours 

Exam Only 

Nursing/Allied Health – Merging Lasers and Technology 

2.0 credit hours 2.4 contact hours 

Design in 2011 Course N/A 8.4 contact hours 

Resurfacing and Contouring Course 3.75 credit hours 4.5 contact hours 

Laser Treatment of Vascular Lesions Course 3.5 credit hours 4.2 contact hours 

Hair and Pigment Removal Course 3.75 credit hours 4.5 contact hours 

Laser Treatment of Patients of Color Course 3.0 credit hours 3.6 contact hours 

Complications, Controversies, and Legal Issues Course 2.75 credit hours 3.4 contact hours 

PDT: Principle and Clinical Role Course 3.0 credit hours 3.6 contact hours 

Student/Post-Doc/Resident Opportunities Course N/A N/A 

Technologies for Fat Related Disorders Course 2.0 credit hours 2.4 contact hours 

Periorbital Therapies Course 2.0 credit hours 2.4 contact hours 

Photography, Treatment Documentation, and Oversight Course 2.0 credit hours 2.4 contact hours 

How to Use Optical Diagnostics in Clinical Laser Medicine Course 1.75 credit hours 2.2 contact hours 

ILT: Principle and Clinical Role Course N/A N/A 

My Approach to Fractional Resurfacing Luncheon 1.0 credit hours 1.2 contact hours 

My Approach to Skin Tightening Technologies Luncheon 

Practical Pearls to Optimize Clinical Outcomes for Laser 

1.0 credit hours 1.2 contact hours 

And Light-Based Procedures Luncheon 1.0 credit hours 1.2 contact hours 

Non-Invasive and Invasive Fat Removal Luncheon 1.0 credit hours 1.2 contact hours 

Difficult Cases and Complications Luncheon 1.0 credit hours 1.2 contact hours 

Scar Revision Luncheon 1.0 credit hours 1.2 contact hours 

Acne Luncheon 1.0 credit hours 1.2 contact hours 

143

144 

CME Mission Statement 





Grapevine, TX 

The American Society for Laser Medicine and Surgery (ASLMS) is a multi-disciplinary organization whose 

membership includes representatives from all medical and surgical disciplines, nursing, dentistry, podiatric 

medicine, veterinary medicine, industry, research and government. 

Purpose 

ASLMS is dedicated to enhancing the understanding of lasers and the application of lasers and related technologies 

in biomedicine. The ASLMS is committed to continuous quality improvement and excellence in all of its activities. 

Target Audience 

The ASLMS is the largest organization of its kind and seeks to enhance dialogue between clinicians, scientists, 

industry and government through its variety of educational formats. The educational offerings are organized so that 

whether a novice or an expert, the attendees are provided with useful information. 

Types of Activities Provided 

The ASLMS accomplishes this goal through committee meetings, general sessions, the Annual Conference, 

educational courses, regional courses and other programs. A variety of educational formats are used including 

plenary lectures, scientific paper and poster presentations, panel discussions, didactic lectures, and educational 

courses. The latest information regarding biomedical applications of laser technologies is presented by experts 

from these fields. The ASLMS also functions as both advocate and advisor to a variety of groups and organizations as 

well as the Food and Drug Administration. These programs are designed to foster dialogue and discussion between 

clinicians, scientists, and manufacturers. 

Content 

Educational programs are designed to enable each participant to select the program and course of learning which 

best meets individual educational needs while at the same time covering a broad and more balanced range of 

topics. 

Expected Results 

Written and verbal evaluations as well as pre-test and post-test results measure the degree to which these 

educational objectives are met and also provide information used for planning and implementation of future 

activities. All attendees will have exposure to basic science and clinical laser use in their particular field(s) of 

interest through their attendance and participation in plenary sessions, focus sessions, specialty breakout sessions, 

and clinical entity-based courses and panel sessions. The multispecialty nature of ASLMS educational offerings, as 

well as the spirit of disclosure among scientists and clinicians, provides cross-fertilization between specialties that 

often leads to breakthroughs in medicine, and facilitates the ability of the participants to fill gaps in their 

knowledge relative to these technologies and their applications. Specialty-specific courses provide exposure to 

information of clinical and scientific importance to those practicing in the field. Other content, including but not 

limited to courses and comprehensive educational activities such as the “Fundamentals of Lasers in Health Care" 

course and regional courses provide educational tools and will measure the degree to which material has been 

learned through the use of standardized testing methods. It is expected that participants in these activities will 

identify gaps in their knowledge, competence, or performance. It is expected that participants will use the 

knowledge gained to improve their clinical outcomes as a result of their improved understanding of the best 

practices relative to patient treatment with these technologies, and their safe use. 

Approved by the Board of Directors, November 10, 2010

Annual Conference Objectives 





Grapevine, TX 


The purpose of the ASLMS Annual Conference is to instruct in basic science and clinical aspects of laser surgery and 

medicine by didactic lectures, panels, courses, and specialty specific lectures. The conference serves as an annual 

clearinghouse for new light based technologies in medicine. 

Designated Participants 

Physicians attending the conference include dermatologists, plastic surgeons, otolaryngologists, urologists, general 

surgeons, ophthalmologists, orthopedic surgeons, neurologists, neurosurgeons, cardiologists, cardiac surgeons, 

oncologists, surgical oncologists as well as other physicians interested in laser technology. The conference is 

organized so that whether a novice or an expert, the attendee will be provided with useful information. Physicians, 

dentists, oral and maxillofacial surgeons, nursing/allied health laser professionals, laser researchers, laser industry 

representatives, students, residents, fellows, post-doctoral associates and governmental laser professionals will 

share information on lasers including clinical and research uses. 


Individuals attending the Annual Conference are not required to have any particular background in laser medicine 

and surgery. 

Expected Learning Outcomes 

All attendees will have exposure to basic science and clinical laser use in their particular field(s) of interest 

through their attendance and participation in plenary sessions, focus sessions, specialty breakout sessions, and 

clinical entity-based courses and panel sessions. In addition, the multispecialty nature of this conference, as well 

as the spirit of disclosure among scientists and clinicians, provides cross-fertilization between specialties that often 

leads to breakthroughs in medicine, and facilitates the ability of the participants to fill gaps in their knowledge 

relative to these technologies and their applications. Specialty-specific courses provide exposure to information of 

clinical and scientific importance to those practicing in the field. Other content, including but not limited to 

courses and comprehensive educational activities such as the “Fundamentals of Lasers in Health Care" program will 

provide educational tools and will measure the degree to which material has been learned through the use of 

standardized testing methods. It is expected that participants in these activities will identify gaps in their 

knowledge and performance and will use the knowledge gained to improve their clinical outcomes as a result of 

their improved understanding of the best practices relative to patient treatment with these technologies and their 

safe use. 

Annual Conference Highlights 

This conference will bring attendees up-to-date on the current understanding and theories of laser-tissue 

interactions. Special panel sessions will be convened on the new laser applications, such as skin resurfacing and 

pediatric treatment of lesions. This years’ conference will emphasize a multidisciplinary approach and integrated 

physician/scientist efforts to solve clinical challenges. The conference will focus on the best international laser 

research. 

CORPORATE MISSION AND VISION STATEMENT 

The mission of the American Society for Laser Medicine and Surgery is to promote excellence in 

patient care by advancing biomedical application of lasers and other related technologies worldwide. 

The vision of the ASLMS is to be the world's preeminent resource for biomedical laser and other 

related technologies, research, education, and clinical knowledge. 

145

146 





Grapevine, TX 

ASLMS Policy on Mechanism to Identify 

and Resolve Conflict of Interest 

The American Society for Laser Medicine and Surgery is accredited by the Accreditation Council for Continuing 

Medical Education (ACCME). As such, we have made the choice to meet the ACCME’s criteria for our practice of 

continuing medical education. Our accreditation is important to us. We look forward to working together to 

provide CME at the highest standard. 

The ASLMS has implemented a process where everyone who is in a position to control the content of an educational 

activity must disclose to us all relevant financial relationships with any commercial interest they and their 

spouse/partner may have received within the last 12 months. Should it be determined that a conflict of interest 

exists as a result of a financial relationship, it will need to be resolved prior to their involvement. In order to do 

this, all individuals who are in a position to control the content must complete a disclosure form. If any conflict 

develops between the time the disclosure form is completed and the educational activity, the individual must 

notify the ASLMS in writing and disclose the additional conflict of interest. Individuals, who refuse to disclose 

relevant financial relationships, will be disqualified from being a part of the planning and implementation of the 

CME activity. 

Process of Identifying and Resolving Conflict of Interest 

Annual Conference (Program Chair, Section Chairs, Speakers) 

1) The President selects the Program Chair. 

2) A Disclosure of Conflict of Interest “COI” form is completed by the Program Chair. 

3) If the Program Chair refuses to disclose relevant financial relationships, he/she will be disqualified from 

participating in the program. 

4) The CME Director reviews the Program Chair disclosure form and completes an Acknowledgement of 

Disclosure Review form. If it appears that the Program Chair has a COI as a result of a financial 

relationship, it will need to be resolved in order for the person to serve as Program Chair. If necessary, 

determination will be made by the CME Director under the guidance of the Board of Directors whether the 

proposed Program Chair can participate in the program. 

5) The Program Chair selects Section Chairs. 

6) A COI form is completed by all of the Section Chairs. 

7) If the Section Chair refuses to disclose relevant financial relationships, he/she will be disqualified from 


8) The Program Chair reviews the Section Chair COI forms and completes an Acknowledgement of Disclosure 

Review form. If it appears that a Section Chair has a COI as a result of a financial relationship, it will need 

to be resolved in order for the person to serve as Section Chair. If necessary, determination will be made 

by the Program Chair and CME Director under the guidance of the Board of Directors whether the proposed 

Section Chair can participate in the program. 

9) The Speakers complete the online abstract form, which contains "required fields" for disclosure. The 

Section Chairs review the abstract and Speaker disclosure and completes an Acknowledgement of 

Disclosure Review form. If it appears that a Speaker has a COI as a result of a financial relationship, it will 

need to be resolved prior to the activity. If necessary, determination will be made by the Section Chair, 

Program Chair and CME Director under the guidance of the Board of Directors whether the proposed 

speaker can participate in the program. 

10) If any conflicts develop between the time the disclosure form is completed and the educational activity, 

the individual must notify the ASLMS in writing and disclose the additional conflict of interest. 

11) The Section Chair and Speaker disclosure information is printed in the Final Program and journal.





Grapevine, TX 

12) At the Annual conference: 

a) Each Section Chair is provided with a checklist of Speakers who are required to disclose COI. The 

Section Chair is instructed to remind the Speaker to verbally disclose COI prior to their 

presentation, sign off on the checklist provided, and return the form to the ASLMS. 

b) In addition to a COI statement being printed in program materials, a COI slide will be prepared by 

the ASLMS Central Office based on the information provided on the completed disclosure form. The 

slide will be inserted before each presentation on the Central Server and will include any 

proprietary interest in any drugs, instruments, or devices discussed in the presentation and/or any 

compensation received. Similarly, a slide will be shown to disclose the fact that the presentation 

content includes off-label uses of drugs or devices. 

c) A copy of the session schedule and disclosure is posted at the entrance of the session room. 

d) If a Speaker discloses a COI in writing, but does not verbally disclose prior to his/her presentation, 

the Section Chair will remind the Speaker at the end of the presentation to disclose the COI. 

e) If a Speaker does not pre-disclose in writing or verbally, but it becomes apparent that a COI exists, 

the Section Chair, Program Chair, CME Director and/or Board Member will notify the audience and 

the Speaker of the perceived COI. The Speaker will be warned that further failures to comply with 

policy will result in the Speaker’s inability to participate in CME related activities of ASLMS in the 

future. (The Board of Directors may, at its discretion, impose other sanctions it feels are 

appropriate). 

f) Board members are provided with audit forms and asked to verify if Speakers disclose COI. 

g) Attendees complete evaluation forms and are asked to comment about proper COI disclosure. 

Evaluation forms are reviewed by the CME Director, Program Chair, and Section Chairs and 

appropriate corrective action is taken. 

Courses (Directors/Faculty) 

1) The Program Chair selects Course Directors. 

2) A Disclosure of Conflict of Interest “COI” form is completed by all Course Directors. 

3) If the Course Director refuses to disclose relevant financial relationships, he/she will be disqualified from 


4) The Program Chair and CME Director review the Course Director disclosure forms. The Program Chair 

completes an Acknowledgement of Disclosure Review form. If it appears that a Course Director has a COI 

as a result of a financial relationship, it will need to be resolved in order for the person to serve as Course 

Director. If necessary, determination will be made by the Program Chair and CME Director under the 

guidance of the Board of Directors if the proposed Course Director can participate in the program. 

5) The Course Director selects Faculty. 

6) The COI forms are completed by all Faculty. 

7) If the Faculty Member refuses to disclose relevant financial relationships, he/she will be disqualified from 


8) The Faculty COI forms are reviewed by the Course Director and CME Director. Course Director completes 

an Acknowledgment of Disclosure Review form. If it appears that a Faculty Member has a COI as a result 

of a financial relationship, it will need to be resolved in order for the person to serve as a Faculty Member. 

If necessary, determination will be made by the Course Director, Program Chair, and CME Director under 

the guidance of the Board of Directors whether the proposed Faculty Member can participate in the 

program. 

9) If any conflicts develop between the time the disclosure form is completed and the educational activity, 

the individual must notify the ASLMS in writing and disclose the additional conflict of interest. 

10) Disclosure information is printed in course books. 

11) At the conference: 

a) The Course Director is provided with a checklist of Faculty Members who are required to disclose 

COI. The Course Director is instructed to remind the Faculty to verbally disclose COI prior to their 

presentation, sign off on the checklist provided, and return the form to the ASLMS. 

147

148 





Grapevine, TX 

b) In addition to a COI statement being printed in program materials, a COI slide will be prepared by the 

ASLMS Central Office based on the information provided on the completed disclosure form. The slide 

will be inserted before each presentation on the Central Server and will include any proprietary 

interest in any drugs, instruments, or devices discussed in the presentation and/or any compensation 

received. Similarly, a slide will be shown to disclose the fact that the presentation content includes 

off-label uses of drugs or devices. 

c) A copy of the session schedule and disclosure is posted at the entrance of the session room. 

d) If a Faculty Member discloses a COI in writing, but does not verbally disclose prior to his/her 

presentation, the Course Director will remind Faculty at the end of the presentation to disclose COI. 

e) If a Faculty Member does not pre-disclose in writing or verbally, but it becomes apparent that a COI 

exists, the Course Director, Program Chair, CME Director and/or Board Member will notify the 

audience and the Speaker of the perceived COI. The speaker will be warned that further failures to 

comply with policy will result in the speaker’s inability to participate in CME related activities of 

ASLMS in the future. (The Board of Directors may, at its discretion, impose other sanctions it feels 

are appropriate). 

f) Board members are provided with audit forms and asked to verify if Faculty discloses COI. 

g) Attendees complete evaluation forms and are asked to comment about proper COI disclosure. 

Evaluation forms are reviewed by the CME Director, Program Chair, and Course Directors and 

appropriate corrective action is taken. 

Board of Directors 

In order for the Society to further the purpose for which it is organized and to maintain its reputation for 

excellence, it is important that Society decisions and actions not be influenced unduly by any special interests or 

individual members. The Society depends upon its members to shape its policies and the actions of those 

organization policy makers must not be inappropriately affected by outside influences. Members of the ASLMS 

Board of Directors are required to complete a Disclosure of Interest Statement annually. Copies of the completed 

disclosure forms are available at the ASLMS Central Office upon request. 

Approved by the Board of Directors, April 15, 2010

ASLMS Learner Bill of Rights 





Grapevine, TX 

The American Society for Laser Medicine and Surgery recognizes that you are a life-long learner who has chosen to 

engage in continuing medical education to identify or fill a gap in knowledge, skill, or performance. As part of 

ASLMS’ duty to you as a learner, you have the right to expect that your continuing medical education experience 

with ASLMS includes: 

• Content that: 

o promotes improvements or quality in health care; 

o is valid, reliable, and accurate; 

o offers balanced presentations that are free of commercial bias for or against a product/service; 

o is vetted through a process that resolves any conflicts of interests of planners, teachers, or authors; 

o is driven and based on learning needs, not commercial interests; 

o addresses the stated objectives or purpose; and 

o is evaluated for its effectiveness in meeting the identified educational need. 

• A learning environment that: 

o supports learners’ ability to meet their individual needs; 

o respects and attends to any special needs of the learners; 

o respects the diversity of groups of learners; and 

o is free of promotional, commercial, and/or sales activities. 

• Disclosure of: 

o relevant financial relationships planners, teachers, and authors have with commercial interests 

related to the content of the activity; and 

o commercial support (funding or in-kind resources) of the activity. 

149

150 





Grapevine, TX

Abrahams, Martine, 71 

Abrahams, Michael, 71 

Adanny, Yossi, 84 

Adatto, Maurice, 75,89,92,98 

Adatto-Neilson, R., 89 

Ahn, Yeh-chan, 93 

Alam, Murad, 85 

Alberico, Stephanie, 45 

Alcantara, Javier, 99 

Alexis, Andrew, 85 

Alissa, Ahmed, 73 

Allison, Ron, 49 

Almeida, Guilherme, 91,94,95,99 

Almeida, Leticia, 91,94,95,99 

Almenshawy, Shahira, 49 

Alster, Tina, 19 

Altshuler, Gregory, 34,38,41,68,80 

Amir, Ruthie, 40,75,84,89,90,98 

Ananthakrishnan, Vasanthi, 34 

Anders, Juanita, 44,45 

Anderson, Carrie, 88,94 

Anderson, R. Rox, 62,64,68,70 

Anderson, Robert, 40 

Andrews, Peter, 66 

Angel, Sylvie, 91 

Angelo-Khattar, Maria, 76 

Angobaldo, Jeffrey, 41 

Anolik, Robert, 31,37,41,49,96 

Anvari, Bahman, 34,35 

Argobi, Yahya, 85 

Arisawa, Emilia, 33 

Arroyo, Cesar,96 

Ash, Caerwyn, 48,72,73 

Attia, Abeer, 49 

Auclair, Mathieu, 42 

Avram, Marc, 65 

Avram, Mathew, 37,64,65,68,70,83 

Ayala, Rao, 35 

Azpiazu, Jose, 96 

Babu, Supriya, 34 

Badiavas, Evangelos, 69 

Presenter Index 

(Abstracts and ePosters) 





Grapevine, TX 

Bagley, Demetrius, 52 

Bahadoran, Philippe, 34,97,100 

Bahmani, Baharak, 

Baier, Robert, 48 

Bakus, Abnoeal, 86 

Barnes, Klressa, 82 

Barolet, Daniel, 42 

Barolet, Francois, 42 

Barolet, Virginie C., 42 

Barrett, Lauren, 94 

Baum, Olga, 35 

Baumler, Wolfgang, 82 

Bayoumi, Wedd, 74 

Beek, Johan F., 75,84 

Been, Stefan, 35,36 

Belikov, Andrey, 34 

Bernstein, Eric, 87 

Bernstein, Leonard, 37,41,49,96 

Betrouni, Nacim, 51,52,97 

Bhattacharya, Kiran, 67 

Bi, Xiaohong, 82 

Biesman, Brian, 84,86 

Bjerring, Peter, 73 

Bodendorf, Marc Oliver, 75 

Boixeda, Pablo, 99 

Bos, Jan D., 75,84 

Bostoen, Jessica, 38 

Boutoussov, Dmitri, 35,36 

Boutros, Sean, 40 

Bown, Stephen, 63 

Bradford, Porcia, 96 

Bradley, Oksana, 80 

Brazil, James, 19 

Brenner-Lavie, Hanit, 75,84,90,98 

Brightman, Lori, 37,41,42,49 

Broekgaarden, Mans, 81 

Brown, Alia, 97 

Brown, Spencer, 82 

Bruce, Suzanne, 83,95 

Bryan, Holly, 19 

Burger, A., 97 

151

152 

Burget, Dianna, 98 

Burton, Claude, 96 

Camara, Luciana, 75,92 

Campbell, Kirby, 67 

Campos, Valeria, 71,90 

Carroll, James, 45 

Cayce, Jonathan, 33,82 

Cengal, Keith,48 

Cervone, Joseph, 94 

Chaarani, Jinan, 81 

Chaffins, Marsha, 38 

Chan, Henry H.L., 41,65,69,70,83,84, 

85,94 

Chan, Johnny C.Y., 84,94 

Chan, Nicola P.Y., 41,83,84,85,94 

Chang, Carolyn, 91 

Chang, Ka-yeun, 

Chapas, Anne,37,41,49 

Chavantes, M. Cristina, 33,71 

Chen, Hong-Duo, 81 

Chen, Kejing, 66 

Chen, Long, 66 

Chen, Tina, 38 

Chen, Yu, 66 

Chen, Zhongping, 93 

Childs, James, 38,41 

Chipps, Lisa, 96 

Chiu, Mona L.S., 94 

Cho, Soyun, 96 

Choi, Bernard, 35,37,66 

Choi, Jae eun, 74 

Choi, Jee Woong, 98 

Christine, Dierickx, 69,72,91 

Chuang, Gary, 70 

Chwalek, Jennifer, 39 

Clement, Marc, 48,73 

Coleman, William, 87 

Coley, Marcy, 85 

Colin, Pierre, 51,52 

Colon-Herdman, Arturo, 52 

Cordero, Tatiana, 71,90 

Cornil, Alain, 35 

Corrons, Natalia, 96 





Grapevine, TX 

Crow, Heidi C., 93 

Cuccia, David J., 80 

Cuerda, Esther, 96,99 

Cunningham, Ryan, 44 

Curry, William, 66 

Dae, Hun Suh, 95 

Daia, Hadi, 93 

Daily, Adam, 67 

Dao, Belinda, 38 

Davis, Stephen, 39,69 

Dayananda, G., 34 

de Kroon, Anton, I.P.M., 81 

De la Quintana, Agustin, 96 

del Pozo-Losada, Jesus, 96,99 

Desai, Nirav, 96 

DeTaboada, Luis, 45,71 

Dhavan, Sahil, 38 

Dhepe, Niteen, 38,86,96,97 

Diagaradjane, Parameswaran, 34,36 

Diaz, Antonio, 96 

DiBernardo, Barry, 53 

Diehl, Joseph, 96 

Dierickx, Christine, 

Dietrich-Comte, Nathalie, 86,97 

Diktaban, Theo, 89 

Doherty, Sean, 41,69 

Domankevitz, Yacov, 70 

Dover, Jeffrey, 41,42,94 

Downie, Gordon, 48 

Dunn, Andrew, 45 

Duong, Steven, 93,94 

Durkin, Anthony J., 80 

Duteil, Luc, 97 

Dwelle, Jordan, 45 

Dyson, Mary, 88 

Edward, Kert, 36 

Eimpunth, Sasima, 85,87 

El Tal, Abdul K., 

Ellis, Darrel, 82 

Epstein, Haim, 40,84 

Eubanks, Leigh Ellen, 95 

Ewart, E., 53

Fabi, Sabrina, 69,95,97 

Fadel, Maha, 49 

Fan, Larry, 87 

Farhat, Elizabeth, 38 

Fatemi, Afschin, 51,74,81 

Feldman, Marc, 45 

Felten, Richard, 66 

Ferrario, Angela, 34 

Fleming, Trudy, 19 

Fournier, Nathalie, 39 

Frankel, Amy Lynne, 81 

Friedman, Paul M., 37,40,41,83,85 

Friedman, Ran, 82 

Fritz, Klaus, 72,90 

Fujimoto, Takahiro, 99 

Garcia, Neila, 33 

Garden, Jerome, 86 

Gentile, Richard, 53 

Geronemus, Roy G., 37,41,42,49,96 

Giles, Robert, 80 

Gill-Sharp, Kelly, 51 

Giraud, Sylvain, 35 

Glaser, Dee Anna, 87 

Goh, B.K., 97 

Goh, C.L., 97 

Goldberg, David, 39,86,97 

Goldberg, Leonard H., 40,41,83,85 

Goldman, Mitchel, 69,95,97 

Golikov, Mikhail, 93 

Gomer, Charles, 34 

Gonnelli, David, 99 

Goodrich, Glenn, 34,36,51 

Gotkin, Robert, 70 

Goturu, Jaisri, 34 

Gowda, Ashok, 51 

Goyette, Thomas, 80 

Graber, Emmy, 39 

Grace, Michael, 34 

Griffin, Robert, 82 

Griggs, Jacob, 46 

Grunewald, Sonja, 75 

Grzywacz, Robert, 71 





Grapevine, TX 

Gu, Chuan, 52 

Gu, Jizhong, 47 

Gu, Xiao, 52 

Guerrero, Yadir, 35 

Guimaraes, Claudia, 97 

Guller, Anna, 35 

Gupta, Anurag, 99 

Gupta, Arun, 99 

Gupta, Sagar, 67 

Gupta, Sharad, 34 

Haedersdal, Merete, 72 

Hage, Raduan, 33 

Halachmi, Shlomit, 75,90,92 

Hale, Elizabeth K., 37,41,49,96 

Haller, G., 89 

Hamblin, Michael R., 44,47,48,65 

Hameed, Sunaina, 74 

Harris, Llinos, 48 

Harris, Ronald, 38 

Harrison, April, 95 

Harth, Yoram, 90 

Healy, Kelly, 52 

Heger, Michal, 81 

Hellman, Judith, 93 

Hemadri, M., 53 

Hennings, Leah, 82 

Herold, Manfred, 53 

Hillenkamp, Franz, 63,66 

Ho, Stephanie G.Y., 83 

Hoang, Michael, 98 

Holtzman, Jennifer, 93 

Homar, Patricia, 96 

Hong, H. Chih-Ho, 69 

Hood, Robert, 36,82 

Houshmand, Elizabeth, 95 

Hsia, James, 70 

Huang, Liyi, 48 

Huang, Ying-Ying, 44 

Hubosky, Scott, 52 

Hughes, Christopher, 64 

Hughes, Rosalind, 74,96 

Hugtenburg, Richard, 73 

153

154 

Huh, Chang Hun, 98 

Hussain, Mussarrat, 39,86,97 

Hwang, Eun Ju, 95 

Iamphonrat, Thanawan, 85 

Ibrahimi, Omar, 70,86 

Izquierdo-Roman, Alondra, 66,67 

Jackson, Cassie, 82 

Jaén, Pedro, 99 

Jang, Kyung-Ae, 95 

Jang, Sang Jai, 95 

Jansen, Duco, 31,33,62,82 

Jenkins, Faye, 63 

Jeong, Chan-Woo, 84 

Jia, Wangcun, 35,52,80 

Jiang, Kerrie, 70 

Johnston, Keith, 45 

Jomah, Jamal, 53 

Jones, Stuart, 73 

Jordao, Juliana, 71,90 

Joseph, Cecil, 80 

Jung, Bongsu, 35 

Jung, Jeanne, 95 

Jung, Jung Bok, 98 

Kaminer, Micheal, 41,87,94 

Kang, Hee-Yang, 97 

Kang, Seung-Hui, 84 

Kang, Yoo Seok, 95 

Kantor, Roman, 75 

Kao, Chris, 33 

Karen, Julie K., 37,41,49,96 

Katsambas, Andreas, 68 

Kaur, Preet, 99 

Kauvar, Arielle, 69,84 

Kavali, Carmen, 89 

Kazmi, S.M. Shams, 45 

Keller, Matthew, 81,82 

Kelly, Kristen M., 37,38,64,80 

Kenkel, Jeffrey, 82 

Kerr, Michelle, 99 

Khan, Ashraf, 66 

Khandelwal, Manish, 53 

Kharkwal, Gitika B., 44 





Grapevine, TX 

Khemis, Abdallah, 97 

Kiernan, Michael, 48,73 

Killian, J. Antoinette, 81 

Kilmer, Suzanne, 18,86,87 

Kim, Bang Soon, 95 

Kim, Do Won, 98 

Kim, Hyunjoo, 

Kim, Il-Hwan, 74 

Kim, Jae hwan, 74 

Kim, Jun Young, 98 

Kim, Soohong, 95 

Kim, Won-Serk, 40 

Kochevar, Irene, 52 

Kono, Taro, 69 

Konrad, Peter, 33 

Koong, Luke, 36 

Kositrana, Garuna, 70 

Kosoglu, Mehmet, 36,82 

Kossida, Theodora, 68 

Krechko, Ksenia, 93 

Krishnamoorthi, Harish, 82 

Krishnan, Sunil, 34,36 

Kroon, Marije W., 75,84 

Krotz, A., 89 

Kshirsagar, Tushar, 86 

Kumar, Arun, 34 

Lacour, Jean-Philippe, 74,96,100 

Lambert, Jo, 38 

Landa, Nerea, 96 

Landau, Jennifer M., 40,83,85 

Landgraf, Werner, 35,36 

Lanzafame, Raymond, 31,44,46 

Lapidoth, Moshe, 75,90,92 

Laquer, Vivian,38 

Lawrence, Ira, 42 

Laznicka, Oldrich, 80 

Lazzari, Tiziana, 94 

Le Duff, Florence, 74 

Lee, Deuk-Pyo, 84 

Lee, Ga-young, 40 

Lee, Jeong-Yeop, 95 

Lee, Jong Hee, 95,96

Lee, Kyung goo, 74 

Lee, Sang geun, 74 

Lee, Sang-jun, 91 

Lee, Seok-Jong, 98 

Lee, Un Ha, 95 

Lee, Weon Ju, 98 

Leite, Francisco, 92 

Lemberg, Vladimir, 35,36 

Lenzi, Thiara, 75 

Leone, Nicholas, 52 

Leroux, Bertrand, 51 

Lev-Tov, Hadar,93 

Levy, Jean-Luc, 97 

Lewis, William, 70 

Li, Fang-Hui, 46 

Li, Guolin, 47 

Li, Pingping, 47 

Li, Qun, 43 

Li, Yuan-Hong, 81 

Liew, Se Hwang, 

Lin, Jennifer, 65 

Linares, Rafael, 96 

Lippert, Jan, 49 

Liu, Timon Cheng-Yi, 46,98 

Liu, Tom, 35 

Liu, Yan-Ying, 46 

Lopes, Renaud, 52 

Lopez-Estebaranz, Jose Luis, 96 

Luke, Janiene, 85 

Luna, Marian, 34 

Luo, Li, 98 

Lupin, Mark, 69 

Lussier, Isabelle, 42 

Mackanos, Mark, 82 

Maffeis, Thierry, 48 

Magacho, Tatiana, 71 

Magalon, Guy, 35,99 

Mahadevan-Jansen, Anita, 33,62,82 

Majaron, Boris, 80 

Makni, Nasr, 51,97 

Makowski, Alex, 82 

Maloney, Jillian, 88 





Grapevine, TX 

Maloney, Ryan, 88 

Malphrus, Jonathan, 33 

Mancuso, Jake, 45 

Mang, Thomas S., 48,93 

Manstein, Dieter, 63,70 

Manuel, Cyrus T., 52 

Manuskiatti, Woraphong, 85,87 

Marini, Leonardo, 85,90 

Mariotto, Guido, 75 

Marmur, Ellen, 81 

Marqa, Mohamad-Feras, 51,52,97 

Marques, Elaine, 91,94,95,99 

Marquez, Denise, 40,83,85 

Marshall, Janelle, 38 

Martin, Patrick, 42 

Martinez, Marcedes, 96 

Martins, Ana Paula, 75,92 

Mazer, Jean-Michel, 91 

McNichols, Roger, 51 

Meesters, Arne A., 75,84 

Meneghel, Tania, 90 

Michel, Jean-Loic, 98 

Mikulski, Lynn, 48 

Milanic, Matija, 80 

Milner, Thomas, 45 

Mitra, Kunal, 34 

Moges, Helina, 45 

Monheit, Gary D., 73 

Moody, Megan N., 40,83,85 

Moor, Eldad, 90 

Moore, P.J., 53 

Mordon, Serge, 31,51,52,97 

Moreno, Carmen, 99 

Morris, Whitney, 86 

Motamedi, Saam, 36 

Moy, Austin, 66 

Moy, Ronald, 38,96 

Muhlbauer, Aaron, 46 

Munavalli, Girish, 40 

Munyon, Thomas, 84 

Na, Jung Im, 98 

Na, Se Young, 96,98 

155

156 

Nachlieli, Tal, 41,84,90 

Nahshon, Genady, 84 

Naik, Ashok, 38,86,96,97 

Nakata, Motoko, 69 

Narurkar, Vic, 84,91 

Nelson, J. Stuart, 31,35,37,52,62,80 

Nelson, Steven, 97 

Nerette, Jean-Claude, 88 

Nevoux, Pierre, 51,52 

Newlove, Tracey, 37 

Nguyen, Amy, 38 

Noh, Tae Woo, 95 

Nossa, Robert, 87 

Novak, P., 89 

Nuijs, Tom, 70 

Nunes, Daniela, 75,92 

Nunes, Guilherme, 75,92 

Nunes, Rafael, 75,92 

Ogden, Neil, 32,66 

Ohshiro, Takafumi, 100 

Ohshiro, Toshio, 100 

Oliver, Jeffrey, 67 

Olson, Sharon, 19 

Ongenae, Katia, 38 

Oni, Georgette, 82 

Onozato, Maristela, 66 

Orenstein, Arie, 90 

Ortiz, Arisa, 69,70 

Ortonne, Jean-Paul, 74,97,100 

Osann, Kathryn, 93,94 

OShaughnessy, Kathryn F., 69 

Owens, Patricia A, 19 

Ozog, David, 38 

Paasch, Uwe, 75 

Palmer, Francis, 84 

Palomar, Maria Angustias, 96 

Pang, Yan, 47 

Parada, Luis, 67 

Paras, Constantine, 82 

Park, Byung-Soon, 84 

Park, Hyun Su, 95 

Park, Jaesook, 36 





Grapevine, TX 

Park, JeeYoung, 91 

Park, Jong Min, 91 

Park, Kyoung Chan,98 

Park, Sangjin, 84 

Park, Seok-Beom, 95 

Parker, Matthew, 36 

Passeron, Thierry, 74,96,97,98,100 

Patel, Rakesh, 66 

Patil, Chetan, 82 

Payne, J. Donald, 51 

Pence, Isaac, 82 

Pereira, Mara, 71 

Pérez-Varela, Lucía, 99 

Perrin, Denis, 98 

Petersen, Corbin, 96 

Peterson, Jennifer, 40,69,95,97 

Phadke, Vaishali, 86,96 

Philandrianos, Cécile, 35 

Pinto, Nathali, 33,71 

Podichetty, Vinod, 88 

Polder, Kristel D., 83,95 

Potdar, Sandeep, 93 

Pozner, Jason N., 31,40,85 

Protsenko, Dmitriy E., 36,52 

Pryaslova, Julia, 93 

Pryor, Brian, 45 

Puech, Philippe, 51,97 

Puri, Puja, 96 

Puvanakrishnan, Priyaveena, 34 

Queiroz, Rachel, 91,94,95,99 

Qui, Suimin, 36 

Quinlan, Robert, 66 

Ranu, H., 97 

Rao, Bheemsain, 34 

Rathi, Srikantha, 97 

Rechmann, Peter, 99 

Redmond, Robert, 52 

Rhee, Chung-Ku, 43 

Rho, JiHo, 91 

Rho, Nark-Kyoung, 84,95 

Richter, Claus-Peter, 62 

Rigopoulos, Dimitrios, 68

Rosende, Laura, 99 

Ross, E. Victor, 38,65,70,100 

Rothaus, Kenneth, 80,94 

Rozenberg, Avner, 84 

Rugg, Elizabeth, 38 

Russe, Elisabeth, 40,53,89 

Russe-Wilflingseder, Katharina, 40,53, 

89 

Rylander, Christopher, 36,66,67,82 

Rylander, Henry, 67 

Saager, Rolf B., 80 

Saai, Sonia, 35,99 

Sachdev, Mukta, 74 

Sadick, Neil, 89 

Saedi, Nazanin, 41 

Saggesse, Steven, 80 

Saini, Ritu, 70 

Sajjadi, Amir, 34 

Sakamoto, Fernanda, 49,65,70 

Sakurai, Hiroyuki, 69 

Salah, Manal, 49 

Sapozhnikova, Veronika, 45 

Sarimollaoglu, Mustafa, 82 

Sarnoff, Deborah, 70 

Sasaki, Katsumi, 100 

Schoenly, Joshua, 99 

Schomacker, Kevin, 70 

Schwartz, Jon, 34,36,51 

Seckel, Brooke, 41 

Sehra, Ruchir, 45 

Seka, Wolf, 99 

Shafirstein, Gal, 82 

Shah, Sejal, 85 

Shah, Shilpa, 38 

Shamban, Ava, 91 

Shanks, Steven, 88 

Sharma, Sulbha K., 44 

Sheb, Lingyue, 47 

Shek, Samantha Y., 41,83,84 

Shekhter, Anatoly, 35 

Sheth, Sameer, 66 

Shetty, Anil, 51 

Shilagard, Tuya, 36 





Grapevine, TX 

Shin, Jang-Hyun, 84 

Shin, Minkyung, 

Shofner, Joshua, 68 

Sillard, Laura, 74 

Silva, Claudia, 33 

Simon, Jan Christoph, 75 

Simonenko, Georgy, 34 

Singer, Giselle, 81 

Sliney, David, 80 

Smirnov, Mikhail, 38,41,80 

Smith, Jason, 45 

Smith, Stacy, 87 

Smucler, Roman, 49 

Snuderl, Matija, 66 

Sobol, Emil, 35 

Sofos, Stratos, 37 

Soltz, Barbara, 44,46 

Soltz, Robert, 44,46 

Son, Ho-Chan, 

Song, Kyeyoung, 91 

Souza, Monica, 92 

Spaliviero, Massimiliano, 52 

Sprague, Rebecca, 18 

Stadler, Istvan, 44,46 

Stafford, James, 81 

Stockman, Gareth, 48 

Strom, Kurt, 52 

Struck, Steven, 70 

Suen, James, 82 

Suh, Dong-Hye, 

Sun, Victor, 35,52 

Sundalam, Shubhangi, 96 

Sundaram, Hema, 85 

Swanson, David, 97 

Tabatadze, David, 34,41 

Takahashi, Takashi, 74 

Tanghetti, Emil, 38 

Taniguchi, Yuki, 100 

Tannous, Zeina, 68,70,73 

Tanzi, Elizabeth, 19 

Tatsutani, Kristine, 84 

Tay, Yong-Kwang, 100 

157

158 

Tayal, Dharam, 48 

Teahan, Maureen, 94 

Thanomkitti, Kanchalit, 87 

Thng, S., 97 

Thomas, Gareth, 73 

Thomsen, Sharon, 33 

Thornfeldt, Carl, 70 

Tierney, Emily, 95 

Tingey, Chad, 38,70 

Toft, Ulrich, 84 

Tolstaya, Anastasia, 93 

Town, Godfrey, 48,72,73 

Treece, Bonnie, 99 

Trelles, Mario, 97 

Truchuelo, Teresa, 99 

Tsilika, Katerina, 74,97,100 

Tuchin, Valery, 34 

Tucker, Travis, 94 

Tulipan, Noel, 33 

Tunnell, James, 34,36,67 

Turner, Ryan, 81 

Uebelhoer, Nathan, 39 

Uro, Laura, 71 

Uro, Michael, 71 

Vakoc, Ben, 64 

Van der Veen, J.P. Wietze,75,84 

Van der Wal, Allard A., 75,84 

van Grootel, Marieke, 70 

van Gulik, Thomas, M., 81 

VanderVeer, Elizabeth, 88,94,98 

Vargas, Gracie, 36 

Vargis, Elizabeth, 82 

Vasily, David B., 38 

Vaynberg, Boris, 40,75,84,89,98 

Veen van der, Albert, 35,36 

Velez, Mariano, 97 

Verdaasdonk, Rudolf, 35,36 

Vergilis-Kalner, Irene J., 40,83,85 

Verhaeghe, Evelien, 38 

Viator, John, 67 

Vidovic, Luka, 80 

Villers, Arnauld, 51 





Grapevine, TX 

Vlk, Marek, 49 

Vogt, William, 66,67 

Vorobieva, Natalia, 35 

Waibel, Jill, 39,64,69,95 

Waiker, Veena, 34 

Walgrave, Susan, 41 

Wallander, Irmina, 41 

Walser, Eric, 51 

Walsh, Alex, 82 

Wang, Guangming, 68 

Wang, Kerith, 43 

Wang, Sean, 43 

Wang, Tianyi, 45 

Wang, Weiwei 

Wang, Ying, 52 

Wanick, Fabiana, 75 

Wanitphakdeedecha, Rungsima, 85,87 

Wasserman, Daniel I., 73,95 

Webber, Jessica, 82 

Wei, En-Xiu, 46 

Weiss, Elliot T.,37,41,42,49 

Weiss, Robert, 38,41 

Welch, Ashley, 67 

Wells, Jonathan, 33,81 

Whitney, Felicia, 68,80 

Wierwille, Jeremiah, 66 

Wilder-Smith, Petra, 93,94 

Willey, Andrea, 49 

Willsey, Brian, 45 

Wilson, Stewart, 80 

Wind, Bas S., 75,84 

Wirth, Dennis, 66 

Wolfsen, Herbert, 48 

Wolerstorfer, Albert, 75,84 

Wong, Brian J.F., 36,52 

Wong, Carson, 52 

Wu, De-Feng, 46 

Wu, Edward C., 52 

Wu, Qiuhe, 44 

Wu, Xingjia, 31,45 

Xu, Qing, 47 

Xu, Tian-Hua, 81

Xu, Xue-Gang, 81 

Xu, Yang-Yi, 

Xuan, Weijun, 44 

Yaghmai, Dina, 86 

Yang, Bruce, 37 

Yang, Owen, 37 

Yanina, Irina, 34 

Yao, Min, 52 

Yaroslavsky, Anna, 66,80 

Yaroslavsky, Ilya, 34,68,80 

Yeung, Chi Keung, 41,83,85 

Yi, Sang min, 74 

Yoo, Jane, 81 

Youn, Sang Woong, 98 

Youssef, Joseph, 94 





Grapevine, TX 

Yu, Carol S., 84,85 

Yu, Emily, 38,100 

Zabalza, Iñaki, 96 

Zachary, Christopher, 41,64,65,70 

Zaman, Raiyan, 67 

Zamorano, María Luisa, 99 

Zelickson, Brian, 41 

Zenzie, Henry, 68 

Zhang, Jun, 94 

Zhang, Lin, 98 

Zhou, Guoyu, 47 

Zhu, Ling, 46 

Zhu, Xinyuan, 47 

Zygouris, Alexander, 75 

159

160 





Grapevine, TX

#1 

AMERICAN SOCIETY FOR 

LASER MEDICINE AND SURGERY 


TRANSLATIONAL 

RESEARCH (FORMERLY 

BASIC SCIENCE) 

SAFETY AND EFFICACY OF INFRARED NEURAL 

STIMULATION IN HUMANS 

Jonathan Cayce, Jonathon Wells, 

Jonathan Malphrus, Chris Kao, Sharon Thomsen, 

Noel Tulipan, Peter Konrad, Duco Jansen, 

Anita Mahadevan-Jansen 

Vanderbilt University Nashville, TN; Lockheed Martin Aculight, 

Bothel, WA; University of Texas, Austin, TX 

Background: Infrared neural stimulation (INS) is a new 

approach for precise neural stimulation that involves pulsed 

infrared laser energy through a non-contact interface, and has 

been well characterized in animal models. However to study the 

potential of this new technique in humans, safety and efficacy 

must be demonstrated. A preclinical safety and efficacy evaluation 

of INS was conducted in patients undergoing selective dorsal root 

rhizotomy. 

Study: Seven patients undergoing selective dorsal root rhizotomy 

were recruited for this study. Each patient was monitored by 

electromyogram (EMG) recordings in seven muscle groups on 

each leg. Electrical stimulation was used to identify dorsal lumbar 

spinal roots which exhibited spasticity. Spinal roots identified for 

transection were optically stimulated on 2–3 sites per nerve with 

our safest clinical laser parameters and muscle responses were 

recorded and compared to electrically evoked potentials prior to 

transection. After laser stimulation, a small portion of the spinal 

root was analyzed histologically. 

Results: Infrared neural stimulation evoked neuromuscular 

responses through anterograde, trans-synaptic excitation of 

alpha-motor neurons, and demonstrated higher spatial precision 

than electrical stimulation and no stimulation artifact. 

Stimulation threshold was identified as 0.53 J/cm 2 . Overall 

efficacy of INS in this study was 63% (34/54) for non-damaging 

radiant exposures between 0.53 and 1.00 J/cm 2 . Damage 

threshold was identified at 1.09 J/cm 2 . The overall safety ratio was 

calculated as 2.05:1 which is similar to the safety ratio identified 

in animal studies. 

ß 2011 Wiley-Liss, Inc. 

American Society for Laser Medicine and Surgery Abstracts 1 

ABSTRACTS 

Conclusion: This study represents the first application of INS to 

humans. The advantages of INS (spatial selectivity, contact-free 

delivery, and no stimulation artifact) demonstrated in animal 

studies were preserved. These results establish the efficacy 

needed for future studies to investigate the utility of INS for 

peripheral nerve mapping applications and functional 

applications. 

#2 

TREATING TRACHEAL STENOSIS USING LOW 

LEVEL LASER THERAPY: AS A POTENTIAL TOOL 

IN AN EXPERIMENTAL STUDY IN RAT MODEL 

Nathali Pinto, Claudia Silva, Raduan Hage, 

Neila Garcia, Emilia Arisawa, 

M. Cristina Chavantes, 

UNIVAP, São José dos Campos, Brazil; USP, São Paulo, Brazil 

Background: Tracheal stenosis (TS) is a life threat complication 

after traumatic procedures in the central airways conduct. The 

study’s aim was to evaluate Low Level Laser Therapy (LLLT) 

preventing and treating tracheal stenosis in an experimental rat 

model that could help treating patients. 

Study: At first stage of this study, 45 Wistar rats were 

anesthetized and induced tracheal stenosis by surgical 

procedure, divided in three groups (15 animals each one): Group 1 

(G1)—Control group, in which laser were simulated; Group 2 

(G2)—LLLT 24 hours after tracheal stenosis induction (surgical) 

procedure; Group 3 (G3)—LLLT 7 days after tracheal stenosis 

induction procedure. After tricotomy, G2 and G3 were irradiated 

w/LLLT transcutaneously onto cervical area (? ¼ 685 nm, 

P ¼ 150 mW, dose ¼ 100 J/cm 2 , T ¼ 13 min). As a second stage, 

five animals of each group were sacrificed and tracheal tissue’s 

samples were collected for histomorphometry by counting 

apoptotic cells, after 3 laser application: G1A, G2A, G3A—7 

days after laser irradiation; G1B, G2B, G3B—14 days post-LLLT; 

G1C, G2C, G3C—21 days after irradiation. 

Results: G1A presented a more intense inflammatory infiltrate in 

the submucosa area, while G2A showed more cells w/a thin 

submucosa and G3A an infiltrate loose tissue. G1B exhibited less 

inflammatory infiltrate while compared w/G2B and G3B. G2C 

presented an intense inflammatory infiltrate, when compared w/ 

G1C e G3C, which showed straighter w/a large number of 

fibroblast near lesion. In all animals observed dilated glands on 

the lesion area w/reduced number in G2C. 

Conclusion: The results suggest that laser phototherapy is an 

effective method to modulate granulated tissue in acute 

inflammatory process and avoiding widespread granuloma and 

scar tissue. The importance of this study for patients w/TS, it is 

Published online in Wiley Online Library 

(wileyonlinelibrary.com). 

DOI 10.1002/lsm.21034

2 American Society for Laser Medicine and Surgery Abstracts 

signing that LLLT can significantly contribute to prevent such 

appalling condition. 

#3 

NOVEL APPROACH FOR HEALING LEG ULCERS: 

CASE STUDY INVOLVING COMBINED EFFECT OF 

LOW LEVEL LASER THERAPY AND 

BIOCERAMICS 

Supriya Babu, Bheemsain Rao, Veena P. Waiker, 

Jaisri Goturu, Vasanthi Ananthakrishnan, 

Dayananda G, Arun Kumar, M.S. Ramaiah 

Institute of Technology, Bangalore, India; M.S. Ramaiah Medical 

College & Hospital, Bangalore, India 

Background: Of all the wounds, leg ulcers are more common in 

Indian population and are a major cause of amputation. An 

increased resistance of micro-organisms in the wound calls for 

novel approaches in wound management and therapy. We propose 

combining the bacteriostatic action of Bioceramics and the wellestablished 

advantages of LLLT in achieving a quick recovery of 

the ulcer with reduced treatment cost. 

Study: A male patient aged 60 years with chronic non-healing 

venous ulcers on both lower limbs. The lateral half of the both the 

wounds was used as control with routine dressings with betadine. 

The medial half of the right leg ulcer was treated with bioceramic 

wound healing device (WHD), The medial half of left leg ulcer was 

treated with LLLT (0.63 mm, 10 mW, CW) for 10 minutes and later 

dressed with WHD. Treatment was given for seven consecutive 

days and serial photographs were taken. Efficacy was assessed by 

taking bacterial culture and sensitivity (C/S) on first and eighth 

day. 

Results: Significant improvement was noticed with respect to the 

exudate amount, color, and edges in ulcer treated with combined 

therapy whereas minimal change was seen in WHD therapy 

alone. No significant changes were seen on control side of the 

wound. The initial C/S report indicated bacterial growth and in 

the final report, no growth of organisms was noted. 

Conclusion: With the promising effects of combination therapy 

for chronic, non-healing venous leg ulcers requires further 

controlled studies with larger study group to validate the results. 

#4 

EFFECT OF POLYETHYLENE GLYCOL COATING 

ON BIODISTRIBUTION OF ICG-LOADED 

POLYMERIC NANOCAPSULES IN MICE 

Baharak Bahmani, Sharad Gupta, Bahman Anvari 

University of California, Riverside, CA 

Background: Nano-constructs with near infrared (NIR) 

absorption capability present a promising technology for optical 

imaging and phototherapy of malformations. The advantage of 

utilizing NIR light is minimum absorption by water and tissue 

components and consequently higher penetration depth. 

Indocyanine green (ICG) is the only FDA approved near infrared 

chromophore used clinically in imaging applications, and is under 

investigation for photothermal and photodynamic therapy. 

However, ICG suffers from short circulation time within the 

vasculature, and is almost exclusively uptaken by the liver. To 

overcome these shortcomings, we have encapsulated ICG within 

polymeric nanocapsules (ICG-NCs). Our long-term objective is to 

enhance circulation time of ICG through nano-encapsulation, and 

use the encapsulated platform for site-targeted optical imaging 

and phototherapy. Here, we investigate if surface coating using 

polyethylene glycol (PEG) will alter the biodistribution of ICG- 

NCs. 

Study: We synthesize ICG-NCs using a self-assembly process 

that utilizes polyallylamine hydrochloride and sodium phosphate 

salt as the encapsulating structure. ICG-NCs are coated 

covalently with PEG of either 5,000 or 30,000 Da molecular 

weight, through reductive amination. PEG-coated ICG-NCs are 

administrated through tail vein injection in healthy mice. Whole 

body florescent imaging is performed at different post-injection 

times. To quantify the biodistribution of PEG-coated ICG-NCs, 

various organs including liver, lungs, spleen, intestine, kidneys 

and heart are harvested and homogenized following euthanasia. 

Blood sample is also collected to investigate amount of PEGcoated 

ICG-NCs remaining in the vasculature at different postinjection 

times. 

Results: Our preliminary results suggest that encapsulation of 

ICG in polymeric nanocapsules alters the dynamic biodistribution 

of ICG in healthy mice. PEGylation of ICG-NCs appears to delay 

the accumulation of ICG within the liver in comparison with 

uncoated ICG-NCs and free ICG. 

Conclusion: Results of this study will provide important 

information in engineering ICG-NCs with prolonged blood 

circulation time and potential applications for fluorescence 

imaging and phototherapy of various abnormalities. 

#5 

NARROWBAND IMAGING OF TARGETED GOLD 

NANORODS IN TUMORS 

Priyaveena Puvanakrishnan, Parameswaran 

Diagaradjane, Glenn Goodrich, Jon Schwartz, Sunil 

Krishnan, James Tunnell 

University of Texas at Austin, Austin, TX; University of Texas/MD 

Anderson Cancer Center, Houston, TX; Nanospectra Biosciences, 

Inc., Houston, TX 

Background: A significant challenge in the surgical resection of 

tumors is accurate identification of tumor margins. Current 

methods for margin detection are time-intensive and often result 

in incomplete tumor excision and recurrence of disease. Gold 

nanoparticles have recently gained significant traction as 

exogenous contrast agents for identifying tumors ex vivo. The 

objective of this study was to determine the potential of topically 

administered antibody conjugated gold nanorods (GNR) for realtime 

tumor margin detection using near-infrared narrowband 

imaging (NIRNBI). NIRNBI images narrow wavelength bands to 

enhance contrast from plasmonic particles in a widefield, portable 

and non-contact device that is clinically compatible for real-time 

tumor margin demarcation. 

Study: We conjugated GNR to Cetuximab, a clinically approved 

humanized antibody that targets the epidermal growth factor 

receptor (EGFR). We excised subcutaneous xenografts of 

squamous cell carcinomas from Swiss nu/nu mice and divided the 

tumors into two groups: (1) the targeted group (anti-EGFR 

conjugated GNR) and (2) the control group (PEG-conjugated 

GNR). After topical application of particles and incubation for 

30 minutes, the tumors were washed and imaged using NIRNBI. 

To quantify the binding of GNR in tumors, we measured the 

contrast enhancement for each particle type. 

Results: The NIRNBI images showed a visual increase in 

contrast from tumors administered with targeted GNR over the 

control particles and without the particles. There was a 

statistically significant increase in contrast (400%) from tumors

after administration of targeted GNR. Additionally, the NIRNBI 

images collected from targeted GNR tumors (n ¼ 4) showed a 

220% increase in contrast compared to untargeted tumors. 

Conclusion: We have demonstrated that a topical application of 

gold nanorods targeted specifically to tumor growth factors results 

in a significantly higher image contrast compared to non-targeted 

gold nanorods. These results demonstrate the initial feasibility of 

NIRNBI in demarcating tumor margins during surgical resection 

using topical administration of targeted GNR. 

#6 

INDUCTION OF LIPOLYSIS IN HUMAN 

ADIPOCYTES BY HYPERTHERMIA ALONE AND 

IN COMBINATION WITH PHOTODYNAMIC 

TREATMENT 

Valery Tuchin, Irina Yanina, Georgy Simonenko, 

Andrey Belikov, David Tabatadze, Ilya Yaroslavsky, 

Gregory Altshuler 

Institute of Optics and Biophotonics, Saratov State University 

Saratov, Russian Federation; Palomar Medical Technologies, Inc., 

Burlington; Laser Center, SPITMO Saint-Petersburg, Russia 

Background: Reduction of fat deposits is a goal of many 

treatment approaches. Liposuction remains de facto goldstandard 

procedure, providing high reduction in the volume of 

adipose tissue in a short period of time. Minimally and noninvasive 

alternatives to liposuction are highly desirable and are 

being actively pursued by many groups world-wide. Objective of 

this study was to investigate feasibility of inducing lipolysis in 

human adipose tissue with hyperthermia alone and by combining 

it with photodynamic treatment. 

Study: Samples of human adipose tissue were subjected to 

hyperthermia (up to 43.58C) using several temporal regimens of 

heating and cooling down. In addition, some samples were stained 

by photosensitizer Brilliant Green (maxima of absorption at 440 

and 650 nm) and then irradiated by a two-color diode lamp 

(W ¼ 70 mW/cm 2 at ? ¼ 442 nm and W ¼ 121 mW/cm 2 at 

? ¼ 597 nm). The viability and status of the adipocytes were 

assessed by light microscopy at several time points. 

Results: Pronounced changes in shape and size of adipocytes 

were registered. Observed dynamics of cell morphology is 

consistent with hypothesis of induced lipolysis. Photodynamic 

treatment accelerated the change significantly. 

Conclusion: Hyperthermic treatment of adipocytes can be used 

to induce lipolysis. The process can be accelerated by 

photodynamic treatment. This technique has a potential for 

minimally or non-invasive fat reduction in vivo. 

#7 


HEAT SHOCK PROTEIN EXPRESSION IN TISSUES 

AFTER SHORT PULSE LASER-INDUCED DAMAGE 

Amir Sajjadi, Kunal Mitra, Michael Grace 

Melbourne, FL 

Background: Effective laser-based therapeutics requires 

detailed understanding of the biochemical mechanisms of laser– 

tissue interaction. Therefore, we characterized the extents of 

thermal damage and heat-affected zones following skin ablation 

by analyzing the spatiotemporal distribution of heat shock 

proteins. 

Study: A focused-beam short-pulse laser was used to ablate the 

skin surface of live anesthetized mice with minimal thermal 

damage to surrounding untreated tissues. After ablation, the 

extent of thermal ablation and the heat-affected zone was 

analyzed by immunofluorescence localization of heat shock 

proteins, the expression of which increases when cells are 

exposed to elevated temperature or other stresses. Thermal 

imaging was performed during laser irradiation to monitor 

temperature effects in real time. To investigate the extent of 

thermal damage and the initial events in healing, 47- and 70-kDa 

heat shock proteins (HSP47 and HSP70) were localized in a 

double-labeling procedure using HSP47- and HSP70-specific 

primary antisera followed by Alexa-dye-labeled secondary 

antisera. HSP analyses were performed at 0, 24, 36 and 48 hours 

after laser irradiation. Images were obtained by laser scanning 

confocal microscopy. 

Results: Expression patterns of HSP70 and HSP47 delineated 

the extent of thermal damage, and may illustrate the biochemical 

process of wound healing. Analysis of the effects of laser 

irradiation over the course of time using different laser 

parameters followed by immunohistochemistry defines the time 

course of laser effects on skin tissues. Extent of damage was 

correlated with temperature rise using measured temperature 

distribution and ablation depth for different laser parameters. 

Conclusion: HSP70 and HSP47 can be simultaneously 

visualized using immunofluorescence and laser scanning confocal 

microscopy, and temporal changes in HSP expression patterns 

may define both the laser-induced thermal damage zone and the 

process of healing. Careful temporal analysis of HSP distribution 

following laser irradiation supports the development of effective 

new laser therapy protocols. 

#8 

MOBILIZATION OF ENDOTHELIAL PROGENITOR 

CELLS FOLLOWING PHOTODYNAMIC THERAPY 

Charles Gomer, Angela Ferrario, Marian Luna 

University of Southern California, Los Angeles, CA; 

Childrens Hospital Los Angeles, Los Angeles, CA 

Background: Photodynamic therapy (PDT) mediated oxidative 

stress induces direct tumor cell kill and, indirectly, modulates the 

tumor microenvironment leading to local responses such as 

inflammation, hypoxia and acute vascular injury. These local 

reactions effect PDT tumor responsiveness by inducing 

angiogenesis. To expand our understanding of PDT-mediated 

tumor responses we are conducting a study to examine whether 

PDT mobilizes bone marrow-derived vascular progenitor cells, a 

mechanism associated with vasculogenesis, growth and 

metastatic potential. 

Study: We monitored the number of circulating endothelial cells 

(CECs) and circulating endothelial progenitor cells (CEPs) 

following PDT using four color flow cytometry. We also examined 

the in vitro and in vivo expression of the chemokine stromal 

derived factor-1 alpha (SDF-1a) and its receptor CXCR4, which 

are key molecules associated with hematopoietic stem cell homing 

and tumor angiogenesis. 

Results: Flow cytometry results showed a twofold increase of 

CECs and CEPs in the peripheral blood of Balb/c mice bearing 4T1 

mammary tumors 24 hours after PDT when compared to 

untreated controls. Western blot analysis of lysates from PDTtreated 

cells showed, at 24 hours, a four- to fivefold increase in 

expression of CXCR4 while no SDF-1a was detected in media by 

ELISA. We observed increase of SDF-1a levels in plasma of 

treated mice as well as activation of the SDF-1a receptor CXCR4 

in 4T1 tumors soon after PDT.


Conclusion: These results indicate that subcurative PDT doses 

lead to induction of SDF-1a/CXCR4 expression and increased 

levels of CECs and CEPs. Studies are currently underway to 

examine if CEC and CEP levels can be used as biomarkers of PDT 

response and to determine if preventing CEP mobilization and 

incorporation into tumor vasculature can, by blocking 

angiogenesis, improve PDT responsiveness. 

#9 

COMPARISON OF ANTIANGIOGENIC AGENTS 

FOR INHIBITING REPERFUSION OF 

PHOTOCOAGULATED BLOOD VESSELS IN AN 

ANIMAL MODEL 

Wangcun Jia, Victor Sun, Tom Liu, Bernard Choi, 

J. Stuart Nelson 

Beckman Laser Institute and Medical Clinic, University of 

California, Irvine, CA; Conrex Pharmaceuticals, Newtown 

Square, PA 

Background: Antiangiogenic agents have been demonstrated to 

reduce the reperfusion of photocoagulated blood vessels with 

varying degrees of success, which might improve the therapeutic 

efficacy of port wine stain laser treatment. Our objective was to 

compare the safety and efficacy of different antiangiogenic agents 

for preventing photocoagulated blood vessels from reperfusing. 

Study: Two macrolide lactones, rapamycin and tacrolimus were 

tested in this study. Rapamycin is a specific mTOR inhibitor and 

tacrolimus is a calcineurin/NFAT inhibitor. Both agents were 

formulated as topical ointments which contained 1% effective 

ingredient, solvent, medical base and a skin penetration 

enhancer. The animal model was the dorsal skinfold window 

chamber on hamster. Immediately after laser irradiation of blood 

vessels in the window, a topical antiangiogenic agent was applied 

to the epidermal side of the window daily for 14 days. Color digital 

photography and laser speckle imaging were used to document 

structure and flow dynamics of blood vessels. 

Results: The reperfusion rate was reduced from nearly 100% for 

control (laser irradiation only) to 39% and 78% for rapamycin and 

tacrolimus, respectively. Skin irritation was observed on animals 

treated with tacrolimus. It was also noted that efficacy varied 

significantly among animals treated with the combined therapy. 

Conclusion: More antiangiogenic agents need to be screened to 

determine the best candidate for combined laser and topical antiangiogenic 

therapy for port wine stain and other cutaneous 

vascular lesions, which is currently being pursued in our lab. 

#10 

INFLUENCE OF PULSE DURATION ON 

EFFICIENCY AND SOME ADVERSE EFFECTS OF 

ND:YAG LASER IRIDOTOMY 

Gregor Hawlina, Brigita Drnovsek-Olup 

Eye Clinic, University Medical Centre, Ljubljana Ljubljana, 

Slovenia 

Background: Most common adverse effects following Nd:YAG 

laser iridotomy are intraocular pressure elevation, reduction of 

endothelial cell count, cystoid macular edema, retinal rupture/ 

detachment and acceleration of cataract. The causes of some 

adverse effects are still poorly understood, but they are more 

frequent when using laser pulses of higher energy level. 

Photodisruptors trigger laser induced breakdown (LIB) by 

transferring very high energy on very small area in focal region. 

LIB has characteristics of microexplosion and is accompanied by 

two secondary phenomena: cavitation bubble and high energy 

pressure wave. In ophthalmic microsurgical procedures 

amplitude of high energy pressure wave determines the area of 

potential damage of nearby tissue, while the size of cavitation 

bubble is proportional to removal of unwanted eye tissue. The area 

of LIB in eye is small, but surrounded by many fragile structures. 

These structures could be damaged by microexplosion itself or by 

secondary effects which could damage more extensive area. The 

size of area of mentioned laser effects is directly proportional to 

laser pulse energy. Lower laser pulse energy level should 

therefore lower the possibility of injuries of surrounding 

structures. 

Study: In the first part LIB and secondary effects in the water 

and porcine vitreous following use of photodisruptor with pulse 

duration of 5 nanoseconds and new model with pulse duration of 

near 1 nanosecond is studied. In the second part we are comparing 

number of pulses, average and total energy needed to create an 

open iridotomy on animal model (porcine iris). 

Results: Nd:YAG laser with shorter pulse duration needs almost 

the same acting power but less energy to reach threshold for laser 

induced breakdown (LIB). Consecutively the size of cavitation 

bubble and amplitude of high energy pressure wave is smaller. To 

create an open iridotomy on porcine iris Nd:YAG laser with 

shorter pulse duration needs lower energy of one pulse and less 

total energy. 

Conclusion: Recently developed photodisruptor based on 

Nd:YAG laser enables shorter pulse duration and consecutively 

lower energy level while performing ophthalmic laser procedures. 

Ophthalmic laser procedures made by this laser should be safer 

with less adverse effects. 

#11 

EFFECTS OF LASER BEAM MODIFICATION ON 

THE ANTERIOR CHAMBER ANGLE STRUCTURAL 

CHANGES AFTER SELECTIVE LASER 

TRABECULOPLASTY IN ANIMAL MODEL 

Rok Grcar, Brigita Drnovsek-Olup 

Eye Hospital Ljubljana, Ljubljana, Slovenia 

Background: Selective laser trabeculoplasty (SLT) is a relatively 

new, efficient and safe method for reduction of intraocular 

pressure in patient with glaucoma and ocular hypertension. 

Histological analysis of human anterior chamber angle after SLT 

showed absence of coagulative necrosis and minor trabecular 

meshwork (TM) damage. After SLT, TM endothelial cells secrete 

certain cytokines and metalloproteinases which increase 

trabecular meshwork fluid permeability resulting in intraocular 

pressure reduction. The effects of laser beam or its modifications 

on structural changes of the anterior chamber angle and the 

mechanism of intraocular pressure reduction are not yet known. 

Study: The effect of laser beam modification on the anterior 

chamber angle structural changes in an animal model (porcine 

eyes) is studied with transmission electron microscopy. The effect 

of new parameters with more constant power density profile is 

compared to the standard SLT parameters, where laser beam with 

power density profile similar to Gaussian curve is used. 

Results: Modified laser beam with more constant power density 

profile induces less damage to the trabecular meshwork than 

classic laser beam with power density profile similar to Gaussian 

curve. 

Conclusion: Modified laser beam with more constant profile is 

expected to deliver energy more evenly to the treated area and to

educe central TM endothelial cell damage. The greater number of 

surviving cells could be stimulated to secrete certain cytokines 

that increase trabecular meshwork fluid permeability, resulting 

in greater intraocular pressure reduction. 

#12 

OPTIMAL WAVELENGTH SELECTION FOR LASH 

TREATMENT OF SKIN PHOTOTYPES I TO VI 

Alain Cornil, Sylvain Giraud, Sonia Saai, 

Cécile Philandrianos, Guy Magalon 

Ekkyo Aix-en-Provence, France; APHM, Hopital Nord, Marseille, 

France 

Background: Previous studies have demonstrated the efficacy of 

laser assisted skin healing (LASH) treatment using a 810 nm 

diode laser for improving scars following surgical intervention. 

However this new modality was limited to phototypes I to IV, due 

to high absorption of melanin at this wavelength. Another 

limitation is linked to the relatively high absorption of hemoglobin 

at 810 nm, which may pose problem when treating surgical 

incisions. This in vitro study aimed at finding the optimal 

wavelength for LASH, in particular with regards to phototype 

compatibility and minimum absorption by blood. 

Study: Eight human skin explants of phototypes I to VI, 

harvested from abdominoplasties, as well as sheep blood plates 

were irradiated using 810, 980, 1,064, 1,210, and 1,320 diode 

lasers. Handpieces were designed to shape the beam profiles into 

rectangular top hat to ensure optimum heating of the full skin 

thickness. Surface temperature was monitored using an IR 

camera. Micro-thermocouples were placed at 2 and 4 mm depth in 

the explants. Temperatures were recorded at baseline and during 

the irradiation. Irradiance was 4 W/cm 2 . Maximum temperature 

and speed of heating were plotted and irradiance needed to 

achieve 508C at 2 mm depth was extrapolated from these data. 

Results: Among the four wavelengths tested, 1,210 nm is the 

optimum compromise between efficacy of heating and minimum 

variance due to phototype and blood. Contrary to other 

wavelengths, no difference in heating patterns was observed at 

1,210 and 1,320 nm when skin explants were soaked in blood or 

not. Less than 18C gradient between surface and 2mm 

temperature was observed at 1,210 nm compared with 48C for 

1,320 nm. 

Conclusion: This in vitro study demonstrate the optimal 

characteristic of 1,210 nm wavelength for heating homogeneously 

skin of all phototypes even in the presence of blood. 

#13 


TISSUE EFFECTS INDUCED BY Er;Cr:YSGG 

LASER PULSES DELIVERED THROUGH A 

RADIAL EMITTING FIBER STUDIED WITH HIGH 

SPEED OPTICAL THERMOGRAPHY 

Rudolf Verdaasdonk, Vladimir Lemberg, Albert 

Veen van der, Stefan Been, Dmitri Boutoussov, 

Werner Landgraf 

VU University Medical Center, Amsterdam, Netherlands; 

Optomix, Santa Clara, CA; University Medical Center Utrecht, 

Utrecht, Netherlands; Biolase, Irvine, CA; Biolase Floss, Germany 

Background: The Waterlase MD Er;Cr:YSGG laser system has 

been successfully used for cutting, removing, shaping and 

contouring of hard and soft tissues including endodontic and 

periodontal therapies. To increase the efficiency of laser treatment 

within the periodontal pockets, a radial emitting perio fiber tip 

(RFPT) was developed. 

Study: The optical, mechanical and thermal effects in tissue of 

Er;Cr:YSGG laser pulses delivered through a radial emitting fiber 

tip were studied using high speed optical thermography. High 

speed color Schlieren techniques were used to visualize the extent 

of heating and thermal relaxation after the laser exposure at 

recording frame rate of 500 f/second (millisecond range). The 

ablation process was observed with back-light illumination with 

frame rates of speed imaging setup up to 8,000 f/second 

(microsecond range). Pulses were delivered to the surface of a 

polyacrylamide gel that acted as a transparent model tissue to 

observe effect below the surface. 

Results: The radial tip created a straight primary beam and a 

secondary conical beam that ablated the tissue in the center 

surrounded by ring of thermal effect at a short distance from the 

surface. In contact with tissue, a small channel was created with 

thermal ‘lobes’ to the side. The energy distributions correlated 

well with ray-trace modeling of the radial tip design. 

Conclusion: The special design radial emitting tip provides a tool 

for effective cutting in combination with moderate thermal effects 

to induce haemostasis during cutting in soft tissue and 

decontamination in cavities like periodontal pockets. The tip 

might also have potentials for precise surgical applications. 

#14 

IS IT POSSIBLE TO PERFORM LASER 

RESHAPING WITHOUT DRAMATIC EFFECT ON 

CHONDROCYTES? 

Emil Sobol, Natalia Vorobieva, Olga Baum, Anatoly 

Shekhter, Anna Guller 

Institute on Laser and Information Technologies, Troitsk, Russia; 

Medical Academy of Moscow, Moscow, Russia 

Background: Laser reshaping of cartilage is a new, effective 

technique which began to be used in otolaryngology and cosmetics 

for correction of cartilage shape of the nose, ear and throat. The 

main objective of the paper is to study the effect of various laser 

settings on morphological alterations in chondrocytes during laser 

reshaping of nasal septum. 

Study: The nasal septums of the pigs have been treated using an 

Erbium glass fiber laser of 1.56 mm in wavelength (Arcuo Medical, 

Inc.) with an opto-thermo-mechanical contactor providing 

mechanical pressing of the mucosa and delivering 1.56 mm laser 

radiation to the spot of 3 mm in diameter. Two series of 

experiments have been performed: (1) to determine the energy 

threshold for stable laser reshaping and (2) to study the effect of 

mechanical loading and irradiation of the fresh pig septum using 

the threshold laser setting and different levels of exceeding 

regimes. Histological analysis of the cartilage samples have been 

performed to study the zones of altered chondrocytes, including 

the sizes and positions of the necrotic zones. 

Results: (1) Stable reshaping of pig nasal septum cartilage has 

been achieved at laser power of 0.8 W, pulse length 0.5 seconds, 

pulse spacing 0.2 seconds, exposure time of 3 seconds. (2) No 

significant changes in chondrocyte shape and structure have been 

observed for above laser setting. (3) Increase of laser power and 

exposure time enhanced dramatically structural alterations in 

chondrocytes. 

Conclusion: The threshold laser settings allow to obtain stable 

reshaping without significant alterations to chondrocytes. 

Exceeding regimes of laser radiation lead to substantial 

alterations (up to necrosis) of the cells. Since cell damage may


activate regeneration processes resulting in new tissue growth 

and therefore in some alteration of cartilage shape obtained 

immediately after laser procedure, the results obtained are of 

importance to forecast the stability of laser reshaping procedure. 

#15 

FLUID CHARACTERIZATION OF A NOVEL 

HOLLOW-CORE MICRONEEDLE DESIGN 

Robert Hood, Mehmet Kosoglu, Matthew Parker, 

Christopher Rylander 


Background: Microneedles have been successfully utilized to 

deliver small fluid volumes for many different applications. We 

are investigating a novel hollow-core microneedle design that will 

permit co-localized, simultaneous light and fluid delivery. 

Successful skin penetration of similar microneedle designs has 

been previously demonstrated by our group. The potential 

applications for such a device range from cosmetic fat reshaping to 

targeted destruction of tumors. The primary objective of this study 

was to determine the optimal microneedle parameters for fluid 

flow. 

Study: Microneedles with tip diameters varying between 15 and 

90 mm were fabricated via a custom melt-draw apparatus from 

capillary tubing (150 mm inner diameter) capable of co-delivering 

light and fluids. A series of experiments characterizing the 

capillary tubing’s fluid resistance were conducted by measuring 

the volumetric flow rate of water through the tubing at constant 

pressures ranging from 10 to 90 psi. Following accurate 

characterization of tubing resistance, additional experiments 

investigating the flow resistance of different microneedle 

geometries were conducted. 

Results: The first set of experiments determined that fluid flow in 

tubing lengths longer than 50 mm adhered highly to Poiseuille’s 

Law in the range of pressures investigated (10–90 psi). For 

lengths < 50 mm, turbulent effects in the flow caused Poiseuille’s 

Law to under-predict the fluid resistance. In either laminar or 

turbulent flow regimes, the flow rate increased significantly as 

tubing length decreased. Increased microneedle resistance was 

correlated with small tip diameter, shorter needle length, and 

bending in the needle bore. 

Conclusion: This study sought to determine the best geometry 

balancing minimal invasiveness and low flow resistance in a novel 

hollow-core microneedle design. The experiments indicated that 

the optimal design involves having a microneedle with a 

completely straight bore, length between 0.5 and 0.8 mm, and tip 

diameter between 40 and 60 mm preceded by the shortest tubing 

length possible. The next developmental step will involve 

determining the best geometries for incorporation of light delivery 

in addition to fluid flow. 

#16 

USING TRIPHASIC THEORY TO EVALUATE 

CARTILAGE MECHANICAL RESPONSE TO 

LASER RESHAPING 

Dmitry Protsenko, Brian Wong 

Beckman Laser Institute and Medical Clinic, 


Background: Laser cartilage reshaping (LCR) has been 

suggested as an alternative to the classical surgical techniques of 

modifying the shape of facial features. The method is based on 

exposure of mechanically deformed cartilaginous tissue to a laser 

heating. Bio-chemical reactions within the tissue lead to reduction 

of internal stress, and establishment of a new equilibrium shape. 

The same reactions offset the electric charge, osmotic and 

hydraulic balances between collagen and proteoglycan matrix and 

interstitial fluid responsible for maintenance of cartilage 

mechanical properties. The objective of this study was to 

investigate correlation between the temperature rise during LCR 

and cartilage mechanical behavior. 

Study: We used a finite element model based on the modified 

triphasic theory to study how internal temperature field 

generated in the laser heating of cartilage can modulate its 

mechanical responses to step displacements in unconfined and 

confined compression. The native concentrations of the ions, 

collagen matrix stiffness and the fluid and ion velocities within the 

specimen were estimated from compression and stress relaxation 

experiments. 

Results: The results from finite element calculations 

demonstrated apparent stress increase during heating due to 

thermal expansion. Generally, stress relaxation following the 

heating accelerates with increase in temperature and irradiation 

time. To compare numerical model with experimental observation 

we measured stress evolution in cartilage during and after lasers 

heating. 

Conclusion: Good correlation between experimental and 

theoretical data (R < 0.9) confirms contribution of thermal 

expansion to stress evolution and suggests softening of collagen 

matrix as a major mechanism of stress relaxation. 

#17 

COMPARISON OF THERMAL AND MECHANICAL 

CHARACTERISTICS DURING TISSUE ABLATION 

OF Er:YAG, Er,Cr:YSGG AND CO2 IN THE 

MICROSECOND TO MILLISECONDS PULSE 

RANGE IN VIEW OF SOFT TISSUE APPLICATIONS 

IN SURGERY 

Rudolf Verdaasdonk, Vladimir Lemberg, Albert 

Veen van der, Stefan Been, Dmitri Boutoussov, 

Werner Landgraf 

VU University Medical Center, Amsterdam, Netherlands; 

Optomix, Santa Clara, CA; University Medical Center Utrecht, 

Utrecht, Netherlands; Biolase, Irvine, CA; Biolase Floss, Germany 

Background: Erbium lasers are being used successfully in 

dentistry for hard tissue ablation. In dermatology, Erbium laser 

dermabrasion has been replaced with fractional techniques 

mainly with CO2 lasers. Due to the precise and controlled 

ablation, Erbium lasers might be considered as alternatives for 

fractional applications as well as for microsurgery in, for example, 

ENT, reconstruction and neurosurgery. In this study, the ablation 

effect of several Erbium lasers was examined in relation to pulse 

duration, wavelength and fiber delivery system. 

Study: Three Erbium based laser modalities, Er:YSGG at 

2.78 mm, pulse 60 or 700 microseconds and Er:YAG at 2.94 mm 

60 microseconds delivered through 200 and 400 mm diameter silica 

tips were compared during the ablation of phantom tissue 

(polyacrylamide gel 90% water content) at pulse energies from 10 

to 100 mJ. High speed and thermal Schlieren imaging techniques 

were applied to visualize the mechanical and thermal effects. 

Results: The differences in ablation depth were significant as 

well as the thermal residual in relation to pulse length. The 

ablation at 2.94 mm was around 25% more effective compared to 

2.78 mm with less thermal residual. There was minimal difference

etween the fiber diameters. The ablation effect observed were 

similar to the microsecond pulsed CO 2 laser; tissue water is 

effectively turned to explosive hot vapour that is expelled from the 

imploding channel leaving some residual thermal energy behind 

depending on pulse length. 

Conclusion: Fiber delivered Erbium lasers can provide 

controlled soft tissue cutting using pulse lengths in the ms toms 

range to control the thermal residual depending on the 

application. 

#20 

REGULATORY PERSPECTIVE OF OPTICAL 

IMAGING DEVICES: TECHNOLOGY, 

INDICATIONS, AND FUTURE CHALLENGES 

Kejing Chen, Richard Felten, Long Chen, Neil 

Ogden 

Office of Device Evaluation, Food and Drug Administration, 

Silver Spring, MD 

Background: Medical imaging is a rapidly developing area that 

provides novel diagnostic information and/or facilitates image 

guided therapy to areas of interest. Optical imaging devices, when 

used in conjunction with minimally invasive endoscopes, collect 

reflected, scattered, laser-induced fluorescent, and other light 

signals in the ultraviolet, visible and near-infrared spectra. Based 

on the collected signal, images are constructed to reveal tissue 

structure information at microscopic level. Contrast to other 

imaging methods, optical imaging could yield high spatial 

resolution near the mm scale. 

Study: In the past, the FDA has cleared a number of optical 

imaging devices, which are currently used in clinical practice, 

through the Premarket Notification process as Class-II Medical 

Devices. Due to the evolution of new technology associated with 

the development of optical imaging devices, there now exist 

challenges, from the regulatory perspective, in the following 

areas: 

Results: (1) The sensitivity and specificity of optical imaging 

devices to detect the claimed diseased lesions. (2) The output 

readability of some optical imaging devices may be in the form of 

action spectrum or numerical readout, which although still 

yielding structure information is unconventional for the reading 

practice of many health practitioners. (3) The use of contrast 

agents to improve the contrast resolution. While most optical 

imaging only requires device technology to produce images, the 

concurrent use of contrast enhancing agents may improve the 

image qualities, particularly for laser induced fluorescence 

imaging systems. The advancement of imaging contrast agents 

has been historically outpaced by that of imaging devices and a 

number of such imaging drugs have been off-label used with 

imaging devices in medical practice. 

Conclusion: In this presentation, we review the optical imaging 

literature, identify its cleared clinical beneficial effects, 

summarize the regulatory status, and analyze the regulatory 

challenges that might be important for bridging the academic 

development and marketing delivery of optical imaging devices. 

#21 


IN VIVO IMAGING OF KIDNEY 

MICROVASCULATURE USING DOPPLER 

OPTICAL COHERENCE TOMOGRAPHY 

Jerry Wierwille, Jeremiah Wierwille, 

Peter Andrews, Maristela Onozato, Yu Chen 

College Park, MD; Washington, DC 

Background: Doppler optical coherence tomography (DOCT) is 

an extension of OCT that detects phase shifts in backscattered 

light resulting from contact with moving scatterers. DOCT 

enables detection of blood flow in vivo. DOCT is potentially very 

useful in a clinical setting having high resolution ( 10–20 mm) 

and the ability to be miniaturized into handheld devices or 

endoscopic probes. While the imaging depth of DOCT is limited to 

2 mm, we have shown that this penetration is sufficient for 

imaging of the kidney hemodynamics in the superficial cortical 

region. 

Study: To image the kidney in vivo, Munich-Wistar rats (n ¼ 3) 

were anesthetized and the kidney exposed beneath a swept-source 

microscope (?0 ¼ 1,300 nm). Many glomeruli were easily identified 

by scanning the surface of the kidney, capturing 3D DOCT 

volumetric data sets at each location. The Doppler signal at each 

en face plane was integrated over its respective area as a measure 

of glomerular blood flow. Flow histograms were also extracted for 

each distinct Doppler signal that could be isolated. To test changes 

in physiological blood flow, mannitol and angiotensin II were 

administered intravenously to induce and increases and decreases 

in glomerular flow, respectively. 

Results: Individual blood flow patterns were readily visible by 

DOCT. 3D reconstructions of these images provided an enhanced 

visualization of the blood flow throughout the capillary network in 

the glomeruli. An increase in glomerular blood flow was observed 

following injection of mannitol and a decrease was observed 

following injection of angiotensin II. These observations were 

confirmed to be significant after calculating and comparing the 

glomerular blood flow affected by each drug. 

Conclusion: DOCT is able to determine different directional flow 

patterns in glomerular capillaries and to detect changes in these 

patterns blood flow in real-time. We conclude that DOCT may be 

helpful in monitoring the status of glomerular blood flow in the 

clinical setting. 

#22 

MULTIMODAL OPTICAL IMAGING FOR 

DETECTING BREAST CANCER 

Rakesh Patel, Ashraf Khan, Robert Quinlan, 

Anna Yaroslavsky 

University of Massachusetts Lowell, Lowell, MA; 

UMass Memorial Healthcare, Inc., Worcester, MA 

Background: Re-excision is required in up to 60% cases of breast 

conserving surgeries, as most are performed without 

intraoperative margin control. Real-time mapping of cancer 

margins during surgeries would be indispensible. The long-term 

goal of this research is to improve the quality of life and survival in 

patients with breast cancer. We seek to improve the surgeon’s 

ability to distinguish breast tissue from tumor over wide-fields 

and on microscopic scale at the margin. 

Study: At the initial stage of the project, we are testing the 

combination of wide-field and high-resolution multimodal 

imaging, that is, polarization, reflectance and fluorescence 

imaging for detecting breast cancer. Fresh excess breast cancer 

tissue is collected from surgeries and subsequently imaged and 

processed for H&E histopathology. Then the histological slides are 

digitized and compared side-by-side with the multimodal optical 

images. 

Results: We have acquired high resolution confocal and 

polarization images of breast cancer tissue and correlated these 

images to the digitized corresponding H&E histopathology. We


are in the process of procuring additional samples, imaging and 

analyzing them. 

Conclusion: The obtained results demonstrate the feasibility of 

the proposed approach to breast cancer delineation. Although this 

study is designed to analyze tissue ex vivo, it will serve as a first 

step that will permit construction and optimization of an in vivo 

system capable of enabling complete and accurate image guided 

resections of cancer. 

#23 

MULTISCALE FLUORESCENCE IMAGER AS AN 

OPTICAL BIOPSY TOOL 

Anna Yaroslavsky, Dennis Wirth 

University of Massachusetts, Lowell, MA 

Background: Accurate real-time pathology detection would be 

indispensible. This contribution reports implementation and 

testing of a multi-scale fluorescence imager as an optical biopsy 

tool. 

Study: The system implements wide-field and high-resolution 

modalities in one instrument. Previous studies have shown 

tetracycline (TCN) and eosin Y (EY) to be good contrast agents in 

pathology detection. For excitation of TCN and EY, we use 402 

and 530 nm diode lasers, respectively. Band pass filters of 

470 40 and 570 20 nm combined with PMT systems are 

employed for simultaneous registration of high-resolution TCN 

and EY emission images, respectively. To accomplish 

simultaneous registration of wide-field images we use a four-way 

image splitter equipped with linearly polarizing and band pass 

filters. The developed system was tested using resolution targets, 

fluorescence phantoms, and ex vivo cancer tissues. 

Results: The system enables simultaneous wide-field, highresolution 

fluorescence and fluorescence polarization images. 

Conclusion: The use of the constructed imager may allow for 

efficient differentiation between normal and pathological 

tissue. 

#24 

FROM LASER TISSUE INTERACTION TO MALDI 

MASS SPECTROMETRY 

Franz Hillenkamp 

University of Muenster, Muenster, Germany 

Background: First biomedical laser application followed the 

invention of the laser 51 years ago almost on the heels, pioneered 

by peers such as Leon Goldmann, Francis L’Esperance, Isaac 

Kaplan and several others. We came into the field in the late 1960s 

with work on laser eye safety. In that work it quickly became clear 

that serious estimates of the risks and even more so any useful 

medical laser application would require a thorough 

understanding of the mechanisms with which laser radiation of 

different wavelengths and pulse duration interacts with tissues. 

Much of our work during the 70th and 80th was devoted to this 

topic. The common interest in such interaction and the question of 

how to correlate physical beam parameters to biological measures 

such as histologic analyses initiated a collaboration with John 

Parrish and Rox Anderson at what is now the Wellman Center of 

Photomedicine at the Mass. Gen. Hospital in Boston, a friendship 

which has continued until today. Parallel to work on laser–tissue 

interaction I got interested early on in laser microirradiation, a 

field I shared with colleagues such as Michael Berns and 

Christian Salet. As a result of this work we developed the Laser 

Micro Mass Analyzer (LAMMA) together with Raimund 

Kaufmann, which eventually led to the invention of the Matrix 

Assisted Laser Desorption/Ionization Mass Spectrometry 

(MALDI)-MS in 1986, jointly with Michael Karas. MALDI-MS is, 

by now, one of the two methods of choice for the routine and high 

throughput analysis of biomedical (macro) molecules and has been 

the main focus of my work during the last 20 years. Still all the 

work until now is based on the search for a better understanding 

of how the laser interacts with tissue and, indeed with the 

molecules it consists of. 

#25 

MECHANICAL TISSUE OPTICAL CLEARING 

TECHNIQUE INCREASES RESOLUTION AND 

CONTRAST OF A TARGET IMAGE BENEATH EX 

VIVO PORCINE SKIN 

Alondra Izquierdo-Roman, William Vogt, 



Background: Tissue optical clearing permits delivery of light 

deeper into turbid tissue, which may improve numerous current 

methods of optical diagnostics as well as laser-based therapeutic 

techniques. Mechanical stimulation of tissue, such as localized 

compression, may reduce light scattering by reversibly displacing 

water from regions of altered stress and strain. In this study, we 

investigated the effects of localized compression on the delivery of 

light through ex vivo porcine skin by evaluating contrast and 

resolution of a USAF 1951 target placed beneath either native or 

compressed specimens. 

Study: A manual force transducer was used to compress 2mm 

thick ex vivo porcine tissue to 1, 5, and 10 lbf with a 5 mm 

hemispherically tipped glass rod for 60 seconds. Resolution and 

contrast of the detected signal through the specimens was 

analyzed using established image processing techniques based on 

image intensity profiles of the compressed and uncompressed 

regions of the skin. 

Results: Experimental results indicate that while uncompressed 

skin did not allow resolution of the lowest line spacing of the 

target (0.25 line-pairs (lp)/mm, 2,000 mm line width), localized 

compression at 1, 5, and 10 lbf allowed resolution of 1.6304 lp/ 

mm 0.31, 1.0265 lp/mm 0.72, and 1.6599 lp/mm 0.72, 

respectively. All values are reported with 95% confidence. Image 

intensity profile analysis showed an enhancement in the target 

peaks distinguishable after compression between 5 lbf 

compression and 10 lbf compression specimens. Contrast also 

increased about 1.5-fold between 5 and 10 lbf compression 

specimens. 

Conclusion: Localized mechanical compression proved to be an 

effective technique for increasing resolution and contrast of a 

target imaged through ex vivo biological tissue. Based on these 

results, implementation of this optical clearing technique may 

enable enhanced resolution and contrast of light-based 

diagnostics. 

#26 

HIGH-RESOLUTION, THICK-TISSUE OPTICAL 

HISTOLOGY OF TISSUE MICROVASCULATURE 

Austin Moy, Bernard Choi 


University of California, Irvine, CA

Background: The microvasculature is the primary route by 

which nutrients are delivered to tissue. Direct visualization of the 

microvasculature would enable detailed study of tissue during 

disease progression. Typically, a histology-based approach is used 

to characterize the microvasculature. This method is impractical 

for characterization of the microvasculature in large tissue 

organs, especially if the three-dimensional architecture of the 

vascular network is desired. Therefore, there is a critical need for 

a technique that will facilitate quick and efficient imaging of the 

entire microvascular network of large tissue volumes. We have 

developed an all-optical method that utilizes optical clearing of the 

tissue and subsequent optical imaging to produce high-resolution, 

depth-sectioned, three-dimensional images of the 

microvasculature in thick tissues. 

Study: Tissue microvasculature is first stained in vivo via cardiac 

perfusion using DiI, a lipophilic dye that binds to the endothelial 

cells of the microvasculature. Tissues are then excised and sliced 

into 1 mm thick sections. These sections are incubated in 

FocusClear (CelExplorer Labs, Hsinchu, Taiwan), a novel optical 

clearing agent, for up to 120 minutes, and then visualized with 

both a CCD based wide-field fluorescence imaging system and a 

laser-scanning multiphoton microscope with the appropriate 

excitation wavelengths and emission filters for DiI. 

Results: We have successfully acquired both fluorescence and 

three-dimensional images of brain and tumor sections 1mm in 

thickness using both our wide-field fluorescence imaging system 

and confocal laser scanning fluorescence microscope. Arterioles, 

venules, and capillaries are readily visualized. 

Conclusion: Tissue microvasculature structure can be visualized 

in three dimensions and with high spatial resolution, in 1mm 

thick tissue sections, using combined ex vivo optical clearing and 

optical imaging techniques. Imaging of serial sections of tissue is 

expected to enable visualization of entire microvascular networks 

in entire organs. 

#27 


PHOTOACOUSTIC DETECTION OF MELANOMA 

AND MICROSPHERES IN VITRO USING A MICE 

MODEL 

Sagar Gupta, Kirby Campbell, Adam Daily, Kiran 

Bhattacharya, Luis Parada, John Viator 

University of Missouri, Columbia, MO 

Background: Metastasis is a complex physiological phenomenon 

that involves the movement of cancer cells from one organ to 

another by means of blood and lymph. An understanding about 

metastasis is extremely important to device diagnostic systems to 

detect and monitor its spread within the body. Photoacoustic 

technology is a sunrise sector, which is gaining prominence as the 

promising field in medical diagnostics. This article makes an effort 

to understand metastasis in a mouse model and also plays a 

crucial role in extending the boundary of photoacoustic circulating 

tumor cell detection in animals. 

Study: Human cultured melanoma cell line HS936 and 

2 micrometer fluorescent microspheres were injected through 

cardiac puncture to the female ICR mice and allowed to circulate 

from 1.5 to 10 min. A study was also performed to identify the 

accumulation of melanoma and microspheres in various organs of 

the injected mice. 

Results: We were able to successfully detect 5-cells/10 ml of the 

injected melanoma and 5-microspheres/10 ml of the injected 

microspheres obtained from the processed mice blood drawn at 

various time intervals in a photoacoustic ultrasound detection 

system. After 10 minutes of circulation time a decreasing 

photoacoustic signal was observed due to increased accumulation 

of cells in the organs. 

Conclusion: Histological studies identified that lungs were the 

most susceptible organs for the accumulation of the injected 

cancer cells and microspheres. We further intend to study the 

photoacoustic detection of induced cancer in mice. 

#28 

MULTIDOMAIN SIMULATION OF MECHANICAL 

TISSUE OPTICAL CLEARING DEVICES: A 

PLATFORM FOR DEVICE OPTIMIZATION 

William Vogt, Alondra Izquierdo-Roman, 



Background: Biological tissues are naturally high-scattering 

media as a result of mismatches in refractive index between 

constituents, including water, fat, and proteins. As a result, the 

efficacy of light-based diagnostic and therapeutic methods is 

drastically reduced. Tissue optical clearing devices (TOCDs) 

utilize localized mechanical loading to induce optical clearing in a 

non-invasive reversible manner. Mechanical clearing is thought 

to be the result of lateral water displacement from compression 

regions in the tissue, but the nature of this water transport and 

resulting clearing effect is not well understood. A coupled 

mathematical model of mechanical deformation and the transport 

of water and light will provide a framework for optimizing TOCDs 

for specific theranostic applications. 

Study: Afinite element model of ex vivo porcine skin compressed 

under a hemispherically tipped indenter was developed using 

Abaqus (Simulia, Providence, RI). A coupled porous medium 

model based on Darcy’s law was used to simulate the coupling 

between mechanical stress/strain and interstitial water transport. 

Experimental stress/strain data were used to fit a hyperelastic 

constitutive model to govern tissue mechanical response. After 

determining spatial distribution of tissue water content, optical 

Monte Carlo simulation was used to determine tissue fluence 

distribution. Simulation was performed using TIM-OS, an open 

source Monte Carlo simulator. 

Results: Simulations indicate that water transport during 

compression is highly sensitive to Poisson’s ratio as well as tissue 

hydraulic conductivity. Fluence distributions are highly sensitive 

to scattering coefficient, which is dependent on both local water 

content and wavelength of light delivered to the tissue. Tissue 

geometry changes may account for 65% of total light 

transmission increase, with optical property changes contributing 

35%. 

Conclusion: This multidomain modeling framework can be used 

to study the coupling of mechanical loading, water transport, and 

light transport through biological tissues. Future work will focus 

on experimentally determining key input parameters, including 

mechanical, chemical, and optical properties. 

#29 

SIGNAL VARIATION OF FLUORESCEIN DYE IN 

ANTERIOR AND POSTERIOR CHAMBERS OF EYE 

Raiyan Zaman, Henry Rylander 

The University of Texas, Austin, TX 

Background: Identifying the location of a drug for treating 

ocular disease is an important aspect for any drug delivery. Thus,


we have tested a hypothesis where signal of a fluorescein dye may 

vary based on the location of the dye either by the presence of 

natural occurring fluorophores of the eye tissue or the dye itself. 

In this study, we have identified a unique phenomenon in signal 

variation of fluorescence emission spectra based on the variation 

of the location. 

Study: We have developed a fluorescence spectrophotometer (FS) 

system to identify the emission spectra at 520 nm from the 10% Na 

fluorescein USP sterile dye. The FS system consists of four main 

components: (i) a tungsten halogen lamp to shine white light (LS- 

1, Ocean Optics), (ii) a low pass filter with transmission between 

390 and 480 nm with cutoff at 505 15 nm wavelength (FD1B, an 

additive dichroic color filter, blue, Thorlabs, Inc., Newton, NJ, 

USA) (iii) a custom-designed fiber-optic probe (core 

diameter ¼ 200 mm; NA ¼ 0.22; FiberTech Optica), and (iv) a 

spectrometer (USB4000, Ocean Optics). The fiber-optic probe 

consists of two individual fibers with core-to-core separation of 

370 mm that are terminated with SMA connectors. For both in 

vitro and in vivo experiments we have injected 0.01 ml dye in 

either the anterior or posterior chamber (not both) of an 

enucleated pig (n ¼ 4) and in vivo rabbit eye (n ¼ 2), respectively. 

Then, fluorescence emission spectra are collected every 2 minutes 

up to 10 minutes using the FS system. However, for the in vivo 

experiment the emission spectra is only collected after the pupil is 

dilated using three drops of 1% tropicamide every 11 2 minutes for 

5 minutes and the dilation completes within 10 minutes. 

Results: Preliminary results showed signal variation between the 

anterior and posterior chambers of the eye. The emission peak of 

the fluorescence signal from the posterior chamber slightly blue 

shifted about 28 nm unlike the anterior chamber. Also, the line 

shape of the emission signal was distinctive for the posterior 

chamber. We eliminated the possibility of this signal difference 

(by further experiment) due to the constituents of the aqueous and 

vitreous humors from the anterior and posterior chambers, 

respectively. Thus, the most likely reason for this blue shift to the 

shorter wavelength may be due to the presence of intrinsic 

fluorescence of protein in the crystalline lens of the enucleated pig 

and in vivo rabbit eyes. The aromatic amino acid residue 

tryptophan (Trp) can cause such a distinct emission shapes. 

Conclusion: These results clearly identify the variability in 

fluorescence emission spectra of the 10% Na fluorescein dye based 

on the location of the dye in the eye. This unique phenomenon 

could help determine the location of a fluorescently tagged 

molecule within the eye and deserves further investigation. 

#30 

IS EXTERNAL SKIN TEMPERATURE AN 

ADEQUATE MODALITY TO SAFELY MONITOR 

PATIENTS DURING LASER LIPOLYSIS? 

Kenneth Rothaus 

New York Presbyterian Hospital Weill Cornell, New York, NY 

Background: Currently, most laser lipolysis systems use 

external skin temperature as a guide to assess adequacy of 

treatment. Reports of complications or unsatisfactory results may 

reflect poor assessments of the effects of laser energy on target 

tissue using external skin temperature as an end point of 

treatment. The purpose of this study is to determine if the change 

in the external skin temperature accurately reflects the change in 

internal temperature during laser lipolysis. 

Study: A 24 W 924/975 nm laser (Palomar Medical Technologies) 

was used to perform laser lipolysis. Treatments were performed 

using local tumescent anesthesia. External and internal skin 

temperatures were recorded at intervals throughout the 

treatment using a non-contact infrared radiometer (Raytek 

Mini-Temp) for external temperature and a internal probe and 

Ebro thermometer for internal temperature. Laser energies were 

delivered until an internal temperature of 45–508C was achieved. 

All internal and external temperature measurements were 

conducted simultaneously and immediately after the cessation of 

lasing. Following the laser lipolysis, the patients underwent 

traditional liposuction using 1.7–2.5 mm cobra cannulae. The 

patients have been followed for up to 1 year post-op for 

complications, results and patient satisfaction. 

Results: Dual data points (585) of internal and external 

temperature were collected from 227 treatment sites in 50 

patients. Statistical analysis revealed low correlation between 

internal and external skin temperatures (correlation ¼ 0.27, 

P < 0.0001). For every degree rise in internal temperature, the 

external temperature rose 0.158. There were no complications. 

Patients reported a high degree of satisfaction with the results. 

Conclusion: Monitoring of the internal temperature during laser 

lipolysis appears to be a more accurate means of assessing the 

desired effects on target tissue. Relying on external temperature 

alone may result in over-treatment or under-treatment of skin 

and adipose tissue and result in either increased complications or 

unsatisfactory results. 

#31 

PREDICTION OF THE MAXIMAL SAFE LASER 

RADIANT EXPOSURE ON AN INDIVIDUAL 

PATIENT BASIS BASED ON PHOTOTHERMAL 

TEMPERATURE PROFILING IN HUMAN SKIN 

Boris Majaron, Matija Milanic, Wangcun Jia, 

J. Stuart Nelson, Luka Vidovic 

Jozef Stefan Institute, Ljubljana, Slovenia, Beckman Laser 

Institute and Medical Clinic, University of California, Irvine, CA 

Background: Despite the application of dynamic cooling, the 

efficacy and safety of cutaneous laser treatments are often 

compromised by nonselective absorption in epidermal melanin, 

which limits the light fluence delivered to the subsurface target 

site (e.g., blood vessel, hair follicle, tattoo granule) and induces a 

risk of permanent side effects, such as scarring or 

dyspigmentation, due to overheating of the basal layer. Our aim is 

to determine the potential of pulsed photothermal radiometric 

(PPTR) temperature depth profiling for prediction of maximal safe 

radiant exposure (Hmax) for human skin on an individual basis. 

Study: Diagnostic PPTR measurements were performed on 326 

distinct spots on the extremities of 13 healthy volunteers using 

3 milliseconds laser pulses at 755 nm and 6 J/cm 2 . From these 

radiometric signals, the respective laser-induced temperature 

depth profiles in skin were reconstructed using a custom iterative 

algorithm with adaptive regularization. The same test spots were 

irradiated with the same laser at radiant exposures from 10 to 

90 J/cm 2 with application of cryogen spray precooling at constant 

settings. The resulting adverse effects were quantified by blind 

scoring and correlated with various characteristics of the 

corresponding PPTR temperature profiles. 

Results: The area under the epidermal part of the reconstructed 

temperature profiles (representing the surface density of the laser 

energy deposited in the epidermis) enables a rather robust 

prediction of individual epidermal damage threshold across a wide 

range of tested skin phototypes (I–IV). 

Conclusion: PPTR depth profiling appears promising for 

prediction of the maximal safe radiant exposure on an individual

patient basis for increased efficacy and safety of cutaneous laser 

treatments. 

#32 

A LED BASED IMAGING SYSTEM FOR 

OPTIMIZATION OF PHOTODYNAMIC THERAPY 

OF BASAL CELL CARCINOMA 

Rolf B. Saager, David J. Cuccia, Steven Saggesse, 

Kristen M. Kelly, Anthony J. Durkin 


California, Irvine, CA; Modulated Imaging, Inc., Irvine, CA 

Background: PDT offers the potential for enhanced treatment of 

BCC skin cancer without the detriments associated with current 

treatment methods: healthy tissue loss, scarring. Yet, PDT has 

still not achieved the consistent performance required to gain 

widespread clinical acceptance for treatment of skin cancer. One 

particular limitation is a lack of quantitative tools to perform in 

vivo dosimetry that monitors the light dose during therapy. Even 

when dosimetry is used, lesion variability leads to treatment plans 

that are not optimum. To this end, we have developed a new 

quantitative imaging device that may enable optimized therapy. 

Study: Clinical imaging of BCC lesions was performed using 

Spatial Frequency Domain Imaging (SFDI). SFDI can quantify 

spatially resolved absorption and reduced scattering coefficients. 

With knowledge of these properties, it is possible to address 

critical aspects of PDT dosimetry including: (1) therapeutic light 

dose within the affected tissue, (2) oxygen supply necessary to 

generate destructive radicals within the lesion and (3) 

photosensitizer distribution and uptake within the tissue. We 

present a device designed to address these aspects by: (1) 

determining the optical properties at the therapeutic wavelength, 

(2) deducing spatially resolved absorption values to determine 

blood oxygenation in the tissue microvasculature, and (3) 

quantifying fluorescence from the photosensitizer by 

compensating for native tissue properties. 

Results: Preliminary clinical study of nine lesions demonstrate 

that optical properties vary greatly both spatially (101%, 48%) for 

absorption and reduced scattering, respectively, and from patient 

to patient (102%, 57%). Oxygenation maps may be generated at 

50-mm resolution. Fluorescence signals from the photosensitizer 

can be accurately converted to drug concentrations to within 

0.2 mg/L. 

Conclusion: These preliminary results indicate that this 

technique provides quantitative, non-invasive assessments 

which characterize lesions based on physiologic parameters 

that are inaccessible to clinicians. This technology may lead to 

the development of subject and lesion specific treatment 

strategies. 

#33 


REFLECTION MODALITY CONTINUOUS-WAVE 

TERAHERTZ IMAGER FOR CANCER 

DEMARCATION 

Cecil Joseph, Anna Yaroslavsky, Thomas Goyette, 

Robert Giles 

University of Massachusetts, Lowell, MA 

Background: Continuous-wave terahertz imaging has the 

potential to offer a non-invasive and comparatively inexpensive 

technique for demarcating skin cancers. The implementation of a 

coherent room temperature detection scheme, which offers 

increased SNR, is critical to the eventual goal of implementing a 

continuous-wave terahertz imaging system that can delineate 

cancer margins. 

Study: The goal of this study was to construct a heterodyne 

receiver based imager at 1.39 THz, determine its resolution and 

available signal-to-noise ratio, and demonstrate imaging of skin 

cancer specimens. CO 2 laser pumped far-infrared gas lasers were 

used as the terahertz sources for the experiments. A room 

temperature heterodyne detection scheme was designed and 

implemented. The system was tested using resolution targets and 

skin cancer specimens. Its resolution and signal-to-noise ratio 

(SNR), in reflection modality, were determined. The samples were 

scanned across the focal plane using a two axis motion controlled 

stage, and the on-axis reflection image was generated. 

Results: The system resolution was determined to be 0.5 mm. The 

SNR was determined to lie between 110 and 130 dB. Preliminary 

imaging data of cancer specimens show good correlation between 

the terahertz images and Hematoxylin & Eosin (H&E) 

histopathology. 

Conclusion: A coherent hetrodyne detection scheme significantly 

improves the SNR of continuous-wave terahertz imaging for 

cancer demarcation. 

#34 

TEST METHODOLOGIES FOR ESTABLISHING 

SAFETY OF HOME-USE LASER BASED DEVICES 

David Sliney, Michail Smirnov, Stewart Wilson, 

Oldrich Laznicka, Oksana Bradley, Felicia Whitney, 

Gregory Altshuler, Ilya Yaroslavsky 

Fallston, MD; Palomar Medical Technologies, Burlington, MA 

Background: A number of home-use, laser-based devices for 

treatment of various skin conditions either have been recently 

introduced to the marketplace or are in different stages of 

development. A common feature of these devices is the presence of 

a safety suite designed to enable safe operation of the device by the 

average person with no prior experience or training. This state of 

affairs highlights the need for formulating realistic, universally 

accepted product safety requirements, reflected in an industrywide 

standard, such as IEC 60825. A Class 1C (conditional Class 

1) has been proposed and is currently under discussion by the 

respective technical groups. One important aspect of codifying the 

safety requirements for such devices is to define the most suitable 

testing techniques to ensure both compliance and practical safety 

of the device. 

Study: Two principal approaches to the test are considered: (1) 

clinical test (possibly with a mock-up device) attempting to 

reproduce real-life scenarios of the device use; and (2) an ex vivo 

and/or phantom test with a pre-formulated set of quantitative 

criteria. Both types of tests have been conducted on a home-use, 

fractional non-ablative laser device (PaloVia, Palomar Medical 

Technologies, Inc.). 

Results: Ocular safety of the tested device has been demonstrated 

with both types of tests. Similarities and differences in the 

outcomes of the two types of testing, as well as their relative 

advantages and disadvantages for the purpose of laser safety 

standards, have been evaluated. 

Conclusion: Phantom test methodologies can be considered the 

preferred method to ensure compliance of the tested device with 

the requirements of the future performance standard.


#35 

COMBINATION THERAPY FOR THE TREATMENT 

OF ERYTHEMATOTELANGIECTATIC ROSACEA 

Jane Yoo, Ellen Marmur, Amy Lynne Frankel, Jinan 

Chaarani, Ryan Turner, Giselle Singer 

Mount Sinai Medical Center, New York, NY 

Background: Rosacea is a common cutaneous disorder 

characterized by facial erythema, papules and pustules and 

telangiectasias. The flushing and telangiectasias associated with 

erythematotelangiectatic rosacea (ETR) are notoriously difficult 

to treat with standard medications. We investigated a novel 

synergistic approach using pulsed dye laser (PDL) in combination 

with topical therapy to treat individuals with ETR. PDL is widely 

considered as the treatment of choice for vascular malformations. 

Calcium dobesilate (2,5-dihydroxybenzene sulfonate) is a drug 

that hinders vascular smooth muscle cell growth and inhibits 

fibroblast growth factor (FGF), thus targeting angiogenic growth 

factors leading to uncontrolled blood vessel growth. 

Study: The objectives of this study were to evaluate the overall 

response rate to treatment and to assess the safety and the 

tolerability of the treatment regimen. We performed a split face, 

single blinded pilot study involving six patients at Mount Sinai 

Medical Center. Patients applied topical calcium dobesilate gel to 

the whole face once daily for 12 weeks and concurrently received 

PDL treatment to one randomized side of the face at 2-week 

intervals for a total of four sessions. Subjects were followed for 4 

and 8 weeks post-treatment. 

Results: Six patients participated in this study. One patient 

discontinued the study after week 6 due to personal reasons. 

Compared to calcium dobesilate alone, topical therapy combined 

with PDL led to a greater reduction in telangiectasias and nontransient 

erythema but there was no difference in the reduction of 

flushing or papules and pustules. At the end of the study, 50% of 

patients experienced moderate improvement of symptoms. No 

adverse effects of lasting pain, persistent purpura, crusting, hypoor 

hyper-pigmentation or scarring were observed during the trial. 

Conclusion: Calcium dobesilate, in conjunction with PDL, 

presents itself as a therapeutic treatment option for patients with 

erythematotelangiectatic rosacea. As this is a single center pilot 

study, further investigation is warranted. 

#36 

EFFECTS ON ADIPOCYTES AND SEPTAL FIBERS 

AFTER HIGH INTENSE HIGH FREQUENCY 

ULTRASOUND 

Afschin Fatemi 

S-thetic Clinic, Duesseldorf, Germany 

Background: HIFU is used to disrupt adipocytes percutaneously 

and can be regarded as a non-surgical treatment for unwanted fat 

deposits. We wanted to find out about tissue effects not only on 

adipocytes, but also on septal fibres. 

Study: We treated abdominoplasty patients immediately before 

and 2 weeks before surgery with different energy settings and 

different focal depths, we looked at gross pathology to determine 

whether there are lesions and how the lesions look like. We looked 

at histologies to see if there are immediate adipocyte disruptions 

and how the lesions are cleared by macrophages and other cells. 

We also analyzed the effects of HIFU on septal fibers. 

Abdominoplasty patients and fresh cadavers were treated with 

different energy settings and histologies were taken and analyzed. 

We looked at different histologic sizes of lesions, measured them 

and put them in relation to treatment parameters. Blood was 

taken from a small group of patients before, and after the 

treatment, up to 3 months to look at serum levels of lipids and 

liver enzymes. We tried to correlate clinical results to histologic 

findings. 

Results: The studies show clearly that adipocytes are disrupted 

by HIFU. The correlation between focal depth, energy levels and 

clinical results is evident. The average circumference reduction 

after treatment of abdomen and waist is 4–5 cm. Extensive proof 

with histologies and gross pathologies was delivered, to show the 

extent of disruption, correlated to focal depth and energy settings. 

Disruptions or denaturation of septal fibre collagen was seen, 

dependent on different treatment parameters. This can be 

correlated to clinical skin tightening effects. The sizes of the 

lesions would vary, dependent on treatment parameters. 

Conclusion: Adipocytes are disrupted by HIFU. Septal fibres are 

heated effectively by HIFU different clinical results can be 

correlated to the different histologic findings. HIFU is effective in 

non-surgical body sculpting. HIFU tightens skin due to effects on 

collagen fibres. 

#37 

LOW-FLUENCE 1,064 NM Q-SWITCHED ND:YAG 

LASER 

Yuan-Hong Li, Tian-Hua Xu, Hong-Duo Chen 

No. 1 Hospital of China Medical University, Shenyang, China 

Background: To evaluate the efficacy and safety of the lowfluence 

1,064 nm Q-Switched Neodymium-doped Yttrium 

Aluminium Garnet (Nd:YAG, QSNY) laser in treating infraorbital 

dark circles. 

Study: Thirty women with infraorbital dark circles (predominant 

color: dark brown) were enrolled in this open-labeled study. The 

subjects received eight sessions of low-fluence QSNY laser 

treatment at 4.2 J/cm 2 at 3- or 4-day intervals. Spot size of 3.5 mm 

was used with pulse duration of 8 nanoseconds. The melanin 

deposition in the lesional skin was observed in vivo by reflectance 

confocal microscopy (RCM). Morphological changes were 

evaluated using a global evaluation, an over-all self-assessment, a 

Mexameter, and a Corneometer. 

Results: Twenty-six of 30 patients showed a global improvement 

as excellent or good. Twenty-eight patients rated the over-all 

satisfactory assessment as excellent or good. Melanin index 

indicated a substantial decrease from 225.84 (baseline) to 182.65 

(P < 0.05). RCM results showed a dramatic decrease of melanin 

deposition in the upper dermal. Adverse actions were minimal. 

Conclusion: The characteristic findings of the dark-brown 

infraorbital dark circles are increased melanin deposition in the 

upper dermis. The treatment of the infraorbital dark circles by 

low-fluence 1,064 nm QSNY laser is rapid and effective. Adverse 

effects were minimal and acceptable. 

#38 

MICROSCOPIC OBSERVATION OF ULTRAPULSE- 

MODE VERSUS SUPERPULSE-MODE 

FRACTIONAL CO2 LASER ON BACK SKIN 

Yuan-Hong Li, Xue-Gang Xu, Hong-Duo Chen 

No. 1 Hospital of China Medical University, Shenyang, China 

Background: Both ultrapulse-mode (UPCO2) and superpulsemode 

(SPCO2) fractional CO2 lasers have been widely used in 

treating photo-aged skin, acne scar, etc. Yet histological evidences

are still needed to prove and compare their short-term and longterm 

effects. 

Study: Seven healthy Chinese women received one pass of 

UPCO2 treatment on left back and SPCO2 treatment on right 

back. The pulse energies were 15 mJ at a density of 5%. The 

clinical outcomes and side effects were evaluated by two blinded 

certified dermatologists. Dermatoscope, in vivo reflectance 

confocal microscopy (RCM) and high frequency ultrasonic 

equipment were used to observe skin responses non-invasively. 

Biopsies were taken for hematoxylin–eosin (HE) stains and 

Verhoeff-iron-hematoxylin stain. 

Results: RCM and the histopathology showed that SPCO 2 

treatment could penetrate as deep as UPCO 2 does. Both UPCO 2 

and SPCO2 treatment need about 7 days for the microscopic 

epidermal necrotic debris (MEND) to shed off. The two modes 

have similar efficacy in stimulating the synthesis and remodeling 

of collagen and elastin, which was also confirmed by 

ultrasonography image. 

Conclusion: There is no significant difference between UPCO2 

and SPCO 2 treatment in skin rejuvenation by histological 

findings, RCM and ultrasonography observation. 

#39 


TRANEXAMIC ACID-CONTAINING LIPOSOMES 

FOR ANTIFIBRINOLYTIC SITE-SPECIFIC 

PHARMACO-LASER THERAPY OF PORT WINE 

STAINS 

Michal Heger, Anton I.P.M. de Kroon 

Academic Medical Center, University of Amsterdam, Amsterdam, 

The Netherlands; University of Utrecht, Utrecht, The Netherlands 

Background: Site-specific pharmaco-laser therapy (SSPLT) is a 

development stage treatment modality for refractory port wine 

stains (PWS), whereby conventional selective photothermolysis is 

combined with the prior administration of a prothrombotic/ 

antifibrinolytic-containing liposomal drug delivery system (DDS). 

The aim of this study was to determine release profiles of 

tranexamic acid (TA, antifibrinolytic agent) from thermosensitive 

liposomes in buffer and plasma at different temperatures and 

osmotic gradients and to determine liposome stability in plasma. 

Study: Thermosensitive liposomes were prepared from DPPC/ 

DSPE-polyethylene glycol (PEG) lipids (96:4 molar ratio) and 

DPPC/MPPC/DSPE-PEG (86:10:4) by the lipid film hydration 

technique using 318 mM TA in 10 mM HEPES, 0.88% NaCl, 

pH ¼ 7.4, 0.292 osmol/kg or with 52.8 mM calcein (self-quenching 

concentration) in hypo- or iso-osmolar HEPES buffer. An offline 

quantification assay was developed to determine TA release from 

liposomes in buffer at the phase transition temperature (Tm) of the 

bilayer and at 48C/ þ 48C/658C/908C as a function of heating 

time. An online spectrofluorometric assay was employed to 

determine passive leakage of calcein from the liposomes at 

increasing plasma concentrations at 378C. Lastly, an RT-PCR 

instrument was used to establish (online) temperature-dependent 

calcein release profiles from the liposomal formulations at 

increasing plasma concentrations. 

Results: TA release rates from DPPC/DSPE-PEG liposomes were 

13%/5.0 min, 96%/2.5 min, 107%/1.5 min, 107%/0.5 min, and 98%/ 

0.5 min for 39.38C/43.38C/47.38C/65.08C/90.08C, respectively. TA 

release rates from DPPC/MPPC/DSPE-PEG liposomes were 0%/ 

5.0 min, 94%/2.0 min, 96%/1.0 min, 105%/0.5 min, and 89%/ 

0.5 min for 36.08C/40.08C/44.08C/65.08C/90.08C, respectively. 

Passive leakage of calcein at 378C was 4.77 and 5.95%/min for 

DPPC/DSPE-PEG and DPPC/MPPC/DSPE-PEG liposomes, 

respectively. Osmolarity had no influence on passive leakage and 

plasma reduced passive leakage rates. Plasma had no notable 

impact on calcein release profiles compared to TA release profiles 

in buffer at any of the assayed temperatures. 

Conclusion: Both liposomal formulations are suitable for 

antifibrinolytic SSPLT in that almost all TA is released within 

2.5 min and no detrimental effects of plasma were found on release 

kinetics and stability. 

#40 

TOWARDS ENHANCEMENT OF PDT EFFICACY IN 

EXTRAHEPATIC CHOLANGIOCARCINOMAS 

USING LIPOSOMAL PHOTOSENSITIZATION 

Mans Broekgaarden, Anton, I.P.M. de Kroon, 

J. Antoinette Killian, Thomas, M. van Gulik, 

Michal Heger 

Academic Medical Center, Amsterdam, The Netherlands, 

University of Amsterdam and Biochemistry of Membranes, 

Membrane Enzymology, Institute of Biomembranes, 

University of Utrecht, Utrecht, The Netherlands 

Background: Photodynamic therapy (PDT) yields suboptimal 

results in the treatment of extrahepatic cholangiocarcinomas 

(EHCCs) due to the use of inferior photosensitizers, insufficient 

photosensitization of the tumor, and the biological properties of 

the malignancy. To optimize PDT for these tumors, a secondgeneration 

photosensitizer, zinc phthalocyanine (ZnPC), will be 

encapsulated in liposomes and targeted to the tumor endothelium, 

tumor cells, and interstitial spaces. Inasmuch as an appropriate 

animal model is lacking, a chicken chorioallantoic membrane 

(CAM) model for EHCC and other tumors was developed for 

testing the PDT efficacy of the liposomal formulations. This work 

describes the development of the animal model and ZnPC 

liposomes for interstitial targeting. 

Study: The CAM model was used to grow Sk-Cha1, HepG2, and 

IGROV-1 cells into EHCCs, hepatocellular carcinomas, and 

ovarian carcinomas, respectively. Tumors were imaged after 4 

days of incubation using stereomicroscopy and 1,300-nm sweptsource 

optical coherence tomography. Liposomes for stromal 

targeting composed of 4.8 mM DPPC and 0.2 mM DSPE-PEG2000 and 0–50 mM ZnPC were characterized for size/polydispersity, 

drug-to-lipid ratio, fluorescence emission, and singlet oxygen 

radical-mediated membrane damage. The latter was assayed by 

fluorometric calcein leakage assays from vesicles with a target 

cell-like lipid composition, on which PDT was performed. 

Results: Successful tumor growth of Sk-Cha1, HepG2, and 

IGROV-1 cells was achieved in ovo, although tumor-type 

associated differences in vascularization and growing patterns 

were observed. Liposomes with various concentrations ZnPC had 

an average size of 105.4 6.4 nm with a polydispersity of 

0.37 0.12. Optimal ZnPC fluorescence was observed at 

drug-to-lipid ratios of 0.002. Maximum PDT-induced leakage of 

calcein from vesicles with a cell-like lipid composition coincubated 

with ZnPC liposomes was observed at drug-to-lipid 

ratios of 0.001. 

Conclusion: Successful tumor growth was achieved for various 

cell lines with different degrees of vascularization. Liposomes 

developed for interstitial targeting were shown to fluoresce and 

produce oxygen radicals, allowing the liposomes to be 

concomitantly imaged and used for therapy. Further research will 

focus on developing and characterizing liposomal formulations for 

tumor cell and vascular targeting as well as on studying the PDT 

efficacy of the formulations in vivo using the CAM models.


#41 

IN VITRO TESTING OF DUAL-MODE THULIUM 

MICROSURICAL LASER 

Matthew Keller, James Stafford, Jonathon Wells 

Lockheed Martin Aculight, Bothell, WA 

Background: The Ho:YAG laser is commonly used for a variety 

of surgical applications, especially in urology. Recently, thulium 

(Tm) fiber lasers have been investigated for use in place of the 

Ho:YAG because their 1.94 mm output is absorbed by tissue 5 

times stronger than the 2.1 mm of the Ho:YAG. Lockheed Martin 

Aculight has recently developed the first truly dual-mode Tm 

laser, which can be operated in either CW or in pulsed mode 

(rather than modulated) to produce high peak power. The goal of 

this study was to assess the ablation performance and collateral 

damage characteristics of this laser in vitro. 

Study: The laser was operated with a 200 mm diameter spot in CW 

and at both 10 and 1 kHz rep rates ( 150 nanoseconds pulse 

width), with total energy delivered to the tissue (chicken muscle) 

held constant for a given comparison. Ablation efficiencies for 5minute 

exposures, crater size for 5-second exposures, and 

collateral damage zones for both stationary and scanned laser 

delivery for 5-second exposures were calculated for the different 

pulse modes and a range of pulse energies (1.1–2.2 mJ). 

Results: The most energy-efficient ablation (lowest J/g) occurred 

for the 10 kHz pulsed mode operating just above ablation 

threshold with 1.1 mJ pulses, while the highest mass removal rate 

occurred in 10 kHz pulsed mode operating at max energy (2.2 mJ). 

In histological sections from short exposures, 10 kHz pulsed 

exposures created slightly larger craters and slightly smaller 

thermal coagulation zones than matched CW exposures, while 

1 kHz deliveries removed smaller volumes and also had smaller 

thermal damage zones. 

Conclusion: The dual-mode Tm laser can provide a variety of 

ablation characteristics in generic soft tissue based on its mode of 

operation and energy/power levels. 

#42 

HYPERTHERMIA ENHANCED IMAGE GUIDED 

LASER-ICG THERAPY 

Klressa Barnes, Gal Shafirstein, Wolfgang Baumler, 

Ran Friedman, Leah Hennings, 

Mustafa Sarimollaoglu, Jessica Webber, 

Cassie Jackson, James Suen, Robert Griffin 

University of Arkansas for Medical Sciences, Little Rock, AR; 

Regensberg University, Regensberg, Germany 

Background: Indocyanine green (ICG) dye effectively converts 

near infrared (NIR) laser light into heat that can destroy 

vasculature and kill tumor cells. However, the short half-life of the 

ICG in the vascular system limits the treatment time and efficacy. 

We postulate that hyperthermia prior to ICG administration and 

near infrared (NIR) laser therapy can improve the efficacy of ICGlaser 

treatment of solid tumors. To test this hypothesis, we 

quantified the effect of local hyperthermia on ICG accumulation in 

the tumor site prior to NIR laser therapy. 

Study: Three groups of A/J mice were inoculated with mammary 

adenocarcinoma cells. Tumor sizes ranged from 7 to 9 mm. The 

first group received an intravenous saline injection prior to laser 

treatment. The second received ICG prior to laser treatment. The 

third was irradiated with a 808-nm NIR laser (5 mm, 0.2 seconds, 

85 W) preceded by tail vein injection of ICG dye (4 mg/kg) and 

60 minutes hyperthermia at 41.58C prior to ICG injection. 

Epidermal cooling was accomplished by applying ultrasonic gel at 

28C to the skin, 1 minute prior to laser irradiation, in all groups. 

Tumor size was measured daily and animals were euthanized at 

specific time points post treatment for histopathological 

evaluation and ICG content measurements. 

Results: We observed elevated temperatures of 308C or greater in 

animals that received ICG above that of saline alone. In those 

animals that received ICG administration prior to hyperthermia, 

we saw an increase in the accrual of ICG in the tumor region. In 

both groups that received ICG before irradiation, there was an 

enhancement in anti-tumor effect compared to laser only. 

Conclusion: Hyperthermia prior to intravenous administration 

of 4 mg/kg ICG significantly enhanced accumulation of ICG in the 

tumor region and, in turn, enhanced the efficacy of thermal 

ablation during a single NIR laser irradiation session. 

#43 

FIBEROPTIC MICRONEEDLES FOR 

MICROSCALE INTERSTITIAL DELIVERY OF 


Mehmet Kosoglu, Robert Hood, Christopher 

Rylander 


Background: Light-based cosmetic procedures such as hair 

removal and skin rejuvenation are limited due to the poor 

penetration depth of light in skin. Novel fiberoptic microneedles 

provide a means for mechanically penetrating tissue several 

millimeters to deliver light directly into a target area. Our goal is 

to develop novel fiberoptic microneedles for minimally invasive 

interstitial delivery of diffuse therapeutic light into epithelial 

tissues. 

Study: A novel manufacturing technique which utilizes angle 

polishing and hydrofluoric acid etching of optical fibers was 

developed to control diffuse light delivery from the microneedle 

surface. The light delivery and the resulting temperature 

distribution for two new microneedle designs and a flat-cleaved 

fiber control were determined. The light delivery on white paper 

was evaluated using microscopic imaging and thermal 

distribution was measured by IR thermography. These microoptical 

diffusers were also used to liquefy ex vivo porcine fat. 

Results: Acid etching removed the fiber cladding, exposing a 

greater length of the fiber core, which allowed the circumferential 

delivery of light along a 3 mm length. Distribution of light 

intensity correlated closely with the resulting temperature map. 

The microneedle design with a double-thinning etched taper 

generated a more homogenous light distribution and lower 

temperatures compared to the other more uniformly etched 

microneedle and the flat cleaved fiber control. In addition, no 

carbonization of the tissue was observed during lipolysis 

experiments for the double-thinned microneedle design while 

delivering 3 W of laser power (1,064 nm wavelength, CW). In 

comparison, the flat-cleaved fiber carbonized the fat tissue sample 

while delivering 1 W of power. 

Conclusion: These novel fiberoptic microneedles avoided 

carbonization of the tissue and thermal damage to the 

microneedle while providing a greater homogeneous light 

distribution than any existing optical diffuser at this scale. 

Promising new modality for the treatment of acne scars in skin of 

color.

#46 

CUTANEOUS LASER 

SURGERY 

INVESTIGATION INTO SAFE AND EFFECTIVE 

TREATMENT INTERVALS OF PORT WINE STAINS 

USING THE PULSED DYE LASER 

Robert Anolik Tracey Newlove, Elliot T. Weiss, 

Anne Chapas, Leonard Bernstein, 

Roy G. Geronemus 

Laser and Skin Surgery Center of New York, New York, NY 

Background: Pulsed dye laser (PDL) therapy is a proven 

therapeutic option in the management of port wine stains (PWSs). 

Although several studies demonstrate greater efficacy when 

treatment is initiated as soon as possible, optimal treatment 

intervals are not yet defined. We suggest more frequent treatment 

intervals may capitalize on the therapeutic advantage of 

delivering additional therapy at more responsive younger ages. In 

addition, more frequent sessions might expedite overall treatment 

period. The purpose of this study is to assess the relative safety 

and efficacy of PDL treatments at 2-, 3-, and 4-week intervals 

among patients with PWSs. 

Study: This is a retrospective chart review of infants with PWSs 

who received at least five PDL treatments in a private 

dermatology center. Twenty-four patients were randomly selected 

by including the first eight PWS patients found to have been 

treated every 2 weeks, every 3 weeks, and every 4 weeks on review 

of charts in reverse chronological order. Charts were screened for 

adverse events and efficacy was assessed by comparison of 

photographs before and after five treatment sessions by blinded, 

non-treating dermatologists. 

Results: Adverse events were equivalent in all interval groups 

and only included expected side effects of erythema, swelling, and 

bruising. These findings resolved before subsequent treatment 

sessions in all groups. No group showed any long-term adverse 

event. In addition, all interval groups showed a diminished 

appearance of their PWSs. Notably, more frequent treatment 

interval groups demonstrated more rapid and effective resolution 

of their PWSs relative to less frequent groups, taking into account 

anatomic location. 

Conclusion: PDL treatments at 2-, 3-, and 4-week intervals 

permit safe and effective management of PWSs. Shorter 

treatment intervals, however, allowed for relatively more rapid 

and effective treatment. Practitioners treating PWSs should 

consider these findings when establishing their own treatment 

protocols. 

#47 


REAL-TIME LASER SPECKLE IMAGING AS AN 

INTRAOPERATIVE DIAGNOSTIC TOOL DURING 

TREATMENT OR PORT WINE STAIN 

BIRTHMARKS 

Bruce Yang, Owen Yang, Kristen Kelly, 

J. Stuart Nelson, Bernard Choi 



Background: Laser speckle imaging (LSI) is a technique in 

which imaging of coherent light remitted from an object results in 

a speckle pattern. The spatio-temporal statistics of this pattern is 

related to the movement of optical scatterers, such as red blood 

cells, and image processing algorithms are applied to produce 

speckle flow index (SFI) maps, which are representative of tissue 

blood flow. If performed in real time, LSI can play an important 

role in image-guided surgery. Previous publications reported use 

of LSI as a tool in assessing photocoagulation during laser 

treatment of port wine stain (PWS) birthmarks; however, the time 

necessary to acquire and process images rarely allowed for 

immediate feedback during laser treatment. Therefore, we 

integrated graphics-processing-unit (GPU)-based processing into 

our clinical LSI instrument. 

Study: With real-time LSI, we have imaged 22 patients ranging 

from 2 to 64 years of age. Imaging at eight frames per second, we 

continuously calculate SFI values for both the treated PWS 

regions as well as the surrounding normal tissue. We look to see if 

treated regions show a uniform reduction in flow exhibited by 

decreased SFI values, similar to that of surrounding normal 

tissue. If the treated region appears to have high or non-uniform 

SFI values, that area will undergo retreatment. 

Results: In general, SFI values within treated regions showed a 

progressive decrease with each treatment pass, as well as a border 

of hyperemia surrounding the treated region. With real-time 

feedback, the physician was in most cases able to achieve uniform 

vascular shutdown in the region of interest. 

Conclusion: Access to real-time blood-flow maps enables direct 

visualization of the degree of photocoagulation achieved with 

pulsed-dye laser therapy. In several cases, we have retreated 

regions with persistent perfusion, to achieve complete vascular 

shutdown, which is the hallmark of a successful PWS treatment 

session. 

#48 

THE USE OF LONG PULSED LASER ND:YAG 

LASER IN THE TREATMENT OF PEDIATRIC 

VENOUS MALFORMATION 

Stratos Sofos, Se Hwang Liew 

Liverpool, United Kingdom 

Background: Venous malformation in the pediatric population 

can present with pain, bleeding or debilitating deformity, which 

can be difficult to manage. Sclerotherapy, surgery and more 

recently the long pulsed Nd:YAG laser have been used with 

variable success rates. We aim to investigate the use of the long 

pulsed Nd:YAG laser in treating symptomatic venous 

malformation, and to identify the specific group of patients most 

likely to benefit from such treatment. 

Study: A prospective clinical trial was carried out on 59 

consecutive patients. Treatment criteria include large facial 

deformity, painful or bleeding lesions. One to three treatments 

were given at 6–8 weekly intervals. Results were evaluated both 

subjectively and objectively. 

Results: A total of 59 patients were treated. The average followup 

was 24 months. Subjective and objective assessment of efficacy 

correlated well, and all patients achieved good to excellent results 

in pain and bleeding control and in reducing size of lesions in lip 

and oral mucosa. It is, however, not effective in reducing the size 

of large, relatively high flow lesions in the limbs. Complications 

from treatment include skin blistering (n ¼ 4), ulceration (n ¼ 4) 

and subsequent hypertrophic scarring (n ¼ 3). Three patients had 

partial.


Conclusion: Complex venous malformation cannot be cured, but 

can be symptomatically controlled with the long pulsed Nd:YAG 

laser. The treatment satisfaction is high, and there is a small but 

definite risk of scarring from treatment. 

#50 

OPTIMIZED SPECTRAL OUTPUT AND PULSE 

SHAPES FOR VASCULAR TREATMENTS 

Robert Weiss, E. Victor Ross, Emil Tanghetti, David 

B. Vasily, James Childs, Mikhail Smirnov, Gregory 

Altshuler 

Maryland Laser, Skin and Vein Institute, Baltimore, MD; 

Scripps Clinic, San Diego, CA; Center for Dermatology and 

Laser Surgery, Sacramento, CA; Aesthetica Cosmetic & 

Laser Surgery Center, Bethlehem, PA; Palomar Medical 

Technologies, Burlington, MA 

Background: An optimized pulsed-light (OPL) device is 

described and its performance is compared with two pulsed dye 

laser (PDL) systems in a vascular phantom setup and with 

computer modeling. Clinical case studies are described to evaluate 

OPL treatment of facial vascular lesions. 

Study: The OPL (MaxG TM , Palomar Medical Technologies) 

provides a dual-band output spectrum from 500 to 670 nm and 850 

to 1,200 nm with pulse widths 3–100 milliseconds and fluences to 

80 J/cm 2 . Two PDL systems (VBeam and Perfecta, Candela Corp.) 

provide 595 nm laser pulses (1.5, 3, 6, or 10 milliseconds). The OPL 

spectral and power output is characterized and described. A 

vascular phantom consists of quartz capillaries filled with 

hemoglobin and placed beneath 1 mm thick porcine skin. 

Capillary temperatures are measured with a FLR 4000 IR camera 

during the pulse sequence. In order to determine PDL and OPL 

settings to treat the phantom, purpuric threshold fluences for 

each device and pulse width were determined clinically on back 

skin. Typical clinical settings for OPL were 50–100 J/cm 2 , 

100 milliseconds and 28–38 J/cm 2 , 10 milliseconds. 

Results: At purpuric threshold settings (PDL, 8 J/cm 2 , 

3 milliseconds and OPL, 38 J/cm 2 , 3 milliseconds), the OPL (88C) 

caused 60% higher vessel temperature rise than the PDL (58C). 

The fraction of near-IR energy from the OPL increases from 35% 

to 60% with decreasing power or increasing pulse width 

(3 milliseconds, 30 J/cm 2 to 100 milliseconds, 100 J/cm 2 ) and 

contributes approximately 15% to phantom vessel heating at 36 J/ 

cm 2 , 3 milliseconds. Clinical results demonstrated effective deep 

vessel closure and clearance of telangiectasia. 

Conclusion: An optimized pulsed arc-lamp device is more 

efficient at larger and deeper vessel treatments with lower risk of 

purpura compared to the PDL devices using a vascular phantom 

setup. Clinical correlation is seen with treatment of facial vascular 

lesions of various sizes. 

#51 

SPLIT-FACE RANDOMIZED TREATMENT OF 

FACIAL TELANGIECTASIA COMPARING PULSED 

DYE LASER AND A NEW OPTIMIZED LIGHT 

HANDPIECE 

Emil Tanghetti 

Center for Dermatology and Laser Surgery, Sacramento, CA 

Background: This study was designed to compare treatment of 

facial telangiectasia with a pulsed dye laser (PDL) and a new 

optimized light handpiece (OPL) that provides enhanced spectral 

absorption, shorter pulsewidths and higher fluences than 

previous intense pulsed light (IPL) devices. 

Study: Sixteen subjects were enrolled with unwanted facial 

telangiectasia. This study was approved by IRB and all subjects 

provided signed informed consent. Facial areas were split 

vertically and the two sides randomized to receive up to three 

treatments approximately one month apart with either PDL 

(VStar 1 , Cynosure, Westford, MA) or OPL (MaxG TM Optimized 

Light Handpiece, Palomar, Burlington, MA). PDL used 595 nm, 

10 milliseconds, 10 mm spot and average fluence of 8.2 0.1 J/ 

cm 2 . OPL used spectral range of 500–670 and 870–1,200 nm; 

10 milliseconds; 10 mm 15 mm tip, and average fluence of 

35.5 0.9 J/cm 2 . Subjects were seen for follow-up at 48–96 hours, 

and 1–2 months. Clinical photographs were taken at each visit to 

score improvement on a 0 (0%) to 5 (100%) Telangiectasia Grading 

Scale (TGS). Presence and severity of side effects were recorded. 

Results: Most commonly reported side effects at 48–96 hours 

were mild, transient purpura (62%), and mild to moderate edema 

(21%) and erythema (18%) which resolved completely by 1–2 

months and were comparable with both study devices. All subjects 

improved with 12/15 (80.0%) subjects having a TGS score of 3 or 

more (50–75%) with OPL versus 11/15 (73.3%) of subjects treated 

with PDL. There were no differences in subject self-assessment 

between the two devices. 

Conclusion: The new OPL tested in this study, with enhanced 

spectral specificity for vasculature, treated facial telangiectasia 

successfully and was equivalent to PDL. 

#52 

ANGIOGENESIS MEDIATOR ALTERATIONS IN 

ANGIOMAS AFTER PULSED DYE LASER 

TREATMENT 

Kristen Kelly, Belinda Dao, Janelle Marshall, 

Amy Nguyen, Vivian Laquer, Elizabeth Rugg, 

Ronald Harris 



Background: Tissue effects of vascular lesion laser treatment are 

incompletely understood. Injury caused by pulsed dye laser 

treatment may result in altered expression of mediators associated 

with angiogenesis. An understanding of laser effects on angiogenesis 

may allow development of novel and improved treatment 

techniques. Our objective is to evaluate tissue presence of vascular 

endothelial growth factor (VEGF), basic fibroblast growth factor 

(BFGF), matrix metalloproteinase 9 (MMP-9) and angiopoietin 2 

(ANG-2) in angiomas before and 1 week after laser treatment. 

Study: Three subjects had one angioma treated with a pulsed dye 

laser (7 mm; 1.5 milliseconds; 9 J/cm 2 ; 30 milliseconds of cryogen 

with a 30 milliseconds delay). One week later, three biopsies were 

taken: normal skin; untreated angioma; angioma treated with 

laser. Tissue was frozen and sections processed for 

immunohistochemistry staining of VEGF, BFGF, MMP-9, and 

ANG-2. Images were taken and were graded in a blinded fashion 

by a board certified dermatopathologist. 

Results: Untreated angiomas demonstrated a slight increase in 

VEGF and ANG-2 expression compared to normal skin. Following 

laser treatment, an increase in ANG-2 and MMP-9 was noted. 

Conclusion: Alterations in angiogenesis mediators were noted 

after laser therapy. Observed changes associated with laser 

treatment were different as compared to those reported with other 

injuries such as punch biopsies. Further understanding of laser 

induced alterations may be used to optimize treatment outcomes.

#53 

NON-ABLATIVE FRACTIONAL LASER 

RESURFACING FOR THE TREATMENT OF SCARS 

AND GRAFTS AFTER MOHS MICROGRAPHIC 

SURGERY: A RANDOMIZED CONTROLLED TRIAL 

Evelien Verhaeghe, Katia Ongenae, Jessica 

Bostoen, Jo Lambert 

University Hospital Ghent, Gent, Belgium 

Background: Mohs micrographic surgery is a tissue sparing 

surgical technique for removal of skin cancer in the head and neck 

region. To optimize the cosmetic result of the scars and skin grafts 

after surgery non-invasive procedures as non ablative fractional 

laser resurfacing are a treatment of choice. The objective of this 

study was to evaluate the efficacy and safety of 1,540 nm nonablative 

fractional laser (NAFL) in the treatment of scars and full 

thickness grafts after Mohs surgery. 

Study: Intra-individual randomized controlled trial (RCT) with 

split lesion design and single blinded outcome evaluations. 

Patients receive four treatments at monthly interval with NAFL 

(Starlux-300 with Lux 1,540 nm fractional hand piece (Palomar 

Technologies)). Patients are evaluated 1 and 3 months after the 

last treatment. Primary outcome measures are clinical efficacy 

(assessed by blinded on site visual and palpable Physician Global 

Assessment (PhGA)), adverse effects and pain (assessed by a 

visual analogue scale (VAS)). Patients Global Assessment (PGA) 

was also measured. 

Results: Preliminary results based on 18 patients show a 

significant difference of the PhGA comparing the laser treated 

parts to the untreated control side 1 (P ¼ 0.04) and 3 months 

(P ¼ 0.007) after treatment (Wilcoxon signed rank test). Patients 

experienced mild to moderate pain (median VAS score 3.1) during 

the treatment. Four days after treatment patients reported 

erythema (69%), edema (38%), crusts (17%), burning sensation 

(13%), purpura (6%) and vesicles (3%). No long-term adverse 

effects were seen 3 months after the last treatment. There is also a 

significant difference of the PGA 1 (P ¼ 0.02) and 3 months 

(P ¼ 0.01) after the last treatment (Wilcoxon signed rank test). 

Conclusion: Based on these preliminary results non-ablative 

1,540 nm fractional laser seems to be a safe and effective treatment 

for the improvement of scars and grafts after Mohs surgery. 

#54 


HISTOLOGIC CHARACTERISTICS OF MATURE 

BURN SCARS BEFORE AND AFTER THREE 

TREATMENTS WITH FRACTIONAL CO2 LASER 

David Ozog, Marsha Chaffins, Ronald Moy, 

Elizabeth Farhat 

Henry Ford Hospital Detroit, MI; UCLA, Los Angeles, CA 

Background: Treatment of mature burn scars (greater than 1 

year since injury) have been reported to show clinical 

improvement after treatment with fractional CO2 lasers in noncontrolled 

studies and case reports. Currently, there are no 

prospective reports showing the histological and gene expression 

changes after treatments. Additionally, little is known about the 

remodeling of collagen by subtype after treatment. This 

prospective study intended to quantify the changes to collagen 

gross structure as well as changes in type I and type III collagen 

after treatment. Additional gene parameters were also examined. 

Study: Ten patients with mature burn scars were recruited from 

the Grossman Burn Center in Sherman Oaks California. The 

average age was 35 years old, average body surface area was 35%, 

and the average treatment area was 280 cm 2 . Patients were 

treated were biopsied prior to treatment with fractional CO 2 

Ultrapulse laser (Lumenis Corp). The area was marked and 

photographed. Over a 6-month timeframe, three treatments were 

performed on subjects. A follow-up biopsy was performed on all 

subjects 1 month after final treatment. Biopsies were stained with 

collagen stains and reviewed by dermatopathologists. 

Results: Patients had significant improvement in gross 

histological appearance of hypertrophic burn scars. Collagen 

subtype profiles returned toward normal ratios. 

Conclusion: Treatment with fractional CO2 lasers of mature 

burn scars improves the histological gross appearance of these 

scars. Additionally, the type of collagen produced trends toward 

normal ratios. 

#55 

SUCCESSFUL TREATMENT OF POST BURN 

SCARS WITH FRACTIONAL CO2 LASER IN INDIAN 

SKIN 

Niteen Dhepe, Ashok Naik, Sahil Dhavan, Shilpa 

Shah 

Pune, India 

Background: There are no reports from India of treatment of 

post burn scars with lasers. We present a report of successful 

treatment of post burn scars with a novel fractional CO2 laser 

delivery system. 

Study: Patients (24) with post-burn scars of average 6-year 

duration were treated with Ultrapulse Deep FX fractional CO2 

laser. Typical protocol is three treatments at an interval of 2–3 

months in between and used 0.12 mm spots with density 5%, 

single stacking and pulse fluence of 20 mJ to 35 mJ/pulse as per 

thickness of scar with topical tetracaine 7% and lignocaine 7%. 

The scars are assessed for thickness, surface wrinkling, color 

match with surrounding at the time of each treatment, 1, 2, and 3 

months post-operatively after last sitting by two independent 

dermatologists on VAS of 4. Pain during treatment is scored by 

patient on a VAS of 4. 

Results: Three months after three sessions of fractional CO2 treatment reduced the scar thickness to a mean VAS score of 3.47 

out of 4. The score increased from 2.14 before second sitting to 3.47 

at 3rd month follow-up of last sitting. Reduction in scar surface 

wrinkling was 3.85, and color match to surrounding was 2.89 on a 

VAS scale of 4. Pain during procedure scored by patient was 1.12 

on scale of 4 using topical anesthesia. 

Conclusion: Fractional CO2 laser with DeepFx scanner is a well 

tolerated and effective treatment of hypertrophic post-burn scars 

in Indian patients. 

#56 

TREATMENT OF SCARS WITH A NEW HANDHELD 

810 NM LASER 

Nathalie Fournier 

Clapiers, France 

Background: Previous evaluations have demonstrated that a 

novel 810 nm diode laser system could improve skin healing 

leading to a scar reduction 1,2 . This technique named Laser 

Assisted Skin Healing (LASH) has demonstrated its efficacy in 

plastic surgery. This study aimed to demonstrate the interest of 

that laser for another application: patients with hypertrophic 

scars or cheloids.


#58 

Study: Patients with at least one hypertrophic active scars or 

cheloid, phototypes I to IV, were enrolled in this prospective study. 

The scar was treated with a (Ekkylite, Ekkyo, Aix en Provence, 

France) 810 nm diode laser system delivering a top hat spot of 

20 mm 4 mm. Treatments were applied every 3 weeks. Clinical 

evaluations, digital pictures, improvement of life quality, patient’s 

satisfaction were performed at each visit, then at 90 and 180 days 

after the last session. 

Results: Fifteen patients, on decoletage, limbs, back, face, 

phototypes I to IV were included. Diminution of itching and 

redness, reduced height and thickness, and whitening were noted 

mostly after three sessions on hypertrophic scars. Results were 

less reproducible on cheloids. 

Conclusion: This innovative 810 nm diode laser is a new device 

already used in practice for aesthetic surgery, and it may be 

utilized to improve hypertrophic scar and cheloid after surgery. 

#57 

TREATMENT OF SCARS USING LASER AND 

LASER ASSISTED CORTICOSTEROID DELIVERY 

Jill Waibel, Stephen Davis, Emmy Graber, 

Nathan Uebelhoer 

Miami Dermatology and Laser Institute: University of Miami 

Miller School of Medicine, Miami, FL; Boston University School of 

Medicine and Boston Medical Center, Boston, MA; Naval Medical 

Center San Diego, San Diego, CA 

Background: Severe cutaneous scarring affects patients 

following trauma, burns and surgical procedures. Treating a scar 

is a dynamic process since the scar changes as therapy progresses. 

A combination of vascular, pigment and resurfacing lasers may be 

needed for maximal scar improvement. Fractional lasers create 

zones of ablation at variable depths. These zones may be used 

immediately post-operatively to deliver drugs and other 

substances to synergistically create a therapeutic response. By 

delivering topical or intralesional corticosteroids immediately 

after fractional laser therapy the drug may take advantage of the 

ablative fractional channels to penetrate deep into dermal scars 

and decrease fibroblast proliferation. Cutaneous scars can be 

complex and thus the approach to therapy may need to be 

multimodal. A new combination therapy is suggested that 

incorporates the use of one or more wavelengths of laser in the same 

treatment session as topical or intralesional triamcinolone acetonide 

to synergistically decrease hypertrophic and keloidal scars. 

Study: Retrospective study with 15 subjects with hypertrophic or 

keloidal scars from 3rd degree burn injury, surgical or traumatic 

injuries. Subjects were treated with three to five treatment 

sessions of at least one or more wavelengths of laser and same day 

immediately post-operative topical or intralesional delivery of 

triamcinolone acetonide injectable suspension into fractional 

ablative tunnels. Three blinded investigators evaluated 

photographs taken at baseline and 6 months after the final 

therapy session. Scores were assigned using a quartile 

improvement score to evaluate overall improvement, dyschromia, 

degree of hypertrophy and texture. 

Results: Combination same session laser therapy and postoperative 

corticosteroid delivery resulted in average overall 

improvement of 2.73/3.0. Dyschromia showed the least amount of 

improvement with texture showing the most improvement. 

Conclusion: Combination same session therapy with multiple 

laser wavelengths and laser assisted delivery of topical or 

intralesional triamcinolone acetonide may offer an efficient, safe 

and effective treatment of challenging cutaneous scars. 

FRACTIONAL ABLATIVE RADIOFREQUENCY 

TREATMENT FOR SKIN TYPES V–VI: RISK- 

BENEFIT ANALYSIS 

Jennifer Chwalek, Mussarrat Hussain, 

David Goldberg 

Skin Laser & Surgery Specialists of NY and NJ, New York, NY 

Background: Laser resurfacing has remained the gold standard 

for the treatment of rhytides, dyspigmentation and skin laxity for 

many years. However, the potential risks of resurfacing such as 

infection, prolonged erythema, pigmentary changes and scarring, 

especially in darker skin types, have led to a search for safer and 

more effective treatments. Radiofrequency (RF) technology 

produces volumetric heating of the dermis to elicit collagen 

shrinkage and skin tightening. Fractionated radiofrequency 

devices create controlled radiofrequency thermal zones (RFTZ) at 

regularly spaced intervals with intervening normal tissue. Unlike 

ablative and nonablative laser modalities, which cause significant 

epidermal damage, RF devices have minimal epidermal effect and 

may be safer for darker skin types. To assess the safety and 

efficacy of a new bipolar ablative radiofrequency device in 

the treatment of rhytides and texture in patients with skin 

types V–VI. 

Study: Twenty-five male and female subjects 35–70 years of age 

with Fitzpatrick skin types V–VI with mild to moderate 

photoaging were evaluated. Subjects underwent three monthly 

full-face treatments with the fractional ablative radiofrequency 

device. Energy settings were increased incrementally at each 

treatment session as tolerated. Follow-up evaluations were 

performed at each treatment interval and at 6 months following 

the final treatment. Two non-treating physicians evaluated each 

subject for changes in rhytides and skin texture. 

Results: All subjects showed improvement in either rhytides or 

skin texture. Post-treatment erythema was seen in 10 subjects. 

Post-treatment swelling was seen in only 1 subject after 1 

treatment. No pigmentary changes or scars was noted. 

Conclusion: Bipolar fractional ablative radiofrequency 

treatments may be successfully used to treat photodamage in skin 

types V–VI. 

#59 

THE EFFECTS OF FRACTIONAL 

RADIOFREQUENCY MICRONEEDLE ON 

PERIORBITAL WRINKLE OF KOREAN PATIENTS 

Won-Serk Kim, Ga-young Lee 

Kangbuk Samsung Hospital, Sungkyunkwan University School of 

Medicine, Seoul, Korea 

Background: Fractional radiofrequency microneedle (FRM), the 

minimally invasive device using insertion microneedles of bipolar 

and monopolar radiofrequency for deep dermal heating, has been 

used for various cosmetic problems in Korea. Asian periorbital 

skin is thicker than white people, so more powerful dermal 

heating is necessary. We investigated the usefulness of FRM for 

periorbital wrinkle reduction. 

Study: Twenty healthy volunteers with periorbital wrinkle over 

grade 2 participated in this study. Every patients had three 

treatments with 1-month interval and checked clinical 

photograph, adverse problems and questionnaire about subjective 

satisfaction and discomforts during 6 months. Pre- and postclinical 

photographs were used for assessing wrinkle severity. It 

was assessed by three independent, blinded dermatologists.

Results: All patients were subjectively satisfied by FRM 

treatment. Seventeen among 20 patients had good or excellent 

improvement, 3 had moderate improvement. Without transient 

bleeding or erythema, no serious adverse effects were found. 

Conclusion: FRM enables the deep dermal fractional heating, 

sparing the epidermis and upper dermis except the penetration 

site of needle. FRM is very safe and powerful tool for the 

treatment of periorbital wrinkle, especially dark and thick 

skinned Asian people. 

#60 

BIPOLAR PARALLEL RADIOFREQUENCY FOR 

REDUCTION DEPTH OF WRINKLES: A 

PROSPECTIVE STUDY VISUALIZED BY COLORED 

3D IMAGING SYSTEM 

Katharina Russe-Wilflingseder, Elisabeth Russe 

Plastische Chirurgie und Laserzentrum, Innsbruck, Austria 

Background: Demand in treatments for wrinkle reduction 

without downtime can be satisfying by using the thermal effects of 

the bipolar parallel radiofrequency (RF) for skin tightening 

induced by neocollagenesis. 

Study: In this prospective study the results of improvement of 

wrinkles after treatment with bipolar parallel RF were evaluated 

by 3D visualization and measurement (face areas). Twenty-five 

areas on different body sites of 10 patients were treated five times 

at an interval of 1 week between first to second procedure and of 2 

weeks between second through fifth. Different handpieces (small 

25–65 J/cm 3 , 2 seconds, vacuum 1–2; medium 20–60 J/cm 3 ,2– 

3 seconds, vacuum 2–3; large 10–20 J/cm 3 ,2–3seconds, vacuum 

1–2) were used and adapted to treatment area. Small for thin skin 

areas like periocular, medium for face, neck, hand and large for 

upper arms, abdomen. Density, pulse duration, number of passes 

used depended on handpiece, area and skin condition. An 

integrated skin cooling controlled the emerging temperature 

automatically to protect the epidermis. Improvement and side 

effects were assessed independently by doctor and therapist. 

Documentation and evaluation was done before and at week 4 and 

12 after last treatment: Height and depth of wrinkles were 

measured by a 3D imaging system; standardized photo 

documentation was evaluated by therapist, doctor and 

independent observer using a visual analog scale (VAS 1–100). 

Patients rated wrinkle reduction, appearance of skin, overall 

satisfaction using a VAS (1–100). 

Results: Reduction of wrinkles improved over time. Better results 

were verified at 3 months compared to one (P < 0.001) by all 

evaluators. Patients rated mean improvement better (P < 0.003) 

than the other evaluators. 3D false color pictures waviness 

calculation showed a reduction of the maximum height of wrinkles 

up to 31%. Results depended on body site. 

Conclusion: Bipolar parallel radiofrequency is effective and safe 

to reduce depth of wrinkles. The improvement is statistically 

significant and increases up to 3 months. 

#61 


A NOVEL ENERGY ASSISTED LIPOLYSIS 

APPROACH USING COMBINED RF AND LASER 

TECHNOLOGY 

Jason Pozner, Haim Epstein, Boris Vaynberg, 

Ruthie Amir 

Cleveland Clinic, Weston, FL; Syneron Yokneam Illit, Israel 

Background: New energy based technologies are being 

developed for effective subcutaneous fat removal with less 

bleeding and minimal down time for the patient while easier, 

faster and smoother to operate for the physician. According to our 

theoretical model, laser energy is the best choice for opening the 

channel in the tissue while the RF energy when used in a bi-polar 

form is an optimal choice for volumetric heating around the 

cannula allowing homogenous fat liquefaction. We investigated in 

vivo the efficacy and safety of combined radiofrequency, laser 

lipolysis and liposuction. 

Study: An IRB approval was obtained in order to evaluate in vivo 

the safety and efficacy of this new RF/laser approach. 

Abdominoplasty patients (n ¼ 2) were infiltrated in a staged 

approach with tumescent fluid. One-half of the abdomen was 

treated with combined 940 nm CW Laser at 25 W and RF power 

at 20 W while the other half was treated with SAL. 

Skin temperature, number of hand strokes and percent 

fat removed were evaluated as well as subjective ease of 

treatment. 

Results: The RF/laser treatment required significantly fewer 

hand strokes to achieve equal amount of fat (3.7 vs. 4.6 strokes per 

cc of fat) and resulted in increased fat extract (23%). The RF/laser 

approach was faster and easier to use for the operating surgeon 

especially in extremely fibrotic tissue (2.1 vs. 3.1 seconds per cc of 

fat). There was no significant increase in skin surface temperature 

during deep layer treatment. No adverse events or complications 

occurred. 

Conclusion: The human data support the efficacy and safety of 

the combined RF and laser approach for subcutaneous fat 

removal. 

#62 

FRACTIONAL BIPOLAR RADIOFREQUENCY 

DELIVERED THROUGH A VACUUM-ASSISTED, 

MICRONEEDLE ARRAY FOR THE TREATMENT 

OF ACNE SCARRING—A PILOT STUDY 

Girish Munavalli, Robert Anderson 

Dermatology Laser and Vein Specialists Charlotte, NC; 

Theravant Corporation, Pleasanton, CA 

Background: Device treatment of acne scarring has historically 

involved ablative laser resurfacing. Fractional resurfacing has 

been shown to be effective with reduced downtime. However, 

recent studies have shown prolonged erythema and postinflammatory 

hyperpigmentation (PIH), especially in darker skin 

types. A vacuum-assisted radiofrequency (RF) device was utilized 

that spares the epidermis and precisely delivers RF in a fractional 

pattern using microneedle array. Bipolar RF energy was delivered 

to dermal depths of 800–1,000 mm, using 1 mm long, 6 4 

microneedle array. Objectives were to show improvement in acne 

scarring, while minimizing epidermal injury and the resulting 

complications thereof. 

Study: Twelve subjects (Fitzpatrick skin types II–V) with 

moderate to severe acne scarring were recruited. The appearance 

and distribution of the lesions involved the bilateral cheeks, and 

was roughly equivalent in severity. Treatments were randomized 

to one side, with contralateral side as control. Each patient 

received four treatments (each treatment was three passes, 

totalling 20 minutes) at 3- to 4-week intervals. Baseline and posttreatment 

standardized photography was obtained. Unlabeled 

baseline and 6-month photography were evaluated by a blinded, 

non-treating physician assessor using a quartile grading scale to 

denote improvement.


Results: Blinded assessment correctly identified the treated side 

over control side in 11/12 patients. Patients (10/12) were graded as 

having at least 50% improvement in the appearance, with 6/10 

showing 75% or greater improvement. Average downtime as 

reported by subjects was less than 4 days, and no incidence of 

prolonged erythema or post-inflammatory hyperpigmentation 

were noted by subjects or the blinded assessor. Histology of postauricular 

treated skin showed typical fractional columnar 

collagen heating. 

Conclusion: In this pilot study, vacuum-assisted bipolar RF 

energy delivered by microneedle array appears to be a safe and 

effective treatment option for treating acne scarring. Other 

attractive features of this technology included rapid treatment 

times, minimal downtime, and no PIH. 

#64 

1,550 NM AND 1,927 NM FRACTIONAL LASER 

RESURFACING FOR THE TREATMENT OF 

ACTINIC KERATOSIS AND PHOTODAMAGE: A 

COMPARATIVE STUDY 

Paul M. Friedman, Jennifer M. Landau, 

Megan N. Moody, Denise Marquez, 

Jennifer D. Peterson, Leonard H. Goldberg, 

Irene J. Vergilis-Kalner 

DermSurgery Associates Houston, TX; Goldman, Butterwick & 

Associates Cosmetic Laser Dermatology, San Diego, CA 

Background: The primary objective of this study was to compare 

the safety and efficacy of a combination treatment with a 1,550 nm 

erbium-doped fiber laser and 1,927 nm thulium laser versus 

treatment with the 1,927 nm thulium fiber laser alone for the 

treatment of actinic keratosis (AK) on the face. Secondary 

objectives included the evaluation of the improvement of skin 

pigmentation and overall photodamage, specifically rhytides, 

lentigines, and texture. 

Study: Fifteen patients, ages 52–82 years, with Fitzpatrick skin 

types I–III and multiple actinic lesions underwent 1–4 split-face 

treatments at 3- to 5-week intervals. Half of the face was treated 

with the 1,927 nm thulium fiber laser and the other half was 

treated with a combination of the 1,550-nm erbium-doped fiber 

laser followed by the 1,927 nm thulium fiber laser. Laser settings 

were as follows: the 1,927 nm thulium fiber laser was set at 

fluences of 10–20 mJ and treatment levels of 5–11, corresponding 

to 40–70% surface area coverage, 4–8 passes. The 1,550-nm 

erbium-doped fiber laser was set at fluences of 20–40 mJ and 

treatment levels of 5–8, corresponding to 14–23% surface area 

coverage, 4 passes. The number of AKs was counted at baseline 

and at all treatment and follow-up visits. Photodamage and 

pigmentation were assessed using a quartile grading scale. 

Biopsies at baseline and 6-month follow-up were taken from both 

sides of the face and stained for p16 and p53. 

Results: The percent reduction in AK count 1 month after 1, 2, 3, 

and 4 combination laser treatments was 47%, 66%, 75%, and 76%, 

respectively. The percent reduction in AK count 1 month after 1, 2, 

3, and 4 treatments with the 1,927 nm laser alone was 43%, 57%, 

71%, and 83%, respectively. The percent reduction in AK count 3 

months after 3–4 treatments (n ¼ 5) was 57% after combination 

laser treatments and 67% after 1,927-nm laser treatments alone. 

The percent reduction in AK count 6 months after four treatments 

(n ¼ 4) was 55% after 1,927 nm laser alone treatments. The 

majority of patients showed moderate to marked improvement in 

pigmentation and photodamage. In the facial areas treated with 

the 1,927 nm alone, evaluators noticed greater improvement in 

pigmentation after fewer treatments as well as more persistent 

improvement of photodamage at long-term follow-up. 

Adverse effects were limited to transient erythema and edema 

localized to the treatment site. Histologic results will be 

presented. 

Conclusion: Combination laser treatment with a 1,550 nm 

erbium-doped fiber laser and 1,927 nm thulium fiber laser and 

treatment with the 1,927 nm thulium fiber laser alone yielded a 

significant decrease in the clinical appearance of actinic lesions 

and improvement of pigmentation and overall photodamage. One 

month after four treatments spaced 3–5 weeks apart, the mean 

reduction in the number of AK lesions was greater than 75%. At 1month, 

3-months, and 6-months after 3–4 treatments, the side 

treated with the 1,927 nm laser alone experienced greater clinical 

reduction in AK counts. Furthermore, pigmentation changes were 

noticeably superior on the side treated by the 1,927 nm alone at 

long-term follow-up. 

#65 

LONG-TERM FOLLOW-UP OF 1,927 NM 

FRACTIONAL RESURFACING FOR ACTINIC 

KERATOSES ON THE FACE 

Elliot Weiss, Rob Anolik, Lori Brightman, 

Anne Chapas, Elizabeth Hale, Julie Karen, 

Leonard Bernstein, Roy Geronemus 

Laser & Skin Surgery Center of New York, New York, NY 

Background: Actinic keratoses (AK) are precancerous epidermal 

proliferations seen on photo-damaged skin. A fractionated 

1,927 nm thulium laser has received FDA approval for treating 

AK. This device delivers microscopic thermal zones within treated 

skin using a wavelength with moderate/high water absorption. 

The resulting laser–tissue interaction creates precise, superficial 

zones of thermal damage best suited for removal of epidermal 

lesions such as AK. We assess the long-term safety and efficacy of 

1,927 nm fractional resurfacing of facial AK. 

Study: Twenty-five subjects with facial AK receiving up to four 

treatments (2- to 6-week intervals) with a 1,927 nm laser (Fraxel 

Dual, Solta Medical, Hayward, CA) were followed for 6 months. 

Topical anesthetic and optional ketorolac were administered 

1 hour before treatment. Treatment parameters ranged from 5 to 

20 mJ/pulse with coverage densities of 30–70%. 

Results: Individual AK counts decreased in all patients during 

treatment. One month after the final treatment, average AK 

clearance per patient was 88.9% (n ¼ 20, range 63–100%). At 3 

months, average AK clearance was 87.5% (n ¼ 16, range 63–100). 

At 6 months, average AK clearance was 75% (n ¼ 8, range 58– 

100%). The average patient score for treatment discomfort was 3/ 

10. Post-treatment, mild/moderate erythema and mild exfoliation 

lasted approximately 7 days. No incidents of infection or scarring 

were observed. At 3 months, average scores for improvement in 

photo-damage and AK were 3.3/4 for both subject and investigator 

ratings. For skin texture and pigmentation, average improvement 

scores were 3.0/4 and 3.1/4 for subject and investigator ratings, 

respectively. At 6 months, average scores for improvement in 

photo-damage and AK were 3.5/4 and 3.8/4 for subject and 

investigator, respectively. For skin texture and pigmentation, 

improvement scores were 3.5/4 and 3.7/4 for subject and 

investigator, respectively. 

Conclusion: 1,927 nm fractional resurfacing safely results in 

dramatic clinical clearing of AK with sustained clearance 

observed over 6 months follow-up. This well-tolerated treatment 

is an effective new field therapy for facial AK.

#66 

NON-ABLATIVE FRACTIONAL RESURFACING 

WITH THE 1,927 NM THULIUM LASER IS AN 

EFFECTIVE, WELL-TOLERATED TREATMENT 

FOR ACTINIC CHEILITIS 

Robert Anolik, Paul M. Friedman, Elliot T. Weiss, 

Anne Chapas, Lori Brightman, Elizabeth K. Hale, 

Julie K. Karen, Leonard Bernstein, 

Roy G. Geronemus, Leonard H. Goldberg, 

Abdul K. El Tal 

Laser and Skin Surgery Center of New York, New York, NY; 

DermSurgery Associates; MD Anderson Cancer Center Houston, 

TX 

Background: Actinic cheilitis is an ultraviolet radiation-induced 

transformation of the vermillion portion of the lower lip. The 

finding raises medical and cosmetic concerns, as it is both 

premalignant and disfiguring. Despite some having apparently 

focal involvement, the entire vermillion should be considered 

during treatment, as actinic cheilitis tends to be a multifocal and 

diffuse process. Absent from existing treatment options are welltolerated 

procedures with little side effect or downtime. Recent 

evidence finds nonablative fractional resurfacing using the 

thullium 1,927 nm laser as effective and well tolerated for the 

treatment of actinic keratosis. The objective of this study is to 

assess its efficacy and tolerability for actinic cheilitis. 

Study: This is a multicenter, retrospective chart review of 

patients presenting with actinic cheilitis to a private laser and 

skin surgery center. Upon chart review in reverse chronological 

order, the first fifteen patients found to have been treated with the 

nonablative fractional 1,927 nm laser for actinic cheilitis were 

selected for analysis. All patients were pretreated with topical 

anesthetic creams and given oral antiviral prophylaxis. Efficacy 

was rated using a quartile improvement scale (0–25%, 25–50%, 

50–75%, and 75–100%) by three blinded, non-treating staff 

dermatologists using pre- and post-treatment standardized 

photographs. Charts were also reviewed for any adverse effects. 

Results: Actinic cheilitis showed marked improvement after laser 

therapy. All patients showed either 50–75% or 75–100% 

improvement after just one or two treatments. No adverse effects 

were observed, and the only side effects were mild erythema and 

edema of 1–4 days duration. 

Conclusion: The non-ablative fractional thullium 1,927 nm laser 

a well tolerated and effective global treatment strategy for 

patients with actinic cheilitis. The treatment is achieved without 

any downtime or significant adverse effects. 

#67 


MULTIPLE TREATMENT, NON-INVASIVE 

CRYOLYPOLYSIS FOR BODY CONTOURING IN 

CHINESE PATIENTS 

Samantha Y. Shek, Nicola P.Y. Chan, 

Henry H.L. Chan 


Background: Non-invasive cryolipolysis has been demonstrated 

to be effective in body contouring. The objective of the study is to 

determine the efficacy of multiple treatments with a cryolipolysis 

device for body contouring in Chinese patients. 

Study: This is a retrospective study where 12 patients, age 35– 

60, with discreet bulges were treated with two treatments of 

cryolipolysis at their own cost. On average, the two treatments 

were 2 months apart. The cryolipolysis system was used and the 

treatment parameters were CIF 41.6 ( 73 mW/cm 2 ) for 

60 minutes per site at the desired anatomical region. The areas 

treated included the abdomen and love handles. At baseline visit, 

their weight was measured and caliper measurement was used at 

the maximum area of fat when standing. Standard photographs 

were taken with Canfield Visia CR system 1 . They were followedup 

2 months after, when the physician will perform assessment 

then a second treatment. Subjects were followed-up again 2 

months post-second treatment. 

Results: During the study, the weight of the subjects remained 

relatively constant. For both the abdomen and love handles, there 

was a statistically significant improvement after one treatment 

(P < 0.001, P ¼ 0.003) with a further improvement after a second 

treatment (P ¼ 0.02, P ¼ 0.084). However, the decrease in 

measurement with the caliper was of lesser extend with the 

second treatment compared to the first. Control sites had no 

significant difference post-treatment. 

Conclusion: Multiple treatment with a cryolipolysis device for 

body contouring in Chinese patients demonstrated a cumulative 

effect. 

#68 

TREATMENT OF THE DERMIS AND HYPODERMIS 

JUNCTION WITH WATER AND FAT SELECTIVE 

LASER WAVELENGTHS USING OPTICAL 

COMPRESSION PINS 

Brian Zelickson, Susan Walgrave, 

Irmina Wallander, James Childs, David Tabatadze, 

Mikhail Smirnov, Gregory Altshuler 

Zel Skin and Laser Specialists, Edina, MN; Marshfield Clinic, 

Marshfield, WI; Palomar Medical Technologies, Inc., Burlington, 

MA 

Background: Indications benefiting from deep reticular and 

hypo-dermis remodeling include cellulite, deep wrinkles and 

scars. 1,540 and 1,208 nm laser micro-beams (mb) are co-aligned 

with optical pins to provide skin compression that minimizes 

epidermal injury while treating deeper skin layers. The fractional 

devices are characterized ex vivo and clinically. 

Study: The 1,540 nm device delivers up to 70 mJ/mb in an array of 

49 pyramid-shaped pins (the XD TM optic, Palomar Medical 

Technologies, Inc., Burlington, MA). The 1,208 nm prototype 

consisted of a five-pin array delivering 4 W/mb in 5–20 seconds 

pulse widths. Porcine skin was treated ex vivo. Abdominal skin of 

two subjects was treated and biopsied prior to abdominoplasty. 

Coagulation profiles were assessed with cell viability staining 

(NBTC) of sections. Effects of compression were assessed clinically 

by measuring the size of pigmented spots on volar forearms or 

back 2 days post-treatment with the 1,540 device and by 

measuring skin transmission through the fingers’ webs with a 

1,450 nm test device. Medial or lateral thighs of two subjects were 

treated with the 1,208 device under local anesthesia and 

evaluated to 3 weeks post. 

Results: In vivo skin transmission of 1,450 nm light increased 

and the diameters of the 1,540 spots decreased with compression 

time. The 1,540 device provided deeper coagulation to 1.5 mm 

depths and less epidermal injury than without compression. The 

depths of the 1,208 device reached below 3 mm into the 

hypodermis with papillary dermis preservation. Clinically 

palpable indurations persisted to 3 weeks post-treatment and 

resolved with no adverse side effects. 

Conclusion: The fractional 1,208 and 1,540 nm devices 

effectively de-couple depth of treatment from epidermal coverage


to remodel deeper reticular dermis and hypodermis without 

increased risk of epidermal injury side effects. Additional clinical 

evaluations are warranted. 

#69 

SIDE EFFECTS AND RISKS ASSOCIATED WITH 

CRYOLIPOLYSIS 

Nazanin Saedi, Jeffrey Dover, Micheal Kaminer, 

Christopher Zachary 

SkinCare Physicians, Chestnut Hill, MA; University of California, 

Irvine, CA 

Background: Cryolipolysis, the non-invasive destruction of fat 

cells by controlled cooling of a targeted treatment area, has been 

shown to be safe and effective in several clinical trials. During the 

initial clinical studies involving 341 patients, common side effects 

included discomfort during treatment, followed by numbness, 

bruising, and soreness/aching. During the first year of clinical use, 

thousands of patients have been treated, allowing for more 

thorough evaluation of adverse events. 

Study: Data were collected from three sources: clinical trials in 

which we (JD and MK) participated as investigators, side effects 

reported to the manufacturer, and the authors’ clinical experience 

using the CoolSculpting procedure. 

Results: The most commonly reported side effects included 

discomfort during treatment, numbness and tingling lasting an 

average of 3.6 weeks, bruising, and erythema which was present 

in most cases and lasted only minutes. Vasovagal symptoms 

during the treatment were very uncommon. Discomfort during 

the procedure could be mitigated by reducing vacuum pressure, 

adjusting applicator placement, and through proper patient 

selection. Several less common side effects, not encountered 

during the original clinical studies, occurred in the first year of 

commercial use during which over 30,000 treatments were 

performed. These include severe pain, skin sensitivity, and skin 

changes. Severe pain during and after the procedure was rare 

(0.03%), and pain medications were not consistently effective. 

This pain was self-limiting, resolving over a few weeks. The 

incidence of first or second degree burns and transient pigment 

changes were low (0.01%). 

Conclusion: The side effects and risks associated with 

cryolipolysis are transient and generally mild. The most 

significant side effects are rare and include severe pain, skin 

sensitivity, and skin changes, all of which appear to fully resolve 

spontaneously. 

#70 

COMPARISON OF LASER-ASSISTED LIPOLYSIS 

AND LIPOSUCTION: HISTOLOGY AND 

SPLIT-BODY CLINICAL RESULTS 

Robert Weiss, Jeffrey Angobaldo, Sean Doherty, 

Brooke Seckel 

Maryland Laser, Skin and Vein Institute Baltimore, MD; 

Renaissance Plastic Surgery, Plano, TX; Boston Plastic Surgery 

Associates, Concord, MA 

Background: Laser-assisted lipolysis (LAL) supplements 

liposuction (SAL) with laser heating of fat and connective tissue. 

The two procedures are compared histologically and clinically in 

multiple-site, split-body studies. 

Study: Two subjects underwent split-body fat-removal 

procedures for arms, thighs, back and flanks with follow-ups to 3 

months. Photographs and physician self-assessments were 

collected to 3 months. Suction cups were applied to sites with 

200 mmHg vacuum pressure to measure the amount of drawn 

skin. Two subjects were tattooed and underwent split-body 

treatment followed by abdominoplasty 3 and 6 months later. 

Clinical endpoint for LAL was 458C temperature 3 mm below the 

skin. Localized hardness developed in one subject who did not 

massage post-op. A fifth subject underwent abdominoplasty 9 

months post-LAL. 

Results: The LAL-treated side had smoother contours, less 

bruising and 10–20% less vacuum-drawn skin than the 

liposuction-only side. Skin contraction increased with time to 20– 

30% vertical and 5–15% horizontal at 3 months on both sides. The 

local hardness was not palpable ex vivo but was sectioned and 

analyzed histologically (H&E). Contour irregularities on the SALtreated 

sites were greater than on the LAL-treated side, one 

subject requested revisions to the SAL-side. The irregularities 

were most pronounced 1 month post-op but still visible at 3 

months. Fibrotic tissue was easily identified 9 months post-LAL 

presumably coincident with the aspiration cannula and/or the 

laser fiber. No adhesion of the dermis to underlying fascia was 

found. 

Conclusion: The results suggest that a laser adjunct to 

liposuction can decrease bruising, improve contours and reduce 

skin laxity compared with suction-assisted liposuction. Histology 

supports the view that thermally altered adipose connective 

tissue can affect skin laxity. Additional multi-site studies are 

warranted. 

#71 

A 24-WEEK CONTROLLED TRIAL TO ASSESS THE 

EFFECTS OF AN INTENSE ULTRASOUND 

TREATMENT ON LOWER FACE SKIN LAXITY 

USING A NOVEL 3-D SELF-POSITIONING LASER 

SCANNER 

Daniel Barolet, Mathieu Auclair, Francois Barolet, 

Virginie C. Barolet, Isabelle Lussier 

McGill University Montreal, Canada; RoseLab Skin Optics 

Research Laboratory, Montreal, Canada 

Background: IUS exposure appears to be safe and effective to 

treat skin laxity of the lower face. The novel 3D laser scanner is a 

promising method for quantitative measurements of the lower 

face following IUS treatment. Further trials to advance 

therapeutic applications of this innovative approach are 

warranted. 

Study: This was 24-week single blinded randomized controlled 

clinical study. Twenty-four healthy adults (42- to 65-year old) with 

skin laxity of the lower face participated in this trial, and received 

either one IUS treatment to the nasolabial folds, jowls, and 

submental areas, or served as controls (2:1). Change in skin 

morphology, measured by a 3D self-positioning handheld laser 

scanner (VIUscan TM ), was determined by computing the ratio of 

the target areas that underwent a variation of 1 mm. 

Additional efficacy assessments included blinded clinical 

impression of change based on digital photographs, subject 

assessments of pain and discomfort, treatment satisfaction, and 

adverse reactions. 

Results: Statistical significant differences in skin topographical 

changes between the IUS-treated and control subjects were 

observed for the submental and jowls areas at week 12 and week 

24, and for nasolabial folds, at week 24 (P < 0.05). Clinical 

impression of change revealed that the majority of treated

subjects improved, while the majority of control subject showed no 

change over the trial period (P < 0.01). Patients’ satisfaction with 

treatment was high. IUS therapy was generally well tolerated 

with no unusual adverse effects observed. The most common 

adverse reactions included transitory mild erythema, oedema, 

and parasthesia. 

Conclusion: IUS exposure appears to be safe and effective to 

treat skin laxity of the lower face. The novel 3D laser scanner is a 

promising method for quantitative measurements of the lower face 

following IUS treatment. Further trials to advance therapeutic 

applications of this innovative approach are warranted. 

#72 

A NOVEL METHOD FOR OBJECTIVELY 

ASSESSING LIPOSUCTION OUTCOMES: 

3-DIMENSIONAL SURFACE IMAGING 

Elliot Weiss, Lori Brightman, Roy Geronemus 

Laser & Skin Surgery Center of New York, New York, NY 

Background: Although the field of body contouring is evolving 

rapidly, quantitative methods of evaluating treatment outcomes 

are lacking. Outcomes are often evaluated with qualitative 

photographic comparisons and tape measure changes in 

circumference. These techniques introduce human error and do 

not allow measurement of 3-dimensional (3D) changes in body 

shape. 3D photography enables precise circumference, skin 

tightening, and volumetric measurements to be performed on preand 

post-treatment 3D images. We present the first series of 

abdominal liposuction outcomes quantitatively evaluated using a 

3D photographic imaging system. 

Study: Five female subjects underwent abdominal laser-assistedliposuction 

procedures, and baseline and follow-up (average 11 

weeks) 3D photographic images were obtained for each treatment 

area. Corresponding baseline and follow-up image were aligned 

using surface landmarks, and quantitative measurements of 

circumference, surface contour, and volume change were 

performed. 

Results: In all treated subjects, 3D photography detected 

decreases in abdominal circumference, surface contour, and 

volume post-liposuction. For abdominal circumference, the 

average reduction at follow-up was 2.26 cm. For each abdominal 

treatment area, average volume reduction at follow-up was 213 cc. 

3D imaging detected surface contour changes in all subjects 

corresponding to the liposuction treated areas. 

Conclusion: 3D photography allows investigators to reliably 

detect and quantify minute changes in body shape. Using a 3D 

photographic imaging system, we have demonstrated the ability 

to reproducibly quantify circumference, surface contour, and 

abdominal volume changes post-abdominal liposuction. 3D 

imaging provides superior objective assessments of liposuction 

treatment outcomes. 

#73 


HIGH-INTENSITY FOCUSED ULTRASOUND 

DEVICE FOR NON-INVASIVE BODY 

CONTOURING: AGREEMENT OF OBJECTIVE AND 

SUBJECTIVE AESTHETIC OUTCOMES 

Jeffrey Dover, Patrick Martin, Ira Lawrence, 

The Sculpt Group 

Skin Care Physicians, Chestnut Hill, MA; Medicis Technologies 

Corporation, Scottsdale, AZ 

Background: In clinical practice, body contouring must achieve 

subjective aesthetic improvement, but clinical trials require 

objective data for analysis. In a randomized controlled trial, 

noninvasive high-intensity focused ultrasound (HIFU) was 

evaluated using change from baseline waist circumference 

(CBWC) as an objective surrogate marker of aesthetic 

outcome. This post hoc analysis compared CBWC with 

subjective investigator and patient assessments of aesthetic 

improvement. 

Study: One hundred eighty adults (mean [SD] age, 42 (11) years) 

with abdominal subcutaneous fat ¼ 2.5 cm thick and body mass 

index < 30 kg/m 2 were randomized to HIFU of the anterior 

abdomen and flanks at energy levels (each of 3 passes total) of 47 

(141 total), 59 (177 total), or 0 (sham) J/cm 2 . CBWC at the level of 

the iliac crest was assessed at week 12 using validated assessment 

tools. Subjective endpoints included investigator-assessed Global 

Aesthetic Improvement Scale and a patient satisfaction survey at 

week 12. 

Results: After 12 weeks, least square mean CBWC was 

statistically significantly superior with 59-J/cm 2 treatment 

( 2.44 cm, P ¼ 0.01) and showed a nonsignificant trend toward 

greater CBWC with 47-J/cm 2 treatment ( 2.06 cm, P ¼ 0.13) 

compared with sham ( 1.43 cm). The proportion of patients rated 

by investigators as improved/very much improved was 

significantly higher with 59-J/cm 2 (78.3%) and 47-J/cm 2 (72.4%) 

treatments compared with sham (15.5%). Similarly, the 

proportion of patients rating their abdomen as improved/very 

much improved was greater with 59-J/cm 2 (68.3%) and 47-J/cm 2 

(55.2%) treatments compared with sham (24.1%; P < 0.001 for 

each comparison). Adverse events (AEs) included procedural/ 

postprocedural discomfort, bruising, and edema. No serious AEs 

were reported. 

Conclusion: Objective CBWC results and subjective 

physician and patient assessments each indicated that 

active HIFU treatments were superior to sham for reduction of 

waist circumference, suggesting that CBWC is a reliable 

surrogate marker of overall aesthetic outcome for body 

contouring. 

#74 

MELANIN OPTICAL DENSITY AS A PREDICTOR 

OF MAXIMUM TOLERATED FLUENCE FOR 

PHOTODERMATOLOGY 

Ilya Yaroslavsky, Gregory Altshuler, 

Guangming Wang, Felicia Whitney, Henry Zenzie 

Palomar Medical Technologies, Inc., Burlington, MA 

Background: Fitzpatrick skin typing (FST) is the standard 

method used to predict maximum tolerated fluence for 

photothermal treatments with visible/near-IR light. FST assesses 

skin response to UV; however, for visible/near-IR wavelengths, 

melanin optical density (MOD) is more appropriate as a predictor 

of maximum tolerated fluence. The goal of this work was to find a 

correlation between maximum tolerated fluence and MOD. We 

present a retrospective analysis of data from five clinical studies. 

Study: Maximum tolerated fluence was measured on over 150 

patients in five clinical studies with different 800 nm pulsed lasers 

and an intense pulsed light source with wavelengths from 400– 

1,200 nm, 500–1,200 m, 500–650/850–1,200 nm, and 600– 

1,200 nm. Testing was conducted on the face, thigh, bikini line, 

axilla, and back. FST was conducted by using a standard patient 

questionnaire, and MOD was measured in the test area by using a 

dual-wavelength backscattering reflectometer. Maximum


tolerated fluence was determined by treating the test areas with a 

series of laser pulses of increasing fluence and assessing the 

patient’s pain rating and erythema. 

Results: Strong correlation was found between the maximum 

tolerated fluence and the MOD. The MOD tended to increase with 

the skin type; however, strong variations of the MOD within given 

skin type were observed. Effect of the pulsewidth on the maximum 

tolerated fluence was also observed, with higher MOD being more 

sensitive to changes of the pulsewidth. 

Conclusion: MOD measurement can be used to predict 

maximum tolerated fluence for visible/near-IR phototreatment 

devices. The MOD measurement device can be integrated into the 

treatment device, which allows real-time MOD measurement and 

automatic adjustment of the treatment fluence. 

#75 

QUALITY CONTROL AND THE PULSED DYE 

LASER: WHEN NOT TO TREAT 

Joshua Shofner, Zeina Tannous, Mathew Avram 


Background: The availability of effective laser treatment for 

cutaneous vascular lesions has risen dramatically in recent years. 

At the same time, there has been a proliferation of laser providers 

with varying amounts of training—both medical and non-medical. 

Study: We performed a retrospective analysis of four cases from 

our clinic, where patients presented for cosmetic evaluation of 

vascular lesions and were discovered to have more significant 

pathologic disease. 

Results: We report four separate cases with images in which 

prompt recognition of a pathologic skin finding directed the 

healthcare provider to pursue a more aggressive work-up, leading 

to the diagnosis of basal cell carcinoma, melanoma, connective 

tissue disease, and immune thrombocytopenic purpura. 

Conclusion: In presenting these cases, we hope to illuminate a 

basic differential diagnosis that exists for cutaneous vascular 

lesions and remind healthcare providers that not all cosmetic 

consults are benign in origin. There is a differential diagnosis 

framework that exists for vascular lesions that is worth reviewing, 

and it should be considered in all patients presenting for laser 

treatment. 

#76 

OPTIMAL TATTOO REMOVAL IN ONE 

TREATMENT SESSION WITH NANOSECOND- 

DOMAIN LASER PULSES 

Theodora Kossida, Dimitrios Rigopoulos, 

Andreas Katsambas, R. Rox Anderson 

A. Syggros Skin Disease Hospital, National and Kapodistrian 

University of Athens Medical School, Athens, Greece; Wellman 

Center for Photomedicine, Massachusetts General Hospital, 

Harvard Medical School, Boston, MA 

Background: Presently, Q-switched lasers are the gold standard 

for safe and effective tattoo removal. However, multiple and costly 

therapeutic sessions are usually required with variable results 

which leads to patients’ dissatisfaction and abandonment of the 

treatment. 

Study: The efficacy of a single laser exposure was compared to 

that of multiple laser exposures about 20 minutes apart within a 

single treatment session. Each of 18 tattoos on 12 adults was 

divided into two symmetrical parts which were then 

randomized for treatment with either the administration of a 

single Q-switched alexandrite laser exposure (755 nm, 

100 nanoseconds pulse duration, 3 mm spot size, 5.5 J/cm 2 ), or four 

consecutive exposures separated by 20 minutes. Digital 

photographs taken 3 months later were blindly evaluated to 

compare tattoo lightening. Biopsies obtained before and 

immediately post-treatment from both halves were also compared 

in blinded fashion. 

Results: Immediate response after the first laser exposure 

consisted of typical whitening which faded over the next 

20 minutes, while little or no whitening appeared right after 

subsequent exposures. Three months later, lightening was much 

greater in all sites treated with four exposures delayed by 

20 minutes (the ‘‘R20’’ method), compared with sites treated 

conventionally with a single laser exposure (P < 0.01). In 

addition, a single treatment session using the ‘‘R20’’ method 

removed most of the tattoos. There was greater epidermal injury 

with the ‘‘R20 method,’’ followed by transient pigmentary 

changes. No permanent side effects or scarring occurred. 

Histology showed greater and deeper dispersion of tattoo ink with 

the ‘‘R20’’ method. 

Conclusion: The ‘‘R20’’ method of tattoo removal was safe, well 

tolerated and much more effective than conventional Q-switched 

laser treatment. This method can potentially reduce the number 

of treatment visits and/or increase overall efficacy for tattoo 

removal. New laser device technology is not required. Larger 

prospective studies are warranted. 

#77 

COMBINATION OF MULTIPLE Q-SWITCHED 

WAVELENGTHS IMPROVES TATTOO 

CLEARANCE COMPARED TO SINGLE 

WAVELENGTH TREATMENT 

Arielle Kauvar 

New York Laser & Skin Care, New York, NY 

Background: Q-switched lasers can safely lighten tattoos, but 

treatment of multicolored tattoos usually requires six or more 

treatments, and incomplete pigment removal is common. The 

purpose of this study was to determine whether using a 

combination of laser wavelengths could improve tattoo clearance 

in multicolored tattoos compared to single wavelength treatment. 

Study: This was an IRB-approved, prospective, split-lesion 

controlled trial of large ( > 6 cm), multicolored tattoos in 13 

subjects with phototypes I–III. Each tattoo was bisected 

symmetrically. The entire tattoo was treated with one pass of a QS 

532 nm laser (50 nanoseconds, 3 mm, 1.5–2.6 J/cm 2 ) to the red, 

yellow and orange pigments and one pass of QS 1,064 nm laser 

(50 nanoseconds, 3 mm, 3.0–5.0 J/cm 2 ) to the black, blue and 

green pigments to an endpoint of tissue whitening. After 

20 minutes, a second laser pass was performed over one-half of the 

tattoo using a QS 755 nm laser (50 nanoseconds, 3 mm, 5.0–9.0 J/ 

cm 2 ) for all pigments to an endpoint of tissue whitening. Each 

tattoo received a total of four treatments, performed at 4- to 8week 

intervals, with follow-up at 1 and 3 months after the last 

laser treatment. Subjects were given the option to continue 

receiving an additional four laser treatments in the same manner 

to their tattoos. Standardized digital photographs and 

chromometer measurements were obtained before each treatment 

session, and at the follow-up visits. Adverse effects were recorded 

at each visit.

Results: At the 3-month follow-up visit, there was 25–50% 

increased clearance on the half of the tattoo that received 

combination compared to single wavelength treatment in 10/11 

tattoos which had already completed treatment and 3-month 

follow-up visits. Less than 25% increased clearance on the side 

treated with the combination of wavelengths versus the single 

wavelength treatment was observed in one tattoo. After the 3month 

follow-up, no subject elected to pursue additional 

treatments under the study protocol due to the increased 

clearance observed on the side treated with the combination of 

wavelengths. Combination treatment did not increase the 

incidence of adverse effects. Additional safety and efficacy data 

will be reported for this ongoing clinical trial. 

Conclusion: The application of a second pass of QS 755 nm laser 

treatment to multicolored tattoos after a first pass treatment 

using either the QS 532 or 1,064 nm lasers to the absorbing 

pigments significantly increased tattoo pigment clearance without 

increasing adverse effects. 

#78 


#79 

REDISTRIBUTION OF INK FOLLOWING LASER 

TATTOO REMOVAL 

Arisa Ortiz, Mathew Avram 

University of California, Irvine, CA; Massachusetts General 

Hospital, Boston, MA 

Background: Q-switched lasers are known to be effective for 

selectively targeting and removing unwanted tattoos with 

minimal damage to the skin. Exogenous pigment is the 

chromophore for Q-switched lasers, which have a shorter pulse 

duration compared to the thermal relaxation time of the tattoo 

pigment particles. By delivering high-energy, nanosecond pulses, 

the laser targets the pigment-containing cells and fragments the 

tattoo pigment into smaller particles which are re-phagocytized 

and cleared by lymphatics. 

Study: Three patients with Fitzpatrick skin type II–III received 

several treatments with a Q-switched 694 nm ruby laser 

(Spectrum RD-1200, Palomar, Burlington, MA) for unwanted 

tattoos on the abdomen, arm, and ankle. All patients were 

anesthetized with approximately 12–15 cc of 1% lidocaine with 

1:100,000 epinephrine using a 30 gauge needle. It was noted that 

the anesthesia for these patients was delivered via numerous 

puncture wounds into the tattoo and surrounding skin. Patients 

were then treated with a 6.5 mm spot and an irradiation of 

4–8 J/cm 2 . 

Results: At follow-up visits, all three patients had good 

improvement of their tattoos. An unexpected finding was 

clinically evident discoloration in the surrounding normal skin 

consistent with the original color of the tattoo. 

Conclusion: We theorize that repeated injury to the skin from 

the needle puncture created tunnels which allowed ink particles 

to disperse into the surrounding tissue after Q-switched laser 

treatment. Another contributing factor may have been excess 

amounts of lidocaine, which assisted in the migration of the ink 

particles through the tunnels. These cases demonstrate a possible 

complication when using multiple injections of anesthesia prior to 

laser tattoo removal. One might avoid this complication by using 

small amounts of lidocaine and minimizing the number of needle 

punctures into the skin prior to laser tattoo removal or by using a 

topical anesthetic. This finding may also indicate a potential 

avenue for new treatment strategies for improved efficacy of laser 

tattoo removal. 

A MULTI-CENTER EVALUATION OF THE 

MIRADRY SYSTEM TO TREAT SUBJECTS WITH 

AXILLARY HYPERHIDROSIS 

Mark Lupin, H. Chih-Ho Hong, 

Kathryn F. O’Shaughnessy 

University of British Columbia, Victoria, Canada; 

University of British Columbia, Vancouver, Canada; 

Miramar Labs, Sunnyvale, CA 

Background: A third generation microwave-based device has 

been developed to treat axillary hyperhidrosis by selectively 

heating the interface between the skin and underlying fat where 

the sweat glands reside. 

Study: Thirty-one (31) adult subjects were enrolled in this 

multi-center, single-group study. All subjects had primary 

axillary hyperhidrosis evidenced by Hyperhidrosis Disease 

Severity Scale (HDSS) ratings of 3 or 4 and a gravimetric sweat 

assessment of at least 50 mg in each axilla (in 5 minutes). Subjects 

were excluded if they had surgery for axillary hyperhidrosis or 

botulinum toxin injections in the axillae in the last 12 months. 

All subjects had between one and three treatment sessions over a 

6-month period to fully treat both axillae. Local anesthetic was 

used for pain management. Follow-up visits between and after 

treatments measured effectiveness by collecting HDSS scores 

and gravimetric assessments at approximately 30-day intervals. 

Subject safety was assessed at each visit. Subjects will be 

followed for 12 months after all treatment sessions are complete. 

Results: The mean age of enrolled subjects was 33 (range 18–65); 

74% were female; mean BMI was 24.8. Efficacy measurements for 

the 21 subjects that had a visit 30 days after their second 

treatment session show 100% with HDSS scores of 1 or 2 and 

gravimetric assessments show 86% have had at least a 50% 

reduction in axillary sweat compared to baseline (while the 

median reduction was 90%). Regarding safety, all subjects 

experienced transient effects in the treatment area such as 

swelling, discomfort or numbness. As of the time of this report, the 

most common adverse event (n ¼ 8 subjects) has been the 

presence of discrete, localized numbness in the arm that appears 

to be resolving. 

Conclusion: The device tested provides an efficacious treatment 

for axillary hyperhidrosis. Further follow-up for safety and 

efficacy duration is planned. 

#80 

A PILOT STUDY OF LASER ASSISTED DELIVERY 

OF ALLOGENEIC MESENCHYMAL STEM CELLS 

Jill Waibel, Evangelos Badiavas, Stephen Davis 

Miami Dermatology and Laser Institute; Miller School of 

Medicine, University of Miami, Cutaneous Surgery Wound 

Healing Research Laboratory, Miami, FL 

Background: Mesenchymal stem cells (MSCs) are multipotent 

cells that can differentiate into a variety of cell types. Optimal 

delivery of stem cells that enable their viability is a current 

challenge to MSC research. Fractional laser technology has 

revolutionized laser therapy. The fractional ablative tunnels can 

be utilized for laser assisted delivery systems of a variety of drugs, 

topicals and other living tissue. This is the first pilot study to test 

the hypothesis that ablative fractional laser could deliver 

mesenchymal stem cells to skin using a porcine full thickness 

wound model.


Study: A porcine model was chosen due to the morphological 

similarities between swine skin and human skin. Allogeneic cells 

were obtained by bone marrow aspiration from a donor pig. 

Mesenchymal stem cells were isolated from the donor bone 

marrow aspirate and transduced with a lentiviral vector 

containing a fluorescent marker gene. One recipient pig was 

placed under general anesthesia and 60 full thickness skin 

wounds were made using a 10 mm punch biopsy. The wounds were 

randomly assigned to two laser treatment regimens: laser CO 2/ 

MSC and laser Er:YAG/MSC. After AFL the stem cells were 

pipetted into the vertical channels. Wounds were covered with an 

occlusive polyurethane film dressing. Three punch and wedge 

biopsies were taken from each group on days 5, 7, and 21. 

Results: Labeled allogeneic bone marrow cells were observed in 

papillary and reticular dermis on days 5 and 7 in both the Er:YAG 

and CO 2 laser treated wounds. Some labeled cells were noted in 

close proximity to the ablated vertical channels created by laser 

treatment. Allogeneic cell showed persistence in the treated 

wounds despite intense inflammation associated with the full 

thickness wounds created. 

Conclusion: Preliminary study suggests that ablative fractional 

lasers may be useful technology to deliver mesenchymal stem 

cells and this has broad implications for many branches of 

medicine. 

#81 

A SPLIT-FACE STUDY INVESTIGATING 

ALLUMERA COMBINED WITH MULTIPLE LASER 

AND LIGHT SOURCES FOR 

PHOTOREJUVENATION 

Sabrina Fabi, Jennifer Peterson, Mitchel Goldman 

Goldman Butterwick & Associates, Cosmetic Laser Surgery, 

San Diego, CA 

Background: Chronic exposure to sun can result in 

photodamage manifested as fine lines/wrinkling, erythema, 

tactile roughness, hyperpigmented macules and patches, 

sallowness, skin laxity, and telangiectasias. Photodynamic 

therapy (PDT) uses a photosensitizer such as aminolevulinic acid 

or methyl aminolevulinic which is converted to protoporphyrin IX 

in vivo. These photosensitizers concentrate in rapidly 

proliferating cells, sebaceous glands, superficial melanin, and 

vasculature. When visible light radiation is applied, reactive 

oxygen species are generated. While originally indicated for the 

treatment of nonhyperkeratotic actinic keratosis, improvement in 

the signs of photoaging was noticed as an advantageous side 

effect. Most commonly, blue fluorescent light or a red light 

emitting diode is used to activate the photosensitizer; however, 

any laser or light source that emits visible light radiation can be 

used including the pulsed dye laser (PDL) and intense pulsed light 

(IPL). When administering PDT in our practice, a sequence of four 

laser and light sources are used: PDL, IPL, blue light, and red 

light to work synergistically to activate the photosensitizer. 

Photocure has developed Allumera cream (Photocure ASA, Oslo, 

Norway), a precursor to photoactive protoporphyrins (PAP), that 

enhances the skin appearance. This product is applied without 

occlusion and allowed to incubate before activation by visible light 

radiation. The purpose of this study is to investigate if the 

addition of Allumera to a series of laser and light sources results in 

further improvement of photoaging as compared to a placebo. 

Study: The primary objective of this study was to evaluate the 

efficacy of Allumera versus placebo combined with a series of laser 

and light sources in the improvement of photoaging as measured 

by the Global Score for Photoaging. Secondary objectives included: 

improvement of fine/lines, hyperpigmentation, telangiectasias, 

tactile roughness, erythema, sallowness, global evaluation of 

response to treatment, patient evaluation of photoaging, patient 

preference and patient satisfaction. A total of 20 patients were 

randomized to receive split face treatment with Allumera cream 

or placebo cream. On day 1 (Visit 1), day 30 (Visit 2), and day 60 

(Visit 3), the face of study subjects was pretreated with 

microdermabrasion and acetone wash, followed by randomized 

treatment to half of the face with Allumera cream (Photocure 

ASA, Oslo, Norway), and the other half with placebo cream, with 

unoccluded application for 1 hour. Photoactivation followed with 

first pulsed dye laser (PDL) to individual lesions, then intense 

pulsed light (IPL) to the entire treatment area, and finally 

treatment to entire face with both red and blue light sources. 

Investigator assessment of global photoaging, fine lines/wrinkles, 

hyperpigmentation, tactile roughness, sallowness, 

telangiectasias, erythema, and adverse events (using a 5-point 

scale) occurred prior to treatment at day 1 (Visit 1), day 30 (Visit 

2), day 60 (Visit 3), and on day 90 (Visit 4). Patient questionnaires 

were completed after day 1 (Visit 1), day 30 (Visit 2), and day 60 

(Visit 3), for a total of 1 week after treatment. Standardized 

photography was completed at day 1 (Visit 1) and day 90 (Visit 4). 

Results: Eighteen of 20 patients (18 females), aged 32–64 years 

old (mean 52.11), had completed visit 2 (day 30) of the study at the 

time of data analysis; and 8 patients of those patients (8 females), 

had completed visit 3 (day 60) by the time of data analysis. All 

patients were Fitzpatrick skin types II–IV with moderate to 

severe photodamage. Investigator assessment (using a 5 point 

scale) comparing baseline to day 30 found a trend towards 

improvement in global photoaging, fine lines/wrinkles, 


telangiectasias, and erythema. Comparing baseline to day 60, a 

statistical significance in improvement was noted in global 

photoaging, fine lines/wrinkles, hyperpigmentation, tactile 

roughness, and sallowness. There was no significant difference 

noted in post-treatment pain, erythema and edema, between the 

Allumera versus placebo-treated side by patients. Patient 

assessment of pain, redness, swelling, and itching for seven days 

following Visit 1 did not show a statistically significant difference 

between the Allumera versus placebo-treated sides. 

Conclusion: Treatment with Allumera shows a trend towards 

improvement in global photoaging, fine lines/wrinkles, 


telangiectasias, and erythema. Allumera is well tolerated by 

patients and does not result in significant post-treatment pain, 

erythema and edema compared to placebo. Preliminary data are 

presented. This is a single-site study of a small cohort of patients 

followed for an average of 45 days at the time of data analysis. 

This study will be completed by February 28, 2011, by which time 

we will have followed all 20 patients for a total of 120 days, and all 

patients will have received an additional photodynamic therapy 

session with Allumera. 

#82 

COMPARISON STUDY OF NON-ABLATIVE 

FRACTIONAL TREATMENT WITH AND WITHOUT 

ADVANCED SKIN COMPRESSION TECHNIQUE 

Taro Kono, Motoko Nakata, Hiroyuki Sakurai, 

Henry Chan 

Tokyo Women’s Medical University, Tokyo, Japan; University of 

Hong Kong, Hong Kong, China

Background: Recently a specially designed point-array 

compression tip (XD Optics, Palomar Medical Technologies, Inc.) 

for fractional non-ablative laser was been investigated. The 

objective of this study is to compare the efficacy and complications 

of fractional non-ablative laser with compression versus without 

compression. 

Study: Twelve Asian patients were enrolled in the study. Half of 

the face was treated with 1,540 nm fractional non-ablative laser 

(45 mJ, 15 milliseconds, 50% overlap, 2 passes, single treatment) 

with compression and the other half of the face was treated with 

same laser without compression. A Canfied Visia CR system was 

used to objectively evaluate the patient. 

Results: There is no significant difference of efficacy. However, 

pain score is significantly lower and dowmtime is significantly 

shorter in fractional non-ablative laser with compression side. All 

patient selected fractional non-ablative laser with compression in 

the next treatment. 

Conclusion: 1,540 nm fractional non-ablative laser with 

compression has a possibility to reduce the epidermal damage and 

pain. Further study is warranted to compare the efficacy with 

multiple treatment sessions. 

#83 


#85 

DEEP HEATING OF DERMIS USING NON- 

ABLATIVE FRACTIONAL TECHNIQUE WITH 

MICRO-COMPRESSION OPTICS 

Christine Dierickx, Sean Doherty 

Laser Clinic Boom, Boom, Belgium; Boston Plastic Surgery 

Associates, Concord, MA 

Background: Non-ablative fractional treatment (NAFT) has 

been proven as safe and effective technique for skin resurfacing. 

Up to recently, however, the depth of NAFT was limited to 1 mm, 

restricted by acceptable level of surface damage. In this study, we 

investigated feasibility of creating fractional coagulative damage 

in the reticular dermis and subcutis without skin cooling by using 

advanced micro-compression optics and pulse stacking. The 

principal hypothesis was that point-like tissue compression 

allowed accumulation of the absorbed optical energy in the deep 

dermis resulting in incremental increase of the size of the zones of 

coagulation. 

Study: A 1,540 nm fractional system with point-array 

compression tip (Lux1540, XD Optics, Palomar Medical) was used. 

The study comprised three parts: (1) computer modeling of optothermal 

dynamics to optimize treatment regime; (2) histological 

ex vivo evaluation of columns of microdamage (CMD); and (3) pilot 

clinical tests with emphasis on facial skin tightening. Up to five 

pulses were stacked, with total cumulative fluence up to 65 J/cm 2 

in three passes. 

Results: Both computer simulations and ex vivo histology data 

suggested feasibility of creating CMDs protruding deep into 

dermis. Pilot clinical tests have been initiated in parallel 

at two centers. Total of seven subjects have been treated on the 

face up to date. The treatment was well tolerated and did not 

require any anesthesia. Side effects included pronounced 

erythema and edema and resolved completely in 2 weeks. 

Follow-ups conducted up to 2 months post-treatment 

demonstrated significant improvement in skin laxity and 

appearance. 

Conclusion: Micro-compression-enhanced NAFT may provide 

means for efficient yet safe treatment of deep dermis and subcutis, 

with the potential benefit of skin tightening. 

HISTOLOGICAL EVALUATION OF A 

NON-ABLATIVE 1,940 NM FRACTIONAL LASER 

E. Victor Ross, Chad Tingey, Yacov Domankevitz, 

Kevin Schomacker, James Hsia 

Scripps Clinic, San Diego, CA; Candela, Wayland, MA 

Background: The standard CO2 and Er:YAG laser nonfractional 

systems for skin resurfacing produce predictable 

cosmetic enhancement, however, because of the prolonged 

recovery period, they have decreased in popularity. Non-ablative 

fractional lasers cause little down time, however, some patients 

want more noticeable results with fewer treatments. The 

1,940 nm wavelength matches one of the water absorption peaks 

in the mid infrared band of electromagnetic energy. The skin 

absorption is much stronger than other non-ablative wavelengths 

(1,440–1,550 nm) and weaker than ablative wavelengths. The 

objective was to characterize laser tissue interactions 

histologically in an ex vivo model. A human study is approved and 

initial treatments are planned. 

Study: Ex vivo porcine samples were irradiated with a fractional 

1,940 nm laser. The thulium laser rod was pumped by a 

3 milliseconds pulsed alexandrite laser. The fractional patterns 

included dot and grid geometries. The ‘‘dot’’ beamlet size was 

230 mm and the fixed pitch between lenslets was 480 mm. There 

were 481 beamlets per macrospot. The macro-spot size was 12 mm 

and a total energy was about 5 J (about 10 mJ per beamlet) and 

fluence of 40 J/cm 2 . The grid pattern included 700 mm wide lines. 

Results: Histological analysis has shown that with the 

appropriate laser settings, damage extended about 200 mm deep to 

the surface. 

Conclusion: The study demonstrated that the 1,940 nm diode 

laser, at appropriate settings, achieves injury patterns capable of 

skin rejuvenation. 

#86 

CLINICAL RESULTS OF NON-ABLATIVE 

FRACTIONAL PHOTOTHERMOLYSIS FOR 

HOME-USE TREATMENT OF PHOTODAMAGED 

SKIN 

Christopher Zachary, Marieke van Grootel, 

Tom Nuijs, Kerrie Jiang, Steven Struck 

University of California, Irvine, CA; Philips Research, Eindhoven, 

The Netherlands; Solta Medical, Hayward, CA; The Struck Clinic, 

Palo Alto, CA 

Background: Fractional photothermolysis (FP) has been proven 

to be effective in the hands of professionals for the treatment of a 

broad range of skin conditions, including pigmented lesions, fine 

wrinkling and textural changes. In this study, we have 

investigated the safety, efficacy and acceptability of repeated, lowdensity 

in-home treatments for photodamaged skin. 

Study: Multiple sequential clinical studies were conducted 

employing a twice weekly treatment regimen for a period of 8–16 

weeks. Studies involved both investigator-conducted and selfadministered 

full-facial treatments and treatment of off-face, sunexposed 

areas. Improvement was assessed by study subjects and 

investigators. Objective improvement was assessed by 

independent blinded evaluators based on clinical photographs. 

Histological analysis was performed on both ex vivo skin and 

on biopsies taken from treated areas according to the study 

regimen.


Results: Independent evaluator assessment demonstrated 

statistically significant improvement in overall appearance, 

pigmented lesions, dyschromia, textural irregularities and fine 

lines of all treated body areas. Near-optimal results were reached 

after 8 weeks of treatment and effects were still apparent 1 month 

and 3 months following the final treatment. Subject perception of 

treatment outcomes was positive. The treatment was welltolerated, 

with a very low incidence of side effects and with limited 

downtime. Histological results revealed that thermal damage, 

epidermal regeneration, pigment removal and neocollagenesis 

were consistently observed and were similar to treatments with 

professional non-ablative FP devices. 

Conclusion: It is demonstrated that self-administered, lowdensity 

FP treatments lead to objective and visible improvement 

of photodamaged and photoaged skin with minimal discomfort 

and downtime. 

#87 

EFFECTS OF DEVIATION FROM FOCAL PLANE 

ON LESION DEPTH AND DIAMETER FOR 

ABLATIVE FRACTIONAL PHOTOTHERMOLYSIS 

Garuna Kositrana, Henry Chan 

Dieter Manstein, Wellman Center for Photomedicine, Boston, MA 

Background: Ablative fractional photothermolysis (AFP) uses 

highly focused laser radiation. Therefore the lesion geometry is 

highly dependent of the positioning of the target relative to the 

focal plane. The effects of deviation from the focal plane on lesion 

diameter and depth were investigated. 

Study: In vitro, full thickness human skin samples and a 

standardized phantom (paper pad, 3 M) were used to investigate 

the lesion diameter and depth generated by an AFP system (deep 

FX, Lumenis). Lesion geometry in tissue was assessed by 

histological analysis of cryosections. Lesions created within the 

paper phantom were simply assessed by counting the number of 

perforated paper sheets and optical measurement of lesion 

diameter. Deviation from focal plane ( 2toþ 3 mm) was achieved 

by insertion of standardized spacers. 

Results: Ablation depth was nearly identical for tissue and paper. 

Deviation from the focal plane by 1 mm caused a reduction of 

ablation depth by approximately 40% and an increase in spot size 

by approximately 40%. 

Conclusion: Minor deviation from focal plane has a marked 

impact on lesion depth and diameter for AFP. A simple paper 

phantom correlates well with tissue ablation and can serve as a 

tool for quick and simple assessment of lesion geometry for AFP. 

#88 

PSEUDOMELANOMA FOLLOWING FRACTIONAL 

CO2 LASER RESURFACING 

Robert Gotkin, Deborah Sarnoff, Ritu Saini 

NYU Medical Center, New York, NY 

Background: Pseudomelanoma has been described as the 

appearance of recurrent pigment following trauma, cryotherapy, 

dermabrasion, various laser treatments and incomplete excision 

of benign nevi. Differentiating between pseudomelanoma and 

malignant melanoma can be extremely difficult, even for an 

experienced dermatopathologist, because pseudomelanoma 

exhibits atypical histologic features in common with malignant 

melanoma. We report the first three cases of pseudomelanoma 

following full face fractional CO2 laser skin resurfacing. 

Study: A retrospective study of 112 consecutive patients who 

underwent full face fractional CO 2 laser skin resurfacing for 

rhytides, photodamage, acne scarring and dyschromia was 

performed. Patients ranged in age from 22 to 85 and were 

Fitzpatrick skin types I–V. There were 11 men and 101 women. 

The lasers used were the DEKA SmartXide DOT and the 

Cynosure SmartSkin CO2 lasers. Preoperative and post-operative 

photographs were taken with the Canfield VISIA-CR photographic 

system. The post-operative photographs were taken at 1 week, 

1 month, 3 months, 6 months and 1 year following treatment. 

Results: Both clinical and photographic analysis revealed three 

patients who developed ‘new’ dark brown pigment in previously 

flesh-toned nevi within the treatment area. Biopsy of the lesions 

revealed the presence of irregularly nested proliferations of 

slightly atypical melanocytes overlying superficial dermal 

fibrosis. 

Conclusion: We postulate that pseudomelanoma is likely to 

occur more frequently following fractional, as opposed to fully 

ablative, CO2 laser resurfacing. The persistence of melanin within 

zones of thermal sparing may give rise to ‘new’ atypical pigmented 

lesions. It is of utmost importance for the clinician to be aware of 

the phenomenon of pseudomelanoma in order to avoid the pitfall 

of misdiagnosis of malignant melanoma. 

#89 

ULCERATION OF MATURE SURGICAL SCARS 

FROM NON-ABLATIVE 1,550 NM FRACTIONAL 

LASER TREATMENTS ASSOCIATED WITH INTRA- 

LESIONAL LIDOCAINE INJECTIONS 

Gary Chuang, Mathew Avram, Zeina Tannous 

Wellman Laboratories, Massachusetts General Hospital, 


Background: Non-ablative fractional laser resurfacing has 

gained increased popularity for treatment of scars, due to its 

efficacy, shortened downtime, and safety profile for treatment of 

scars in comparison to traditional ablative resurfacing. Topical 

and injectable local anesthetics are routinely applied to the skin 

prior to the laser treatment. Injected anesthetics are especially 

useful due to their immediate effects. To date, ulceration with 

non-ablative fractional laser treatment of surgical scars has not 

been reported. Here, we report two cases of mature surgical scars 

developing ulceration after treatments with a non-ablative 

1,550 nm fractional laser treatment associated with intra-lesional 

lidocaine injection. 

Study: Two patients presented for treatment of mature 

abdominal surgical scars. Both were treated with the same nonablative 

1,550 nm fractional laser. Prior to these treatments, both 

patients were injected with multiple intra-lesional 1% lidocaine 

with 1:100,000 epinephrine. Each of these patients developed 

ulceration shortly after non-ablative fractional laser resurfacing. 

The first case was a 20-year-old man with a 26 cm linear surgical 

scar on the abdomen from a biliary surgery as an infant. The scar 

was treated with a non-ablative fractional 1,550 nm laser at a 

pulse energy of 40 mJ (1,120 mm) and treatment level 8 (23% 

surface area). Subsequent treatments were spaced 2–3 weeks 

apart at the pulse energy of 50 mJ (1,224 mm) with level 9 (26% 

surface area) and 60 mJ (1,300 mm) with level 10 (29% surface 

area). The scar showed improvement with the laser treatments. A 

few days after the third treatment, an ulceration was noted 6 cm 

from one end of the scar. The second patient is a 47-year-old 

woman who presented with a 38 cm abdominal scar from an 

abdominoplasty 8 years ago. The scar was anesthesized with

intra-lesional lidocaine injection prior to non-ablative fractional 

1,550 nm laser treatment. The pulse energy was 45 mJ (1,176 mm) 

with level 7 (20% surface area) at the first treatment. The same 

treatment settings were repeated 1 month later. One week after 

the second laser treatment, multiple superficial ulcerations 

occurred where injectable lidocaine was applied. 

Results: In both of these cases, the ulcerations occurred on the 

sites of intra-lesional lidocaine injections. Cellular studies have 

demonstrated that injected local anesthetics such as lidocaine can 

lead to thermal destabilization of cellular membrane. 

Conclusion: Although non-ablative fractional resurfacing has 

shown good safety profile, ulceration can occur in the setting of 

intra-lesional lidocaine injection prior to laser treatment. 

Ulceration is likely caused by the thermal instability of skin 

cellular membrane to exposure to lidocaine. We recommend that 

topical application of local anesthetics prior to a non-ablative 

fractional laser treatment. 

#227 

ABLATIVE FRACTIONAL RESURFACING FOR 

TATTOO REMOVAL 

Omar Ibrahimi, Fernanda Sakamoto, 

Mathew Avram, R. Rox Anderson 

Wellman Center for Photomedicine, Boston, MA 

Background: Currently, Q-switched lasers are the gold standard 

for tattoo treatment. Allergic tattoo reactions present a 

challenging treatment dilemma. We present the application of 

ablative fractional resurfacing as a novel method for the removal 

of tattoos in two patients with tattoo allergies. 

Study: We describe two patients with tattoo allergies, referred to 

us for treatment. Ablative fractional erbium (Er:YAG; 2,940 nm) 

laser resurfacing was used in a series of treatments, to remove the 

allergic-ink portion of a large multi-colored tattoo on the upper 

extremity of a 52-year-old man. In a 31-year-old woman with a red 

and black tattoo on her lower extremity, ablative Er:YAG laser 

fractional resurfacing was combined with a Q-switched Nd:YAG laser. 

Results: Following a series of treatments, both patients 

experienced significant to complete removal of the offending tattoo 

inks with substantial or complete resolution of their symptoms. 

Conclusion: Ablative fractional laser resurfacing appears to be 

safe and effective for staged removal of allergic tattoos. Fractional 

laser resurfacing can be combined with other treatments such as 

Q-switched lasers. The potential for a series of fractional ablative 

laser treatments to remove tattoos, including allergic tattoos and 

inks of any color, merits further study. 

#91 


TREATMENT OF MELASMA IN FITZPATRICK 

SKIN TYPES IV–V WITH NON-ABLATIVE 

FRACTIONAL PHOTOTHERMOLYSIS: A REPORT 

OF 14 CASES WITH LONG-TERM FOLLOW-UP 

Paul M. Friedman, Jennifer M. Landau, 

Kristel D. Polder, Megan N. Moody, 

Irene J. Vergilis-Kalner, Denise Marquez, Leonard 

H. Goldberg 

DermSurgery Associates, Houston, TX; 

Rodgers Dermatology Dallas, TX 

Background: The objective of this study was to determine 

optimal treatment parameters utilizing non-ablative fractional 

photothermolysis for the treatment of melasma in patients with 

Fitzpatrick skin types (FST) IV–V. Patients were evaluated for 

improvement at variable follow-up intervals. 

Study: Fourteen patients (13 female, 1 male), FST IV–V, with 

melasma of the face were treated with a 1,550-nm fractionated 

Erbium-doped fiber laser. Patients underwent 2–5 treatments at 

6- to 8-week intervals (4–12 passes per treatment session) at 

energy fluences ranging from 5 to 20 mJ and treatment levels 

ranging from 3 to 7, which corresponds to surface area coverage of 

9–20% (0.58–3.70 total kJ; average 2.06 kJ). All patients were 

started on a topical bleaching cream at their initial treatment visit 

and continued use in between and after laser treatments. Patients 

were evaluated for improvement in the clinical appearance of 

melasma before each treatment and at a follow-up visit after the 

final treatment. 

Results: 57.1% of subjects (8 of 14) had greater than 50% initial 

improvement, 35.7% of subjects (5 of 14) had greater than 25% 

initial improvement, and 7.1% of subjects (1 of 14) had less than 

25% initial improvement following the last treatment session. 

Eight subjects had 2- to 6-month follow-up, three subjects had 6to 

12-month follow-up, and three subjects had follow-up greater 

than 12 months after the last treatment session. Only one subject 

noted a worsening of the condition at follow-up greater than 1 year 

post-treatment. Side effects were limited to mild, transient 

erythema and edema. One patient developed PIH which improved 

with bleaching creams. 

Conclusion: Our results indicate that fractional photothermolysis 

with the 1,550 nm erbium-doped fiber laser is a safe and effective 

treatment option for melasma in patients with FST IV–V. 

#92 

TREATMENT OF MELASMA WITH A NOVEL 

FRACTIONATED 1,927 NM THULIUM FIBER 

LASER 

Kristel Polder, Suzanne Bruce 

University of Texas Houston; Suzanne Bruce and Associates, 

Houston, TX 

Background: Non-ablative laser devices have been 

demonstrated to be highly effective treatment options for skin 

resurfacing. This study is the first to investigate the clinical 

efficacy of a new non-ablative 1,927 nm fractional thulium fiber 

laser for improvement of facial melasma. 

Study: Eighteen subjects with an average age of 48.2 9 years, 

with clinically identifiable facial melasma were enrolled and 

consented at one dermatologic laser center. Five subjects were 

Fitzpatrick Skin Type (FST) II; four were FST III; and seven were 

FST IV. The subjects received 3–4 full face treatments with the 

1,927 nm laser at 3- to 4-week intervals. Subjects were treated at 

settings of 10–15 mJ with treatment levels ranging from 2 to 7 

(25–50% coverage), and eight passes at each session. 

Investigators performed baseline and follow-up skin assessments 

using a melasma severity scale and pigmentation intensity scale. 

Photographs were taken prior to and immediately after each 

treatment and at follow-up visits occurring at 1, 3, and 6 months 

after the final laser treatment. Side effects were assessed at all 

study visits, and patients rated pain using a visual analog scale 

(0–10). 

Results: At baseline, the average melasma disease severity was 

rated 3.70 (0 ¼ none, 1 ¼ minimal trace, 2–3 ¼ mild, 

4–5 ¼ moderate, 6–7 ¼ marked, 8 ¼ severe). At the 1-month 

follow-up, melasma disease severity was rated as 1.77; 3-month 

follow-up was 1.50; and 6-month follow-up was 3.00. Pigmentation 

intensity scores averaged 3.50 at baseline; 1.38 at the 1-month


follow-up; 1.50 at the 3-month follow-up; and 2.00 at the 6-month 

follow-up. Average pain reported over all treatments was 4.5. 

Moderate erythema and mild edema were post-treatment responses. 

Therewerenoincidencesofscarringorpost-inflammatory hyper- or 

hypopigmentation throughout the course of this study. 

Conclusion: Non-ablative fractional resurfacing with the 

1,927 nm thulium fiber laser is a safe and effective treatment 

modality for melasma on the face. 

#93 

EFFICACY OF 1,927 NM THULIUM FIBER LASER 

FOR THE TREATMENT OF MELASMA IN CHINESE 

PATIENTS 

Samantha Y. Shek, C.K. Yeung, Stephanie G.Y. Ho, 



Background: 1,927 nm thulium fiber laser contains two fiber 

lasers in one system. It is FDA approved for non-ablative skin 

resurfacing and rejuvenation. The objective of the study is to 

assess the efficacy of 1,927 nm thulium fiber laser for the 

treatment of melasma in Chinese patients. It provides a higher 

wavelength with higher absorption. 

Study: Twelve female subjects aged 44–58 with mild to severe 

melasma were recruited. All subjects received a single treatment. 

They were assessed at baseline, 1 day, 7 days, 1 month and 2 

months post-treatment. Adverse effects were noted and clinical 

photos were taken using (Canfield Visia CR System). A 

questionnaire was given at the follow-ups for the subjects to rate 

the pain level, swelling, dryness, wrinkles, pore size, 

pigmentation, any hyper/hypopigmentation as well as overall 

satisfaction. Two independent physicians assessed the clinical 

photos, giving the MASI score, rating the skin texture and 

identifying any adverse effects. 

Results: All subjects experienced pain and swelling, all of which 

subsided within 7 days post-treatment. 54.5% and 58.3% subjects 

noticed an improvement in their melasma at 1 and 2 months posttreatment, 

respectively. A decrease in wrinkles was observed by 

36.4% at 1-month post-treatment but the effect only lasted in 

16.7% by 2 months post-treatment. Sixty-two percent noticed an 

improvement in pore size. Physician assessment supported the 

above with a statistically significant improvement in MASI score 

(P ¼ 0.018), pore size (P ¼ 0.011) and skin texture (P ¼ 0.005). 

The improvement in fine lines was also significant at 1-month 

follow-up (P ¼ 0.014) but was not enough to be statistically 

significant at 2 months follow-up. 

Conclusion: 1,927 nm thulium fiber laser is temporarily effective 

for treating melasma in Chinese patients. The treatment also 

improves the overall skin texture. 

#94 

NON-ABLATIVE 1,550 NM FRACTIONAL LASER 

THERAPY NOT EFFECTIVE FOR ASHY 

DERMATOSIS AND POSTINFLAMMATORY 

HYPERPIGMENTATION: A PILOT STUDY 

Bas Wind, Marije W. Kroon, Bas S. Wind, 

Arne A. Meesters, Albert Wolkerstorfer, 

J.P. Wietze Van der Veen, Jan D. Bos, 

Allard A. Van der Wal, Johan F. Beek 

The Netherlands Institute for Pigment Disorders Amsterdam, 

The Netherlands 

Background: Ashy dermatosis, also known as erythema 

dyschromicum perstans, is an acquired benign disease, 

characterized by blue-gray pigment patches with erythematous 

borders. No effective treatment is available. Postinflammatory 

hyperpigmentation is a pigment disorder resulting after 

inflammation of the skin due to various causes. Existing 

treatments often show disappointing effects. The aim of this study 

was to assess the efficacy and safety of non-ablative 1,550 nm 

fractional laser therapy (FLT) in the treatment of 

postinflammatory hyperpigmentation and ashy dermatosis. 

Study: Eight patients with ashy dermatosis (skin type IV–V) and 

six patients with postinflammatory hyperpigmentation (skin type 

II–V) were included in a randomized controlled, observer blinded 

trial. In each patient, two similar square test regions of 5–10 cm 2 

were randomized to receive either five non-ablative FLT 

treatments (?: 1,550 nm, 15 mJ/microbeam, final coverage: 14– 

17%; 3 weeks inter-treatment interval) in combination with 

intermittent daily topical bleaching (to prevent laser-induced 

postinflammatory hyperpigmentation) or the same intermittent 

regimen of topical bleaching alone (to allow comparison of the 

regions). Three months after the last treatment clearance of 

hyperpigmentation was assessed by melanin index, reflectance 

spectroscopy, physician’s global assessment, patient’s global 

assessment and patient’s satisfaction. In addition, a biopsy of both 

treated and control site was evaluated by an independent blinded 

pathologist. 

Results: Three months after the last laser treatment, no clinical 

improvement of hyperpigmentation was observed. Reflectance 

spectroscopy, melanin index, number of melanocytes and amount 

of dermal melanin did not significantly differ between both 

regions. Patient’s global assessment and patient’s satisfaction 

were both 3.6 and 5.7, and 4.5 and 4.5, respectively (visual 

analogue scale 0–10). Moreover, three patients developed laserinduced 

postinflammatory hyperpigmentation. 

Conclusion: With these laser settings, non-ablative FLT was not 

effective for the treatment of ashy dermatosis and 

postinflammatory hyperpigmentation. 

#95 

ABLATIVE FRACTIONAL RESURFACING OF 

EYELIDS: A PROSPECTIVE EVALUATION 

Brian Biesman 

Nashville Centre for Laser and Facial Surgery, Nashville, TN 

Background: Ablative fractional resurfacing of the eyelids has 

been previously described. These reports are few and have not 

evaluated many of the factors important to eyelid aesthetics. The 

goal of this study was to evaluate the outcomes of eyelids treated 

via ablative fractional techniques. 

Study: This was a single site, prospective study in which 20 

subjects underwent fractional ablative resurfacing using a carbon 

dioxide (CO2) laser (Lumenis, Inc., Santa Clara, CA). The laser 

was used in two separate modes, one in which small (120 m) spots 

were used to create deep injury and another in which larger 

(1.3 mm) spots were used to treat more superficially. Energies 

used with the small spot ranged from 12.5 to 20 mJ and with the 

larger spot ranged from 80 to 100 mJ. All treatments were 

performed under topical anesthesia only. Follow-up was at 1 

week, 2 weeks, 3 months, and 6 months. Subjects were assessed 

for skin wrinkling, color, roughness, erythrosis and texture, upper 

eyelid hooding, lower eyelid appearance, and crow’s feet 

appearance. Professional photographs were taken at baseline, 

3 months, and 6 months after treatment.

Results: Average treatment times for the deep and superficial 

treatments were 3.1 and 3.6 minutes, respectively. No serious 

adverse events occurred. Seventy-five percent of subjects 

demonstrated improvement in upper eyelid hooding at the 6month 

follow-up visit using a novel grading scale. This scale will 

be presented and discussed. Eyelid skin wrinkling improved in 

70% of subjects. Improvement in lower lid appearance was noted 

in 80% of subjects at the 6-month follow-up. Sixty percent of 

subjects demonstrated improvement in the appearance of crow’s 

feet lines at 6 months. Change from baseline in other endpoints 

was more variable. 

Conclusion: Ablative fractional resurfacing can produce 

dramatic improvement in eyelid appearance. Some characteristics 

predispose favorable outcomes. 

#96 

COLD INDUCED MODULATION OF TARGETED 

FACIAL NERVES. A PILOT STUDY OF A 

MINIMALLY INVASIVE CRYOPROBE DEVICE FOR 

IMMEDIATE REDUCTION OF DYNAMIC 

WRINKLES 

Vic Narurkar, Francis Palmer, Thomas Munyon, 

Kristine Tatsutani 

Los Angeles, CA; California Pacific Medical Center, 

San Francisco, CA; Munyon Dermatology; Myoscience, 

Redwood City, CA 

Background: Reduction of dynamic lines using neurotoxins is 

the most demanded procedure in the United States. The study 

objective was to evaluate a minimally invasive cryoprobe device 

that targets motor nerves to achieve immediate reduction of 

dynamic wrinkles without the use of a neurotoxin. 

Study: In a cohort of 31 subjects a 27 gauge cryoprobe was 

inserted subcutaneously near the temporal branch of the facial 

nerve that innervates the frontalis muscle. After administering 

each cooling cycle of less than 60 seconds, the investigator 

monitored reduction in muscle contractility to determine if 

additional cryoprobe insertions were needed to achieve the 

desired cosmetic effect. 

Results: One hundred percent of subjects experienced immediate 

dynamic line reduction after two to eight cryoprobe insertions 

near the motor nerves that power the frontalis muscle. The most 

frequent observed side effects were headaches and small focal 

areas of minor epidermal cold injury. Efficacy was sustained 

through subsequent follow-up visits. 

Conclusion: Cold induced neuromodulation using a minimally 

invasive cryoprobe results in immediate and sustained reduction 

of dynamic lines of the frontalis by targeting the associated facial 

nerve. Immediate endpoint observation allows optimization of the 

effect for facial muscle groups. 

#97 


ENHANCED SKIN REJUVENATION: A NOVEL 

COMBINED NON-ABLATIVE AND FRACTIONAL 

APPROACH 

Hanit Brenner-Lavie, Yossi Adanny, 

Avner Rozenberg, Haim Epstein, Genady Nahshon, 

Ruthie Amir, Ulrich Toft, Tal Nachlieli, 

Boris Vaynberg 

Syneron Medical, Ltd, Yokneam Illit, Israel; Assuta Medical 

Center, Haifa, Israel 

Background: Ablative devices provide high efficacy but with 

prolonged recovery times, whereas non-ablative devices have 

shortened recovery periods but offer modest efficacy. Fractional 

devices have shorter downtime and fewer adverse effects than 

ablative devices and greater efficacy than non-ablative devices. 

Combining non-ablative and fractional treatment can offer higher 

efficacy than achieved by each procedure alone. 

Study: We used physical modeling to describe temperature 

distribution in the skin induced by the application of combined 

broadband IR light and bipolar RF. Histology of human facial skin 

under the impact of sublative RF evaluated in vivo the biological 

tissue effects. A biological model for the combined application 

mechanism of action has been developed. 

Results: Based on biophysical modeling, combined broadband IR 

light and bipolar RF applied simultaneously with cooling of the 

skin surface creates reticular dermal tissue islands reaching 

> 50–558C, surrounded by deep volumetric heating of the entire 

dermis (45–508C) with complete sparing of the epidermis. In vivo 

analysis of fractional sublative RF demonstrates epidermal tissue 

ablation up to 150 mm depth beyond which the papillary dermis is 

affected mainly by coagulation (up to 150 mm deeper and 

occasionally lateral). A biological model for the combined 

application will be presented. 

Conclusion: The underlying mechanism of action of this unique 

combination is the synergistic induction of local healing response 

leading to modification of connective tissue via collagen 

remodeling. With sublative RF, tissue injury leads to 

inflammatory reaction and the responsive healing process 

involves ECM remodeling of the upper dermis. Conversely, deep 

volumetric heating by the non-ablative application causes 

immediate tissue tightening due to collagen denaturation and 

collagen contraction followed by a delayed healing response of the 

deep dermis. Ongoing clinical studies suggest that this novel 

approach promotes the desired biological responses leading to a 

more and better organized younger dermal matrix. 

#98 

LONG-TERM EFFICACY AND SAFETY OF MICRO- 

FOCUSED ULTRASOUND FOR SKIN TIGHTENING 

AND LIFTING: RESULTS IN 183 KOREAN 

SUBJECTS 

Nark-Kyoung Rho, Chan-Woo Jeong, Deuk-Pyo Lee, 

Sangjin Park, Seung-Hui Kang, Jang-Hyun Shin, 

Byung-Soon Park 

Leaders Aesthetic Laser & Cosmetic Surgery Center, Seoul, Korea 

Background: The objective of this study was to evaluate the longterm 

safety and efficacy of a micro-focused ultrasound treatment for 

non-invasive skin tightening and lifting in Korean patients. 

Study: A total of 183 Korean subjects ranging in age from 25 to 76 

received a full face treatment utilizing the micro-focused 

ultrasound therapeutic system. For upper third of the face, only 

the 3.0 mm-depth transducer was used while two transducers 

(3.0 mm, 4.5 mm) were used in combination for the treatment of 

mid- and lower face. Photographs taken at 1 month, 3 months, 6 

months, and 9 months following treatment were evaluated by two 

independent dermatologists not involved in the treatment. 

Clinical improvement was also assessed subjectively. Any adverse 

events and patient discomfort was also recorded. 

Results: Overall, the percentage of subjects responding with an 

improvement was 82% at 1 month, 87% at 3 months, 79% at 6 

months, and 65% at 9 months following treatment. Objective 

assessment at 3 months showed significant improvement for


eyebrow position (85%), midface laxity (81%), jawline definition 

(77%), mentolabial folds (68%), infraorbital folds and wrinkles 

(64%), cervicomental angle (62%), and nasolabial folds (44%). 

Assessment at 6 and 9 months revealed that mid- and lower face 

improvement lasted longer than the upper third of the face. Other 

than slight transient erythema and edema immediately posttreatment, 

generally, there were no major adverse effects noticed. 

There were three cases of linear erythematous papules on the 

neck which lasted 2–4 weeks. Slight infraorbital nerve palsy was 

observed in two subjects. Distressful scalp paresthesia developed 

in one subject. All neurologic symptoms resolved spontaneously 

within a month. 

Conclusion: The micro-focused ultrasound technique is a safe 

and effective treatment for lifting and tightening facial soft tissue 

in Koreans. Our study showed that in Korean subjects, treatment 

of the mid- and lower face showed more patients’ satisfaction and 

longer-lasting effects than upper face treatment. 

#99 

CLINICAL STUDY OF TRANSCUTANEOUS 

FOCUSED ULTRASOUND FOR LOWER FACIAL 

AND SUBMENTAL SKIN TIGHTENING IN ASIANS 

Nicola P.Y. Chan, Carol S. Yu, Johnny C.Y. Chan, 

Samantha S. Shek, Henry H.L. Chan 

The University of Hong Kong; Eye Institute, Hong Kong, China 

Background: The objective of this study was to determine the 

clinical efficacy of a focused ultrasound device for the treatment of 

lower facial and submental skin laxity in Asians. 

Study: Each patient received one treatment with the 

transcutaneous focused ultrasound device. Two transducers 

(7.5 MHz, 3.0 mm depth; 4.0 MHz, 4.5 mm depth) were used to 

deliver two passes of microthermal areas of coagulation over the 

lower facial and submental regions at two different depths. 

Standardized photos and three-dimensional images were taken 

with the Canfield Visia CR and Vectra systems 1 , respectively, at 

baseline, 1 month and 3 months post-treatment. They assessed by 

two independent physicians. 

Results: Sixteen Chinese patients were included. Erythema and 

edema were the only temporary adverse effects, which resolved by 

1 month. Preliminary objective assessment of standardized photos 

showed statistically significant improvement for skin laxity along 

the jawline (P ¼ 0.046), and cheek (P ¼ 0.008) at last follow-up. The 

degree of improvement was graded as slight to moderate. Vectra 3D 

images showed positive skin tightening in submental region. 

Conclusion: The dual-plane approach of energy delivery with 

transcutaneous high intensity focused ultrasound appeared 

effective for lower facial and submental skin laxity in Asians. 

Further studies to optimize treatment parameters may enhance 

clinical outcomes. 

#100 

CLINICAL AND HISTOPATHOLOGICAL 

EVALUATION OF A NEW NON-INVASIVE BODY 

CONTOURING DEVICE COMBINING HIGH 

POWER BIPOLAR RADIOFREQUENCY, 

INFRARED LIGHT, NEGATIVE PRESSURE AND 

MECHANICAL TISSUE MANIPULATION 

Hema Sundaram, Jason N. Pozner 

Sundaram Dermatology, Cosmetic & Laser Surgery, Fairfax, VA; 

Sanctuary Plastic Surgery, Boca Raton, FL 

Background: The combination of externally applied bipolar 

radiofrequency (RF), infrared light (IR), negative pressure and 

mechanical tissue manipulation has been shown to be safe and 

efficacious for temporary circumferential reduction and cellulite 

improvement. The bipolar RF allows for a reduction in optical 

energy applied to the skin. Furthermore, bipolar RF is not 

preferentially absorbed by melanin and thus has potential utility 

in treating all Fitzpatrick skin phototypes. It was hypothesized 

that increasing the power of the bipolar RF would enhance 

treatment efficacy and might allow reduction in the duration and/ 

or number of treatment sessions required. 

Study: In this prospective study, patients received one treatment 

per week over 6 weeks to one thigh while the non-treated thigh 

served as the control. Patients were followed for several months 

post-completion of the treatment protocol. Thigh circumferences 

were measured and baseline to post treatment comparisons were 

made. Thigh circumference reductions were compared between 

the treated and non-treated thighs. Safety issues and treatmentemergent 

adverse effects were monitored throughout the study. 

Results: There was a significant difference in mean 

circumferential reduction from baseline to post 6 treatments 

between the treated and the non-treated thighs. The incremental 

reduction in thigh circumference appeared as soon as 2 weeks 

from the beginning of treatment and occurred exclusively in the 

treated thighs. Overall improvement in body contour was clearly 

noticeable on comparison of the before and after photographs. The 

use of high power bipolar RF was well tolerated and was not 

associated with adverse events or complications. 

Conclusion: External application of high power (200 W) RF energy 

combined with IR, negative pressure and tissue manipulation 

appears to be a safe and efficient modality for temporary 

circumferential reduction and body contouring. Histopathological 

correlation suggests that the underlying mechanism of action is 

reduction in the hypodermal adipose tissue volume via confined 

thermal targeting. 

#102 

COMPARISON OF FRACTIONAL ER:YAG AND CO2 LASERS IN RESURFACING OF ATROPHIC ACNE 

SCARS IN ASIANS 

Woraphong Manuskiatti, Thanawan Iamphonrat, 

Rungsima Wanitphakdeedecha, Sasima Eimpunth 

Siriraj Hospital, Mahidol University, Bangkok, Thailand 

Background: Ablative fractional lasers including fractional 

Er:YAG and CO2 lasers have recently been introduced to address 

some limitations of nonablative fractional lasers. There has been 

very little evidence on the comparative efficacy and safety of these 

two laser systems, especially in dark-skinned patients who inherit 

higher risk of adverse effects following ablative laser treatment. 

The aim of the present study was to compare the efficacy and 

safety of fractional Er:YAG and CO2 lasers in the treatment of 

atrophic acne scars in Asian individuals. 

Study: This is a split-face, single-blind, controlled, comparison 

study. Twenty-four Thai subjects with atrophic acne scars were 

randomly treated using a fractional Er:YAG laser on one side of the 

face and a fractional CO2 laser on the other side. Each subject 

received with two treatments at 2 months apart. Objective 

(ultraviolet A-light video camera) and subjective (clinical evaluation 

by two blinded dermatologists) assessments were obtained at 

baseline and at 1, 3, and 6 months after the 2nd treatment. The 

assessment of pain score, recovery time, side effects, and patient 

satisfaction were recorded at every follow-up visit.

Results: At the 1-month follow-up, 25% of the subjects were rated 

as having at least 25–50% improvement of their scars on both 

treatment sides. There was no significant difference in 

therapeutic outcome between the sides treated with fractional 

Er:YAG and CO 2 lasers. However, postinflammatory 

hyperpigmentation (PIH) and discomfort were significantly more 

pronounced on the CO2 laser side. 

Conclusion: Ablative fractional Er:YAG and CO2 lasers are safe 

and effective for treatment of atrophic acne scars in Asians. As of 1 

month following the treatment, both laser systems showed 

comparable post-operative healing periods and comparable 

cosmetic improvement. However, the side treated with fractional 

CO 2 lasers was associated with higher degree of pain and was 

complicated with higher incidence of PIH. 

#103 


#104 

A PROSPECTIVE RANDOMIZED SPLIT-FACE 

COMPARISON STUDY OF NON-ABLATIVE 

FRACTIONAL LASER RESURFACING IN THE 

TREATMENT OF ACNE SCARRING IN 

FITZPATRICK SKIN PHOTOTYPES IV–VI 

Andrew Alexis, Marcy Coley, Murad Alam, 

Janiene Luke, Sejal Shah, Yahya Argobi 

Downstate Medical Center, Brooklyn, NY; Northwestern 

University Chicago, IL; Skin of Color Center, St. Lukes Roosevelt 

Hospital, New York, NY 

Background: Optimal treatment parameters for fractional laser 

resurfacing in darker skin types have not been clearly established. 

The purpose of this study is to compare the efficacy and safety of 

two different settings of a fractional nonablative laser in darkly 

pigmented subjects with acne scarring. 

Study: This is a prospective, split-face, randomized, controlled 

study involving 18 subjects aged 18–65, with Fitzpatrick skin 

types IV–VI, and acne scarring on the face bilaterally. Subjects 

were treated with a 1,550 nm erbium-doped fractionated laser 

using two different settings, one per side of the face. Each side was 

treated with 40 mJ and treatment level 4 (11% surface area 

coverage) versus 40 mJ and treatment level 7 (20% surface area 

coverage), randomized to the left or right face. A total of four 

treatments were performed at 4-week intervals. Efficacy 

endpoints include improvement from baseline in: quantitative 

global scarring grading system score (QGSGSS), blinded 

investigator global visual analog scale (VAS), and Skindex-16. 

Safety evaluations include development of dyspigmentation or 

scarring. Preliminary results at week 16 are presented here. 

Results: In our preliminary analysis of six subjects who have 

completed four treatments and were evaluated at 1 month after 

the final treatment, all subjects showed improvement from 

baseline by blinded live investigator VAS. The mean 

Investigator VAS was 6.0 and 3.8 for the high and low density 

treatments, respectively, where 0 is ‘‘no change’’ and 10 is ‘‘like 

normal skin.’’ The mean reduction from baseline in QGSGSS for 

both high and low density treatments was 1. Two of the six 

subjects and 1/6 subjects had mild hyperpigmentation and 

erythema bilaterally at week 16 (1 month post 4 treatments) 

respectively. 

Conclusion: The 1,550 nm erbium-doped fractional laser is 

efficacious and safe in the treatment of acne scarring in 

darker skin types. Greater efficacy was observed with 

higher treatment density without an increase risk of 

hyperpigmentation. 

EVALUATION OF THE COMBINED TREATMENT 

WITH FRACTIONAL LASER AND FRACTIONAL 

RADIOFREQUENCY FOR ACNE SCARS IN ASIANS 

Chi Keung Yeung, Nicola P.Y. Chan, Carol S. Yu, 


The University of Hong Kong; Eye Institute, Hong Kong, China 

Background: The fractionated RF induces deep dermal heating 

while leaving the epidermis less affected. Thus it may reduce 

downtime and lower the risk of postinflammatory 

hyperpigmentation. Combining fractional bi-polar RF and diode 

laser is intended to improve acne scars by enhancement of 

collagen production in the scar indentation and by causing 

ablation and resurfacing of the scar edges. The objective is to 

determine the safety and efficacy of the combined treatment on 

acne scars in Asians. 

Study: Twenty-one Asians with skin types IV–V and acne scars 

were recruited. Each received three treatments with fractional 

915 nm laser using Matrix IR (Syneron, Irvine, CA) with fluence 

at 70 J/cm 2 , RF at 100 J/cm 3 , double passes followed by fractional 

RF using Matrix RF at energy of 62 mJ/pin, at 4 week intervals. 

Serial standardized photographs were assessed by two 

independents observers. Subjective evaluation was also obtained. 

Results: Nineteen patients completed third treatment. There was 

significant improvement of acne scarring with mean score 

decreased from 7.5 to 5.9 out of 10 (P < 0.001) and 67% were rated 

at least moderate objective global improvement. There was also 

significant objective improvement of mean scores for skin texture, 

pore size and pigmentary irregularities (P < 0.001). 57.1% of 

subjects rated moderate to significant improvement and 81.9% 

were satisfied with the procedure. One case developed blisters 

near the jaw area and 7.5% developed transient postinflammatory 


Conclusion: Combining fractional laser and radiofrequency 

appears to be safe and effective for acne scars in Asians. 

#105 

THERMO-FRACTIONAL PDT FOR PERSISTENT 

WARTS 

Leonardo Marini 

Trieste, Italy 

Background: Previous studies demonstrated the clinical efficacy 

of PDT in recalcitrant warts. Both 2,940 nm Er:YAG and 10.600 

CO2 laser fractional ablation has shown to enhance the 

penetration of actives through the skin. The objective of this study 

was to investigate the safety and efficacy of a combined thermofractional 

PDT comparing two different laser wavelenghts (2,940 

and 10.600 nm) as fractional trans-stratum corneum penetration 

enhancers. 

Study: Fifty seven recalcitrant HPV lesions belonging to 20 

subjects (10 females and 10 males, Fitzpatrick 2–3, 12- to 37yeard 

old mean 21) were treated according to the thermofractional 

PDT technique. A full field 2,940 nm Er:YAG laser 

photovaporization was performed on all lesions to eliminate 

hypercheratosis (4 mm spot–300 microseconds–6 J/cm 2 –8Hz– 

Fotona Dynamis XS). Thermotherapy was subsequently 

performed with three sequential passes of a long pulse 1,064 nm 

Nd:YAG laser (3 mm spot, 35 milliseconds–50 J/cm 2 –scanner– 

Fotona Dynamis XS). Thirty-two lesions were treated with 

2,940 nm Er:YAG fractional laser as an active trans-stratum 

corneum penetration enhancer (0.250 mm spot, 8 J/cm 2 ,


0.175 milliseconds, 10% coverage—Fotona Dynamis XS) and 25 

lesions were treated with a CO 2 fractional laser (0.300 mm spot, 

14 W, 500–900 dwell depth—DEKA SmartXide Dot). Ten percent 

5-ALA liposome gel under polyurethane occlusion was applied on 

all lesion and left for 6 hours. 635 nm LED irradiation (Omnilux) 

was finally performed (4\ 0 –20\ 0 pause–14 m\ 0 ). Blind clinical 

evaluation at 7–30–60–90–180 days was performed. 

Results: Both lesion grouls required an average of 1.5 treatments 

to achieve complete eradication. Maximal post-op localized pain 

was reported 24–48 hours after the procedure. No scars and/or 

infections were observed. Two percent transitory PIH was 

observed (two Er:YAG and two CO 2 treated patients). No clinical 

recurrences were observed after 180 days. 

Conclusion: Thermo-fractional PDT appears to be a very 

promising combined technique to treat recalcitrant HPV 

infections. No significant differences were observed between 

Er:YAG and CO 2 fractional trans-stratum corneum penetration 

enhancement of 5-ALA liposome gel as far as clinical results are 

concerned. More studies are needed to optimize all different steps 

of this innovative treatment approach. 

#106 

308 NM EXCIMER LASER TREATMENT OF 

PALMOPLANTAR PSORIASIS 

David Goldberg, Nathalie Dietrich-Comte, 

Mussarrat Hussain 


Background: Palmoplantar psoriasis is difficult to treat and 

often recalcitrant to traditional therapies such as topical 

corticosteroids. Since the excimer laser can selectively treat 

psoriatic plaques with higher fluences than is tolerated with 

traditional phototherapy, it could be a therapeutic modality for 

the thicker skin on the palms and soles. We undertook a study to 

evaluate the safety and efficacy of the 308 nm excimer for the 

treatment of psoriasis involving the hands and feet. 

Study: A total of thirty male and female subjects between the 

ages of 18–75 years with mild to severe psoriasis involving the 

palms and soles were treated. All subjects discontinued all other 

treatments for 4 weeks prior to starting the study. Subjects 

received up to 16 laser treatments over the course of 3 months 

with a 308 nm excimer laser. Treatment parameters (400–600 mJ/ 

cm 2 ) were determined by the severity of disease. Treatments were 

performed biweekly. Clearance was evaluated by the PASI scale. 

Results: A mean number of 11 sessions (from 7 to 14) was 

provided to each subject. By the 5th treatment, all subjects 

showed improvement in the PASI score. At the end of treatments, 

all subjects showed improvement between 50% and 100% as 

evidenced by decreased scale, decreased erythema, and flattened 

plaques. No relapse was detected at 3-month post-treatment 

follow-up. Relapses were seen in 60% of subjects at 6 months after 

treatment. 

Conclusion: The 308 nm excimer laser is a treatment option for 

palmar–plantar psoriasis. 

#107 

STUDY OF EFFICACY AND TOLERABILITY 

MONOCHROMATIC EXCIMER LIGHT IN 

TREATMENT OF VITILIGO 

Niteen Dhepe, Tushar Kshirsagar, Ashok Naik, 

Vaishali Phadke 

Pune, India 

Background: To study the efficacy and the safety of the 

monochromatic excimer light (MEL) in the treatment of vitiligo. 

To make comparison in efficacy between the two treatment 

frequencies of monochromatic excimer light in treatment of 

vitiligo. To evaluate the safety of the once weekly and twice 

weekly regimens of the monochromatic excimer light in treatment 

of vitiligo. 

Study: Eighty-eight patches from 16 patients of bilateral 

symmetrical vitiligo were selected for the treatment with 

monochromatic excimer laser. Forty-four patches were treated, 

while 44 patches on the opposite side in the same patients were 

kept as controls. The patches were divided in two groups MEL 1 

group where the treatments were given once weekly and MEL 2 

group where treatments were given twice weekly. A total of 24 

sessions were delivered with dose elevations by 100 mJ/cm 2 every 

session. Assessment was done by visual analogue scores at the end 

of the treatments. Patient satisfaction scores were also noted. 

Results: MEL was found to be effective modality of the treatment 

as 61.36% of the patches achieved > 50% repigmentation in 24 

sessions. The repigmentation could be even more if the treatment 

in continued further. There was no difference found in average 

visual analogue scores in MEL 1 and MEL 2 groups. Patient 

satisfaction was; however, higher for the MEL 2 group than MEL 

1 group. Both twice weekly and once weekly regimens were well 

tolerated with no difference between them. 

Conclusion: Our study shows effectiveness of the monochromatic 

excimer light in the treatment of vitiligo and it can be considered a 

treatment option for the treatment. Also there was no difference 

found in the repigmentation achieved by once weekly or twice 

weekly regimens. 

#108 

USE OF COMBINATION LASERS FOR MORE 

EFFECTIVE HAIR REMOVAL 

Dina Yaghmai, Abnoeal Bakus, Jerome Garden 

Northwestern Hospital, Chicago, IL 

For many patients single laser approaches to hair removal have 

not been fully effective. Use of a given laser can result in the 

reduction of only hair shafts with a specific diameter or in the 

miniaturization of the hair shaft, resulting in the persistence of 

many hairs. The objective of this study was to evaluate the 

effectiveness of sequential treatments with two different lasers for 

more improved hair removal. Fifteen subjects with skin types I– 

V, pigmented fine and coarse caliber hair, underwent a series of 

laser treatments at monthly intervals. Each of the subjects were 

treated with either the combination of 810 nm diode and 1,064 nm 

Q-switched Nd:YAG or combination of the long pulsed 1,064 nm 

and the Q-switched Nd:YAG lasers. Sequential treatments with 

two lasers were done during the same treatments session. 

Subjects on average underwent 5–7 treatments with the use of 

the combination lasers. This resulted in an increase in hair 

reduction compared to previous methods. The treatments were 

well tolerated. Combination lasers are a more effective treatment 

option for laser hair removal, relative to the standard single laser 

treatment approach. 

#109 

CLINICAL EVALUATION OF A 800 NM 

LONG-PULSED DIODE LASER DEVICE WITH A 

LARGE SPOT SIZE AND VACUUM-ASSISTED 

SUCTION FOR HAIR REMOVAL 

Omar Ibrahimi, Suzanne Kilmer

UC Davis Medical Center, Sacramento, CA; Skin and Laser Center 

of Northern California, Sacramento, CA 

Background: The long-pulsed diode (800–810 nm) laser is one of 

the most commonly used and effective lasers for hair removal. 

Limitations of currently available devices include a small 

treatment spot size, treatment-associated pain and the need for 

skin cooling. Here, we evaluate the hair reduction capabilities of a 

long-pulsed diode laser with a large spot size and vacuum assisted 

suction. 

Study: A prospective, self-controlled, single center study of 

axillary hair removal consisting of 35 subjects. The study 

consisted of three treatments using a long-pulsed diode laser with 

a large spot size and vacuum assisted suction at 4- to 6-week 

intervals, followed by a single follow-up visit 6 months after the 

last treatment. Hair reduction was quantified using macro hair 

count photographs taken at baseline, prior to each treatment and 

at the 6-month follow-up visit. The level of treatment-associated 

pain, treatment time and adverse events were additional study 

endpoints. 

Results: There was statistically significant hair reduction 

at 6-month follow-up for 33/35 patients. Ninety-one percent of 

subjects demonstrating hair reduction had hair clearance 

greater than 25%. Seventy percent of these subjects showed 

clearance that is equal to or greater than 50% and nine percent 

showed 75–100% clearance. The majority of subjects 

reported feeling up to moderate pain during treatment without 

the use of pre-treatment anesthesia or skin cooling. There was 

one adverse event in the study unrelated to the treatment 

protocol. 

Conclusion: A long-pulsed diode laser device with a large spot 

size and vacuum-assisted suction is safe and effective for the 

removal of unwanted hair. Compared to other commercially 

available long-pulsed diode devices, treatments are faster to 

perform and less likely to be painful. 

#110 


SAFETY AND EFFICACY OF A HAND-HELD DIODE 

LASER FOR UPPER LIP HAIR REMOVAL 

Brian Biesman, Whitney Morris 

Nashville Centre for Laser and Facial Surgery, Nashville, TN 

Background: To evaluate the safety and efficacy of high powered 

lasers for permanent hair reduction is well recognized. Hand-held 

diode lasers are known to be safe and effective at achieving 

permanent hair reduction in certain anatomic region but not in 

the upper lip. The goal of this study was to establish the safety and 

efficacy of a hand-held diode laser for permanent hair reduction on 

the upper lip. 

Study: Fifty women (Fitzpatrick skin type II–IV) with unwanted 

hair in the upper lip area underwent eight self-treatments at 3week 

intervals using a hand-held, battery powered diode laser 

(810 nm). The energy density for treatment ranged from 7 to 20 J/ 

cm 2 as chosen by the subject based on comfort. Subjects were 

followed for 12 months after last treatment. Hair counts and 

digital photographic analysis of the width and color of the hair 

were performed at baseline, 1 month and 12 months after last 

treatment. 

Results: Of 50 subjects enrolled, 43 attended the 1-month followup 

visit and 38 completed the 12-month follow-up visit. 

Treatments were tolerated well; the only side effect was transient 

erythema. Reduction in dark terminal hair was statistically 

significant compared to baseline and was > 50% at 1-month 

follow-up and > 30% at 12-month follow-up. A significant 

percentage of hairs present 12 months after the final treatment 

were thinner and lighter than those present at baseline. 

Conclusion: Self-treatment with the diode laser has a good safety 

profile and is an effective method for permanent hair reduction in 

women with dark terminal hair in the upper lip. 

#111 

BILATERAL AXILLA HAIR REMOVAL 

COMPARING A SINGLE WAVELENGTH 

ALEXANDRITE LASER WITH COMBINED 

MULTIPLEXED ALEXANDRITE AND ND:YAG 

LASER TREATMENT FROM A SINGLE LASER 

PLATFORM 

Eric Bernstein 

University of Pennsylvania, Ardmore, PA 

Background: The 1,064 nm Nd:YAG has been shown to be 

effective in removing dark hair in darker skin types but can less 

effective at treating fine or lighter hair. The 755 nm alexandrite 

wavelength has been shown to be clinically effective for almost all 

hair types but is safest for lighter skin types. These two treatment 

modalities were compared for effectiveness and safety in a 

bilateral comparison of axillary hair removal. 

Study: Twenty-two Caucasian females with Fitzpatrick skin 

types II–V were enrolled in this IRB-approved study. Subjects 

underwent four treatments at 4- to 6-week intervals. One axilla 

was treated with the alexandrite laser, while the other received 

treatment with multiplexed Nd:YAG/alexandrite laser. A 

mathematical model was used to estimate the necessary energy 

needed for equivalent follicle heating between the two treatment 

modalities. A 15 mm spot size was used delivering fluences up to 

32 J/cm 2 . Digital photographs were taken by canfield Scientific 

following the 3rd treatment visit, as well as 2 months and 6 

months following the final treatment. 

Results: Clearance rates as measured by blinded hair counts 

averaged 67–74% 4 weeks following the second treatment, 67– 

77% at 2 months following the four treatment, and 78–85% at 6 

months after the 4th treatment. 

Conclusion: Both the alexandrite laser and the multiplexed 

alexandrite/Nd:YAG laser modes were safe and effective for the 

removal of unwanted axilla hair. The multiplexed mode achieved 

equivalent clearance to the alexandrite single wavelength mode. 

#112 

A SPLIT AXILLA COMPARISON STUDY OF 

AXILLARY HAIR REMOVAL WITH LOW FLUENCE 

HIGH REPETITION RATE 810 NM DIODE LASER 

VERSUS HIGH FLUENCE LOW REPETITION RATE 

1,064 NM ND:YAG LASER 

Rungsima Wanitphakdeedecha, 

Kanchalit Thanomkitti, Sasima Eimpunth, 

Woraphong Manuskiatti 

Siriraj Hospital, Bangkok, Thailand 

Background: Laser hair removal has emerged as the gold 

standard to remove unwanted hair; however, it is associated with 

pain and side effects, especially when treating patients with 

darker skin tone. A novel low fluence high repetition rate 810 nm 

diode laser using multiple passes in constant motion technique 

has been recently introduced as the other option of hair removal 

with less discomfort and fewer side effects when compared to 

traditional laser hair removal. The objectives of this study were to


quantitatively assess hair reduction and side effects after using 

low fluence high repetition rate 810 nm diode laser versus high 

fluence low repetition rate 1,064 nm Nd:Yag laser and to 

determine efficacy at 1- and 6-month follow-up after treatment. 

Study: This is a prospective single-center, bilaterally paired-, 

blinded-, randomized-comparison study. Fifty female volunteers 

were recruited to the study. The volunteers were randomly 

treated with low fluence high repetition rate 810 nm diode laser on 

one side of their axilla and high fluence low repetition rate 

1,064 nm Nd:YAG laser on the other side of their axilla. They 

received five treatments at 4 weeks interval. Axillary hair count 

and patient satisfaction rating were measured at baseline, 1-, and 

6-month follow-up after complete treatment protocol. Treatment 

time of each laser and pain score were also rated at 1st treatment. 

Results: Until now, the study has not yet been completed. All 

subjects received five treatments and attended 1-month follow-up 

visit. Forty-one of the 51 subjects continued with the study 

protocol. Percentage of axillary hair reduction at 1-month followup 

visit after receiving 810 nm diode and 1,064 nm Nd:YAG laser 

treatment were 71.0 21.1%, and 82.3 18.0%, respectively. 

There was a significant difference in hair reduction and pain score 

between both laser treatment (P ¼ 0.003, and P < 0.001, 

respectively). However, there was no statistically significance 

difference in patient satisfaction rating and treatment time 

(P ¼ 0.12 and P ¼ 0.09). Side effects were mild and limited to 

transient erythema and swelling. The final results will be 

presented in the meeting. 

Conclusion: Both low fluence high repetition rate 810 nm diode 

laser and high fluence low repetition rate 1,064 nm Nd:YAG laser 

are safe and effective procedures for hair removal. High fluence 

low repetition rate 1,064 nm Nd:YAG laser is superior in hair 

reduction. However, low fluence high repetition rate 810 nm diode 

laser is less painful. And long-term follow-up is needed. 

INTERNATIONAL 

EXPERIENCE IN LASERS 

IN DERMATOLOGY 

#113 

GUIDELINES ON THE SAFETY OF LIGHT-BASED 

HOME-USE DEVICES FROM THE EUROPEAN 

SOCIETY FOR LASER DERMATOLOGY 

Godfrey Town, Caerwyn Ash, Christine Dierickx, 

Merete Haedersdal, Klaus Fritz 

University of Wales, Global Academy, Swansea Metropolitan 

University, Swansea, United Kingdom; University Hospital 

Ghent, Ghent, Belgium; Massachusetts General Hospital, Boston, 

MA, Copenhagen, Denmark; European Society of Laser 

Dermatology, Landau, Germany 

Background: In the past 2 years since their first introduction, 

there has been a rapid proliferation of light-based hair removal 

and wrinkle treatment devices intended for home-use. In Europe, 

sales already run into several tens of thousands of units with 

multi-national companies such as Phillips, Remington and 

Alliance Boots entering the market. This review is intended to 

inform healthcare professionals about home-use light-based 

technology and influence manufacturers wishing to sell in Europe 

to adopt ‘best practice’. The study considers the risks to the eyes 

and skin from optical radiation both to the consumer and persons 

in the vicinity of the user. 

Study: The review draws upon a preliminary study by two of the 

authors investigating the technical performance of a range of 

professional and home-use devices tested with particular focus 

on recognized critical parameters for the safe and effective 

use of light-based technology in hair removal and wrinkle 

treatment. 

Conclusion: There is an urgent need for regulation of intense 

pulsed light and LED devices as well as lasers, which will include 

manufacturing standards for both professional and home-use 

devices intended for hair removal, treatment of alopecia, wrinkle 

treatment, skin tone and texture, etc. 

#114 

INVESTIGATION AND DEVELOPMENT OF A 

MEASUREMENT TECHNIQUE FOR THE SPATIAL 

ENERGY DISTRIBUTION OF HOME-USE INTENSE 

PULSED LIGHT SYSTEMS 

Gareth Thomas, Caerwyn Ash, 

Richard Hugtenburg, Michael Kiernan 

Godfrey Town, Swansea University; University of Wales, 

Global Academy, Swansea, United Kingdom 

Background: The current annual global market for domestic 

intense pulse light (IPL) hair removal has been estimated at US 

$1 billion and continues to grow. It is widely recognised that there 

are five key technological parameters to consider in cutaneous 

photo therapy, namely wavelength, energy density, pulse 

duration, spot size and spatial distribution. Uneven energy 

distribution in the treatment area can result in over or under 

treatment of the treated area, thus causing dissatisfaction to the 

patient. 

Study: This study investigates a method in measuring and 

analysing spatial distributions of five commercially available 

home-use IPL systems as there is no quantitative method to 

conduct and compare spatial profiles. Using a CCD camera and a 

phosphorescent screen to extend the pulse duration, averaged 

time frames were analysed in Matlab software where dark 

reference frames were taken to minimise noise. Normalised for 

energy, 3-D graphical images of the data are presented to show 

the spatial profile of five commercially available IPL systems. 

Numerical analysis of the data was completed by two methods, 

arithmetical mean roughness (Ra) and path difference (Pd) at 80% 

and 13.5% of maximum value. 

Results: One system has both the lowest Ra value on the 80% 

border and the lowest Ra value on the 13.5% border. Two systems 

have obviously poor distribution of spatial energy. Such numerical 

analysis provides valuable information on treatment performance 

previously unseen. 

Conclusion: This study recorded two systems with clear uneven 

distribution of energy across the treatment area. This could result 

in over and/or under treatment at the claimed energy density that 

might produce blistering, hyper pigmentation or 

hypopigmentation in areas of increased fluence and paradoxical 

hair growth or limited effectiveness in areas of reduced fluence. 

Such clear unevenness in spatial distribution requires the 

consumer to overlap treatment thus increasing treatment time 

and user dissatisfaction.

#115 

OPTIMUM CHOICE OF IRRADIATION 

WAVELENGTH FOR SKIN COLOR 

DETERMINATION USING SKIN REFLECTANCE 

MEASUREMENTS 

Caerwyn Ash, Stuart Jones, Godfrey Town, 

Marc Clement, Peter Bjerring, Michael Kiernan 

Swansea University; CyDen, Ltd; University of Wales, 

Global Academy, Swansea, United Kingdom; Molholm Hospital, 

Vejle, Denmark 

Background: The need for objective, non-invasive methods to 

measure melanin concentration in vivo in human skin, 

independent of the competing chromophore, haemoglobin is much 

needed in the field of skin colour determination. The classification 

of skin types is based on human skin reaction to ultraviolet 

exposure and used to help predict skin response in laser/IPL 

treatments. There is an ever increasing need to quantify skin 

colour for beauty treatments, and home use IPL/laser systems are 

increasingly practiced by non-medically trained personnel who 

may lack the requisite skills necessary to predict accurately, safe 

treatment parameters. To evaluate the optimum wavelength 

choice to categorize skin tones into one of the six Fitzpatrick 

groups to optimise safety in light-based skin treatments. 

Study: A calibrated prototype device consisting of an optical head 

with four wavelengths (460, 522, 594, 617 nm), broadband 

detector, microprocessor and an LCD display was used alongside a 

commercial RGB colorimeter on the inner arm of nine subjects, 

which typically has little UV exposure and minimal hair. To 

establish the effect of haemoglobin on skin colour two addition 

tests show the effect of oxy and deoxyhaemoglobin using induced 

reduced haemoglobin and controlled erythema, were made on two 

subjects. 

Results: Four hundred and sixty nanometer has a clear linear 

relationship with skin colour when comparing against other 

wavelengths in standard, under reduced haemoglobin, and 

erythema conditions for a range of skin colours. At this 

wavelength absorption of melanin dominates other chromophores 

when comparing skin colour. Five hundred and twenty-two, 694, 

and 617 nm wavelengths showed variation practically on light 

skin tone subjects. 

Conclusion: Through accurate detection of skin melanin, a novel 

device using 460 nm may significantly decrease the risk of side 

effects by overtreatment and extend treatment to wider patient 

populations with light based dermatological procedures. 

#116 


CONCOMITANT USE OF LASER AND 

ISOTRETINOIN, HOW SAFE? 

Ahmed Alissa 

National Center for Vitiligo and Psoriasis, Riyadh, Saudi Arabia 

Background: Isotretinoin-induced keloid formation has 

occasionally been reported in patients who had undergone 

dermabrasion or laser treatment. According to a safe 

dermatologist practice, laser should be used during or within 6–8 

months after Isotretinoin; however, few recent reports suggest 

using isotretinoin and laser hair removal is a safe practice. It is 

well known in laser hair removal that there is no real significant 

epidermal damage. 

Study: This paper present 100 patients who underwent to laser 

hair removal, erbium laser, vascular laser, Q-switched 

alexandrite and Q-switched 532 nm double frequency, Q-switched 

1,064 Nd-YAG, and non-ablative fractional laser. All of them have 

received isotretinoin therapy, during their laser treatment 

sessions. 

Results: We have up to 7 years follow-up (for some patients) none 

of our patients develop hypertrophic scar or keloid. Also all the 

previous reported cases in the literature will be reviewed and 

summarized. 

#117 

A PROSPECTIVE PILOT STUDY OF THE 

ALEXANDRITE LASER ON BASAL CELL 

CARCINOMAS 

Daniel I. Wasserman, Zeina Tannous, 

Gary D. Monheit 

Total Skin & Beauty Dermatology Center, Birmingham, AL; 


Background: Basal cell carcinomas (BCC) are the most common 

form of human cancer. Treatments include Mohs micrographic 

surgery, excision, electrodessication and curettage, cryosurgery, 

topical immunomodulators, photodynamic therapy, and 

radiotherapy. The pulsed-dye laser (PDL) (595 nm) has 

demonstrated considerable efficacy for superficial BCCs, however, 

is limited by an approximate penetration of 2 mm. Based on the 

3 mm penetration and a small peak of hemoglobin absorption in 

the near infrared range, we investigated whether superficial and 

nodular basal cell carcinomas can be successfully treated using a 

755 nm alexandrite laser. The goal of this pilot study is to 

determine whether superficial and nodular BCCs can be 

successfully treated using the alexandrite laser. 

Study: Thirteen tumors, in nine subjects, less than 2 cm located 

on the trunk or extremities were enrolled in this study. Each 

tumor was treated with the 755 nm alexandrite laser either once 

(N ¼ 10) or four times (N ¼ 3) at 4-week intervals. Four weeks 

following the final treatment, all tumors were excised and 

reviewed histologically. Additionally, pain, purpura, edema, and 

blistering following treatments were measured during the study. 

Photos were taken throughout the study. 

Results: All 3 tumors treated in the 4-treatment arm completely 

resolved, while 4 out of 10 tumors in the single treatment arm 

completely resolved. All patients experienced significant purpura 

and edema with some experiencing mild blistering. Scarring was 

found in only one patient, while hypopigmentation was frequently 

present on follow-up visits. 

Conclusion: The 755 nm long-pulsed alexandrite laser appears to 

produce considerable efficacy when tumors are treated four times. 

Meanwhile, single treatments of tumors produced complete 

clearance in less than half of the tumors suggesting that the longpulsed 

alexandrite may be a suitable non-surgical option for the 

treatment of BCCs. Additional studies are needed in order to 

determine ideal treatment settings and number of treatments 

required for reliable rates of complete clearance. 

#118 

PROPOSING CONCEPT OF SELECTIVE 

PHOTOTHERMOCOAGULATION AND VARIOUS 

DERMATOLOGIC INDICATIONS BY USING 

1,444 NM ND:YAG LASER 

Kyung Goo Lee, Sang Geun Lee, Sang Min Yi, 

Jae Hwan Kim, Jae Eun Choi, Il-Hwan Kim 

Korea University Hospital, An-San Si, Korea


Background: Dermatologic laser treatment is based on selective 

photothermolysis (SP) which specifically targets chromophore of 

each disease. The concept of SP became possible after the pulsed 

irradiation of laser was technically available. However, SP theory 

has certain limitations that treatment efficacy significantly 

decreases when lesion’s chromophore is not clear or the leisons’s 

size is too big. 

Study: 1,444 nm Nd:YAG laser (Acculculpt TM , Lutronic, Korea) is 

relatively specific for fat and water and primarily indicated for 

liposuction, lipo-plasty and facial lifting. Authors experienced 

that this laser has great effect on coagulation of target ‘‘structure’’ 

such as blood vessel and water rich organelles. And also this 

infrared laser has greater lateral heat diffusion capacity than 

conventional CO2 and Erbium YAG laser which enables to stack 

more heat energy to dermal portion of skin. As this laser is pulsed 

laser, to control amount of energy stacking is also easily possible. 

These findings led us to propose a new concept named ‘‘selective 

photothermal-coagulation (SPTC),’’ which supplements the 

limitations of SP theory mentioned above. 

Results: Using this new concept, authors applied this 1,444 nm 

Nd:YAG laser for treatment of various diseases such as 

angiokeratoma, venous malformation, pyogenic granuloma, 

mucocele, neurofibroma and xanthelasma. Certain and 

satisfactory treatment results were observed at above cases 

without recurrence for over at least 6 months. 

Conclusion: This SPTC, using 1,444 nm Nd:YAG laser have few 

advantages. First, unlike CO 2 laser, bleeding is simultaneously 

coagulated while laser irradiation which make physician able to 

precisely visualize procedure field. Second, as this beam 

irradiation can be done by external handpiece, it is much simpler 

than surgical procedure and easily repeatable even if the lesions 

recur. Herein, authors propose a new concept of SPTC using 

1,444 nm Nd:YAG laser, and report our experiment of various 

possible indications using SPTC theory. 

#119 

ERBIUM LASER DERMABRASION FOR TREATING 

VITILIGO: A COMBINATION APPROACH 

Thierry Passeron, Wedd Bayoumi, Florence Le Duff, 

Laura Sillard, Jean-Philippe Lacour, 

Jean-Paul Ortonne 

University Hospital of Nice, Nice, France 

Background: No treatment gives fully satisfactory results for 

treating vitiligo, especially on difficult areas such as bony 

prominences and extremities. The objective of the study was to 

evaluate in vitiligo patients, the interest of a laser dermabrasion 

in addition to the association of topical steroids and UVB in 

difficult to treat areas. 

Study: Monocentric prospective randomized trial with intraindividual 

comparison. Inclusion criteria: non-segmental vitiligo 

with at least two symmetrical lesions of more than 4 cm 2 , located 

on bony prominences and/or extremities. Intervention: Day 0: 

Erbium laser dermabrasion on one side (randomly assigned). 

After 48 h, hydrocortisone 17-butyrate cream was applied daily 3 

weeks/4 for 12 weeks, on both sides and associated with 

narrowband UVB 2 sessions/weeks for 12 weeks. A blinded 

evaluation was done by two independent physicians on 

standardized pictures. The criterion of success was a 

repigmentation of at least 50% at 1 month after the end of the 

treatment. 

Results: Eighteen patients were included; two drop off for 

personal reasons. A significant higher repigmentation was noted 

in laser dermabrasion side as compared to UVB and topical 

steroids alone (P < 10 4 ). Almost 50% of lesions achieved at least 

50% of repigmentation in difficult to treat areas while only 4.2% 

did with topical steroids and UVB alone. No repigmentation 

> 50% was achieved in the extremities of the fingers. A high rate 

of side effects was noted with delayed healing, pain, and two 

hypertrophic scars. The tolerance and satisfaction of the patients 

were 4.2 and 4/10 in laser side and 8.4 and 3/10 in UVB and 

steroids alone group, respectively. 

Conclusion: The laser dermabrasion improves the 

repigmentation rate in vitiligo patients. Despite the high rate of 

repigmentation in such difficult areas the global satisfaction was 

moderate to low. The actual side effects strongly limit its use in 

current practice. However, studying the mechanism of action of 

the laser dermabrasion for inducing pigmentation should provide 

interesting clues for treating vitiligo. 

#120 

STUDY ABOUT EFFICACY AND SAFETY IN LASER 

ASSISTED SWEAT GLAND REDUCTION FOR 

AXILLARY HYPERHIDROSIS (LASR-H) 



Background: Axillary Hyperhidrosis is still a challenge, when it 

comes to the treatment options. Btx is efficient, but most patients 

wish for a permanent solution and are therefore ready to undergo 

surgery, it was efficient. 

Study: Three hundred seventy-five patients were treated by 

Laser Assisted Sweat Gland Reduction for Hyperhidrosis (LASR- 

H) in tumescent local anesthesia, using a special technique. 

Histologies of the aspirate and the tissue some months after the 

treatment were taken. In a retrospective, quantitative study, 

patients were screened up to 18 months retrospectively about 

success by this treatment. In a prospective, qualitative study, a 

group of 20 patients had weight measurements before, 6 months 

and 1 year after surgery. 

Results: Out of 375 patients, less than 10% still had some 

residual sweating after the first surgery. After a touch up 

procedure, this number went down to 1%. The studies also 

showed, that in 90% of the patients the reduction of axillary sweat 

was > 85% and it stayed like this 18 months after the surgery. 

Complications were temporary in most cases, there was visible 

necrosis in two patients. 

Conclusion: Laser Assisted Sweat Gland Reduction LASR-H 

using a certain technique is efficient and reliable and safe. 

#121 

TREATMENT OF SEVERE OR REFRACTORY ACNE 

WITH NON-ABLATIVE 1,450 NM DIODE LASER 

Thierry Passeron, Rosalind Hughes, 

Katerina Tsilika, Jean-Paul Ortonne, 

Jean-Philippe Lacour 


Background: Several laser treatments have been reported for 

acne but most of them studied only mild or moderate acne 

patients. The objective of the study was to evaluate the long-term 

efficacy and the tolerance of the non-ablative 1,450 nm diode laser 

alone or combined with pulse dye laser (PDL) in treating severe or 

refractory acne. 

Study: Prospective randomized trial. Inclusion criteria: patients 

with severe acne or moderate acne who resisted to topical

treatment associated with oral antibiotics. Intervention: V0: PDL 

(Vbeam, Candela 1 ) treatment on one hemi face (randomly 

assigned) (10 mm, 10 milliseconds, 10 J/cm 2 , DCD 30/30). V1: 2 

weeks after the first PDL session 1,450 nm diode laser 

(Smoothbeam, candela 1 ) was done on the entire face (6 mm, 14 J/ 

cm 2 , DCD 40). Three sessions of diode laser were performed (one 

per month). A blinded evaluation on standardized pictures was 

done by an independent physician at each session and at 1, 6 and 

12 months follow-up. The main criterion of evaluation was the 

count of acne lesions. Pain and satisfaction of the patients were 

evaluated on a visual analogical scale. 

Results: Twenty patients were included. Four were lost in followup. 

The mean count of lesions were 75 before treatment, and 40, 

29 and 23 at 1, 6 and 12 months follow-up, respectively (P < .001). 

The mean pain during treatment was 6.9/10 and the satisfaction 

was 6.6/10. No significant difference was observed in term of 

efficacy and pain when diode and diode þ PDL laser treated sides 

were compared. Side effects were limited to three postinflammatory 

hyperpigmentation, all in phototype IV patients. 

Conclusion: The non-ablative 1,450 nm diode laser is effective in 

treating severe or refractory acne with an improvement 

remaining for at least 12 months. Adding a PDL session before 

diode treatment is not useful. Pain during treatment and postinflammatory 

hyperpigmentation are the two main limitations of 

this approach. 

#122 

FRACTIONAL ER:YAG LASER FOR ACNE SCARS 

IN SKIN OF COLOR 

Mukta Sachdev, Sunaina Hameed 

Manipal Hospital; MS Skin Clinic, Bangalore, India 

Background: Fractional photothermolysis is a new technique for 

the treatment of acne scars, in which an array of microscopic 

treatment zones (MTZ) is induced into the skin to stimulate a 

therapeutic response deep in the dermis. Fractional ablative 

lasers are more effective than non-ablative lasers, and safer than 

ablative resurfacing lasers, especially in Indian skin. 

Objective: To present a pilot study on the safety and efficacy of 

fractional ablative Erbium:YAG laser in the treatment of acne 

scars. The ECCA grading system for acne scars has been 

employed, in order to achieve a more standardized assessment of 

treatment efficacy. 

Study: Thirty subjects in age group varying from 22 to 45 (mean 

28.05), received 4–6 treatment sessions (mean 2.93) with 

fractional ablative Er:YAG laser, for the correction of their acne 

scars. Pre-treatment and end of treatment ECCA scores were 

graded using photographic analysis. Subjects were also asked to 

assess their own progress based on their before and after 

photographs. 

Results: All subjects showed an improvement in their ECCA 

scores. The mean score after treatment significantly reduced from 

183.75 to 134.25 with P < 0.001. 

Conclusion: Fractional ablative Erbium:YAG laser is a safe, 

effective and promising new modality for the treatment of acne 

scars in skin of colour. 

#123 


THE CLINICAL EFFICACY AND STATISTICAL 

EVALUATION OF 150 ACNE SCARS BY 

INSULATED MICRO-NEEDLING FRACTIONAL RF 

TECHNOLOGY 

Takashi Takahashi 

Shibuya-ku, Japan 

Background: We stared the treatment for acne scars and skin 

tightening for Asian patients with RF technology called as 

‘‘Insulated Micro-needling Fractional RF technology’’ since May of 

2009 in Japan. We will report about the clinical evaluation of 150 

acne scar patients. 

Study: We evaluated by the photograph of baseline, 1 week after 

and 4 weeks after the treatment and the questionnaire from the 

patients. Some patients could be also evaluated their 3D structure 

using the silicon replica method. 

Results: One hundred forty out of the total of 150 patients were 

satisfied or very much satisfied. Ten patients complained no 

change. However, in fact, 6 out of those unsatisfied 10 have shown 

adefinite change by photograph. No skin burn or PIH happened in 

this study. 

Conclusion: As the Insulated Micro-needling Fractional RF 

technology can heat the target selectively and does not affect any 

thermal damage to the surface of the skin, the downtime is 

minimized comparing with the fractional laser system. And it will 

be helpful for many indications with its selectivity of the depth 

and the strength of the RF. 

#124 

LONG-TERM RESULTS OF AXILLARY HAIR 

REMOVAL WITH A CONTINUOUSLY SCANNED 

DIODE LASER AND A SPOT-TO-SPOT SCANNED 

ALEXANDRITE LASER (EPICON-STUDY) 

Uwe Paasch, Sonja Grunewald, 

Marc Oliver Bodendorf, Alexander Zygouris, 

Jan Christoph Simon 

University of Leipzig, Leipzig, Germany 

Background: With an increasing request for permanent removal 

of unwanted hair, new devices are generated in order to increase 

quality and efficacy of laser epilation. A newly developed 

continuously scanned 808 nm diode laser (Leda, Quantel Derma, 

Germany) allows very fast treatments due to the unique 

application of the laser beam. The EpiCon-Study compared a spotby-spot 

scanned alexandrite laser (‘‘Arion’’, 755 nm, Quantel 

Derma, Germany) with the continuously scanned diode laser for 

axillary epilation (right vs. left axilla) in 31 patients (28 female, 3 

male). After six laser treatments with 4–6 weeks intervals a 

significant hair reduction was found in both axillae. The linear 

scanned diode laser was significantly faster ( 20% of the time 

consumption of the alexandrite laser), but more painful. Until now 

no long-term results were available. In order to compare the longterm 

effects of a newly developed continuously scanned diode 

laser (808 nm) and a spot-to-spot scanned alexandrite laser 

(755 nm), we present now the data of the 18-month follow-up visit 

of the EpiCon-Study. 

Study: A total of 10 out of the 31 patients that completed the 

EpiCon-Study were available 18 months after the last laser 

treatment. In concordance with the evaluation during the study, 

again lens-enlarged photographs of the treated areas were taken 

with a dermoscope (Trichoscan 1 , Foto Finder Systems GmbH, 

Germany) and hair reduction was documented. In addition, 

patients filled in a questionnaire regarding convenience and 

efficacy of both laser systems. 

Results: Eighteen months after the last laser epilation both 

axillae showed still a comparable, significant hair reduction. 

Compared to the pre-treatment visit of the 10 available patients 

the mean axillary hair count was reduced down to 25.9%


(continuously scanned 808 nm diode laser, P < 0.01) and 25.3% 

(spot-by-spot scanned alexandrite, P < 0.01). There was no 

significant difference in both axillae to the hair reduction achieved 

at the last treatment visit 18 months before. All patients were 

satisfied with the results, no permanent side effects were 

observed. 

Conclusion: The continuously scanned diode laser system shows 

comparable results to a spot-to-spot scanned alexandrite laser 

when removing unwanted axillary hair. Both lasers removed 

about 75% of the axillary hairs, this epilation effect is now proven 

to last for at least 18 months. 

#125 

INCREASED FORMATION OF FIBROSIS AFTER 

TREATMENT WITH ABLATIVE VERSUS NON- 

ABLATIVE FRACTIONAL LASER THERAPY 

Bas S. Wind, Arne A. Meesters, Marije W. Kroon, 

Johan F. Beek, J.P. Wietze Van der Veen, 

Allard C. Van der Wal, Jan D. Bos, 

Albert Wolkerstorfer 

Netherlands Institute for Pigment Disorders (SNIP), 

Academic Medical Center, University of Amsterdam, Amsterdam, 

The Netherlands 

Background: Fractional laser therapy (FLT) has become a 

widely accepted modality for skin rejuvenation, but has also been 

used in various skin disorders. Aim of this study was to compare 

long-term histological effects of non-ablative and ablative FLT in 

the treatment of pigment disorders. 

Study: A randomized controlled observer-blinded study was 

performed in a total of 18 patients with pigment disorders. In each 

patient, two similar test regions were randomized to receive either 

FLT in combination with intermittent topical bleaching (to 

prevent laser-induced postinflammatory hyperpigmentation) or 

topical bleaching alone (to allow comparison of the regions). 

Patients with ashy dermatosis and postinflammatory 

hyperpigmentation were treated with non-ablative 1,550 nm FLT 

(15 mJ/microbeam, 14–20% coverage), whereas patients with 

Becker’s nevus were treated with ablative 10,600 nm FLT (10 mJ/ 

microbeam, 35–45% coverage), for a total of four to five sessions. 

Biopsies were obtained three months after the last laser 

treatment, and analyzed by a blinded dermatopathologist using 

hematoxylin and eosin stain. 

Results: At follow-up, dermal fibrosis was observed in four 

patients treated with ablative FLT. No fibrosis was observed in 

patients treated with non-ablative FLT. Comparing both laser 

modalities, development of fibrosis was seen significantly more 

often in patients treated with ablative FLT (P < .05). 

Conclusion: At the used settings, ablative fractional laser 

therapy induces formation of fibrosis, whereas treatment with 

non-ablative fractional laser therapy does not. Whether formation 

of fibrosis has to be regarded as dermal remodeling or a subtle 

subclinical form of scarring should be investigated in future 

research. 

#126 

FRACTIONAL RADIOFREQUENCY FOLLOWED BY 

HYDROQUINONE FOR TREATMENT OF 

MELASMA 

Shlomit Halachmi, Moshe Lapidoth 

Rabin Medical Center, Petach, Tikva, Israel 

Background: Melasma has been classically treated with topical 

hydroquinone (HQ), but poor absorption remains a barrier to 

effective treatment. The use of fractional lasers, both ablative 

and non-ablative, has gained popularity in recent years. 

However, the use of fractional lasers does not allow a durable 

effect, in contrast to continuous application of HQ. Furthermore, 

fractional therapies are accompanied by a risk of 

hyperpigmentation. The use of a fractional energy in 

combination with topical HQ should improve the therapeutic 

index of either alone: the fractional ablative treatment will 

offer a short-term benefit in melasma, which also creating 

temporary channels for increased HQ absorption. Conversely, 

the HQ should reduce the risk of post-treatment 


Study: Eight patients with Fitzpatrick III–IV skin underwent a 

single treatment with fractional radiofrequency in an open-label 

pilot study. Immediately after treatment all patients began daily 

application of 2% hydroquinone. Results were monitored after 1, 

3, and 6 months. 

Results: All patients tolerated the procedure well. No adverse 

events were reported. Notable improvements in melasma were 

appreciable at 1 month. Durable improvement was seen in all 

patients at 3 and 6 months. 

Conclusion: The combination of fractional radiofrequency and 

topical hydroquinone provides a well-tolerated and beneficial 

approach to the treatment of melasma. 

#130 

A PILOT STUDY OF PULSED MAGNETIC 

THERAPY IN BODY CONTOURING 

Shlomit Halachmi, Maurice Adatto, 

Moshe Lapidoth 

Rabin Medical Center, Petach, Tikva, Israel; SkinPulse, Geneva, 


Background: Pulsed magnetic field (PMF) therapy has been 

used in orthopedics and physiotherapy for over 30 years. Based on 

its demonstrated effects on angiogenesis and fibroblast 

stimulation, it is at times applied to treatment of chronic wounds 

and post-operative healing. However, its use in dermal 

stimulation for aesthetic indications has not previously been 

assessed. 

Study: Twenty-five patients with moderate skin laxity of the 

abdomen or with moderate cellulite underwent a series of six to 

eight treatments of pulsed magnetic therapy with deep dermal 

heating, in a pilot, open-label, multi-center study. All patients 

signed informed consent. Magnetic pulses were administered at 

15 Hz, 15 Gauss over a multipolar 1 MHz 5.5 cm RF handpiece. 

Patients were assessed by photography, circumference 

measurements, and overall improvement at 1, 3, and 6 months 

after the completion of treatment. Analyses were made by three 

independent observers. 

Results: All patients completed the treatments. Patient 

satisfaction was universally good. Photographic assessments and 

overall improvement rating revealed notable improvements in 

skin laxity and cellulite. A trend toward circumference reduction 

was noted. No adverse events were reported. 

Conclusion: Pulsed magnetic field therapy is an untapped 

energy-based approach with demonstrated safety and 

applicability to aesthetics in general and body contouring in 

particular. Additional studies are required to determine optimal 

treatment protocols.

#131 

RADIAL ACOUSTIC WAVES FOR THE 

TREATMENT OF CELLULITE: A DOUBLE 

BLINDED RANDOMIZED PROSPECTIVE STUDY 

VERUM VERSUS PLACEBO 

Katharina Russe-Wilflingseder, Elisabeth Russe 


Background: Acoustic wave treatment is a new approach to 

improve the appearance of cellulite. Pulses are penetrating into 

the tissue leading to stimulation of tissue metabolism and blood 

circulation, inducing a natural repair process with cell activation 

and stem cells proliferation. It is related to extracorporeal shock 

wave treatment, which showed evidence of collagen remodeling 

within the dermis and of stimulating microcirculation in fatty 

tissue and is concluded to have a fibrosclerosis-preventing effect. 

In our previous controlled clinical study we could show the clinical 

efficacy of acoustic waves for treating cellulite. 

Study: Double blinded randomized prospective study was 

performed to assess the efficacy of AWT by combining superficial 

and deeper penetrating radial waves within one treatment 

session. Fifteen females included: 11 verum, 4 placebo; BMI 22.7 

SD 1.7; age 42.5 SD 7.6; 8 treatments with D-Actor 200; 10.500 

pulses (1/3 deep, 2/3 superficial AW) applied per side (upper-leg 

and buttock) using maximal tolerated pressure (DI 1.4–3 bar, 

D20S 3–5 bar) at 12 Hz. Documentation and evaluation was done 

before, 1 week after 7 treatment and at week 4 and 12 after last 

treatment with 3D imaging system, patient’s questionnaire, 

weight control, measurement of circumference of upper leg and 

standardized photography. 

Results: Comparing verum versus placebo results were 

significant different at baseline and 2nd follow-up shown by 3D 

measurements in Sq P ¼ 0.006 (root mean square height) and Sz 

P ¼ 0.021 (maximum height). Patient’s questionnaire revealed 

improvement in number and depth of dimples, skin firmness and 

texture, little change or no change in shape of treated area and 

reduction of circumference of the upper leg Patients’ average 

rating of treatment success stated for the verum a constant 

improvement at all follow-ups, for the placebo not. 

Conclusion: The study could prove the efficacy of superficial and 

deep radial acoustic waves in treating cellulite. No side effects 

were seen. 

#132 


BODY SCULPTING WITH ACOUSTIC WAVE 

THERAPY: RANDOMIZED, CONTROLLED, STUDY 

ON 14 SUBJECTS 

Maurice Adatto, R. Adatto-Neilson, P. Novak, 

A. Krotz, G. Haller 

Skinpulse Dermatology & Laser Center, Geneva, Switzerland; 

Storz Medical, Tagerwilen, Switzerland 

Background: Reduction of localized adiposities by non-invasive 

means is a very frequent request among the female and male 

population. The areas most frequently requested for loss of volume 

are abdomen, saddle bags, flanks, love handles, inner thighs and 

inner knees. Acoustic Wave Therapy 1 (AWT 1 ) is a non-invasive 

technique using mechanical sound waves. Its efficacy in 

improving cellulite appearance and increasing skin elasticity has 

been demonstrated in previous studies. The objective of this study 

is to demonstrate the efficacy and safety of AWT 1 , combining two 

different mechanical waves during the same session, in volume 

reduction of saddle bags in women. To demonstrate this we used 

clinical evaluation by comparing before and after pictures as well 

as standard measurement plus an objective measurement method 

using an ultrasound imaging system. 

Study: Treatment was performed on the saddle bags areas of 14 

female patients, with the CELLACTOR 1 SC1 (Storz Medical AG, 

Tägerwilen, Switzerland). This device includes two applicators, 

the C-ACTOR and D-ACTOR. The D-ACTOR is a vibrating 

massage system that operates by compressed air to perform pulse 

activation therapy on target muscles and tissues with acoustic 

radial waves. The C-ACTOR is a high intensity system with 

acoustic planar waves. Within 4 weeks, eight AWT 1 treatment 

sessions have been performed with both applicators. With the 

D-ACTOR 3000 pulses at energy intensity between 3 and 4 bar 

have been applied to each saddle bag area. With the C-ACTOR 

1500 pulses were used at energy between 0.45 and 1.24 mJ/mm 2 

depending on sensitivity of the patient. Follow-up visits were 

performed at 1, 4 and 12 weeks after the last treatment. 

Results: Measurements with the ultrasound system clearly 

demonstrate a significant diminution in the subcutaneous fat 

layer thickness with an average of 1.3 mm (11.8%) at 1 FU and 

2.2 mm (19.7%) at 2 FU. The averaged circumference has been 

reduced from 59.6 cm in the beginning to 58.3 cm at 1 FU and to 

57.2 cm at 2 FU. This is a reduction by 1.3 and 2.4 cm. Patients 

satisfaction after eight treatments was very good to excellent for 9 

of the 14 patients. There were no significant side effects observed 

except some minor bruising in two patients. This study, although 

performed on a small number of patients, tends to show the 

safety and efficacy of AWT 1 in treating localized fat areas in 

a non-invasive way. There is also an additional benefit for 

patients in reducing the cellulite aspect at the same time by 

using AWT 1 . 

#133 

REDUCTION IN ADIPOSE TISSUE VOLUME 

USING A NEW HIGH POWER RADIOFREQUENCY 

TECHNOLOGY COMBINED WITH INFRARED 

LIGHT AND MECHANICAL MANIPULATION FOR 

BODY CONTOURING 

Maurice Adatto, Boris Vaynberg, Ruthie Amir 

Skinpulse Dermatology & Laser Center Geneva, Switzerland; 

Syneron Medical, Yokneam Illit, Israel 

Background: A growing patient demand for a youthful skin 

appearance with a favorable body shape has led to the recent 

development of new non-invasive body contouring techniques. We 

have previously demonstrated that the combination of bi-polar 

radiofrequency and optical energies with tissue manipulation is 

an efficient reshaping modality. Here, we investigated the 

efficiency of a new high power version of this combined 

technology, in terms of adipose tissue reduction and skin 

tightening. 

Study: Twelve patients received one treatment per week over 6 

weeks in their abdomen/flank areas and were followed-up to 3month 

post-completion of the treatment protocol. This new device 

has an increased power in the bipolar RF as this parameter seems 

to be the most important issue for volume reduction. Patient 

circumferences were measured and baselines to post-treatments 

comparisons were made. Diagnostic US measurements were used 

to evaluate the reduction in adipose tissue volume. Improvement 

in skin tightening was evaluated using a cutometer device. 

Results: We observed a gradual decline in patient circumferences 

from baseline to post six treatments. The overall body shaping 

effect was accompanied with improvement in skin tightening and


#135 

was clearly noticeable in the comparison of the before and after 

photographs. These findings correlated with measurements of 

adipose tissue volume and skin firmness/elasticity using 

diagnostic US and cutometer, respectively. The thickness of the 

fat layer showed on average a 29% reduction between baseline and 

1-month follow-up, 93% of the subjects had a 1–60% change in fat 

layer thickness. Patients subjectively described comfort and 

satisfaction from treatment and 97% of them were satisfied with 

the results at the follow-up visit. 

Conclusion: The application of high power RF energy combined 

with IR, mechanical massage and vacuum appears to be an 

efficient modality for reduction in circumferences and 

improvement in skin appearance. The present study performed 

with a new device suggests that the underlying mechanism of 

action is reduction in the hypodermal adipose tissue volume and 

intensification in dermal matrix density. 

#134 

POST FACE LIFTING RF TREATMENT: CASE 

REPORTS AND FUTURE DIRECTIONS 

Hanit Brenner Lavie, Tal Nachlieli, Ruthie Amir, 

Eldad Moor 

Assuta Medical Center, Haifa, Israel; Syneron Medical Ltd., 

Yokneam Illit, Israel; Ramat Aviv Medical Center, Tel Aviv, 

Israel 

Background: Optimal rejuvenation of aging face requires 

multimodality intervention tailored to both anatomic and 

histological changes. Traditional surgical procedures, including 

face lift and forehead lift, can result in repositioning of ptotic 

structures. However, actinic changes and wrinkles remain, 

revealing patients’ true age. Dermabrasion, chemical and laser 

peels and monopolar radio frequency have been used as a 

complementary treatment to incision procedures by producing a 

more youthful and rejuvenated appearance. The purpose of this 

study was to evaluate the clinical outcome of post face lift patients 

treated with bipolar RF technology which was delivered to the 

skin in a fractional manner. 

Study: This was a prospective study. All patients were post a 

traditional procedure which included a face lift with or without an 

additional surgical treatment such as forehead lift, brow lift or 

blepharoplasty. The first treatment began at 11–14 weeks postoperation, 

depending on the patient’s healing period. All patients 

received three treatments using the high density electrode pin 

array of sublative RF, at 3- to 4-week intervals. Before and after 

standardized digital photos were taken and evaluated for clinical 

improvement. A questionnaire on patient’s satisfaction was given 

to each patient. 

Results: According to the investigators’ assessment, measurable 

clinical improvements were noticed for all parameters tested, 

including wrinkles, pores, tightness, brightness and coloring. In a 

similar manner, the majority of the subjects found the treatment 

efficient and saw significant improvement in the facial areas 

treated. Patients’ satisfaction was high while complaints were 

minor and included itching, prolonged redness and skin pin marks 

(up to 72 hours). 

Conclusion: For the last four decades face lifting has become the 

most popular procedure for facial rejuvenation. Even with 

successful resuspension of ptotic soft tissues, some wrinkles, 

textural problems and dyschromia of the skin remain. The usage 

of bipolar RF treatments to complement face lift improves the 

surgical procedure and yields harmonious facial rejuvenation 

results. 

EFFICACY AND PATIENT SATISFACTION OF A 

NEW NON-ABLATIVE FRACTIONAL LASER 

1,340 NM FOR THE FACIAL REJUVENATION IN 

BRAZILIAN PATIENTS 

Valeria Campos, Tatiana Cordero, Juliana Jordao 

Jundiai, Brazil; Campinas, Brazil; Curitiba, Brazil 

Background: There is a growing demand from patients for a less 

aggressive treatment to address wrinkles and uneven texture 

while minimizing recovery time and downtime, compared to 

ablative technologies. To determine the efficacy, safety and 

patient satisfaction of a new non-ablative fractional laser 

1,340 nm in facial skin rejuvenation in Brazilian skin types and 

compare two laser parameters (low fluence multiple passes vs. 

high fluence single pass). 

Study: Twenty subjects (skin phototypes II to VI) with visible 

cutaneous photodamage were treated with the new device 

Etherea 1,340 nm (Industra, São Carlos, Brazil). Treatments were 

performed using the 8 mm diameter handpiece, density of 

100 MTZ/cm 2 and pulse duration of 3 milliseconds. One-half of the 

face was treated with a single pass using 110–140 mJ/MTZ, the 

other half of the face was treated with three passes using 

80–110 mJ/MTZ. Patients returned every 4 weeks for a total of 

three sessions. Patients were followed-up with monthly photos 

and grading until 6 months after their last treatment session. 

All patients were asked to fillout a ‘severity scale’ on which 

pigmentation, rhytides, skin tone/tightness, texture, and patient 

satisfaction was noted after the last treatment. Pigmentation, 

rhytides, skin tone/tightness, and texture were also evaluated by 

two physicians not involved in the study using the pictures taken 

with Canfield VISIA Complexion. 

Results: According to photo analyses at the 3-month follow-up. 

The Single-Pass Treated Side: 60% of patients showed 

improvement in pigmentation, 50% in skin tone/tightening and 

skin texture, and 70% in rhytides. The Three-Passes Treated Side: 

70% patients showed improvement in pigmentation, 50% in skin 

tone/tightening and skin texture, and 60% in rhytides. According 

to the patients, 80% of patients showed improvement in 

pigmentation, 90% in skin tone/tightening and skin texture, and 

80% in rhytides. All patients were very satisfied with treatments 

and they did not notice any difference between the two halves of 

the face. No permanent side effects or scarring were seen. 

Conclusion: A new fractionated nonablative 1,340 nm laser can 

safely and effectively treat photodamage in darker skin types. 

We did not observe significant difference in the outcome after a 

low fluence multiple pass versus high fluence single pass 

treatment. 

#136 

A PILOT STUDY OF FRACTIONAL 

MICRO-PLASMA RADIOFREQUENCY FOR 

TREATMENT OF FACIAL SCARS AND RHYTIDS 

Shlomit Halachmi, Arie Orenstein, Tania Meneghel, 


Rabin Medical Center, Petach, Tikva, Israel; Tel Hashomer 

Hospital, Tel Hashomer, Israel; Renaissance Medical Center, 

Sao Paulo, Brazil 

Background: Fractional ablative and non-ablative lasers have 

gained popularity due to their efficacy and improved tolerability. 

Both plasma and fractional radiofrequency (RF) have been 

addressed as alternative methods for ablative or non-ablative

energy delivery for similar indications. We report the initial 

experience with a fractional micro-plasma RF-based device in the 

treatment of acne scars or facial rhytids. 

Study: Porcine skin models demonstrated that the depth and 

diameter of fractional plasma-RF penetration depend on the RF 

power and pulse duration, and range from 100 to 150 mm in depth 

and from 80 to 120 mm in diameter. Based on the results in this 

model, 16 patients with facial acne scars or facial rhytids 

underwent a series of treatments at 3- to 4-week intervals. 

Results were monitored photographically 6 months after 

treatment. 

Results: Acne scars showed marked improvement after 2–4 

treatments. Facial rhytids demonstrated reduced depth after two 

treatments and marked improvement after four treatments. 

Treatment was well tolerated by all participants, with transient 

erythema and short downtime. 

Conclusion: Fractional micro-plasma RF technology is a 

beneficial, low downtime, and well-tolerated modality for the 

treatment of acne scars and facial rhytids. 

#137 


#138 

TREATMENT OF DEPRESSED ACNE SCARS 

AND DEEP WRINKLES WITH A NOVEL 

MULTI-SOURCE FRACTIONAL 

RADIOFREQUENCY DEVICE—HISTOLOGICAL 

AND CLINICAL RESULTS ON 50 PATIENTS WITH 

LONG-TERM FOLLOW-UP 

Yoram Harth, Klaus Fritz 

OR Medical Center, Herzlya, Israel; University Hospital, Bern, 


Background: Acne scars are one of the most difficult disorders to 

treat in dermatology. The optimal treatment system will provide 

minimal downtime resurfacing for the epidermis and non-ablative 

deep volumetric heating for collagen remodeling in the dermis. A 

novel therapy system (EndyMed Ltd, Cesarea, Israel) uses phase 

controlled multisource RF to provide simultaneous one pulse 

microfractional resurfacing with independent volumetric skin 

tightening. 

Study: In the first stage of the study we treated in vivo animal 

skin. Skin specimens from treatment area were harvested for 

histology immediately after, 3 days and 14 days after the 

treatment. In the clinical study, 30 subjects (Fitzpatrick’s skin 

types 2–5) with moderate to deep wrinkles (Fitzpatrick’s scale 

> 3) and 20 subjects with depressed acne scars were enrolled. 

Treatment was repeated each month up to a total of three 

treatment sessions. Patients photographs were graded 

according to accepted scales by two uninvolved blinded 

evaluators. 

Results: In vivo histologies showed various degrees of ablation, 

coagulation and dermal heating according to power settings. 

All treated subjects experienced mild-moderate edema and 

erythema as an immediate response to treatment. Edema resolved 

after up to 1-hour post-treatment and mild erythema lasted up to 

2 days. Micro ablative crusts lasted up to 5 days. Significant 

reduction in the depth of wrinkles and acne scars was noted 4 

weeks after therapy with further improvement at the 3 months 

follow-up. 

Conclusion: Our data show the histological impact and clinical 

beneficial effects of simultaneous RF fractional microablation and 

volumetric deep dermal heating for treatment of wrinkles and 

acne scars. 

SEQUENTIAL PHOTOTHERMAL 1,064 ND:YAG 

AND 2,940 NM ER:YAG FRACTIONAL 

RESURFACING AND REMODELING VERSUS 

2,940 NM ER:YAG FRACTIONAL RESURFACING 

ALONE: A COMPARATIVE STUDY 

Leonardo Marini 

The Skin Doctors’ Center, Trieste, Italy 

Background: The main objective of this study was to assess the 

clinical and histologic effects of a sequential photo-thermal 

short þ long pulse 1,064 nm Nd:YAG followed by a fractional 

2,094 nm Er:YAG according to a laser layering technique (LLT) 

compared to a 2,940 nm Er:YAG fractional resurfacing in facial 

chrono- and photo-aged skin. 

Study: Two different photo-thermal laser protocols were 

randomly applied to facial skin of two groups (a. n.55—38–60 

years, mean 45; b. n.45—40–62 years, mean 48) of Fitzpatrick 

type 2–3 patients affected by photo- and chrono-aging. Group a 

was treated with a sequence of short and long 1,064 nm laser 

pulses (0.3 milliseconds–35 J/cm 2 —scanner-operated 3 mm spot; 

followed by 35 milliseconds–50 J/cm 2 —scanner-operated 3 mm 

spot) immediately followed by two passes of fractional 2,940 nm 

Er:YAG laser resurfacing (0.250 mm spot–12 J/cm 2 – 

600 microsecond—40% coverage). Group b was treated by two 

passes of 2,940 nm Er:YAG laser resurfacing with the same 

parameters. Standardized clinical photographs were taken at day 

0–30–60–90. Three millimeter punch biopsies were performed at 

30 and 90 days on the natural crease between the cheek and earlobule 

just across treated and non-treated sites. Non-treated sites 

were marked in blue. All histological specimens were processed 

with standard EE. A self-evaluation clinical diary was given to all 

patients. 

Results: Clinical pictures were blindly evaluated by two 

dermatologists with a 90% of concordance. Overall clinical 

improvement was considered higher (37%) in group a 

(Nd:YAG þ fractional Er:YAG) compared to group b (fractional 

Er:YAG). Histologic evaluation was blindly performed by a 

dermatopathologist who confirmed a 32% higher collagen 

rearrangement in the same group of patients. The majority of 

Patients considered the procedures acceptable (a. 85% b. 87%). 

Patients’ perceived clinical improvement was higher (78%) in 

group a than in group b (62%). Both patient groups confirmed 

their willingness to repeat the procedures to progressively reach 

and/or maintain a good level of anti-aging effect. 

Conclusion: Sequential 1,064 nm Nd:YAG and 2,940 nm Er:YAG 

photo-thermal fractional resurfacing and remodeling showed to be 

clinically superior to fractional 2,940 nm Er:YAG laser 

resurfacing alone according to both patients and dermatologists’ 

evaluation. More studies are needed to assess different sequences 

of laser wavelenghts to further improve the clinical efficacy of 

what can be described as laser layering technique (LLT) 

#139 

COMBINED FRACTIONAL, NON-ABLATIVE 

TREATMENT OF STRIAE: CLINICAL AND 

HISTOLOGICAL OBSERVATIONS 

Vic Narurkar, Christine Dierickx, Carolyn Chang, 

Ava Shamban 

Bay Area Laser Institute/CPMC, San Francisco, CA; Skin and 

Laser Center, Boom, Belgium; CPMC, San Francisco, CA; Laser 

Institute for Derm and European Skin Care, Santa Monica, CA


Background: The 1,540 nm laser is the first and only fractional 

ablative handpiece to receive FDA clearance for the treatment of 

striae. We evaluate the effect of density and depth of treatment 

using the 1,540 and 1,440 nm handpieces, and three different 

optics. 

Study: Bilateral treatments were performed on thigh striae. 

Striae were trisected and treated with the 1,440 or 1,540 nm 

handpiece and the 10 mm (70 mJ, 100 mb/cm 2 ), 15 mm (10 mJ, 

320 mb/cm 2 ) or XD optic (70 mJ, 25 mb/cm 2 ). Baseline and 3month 

histology was performed on two subjects receiving 

1,540 nm treatment. One subject received a single high-coverage 

treatment and a second subject received three treatments at 

6-week intervals. Hematoxylin and eosin staining (H&E) and 

elastin immunohistochemistry were performed on serial sections. 

Clinical assessments using a quartile improvement scale (Grades 

I to IV) and subject self-assessment data were collected from 20 

subjects treated with the 1,540 nm handpiece. 

Results: Treatments were well-tolerated yielding only trace 

erythema and transient hyperpigmentation in two subjects which 

resolved. Optimal results, including significant restoration of 

natural color to striae alba and a reduction in palpable depression, 

were obtained using the 15 mm optic for the first treatment 

followed by the 10 mm optic for the remaining treatments. One 

hundred percent of patients showed improvement, ranging from 

Grade II to Grade III. Histology demonstrates remodeling of 

collagen and elastin fibers. 

Conclusion: The 1,540 and 1,440 nm handpieces can be used to 

safely and effectively treat a wide variety of striae over a wide 

range of skin types. A strategy combining remodeling of the upper 

and deeper dermis using different optics was beneficial for 

optimizing treatment of striae. 

#140 

CLINICAL EFFICACY OF FRACTIONAL ERBIUM 

FIBER 1,410 NM LASER FOR TREATMENT OF 

DILATED PORES IN KOREANS 

JeeYoung Park, SangJun Lee, JiHo Rho, 

KyeYong Song 

Arundaunnara Dermatologic Clinic; Chung-ang University, 

Seoul, Korea 

Background: Skin pores are openings of the pilosebaceous units 

and increased sebum production and decreased skin laxity are 

considered to be two major causes of dilated pores. Dilated skin 

pores are cosmetic concerns in many people and various 

treatments have been tried but current treatments have shown 

limited efficacy. We evaluate clinical efficacy of 1,410 nm 

fractional erbium fiber laser for treatment of dilated pores. 

Study: Total 38 patients with dilated pores were enrolled in this 

study. Patients are divided into two groups according to degree of 

sebum secretion. Both group patients received three sessions 

treatment at 3–4 weeks intervals and followed-up for 6 months. 

Clinical efficacy was evaluated with photographic evaluation by 

physician and satisfaction evaluation by patients at 3 months and 

6 months after last laser treatment. Histologic examination from 

three patients were performed at baseline and at 2 months after 

last laser treatment. 

Results: Twenty-eight patients were in group 1 (dilated pores 

without active sebum secretion) and ten patients were in group 2 

(dilated pores with active sebum secretion and acne). Treatment 

was well-tolerated in all patients and there was no serious 

complication. At evaluation of 3 months after treatment, group 1 

showed 78% and group 2 showed 67% clinical improvement in 

average. At evaluation of 6 months after treatment, group 1 

showed 75% and group 2 showed 60% clinical improvements. In 

evaluation of satisfaction by patients, group 1 showed higher 

satisfaction degree than group 2 in both 3 and 6 months’ 

evaluation. On histology, increased collagen production of upper 

dermis was observed in all three patients. 

Conclusion: Fractional Erbium doped 1,410 nm laser resurfacing 

could be one of effective and safe treatment modalities for dilated 

pores in Asians. Especially, dilated pores patients with less sebum 

secretion showed better and longer clinical efficacy and high 

satisfaction degree in this study. 


#145 

NEW TECHNIQUE FOR DELIVERING LASER 

ENERGY DEEPER INTO TISSUE 

Sean Wang, Qun Li, Kerith Wang 

B&W TEK, Inc., Newark, DE 

Background: In laser therapy, it is necessary to effectively 

deliver a required level of laser energy deep into tissues for 

treatment of acute stroke, spinal cord nerve regeneration, PDT for 

certain deeply embedded cancers, etc. However, biological tissue 

is an optically inhomogeneous and highly scattering media in 

additional to wavelength selective absorption. The depth of 

penetration is severely limited due to strong diffractive scattering/ 

reflection/trans-refraction of the cells with their physical 

dimensions on the order of micrometers, which is within the 

strong optical diffractive regions of visible/NIR light. 

Study: In this paper, we will discuss and explore several novel 

techniques, such as multi-beam coherent mixing, non-diffracting 

beam conversion which can effectively increase and control the 

depth of laser beam penetration into tissues. 

Results: Experimental demonstrations will also be presented. 

Conclusion: These novel approaches will further advance the 

effectiveness of applying laser bio-modulation in a real clinical 

environment. 

#147 

EFFECTS OF VEGF MIMICKING PEPTIDES AND 

PHOTORADIATION ON WOUND HEALING IN A 

MURINE PRESSURE ULCER MODEL 

Raymond Lanzafame, Istvan Stadler 

Rochester General Hospital, Rochester, NY 

Background: Chronic wounds are a growing problem. The 

activity of VEGF mimetic peptides and phototherapy were 

evaluated in an animal pressure ulcer model. 

Study: Pressure ulcers were created (J Invest Surg, 17:221–227; 

2004) on nine groups of Balb/C mice (n ¼ 10). Photoradiation at 

670 nm (LLLT) was administered daily for 18 days post-ulcer 

creation, delivered in two 2.5 J/cm 2 fractions/day at 

40 mW 62.5 seconds using LED arrays (Quantum Devices, 

Barneveld, WI). The ulcers were covered with Tegaderm TM 

dressings. Two peptides (P1, P2) at 0.01 mg, two scrambled 

peptides (S1, S2), or vehicle (V) alone were applied in saline 2 /

day. LLLT, P1 LLLT, P2 LLLT, S1, S2, V and Control (C) 

regimes were tested. Control animals received neither drug nor 

light therapy, but were handled in a similar fashion. Ulcer 

stages were graded using a standardized scale. Changes in 

staging, and digital photographs were recorded daily. Wound 

diameter and area were assessed and wound closure rates were 

calculated. Histology was evaluated (H&E, Masson’s Trichrome 

stain). 

Results: LLLT alone or combined with P1 or P2 significantly 

accelerated wound healing. The slope of the wound closure rate 

trendline was greatest for P2 þ LLLT The administration of P1, 

P2, S1 or S2 alone delayed wound closure in this model. V alone 

had no effect on wound healing. 

Conclusion: VEGF mimicking peptides delayed wound healing 

in pressure ulcers. Phototherapy appears to mitigate the 

inhibitory effects of these peptides. The photostimulatory effects 

of 670 nm light appear to be independent of the VEGF pathway. 

Further studies of these effects are warranted. 

#148 


PHOTOACTIVATED ANTIMICROBIAL COLLAGEN 

REDUCES BIOBURDEN IN A MURINE PRESSURE 

ULCER MODEL 

Raymond Lanzafame, Istvan Stadler, 

Ryan Cunningham, Robert Soltz, Barbara Soltz 

Rochester General Hospital, Rochester, NY; Conversion Energy 

Enterprises, Spring Valley, NY 

Background: Topical antiseptics are of interest due to increasing 

bacterial antibiotic resistance. This study examines the feasibility 

of photoactivated collagen-embedded riboflavin-5-phosphate 

(PCRB) in an infected pressure ulcer model. 

Study: Female Balb/C mice (n ¼ 24, 35 g) were anesthetized with 

50% CO2: 50% O2. Pressure ulcers were created. Dorsal hair was 

shaved, depilated, and skin cleansed with 70% isopropanol. The 

skin was placed between 2 and 12 mm diameter magnets (5 mm 

thick, 1,000 Gauss). A 5 mm skin bridge was maintained between 

magnets and the carnosis muscle was captured ( 12 h on 12 h 

off). After three I/R cycles, animals were anesthetized with IP 

xylazine and pentobarbital, ulcers and surrounding skin were 

covered with Tegaderm TM and inoculated with 0.1 ml of 

1 10 5 CFU/ml of MRSA. Fluid was permitted to reabsorb for 

10 min. One wound from each animal was treated using PCRB 

and photoradiated or photoradiated alone (n ¼ 11). Composite 

dressing-treated wounds received 1 cm 1 cm PCRB wafers, 

applied by excising Tegaderm TM overlying the ulcer, placing 

PCRB over the wound and covering the wound with Tegaderm TM . 

Wounds were irradiated at 457 nm (350 mW, 1 cm spot diameter, 

15 min) using a diode pumped solid state laser (DPSSL) 10 min 

after dressing placement. Control wounds did not receive PCRB or 

photoradiation. Animals were euthanized at 24 hr post-therapy. 

Quantitative bacterial counts (CFU/g tissue) were determined to 

measure bactericidal efficiency. 

Results: PCRB plus photoradiation resulted in a statistically 

significant reduction in bacterial counts at 24 hours as compared 

to untreated controls (P < 0.0001). Photoradiation alone was no 

different from untreated controls (P ¼ 0.24). 

Conclusion: This preliminary study demonstrated that 

photoradiation at 457 nm after placement of collagen-embedded 

riboflavin-5-phosphate inhibits bacterial growth in an infected 

pressure ulcer model confirming earlier studies demonstrating a 

2–3 log reduction in bacterial counts following treatment with 

PCRB and photoradiation. Further studies to develop this wound 

care modality are warranted. *Supported by NIH NIGM Grant # 

1R43GM087753-01. 

#149 

IN VITRO AND IN VIVO STUDIES OF LLLT FOR 

TRAUMATIC BRAIN INJURY 

Michael Hamblin, Weijun Xuan, Qiuhe Wu, 

Ying-Ying Huang, Sulbha K. Sharma, 

Gitika B. Kharkwal 

Wellman Center for Photomedicine, Massachusetts General 

Hospital, Harvard Medical School, MIT Boston, MA 

Background: Low-level laser (or light) therapy (LLLT) is 

attracting growing interest to treat both stroke and traumatic 

brain injury (TBI). The fact that near-infrared light can penetrate 

into the brain allows non-invasive treatment to be carried out with 

a low likelihood of treatment-related adverse events. It is 

proposed that red and NIR light is absorbed by chromophores in 

the mitochondria of cells leading to changes in gene transcription 

and upregulation of proteins involved in cell survival, antioxidant 

production, collagen synthesis, reduction of chronic inflammation 

and cell migration and proliferation. 

Study: We cultured primary cortical neurons from embryonic 

mouse brains and studied the effects of red and near-infra-red 

laser light on the generation of reactive oxygen species, nitric 

oxide release, transcription factor activation, intracellular 

calcium and ATP. Two models of TBI in mice were developed; a 

closed head weight drop and an open skull controlled cortical 

impact. Transcranial laser therapy consisting of a single exposure 

4-hours post-TBI to 36 J/cm 2 of various lasers was delivered. 

Results: There was a biphasic dose response in cultured cortical 

neurons for generation of ROS, NO, intracellular calcium, 

mitochondrial membrane potential and ATP. 810-nm or 660-nm 

laser significantly improved neurological severity score in TBI up 

to 4-weeks post-TBI. Laser therapy at 730 or 980 nm was 

ineffective. Histological studies at necropsy suggested that the 

cortical lesion was repaired by neural progenitor (stem) cells from 

the subgranular zone of the dentate gyrus, possible stimulated by 

the laser. 

Conclusion: Transcranial laser therapy is a promising treatment 

for acute (and chronic TBI) and the lack of side effects and paucity 

of alternative treatments encourages early clinical trials. 

#150 

PULSE LIGHT IRRADIATION IMPROVES 

BEHAVIORAL OUTCOME IN A RAT MODEL OF 

CHRONIC MILD STRESS 

Xingjia Wu, Stephanie Alberico, Helina Moges, 

Ruchir Sehra, Luis DeTaboada, Juanita Anders 

Uniformed Services University of the Health Sciences, Bethesda, 

MD; PhotoThera, Inc., Carlsbad, CA 

Background: The success of transcranial light therapy (TLT) for 

the treatment of stroke in clinical trials suggests that TLT could 

be used to treat other brain disorders such as depression. Current 

therapy for depression emphasizes pharmaco-therapeutics, which 

are effective in half of treated patients and often cause side effects. 

TLT was studied in a rat model of chronic mild stress (CMS) as a 

treatment for depression. 

Study: Wistar rats were randomized into four groups: (1) nostress, 

(2) stress without treatment (Control), (3) stress with 

antidepressant (Drug), and (4) stress with TLT (TLT). All stressed


groups underwent 8 weeks of CMS. Starting at week 6 and for the 

remainder of the study, the Drug group was given daily injections 

of Fluoxetine (10 mg/kg), and the TLT group was irradiated three 

times a week (810 nm, 3 mm diameter, 350 mW peak power, 

100 Hz with 20% duty circle, 2 min treatment). After 3 weeks of 

treatment, a forced swimming test (FST) was performed. Rats 

were weighed weekly. Animals were euthanized after 8 weeks. 

Results: Starting at week 5 the no-stress group had significantly 

higher body weight than all Stress groups (P < 0.05), there was no 

difference in weight between the three Stress groups. However, 

the Drug group had significantly less body weight than both 

control and TLT groups (P < 0.05) after week 7. FST showed that 

the Control group had significantly more immobility than the nostress 

group (P < 0.05). Both Drug and TLT groups had 

significantly less immobility than Control (P < 0.05). There was 

no significant difference in immobility between the Drug and TLT 

groups (P ¼ 0.62). 

Conclusion: TLT was comparable with fluoxetine in improving 

behavioral outcome after CMS. TLT did not cause weight loss, 

which is consistently seen in patients treated with fluoxetine. This 

study indicates that TLT may be an effective treatment for 

depression (This study was funded by USU Intramural Concept 

Award, RO704A). 

#151 

980 NM LASER IRRADIATION IMPROVED 

FUNCTIONAL RECOVERY AFTER PERONEAL 

NERVE INJURY IN RABBITS 

Helina Moges, Xingjia Wu, Brian Pryor, 

Jason Smith, Juanita Anders 

Uniformed Services University of the Health Sciences, Bethesda, 

MD; LiteCure, Newark, DE 

Background: Light therapy (LT) has been shown to promote 

peripheral nerve regeneration using wavelengths primarily 

within 600–900 nm. Longer wavelengths are not commonly used 

for repair of the peripheral nervous system and their effects in 

promoting peripheral nerve regeneration have not been 

adequately researched. Our objective in this study was to 

investigate for the first time the capacity of 980 nm wavelength 

laser irradiation to improve post-traumatic peripheral nerve 

regeneration. 

Study: Twelve White New Zealand rabbits were randomized into 

two groups: (1) control, no light; and (2) LT, light treatment using 

parameters: 980 nm wavelength, 1.5 W output power, 40 seconds 

duration, and 8 cm 2 area at the skin surface. The left peroneal 

nerve was completely transected and repaired using epineural 

suture with 8-0 ethilon. Light was applied transcutaneously 

immediately after closure of the skin and daily thereafter for a 

total of 10 days. Control group was treated exactly the same but 

with laser off. To measure functional recovery, toe-spreading 

reflex test was performed at baseline and weekly starting from the 

forth week post-injury. Animals were euthanized at week 9 postinjury. 

Results: At week 4, toe spread was 63.7 2.6% and 65.3 2.9% 

of baseline for control and LT groups, respectively, indicating 

functional loss in both groups. At week 6, LT group showed 

statistically significant functional recovery compared to week 4 

(P < 0.05), while control group did not show functional recovery 

(P ¼ 0.68). LT group consistently performed significantly better 

in the toe spread reflex test compared to the control group starting 

from week 6, with a return of function to 86.9 4.2% in LT group 

and 72.2 3.6% in control group (P < 0.05) by week 9. 

Conclusion: Our results demonstrate that 980 nm laser 

irradiation successfully promoted earlier and faster functional 

recovery after peroneal nerve transection and surgical repair. 

This study warrants further investigations into use of 980 nm 

lasers as treatment for nervous system injuries. (This research 

was funded by the Comprehensive National Neuroscience 

Program, Grant # G1704T.) 

#152 

COMBINED OCT AND MULTI-PHOTON 

LUMINESCENCE MICROSCOPY FOR 

MACROPHAGE DETECTION IN 

ATHEROSCLEROTIC PLAQUES USING 

PLASMONIC GOLD NANOROSE 

Tianyi Wang, S.M. Shams Kazmi, Jordan Dwelle, 

Veronika Sapozhnikova, Jake Mancuso, 

Brian Willsey, Keith Johnston, Marc Feldman, 

Andrew Dunn, Thomas Milner 

University of Texas at Austin, Austin, TX; University of Texas 

Health Science Center at San Antonio, San Antonio, TX 

Background: Macrophages are an important cell type involved 

in the progression of atherosclerosis which can lead to myocardial 

infarction. We report combined OCT and multi-photon 

luminescence (MPL) microscopy to visualize macrophages in 

atherosclerotic plaques using plasmonic gold nanorose as a 

biocompatible contrast agent. 

Study: Atherosclerotic lesions were created in the aorta of a New 

Zealand white rabbit subjected to a high cholesterol diet and 

double balloon injury. The rabbit was injected with a suspension 

of 30 nm diameter gold nanoroses coated with dextran. The 

macrophages endocytosed nanoroses and ex vivo atherosclerotic 

tissues were imaged by OCT and a custom-built scanning multiphoton 

microscope. A mode-locked femtosecond Ti:Sapphire laser 

(800 nm) was used as an excitation light source in the multiphoton 

microscope, a band-pass filter (670–730 nm) and a 

photomultiplier tube (PMT) were utilized to collect luminescence 

emission. 

Results: MPL images show the presence and location of 

nanoroses, and are merged into co-registered OCT images to show 

both plaque structure and composition. 

Conclusion: Results of our study suggest that the spatial 

distribution of macrophages endocytosing gold nanoroses in 

atherosclerotic plaques can be identified by combined OCT and 

MPL microscopy. 

#155 

THE EFFECTS OF RED LIGHT ON HIGH GLUCOSE 

INDUCED DYSFUNCTIONAL MYOBLASTS AND 

THEIR MECHANISM 

Fang-Hui Li, Timon Cheng-Yi Liu, En-Xiu Wei, 

Yan-Ying Liu 

Laboratory of Laser Sports Medicine, South China Normal 

University, Guangzhou, China 

Background: Photobiomodulation promotes the wound healing 

of diabetes. Summer sunlight improves diabetes. These 

phenomena were simulated with the modulation of red light 

(640 15 nm) at 0.35 W/m 2 from light emitting diode array for 

15 min (RLED) on high glucose at 90 mmol/L induced 

dysfunctional C2C12 myoblasts (DCMs) in this paper.

Study: The effects of RLED and resveratrol at 10 mmol/L (RES) on 

the cell numbers, ATP activity, cell cycle, reactive oxygen species 

level (ROS), mitochondrial membrane potential (MMP), the 

mRNA expression of sirtuin 1 and manganese superoxide 

dismutase (MnSOD) of DCMs were assessed in comparison with 

C2C12 myoblasts in glucose at 22.5 mmol/L (CON). 

Results: RLED promoted the mRNA expression of sirtuin 1 

(P < 0.05) and MnSOD (P < 0.05). RLED, RES and N-acetyl 

cysteine at 5 mmol/L (NAC) significantly reduced DCM ROS 

(P < 0.05) at 18 h, increased DCM ATP activity (P < 0.05) at 72 h 

and increased DCM MMP (P < 0.05) at 48 and 72 h, respectively, 

among which the effects of RLED and RES were inhibited 

(P < 0.05) by phosphatidylinositol 3-kinase (PI3K) inhibitor, 

LY294002, respectively, and there were no significant effect 

differences between RLED and RES. 

Conclusion: Being similar with RES, the improvement of RLED 

on DCMs might be mediated by sirtuin 1, MnSOD and PI3K. 

#156 

SIRTUIN1-MEDIATED PHOTOPROMOTION ON 

TNF-ALPHA INHIBITED EXPRESSION OF 

CIRCADIAN CLOCK GENES IN CULTURED 

NIH3T3 FIBROBLASTS 

Timon Cheng-Yi Liu, De-Feng Wu, Ling Zhu 



Background: Tumor necrosis factor-alpha (TNF-alpha) 

inhibited expression of the circadian clock genes has been found to 

be modulated with low intensity 810 nm laser irradiation (LIDL) 

in our laboratory. Its mechanism was further studied in this 

paper. 

Study: The expression of the circadian clock genes in NIH3T3 

fibroblasts was synchronized by 50% horse serum shock for 2 h, 

inhibited with TNF-alpha at 10 ng/ml, and then irradiated with 

LIDL at 10 mW/cm 2 for 20 min. The mRNA expression of the 

circadian clock genes and Sirtuin 1 (SIRT1), and the ratio of 

nicotinamide adenine dinucleotide (NAD þ ) and its reduced form 

NADH, NAD þ /NADH, were assessed every 6 h for 36 h. 

Results: TNF-alpha inhibited the mRNA expression of Dbp 

(P < 0.005) and Bmall (P < 0.05) at 18th hour, Per2 (P < 0.05) at 

18th and 30th hours, Clock (P < 0.05) at 12th and 18th hours, and 

SIRT1 (P < 0.05) at 18th and 24th hours, respectively, and 

decreased NAD þ /NADH (P < 0.005) at 6th, 12th, 18th and 30th 

hours, respectively. LIDL inhibited the effects of TNF-alpha on 

Dbp (P < 0.05) and Per2 (P < 0.005) at 30th hours, Clock 

(P < 0.05), Bmall (P < 0.05) and SIRT1 (P < 0.005) at 18th 

hours, and NAD þ /NADH at 6th (P < 0.005), 12th (P < 0.05) and 

18th (P < 0.05), respectively. 

Conclusion: The promotion of LIDL on TNF-alpha inhibited 

expression of the circadian clock genes may be mediated by 

NAD þ /SIRT1. *It was supported by NSFC. 

#158 


A NEW POSSIBILITY TO TREAT SEVERE 

TRACHEAL STENOSIS APPLYING LOW LEVEL 

LASER THERAPY: PILOT STUDY 

Nathali Pinto, Tatiana Magacho, Mara Pereira, 

M. Cristina Chavantes 

University of São Paulo, São Paulo, Brazil; Pitagoras University, 

Vila Velha, Brazil 

Background: Tracheal stenosis (TS) is a serious complication 

that arises after endotracheal intubation’s problem, 

tracheostomy, gastroesofagic reflux, etc. The most common benign 

cause of upper airway stenosis, in all age groups, is postintubation 

tracheal injury, which occurs in less than 5% of patients 

submitted to long-term ventilation. Serious cases of severe 

stenosis are very tough condition to be treated. Although, 

untreated airway obstruction causes significant pulmonary 

morbidity and it can progress to life-threatening airway 

compromise. Several tracheal’s dilatations and surgery 

(tracheoplasty) is a conventional treatment for such cases. In this 

work, we aimed to investigate the Low Level Laser Therapy 

(LLLT) effect in severe tracheal stenosis process, when all 

previous treatment failure. 

Study: Five cases w/resilient TS that had more than 75% of 

tracheal obstruction, due to exaggerated granulation and scar 

tissue, had received a previous traditional treatment without 

success. They had complicated health conditions which forbidden 

to undergoing to a new conventional surgical procedure. At first, 

surgical laser was applied and afterwards LLLT w/? ¼ 685 nm, 

P ¼ 35 mW, Dose ¼ 8 J/cm 2 were applied into endotracheal mode. 

The time ranged according to tracheal lesion extent. 

Results: The results showed that LLLT was extremely efficient to 

control granulation tissue growth, even resilient scar tissue, due 

to tracheal stenosis, was prevented through a bioinhibition effect 

of LLLT. All patients were kept clear of tracheal stenosis, after 2 

years, using lasers procedures. The histopathological specimens of 

TS’ experimental study in vivo showed that LLLT was able to 

control the tracheal mucosa healing process, preventing 

inflammatory granulation tissue formation. 

Conclusion: Laser accomplished to restore normal tracheal 

lumen, due its biomodulation effect, as a less invasive treatment. 

Thus, endoscopic laser management of tracheal stenosis, applying 

LLLT, signalize be an effective method to control patient 

predicament, successfully. 

#159 

LASER THERAPY FOR THE TREATMENT OF 

CERVICAL PATHOLOGIES: A CLINICAL STUDY 

Renato Jr. Liboro, Fred Kahn, Renato Liboro, 

Fernanda Saraga 

Meditech International, Inc., Toronto, Canada 

Background: Cervical spine problems affect over 10% of the 

adult population. They are generally characterized by pain which 

impacts activity levels resulting in loss of time from work and 

negatively affecting quality of life. Conditions encountered 

include soft tissue and repetitive stress injuries, traumatic 

episodes including whiplash injuries and herniated discs. The 

wear and tear factors accompanying aging comprise a significant 

percentage of the problems that present. If acute conditions are 

not resolved in a timely manner, they become chronic, 

compromising resolution with conventional therapies, including 

pharmaceuticals and surgery. Recent, published literature 

indicates that laser therapy has become established as an effective 

therapeutic approach in the treatment of these problems, 

resulting in the elimination of pain along with the restoration of 

the quality of life and normal activity levels. In this study, we 

examine the efficacy of laser therapy utilizing red and infrared 

LED arrays along with laser probes as the choice of therapy. 

Study: In a follow-up clinical study subsequent to our previously 

published 2006 SPIE conference proceedings, we have analyzed a 

cross-section of patients treated for a variety of neck problems


#161 

that present at our Laser Rehabilitation Clinics on a daily basis. 

The various categories of cervical spine pathologies, are reviewed 

on the basis of age, gender distribution, number of treatments and 

overall improvement percentages. 

Results: Of the 101 patients included in this study, 49% 

presented with degenerative osteoarthritis, 22% with repetitive 

stress injuries, 18% with sports injuries and 12% with trauma. On 

average 10 treatments of 30–45 minutes in duration were 

administered for the individual patient, resulting in a significant 

improvement rate averaging 94.5%. 

Conclusion: Laser therapy confers benefit at both the cellular 

and systemic levels, activating a variety of mechanisms 

including DNA synthesis, improved microcirculation and both an 

analgesic and anti-inflammatory effect. With a combination of 

red and infrared LED’s and laser diodes as a light source 

treatment was effective for an extensive variety of cervical spine 

problems. 

#160 

INNOVATIVE METHOD TO IMPROVE EFFICACY 

AND TOLERABILITY OF PDT TREATMENTS 

Carl Thornfeldt, CT Derm 

Fruitland, ID 

Background: To produce a photodynamic therapy (PDT) 

regimen with improved efficacy and patient tolerability while 

allowing faster administration time. This regimen consists of: 

(1) Microdermabrasion. 

(2) Infrared LED at 830 nm for 20 minutes to inhibit neurogenic 

inflammation and stimulate deep dermal collagen, elastin and 

glycosaminoglycan synthesis. 

(3) 540 nm green light laser. 

(4) 570 nm yellow light laser. 

(5) 628 nm red LED for 20 minutes. 

Study: Ten Caucasian panelists participated in an open label 

unblinded clinical trial comparing results to baseline with two 

PDT treatments each 4–8 weeks apart. Efficacy was graded four 

weeks after second treatment. Post-op care required applying a 

gel mask containing meadowfoam extract to provide DHA and 

fatty acids for acetylcholine synthesis and anti-inflammatory 

effect. Home care consisted of applying a barrier repairing cream 

that is twice as effective as 100% petrolatum in repairing barrier 

function every 2–4 hours while awake for the next 4 days. All 

panelists stayed indoors for 24 hours after the treatment. 

Tolerability was subjectively assessed by panelists retrospectively 

comparing pain, tenderness, itching and soreness to previous 

chemical peels and red and/or blue light LED-activated PDT 

treatments. Fine lines, shallow wrinkles, sallowness and 

roughness were measured on a 5-point scale by a board certified 

dermatologist 4 weeks after the second treatment. Panelists 

rated visible improvements and treatment symptoms on a 4-point 

scale. 

Results: All 10 panelists experienced at least a 1 point 

improvement (20%) in all parameters. Six patients experienced 3 

point improvement (60%) in all parameters. Subjectively all 

patients reported good to marked (50–75%) improvement. All 

patients stated the test regimen was markedly (75%) more 

tolerable. 

Conclusion: This unique regimen utilizes longer wavelength 

light to maximally activate the smaller aminolevulinic acid peaks, 

but not blue light peaks, yet is more effective and better tolerated 

due to deeper penetration. 

A PROSPECTIVE SPLIT-FACE DOUBLE-BLIND 

RANDOMIZED PLACEBO-CONTROLLED TRIAL 

TO ASSESS THE EFFICACY OF LIGHT-EMITTING 

DIODE POSTFRACTIONAL ABLATIVE LASER FOR 

SKIN REJUVENATION 

Valeria Campos, Juliana Jordao, Tatiana Cordero 

Clinica Valeria Campos, Jundiai, Brazil; Clinica Valeria Campos, 

Curitiba, Brazil; Clinica Valeria Campos, Campinas, Brazil 

Background: Light-emitting diodes (LEDs) are considered to be 

effective to stimulate fibroblast activity and hasten wound 

healing. We investigated the clinical efficacy of LED phototherapy 

on wound healing and for improvement of discomfort 

postfractional ablative laser. 

Objective: To determine whether LED treatment immediately 

after fractional laser skin resurfacing affects the severity and 

duration of postoperative pain, erythema and wound healing. 

Study: Twenty patients received treatment with a LED array 

(Multiwaves, Industra, Brazil) to randomly selected facial halves 

immediately after full-face fractional laser skin resurfacing with 

2,940 nm erbium laser (Etherea, Industra, Brazil) and 1 week 

after the laser treatment. The LED treatments were daily 

alternating wavelengths of 635 nm (red) with 940 nm (infrared) 

with fluences of 19.78 J/cm 2 or 11 mW/cm 2 and 9 J/cm 2 or 5 mW/ 

cm 2 respectively, 20 minutes of light exposure. All laser 

procedures were performed by a single operator. Clinical 

improvement was evaluated by participants and two blinded 

physicians by observing the comparative photographs. The rate of 

re-epithelialization, duration of pain, erythema, and presence of 

complications were recorded immediately after the procedure and 

1 hour, 24 hour, 2, 3, 4, 5, 7, 30 days post-treatment. 

Results: The LED-treated facial halves were less painful in half 

of the patients after the first LED session. The average time to reepithelialization 

was 3 days in the LED-treated facial halves and 4 

days in the LED untreated facial halves. 

Conclusion: We believe that the LED after fractional ablative 

laser skin resurfacing will greatly enhance the natural wound 

healing process, and more quickly return the patient to a 

pretreatment level of activity. 

#162 

SAFETY AND EFFICACY OF FOOTLASER 

TREATMENT OF ONYCHOMYCOSIS IN PRIVATE 

PRACTICE 

Michael Uro, Laura Uro, Michael Abrahams, 

Martine Abrahams, Robert Grzywacz 

Foot Doctor Laser Center, Sacramento, CA; 

The London Nail Laser Clinic, London, England; Las Vagas, NV 

Background: The aim of this study was to evaluate in a private 

practice the effectiveness of a single treatment with the PinPointe 

FootLaser for onychomycosis. 

Study: One hundred and ninety-seven patients (321 great toes) 

from three private practices with clinical evidence of fungal nails 

received a single treatment of either one-pass or two-passes of the 

laser energy over all ten toe nails. Pre-treatment and follow-up 

post-treatment photographs of the hallux were digitized and 

computer-analysed to evaluate safety and determine efficacy and 

the change in percent clear nail out to 12 months. 

Results: The 2-pass treatment showed a greater treatment effect 

than the 1-pass treatment (11.2% vs. 4.4% increase in clear nail at 

6-months, respectively). Efficacy, percent of patients who showed

positive improvement, ranged from 55% to 90% and was mostly 

sustained throughout the 12-month evaluation period. 

Effectiveness improved with degree of fungal nail involvement. 

No serious adverse events were reported. 

Conclusion: In these private practices a single treatment with 

the FootLaser was non-toxic with an over-all efficacy of 70–80%. 

#164 

REVIEW OF MECHANISMS BY WHICH THE 

SPONTANEOUS EFFECTS OF PHOTONS ARE 

AMPLIFIED IN VIVO: THE PASER PRINCIPLE 

Mary Dyson 

King’s College London, United Kingdom 

Background: The spontaneous effects of radiation produced in 

cells that have absorbed it can be amplified by the neuro-endocrineimmune 

and circulatory systems. Both direct (local) and indirect 

(distant) effects occur in the body when photons are absorbed. 

Study: It is proposed that the response of a patient to therapeutic 

levels of photons and other forms of radiation be described as 

Patient Amplification of the Spontaneous Effects of Radiation, 

that is, PASER. Direct effects are produced spontaneously in the 

cells that absorb photons. These direct effects can initiate indirect 

amplified effects in sensitive target cells elsewhere in the body. 

The role of the neuro-endocrine immune system and the 

circulatory system is this amplification will be described. 

Publications describing experiments supporting amplification will 

be reviewed. Photons can produce both direct effects on the cells 

that absorb them and indirect effects on other cells of the body, 

even if the cells are treated in vitro and then retransfused. In vitro 

or in vivo treatment can give rise to spatially and temporally 

amplified in vivo effects. 

Results: Provided that some of the individual’s cells absorb 

photons within the therapeutic window of effectiveness, other 

cells that have not absorbed photons can be affected by them 

indirectly via soluble protein mediators, for example, chemokines, 

other cytokines and growth factors. These secretions can reach 

and act on sensitive target cells, for example, those at sites of 

injury, when transported to them by lymph or circulating blood. 

Direct effects can also be produced in circulating cells during their 

transit through dermal capillaries accessible to photons. The 

longer the duration of treatment within the therapeutic range, the 

greater the number of circulating cells in which direct effects can 

be produced. 

Conclusion: Duration is thus a clinically important parameter. 

The direct and indirect effects of photons may have considerable 

therapeutic benefit to the patient. 

#165 


A 764 PATIENT RETROSPECTIVE STUDY 

REGARDING THE EFFICACY OF LOW-LEVEL 

LASER THERAPY FOR NON-INVASIVE BODY 

SLIMMING OF THE WAIST, HIPS, AND THIGHS 

Jillian Maloney, Ryan Maloney, Steven Shanks 

Erchonia, McKinney, TX; University of Arizona, Gilbert, AZ 

Background: Low-level laser therapy (LLLT) is a non-invasive 

treatment for a wide-assortment of medical ailments. A recent 

application is for non-invasive body slimming. A Level 1 clinical study 

was completed and recorded a significant reduction in circumferential 

measurements across waist, hips, and thighs compared to placebo 

subjects. Questions remain unanswered to whether the result 

observed was based upon simple fluid redistribution. The purpose of 

this retrospective study was to evaluate the efficacy of low-level laser 

therapy for non-invasive body slimming and determine if the loss was 

attributable to fluid or fat relocation. 

Study: Data from 1,136 participants were obtained, and 

764 participants were selected for device evaluation (The Zerona, 

manufactured by Erchonia Corp.). Patient data were not 

pre-selected; all reports provided by clinics using LLLT for 

body contouring were required to properly evaluate the efficacy of 

the treatment. Participants received a total of six LLLT 

treatments across 2 weeks having baseline and post-procedure 

circumferential measurements recorded. Measurement sites 

included waist, hips, thighs, arms, knees, neck, and chest. 

Results: A total of 726 (95.0%) participants demonstrated an 

overall average reduction in the circumferential measurement 

across all measurement sites of 5.5 in. (range, 0.1–26.0 in.; 

P < 0.0001). An overall reduction was observed across each 

measurement site. The average reduction in the circumferential 

measurement for all participants was 3.25 in. across the waist, 

hips, and bilateral thighs (P < 0.0001). 

Conclusion: These data reveal that subsequent LLLT the 

circumferential reduction is not attributable to fluid or fat 

relocation as all measurement points, including non-treated 

regions, produced an inch loss. 

#166 

LOW LEVEL LASER THERAPY FOR ADIPOSE 

REDUCTION IN 30 WOMEN 

Elizabeth VanderVeer, Carrie Anderson 

VanderVeer Center, Portland, OR 

Background: The 635 nm ‘‘Cold’’ laser has recently been FDA 

cleared, but prior to August 2010, the laser was used off-label for 

body contouring without much supporting documentation. It was 

stated that a patient could expect greater than 3 in. of 

circumferential loss from their bodies in over 10 measurement 

points after only six 40-minute sessions under the Low Level 

Laser Therapy (LLLT). Our study used a similar treatment 

protocol to independently evaluate the results in women without 

exclusion for prior cosmetic procedures; older age; menopausal 

status; current health conditions; or current medications. 

Study: Thirty women were enrolled in a prospective study using 

LLLT to contour their body. The average age of the participants 

was 50 (range 32–72) and average BMI of 25 (15 ranging 20–25, 

15 ranging 26–30). The women received six 40-minute LLLT 

treatments with a ‘‘cold laser’’ consisting of five diodes, 15 mW 

each, placed 20 cm above the patient’s bare skin. The linear diodes 

rotated and slightly overlapped each other on the patient’s body to 

target the main areas of adipose tissue. Patients exposed their 

front and back treatment area to the laser for 20 minutes per side. 

Treatments occurred every 48 hours for a total of six treatments. 

Patients were asked to abstain from alcohol; exercise 30 minutes a 

day; and to drink 64 oz of water daily. Clinical photography and 

pre- and post-treatment measurements were taken from 10 points 

on the body. Clinical photography and measurements were used 

to determine the success of the treatment. 

Results: Thirty patients completed the study. No adverse events 

were reported. Treatment was described as a ‘‘relaxing.’’ 

Significant inch loss was observed with an average combined loss 

of 6.8400 from 10 measurement points on the body. No patient 

‘‘failed’’ to lose inches. 

Conclusion: This study demonstrates the safety and efficacy of 

LLLT for non-invasive body contouring.


#167 

NOVEL NON-INVASIVE TECHNIQUE USING LOW 

LEVEL LASER FOR CHIN REJUVENATION 

Vinod Podichetty, Jean-Claude Nerette 

Research Practice Parterns, Inc., Miramar, FL; Bellissimo 

Medical Center, Weston, FL 

Background: Removal of excess fat pocket in the chin can 

significantly define a lower facial structure but is often neglected 

in rejuvenation efforts of the face and neck. A complete 

rejuvenation of the neck should address contours in the chin area 

reducing the subcutaneous fat to provide angularity between the 

various planes of the lower face and neck. The aim of the study is 

to evaluate the efficacy of low level laser therapy (LLLT) applied 

on subcutaneous fat in the chin area in patients with undesirable 

accumulation of submental fat. 

Study: A total of 10 subjects were examined for the study. All 

patients received LLLT using a AlGaInP laser diode source 

(Meridian Medical, Inc., Vancouver, BC) at 658 nm wavelength 

with a maximum output power of 30 mW/beam. Subjects received 

five treatment sessions lasting 20 minutes each over a 2-week 

period with a minimum follow-up of 6 months and post-treatment 

assessment. Two clinicians performed the therapy, physical 

examination, skinfold-caliper measurement and blinded 

photographic evaluation. 

Results: Laxity of the skin improved in all 10 patients. 

Photographic assessment in 9 out of 10 patients studied revealed 

significant changes in submental profiles after an average of four 

treatment sessions. Mean degree of improvement (0 ¼ none, 

1 ¼ mild, 2 ¼ moderate, 3 ¼ significant) was 2.8 ( 0.02). 

Physician/subject assessment of fat loss (FL), skin tightening (ST), 

chin profile (CP), and overall performance (OP) averaged a score of 

9.5/9.0 (FL); 9.0/9.0 (ST); 8.5/9.0 (CP) and 9.5/9.5 (OP) (on a 1–10 

scale; with 1 ¼ minimum; 10 ¼ maximum improvement). Results 

were consistent at 6-month follow-up. One patient had transient 

erythema and local swelling which resolved in 24 hours without 

intervention. 

Conclusion: Treatment choice to address skin changes and 

subcutaneous fat deposition in chin area is typically surgical and 

non-invasive options are currently unavailable. The current novel 

study clearly demonstrates efficacy of low level laser in reducing 

chin fat with restoration of neck contour and overall aesthetic 

result. 


#168 

IN VITRO STUDY OF THE PHOTODYNAMIC 

THERAPY OF NANO-PHOTOSENSITIZER ON 

HUMAN ORAL TONGUE CANCER CAL-27 CELLS 

Guoyu Zhou, Pingping Li, Guolin Li, Yan Pang, 

Lingyue Sheb, Qing Xu, Jizhong Gu, Xinyuan Zhu, 

Michael R. Hamblin 

College of Stomatology, Ninth People’s Hospital, Shanghai Jiao 

Tong University School of Medicine; Shanghai Research Institute 

of Stomatology; Shanghai Key Laboratory of Stomatology, 

Shanghai, China; The First Affiliated Hospital of Haerbin 

Medical University, Haerbin, China; College of Chemistry and 

Chemical Technology, Shanghai Jiao Tong University, Shanghai, 

China; Wellman Center for Photomedicine, Massachusetts 

General Hospital, Boston, MA 

Background: To study the effect of photodynamic therapy of 

HPEE-ce6 nanoparticles on the human oral tongue cancer CAL-27 

cells. 

Study: Hyperbranched poly(ether-ester)-chlorin e6 nanophotosensitizer 

(HPEE-ce6) were prepared by the reaction of 

HPEE and ce6, and analyzed by confocal laser scanning 

microscopy (CLSM) for cell internalization. With free chlorin e6 

(ce6) for the control group, the phototoxicity of HPEE-ce6 

nanoparticles on human oral tongue cancer CAL-27 cells was 

detected by MTT assay. 

Results: The nanoparticles with a diameter of ca. 50 nm were 

synthesized by the covalent binding between hyperbranched 

poly(ether-ester) (HPEE) and ce6. HPEE-ce6 were uptaken by 

CAL-27 cells in vitro, mainly in cytoplasm. MTT assay showed the 

significant effect of phototoxicity after comparison with ce6 

control experiments (P < 0.05). 

Conclusion: The results indicate that HPEE-ce6 could be used 

as promising drug carriers in photodynamic therapy on CAL-27 

cells. 

#169 

PDT DISINFECTION OF ORAL BIOFILM 

Thomas Mang, Lynn Mikulski, Dharam Tayal, 

Robert Baier 

University at Buffalo, Buffalo, NY 

Background: The ability of Photofrin mediated photodynamic 

therapy to treat the bacterial strain S. mutans and different species 

of Candida including Fluconazole and Amphotericin B resistant 

isolates in planktonic cultures and on biofilm was studied. 

Study: S. mutans were treated with PDT (630 nm) at 1.5, 3, 4.5, 9, 

and 18.5 J/cm 2 after being incubated with Photofrin. An XTT 

assay was performed on Biofilm grown on PMMA squares treated 

with Photofrin and laser light (630 nm) at 9, 27, 54, and 63 J/cm 2 . 

ATCC Candida strains C. albicans, C. glabrata, C. parapsilosis, C. 

krusei, and C. tropicalis were examined along with antifungal 

resistant isolates C. albicans, C. glabrata, C. guilliermondi, C. 

tropicalis and C. krusei, for PDT susceptibility testing. The 

resistant strains were from isolates from the oral cavities of 

patients from a study on adults with AIDS. Candida (C. albicans, 

C. glabrata and C. krusei) grown on SDA plates were inoculated 

into appropriate media for planktonic experiments. Candida for 

biofilm experiments were introduced to pre-conditioned PMMA 

strips. Experiments were also performed using a flow cell system 

and various substrata treated with radio frequency glow discharge. 

Results: Experiments demonstrate that S. mutans have a high 

level of susceptibility to the effects of Photofrin and 630 nm light 

resulting in a statistically significant reduction in viability 

(P < 0.0004; Mann–Whitney test). Light doses as low as 4.5 J/cm 2 

resulted in a reduction of colonies to less than 0.1% of controls in 

both planktonic and biofilm experiments. In Candida planktonic 

and biofilm preparations PDT demonstrated significant killing in 

both antifungal resistant strains. Experimental conditions 

resulted in significant reductions in all strains (P ¼ 0.0006). 

Conclusion: The results of this study, thus far, demonstrate the 

efficacy of PDT for the treatment of oral microbes in planktonic or 

biofilm conditions, including antifungal resistant isolate strains of 

Candida.

#170 

MECHANISMS OF ANTIMICROBIAL 

PHOTODYNAMIC THERAPY: AN IN VITRO STUDY 

ON GRAM-NEGATIVE AND GRAM-POSITIVE 

BACTERIA 

Liyi Huang, Michael Hamblin 

Boston, MA 

Background: Photodynamic inactivation (PDI) is a rapidly 

developing antimicrobial technology which employs a nontoxic 

dye termed a photosensitizer (PS) and low-intensity visible light, 

which in the presence of oxygen produce reactive oxygen species 

(ROS), such as singlet oxygen ( 1 O2), superoxide and hydroxyl 

radical (OH . ). Lately PDI has been studied for its potential in 

infectious diseases. The aim of this present study is to explore 

mechanisms of PDI effect on Gram-positive and Gram-negative 

bacteria by using type I and type II photosensitizers. 

Study: Fluorescence probes such as 30-(p-aminophenyl) fluorescein (APF), 30-(p-hydroxyphenyl) fluorescein (HPF) and 

Singlet Oxygen Sensor Green reagent were used to determine 

type I (OH . ) and type II ( 1 O2) mechanisms in antimicrobial 

photosensitizers: tris-cationic buckminsterfullerene (BF6) and a 

conjugate between polyethylenimine and chlorin (e6) (PEI-ce6). 

Thiourea is a potent OH . scavenger. Sodium azide (NaN3)isa scavenger of 1 O2. Both PDI and Fenton reaction (generation of 

OH . ) were carried on Gram-positive bacteria (Staphylococcus 

aureus and Enteroccoccus fecalis) and Gram-negative bacteria 

(Escherichia coli, Acinetobacter baumannii and Pseudomonas 

aeruginosa) in phosphate-buffered saline (PBS) or deuterium 

oxide (D2O) solution. PDI mediated by conjugate PEI-ce6, BF6 or 

non-PDI Fenton reagent was examined in the presence or absence 

of NaN3 or thiourea on all tested bacteria. 

Results: Conjugate PEI-ce6 mainly produced 1 O2, and D2O 

enhanced the 1 O2 yield in ROS probe study. PEI-ce6 is considered 

as type II PS. BF6 is a type I PS because it produced markedly 

more OH . in APF and HPF probes study. All tested bacteria were 

killed via OH . generated through the Fenton reaction. Grampositive 

bacteria needed much higher concentration of Fenton 

reagent than Gram-negative bacteria did. Surprisingly D2O dramatically potentiated Fenton reaction on all tested Gramnegative 

bacteria. 10 mM NaN3 inhibited PEI-ce6 mediated PDI 

on all tested bacteria in PBS. NaN3 failed to protect all tested 

Gram-positive and Gram-negative bacteria in PEI-ce6 mediated 

PDI in D2O. This is because D2O prolongs the lifetime of 1 O2 to 

suppress NaN3 quenching 1 O2. Thiourea inhibited Fenton reaction 

in PBS solution on all examined bacteria. Thiourea inhibited BF6 

mediated PDI on all tested bacteria in PBS and D2O. Conclusion: Based on the findings in the present study, 

mechanisms of PDI effect on Gram-positive and Gram-negative 

bacteria are different. It seems Gram-negative bacteria are more 

susceptible for OH . while Gram-positive bacteria may be more 

susceptible to 1 O2. 

#171 


MECHANISM OF PROPIONIBACTERIUM ACNE 

DESTRUCTION BY INITIATION OF REACTIVE 

OXYGEN SPECIES BY 414 NM ABSORPTION 

Caerwyn Ash, Llinos Harris, Thierry Maffeis, 

Marc Clement, Gareth Stockman, Michael Kiernan 

Godfrey Town, School of Medicine, Swansea University, 

School of Nanotechnology, University of Wales, Global Academy, 

Swansea, United Kingdom 

Background: This study provides scientific evidence to the 

clinical explanation of photodynamic therapy of Acne clearance 

using 414 nm LEDs or intense pulsed light (IPL). Our group 

viewed propionibacterium using a cryo Scanning tunnel Electron 

Microscope (SEM) offering the potential to visually show the 

destructing mechanism of free radical generation by porphyrin 

absorption. The safe and effective benefits of using light to treat 

acne vulgaris are well known. 

Study: Cultured propionibacterium was grown at a controlled 

population density and separated into 15 individual plates. Three 

used as control, six for IPL exposure (400–1,100 nm, 3–11 J/cm 2 ), 

six for LED exposure at 414 nm (10–100 J/cm 2 ). Propionibacterium 

control samples and after exposure was evaluated for cellular 

necrosis viewed using a cryo SEM for cellular damage. 

Results: The 414 nm LED Exposure at 100 J/cm 2 produced the 

highest decrease in culture population of 98.3% on average of 

five repeated tests; the lowest decreased in population was 

shown to be 38%. The control group showed no decrease in 

colony size during the experiment. A SEM was used to view 

cleaved samples of propionibacterium exposed and control 

showing cellular damage caused by exposure to visible light. 

Conclusion: This study shows the mechanism of photodynamic 

therapy of propionibacterium on a cellular level. This study showed 

cell membrane perforation due to free radical generation, thus 

demonstrating the mechanism of photodynamic treatment of acne. 

#176 

TEMPERATURE MODULATED PHOTODYNAMIC 

THERAPY FOR THE TREATMENT OF ACTINIC 

KERATOSES ON THE EXTREMITIES 

Andrea Willey, Fernanda Sakamoto 

Solano Dermatology, Laser & Skin Surgery Center, UC Davis, 

Sacramento, CA; Wellman Center for Photomedicine, Boston, MA 

Background: The efficacy of cutaneous photodynamic therapy 

(PDT) using 5-aminolevulinic acid (ALA) in the treatment of 

actinic keratosis has been demonstrated in a large number of 

clinical trials and is particularly useful for the treatment of large 

surface areas in the setting of field cancerization. However, 

clearance rates are substantially lower for distal extremities 

compared to the head and neck areas. Recent research has 

demonstrated a strong relationship between temperature and 

porphryin metabolism in biologic tissue, suggesting that 

temperature modulation may offer a previously unrecognized 

opportunity to increase efficacy of PDT in areas where biologic 

temperatures are naturally lower. The aim of this study is to 

evaluate the efficacy and tolerability of temperature modulated 

PDT for the treatment of actinic keratosis in the setting of field 

cancerization. 

Study: Ten of 20 subjects have been enrolled to date in this 

blinded, randomized, single center, IRB approved study. Upper 

and lower extremities were treated with 20% ALA under 

occlusion, followed by exposure to 10 J/cm 2 417 nm light. One 

randomly chosen extremity was heated during the 1-hour 

incubation. Skin surface temperatures were monitored 

throughout incubation and tolerability was measured during and 

following treatment on a four point scale. Lesions counts were 

performed by an unblinded investigator and photographs were 

evaluated by a blinded investigator at baseline, 2 and 6 months 

following treatment. 

Results: Twenty subjects will be enrolled and 10 will have 

completed 6 months follow-up at the time of presentation. 

Temperatures ranged from 37 to 408C on the heated extremity. By


unblinded evaluation PDT reactions were enhanced and clearance 

rates increased on the treated extremity compared to the nontreated 

extremity. The treatment was generally tolerated well. 

Conclusion: Warm-skin PDT appears to improve the efficacy of 

the treatment of actinic keratoses on the extremities with 

reasonable tolerability and may be a useful adjunct in the setting 

of field cancerization. 

#177 

FRACTIONAL CO2 LASER IMPROVES 

TREATMENT OF NBCC WITH ALA-PDT 

Roman Smucler, Jan Lippert, Marek Vlk 

Charles University, Prague, Czech Republic 

Background: Photodynamic therapy with aminolevulic acid 

(ALA-PDT) is well-established treatment method for superficial 

form of basal cell carcinoma (BCC) and actinic keratosis mostly. 

Nodular form of BCC is perceived as contraindication due to 

tumor layer bigger then 2 mm. Proper penetration of 

photosensitizer is crucial. Classical approach is curettage. 

Authors previously improved results with ablative laser. Another 

possibility offers ablative fractional laser which produce skin 

microtubules. This principle can enhance penetration of ALA but 

necrotic tissue surrounding tubules can decrease effectiveness. 

Aim of our study is to evaluate fractional laser as pre-treatment 

before ALA-PDT in nodular BCC. 

Study: Twenty-five histologically verified nBCC were under 

control of ultrasound ablated with 980 nm diode laser up depth 

between 1 and 3 mm. Three weeks later half of tumor was treated 

with curettage and second with fractional CO2 laser—density 

40%. Study was blinded with different side treatment. 

Immediately after we applied mALA, 3 hours occlusion, Aklilite 

irradiation 40 J cm 2 . Checkups every months with fluorescence 

(ALA based) and defined photography. Single-blinded. Evaluator 

compared fluorescence with use of scale. After 12 months biopsy 

from both sides. 

Results: Twenty-five nBCC treated compare 22 in control 

group. Fluorescence significantly lower in treatment group. More 

adverse effects and longer down time in treatment group. 

Conclusion: Fractional laser pre-treatment can enhance ALA- 

PDT but we do not know proper parameters, optimal laser, protocol. 

Many studies will be necessary before finalclinicaloutcomes. 

#178 

NEW TOPICAL PHOTODYNAMIC THERAPY FOR 

MANAGEMENT OF PRIMARY AXILLARY 

HYPERHIDROSIS 

Abeer Attia, Manal Salah 

National Institute of Enhanced Laser Sciences, Cairo, Egypt 

Background: A variety of treatment modalities have been used 

in the management of primary axillary hyperhidrosis but no ideal 

treatment yet. Recurrence and side effects of these modalities 

suggested the need for a long acting treatment with a strong 

safety profile. To study the efficacy and safety of photodynamic 

therapy in management of primary axillary hyperhidrosis using 

topical Eosin gel and intense pulsed light. 

Study: Twenty patients were treated using intense pulsed light 

with a 400 nm filter, 20 milliseconds pulse duration and 25 J/cm 2 

fluence, once weekly, for four sessions after applying Eosin gel to 

the right axilla for 1 hour and placebo gel to the left. Efficacy was 

measured by hyperhidrosis disease severity scale (HDSS), and 

assessment of sweating area reduction using the minor iodine 

starch test. Liposomal eosin hydrogel has been prepared and 

applied on 24 rats to test for sensitivity reaction, and autopsies 

were examined histologically after irradiation of liposomal Eosin 

hydrogel with light emitting diode (LED). 

Results: A highly significant reduction of the mean hyperhidrotic 

area from 65 28.2 cm 2 before treatment to 5.7 5.2 cm 2 at the 

end of treatment (P < 0.01). A 90.1% reduction in the area of 

hyperhidrosis of the right axilla was obtained versus 2.2% 

reduction in the placebo site. A 3-point improvement on the 4point 

(HDSS) was reported in seven patients (35%), a 2-point 

improvement was reported in nine patients (45%) and 1-point 

improvement was elicited in four patients (20%). Three patients 

(15%) reported a 1-point improvement from HDSS score 4 to score 

3 at the placebo site. No recurrence occurred during the 8-month 

follow-up period. 

Conclusion: Photodynamic therapy using Eosin gel, which is 

photoactivated by IPL, is a non-invasive, safe and effective 

method for management of primary axillary hyperhidrosis with 

no risk of multiple frequent injections and is not time consuming. 

Further studies and long-term follow-up are needed. 

#179 

INVESTIGATION OF THE EFFECTIVENESS OF 

NON-COHERENT BLUE LIGHT IN 

INTRALESIONAL PHOTODYNAMIC THERAPY OF 

BASAL CELL CARCINOMA 

Robert Anolik, Lori Brightman, Anne Chapas, 

Elliot Weiss, Leonard Bernstein, Roy G. Geronemus, 

Elizabeth K. Hale, Julie K. Karen 


Background: Innovative treatments are urgently needed for the 

more than 1 million non-melanoma skin cancers (NMSCs) that 

arise in the US annually, particularly for those prone to numerous 

NMSCs or poor surgical candidates. Topical photodynamic 

therapy (PDT) offers a novel strategy. Injection of 

photosensitizing agents may enhance PDT efficacy by increasing 

depth of activity around localized tumors. The purpose of this 

study is to determine the effectiveness of non-coherent blue light 

in the intralesional PDT of BCC. 

Study: This is a prospective, IRB-approved study of 20 BCCs in a 

private dermatology center. Each BCC was injected with 20% 

aminolevulinic acid, incubated for one hour, and exposed to noncoherent 

blue light. If without clinical clearance at 8 weeks, a 

second treatment was performed. Clinical evaluations were 

performed at each treatment and repeated at 16 weeks, 1 year, 

and 2 years after PDT. These follow-up visits included subjective 

patient assessments and punch biopsies of the treatment sites. 

Results: To date, no patient has been lost to follow-up. All 20 

BCCs were evaluated at 16 weeks, showing recurrence at two sites 

on histology. For those 18 sites still negative at 16 weeks, 13 have 

been re-evaluated at 1 year, with an additional 4 sites of 

recurrence. Five have returned for their 2-year exam and showed 

recurrence at 1 more site. Although the number may increase with 

the remaining 1- and 2-year follow-up visits, the overall 

recurrence rate to date is 35% (7 of 20 sites) at 2 years. Notably, 

physicians graded cosmetic outcome as good-to-excellent in 2/3 or 

more of the treatment sites at all follow-up exams. No unusual 

adverse event was appreciated. 

Conclusion: Intralesional PDT offers a potential alternative for 

effective and cosmetically acceptable treatment of BCC, although 

recurrence rates are higher than some other options.

SURGICAL APPLICATIONS 

INTERSTITIAL LASER 

THERAPY 

#181 

USE OF GOLD-BASED NANOPARTICLES TO 

DIRECT LASER INTERSTITIAL PHOTOTHERMAL 

CANCER THERAPY 

Jon Schwartz, Glenn Goodrich, Kelly Gill-Sharp, 

J. Donald Payne 

Nanospectra Biosciences, Inc., Houston, TX 

Background: Laser-delivered thermal energy, if it can be 

adequately targeted and calibrated holds the possibility for 

treatment of tumors that are otherwise non-resectable due either 

to their proximity to critical structures which limit radiation and 

surgical options, or due to accumulated multi-drug resistance. We 

have investigated nanoparticles as a means of directing 

photothermal treatment to cancer by determining that: (1) 

nanoparticles accumulate passively in tumors, (2) there exists 

appropriate laser dosimetries that ablate target tissue and 

simultaneously minimize thermal damage to neighboring healthy 

tissue, and (3) particle infusion and selective laser ablation may be 

combined therapeutically. 

Study: Nanoparticle specificity for tumor was determined by 

infusing nanoparticles into a variety of murine (CT26.wt) and 

canine (cTVT, J3T) tumor lines and sampling tissues at necropsy. 

Elemental analysis was used to quantify nanoparticle 

accumulation in various tumor types and organs. Laser doses at 

various power levels and temporal durations were tested in vitro 

and in vivo to derive a laser dosimetry that is sub-ablative in 

native tissue, but which results in thermal ablation lesions if 

nanoparticles are present. Finally, in a set of pre-clinical studies, 

we ablated tumors in which therapeutic nanoparticles had been 

either directly injected or accumulated passively. 

Results: Gold-based nanoparticles circulate in the bloodstream 

with half-lives of 2–4 hours, passively accumulate in the 

fenestrations of tumor capillaries, and are cleared by the reticuloendothelial 

system (RES). Near-infrared laser energy, delivered 

percutaneously using an optical fiber system with an isotropic 

diffuser was used to deliver 3–7 W into native brain and prostate 

(canine) and muscle (murine and canine) and the power adjusted 

to arrive at a threshold for ablation in vivo. 

Conclusion: Based on in vitro and in vivo studies we have shown 

that solid tumors may be treated with 1–3 mm thermal damage 

margins using directly injected or systemically delivered 

nanoparticles combined with NIR laser irradiation. 

#182 


MR-GUIDED LASER ABLATION OF LIVER AND 

KIDNEY TUMORS 

Ashok Gowda, Eric Walser 

Visualase, Inc., Houston, TX; Mayo Clinic, Jacksonville, FL 

Background: MR-Guided Laser Ablation may offer advantages 

in minimizing tumor recurrence and enhancing safety near 

critical structures during ablation of tumors in the liver and 

kidney. The goal of this work was to perform pilot clinical work in 

patients suitable to thermal ablation and evaluate the safety and 

preliminary efficacy of MR-guided laser interstitial therapy 

(MRgLITT) with real-time MR temperature monitoring in 

patients with liver and kidney tumors. 

Study: Six patients (three kidney and three hepatic) were treated 

using the Visualase Thermal Therapy System (Visualase, Inc.). 

All procedures were completed with patients under general 

anesthesia positioned within a 1.5 T MRI system. A 14 Ga catheter 

with MR-compatible titanium stylet was placed percutaneously 

into target masses under MR-guidance. Once positioning, the 

stylet was replaced with a cooled laser applicator (600-mm core 

diameter with 1.5 cm diffusing tip and 1.85 mm OD cooling 

catheter). Under continuous thermal imaging, a single laser 

applicator in two cases and two applicators in three cases were 

used to create 2–4 ablation zones per tumor using 30 W of 980 nm 

laser power for between 90 and 120. Post-treatment contrast 

images were compared to estimated treatment zones. 

Results: There were no complications in any procedures and 

thermal imaging was performed successfully during short 

breath holds, and in some cases during normal breathing. In all 

cases, the user could appreciate the area of ablation in near 

real-time within the tissue which was estimated from a damage 

model and overlaid on corresponding real-time magnitude images. 

In three patients at 3 months post-ablation, there is no evidence of 

recurrent or residual tumor by MR examination. One patient went 

on to liver transplant and pathology confirmed complete necrosis 

of the treated area. Two patients are pending initial follow-up 

imaging. 

Conclusion: MRgLITT of liver and kidney tumors is safe and 

feasible, and thus far has been performed without complications 

or side effects. 

#183 

LASER INTERSTITIAL THERMOTHERAPY FOR 

PROSTATE CANCER: ANIMAL MODEL AND 

NUMERICAL SIMULATION OF TEMPERATURE 

AND DAMAGE DISTRIBUTION 

Mohamad-Feras Marqa, Pierre Colin, 

Pierre Nevoux, Serge Mordon, Nacim Betrouni 


Background: Laser interstitial thermo therapy (LITT) ablation 

of low volume prostate cancer is feasible. However, conformation 

of the treated area within the tumor remains a major issue. One of 

the effective methods to perform pre-treatment planning is the 

simulation. 

Study: We used Dunning R3327-AT2 prostate adenocarcinoma 

implanted in the flank of Copenhagen rat. Ten rats were used. The 

laser was a diode system emitting at 980 nm. The device was 

equipped with cylindrical diffusing fiber (CDF) of 10 mm length 

with a 500 mm core diameter. The CDF was inserted into the 

center of the tumor; the power provided was 5 W with energy 

fluence of 1,145 J/cm 2 . The irradiance duration was 75 seconds. 

Thermal camera was used to measure temperature at the tip end 

of fiber. MR acquisition was performed at t þ 48 hours. The 

images were used to estimate the thermal damage volume. The 

heat elevation in prostate tissues and thermal damage was 

modeled using COMSOL MultiphysicsV4.0. Transient analysis of 

the Bioheat equation application mode was used to describe the 

thermal process. Damage inside the irradiated tissue was 

estimated by solving the Arrhenius integral. Validation of the 

model was performed by comparing the results of the bioheat 

equation with results of the MR images.


Results: The maximum heat diffused from the (CDF) in the 

simulation was 156.38C versus 1558C measured. The mean 

volume of the tissue necrosis, estimated on MRI, for the ten rats 

was 0.98 0.05 cc while simulations volumes were: 1.38 cc when 

T ¼ 448C, 1.1 cc for T ¼ 468C and 1.00 cc when T ¼ 508C. 

Conclusion: LITT treatment of the prostate is a promising 

therapy method. It needs further more evaluation and 

understanding of the heat extent in tissues to be a surgical method 

applied in the routine hospitalization. Simulation has enabled 

greater understanding of global impact of LITT. 

#184 

A PHANTOM FOR INTERSTITIAL LASER 

THERMOTHERAPY OF PROSTATE CANCER 

TRAINING 

Pierre Nevoux, Pierre Colin, Bertrand Leroux, 

Philippe Puech, Arnauld Villers, Serge Mordon, 

Nacim Betrouni, Nasr Makni, 

Mohamad Feras Marqa 

CHRU Lille and Inserm, U703, Université Lille Nord de France, 

CHRU Lille, Lille, France 

Background: To construct a prostate phantom magnetic 

resonance (MR) and ultrasound (US) imaging compatible to 

locate, target and monitor a planned procedure of laser interstitial 

thermotherapy (LITT) with a 980 nm diode laser. 

Study: A removable portion with human prostate optical and 

thermal properties was included in a 45 cc anatomically correct 

prostate phantom. It was composed of gelatin. A defined volume of 

coagulable gel was inserted into the prostate to recreate a tumor. 

The other part was fixed and represented perineum and rectum. 

The phantom was evaluated using transrectal ultrasound, MRI 

and real-time thermometry. Diffusing fibers were inserted into 

the model via an 18 G introducing catheter using either a 

brachytherapy grid (transperineal access) or a transrectal probe 

(transrectal access). Prostate cancer boundaries and laser fiber 

placement were assessed by transrectal ultrasound sonography. 

The laser treatment of a predetermined focal lesion was identified 

and targeted by treatment planning simulation. LITT was 

performed with a 980 nm diode laser (power 5 W) during 

75 seconds (fluence rate of 1,145 J/cm 2 ). 

Results: The phantom had characteristics of a prostate including 

areas of interest in focal therapy: prostate cancer area, urethra, 

rectum, sphincter and neurovascular bundles. The prostate model 

allowed us to generate focal thermal lesions. Treatment was 

feasible by both transperineal and transrectal access. LITT 

procedures were performed on this model and treatment effects 

were visible on MRI. 

Conclusion: Current innovations in multimodality imaging 

coupled with new therapeutics like LITT for treatment of localized 

prostate cancer require preclinical evaluation. The described 

prostate phantom is simple, allows treatment planning and 

simulation and LITT training. 

#185 

MINIMALLY INVASIVE FOCAL LASER ABLATION 

FOR PROSTATE TUMORS 

Roger McNichols, Anil Shetty, Ashok Gowda 

Visualase, Inc., Houston, TX 

Background: Focal interstitial laser therapy (ILT) for localized 

prostate cancer may overcome side effects associated with the 

current standard, radical prostatectomy. The goal of this study 

was to develop techniques for implementing MR-guided focal ILT 

with real-time MR temperature monitoring in patients with lowrisk, 

low-volume disease. 

Study: Men with biopsy-confirmed, MR-imageable prostate 

cancer with Gleason score < 7 were offered focal ILT. At 

treatment, patients were placed supine inside the bore of the MR, 

fitted with a perineal needle guide template and imaged in the 

axial plane trough both the prostate and the template. Images 

were transferred to a therapy workstation (Visualase, Inc., 

Houston, TX) and analyzed with software which allowed 

identification of three fiducials on the template and subsequent 

projection of needle guide trajectories through the prostate 

volume. A 14-cm catheter with titanium stylet was inserted 

through the designated guide hole to a target in the prostate. The 

stylet was replaced with a laser applicator (400-mm-core-diameter 

silica fiber with diffusing tip in a 1.65 mm water-cooled sheath) 

connected to a 15-W 980-nm laser. During continuous MR 

imaging, laser energy was delivered and the therapy workstation 

transferred MR images in real-time to display temperature 

changes in the tissue with an update rate of approximately 

5 seconds. Laser doses of 7–12 W were delivered for 60– 

120 seconds. Post-treatment contrast images were used to confirm 

treatment zones. 

Results: Reproducible, accurate placement of applicators into 

targets was achieved. Real-time thermal monitoring was useful to 

ensure target destruction while avoiding heating of structures 

including rectal wall, neurovascular bundles, and urethra. 

Conclusion: MR-guided ILT of prostate tumors with real-time 

thermal imaging is technically feasible, safe, and has a low rate of 

complications or side effects. However, focal ILT has not yet been 

validated as an effective treatment for prostate cancer. 

#186 

COMPARISON OF TISSUE EFFECTS AFTER PAL, 

WAL, SAL, UAL AND LAL 



Background: There are different ways to do liposuction, just by 

suction (SAL), power assisted (PAL), by Waterjet (WAL), by 

ultrasound (UAL), laser assisted lipolysis (LAL). But how does the 

tissue look like after impact, is there a ‘better’, less traumatic way 

to do liposuction? 

Study: Cadavers were treated with different techniques, the 

effect on the tissues, especially on the fat cells and on the septal 

fibers were analyzed. Abdominoplasty patients were treated and 

the tissues analyzed the same way. The tissues were analyzed by 

direct comparison after different ways of liposuction, by endoscopy 

and in open surgery and the corresponding clinical results. In an 

additional histological study, the effect on septal fibers were 

analyzed. 

Results: There were clearly visible differences between the 

different kinds of liposuction: Some specific complications were 

mostly due to the more or less traumatic effects of the cannula to 

the septal fibres and the dermis. Histologies showed the effect on 

microstructure. After LAL collagen tissue was partially 

denaturated, attracting fibroblasts. PAL and LAL were the 

techniques where most septal fibres were preserved. 

Conclusion: Certain aesthetic and medical complications after 

liposuction can be correlated to certain tissue effects after certain 

types of liposuction. The tissue effect after laser assisted 

Liposuction offers superior results because most septal fibres were

preserved and denaturated, inducing fibroblast activation and 

collagen neoformation. 

#187 

TREATMENT PLANNING OPTIMIZATION OF 

PHOTODYNAMIC THERAPY OF PROSTATE 

CANCER USING WST11-TOOKAD SOLUBLE 

Nacim Betrouni, Renaud Lopes, 

Marqa Mohamad-Feras, Pierre Colin, 

Pierre Nevoux, Serge Mordon 


Background: Interstitial photodynamic therapy (iPDT) appears 

as a promising technique to treat some early stage prostate 

tumours. Traditionally drugs target the cellular compartments to 

destroy a tumour but newer vascular-targeting (VT) 

photosensitizers as WST11 are activated while in vasculature. 

This property is exploited to cause vascular damage and to 

enhance tissue necrosis. In this study we were interested by the 

dosimetric planning of iPDT of prostate cancer using WST11. 

Study: Retrospective analysis was executed using results from 28 

patients enrolled in phase II trials of VTiPDT with the WST11 

drug. An optimised action radius was determined using the 

following parameters of: (i) 4 mg/kg drug dose of, (ii) 200 J/cm light 

dose, (iii) devascularised volume, measured after swelling 

correction, on the D7 MR images. Treatment planning is then 

performed, based on this optimal radius, by optimising the fibres 

number, their lengths and their positions using the Powell 

algorithm. 

Results: Validation of the method carried out on six patients 

indicated that the software is able to predict the final damage with 

an overlap of at least 84% corresponding to a margin of less than 

2 mm. 

Conclusion: The proposed model and treatment planning 

method allow realistic simulation of the iPDT results. They are 

not based on light dose distribution analysis through the 

evaluation of the prostate optical properties but are based on a 

correlation between the two main factors influencing the therapy: 

drug and light doses. 

#188 


THE 180 W GREENLIGHT XPS—LASER 

PHOTOSELECTIVE VAPORIZATION 

PROSTATECTOMY FOR SYMPTOMATIC BENIGN 

PROSTATIC HYPERPLASIA: PRELIMINARY 

RESULTS 

Kurt Strom, Xiao Gu, Massimiliano Spaliviero, 

Carson Wong 

The University of Oklahoma Health Sciences Center, 

Oklahoma City, OK 

Background: GreenLight XPS TM laser PVP is a recently 

approved treatment option for lower urinary tract symptoms 

(LUTS) secondary to BPH. We review our perioperative 

experience using the GreenLight XPS TM laser system. 

Study: We prospectively evaluated our initial experience with 

GreenLight XPS TM laser PVP. All patients who failed medical 

therapy and/or surgery underwent GreenLight HPS TM laser PVP 

(CW). All had American Urological Association Symptom Score 

(AUASS), Sexual Health Inventory for Men (SHIM) score, 

American Society of Anesthesiologists (ASA) risk score, serum 

prostate specific antigen (PSA), maximum flow rate (Qmax) and 

post void residual (PVR) determinations and volumetric 

measurements with transrectal ultrasonography. Transurethral 

PVP was performed using a GreenLight XPS TM side-firing laser 

system. 

Results: Eight consecutive patients were identified, having a 

mean age of 73.0 12.1 years. The mean prostate volume was 

67.5 16.4 ml and mean ASA score was 3.1 0.6. Mean laser 

time, operating time and energy usage were 5.9 3.0 minutes, 

24.0 11.0 minutes, and 79.8 17.9 kJ, respectively. All were 

outpatient procedures with six (75.0%) patients catheter-free at 

discharge. One (12.5%) patient required catheter drainage for 1 

week. One (12.5%) patient developed a urinary tract infection. 

None had persistent hematuria > 1 week or post-procedure 

irritative voiding symptoms. No bladder neck contractures or 

urethral strictures have been noted. Mean AUASS decreased from 

24.6 at baseline to 7.3 and 6.9 at 1 and 4 weeks. Q max and PVR 

values also showed statistical significant improvement (P < 0.05). 

Conclusion: Our preliminary results suggest that GreenLight 

XPS TM laser PVP is safe, effective and efficient for the 

treatment of LUTS secondary to BPH. Continued follow-up is in 

progress. 

#189 

INCIDENCE OF URETERAL STRICTURES 

FOLLOWING LASER ABLATION OF TCC 

Kelly Healy, Arturo Colon-Herdman, 

Nicholas Leone, Scott Hubosky, Demetrius Bagley, 

Thomas Jefferson 

Philadelphia, PA 

Background: The holmium and neodymium:YAG lasers are 

commonly used for the endoscopic treatment of upper tract 

transitional cell carcinoma (TCC). Laser ablation is an efficacious 

nephron-sparing surgical option in select patients. However, 

ureteral stricture is a recognized complication of ureteral tumor 

laser ablation. The aim of this study was to evaluate the rate of 

ureteral stricture formation following laser ablation of ureteral 

tumors. 

Study: We analyzed all consecutive patients undergoing ureteral 

tumor laser ablation over a 3-year period at our institution by a 

single surgeon. Operative histories were reviewed for prior upper 

tract TCC treatment episodes. The amounts of Ho:YAG and 

Nd:YAG laser energy used for ureteral tumor ablation were 

recorded for each treatment episode. All subsequent operative 

reports were reviewed for documentation of a new diagnosis of 

ureteral stricture based on endoscopic and/or radiographic 

findings after at least one ureteral tumor treatment. 

Results: A total of 32 patients (36 treated ureters) had complete 

data available for analysis. Of these, 44.4% (16/36) were 

eventually diagnosed with a ureteral stricture on either follow-up 

ureteroscopy or retrograde ureterography. Ho:YAG laser was 

used in all treated ureters, whereas Nd:YAG laser was used in 

only 27.8% (10/36) ureters. The strictured ureters had received a 

mean cumulative dose of 2.35 3.16 kJ Ho:YAG compared to 

2.53 4.50 kJ Ho:YAG among non-strictured ureters (P ¼ 0.88). 

While strictured ureters received a mean cumulative dose of 

1.91 4.80 kJ Nd:YAG, non-strictured ureters received a mean 

cumulative dose of only 0.19 0.45 kJ Nd:YAG (P ¼ 0.11). No 

significant difference in mean tumor size was detected between 

the two groups (strictured 18.74 mm vs. non-strictured 13.33 mm, 

P ¼ 0.20). 

Conclusion: Among patients undergoing Nd:YAG laser ablation 

of ureteral tumors, we demonstrated a trend toward increased


ureteral stricture formation. Compared to the controlled holmium 

energy source, Nd:YAG causes a deeper tissue effect. Based on 

these findings, we typically prefer to use the holmium laser for all 

ureteral lesions. 

#190 

PHOTOCHEMICAL TISSUE BONDING: A 

POTENTIAL STRATEGY FOR TREATING LIMBAL 

STEM CELL DEFICIENCY 

Chuan Gu, Robert Redmond, Irene Kochevar, 

Min Yao, Ying Wang 

Wellman Center for Photomedicine, MGH, Harvard Medical 

School, Boston, MA 

Background: The goal of this study was to determine the 

feasibility of using a new light-activated method for attaching 

human amniotic membrane (HAM) pre-cultured with limbal stem 

cells (LSCs) to the cornea. 

Study: LSCs were isolated from the eyes of rabbits, and then 

cultured on denuded HAM to create grafts. These were then 

transplanted onto rabbits with an eye limbal stem cell deficiency 

(LSCs) and secured either by sutures or by photochemical tissue 

bonding (PTB). Evaluated outcomes included corneal opacity, 

inflammation, neovascularization, and collagen alignment. 

Results: The isolated and cultured cells were verified to be LSCs 

based on their K19 þ /intergrin b1 þ /P63 þ /K3 properties. 

Securing the graft with PTB provided better outcomes than that 

with sutures. At 28 days post-surgery, the corneal opacity scores 

were significantly lower in PTB treatment compared with sutures 

(0.75 0.5 vs. 1.75 0.5, P < 0.01). Similarly, 

neovascularization scores were also lower in PTB treated 

animals (0.75 0.5 vs. 1.5 0.57, P < 0.01). For PTB treated 

samples, the quantification of MPO and CD31 levels from 

immunofluorescent images indicated less neutrophil infiltration 

(5.25 2.21 vs. 13.25 3.09, P < 0.01) and less 

neovascularization (2.0 0.81 vs. 6.25 1.25, P < 0.01) 

forming at the wound site. The collagen alignment shown in 

immunofluorescent and second harmonic generation images 

was better organized than those in the suture group. 

Conclusion: Compared to suture attachment, the light-activated 

technique is a promising modality for treating patients with 

LSCD. Attaching LSC grafts with PTB produced improved 

outcomes. 

#191 

SURFACE TEMPERATURE DISTRIBUTIONS IN 

RABBIT AURICULAR CARTILAGE FOLLOWING 

LASER CARTILAGE RESHAPING WITH CARBON 

DIOXIDE SPRAY COOLING 

Edward C. Wu, Victor Sun, Wangcun Jia, 

Dmitriy E. Protsenko, Cyrus T. Manuel, 

Brian J.F. Wong, J. Stuart Nelson 



Background: Laser cartilage reshaping (LCR) used in 

conjunction with cryogen spray cooling is a promising modality for 

effecting cartilage shape change while minimizing cutaneous 

thermal injury. However, LCR in thicker tissues such as auricular 

cartilage generally require higher laser power, thus increasing 

surface cooling requirements. To eliminate the risks of freeze 

injury characteristic of high cryogen spray pulse rates, we propose 

instead a carbon dioxide (CO 2) spray, which evaporates quickly 

and does not deposit for significant periods of time on the skin, as 

the cooling medium. This study aims to identify optimal 

parameters to perform LCR with CO2 spray cooling in ex vivo 

rabbit auricular cartilage; specifically, to determine the effects of 

laser dosimetry and CO2 cooling parameters on the spatial and 

temporal evolution of surface temperature. 

Study: Parameters used in previous LCR studies with cryogen 

spray cooling were used to approximate optimal laser dosimetry 

and cooling parameters. Excised whole rabbit ears were irradiated 

at three sites with a 1.45 mm wavelength diode laser (13–14 J) 

with concomitant application of CO 2 spray (pulse rate 25– 

85 milliseconds, 1–4 cycles) to the skin surface. Surface 

temperature distributions were measured during irradiation. 

Results: At either laser dosimetry, skin surface temperature 

reached 808C above 2 heating/cooling cycles. Gross inspection 

showed significant cutaneous injury of the irradiated sites with 

minimal cooling (25 milliseconds pulse duration). Increasing 

cooling pulse duration demonstrated improved skin protection 

during irradiation. 

Conclusion: Due to its minimal risk of frostbite during prolonged 

application to tissues, CO2 spray cooling can potentially serve as 

an alternative to cryogen spray cooling in LCR, and may be the 

preferred cooling medium in thicker tissues. At this time, the 

optimal laser dosimetry and cooling parameters are still being 

explored. Future studies evaluating preclinical efficacy in an in 

vivo rabbit model are underway. 

#192 

LASER ASSISTED FACIAL RHYTIDECTOMY AND 

FACIAL REJUVENATION: A REVIEW OF THE 

FIRST 500 PROCEDURES 

Richard Gentile 

Northeastern Ohio College of Medicine, Youngstown, OH 

Background: In 2006 the FDA approved the SmartLipo TM laser 

for subcutaneous lipolysis as well as use on soft tissue. In 2007 we 

began using the 1,064 Nd:YAG laser as an adjunctive technique 

for rhytidectomy specifically using it to elevate the facial flaps. An 

immediate observation in our early procedures was a significant 

and reproducible reduction in facial flap bleeding due to the 

presumed hemostatic effect of the pulsed laser. We then began 

routinely using the laser for facial flap elevation as well as 

forehead and neck rhytidectomy. In addition to the hemostatic 

effects of the laser skin tightening and firming are evident due to 

dermal heating and concurrent laser lipolysis. 

Study: A retrospective review of over 500 procedures completed 

with laser assisted facial dissection was conducted. The 

procedures were carried out by the same surgeon at the same 

facility and include laser irradiation intended to promote laser 

lipolysis, interstitial heating and laser contouring procedures. The 

aesthetic results are reviewed as well as the improvements in 

hemostasis and operating times. 

Results: The photographs pre- and post-operative were examined 

to evaluate whether or not the objectives of the surgery were met 

and for evidence of skin tightening and correction of facial laxity. 

The improvement in hemostasis were evaluated on the basis of 

sponge counts and photodocumentation. Over 95% of patients 

demonstrated significant improvement from their preoperative 

status in terms of aesthetic improvement. 

Conclusion: FiberLaser assisted facial rhytidectomy and facial 

rejuvenation or SmartLifting TM allows for the coagulation of 

small blood vessels in the subcutaneous plane preserving the

dermal plexus of vessels. Skin tightening through tissue 

coagulation also occurs concurrently with the tissue separation. 

This review of the first 500 procedures again demonstrated the 

significant benefits in reducing blood loss and operating time in 

addition to facilitating the aesthetic improvement the patient 

requests. The laser used as a dissecting tool facilitates elevation 

over certain anatomical regions that are difficult to elevate such 

as the nasal labial folds and oral commissure. 

#193 

TREATMENT OF CELLULITE WITH 1-YEAR 

FOLLOW-UP USING A 1,440 NM PULSED LASER: 

PRELIMINARY REPORT 

Barry DiBernardo 

University of Medicine and Dentistry of New Jersey, Newark, NJ 

Background: Cellulite is characterized by a thinning dermis, 

hypodermal fat lobules that extend upward into the dermis and 

expand and stretch fibrous septae that separate the fat lobules. 

Eventually the septae contract and harden (sclerosis) holding the 

skin at a non-flexible length, while the surrounding tissue 

continues to expand. Various devices, requiring multiple 

treatments have been cleared by the FDA for temporary 

improvement of the appearance of cellulite. The purpose of this 

study is to evaluate the efficacy, safety, and duration of the clinical 

benefit associated with a single treatment pulsed laser that 

delivers 1,440 nm energy to the dermal–hypodermal interface for 

the treatment of cellulite and to evaluate the changes in the 

dermal structure that effect the appearance of cellulite. 

Study: Healthy female subjects (n ¼ 10, aged 47 5.4 years) 

with cellulite on their thighs enrolled in a prospective, 

IRB-approved study. Subjects received a single treatment with a 

1,440 nm pulsed laser using a specialized ‘‘side-firing’’ fiber. 

Energy was delivered to the subdermal tissue through a fiber 

designed for targeted delivery of laser energy and enclosed in a 

cannula. Treatment addressed the thinning dermal layer, 

hypodermal fat lobules that extend upward into the dermis, and 

fibrous septae by thermal subcision. Ultrasound, skin elasticity 

measurements and photographs were conducted at baseline, 1, 3, 

6, and 12 months. Subject and physician evaluations were 

conducted at 3, 6, and 12 months. 

Results: Mean skin thickness (as shown by ultrasound) and skin 

elasticity significant (P < 0.001) increases at each time point at 1, 

3, 6, and 12 months as shown by objective measurements. 

Subjective physician and subject evaluations indicated 

improvement, high subject satisfaction, and minimal adverse 

effects. 

Conclusion: A single treatment with the 1,440-nm pulsed 

laser improves the appearance of cellulite and the 

improvement persists for at least 1 year with minimal adverse 

effects. 

#194 


HIGH DEFINITION BODY CONTOURING USING 

LASER ASSISTED LIPOSCULPTURE 

Jamal Jomah, Med Art Clinics 

Riyadh, Saudi Arabia 

Background: Precision Liposculpture and definition of muscles 

has become the new trend in body contouring surgery. This 

method is geared to the healthy non-obese patients who request 

an athletic look. To achieve this, a meticulous Liposculpture and 

Laser Lipolysis are required. A sound knowledge of the muscular 

and adipose layer anatomy is essential. The basic principle of 

Laser Lipolysis lies on the tissue tightening and coagulation that 

result from delivering a controlled thermal energy to the adipose 

and the subcutaneous tissue. This energy causes collagen 

denaturation and collagenesis remodeling and the ultimate 

outcome is measurable shrinkage of the tissue area with definition 

of the underlying muscles. 

Study: The aim of this presentation is to demonstrate the Laser 

Assisted Liposculpture technique and the results of using a 

combined precision Classic Liposculpture with Laser Lipolysis. 

Twenty-seven male and female subjects were treated with Laser 

Assisted Liposculpture. The laser used were 980 diode, 1,320 

Nd:YAG and 1,444 Nd:YAG. An attempt to define the anatomic 

landmarks of the underlying musculature was performed. 

Tumescent anesthesia was used for all patients. The laser probe 

was introduced into the subcutaneous tissue and lasing performed 

in a homogenous way by transillumination and continuous 

motion. 

Results: There were 3 males and 24 females patients. Total areas 

treated were 38. Areas included face, neck, torso, buttocks, and 

thighs. The energy delivered and amount of fats aspirated were 

recorded. The patients were followed for minimum of 6 months. 

Examples of before and after photos will be presented. 

Conclusion: The use of Laser Lipolysis has made a significant 

impact on the patients on the pre-operative consultation and there 

was a good tool to convince the patients. For the aim of volume and 

size reduction the clinical advantage appears to be marginal 

compared to the Classic Liposuction. The length of operation was 

significantly longer with the use of the laser. For the purpose of 

high definition and skin shrinkage it had a significant effect. The 

laser added more shrinkage to the skin and also defined the 

muscles of the abdomen (the athletic 6 pack). The temperature 

surface that was required to achieve the significant result should 

be 458C and immediate sub dermal temperature was 40–428C. 

But further studies were needed. 

#195 

A CONCEPT OF BODY CONTOURING BY 

COMBINING MINIMAL INVASIVE AND NON- 

INVASIVE PROCEDURES: LASER LIPOLYSIS, 

RADIOFREQUENCY AND ACOUSTIC WAVES 

Katharina Russe-Wilflingseder, Elisabeth Russe, 

Manfred Herold 


Background: Request for aesthetic body contouring procedures 

is increasing. Long downtimes are less accepted. Various 

techniques as laserlipolysis (LAL), radiofrequency (RF) and 

acoustic waves (AW) cope with these requests. 

Study: Thirty patients were treated combining these 

technologies. Lipodystrophy and skin laxity on abdomen, upper 

arms, thighs were operated with LAL (1,064 nm and 1,320 nm, 

blended 1:1 or 1:3; 12–46 W) in TLA. Interstitial temperature 

control ensured efficient lipolysis and neocollagenesis. Liquidized 

fat was aspirated. Postoperative compression garments were 

given for 7–14 days. Starting 3-month postoperative a series of 4– 

6 bipolar RF treatments (10–20 J/cm 3 ,2–3seconds) and 6–8 

superficial and deeper penetrating AW treatments (D20S 3–5 bar; 

DI 1,4–3 bar) were applied. Number of treatments was given 

according to skin quality at intervals of 1–2 weeks.


Results: With LAL not only fat could be removed but also tissue 

tightened due to thermal effect on collagen fibers, a main 

advantage compared to traditional liposuction. LAL achieved good 

results for skin tightening without leaving visible scars. 

Convalescence and down time was highly reduced compared to 

lifting surgery. In addition skin quality and elasticity could be 

improved with RF. The electromagnetic waves of RF penetrated 

deep enough and stimulated the neocollagenesis in the dermis by 

thermal effect. The subsequent tightening of skin leaded to a 

reduction of wrinkles and refining of skin texture. In AWT shock 

waves penetrated into dermis and reached subcutaneous fatty 

tissue. AW stimulated cell metabolism, proliferation of stem cells 

and blood circulation in adipose tissue, induced a natural repair 

process. In addition, there was a collagen remodeling. 

Conclusion: LAL, RF, AW for body contouring and skin 

tightening have their specific pros and cons. Their effectiveness 

has been proven individually. AW and RF are ideal 

complementary applications for body treatments due to the 

different depth and mode of action and very effective after LAL for 

improving and maintenance of skin quality and elasticity. 

Combination of these procedures can increase clinical results and 

patients’ satisfaction. 

#196 

LASER HAEMORRHOIDECTOMY: 

RETROSPECTIVE STUDY OF AN EFFECTIVE AND 

AMBULATORY HAEMORRHOIDECTOMY 

Manish Khandelwal, M. Hemadri, E. Ewart, 

P.J. Moore 

Scunthorpe, United Kingdom 

Background: Laser haemorrhoidectomy is performed as a day 

case procedure under local anaesthetic and sedation for 

symptomatic grade 3 and 4 haemorrhoids. The conventional 

operation, Milligan-Morgan haemorrhoidectomy which consists of 

excision of haemorrhoids is done under general anaesthetic with a 

diathermy or sharp dissection. Laser seal is obtained by Diomed 

810 nm or CO2 10,600 nm at 20 W. We want to present our results 

of 102 consecutive patients who underwent this procedure. They 

were admitted in our day surgery unit and prepared according to 

our established protocol (which has ethical approval). They were 

all administered phosphate enema pre-operatively. 

Study: Retrospective analysis of 102 consecutive patients who 

have undergone the laser haemorrhoidectomy from 2006 to 2009. 

They had regular clinic follow-up at 2 weeks, 6 weeks and 6 

months post-operatively. 

Results: One hundred and two patients in 3 years. Male/female 

ratio was 48:54, age range: 32–81 years. One patient was 

converted to general anaesthetic (1%). All patients (except two, i.e. 

2%) were discharged within 2 hours. One due to administration of 

general anaesthetic who was discharged as day-case; other due to 

post-operative bleeding and was admitted for 3 days of 

conservative management. Four readmissions (4%) (two patients 

due to post-operative oedema, two patients due to post-operative 

oedema and pain). All of them were discharged after observation. 

Four patients developed post-operative chronic anal fissures (4%). 

All of them healed with 6 weeks of 0.2% glyceryl trinitrate cream. 

Conclusion: Laser seal haemorrhoidectomy in our hands is 

showing good results. It enhances patient experience. It also has 

cost benefits due to very short stay as most patients go home 

within 2 hours of procedure. It also avoids the risks of a general 

anaesthetic in most of the cases. 

#200 

ELECTRONIC POSTER 

(ePoster) 

STRIAE IMPROVEMENT WITH A NOVEL 

APPROACH BY SUBLATIVE REJUVENATION: 

A PRELIMINARY REPORT 

Maurice Adatto, Boris Vaynberg, Ruthie Amir, 

Hanit Brenner-Lavie 

Skinpulse Dermatology & Laser Center, Geneva, Switzerland; 

Syneron Medical, Yokneam Illit, Israel 

Background: Striae distensae, or stretch marks, are linear scars 

in the dermis which arise from rapid stretching of the skin over 

weakened connective tissue. Ninety-five of women are affected by 

this phenomenon either during puberty or pregnancy. Although 

being not considered as a disease, striae can affect psychologically. 

In this study, we are looking at the efficiency of a new ablative 

fractionated bipolar radiofrequency, in terms of improvement of 

the global aspect of striae, not only in depth but also in width. 

Study: Six patients received one treatment per month over 4–6 

months in the areas where the striae were more prominent 

(abdomen, buttocks, thighs). This new device has the ability to 

place the heat energy within the dermis, with a minimal 

epidermal impact. All patients were treated with the 144 pin tip at 

energies varying between 30 and 36 mJ/pin. Results were 

evaluated by clinical pictures and patient self-evaluation at 

1-month post-last treatment. 

Results: All patients have seen a visible improvement after the 

first or second treatment. As the study is still ongoing, the final 

results will be given at the meeting. Treatments were 

performed without any anesthesia and post-operative care 

consisted in the application of a moisturizing cream, twice a day, 

for 3 days. 

Conclusion: The application of this new sublative fractionated 

bipolar radiofrequency for improvement of striae seems 

promising. This preliminary study performed with this device 

suggests a similar mechanism of action on collagen as in facial 

treatments for acne scar improvement and wrinkle reduction. 

#201 

AGE OF TATTOO IS AN INDICATOR FOR THE 

RATE OF SUCCESS OF LASER-ASSISTED TATTOO 

REMOVAL 

Robert Anolik, Julie K. Karen, Elizabeth K. Hale, 

Leonard Bernstein, Roy G. Geronemus, 

Elliot T. Weiss, Anne Chapas, Lori Brightman 


Background: Tattoos as well as their removal have continued to 

be popular in the United States. When patients consult physicians 

regarding laser-assisted tattoo removal, a common question for 

their physician is how many treatments are necessary to achieve 

satisfactory results. Although it is not possible to give patients a 

precise number, estimation based on tattoo characteristics are 

valuable. It has been the authors’ experience that older tattoos 

respond more quickly to laser treatment when compared to newer

tattoos. The purpose of this study is to assess the rate of resolution 

of older tattoos when compared to newer tattoos. 

Study: The study is a retrospective chart review of patients 

seeking laser-assisted tattoo removal in a private laser and skin 

surgery center. Charts of patients with at least six treatment 

sessions using any combination of the ruby, neodymium-doped 

yttrium aluminium garnet, and alexandrite lasers were reviewed 

in reverse chronological order. The first ten patients with tattoos 

older than 10 years were compared to patients with tattoos newer 

than 5 years. Before and after photographs were evaluated by 

blinded, non-treating staff physicians. 

Results: All 20 patients demonstrated marked resolution of their 

tattoos, exceeding greater than 50% clearance. However, no 

patient with newer tattoos demonstrated near total clearance, 

while 4 (40%) of those tattoos older than 10 years did. 

Conclusion: Age of tattoo serves as an indicator for the rate of 

success of laser-assisted tattoo removal and may be discussed with 

patients when reviewing treatment expectations. 

#202 


#203 

LASER ABLATION OF WOUND EDGES ENHANCES 

COSMETIC OUTCOME OF SUPERFICIAL MOHS 

MICROGRAPHIC SURGICAL SITES 

Robert Anolik, Elliot T. Weiss, Roy G. Geronemus, 

Anne Chapas, Lori Brightman, Julie K. Karen, 

Elizabeth K. Hale, Leonard Bernstein 


Background: Laser surgery allows for precise management of 

unwanted skin changes. When combined with the precision of 

Mohs micrographic surgery, the possibility of achieving skin 

cancer cure along with minimal tissue deformity becomes more 

likely. The purpose of this study is to investigate whether laser 

ablation at the time of Mohs surgery to the edge of superficial 

wounds enhances cosmetic outcome. 

Study: This is a retrospective chart review of patients with facial 

non-melanoma skin cancers treated in a private laser and skin 

surgery center that were allowed to heal by secondary intention. 

Twenty patients were selected by including the first 10 patient 

charts that documented non-fractional erbium laser ablation to 

wound edges immediately following Mohs surgery and the first 10 

patients without ablation. Cosmetic outcome was assessed by 

comparison of photographs 3–4 months after surgery by blinded, 

non-treating dermatologists. Objective assessment was 

determined using the Primos optical tomography imaging system 

(Primos, Canfield Scientific, Inc., Fairfield, NJ) to evaluate 

quantifiable differences in skin surface irregularities. 

Results: When patients with and without laser ablation to the 

edge of superficial Mohs micrographic surgical sites were 

compared, those with laser ablation displayed less noticeable 

scars. Cosmetic benefit was attributed by assessors to less evident 

vertical ‘‘drop-off’’ and shadowing at the border of uninvolved to 

involved skin. The perception of improved border transition was 

quantifiably demonstrated on Primos topographic imaging 

(Primos, Canfield Scientific, Inc., Fairfield, NJ). Other than 

scarring, adverse events were equivalent between the two groups 

and only included expected short-term side effects of erythema, 

swelling, and bruising. 

Conclusion: Laser ablation to the edge of superficial wounds at 

the time of Mohs micrographic surgery enhances cosmetic 

outcome. The subjective benefit is confirmed with objective 

topographic imaging, which demonstrates quantifiable 

differences in the rate of border transition into the wound bed. 

HAIR REMOVAL WITH ALEXANDRITE LASER ON 

SKIN GRAFTS AFTER RECONSTRUCTIVE FACIAL 

SURGERY 

Cesar Arroyo, Antonio Diaz, Marcedes Martinez, 

Agustin De la Quintana, Patricia Homar 

Madrid, Spain 

Background: One of the advances in reconstructive surgery has 

been the ability to solve those cases where the removal of an injury 

would leave a flaw due to the loss of substance that can only be 

solved by using cutaneous covering techniques by performing skin 

grafts. This may bring some side effects, besides being 

anaesthetic. It can also interfere in the lives of patients who have 

undergone this procedure. 

Study: In this study, we selected a group of patients with hair 

follicles in skin grafts performed to cover different types of lesions 

(tumors, trauma) and subjected them to serial treatment with 

alexandrite laser (775 nm) consisting of conducting no fewer than 

four sessions at intervals varying from 4 to 6 weeks. Patients 

treated with skin grafts from the thigh (donor site) to cover defects 

in the facial area after surgery (oral cavity, nasal region, ear, etc.) 

by the Reconstructive and Plastic Surgery Service of our hospital 

over the past 6 months. Laser Alexandrite 755 nm (Elite, 

Cynosure INC). Smart Cool 5 Skin cooling system (compressed 

air). Digital Photo System (Cannon D70). 

Results: Percentual decline of over 70% fewer sessions compared 

with normal skin hair observed in all the treatments, without 

effect on the grafted tissue and high patient satisfaction. 

Conclusion: Preliminary results are very encouraging and give 

us an alternative for solving these cases, where the problem 

ranges from visual aesthetic defects to functional problems such 

as swallowing disorders in the case of skin coverage with grafts in 

oral cavity and where it may be considered to perform the hair 

eradication treatment on the donor first, given the lack of impact 

on the vitality of the graft. 

#204 

AGMINATED BLUE NEVI ARISING WITHIN A 

CONGENITAL MELANOCYTIC NEVUS: 

TREATMENT WITH 755 NM ALEXANDRITE LASER 

Porcia Bradford, Corbin Petersen, Puja Puri, 

Claude Burton 

Duke University Medical Center, Durham, NC 

Background: Blue nevus is a benign, localized collection of 

dermal melanocytes; however, blue nevi may rarely appear 

grouped in an agminated pattern within a congenital melanocytic 

nevus. Agminated blue nevi arising within a congenital 

melanocytic nevus can cause significant cosmetic and 

psychological disturbances. Serial surgical excisions are usually 

recommended; however, this can cause major morbidity for the 

patient. The purpose of this study was to evaluate the clinical 

response to alexandrite laser in a patient with agminated blue 

nevi arising within a congenital melanocytic nevus. 

Study: A 34-year-old Caucasian woman presented with a large 

(30 cm 15 cm) congenital melanocytic lesion, punctated with 

multiple dark blue papules on the right arm. Histopathologic 

examination of one of the papules revealed a dermis with heavily 

pigmented fusiform and dendritic melanocytes embedded in a 

sclerotic stroma, consistent with a blue nevus. A long-pulsed 

alexandrite laser with a wavelength of 755 nm and a pulse 

duration of 3 milliseconds was used to treat the lesion. The patient


was treated at a fluence of 50–55 J/cm 2 and a spot size of 8 mm. 

Treatments were performed at 2-month intervals. Cryogen spray 

cooling was used. 

Results: Flattening of the blue nevi was observed after six 

treatment sessions with the alexandrite laser. Side effects 

included mild blistering and moderate scabbing. The treatment 

area healed without scarring. Hyperpigmentation or 

hypopigmentation were not present in the treated area. 

Conclusion: The 755 nm alexandrite laser is a safe and effective 

treatment for agminated blue nevi arising within a congenital 

melanocytic nevus. 

#205 

LOW FREQUENCY ULTRASOUND FOR 

NON-INVASIVE FAT CONTOURING 

Joseph Cervone 

UMDNJ, West Orange, NJ 

Background: A burgeoning search for non-invasive technologies 

as alternative to traditional liposuction has been fueled by 

perioperative risks for lack of acceptable cosmetic appearance and 

adequate skin tightening. In this series we examine the efficacy of 

noninvasive transepidermal low frequency ultrasound (Vaser 

Shape—Sound Surgical Technologies) to eliminate fat cells 

through use of cavitation without need for topical or tumescent 

anesthetic. Changes in circumferential measurements areas of 

lipodystrophy in the abdomen, back and flanks were recorded and 

digitally photographed. 

Study: Seven subjects, 39–58 years old underwent one to five 

treatments administered across areas at 5 10 in. bilaterally 

with the Vaser Shape (Sound Surgical Technologies) utilizing 

dual transducers delivering ultrasonic energy at modulated 

presets. Each subject had a minimum of five minutes of manual 

lymphatic drainage massage prior to and following treatments. 

The ultrasound treatments were followed at 4- to 5-day intervals 

by a zonal massage to the previously treated areas administered 

by the integrated handpiece. We examine the results achieved 

from seven patients treated in the abdominal, back or flank areas. 

Skin temperatures of 38–448C were reached and monitored 

directly thru the transducers in the ultrasound handpiece. Static 

photographs and circumferential measurements were taken pre 

and post each treatment to quantify reductions in measurements 

and assess changes in skin laxity. 

Results: Significant reductions in circumferential measurements 

and skin tightening were achieved in all subjects without any 

significant discomfort or adverse events. Erythema seen during 

each treatment was self-limited resolving within hours. The range 

of circumferential measurement reductions was from 300 

00 

4 to 3.5 

with an average of 2.5 cm. 

Conclusion: Transepidermal ultrasound showed safety and 

efficacy in reduction of fatty deposits as evidenced by decreased 

circumferential measurements with significant improvement in 

skin laxity. 

#206 

TREATMENT WITH DUAL WAVELENGTH 1,550 NM 

AND 1,927 NM FRACTIONAL LASER FOR FACIAL 

SKIN REJUVENATION IN ASIANS 

Nicola P.Y. Chan, Johnny C.Y. Chan, 

Mona L.S. Chiu, Henry H.L. Chan 

The University of Hong Kong; Prince of Wales Hospital, 

Hong Kong, China 

Background: The objective of this study was to assess the 

efficacy and side effects of dual wavelength treatment with 

fractional 1,550 nm erbium-doped fiber laser and a novel 1,927 nm 

thulium fiber laser for facial skin rejuvenation in Asians. The 

combination wavelengths aimed to achieve both deep and 

superficial resurfacing within one treatment. 

Study: Each patient received one full-face treatment with two 

passes of 1,550 nm laser followed by two passes of 1,927 nm laser. 

Standardized photos were taken with the Canfield Visia CR 

system at baseline, 1 month and 3 months post-treatment, and 

were assessed by two independent physicians. 

Results: Eight Chinese female patients were included. The 

energy levels for 1,550 nm laser and 1,927 nm laser were 40 and 

10 mJ, respectively. The total densities (MTZ/cm 2 ) ranged from 66 

to 114 for 1,550 nm laser; and 144–222 for 1,927 nm laser. 

Preliminary results demonstrated statistically significant 

improvement in skin texture (P ¼ 0.01), skin laxity (P ¼ 0.01), 

wrinkles (P ¼ 0.01), enlarged pore (P ¼ 0.026) and overall 

pigmentation irregularity (P ¼ 0.017) at last follow-up. The 

degree of improvement was graded as slight to moderate. 

Erythema was seen in one patient at last follow-up. No 

hyperpigmentation was recorded. All patients were satisfied with 

the treatment at 3 months follow-up. 

Conclusion: A single treatment with the dual wavelength lasers 

achieved significant clinical improvement with a good safety 

profile for facial skin rejuvenation in Asians. 

#207 

HOME-USE HAIR REMOVAL DEVICES: DO THEY 

HAVE THE PARAMETERS DECLARED? 

Esther Cuerda, Jose Luis Lopez-Estebaranz, 

Jesus del Pozo-Losada, Maria Angustias Palomar, 

Rafael Linares 

Fundación Universitaria Hospital Alcorcón; Universidad Rey 

Juan Carlos, Madrid, Spain; Hospital Universitario Juan 

Canalejo, A Coruna, Spain 

Background: Hair removal is one of the most demanded cosmetic 

treatments. The home use hair removal devices is expanding and 

there are an increasing number of devices available to consumer, 

most of them intense pulsed light (IPL) but other systems as diode 

laser are available too. 

Study: This study compared three home devices for hair removal: 

Silkn (Home Skinovations Ltd, Israel), iPulse (CyDen Ltd, UK) 

and Tria (SpectraGenics, Inc., CA, USA). Parameters measured 

were: emitted wavelength spectrum, fluence, time of emission, 

frequency and spatial distribution of the energy. Practical 

questions as weight, spot size, battery duration, application 

simplicity, lamp duration or time necessary for epilation were 

measured. 

Results: This study, using established measure methods, has 

shown that all parameters, except emitted wavelength spectrum, 

were different from declared by manufacturer. They had different 

pulse duration: Silkn (not declared by manufacturer; 5.01– 

5.1 milliseconds measured), iPulse (25–60 milliseconds declared 

by manufacturer; 26–61 milliseconds measured), Tria (125– 

600 milliseconds declared by manufacturer; 5 milliseconds 

measured), and fluences: Silkn (5 J/cm 2 declared by 

manufacturer; 2.8–4.2 J/cm 2 measured), iPulse (7–10 J/cm 2 

declared by manufacturer; 7–10 J/cm 2 measured but in different 

energy levels than declared), Tria (6–24 J/cm 2 declared by

manufacturer; 4–11.8 J/cm 2 measured). Other difficulties for 

application were found as limited battery duration, slowness or 

difficulty for auto-application. 

Conclusion: In conclusion, these home devices for hair removal 

tested, shown different parameters from declared by 

manufacturer. 

#208 

REVIEW OF THE LITERATURE: LOW LEVEL 

LASER THERAPY IN THE TREATMENT OF 

TEMPOROMANDIBULAR DISORDERS 

Hadi Daia, Heidi C. Crow, Thomas S. Mang 

Buffalo, NY 

Background: Low level laser therapy (LLLT) has been used for 

over two decades in the treatment of temporomandibular 

disorders (TMD). This review of the literature evaluates the 

current evidence for the use of LLLT as a treatment modality in 

treating patients with TMD. 

Study: The literature was searched for published clinical 

trials or retrospective studies including participants with 

one or more TMD diagnoses, and using LLLT in the treatment. 

Twenty studies were identified, 2 retrospective studies 

and 17 clinical trials. These studies were evaluated and 

discussed. 

Results: All retrospective studies and 9 out of the 17 clinical trials 

had positive results. Studies with negative results are most likely 

due to insufficient dosing or improper design. 

Conclusion: LLLT can be considered as an alternative physical 

medicine modality in treating patients with TMD. State of the art 

dosing is suggested. More studies are needed to define the 

ultimate dose specific to each TMD condition. 

#209 


PORT WINE STAINS PREVIOUSLY TREATED 

WITH AN INTENSE PULSED LIGHT SYSTEM. 

TREATMENT WITH A DUAL-WAVELENGTH 

LASER SYSTEM (595, 1,064 NM) IN 40 PATIENTS 

Jesu´s Del Pozo, Esther Cuerda, Lucía Pérez-Varela, 

Laura Rosende 

CHU A Coruña, A Coruña, Spain; University Rey Juan Carlos, 

Madrid, Spain 

Background: The elective treatment for port wine stain (PWS) is 

considered the pulsed dye laser. Other light devices like intense 

pulsed light (IPL) systems have shown efficacy in the treatment of 

PWS. In our experience only about 25–30% of the PWS treated 

with IPL achieved complete clearance. To understand the effect of 

the dual PDL-Nd:YAG laser on resistant PWS, 40 patients 

previously treated with an IPL system received additional 

treatments with the dual laser. 

Study: Forty patients 28 females and 12 males, average age of 

35.5 years (14–72 years) previously treated by an IPL 

(Photoderm-Vasculight, Lumenis, Yokneam, Israel) were enrolled 

in a study to receive treatment with the and dual PDL-Nd:YAG 

laser (Cynergy with Multiplex, Cynosure, Westford, MA, USA). 

The recalcitrant PWS were located: 3 on the leg, 4 on the arm, 7 on 

the trunk and 26 on the face. In two patients the PWS was 

associated with Sturge–Weber syndrome and in three patients 

with stable hypertrophy. In six patients a CO2 laser was used to 

treat the nodules. Four patients received between 1 and 5 IPL 

treatments, 10 patients received 5–10, 8 patients received 10–15 

treatments and 18 patients received more than 15 treatments. 

Patients were subsequently treated with the dual wavelength 

laser using parameters in group IV, a 7 or 10 mm spot size, PDL 

fluency between 7 and 11 and YAG fluency between 40 and 60. 

Twenty patients received two treatments with the dual laser, 18 

patients received three treatments and 2 patients received four 

treatments. 

Results: Improvement with IPL treatments were as follows: two 

patients had no change. Fifteen patients improved 0–25%, 11 

patients had 25–50% improvement, 11 patients had 50–75% 

improvement and 1 patients had > 75% improvement. After dual 

laser treatments, five patients (four with facial lesions), had no 

improvement. Twenty-three patients improved between 25% and 

50%; 10 subjects improved between 50% and 75% and 1 patient 

achieved > 75% improvement. Ten of the 40 subjects indicated 

that the dual laser was more painful and 20 patients felt 

equivalent pain. Eight patients had edema and crusting, 5 

patients experienced persistent erythema, 2 hypopigmentation, 6 

patients had textural changes and one hypertrophic scar. The 

percentage of secondary effects were a result of delivering high 

fluencies on resistant PWS. 

Conclusion: 87.5 of patients improved after dual laser 

treatment. Of patients who had no response of dual laser 

treatment 80% had lesions on the face. In summary, dual 

treatment might be an option in treating PWS resistant to IPL 

systems. 

#210 

TREATMENT OF BECKERS NEVUS WITH 

MODIFIED INTENSE PULSED LIGHT IN 

INDIAN SKIN 

Niteen Dhepe, Ashok Naik, Vaishali Phadke, 

Shubhangi Sundalam, Nirav Desai 

Pune, India 

Background: Few reports have been published about the 

treatment of Becker’s Nevus using Er:YAG, Qs-Nd:YAG, LP Ruby 

and intense pulsed light without impressive results. To evaluate 

the efficacy and safety of modified IPL in the treatment of Becker’s 

nevus in Fitzpatrick skin type IV and V. 

Study: Nine patients (four male, five female), 13–29 years of age, 

and of skin phototype IV and V were treated with modified IPL 

(LEO 540 on Harmony platform, Alma Lasers) with 540 nm filter, 

fluence energy of 16–20 J/cm 2 , pulse width of 10–12 milliseconds, 

at 1–4 months intervals for 4–6 sittings. VAS scoring (VAS 1–4) 

is done two blinded dermatologists for evaluation of pigment 

lightening, color matching with surrounding skin and 

complications. All the patients were followed for 6–18 (average 7) 

months after the last treatment session. 

Results: At end of four sessions mean pigment reduction was 2.9 

on VAS of four while it was 3.8 at six sessions. Color match with 

surrounding skin was observed excellent ( > 75%) in 4/9, good (50– 

75%) in 4/9, fair (25–50%) in 1 patient. Clearance was better and 

longer lasting at fluence 19–20 J/cm 2 than 16–18 J/cm 2 and better 

at 10 milliseconds than 12 and 15 milliseconds. Transient 

hypopigmentation, erythema and hyperpigmentation is observed 

for a variable period of 4–12 weeks while no scarring is seen in 

any patient. 

Conclusion: LEO 540 at narrow pulse width and high fluence 

is safe and effective treatment for Becker’s Nevus in Indian 

skin.


#211 

USE OF A FRACTIONATED Q-SWITCHED RUBY 

LASER FOR TREATMENT OF FACIAL 

LENTIGINES 

Joseph Diehl, Lisa Chipps, Ronald Moy 

David Geffen School of Medicine at UCLA, Los Angeles, CA 

Background: Fractionated laser technology is associated with 

decreased post-treatment morbidity, but has not been applied to 

Q-switched ruby lasers (694 nm). Standard Q-switched ruby 

lasers have been used effectively for the treatment of pigmented 

lesions, but require post-operative wound care and significant 

recovery time. 

Objective: To report on the suitability of a new fractionated 

handpiece for a Q-switched ruby laser for the treatment of facial 

lentigines. 

Study: Patients with facial lentigines were treated with or 

without topical anesthetic with a fractional Q-switched ruby laser 

at a fluence that caused tissue whitening. 

Results: Fifteen patients were treated one to two times. All 

patients experienced clinical improvement in hyperpigmentation, 

with minimal post-treatment erythema and crusting. 

Conclusion: The fractionated Q-switched ruby laser is an ideal 

treatment for facial lentigines, causing clinical improvement with 

minimal post-treatment morbidity. 

#212 

PATIENT SATISFACTION AT 2 AND 6 MONTHS 

AFTER A SINGLE NON-INVASIVE 

CRYOLIPOLYSIS TREATMENT FOR 

SUBCUTANEOUS FAT LAYER REDUCTION 

Jeffrey Dover, Michael Kaminer, Maureen Teahan, 

Lauren Barrett 

SkinCare Physicians, Chestnut Hill, MA 

Background: Cryolipolysis is a noninvasive, FDA-approved 

procedure used for fat layer reduction. Cryolipolysis, or coldinduced 

apoptotic fat cell death, is used to reduce the thickness of 

the subcutaneous fat layer without damage to the overlying skin 

or associated structures. Clinical studies have reported an 

approximate 20% reduction in the fat layer with a single 

treatment. Results appear as early as three weeks, with full 

results usually visible within 2–6 months. This study evaluated 

patient satisfaction with the CoolSculpting procedure after a 

single treatment. 

Study: Male and female subjects ¼ 18 years of age who had 

received a single cryolipolysis procedure (CoolSculpting, Zeltiq, 

Inc., Pleasanton, CA) for fat layer reduction on the flanks (love 

handles) or abdomen were surveyed by telephone at 2 and 6 

months. 

Results: Sixteen of 21 patients treated (72.7%) completed the 2month 

survey; 15 of the 16 (93.7%) also completed a follow-up 

survey at 6 months. At 6 months, 80% of patients reported they 

were happy with the results of their treatment, compared with 

50% at 2 months. Only one patient at 2 months, and no patients at 

6 months, reported that they were not happy with treatment. Of 

those who did not say they were happy with their result, most said 

they were ‘‘not sure.’’ At 6 months, patients rated their results at 

an average of 6.6 on scale of 1–10, compared with 4.2 at 2 months. 

Conclusion: In this survey of patients who had received a single 

cryolipolysis procedure, both overall satisfaction and patientrated 

results of treatment improved significantly from 2 to 6 

months, consistent with the gradual nature of improvement 

previously reported for cryolipolysis. Six months after treatment, 

overall satisfaction was very high, with 80% of patients reporting 

they were happy with their results. 

#213 

THE USE OF A PERFLUROCARBON EMULSION 

AS A POST-LASER TREATMENT 

J. Kevin Duplechain, Mark G. Rubin, 

Mark G. Fontenot 

Tulane University, Lafayette, LA; Lasky Clinic, Beverly Hills, CA; 

Gabriel Medical, Palo Alto, CA 

Background: Carbon dioxide laser resurfacing continues to be a 

very desirable treatment with the advent of fractionated 

treatment devices. Complications still develop at undesirable 

rates with several recent articles demonstrating the effect of 

infection and varied treatment protocols. The use of a 

perflurocarbon emulsion was undertaken in 100 consecutive 

patients to determine if reduced complications with such an 

emulsion were possible. 

Study: One hundred patients underwent CO2 resurfacing. Each 

patient was treated with the perflurocarbon emulsion three times 

daily. Antivirals were prescribed in all cases, but the use of 

antibiotics and steroids were excluded. Patients were advised to 

report any side effects during the treatment which including 

increased erythema, prolonged healing, or signs of infections. 

Results: Ninety-nine patients completed the study. One patient 

withdrew from the study to use a petrolatum based product 

because of perceived dryness. The patient developed an acneform 

eruption and was subsequently treated with the perflurocarbon 

emulsion with good success. Two patients developed a single site 

pustule that was treated by unroofing the lesion with a needle. No 

other complications were noted. 

Conclusion: The use of a perflurocarbon emulsion provides an 

excellent post laser treatment with less complications than 

previously reported when petrolatum based products were 

utilized. Overall patient satisfaction with the laser treatment and 

the post-laser emulsion were very high indicating that minimizing 

post-treatment complications may increase patient interest in 

laser skin resurfacing. 

#214 

COMBINATION 15% AZELAIC ACID GEL AND 

INTENSE PULSE LIGHT THERAPY FOR MILD TO 

MODERATE ROSACEA 

Sabrina Fabi, Jennifer Peterson, Mitchel Goldman 

Goldman Butterwick & Associates, Cosmetic Laser Surgery, 

San Diego, CA 

Background: Rosacea is a chronic inflammatory skin condition 

of adulthood that affects women more commonly than men, 

though men may suffer from more severe rosacea. Clinical 

manifestations include telengiectasias, centrofacial erythema, 

and acneiform papules and pustules. The inflammatory 

papulopustular eruption of rosacea can be treated with both 

topical and oral medications, including topical sulfa agents, 

metronidazole, azelaic acid, and oral antibiotics. Although overall 

redness is often decreased with the use of 15% azelaic acid gel, 

telengiectasias are best treated with vascular laser surgery. We 

propose that the combination of 15% azelaic acid gel and IPL 

therapy will have an improved treatment outcome in the 

treatment of rosacea compared to laser therapy alone.

Study: The primary objective of this study was to compare the 

efficacy and tolerability of combining 15% azelaic acid gel and IPL 

therapy in the treatment of mild to moderate rosacea. Patients 

were randomized to receive split area treatment with 15% azelaic 

acid gel. All subjects received 15% azelaic acid gel and were 

instructed to apply the study drug to one-half of the face, twice 

daily and instructed to not apply 15% azelaic acid gel for 48 hours 

prior to the IPL treatment. Subjects then continued to use 15% 

azelaic acid gel to one-half of the face for the duration of the study. 

Assessment of global improvement, telangiectasias, papules, 

pustules and nodules was performed at Screening/Baseline, week 

2 (prior to IPL treatment), and week 6/End of Study. Patient 

questionnaires were completed at Baseline, Week 2 and at Week 

6/End of Study visits. Standardized photography was completed 

at each of the three clinic visits. 

Results: Eleven of 20 patients (9 females, 2 males), aged 34–65 

years old (mean 46.5), completed the study at the time of data 

analysis. All patients had mild to moderate rosacea. A statistical 

significance was found in the investigator global assessment 

(using a 6 point scale) comparing baseline to day 42 in the 15% 

azelaic acid gel with IPL treated side (P ¼ 0.01); compared to the 

IPL treated side. No statistical significance was found in the 

investigator global assessment (using a 6 point scale) comparing 

baseline to day 42. More improvement was also noted comparing 

baseline to day 42 with combination therapy using 15% azelaic 

acid gel and IPL versus IPL treatment alone, in the amount of 

telangiectasias, papules, and pustules (using a 4 point scale). 

Patient assessment of improvement from baseline to day 42 on the 

15% azelaic acid gel treated side resulted in a statistically 

significant improvement in five categories: overall skin 

appearance, amount of acne bumps, skin dryness, amount of 

moisturizer needed, and overall assessment of skin. There was no 

statistically significant difference between patient assessment of 

facial itching, burning, irritation, redness, warmth, and overall 

skin comfort. There was no statistically significant difference 

between patient assessment of facial itching, burning, irritation, 

redness, warmth, and overall skin comfort. Only one patient 

noticed an increase in skin itching, which resolved by day 42, and 

of the four patients who noted skin burning at day 14, only one 

continued to report burning at day 42. 

Conclusion: Combination therapy with 15% azelaic acid gel and 

IPL is more efficacious in the treatment of mild to moderate 

rosacea than IPL treatment alone. Combination therapy proved to 

be tolerable and patients noted more improvement in overall skin 

appearance, amount of acne bumps, skin dryness, amount of 

moisturizer needed and overall skin assessment with combination 

treatment versus therapy with IPL alone. Fifteen percent azelaic 

acid gel and IPL may be combined safely for the treatment of 

rosacea. 

Limitations: Preliminary data are presented. This is a single-site 

study of a small cohort of patients followed for an average of 30.5 

days at the time of data analysis. This study will be completed by 

October 31, 2010, by which time we will have followed all 20 

patients for a total of 44 days, and all patients will have received 

44 days of treatment with 15% azelaic acid gel. 

#215 


LASER DOPPLER INVESTIGATION OF TOOTH 

ARCHWIRE ENGAGEMENT 

Laura Maria Filip, Mariana Ioana Miron, 

Cosmin Balabuc, Diana Lungeanu, Carmen Todea 

School of Dentistry, Victor Babe, University of Medicine and 

Pharmacy, Timisoara, Romania 

Background: Any alteration in blood flow or vascular pressure 

caused by a trauma may damage the pulp tissue. Laser Doppler 

Flowmetry provides means of recording pulpal blood flow within 

teeth and has been described as a very sensitive method for tooth 

vitality evaluation. The purpose of this study was to evaluate the 

human pulpal blood flow changes after orthodontic forces 

application. 

Study: Recordings were made of five volunteers scheduled for 

fixed orthodontic therapy, with interdental spaces between teeth 

33–34 and 34–35 or 43–44 and 44–45. Pulpal blood flow was 

recorded by means of Laser Doppler Flowmetry for each of the 15 

teeth, before treatment, 24 hours after the initial archwire 

engagement and 5 days later. The Laser Doppler Flowmetry probe 

was held in place by a splint constructed of a silicon impression 

material, to prevent instability and to permit reproducibility of 

the probe position. An opaque rubber dam was applied to the teeth 

during laser Doppler Flowmetry measurement. All data 

acquisitioned were collected and analyzed using specific software 

provided by the equipment producer. 

Results: Student’s t-test was used for statistical analysis. The 

comparison of basal pulpal blood flow during the three observation 

periods showed a significant pulpal blood flow decrease 24 hours 

after archwire engagement (P < 0.005), followed by a partial 

recovery 5 days after. 

Conclusion: The results indicate that the measurement 

technique used in the study is able to detect pulpal blood flow 

changes produced by orthodontic force application and could be 

used as a diagnostic tool for determining aggressive forces over 

the pulpal biological limits of tolerance. 

#216 

CLINICAL EVALUATION OF LASER-ASSISTED 

SKIN HEALING AFTER NAEVI SURGERY 

Nathalie Fournier 

Clapiers, France 

Background: Previous evaluations have demonstrated that a 

novel 810 nm diode laser system could improve skin healing 

leading to a scar reduction. This technique named Laser Assisted 

Skin Healing (LASH) has demonstrated its efficacy in Plastic 

Surgery to improve the appearance of scars. This study aimed to 

demonstrate the interest of LASH in patients enrolled for nevi 

excision. 

Study: Patients with two nevi were enrolled in this prospective 

study. Nevi were removed by simple surgical excision under local 

anesthesia. One incision was treated immediately after suturing 

with Ekkylite (Ekkyo, Aix en Provence, France). This 810 nm 

diode laser system delivers a top hat spot of 20 mm 4 mm. The 

second incision served as an untreated control. Clinical 

evaluations, digital pictures on all scars were conducted at 7, 15, 

90, and 180 days. 

Results: Thirteen patients, on decoletage, limbs, back, face, 

phototypes I to IV were included. Seven days after surgery a 

reduced inflammation was noted on the LASH treated incision, at 

3 months a quicker resolution on treated scar compared to the 

non-treated side. At 3 months no hypertrophic scar was observed 

on treated sites. 

Conclusion: LASH is a new procedure already used in practice 

for aesthetic surgery, and it may have a great role in prevention of 

hypertrophic scar after dermatologic surgery.


#217 

CLINICAL EVALUATION OF 1,550 NM AND 

1,927 NM LASER DELIVERED BY FRACTIONAL 

FOR ASIAN PATIENTS OF MELASMA AND 

ACNE SCARS 

Takahiro Fujimoto 

ClinicF, Tokyo, Japan 

Background: There is a growing demand among patients and 

practitioners for a more aggressive treatment to address wrinkles 

and uneven texture while minimizing the recovery time 

experienced with other ablative technologies. The signs of 

superficial photoaging are typically confined to the epidermis and 

upper dermis, resulting in a typical pattern of textural changes, 

fine lines, wrinkles, and pigmentary alterations. The degree of 

photodamage is cumulative and largely age dependent. In young 

skin, little or no photodamage is evident. The depth of 

accumulated photodamage increases roughly with age reaching a 

thickness of approximately 200–250 mm. In this study, we 

investigate that clinical evaluation of 1,550 and 1,927 nm laser 

delivered by fractional for treatment. 

Study: Twenty-four patients, skin types III to IV, age from 20 to 

50 seconds were treated with two laser sessions each at our clinic. 

Cosmetic skin rejuvenation was accomplished using Fraxel 

re:store DUAL (Soltamedical, CA, USA) with & two wavelengths 

of 1,550 nm fluence of 4.0 J/cm 2 and 1,927 nm fluence of 10.0 J/cm 2 . 

Treatment sites were evaluated compared with the baseline (pretreatment) 

regarding the skin texture, pore size, fine wrinkles and 

spotty pigments. 

Results: At 6 months’ follow-up, the investigators reported 

improvement in skin texture, pore size, fine wrinkles and spotty 

pigmentation compared with the baseline values. Patients’ 

satisfaction rate was deferent in each parameter, respectively. 

There were no serious complications, including post inflammatory 

hyper-pigmentation. 

Conclusion: The deep penetrating Erbium fiber laser (1,550 nm) 

or the new, more superficial Thulium fiber laser (1,927 nm) offers 

a safe cosmetic method of improving skin texture for Asian skin 

with no serious adverse sequelae. 

#218 

MULTIPLE SESSION LOW FLUENCE Q- 

SWITCHED ND:YAG LASER TREATMENT OF 

MELASMA 

David Goldberg, Nathalie Dietrich-Comte, 

Alia Brown, Mussarrat Hussain 


Background: Melasma is a common pigmentary disorder often 

recalcitrant to various treatments. Laser treatments for melasma 

has shown inconsistant and unsatisfactory outcome with poor 

long-term results. The aim of this study was to evaluate the 

efficacy and safety of multiple treatment low fluence 1,064 nm Qswitched 

Nd:YAG laser treatment of melasma. 

Study: Twenty subjects were treated with a 1,064 nm Q-switched 

Nd:YAG laser, using a 6-mm spot size, with fluences of 2 J/cm 2 . All 

subjects underwent eight treatments at 1- to 2-week intervals. 

The melasma area and severity index (MASI) was assessed at 

baseline, 1 month and 6 months after final treatment. 

Results: All subjects showed progressive improvement in both 

melasma area and MASI evaluations. At 6 months after treatment 

12 subjects showed continued improvement while 8 subjects 

showed some recurrence of their melasma. 

Conclusion: Treatment of melasma with a low fluence Qswitched 

1,064 nm Nd:YAG laser can be used as a safe temporary 

approach to the treatment of melasma. 

#219 

LASH WITH A 1,210 NM DIODE LASER IN 

SECONDARY KELOID SCAR PREVENTION, 

SAFETY RESULTS IN 20 PATIENTS 

Sonia Saai, David Gonnelli, Guy Magalon 

APHM, Hopital Conception, Marseille, France; Ekkyo, 

Aix-en-Provence, France 

Background: Keloids scars result from complex alteration of the 

wound healing process no treatment consensus has yet been 

established. Because of the high recurrence rate and the incidence 

of side effects associated with these treatments it remains difficult 

to effectively treat them. The use of lasers has been proposed for 

scar prevention. The Laser-Assisted Skin Healing (LASH) 

technique induces a temperature elevation in the skin which 

modifies the wound-healing process. Previous clinical trials 

demonstrated an improvement of healing process in skin type I to 

IV with 810 nm diode laser. We report a prospective clinical trial 

aimed to investigate the safety of 121,078 nm diode laser 

treatment as a prophylactic method following surgical resection of 

keloid scars. 

Study: Twenty patients (age 18–39, Fitzpatrick skin type I to VI) 

with keloids scars due to acne, surgery, trauma, were enrolled 

in this clinical trial. The laser dose was similar for all patients 

and calculated by the device’s software to induce an optimal 

thermal shock response. Following surgery scar revision, the 

laser was immediately used after skin closure. Each surgical 

incision (e.g. presternal area, upper-back, shoulder, arm, lower 

limbs, ears) was entirely treated and silicone gel sheeting 

applied 15 days post-treatment. Clinical evaluations are 

conducted at 15 days, 11 2 , 3, 6, 12, 18 and 24 months. Safety was 

documented by adverse effects monitoring at 15 days and 

11 2 months follow-up. 

Results: No treatment-related adverse effects were reported at 

15 days and 11 2 months follow-up. No superficial burns occurred. 

Conclusion: This preliminary result demonstrates that 1,210 

diode laser treatment, performed immediately after skin closure, 

can be used safely in skin type I to VI. The controlled skin 

temperature and a homogeneous skin treatment lead to an 

adequate safety control. 

#220 

TRIAL OF LOW LEVEL LASER ACUPUNCTURE 

THERAPY FOR SMOKING CESSATION 

Anurag Gupta, Bonnie Treece, Michelle Kerr, 

Preet Kaur, Arun Gupta 

New York, NY; Monroe, MI 

Background: According to the World Health Organization, 

cigarette smoking is linked to more than 5 million deaths 

worldwide and 400,000 deaths in America. National surveys 

indicate 20% of American adults smoke cigarettes and 70% of 

those smokers indicate desire to quit. In this retrospective study, 

we investigate the efficacy of laser acupuncture as an adjunct in 

the treatment of smoking cessation. 

Study: Under IRB approval and FDA stage 2 clinical trials, we 

have treated patients since 2005 in a rural community primary 

care setting. Licensed technicians were trained to perform a

standardized treatment protocol supervised by a medical director. 

Patients received one 30-minute treatment involving low level 

laser acupuncture therapy and one 30-minute session of 

behavioral modification therapy. Follow-up was conducted at 3 

months by telephone or email communication to verify patients 

were both cigarette and nicotine free. 

Results: Between 2006 and 2009, 357 patients underwent the 

treatment protocol. At 3 months, 179 patients were lost to followup. 

Of the remaining 178 patients, 40 patients stated they had 

relapsed one or more times and 138 patients stated they remained 

cigarette and nicotine free. 

Conclusion: Our data show that of all patients treated with 

appropriate follow-up, 78% had a successful outcome. In 

comparison to leading psychotherapy and pharmacotherapy 

interventions for smoking cessation, one intervention of laser 

acupuncture with behavioral modification has similar or better 

results at three months. We recommend a multidisciplinary 

treatment plan for patients to optimize their freedom from 

chemical dependency. 

#221 

META-ANALYSIS OF LASER THERAPY FOR 

MELASMA 

Shlomit Halachmi, Marete Haedersdal, 


Rabin Medical Center, Petach Tikva, Israel; 

University of Copenhagen, Copenhagen, Denmark 

Background: Melasma is a common and challenging disorder. 

The superficial location of the pigment should make the treatment 

amenable to laser therapies. However, the pigmentation is due to 

a life-long process of abnormal melanocyte activity and is 

therefore difficult to halt for prolonged periods of time by the use 

of episodic interventions. Furthermore, melasma is more common 

in darker skin, which skin type poses a risk for energy-based 

interventions. For all these reasons, laser treatments for melasma 

are a topic of controversy. 

Study: A meta-analysis was performed of English language 

publications on Medline. Twenty-six studies were identified as 

clinical studies in humans. Studies that combined topical 

therapies were excluded. 

Results: Studies of a wide range of energy-based approaches were 

identified, including pigment based (melanin or vascular) lasers, 

intense pulsed light, and fractional ablative and non-ablative 

lasers. Of the 26, 19 studies demonstrated appreciable efficacy in 

improvement of melasma. Duration of response was limited when 

reported. Seven studies exhibited results that do not support the 

use of lasers or light sources in melasma due to low efficacy, short 

duration of effect, or risk of adverse events. 

Conclusion: Lasers can offer benefit in melasma in certain 

patients. However, they are not universally effective, and the 

effects are in most cases temporary. The non-durable benefit as 

well as the risk of adverse events may limit the widespread use of 

lasers in melasma. 

#222 


NEOVASCULARIZATION FOLLOWING FACIAL 

SURGERY: POSSIBLE ETIOLOGY AND 

TREATMENT 

Shlomit Halachmi, Maurice Adatto, Ran Kornowski, 


Rabin Medical Center, Petach Tikva, Israel; SkinPulse, Geneva, 


Background: Angiogenesis is an integral part of any wound 

healing process. However, following facial surgery the 

angiogenic response can be exaggerated and result in 

telangiectasia. We describe this relatively unknown phenomenon 

and demonstrate the safety and efficacy of long-pulsed 595 nm 

pulsed dye laser for the treatment of post-surgical facial 

telangiectasia. 

Study: Sixteen patients (14 women, 2 men) with Fitzpatrick skin 

types II to IV who had undergone facelift (11 patients) or Mohs 

surgery for basal cell carcinoma (5 patients) were studied. All 

noticed peri-incisional telangiectasia 2–3 months post-surgery. 

Patients underwent 1–3 treatments with pulsed dye laser. Lesion 

clearance was evaluated by two specialists on the basis of digital 

photographs taken before the first treatment and 2 months after 

the last treatment. 

Results: All patients had an excellent response (clearance rating 

75–100%). Mild transient purpura and minimal pain were 

present in all patients. No persistent adverse events were 

recorded. 

Conclusion: Long-pulse pulsed dye laser is a safe, effective, and 

well-tolerated treatment for post-surgical facial telangiectasis. 

The mechanism underlying post-surgical telangiectasis is unclear 

but may include angiogenesis secondary to wound healing 

processes, peri- or post-procedural ischemia, surgical 

manipulation of the skin, or stretch. 

#223 

PURPURIC PULSE DYE LASER TREATMENTS OF 

ACNE REDUCE LESIONS—A CHART REVIEW 

Hadar Lev-Tov, Judith Hellman 

Mount Sinai School of Medicine, New York, NY; SUNY Downstate 

College of Medicine, Brooklyn, NY 

Background: We report a highly successful acne treatment 

modality using light energy, utilizing the 585 pulse dye laser 

(PDL). Previous regimens with the 585 PDL were intent on 

using non-purpuric settings and led to marginal results. We 

used settings that deliberately were in the purpuric range, in a 

monthly repeating protocol for 3–4 times in most cases. This 

regimen consistently resulted in significant and dramatic 

reduction in the severity of acne and often led to complete 

remission. 

Study: We reviewed all charts of patients who had laser 

treatment for acne between November 2003 and November 2009 

in our facility. We included in our analysis patients who had no 

more than four treatments and had pre-operative and 

post-operative pictures. The final number of patients included was 

n ¼ 17. Acne severity was determined based on the type and 

number of the lesions. All patients were treated with a 585 nm 

PDL with spot size of 7 mm 2 Energy levels ranged from 4.2 to 

6.7 J/cm 2 and were graded based on patients’ tolerance and 

Fitzpatrick skin type. 

Results: Ninety-four percent of patients had significant reduction 

in severity of lesions. Based on our scoring system the average 

starting score was 4.44 and the average score after treatments 

was 0.88 (average reduction ¼ 3.6 points). Nine patients 

experienced complete remission. Presently, two patients had 

sustained the remission for over 3 years. 

Conclusion: Five hundred eighty-five PDL treatments of acne 

with purpuric settings may result in effective and lasting 

reduction of lesions.


#224 

OPTICAL COHERENCE TOMOGRAPHY CAN 

DETECT AND QUANTIFY 

CHEMOTHERAPY-INDUCED ORAL MUCOSITIS 

Michael Hoang 

Irvine, CA 

Background: A preliminary study to assess non-invasive optical 

coherence tomography (OCT) for early detection and evaluation of 

chemotherapy-induced oral mucositis in 48 patients, 12 of whom 

developed clinical mucositis. 

Study: In 48 patients receiving neoadjuvant chemotherapy for 

primary breast cancer, oral mucositis was assessed clinically, 

and imaged using non-invasive OCT. Imaging was scored using a 

novel imaging-based scoring system ranging from 0 to 6. 

Conventional clinical assessment using the Oral Mucositis 

Assessment Scale (OMAS) scale was used as the gold standard. 

Patients were evaluated on days 0, 2, 4, 7, 11 after commencement 

of chemotherapy. OCT images were visually examined by three 

blinded investigators. 

Results: The following events were identified using OCT: (1) 

change in epithelial thickness and subepithelial tissue integrity 

(beginning on day 2), (2) loss of surface keratinized layer 

continuity (beginning on day 4), (3) loss of epithelial integrity 

(beginning on day 4). Imaging data gave higher scores 

compared to clinical scores earlier in treatment, suggesting that 

the imaging-based diagnostic scoring was more sensitive to 

early mucositic change than the clinical scoring system. Once 

mucositis was established, imaging and clinical scores 

converged. 

Conclusion: Chemotherapy-induced oral changes were 

identified prior to their clinical manifestation using OCT, and the 

proposed scoring system for oral mucositis was validated for the 

semi-quantification of mucositic change. 

#225 

OCT VERSUS CURRENT CLINICAL STANDARDS 

FOR EARLY-STAGE CARIES DETECTION 

Jennifer Holtzman, Kathryn Osann, 

Sandeep Potdar, Steven Duong, Yeh-chan Ahn, 

Zhongping Chen, Petra Wilder-Smith 


University of California, Irvine, CA; Herman Ostrow School of 

Dentistry, Los Angeles, CA 

Background: To compare optical coherence tomography (OCT) 

with current clinical standard treatment to detect and monitor 

early natural caries. Clinicians currently rely on clinical 

observations and radiography to detect caries, however, these 

methods are unable to reliably diagnose early primary or monitor 

possible disease activity under restorations. Clinicians may be 

unnecessarily placing, and replacing, restorations on teeth that 

are stained or discolored, but otherwise sound. Clinicians require 

better tools that they can use clinically to detect early stages of 

caries, including recurrent caries, to reduce overtreatment, and 

make the best use of health care providers’ resource, and health 

care dollars. 

Study: Two hundred teeth in various stages of soundness 

including occlusal, proximal and radicular decay (determined 

clinically) were photographed, radiographed, and imaged with 

OCT (512 sequential 2D-OCT images). Teeth were then 

restored, imaged again and radiographed, and then sectioned. 

Blinded examiners reviewed radiographic and OCT images and 

assigned decay status. Decay status was confirmed with 

histological examination after sectioning and microscopic 

evaluation. 

Results: Clinician agreement (k) regarding tooth diagnosis 

with OCT was overall 0.907 (SE ¼ 0.034). OCT was able to 

detect early caries more reliably that visual, radiographic, or 

combined methods. Areas that were truly carious were identify 

as such (sensitivity > 90%); teeth that identified as sound were 

truly sound (specificity > 85%). Radiographs outperformed OCT 

only when decay was > 2 mm below the tooth surface. OCT 

images of sound tooth showed an area of intense light 

backscattering at the tooth surface, with a rapid reduction of 

backscattered light beyond the initial first few microns. In 

contrast, carious sites appeared as areas of diffuse nonhomogenous 

scattering intensity and reduced macrostructure 

definition. 

Conclusion: These findings support the potential clinical utility 

of OCT for early caries detection and monitoring under dental 

restorations. 

#226 

NEW TOTAL COMBINATION TECHNIQUES WITH 

PUNCH, FRACTIONAL AND LONG-PULSED 

ER:YAG LASER FOR THE TREATMENT OF ACNE 

SCARS COMPARED WITH THE CLASSIC 

SEQUENTIAL COMBINATION THERAPY 

Eun Ju Hwang, Jeanne Jung, Jong Hee Lee, 

Hun Suh Dae 

Klaripa Clinic; Boramae Hospital; Seoul National Hospital, 

Seoul, Korea 

Background: Many lasers have been used to treat acne scars. 

Deep acne scars require punch or surgical methods. For better 

results, a combination of procedures may be needed. However, a 

comparative study to combine surgical techniques with lasers is 

very limited. We investigated the effects and safety of new 

developed combination therapy using punch, fractional and 

Er-YAG laser. 

Study: In Group I, 26 patients with moderate to severe atrophic 

acne scars received new combination techniques using punch, 

Profractional 1 and long-pulsed Er-YAG laser all together in a 

session. Each patient was treated with a combination 

procedure depending on the type and depth of their scars. 

In Group II, 10 patients were sequentially treated with punch 

excisions followed by laser skin resurfacing. In Group III, three 

patients were treated with two sessions of laser skin 

resurfacing and another three patients over three sessions with a 

fractional laser in Group IV. Comparative photographs were 

taken immediately before and 5 months after the end of the 

treatment. Physician evaluations and patient satisfaction was 

graded on a numerical scale. Three dermatologists not involved in 

this study evaluated the improvement with blinded method on a 

score of 0–100. Side effects were recorded during the follow-up 

visit. 

Results: Clinical improvement of acne scar treatment assessed by 

dermatologists the mean clinical score difference was 

72.30 13.54, 43.83 22.41, 60.00 2.88 and 15.00 7.26 in 

Group I, II, III and IV, respectively. Long-lasting erythema at 

2 months post-treatment decreased in the following order: Group 

III, Group I, Group II and Group IV. Ten of 26 patients in Group I 

showed hyperpigmentation. Scarring, suture marks or secondary 

widening occurred, especially in Group II. Hypopigmentation also 

occurred in Group II.

Conclusion: This new total combination therapy provides a 

promising treatment option for acne scars, and decreases side 

effects more than classic laser skin resurfacing or sequential 

combination therapy. 

#228 

CLINICAL STUDY TO EVALUATE THE EFFICACY 

AND SAFETY OF FRACTIONAL 

RADIOFREQUENCY SYSTEM 

Taewoo Noh, Tae Woo Noh, Yoo Seok Kang, 

Un Ha Lee, Hyun Su Park, Sang Jai Jang, 

Bang Soon Kim 

Sanggye Paik Hospital; S & U Clinic, Seoul, Korea 

Background: Fractional lasers achieved good results of 

rejuvenation with lesser epidermal damages. The eMatrix 

(Syneron Medical Ltd, Yokneam, Israel) is capable of delivering 

ablative radiofrequency (RF) energy to the skin in a nonhomogeneous 

fractional manner via an array of multi-electrode 

pins. The electrode pins lead to ablation of the skin directly and bipolar 

RF make the inverse cone shape of heating zone below the 

every electrode, leaving intact or slightly affected zones in 

between the targeted areas. The key differences between eMatrix 

and other fractional lasers are that there is very little epidermal 

disruption (5%) with relatively wider, deep dermal heating. 

Study: We conducted clinical study to assess the clinical efficacy 

and safety in 16 Korean patients. As the purpose of this study was 

also to find the optimal parameters for better outcome, different 

parameter (A mode vs. C mode) was assigned randomly to split 

faces of 16 patients. Ten patients were treated randomly with A or 

C mode in one cheek and with C or A mode in the other cheek, 

respectively, with 3–5 sessions of 3- to 4-week interval. The other 

six patients were treated in only one cheek with five sessions and 

after then were treated in the other untreated cheek with 

different parameter. Clinical evaluations for the improvement 

and possible side effects were conducted every session, 8 weeks 

and up to 7 months after the last treatment. 

Results: All 16 patients showed improvement in skin brightness, 

skin tightness and wrinkles. Ten and six of patients had > 75% 

and 51–75% improvement, respectively. Typical initial response 

to treatment was mild to moderate erythema and edema which 

resolved within usually 1–5 days depending on applied energy. 

There was no postinflammatory hyperpigmentation developed. 

Conclusion: Fractional bipolar RF device, the eMatrix is 

effective and safe treatment for skin rejuvenation in Korean 

patients. 

#229 


EFFECTIVE SCAR TREATMENT USING A 

FRACTIONAL 1,440 OR 1,540 NM LASER 

EQUIPPED WITH A POINT-ARRAY 

COMPRESSION OPTIC 

Arielle Kauvar, David Vasily, Christine Dierickx 

New York Laser & Skin Care, New York, NY; Aesthetica Cosmetic 

& Laser Center, Bethlehem, PA; Skin and Laser Center, Boom, 

Belgium 

Background: Treatment of scars appears to require remodeling 

of the abnormal dermal architecture, which often exceeds 1 mm in 

depth. Previous studies have shown that a fractional point-array 

compression optic (PCA) used with either 1,440 or 1,540 nm lasers 

can increase microbeam (mB) penetration and minimize 

epidermal disruption. This study observed the effects of this PCA 

optic with 1,440 or 1,540 nm lasers on scars. 

Study: This was an observational study of over 100 subjects with 

a wide variety of scars, including hypertrophic and keloidal, burn, 

traumatic, surgical, acne and hyperpigmented scars. Following 

application of a topical anesthetic, a 1,440 or 1,540 nm laser with a 

14 by 14 mm array PCA (XD TM , Palomar Medical Technologies, 

Inc.) delivered 49 mB with 2 mm pitch. Pulses were delivered with 

50% overlap in the vertical and horizontal direction or using a 

novel approach for a surface coverage of approximately 30–40%. 

Treatments occurred at 4- to 6-week intervals, and hypertrophic 

scars were treated adjuvantly with a topical corticosteroid. 

Results: Scar height, thickness, color and pliability improved at 

least 50% in 24 of the 26 subjects who have already completed 

follow-ups. In two subjects with erythematous, symptomatic 

keloidal scars, treatment had no effect and was discontinued after 

two sessions. The number of treatment sessions ranged from one 

to four. Post-treatment erythema and pinpoint micro-crusts 

persisted for 1 to 2 weeks. Two phototype IV subjects treated with 

the 1,440 nm laser experienced transient hyperpigmentation, but 

there were no other adverse effects. Studies with both these lasers 

are ongoing and additional safety and efficacy data will be 

presented. 

Conclusion: A 1,440 or 1,540 nm laser with a fractional pointarray 

compression tip significantly improved the appearance of a 

wide variety of scar types, with minimal anesthesia requirements 

and recovery times following high coverage treatment with high 

energies. 

#230 

CLINICAL EVALUATION OF A NON-INVASIVE 

CRYOLIPOLYSIS FOR THE TREATMENT OF 

SUBCUTANEOUS FAT REMOVAL IN KOREAN 

PATIENTS 

Hyunjoo Kim, Donghye Suh, Jiyoung Park, 

Jiho Rhue, Sangjun Lee, Kyeyoung Song, 

Minkyung Shin, Chulsu Ok 

Anacli Dermatologic Clinic, Sungnam, South Korea; Anacli 

Dermatologic Clinic; JungAng University; KyungHee University; 

Mediscope Clinic, Seoul, South Korea 

Background: Fat cells are more cold-sensitive than other cells, 

including epidermis. Cryolipolysis is a new method of noninvasive 

fat layer reduction, which has been shown to significantly 

reduce fat layer thickness without damage to the skin or other 

surrounding tissues. To evaluate the safety and efficacy profile of 

cryolipolysis for fat layer reduction of the abdomens or flanks in 

Koreans. 

Study: Twenty-five subjects with fat bulges on their abdomens or 

flanks (‘‘love handles’’) were treated unilaterally or bilaterally 

with a non-invasive cooling device (Zeltiq Aesthetics, Pleasanton, 

CA). The results were evaluated based on clinical photos before 

and after session, physician assessments. Computed tomography 

and microscopic pathology were being performed at pretreatment 

and posttreatment in some patients. 

Results: Photographic, physician assessment showed 

cryolipolysis results in a visible contour change in 20 subjects 6 

months later. Five subjects were developed petechia on their skin 

after treatment. This was almost completely disappeared after 1 

week. 

Conclusion: Cryolipolysis is a very low risk, no downtime 

procedure that produces consistent observations of modest, 

gradual fat layer reductions in properly selected patient.


#231 

Tiziana Lazzari 

URTICARIA INDUCED BY LASER EPILATION: 

STUDY OF 36 PATIENTS—BRIEF: A CLINICAL 

AND HISTOLOGICAL ASSESSMENT OF 

36 PATIENTS 

Nerea Landa, Natalia Corrons, Iñaki Zabalza, 

Jose Azpiazu 

Dermitek Clinic; Sinpelo Clinic, Madrid, Spain; 

Galdakao Hospital, Bilbao, Spain 

Background: Laser epilation is currently one of the most 

common laser based procedures in the world. Although side effects 

are rare the most common are hyper or hypopigmentation. We 

describe a unique side effect consisting of delayed persistent 

urticarial rash after laser epilation. 

Study: From January 2006 to March 2010, a total of 13,284 

patients have laser epilation at our clinics. Of these 36 patients 

(35 women and one man) treated with Alexandrite laser, 

MiniGentle or GentleMax-Candela, developed a severe persistent 

pruritic urticarial rash 6–48 hours after the treatment within the 

treated skin. The eruption occurred most often on the legs or in the 

groin and only occasionally within the axillae. It consisted on 

multiple pruritic perifollicular papules and plaques. Most patients 

required oral corticosteroids to control the severe itching. Lesions 

resolved in 7–15 days without sequalae. The eruption occurred 

mostly on the first treatment and tended to recur in subsequent 

treatments. Pretreating patients with systemic corticosteroids 

helped to prevent or limit the eruption. Remarkably, all the 

patients but two reported allergic rhinitis or some other allergy in 

the past. 

Results: Description of Urticarial Rash: The eruption 

occurred most often on the legs or in the groin and only 

occasionally within the axillae. It consisted on multiple pruritic 

perifollicular papules and plaques. Most patients required oral 

corticosteroids to control the severe itching. Lesions resolved in 

7–15 days without sequalae. The eruption occurred mostly on 

the first treatment and tended to recur in subsequent 

treatments. Pretreating patients with systemic corticosteroids 

helped to prevent or limit the eruption. Remarkably, all the 

patients but two reported allergic rhinitis or some other allergy in 

the past. 

Histopathology: Biopsies performed in three patients showed 

edema and a deep and dense infiltrate in mid and lower dermis 

consistent of lymphocytes mixed with eosinofiles in a perivascular 

pattern, and occasionally perifollicular. 

Discussion: Rupture of the hair follicle by laser heat could 

trigger a hypersensitivity type I reaction in some predisposed 

allergic patients. An antigen derived from the disrupted hair 

follicle could be the triggering factor. 

Conclusion: Persistent urticarial rash is a side effect of laser 

epilation which seems to happen in a subset of allergic patients. 

To prevent this side effect laser epilation should be preceded by an 

extended laser patch test done in a thick hair area. The result 

should be evaluated 48 later and preventive prednisone 

prescribed in those who develop a delayed, itchy and persistent 

urticarial rash on the test area. 

#232 

LASER LIPOLYSIS WITH A 980 NM DIODE LASER 

VERSUS TRADITIONAL AND ULTRASOUND 

ASSISTED LIPOSUCTION: PERSONAL 

EXPERIENCE 

Genova, Italy 

Background: Since its advent in the 1970’s to now the technique 

of liposuction has undergone continuous improvements and 

become a valuable security tool for the treatment of localized 

lipodystrophies. The purpose of this study was to evaluate the 

efficacy and safety of a 980 nm laser for laser-assisted 

liposculpture traditional and ultrasound assisted liposuction. 

Laser lipolysis is designed to provide selective adipose damage, 

while simultaneously facilitating fat removal, enhancing 

hemostasis and increasing tissue tightening. 

Study: Sixty patients of both sexes (ranging in age from 25 to 55 

years) with indications for liposculpture by showing the presence 

of localized fat on the abdomen, flank, trochanteric region and 

knees were selected for the treatment of laser-assisted 

liposculpture. After the tumescent anesthesia this technique 

involves an incision of 1 mm to introduce a tube about 1 mm in 

diameter and 15 cm in length through which is inserted into a 

fiber of 600 mm. The laser pulse is set to continue from 5 to 

18 W. The emitted energy varies from 2000 to 10,000 J per area. 

Laser application is followed by the aspiration of adipose tissue 

zone. 

Results: In all 60 patients we have achieved good results without 

major complications. 

Conclusion: Following a correct methodology, the laser-assisted 

liposculpture performed by laser 980 has proved a reliable and 

efficient technique for the surgical reshaping of the body. 

Although laser lipolysis is not intended to replace traditional 

liposuction or ultrasound assisted liposuction, it offers to the 

patients a procedure that achieves similar benefits with fewer 

complications and faster recovery. 

#233 

INTENSE PULSED LIGHT AND LOW-FLUENCE Q- 

SWITCHED ND:YAG LASER ELICITS MORE RAPID 

CLINICAL IMPROVEMENT IN ASIAN PATIENTS 

WITH MELASMA 

Jong Hee Lee, Se Young Na, Soyun Cho 

Seoul National University, Boramae Hospital, Seoul, Korea 

Background: Recently low fluence collimated Q-switched 

Nd:YAG laser has drawn considerable attention for the 

treatment of melasma in Asian patients. However, it needs a lot 

of treatment sessions to achieve substantial clinical effects. This 

study was performed to see if there are any beneficial effects 

with the combinational treatment using intense pulsed light (IPL) 

and low fluence Q-switched Nd:YAG laser over laser treatment 

alone. 

Study: Retrospective case series of 35 female patients with mixed 

type melasma were analyzed using medical records. Patients in 

group A were selected when IPL and consecutive four times of low 

fluence Nd:YAG laser treatments were applied. The patients who 

were treated successively with only laser every week were 

grouped into B. At every visit before and after the treatment, 

digital photographs were taken under the same condition. 

Erythema and melanin index was measured on the highest 

point on cheekbones. Modified MASI scores before and after the 

last treatment were marked using photographs by two 

investigators. 

Results: In both groups, the mean values of MI and EI decreased 

significantly in comparison with baseline but P-values were lower 

in group A (EI: P ¼ 0.000 vs. P ¼ 0.047, MI: P ¼ 0.000 vs. 

P ¼ 0.0004). There was a statistically significant difference

etween two groups for MI after treatment(s) (P ¼ 0.030). 

Spearman correlation analyses of skin color parameters in 

combined treatment group revealed significant positive 

relationship between MI after IPL and MI after both treatments 

(R ¼ 0.694), and EI after IPL and EI after both treatments 

(R ¼ 0.544). Clinical improvement was evaluated as modified 

MASI score. Modified MASI score reduction were 65.31% and 

43.92% in group A and B, respectively. In terms of safety, no 

serious adverse events occurred in the treatment period for both 

groups. 

Conclusion: IPL and successive subthreshold level of laser 

exposures may provide more rapid clinical resolution than laser 

irradiation alone in mixed type melasma. 

#234 

LASER THERAPY FOR THE TREATMENT OF 

NECK PAIN: A CLINICAL STUDY 

Renato Liboro, Fred Kahn, Fernanda Saraga 

Meditech International, Inc., Toronto, Canada 

Background: In most statistics presented, neck pain is 

commonly lumped together with low back pain as a presenting 

chief complaint that experts believe 85% of the North American 

adult population will experience at one point in their lives. 

However, when literature is concerned, a huge amount of peerreviewed 

articles have been devoted solely on neck pain as it is a 

common and burdensome problem, and according to Workplace 

Safety and Insurance Board, an underrated but significant cause 

of loss of productive work hours. Many studies have been done to 

determine which among the most commonly prescribed neck pain 

treatments such as non-steroidal anti-inflammatory drugs 

(NSAIDS), exercise and manual therapies was the best choice, yet 

no option has ever been clearly deemed superior. The introduction 

of Low-Intensity Laser Therapy as another therapeutic modality 

for successfully treating neck pain and improving the quality of 

life of long-term neck pain sufferers has gained significant 

interest in the last decade. 

Study: In a follow-up clinical study to our previously 

published 2006 SPIE conference proceeding, we analyzed 

a cross-section of patients treated for a variety of neck pain 

problems that present at our Meditech Laser Rehabilitation 

Clinics on a daily basis including age and gender distribution, type 

of pathology, number of treatments and percent of overall 

improvement. 

Results: Of the 101 patients with neck pain pathologies included 

in this study, 49% presented with degenerative osteoarthritis. On 

average 10 treatments, each 30–45 minutes in duration, were 

administered for the individual patient resulting in a significant 

improvement rate averaging 94.5%. 

Conclusion: Laser therapy is active at both the cellular and 

systemic levels activating a variety of mechanisms including DNA 

synthesis, improved microcirculation, cartilage regeneration, and 

an analgesic and anti-inflammatory effect. 

#235 


SELF-ADAPTIVE EFFECTS OF LOW INTENSITY 

LASER IRRADIATION IN PROPHYLAXIS OF 

MUSCULAR FIBROSIS 

Timon Cheng-Yi Liu, Li Luo, Lin Zhang 

School of Sports Science, Soochow University, Suzhou, China; 



Background: Fibrosis is one of the largest groups of diseases, but 

there is no effective therapy. Fibrosis may be resulted from many 

dysfunctions which might be modulated with low intensity 

gallium aluminum arsenide 635 nm laser irradiation (LIGL) in 

this paper. 

Study: Ninety-six male Sprague–Dawley rats were randomly 

divided into three groups: control, contusion and LIGL groups. 

LIGL at 17.5 mW/cm 2 was administered to the gastrocnemius 

contusion for 30 min each time once a day 10 days. The 

histological examination and biochemical assessment were done 

for 4 weeks. 

Results: LIGL increased the numbers of regenerating myofibers 

(P < 0.01) on the 7th and 14th day, but decreased the ones 

(P < 0.05) on the 21st and 28th day, and increased the diameters 

of regenerating myofibers (P < 0.05) but decreased the fibrotic 

area in the injured muscles (P < 0.01) on 14th, 21st and 28th day, 

respectively. LIGL decreased muscular malondialdehyde (MDA) 

(P < 0.01) and promoted muscular superoxide dismutase activity 

(P < 0.05) on the 1st, 2nd and 3rd day, respectively, and 

decreased MDA on the 7th day (P < 0.05). LIGL promoted 

(P < 0.05) insulin-like growth factor-1 (IGF-1) mRNA expression 

on the 1st, 2nd, 3rd and 7th day, but inhibited (P < 0.01) the one 

on the 14th and 21st day, respectively. LIGL increased (P < 0.05) 

IGF-1 level on the 2nd, 3rd and 7th day, but decreased (P < 0.01) 

the one on the 14th and 21st day, respectively. LIGL decreased 

(P < 0.05) transforming growth factor (TGF)-beta1 level on the 

3rd and 28th day, but increased (P < 0.05) the one on the 7th and 

14th day, respectively. 

Conclusion: LIGL inhibited fibrosis by promoting the 

regeneration of muscle. The LIGL effects on IGF-1, TGF-beta1 

and oxidative stress might be self-adaptive. *It was supported by 

NSFC. 

#236 

GUIDING PROSTATE CANCER PDT/LITT 

THERAPIES USING AUTOMATIC WARPING OF 

MRI-BASED PLANNING DATA 

Nasr Makni, Philippe Puech, Feras Marqa, 

Serge Mordon, Nacim Betrouni 

Inserm U703; CHU, Lille, France 

Background: In the last decade, new prostate cancer treatment 

options have been developed thanks to the advances in laser 

ablation techniques. PDT and LITT are currently being 

experimented in order to ablate index lesions while minimizing 

treatment morbidity. In these modalities, fibres’ positions 

planning and light dose simulations are usually performed on 

MRI, while transrectal ultrasound is used to guide the treatment. 

Physicians have then to mentally register planning data to realtime 

ultrasound, which induces time waste, imprecision and interoperator 

variability. In order to optimise this process, we 

introduce a method for automatic registration of PDT/LITT 

planning data from MRI to ultrasound. 

Study: The method is a geometric feature registration based on 

the Robust Point Matching algorithm, proposed by Chui and 

Rangarajan (2003), combined with the Thin Plate Spline non rigid 

transformation. An optimal warping is computed based on 

landmarks initialization as performed by an expert, and fibres’ 

positioning is then optimised and displayed on ultrasound images, 

with respect to the brachytherapy frame. We test and evaluate our


#238 

algorithm using physical phantom, which enables comparison to 

real ground truth. Patients’ data, with expert interpretation, are 

also used in these evaluations while taking into account the interobserver 

variability. 

Results: Preliminary results showed that the method is 

satisfyingly accurate, as Target Localization Errors were of 

1.92 0.14 mm and 1.85 0.26 mm for phantom and patients’ 

data, respectively. This performance was not correlated neither to 

the number of landmarks nor to the expert who defines them. 

Conclusion: As a part of a Treatment Planning System for 

prostate cancer PDT and LITT, our method can bring significant 

improvement in fibres’ positioning accuracy, and hence contribute 

in increasing laser therapies precision. Application of this method 

to breast cancer LITT is currently being investigated. 

#237 

THE ADIPOCYTE AS AN ENDOCRINE ORGAN? 

A SYSTEMATIC REVIEW OF RECENT 

LITERATURE ELUCIDATING THE 

FUNCTIONALITY OF ADIPOCYTES 

Jillian Maloney, Ryan Maloney, Steven Shanks 

Erchonia, McKinney, TX; University of Arizona, Gilbert, AZ 

Background: Invasive or non-invasive strategies for body 

slimming represent the most frequently performed cosmetic 

procedure in the United States. The therapeutic target has 

remained unchanged for decades, which is the adipocyte. Studies 

indicate that adipose tissue is responsible for the synthesis of 

bioactive peptides and hormones participating in autocrine, 

paracrine, and endocrine communication pathways. Emerging 

functionality has established the adipocyte as an endocrine organ 

and has raised new questions regarding the overall health benefit 

of cosmetic slimming procedures. 

Study: A standard literature review was performed using the 

following keywords ‘‘adipocyte,’’ ‘‘adipokines,’’ ‘‘endocrine organ,’’ 

‘‘leptin,’’ ‘‘adiponectin,’’ ‘‘visfastin,’’ ‘‘resistin,’’ and ‘‘proinflammatory 

cytokines.’’ The evidence-based medicine (EBM) 

search engine at the University of Arizona Health Sciences 

Library was used. The EBM search engine is an adopted version of 

the Oxford Center for Evidence-Based Medicine Levels of 

Evidence. No standard inclusion or exclusion process was 

established for the articles used in the review process. 

Results: Studies have revealed gene expression of a diverse 

collection of peptides, hormones, and cytokines that are 

synthesized by adipocytes which are commonly referred to as 

‘‘adipokines.’’ Adipocyte-derived bioactive substances are 

correlated with numerous metabolic disorders and play a pivotal 

role in the prevention of cardiovascular disease and diabetes. 

Adipokines are linked with lipid metabolism and homeostasis, 

energy consumption and expenditure, immunity, insulin 

sensitivity, and blood pressure. In a lean mass state adipocytes 

synthesize a unique arrangement of adipokines; conversely, 

hypertrophic adipocytes become impaired and begin to secrete 

deleterious bioactive substances promoting obesity-related 

comorbidities. 

Conclusion: Increased adipose mass is strongly correlated with 

obesity-related diseases, but adipocyte reduction as observed in 

lipoatrophic patients possesses severe metabolic consequences. 

Adipose tissue in recent years has displayed endocrine organ 

characteristics central to the dynamic control of energy 

metabolism and insulin sensitivity, and cosmetic strategies 

aimed at adipocyte destruction may possess noxious metabolic 

effects. 

THE NEW FASHION VECTORIAL WAY TO 

IMPROVE FAT REMODELING AND SCULPTING 

THE FACE USING NON-INVASIVE IN MOTION 

SELECTIVE SHEAR WAVES ULTRASOUND 

(ACCENT ULTRA) 

Elaine Marques, Guilherme Almeida, 

Leticia Almeida, Rachel Queiroz 

Hospital Sirio Libanes, Sao Paulo, Brazil 

Background: The demand for a nonsurgical, noninvasive 

treatment of located fat has inspired some manufactures to invest 

in a new age of sophisticated devices and treatment therapies to 

repair the skin and improve contours. The aim of this paper is to 

present a new vectorial fashion way to improve of fat remodeling 

and sculping the face using the combination of non invasive in 

motion selective ultrasound (ACCENT ULTRA, Alma Lasers). 

Study: Forty-two patients with located fat on the submental and 

malar were treated (age 18–76). The sessions with Ultra were 

separated by 14 days apart in a total of three treatments using the 

same parameters of 8 minutes (cool waves) and level 3 (hot waves) 

on submental and 4 minutes and level 5 each malar part. Results 

were evaluated by standard and three-dimension photography 

(VECTRA 3D, Canfield) before and after treatments (0 day, 6 

weeks, and 6 months). Both patient and physician investigator 

evaluated the treatment using a grading scale of improvement 

ranging from I (no), II (less than 25%), III (26–50%), IV (51–75%), 

and V (76–100%). Only grades IV and V were considered 

satisfactory. 

Results: The mode of propagation of mechanical waves generated 

is called shear waves. The shear waves histological damages the 

membrane of fat cells and causes disruption of that, damaging 

also the septa of the fat layer with no epidermal and dermal 

damage. The mean patients rate of satisfaction with a grade IV 

and V was 70%. No side effects were related to the treatment only 

5% of transitory redness and 10% of purpura. 

Conclusion: The treatment sessions with non-invasive selective 

ultrasound produce fat remodeling and sculping the face with 

efficiency and safety. Based on this good result, others protocols 

should be encouraged in view of the results are maintained over 

time. 

#239 

THE NEW FASHION WAY TO IMPROVE THE 

APPEARANCE OF CELLULITE USING THE 

COMBINATION OF NON-INVASIVE SELECTIVE 

ULTRASOUND (ACCENT ULTRA) WITH IN 

MOTION UNIPOLAR RADIOFREQUENCY 

(ACCENT UNIFORM) 

Elaine Marques, Guilherme Alemida, 



Background: Cellulite affects 85–98% of post-pubertal females. 

The aim of this paper is to present a new fashion way to improve 

the appearance of cellulite using the combination of non-invasive 

selective ultrasound (ACCENT ULTRA, Alma Lasers) and 

radiofrequency (ACCENT UNIFORM). 

Study: Thirty female patients with the diagnosis of cellulite on 

the buttocks were treated. The sessions with uniform were weekly 

during 10 weeks using the same parameters of 190 W and 

accumulating 100 kJ each buttocks. The sessions with ultra were 

separated by 14 days apart in a total of five treatments using the

same parameters of 30 minutes (cool waves) and level 5 (hot 

waves) each buttocks. Results were evaluated by standard and 

three-dimension photography (VECTRA 3D, Canfield) before and 

after treatments. Both patient and physician investigator 

evaluated the treatment using a grading scale of improvement 

ranging from I (no), II (less than 25%), III (26–50%), IV (51–75%), 

and V (76–100%). Only grades IV and V were considered 

satisfactory. 

Results: The ultra module provides a pain-free treatment, noninvasive 

system, in-motion technology, with no downtime, and no 

uncomfortable side effects. The mode of propagation of mechanical 

waves generated are called shear waves. The shear waves 

damages the membrane of fat cells and causes disruption of that 

damaging also the septa of the fat layer with no epidermal and 

dermal damage. The synergetic effect of the mechanical applicator 

with radio-frequency facilitates moving the interstitual fluids and 

contracting connective tissue which provides a temporary 

reduction in the appearance of cellulite. This means patient rate of 

satisfaction with a grade IV and V was 62%. 

Conclusion: The treatment sessions with the combined noninvasive 

selective ultrasound with unipolar radiofrequency 

produce improvements in the overall cellulite appearance and 

skin condition with efficiency and safety. Based on these good 

results, others protocols should be encouraged in view of the 

results are maintained over time. 

#240 


THE SAFETY AND EFFICACY OF 

MICRO-ABLATIVE FRACTIONAL CO2 LASER IN 

THE TREATMENT OF NON-FACIAL SKIN 

PHOTODAMAGE, WRINKLES, PIGMENT 

DISORDERS AND LAXITY: A CASE SERIES OF 

480 BRAZILIAN PATIENTS 

Elaine Marques, Guilherme Almeida, 



Background: The use of the fractional CO2 is the gold standard 

laser treatment for facial skin rejuvenation. Most recently the 

concept of deep dermis micro-ablation with a high power, high 

speed, high pulsed, low density fractional CO2 laser was 

introduced. Physicians from the entire world had started using 

this device in an extra facial region with some good and excellent 

results but also with some scars, hypo- and hyperpigmentation. 

We decided only to use the device with low densities to avoid the 

collateral effects and the down time as presented in our previous 

report for the treatment of facial skin rejuvenation of 200 

Brazilian patients. Now, this new report evaluated MAFCO2 for 

the treatment of non-facial skin photodamage, wrinkles, pigment 

disorders and laxity with 480 Brazilian patients (Fitzpatrick II to 

VI) followed after 12 months with high rate of satisfaction and 

non-incidence rate of post-inflammatory hyperpigmentation 

(PIH), hypochromia and scarring. 

Study: Four hundred and eighty patients (neck, chest, arms, 

hands and legs) were treated with DEEP FX. Each patient was 

treated with 1 single pass with DEEP FX device with 10–25 mJ, 

pattern 2, and density 1. Responses and side effects were recorded 

with VECTRA 3D, patient’s and physicians’ assessment. 

Results: Significant improvement on the appearance was 

noticed. Everyone experienced erythema only for a maximum 

period of 3–15 days, edema for 48 hours, only 5% pinpoint 

purpura after the use of AINH, none PIH, late hypochromia or 

scarring. 

Conclusion: The development MAFCO2 technology and 

refinement of treatment protocols may allow for more dramatic 

modulation of the underlying deeper structures, improving the 

consistency of results. This study indicates that MAFCO2 is 

highly safe and effective to treat non-facial skin damages even 

when is used in dark skin but care should be taken when treating 

non-facial skin. 

#241 

PULSED DYE LASER TREATMENT FOR 

JESSNER’S LYMPHOCYTIC INFILTRATION OF 

THE SKIN 

Thierry Passeron, Jean-Loic Michel, Denis Perrin 

Laser Center, St-Etienne, France; Laser Center Strasbourg, 

France; University Hospital of Nice, Nice, France 

Background: Jessner’s lymphocytic infiltration of the skin (LIS) 

is a chronic, benign T-cell infiltrative disorder, usually presenting 

as erythematous papules or plaques on the face, neck and back. 

Many treatments have been reported to be effective, mostly based 

on isolated cases. They include topical, intralesional or systemic 

steroids, oral hydroxychloroquine, cryotherapy, methotrexate or 

thalidomide. We report a retrospective study on the use of pulsed 

dye laser for treating LIS. 

Study: We conducted a multicenter retrospective study on seven 

patients with LIS confirmed by histological examination. The 

lesions were located on the neck or the trunk. In all cases, the 

response to high potent topical steroid was inconsistent or 

negative. The patients were treated with 595 nm PDL 

(Photogenica Vstar 1 and Cynergy 1 , Cynosure 1 ; VBeam 1 

Candela 1 ). The parameters were fluency from 5.5 to 9 J/cm 2 , 

pulse duration 0.5 milliseconds with a 7 mm hand piece. 

Results: All the lesions were cleared after one to three sessions 

without side effect. The mean follow-up was 3 years (6 months–8 

years, median 1 year). Only one patient had a recurrence 1 year 

after one session of PDL. He responded to one additional session 

and did not have new flares. 

Conclusion: Only one case of Jessner-Kanof’s disease treated by 

PDL has been described. However, several cases and small series 

have emphasized the efficacy of PDL in treating cutaneous lupus. 

In both cases, the PDL might be effective by inducing a 

selective destruction or coagulation of the vessels of the lesions 

that ultimately leads to a modulation of the local inflammation. 

The 595 nm PDL offers a valuable therapeutic alternative, and 

to the light of our results that showed a high rate of success 

and a good tolerance, it could even be proposed a first-line 

option. 

#242 

SAFETY AND EFFICACY OF A DUAL 1,550/1,927 NM 

NON-ABLATIVE FRACTIONAL LASER FOR 

FACIAL AND NON-FACIAL PHOTODAMAGE 

Vic Narurkar, Sara Loehmer, Ava Shamban 

Bay Area Laser Institute/CPMC San Francisco, CA; Laser 

Institute for Derm and European Skin Care, Santa Monica, CA 

Background: Fractional resurfacing lasers have become popular 

treatment options for photodamaged skin. While single 

wavelength treatments are common, this study examined the 

safety and efficacy of a device with adjustable spot sizes intended 

for epidermal and superficial dermal coagulation, including 1,550 

and 1,927 nm wavelengths, to treat photodamaged skin.


Study: Ten subjects, skin types I–IV, with facial and non-facial 

photodamage received an average of two treatments (14- to 45-day 

intervals) using 1,550 nm immediately followed by 1,927 nm 

(Fraxel re:store 1 DUAL, Solta Medical, Inc.). Topical anesthetic 

was applied 1 hour before treatment. Laser settings of 20–40 mJ/ 

pulse and coverage density of 14–26% were used for the 1,550 nm 

wavelength, and 5–15 mJ/pulse and 30–40% for the 1,927 nm 

wavelength. Subjects were evaluated for safety and efficacy at 

each study visit. 

Results: Moderate-marked improvement in photodamage and 

pigmentation was observed for all subjects. Significant 

improvement in fine and coarse wrinkling, lentigines, sallowness 

and skin texture was observed during follow-up visits. Average 

subject discomfort score was 3.3/10 (0–10 scale). Post-treatment 

responses included mild-moderate transient erythema and 

edema, with no adverse events reported. Patient satisfaction with 

clinical outcome was high. 

Conclusion: The clinical results of this study support the use of 

combining 1,550 and 1,927 nm wavelengths for safe and effective 

treatment of photodamaged skin on facial and off-face areas. 

Fewer sessions than traditional nonablative fractional laser 

resurfacing were necessary. This well-tolerated treatment option 

addresses both superficial and underlying dermal effects 

associated with photodamage, with limited or no additional 

downtime for patients. 

#243 

SELF-ETCH ADHESIVES AND LASER TOOTH 

PREPARATION, IS IT A REASONABLE 

COMBINATION? 

Ali Obeidi, Weiwei Wang, Jeema Dad, 

Jacquie Duong, Petra Wilder-Smith 

University of Texas Health Science Center, Houston, TX; 

ATSU Arizona School of Dentistry & Oral Health, Mesa, AZ; 



Background: The development of self-etch bonding systems and 

on the other hand introduction of Erbium lasers to restorative 

dentistry has allowed the practitioners to carry out minimal 

invasive treatments, but studies have been reported lower bond 

strength of the new self-etch systems. It was also the same for the 

bond strength of laser prepared cavities. The purpose of this study 

was to investigate the combination of these two technologies and 

also the possibility to restore the bond strength. 

Study: Two hundred human molars were used to test bond 

strength of five self etch adhesives [Clearfil SE (CFSE), ClearfilS3 

Bond (S3), Schotch Bond SE (SBSE), Easy Bond (EB) and 

OptiBond All-in-One (OB)] to enamel and dentin surfaces after 

application of four different preparation techniques: Bur, Laser 

[Er,Cr:YSGG, 4.5 W, 60% air, 80% water (enamel) 3 W, 60% air, 

70% water (dentin)], Laser þ Excavation (LExc) and 

Laser þ Excavation þ Acid Etch (LExcAE). Acid Etch 

(phosphoric acid 37%) has been applied for 20 (enamel) and 15 

(dentin) seconds, then washed out with water. Adhesive procedure 

were followed according to the manufacturer’s recommendations, 

a composite cylinder (Z 100, 3 M ESPE) was placed on the treated 

surface using Ultradent gig (d ¼ 2.3 mm), light cured for 

40 seconds and stored at 378C at 100% humidity for 24 hours prior 

to shear bond strength (SBS) testing (0.5 mm/min) and data were 

analyzed (ANOVA, Tukey’s, P < 0.05). 

Results: Statistical analysis showed significant improvement 

(P < 0.05) to the bond strength of the laser prepared samples in 

favor of LExcAE in most of the bonding—substrate groups. But 

there were no significant differences between techniques in 

CFSE-Enamel groups, S3-Dentin groups and EB-Dentin groups. 

Conclusion: Within the limits, it can be concluded that 

excavation and subsequent conventional etching may 

significantly increase the bond strength of composite resin to 

enamel and dentin prepared by laser when using a 6th or 7th 

generation self-etch bonding system. 

#244 

MULTI-WAVELENGTH LASER TREATMENT FOR 

CUTANEOUS VASCULAR LESIONS IN ASIANS 

Takafumi Ohshiro, Toshio Ohshiro, Katsumi Sasaki, 

Yuki Taniguchi 

Ohshiro Clinic, Tokyo, Japan 

Background: Pulsed dye laser (PDL) is the golden standard 

method for the treatment of port wine stains (PWS). Although the 

clinical results have been remarkably improved using the 

revolutionary PDL system, it is difficult to treat the lager/smaller 

diameter micro-vessels and deeply situated vessels in dermis. 

Since 2006 we have applied the dual wavelength laser system 

(Cynergy Multiplex, Cynosure, USA) for various vascular lesions. 

Cynergy Multiplex can emit the two wavelengths (595 and 

1,064 nm/PDL and Nd:YAG) separately by millisecond time delay. 

The purpose of the study is whether this dual wavelength laser 

system is effective for the cutaneous vascular lesions in Asians. 

Study: We have applied the 595/1,064 nm wavelength laser 

system for the various cutaneous vascular lesions such as PWS, 

venous malformations, nodular type angiomas in Asians. 

Results: Longer pulse PDL and low Nd:YAG fluence could allow 

the good clearance. Our 5 years’ experience has revealed that this 

sequential emission could fade the refractory PWS, and could 

downsize the venous malformations and nodular angiomas with 

no permanent adverse effects. 

Conclusion: In Asians the sequential emission could be a 

treatment option for cutaneous vascular lesions, which consist of 

deeply situated micro-vessels or larger diameter micro-vessels. 

#245 

PIGMENTATION SEQUELAE OF CUTANEOUS 

AIDS-RELATED KAPOSI’S SARCOMA 

SUCCESSFULLY TREATED BY Q-SWITCHED 

ALEXANDRITE AND ND:YAG 532 NM LASERS 

Thierry Passeron, Rosalind Hughes, 

Lacour Jean-Philippe 


Background: Despite the improvement of the treatment for 

AIDS related Kaposi sarcoma (AIDS-KS), the lesions can lead to 

unsightly pigmentary sequelae, suggestive the underlying 

diagnosis. Such pigmentations are due to hemosiderosis. We 

report a case successfully treated with Q-switched laser. 

Study: A 53-year-old male, presented with AIDS-KS pigmentary 

sequelae. He had a complete response to the highly active antiretroviral 

therapy (HAART) and systemic vincristin 

chemotherapy. However, the KS lesions left disfiguring, large 

purple to brown patches on the shins, ankles and calves that 

remained unchanged one year after the cessation of 

chemotherapy. A test session was done on a large plaque on the 

right shin using several wavelengths: 532 nm Q-switched Nd:YAG 

laser (6 J/cm 2 ), 1,064 nm Nd:YAG laser (6 J/cm 2 ), 755 nm

Q-switched Alexandrite laser (6.5 J/cm 2 ) and 694 nm Ruby laser 

(8.4 J/cm 2 ). 

Results: Two months later, the areas treated by 755 nm 

Alexandrite and 532 nm Q-switched Nd:YAG, and to a lesser 

extent, that treated with the 694 nm Q-switched Ruby laser were 

significantly paler. There was no appreciable change in the site 

treated with the 1,064 nm laser. All lesions were subsequently 

treated, at 2-month intervals, with the 755 nm Alexandrite laser. 

Treatment was started with a fluency of 6.5 J/cm 2 . At each session, 

the fluency was increased as the pigment faded, as tolerated, to a 

maximum of 18 J/cm 2 . After four sessions, all treated lesions 

showed a lightening in pigmentation by 50–70%. For the 

following two sessions, the patient was treated with the 532 nm Qswitched 

Nd-YAG laser (fluency 5 J/cm 2 ), resulting in a further 

reduction in discoloration, such that most lesions were only barely 

visible. Treatment was well tolerated with no adverse events and 

no recurrence of pigmentation at 6 months follow-up. 

Conclusion: We suggest that a combination of the Q-switched 

Alexandrite and 532 Nd:YAG lasers represents a safe and 

effective treatment for pigmentary sequelae of KS. 

#246 


SUPERFICIAL LYMPHANGIOMA TREATED WITH 

FRACTIONAL ABLATIVE LASER: CLINICAL AND 

REFLECTANCE CONFOCAL MICROSCOPY 

EVALUATION 

Thierry Passeron, Katerina Tsilika, 

Jean-Philippe Lacour, Philippe Bahadoran, 

Jean-Paul Ortonne 


Background: Superficial lymphangiomas are benign vascular 

malformations due to the dilatation of lymphangitic vessels. No 

treatment approach gives actually satisfactory results. We report 

a case of superficial lymphangioma treated with fractional 

ablative laser. 

Study: A 13-year-old boy presented with a superficial 

lymphangioma of the right arm that as already recurred after a 

first surgical treatment. His lymphangioma was inducing almost 

permanent flow, clearly impairing his quality of life. A treatment 

using fractional ablative 2,940 nm erbium laser was proposed. 

After topical anesthesia with prilocaine and lidocaine cream, two 

sessions of fractional erbium laser were performed at 2 months 

interval (180 J/cm 2 with coagulation 4 J/cm 2 ). The evaluation was 

done before treatment, 2 months after the 1st session and after 6 

months follow-up. Clinical examination, digital photos and 

reflectance confocal microscopy (RCM) were performed. The 

number of days with flows in the months before the evaluation 

was also noted. 

Results: A worsening of the symptoms with daily flow was 

observed in the first 15 days after the first session. Then the flows 

gradually decreased. After the second session some flows were 

noted three times in the 2 first months, then no more flows were 

observed. Concomitantly, the number of vesicles was almost 

cleared. The RCM showed before treatment numerous dark 

cavities filled with low circulation flow (as compared to vascular 

flow). The RCM examination performed immediately after the 

laser session showed the photoablation holes down to the 

superficial dermis. At 6 months follow-up, the RCM showed the 

clearing of vesicles in the epidermis and superficial dermis but 

noted residual lesions in the lower parts of the dermis. The 

tolerance of the treatment was good and no side effect was 

observed. 

Conclusion: The fractional ablative erbium laser appears to be a 

useful and safe treatment for superficial lymphangiomas. The 

RCM examination showed residual lesions in the lower dermis 

and may suggest long-term recurrences. 

#247 

CLINICAL EFFECTS OF GROWTH FACTOR BASED 

GEL VERSUS VEHICLE IN PATIENTS TREATED 

WITH A NON-ABLATIVE, FRACTIONATED 

RESURFACING PROCEDURE 

Jennifer Peterson, Sabrina Fabi, Mitchel Goldman 

Goldman Butterwick & Associates, Cosmetic Laser Dermatology, 

San Diego, CA 

Background: A novel growth factor based gel generated from 

neonatal human dermal fibroblasts has been demonstrated to 

improve signs of photodamage including fine lines and wrinkles 

following twice daily application. The primary objective was to 

evaluate the efficacy and patient preference for a topical growth 

factor based gel versus matched placebo combined with a 

fractionated, non-ablative laser for the treatment of photoaging. 

Study: We performed a double-blinded, split-face, investigator 

initiated clinical study with a single study site. Fifteen patients, 

skin types I–IV, received a single treatment using a fractionated 

1,440 nm (7.3–8 mJ) and 1,320 nm (2.3–3 mJ) Nd:YAG in a 

multiplex mode with two passes at baseline. Following the 

procedure, the new skin care regimen was begun. Patients were 

evaluated at 30, 60, and 90 days. Photographs were obtained at 

each visit with the Canfield Vectra 3-D system. Investigator 

evaluated signs of photoaging were performed at each visit based 

on a 9-point scale assessing fine lines and wrinkles, coarse 

wrinkles, firmness, tone, mottled hyperpigmentation, tactile 

roughness, and overall photodamage for each side of the face. A 3point 

investigator evaluated tolerability scale was performed at 

each visit for each side of the face. At all visits, subjects evaluated 

tolerability to the gels on each half of their face. At day 30, 60, and 

90, 3-D photographs were compared to baseline to evaluate 

global improvement. At the final visit, patient preference was 

obtained. 

Results: At the time of preliminary data analysis, all 15 patients, 

Skin types II–IV had received treatment. This study is scheduled 

to be completed by January 2011. Results will be presented at the 

meeting. 

Conclusion: Our preliminary analysis of patients at 30 days 

suggests the addition of growth factor gel to a non-ablative 

fractionated laser improves photoaging more than with a 

nonablative fractionated laser alone. 

#248 

PH CORRELATION WITH THE DOSE OF LOW 

LEVEL LASER THERAPY IN CHRONIC VENOUS 

ULCER—CASE REPORT 

Nathali Pinto, Mara Pereira, Carla Albhy, 

Elisabeth Yoshimura, M. Cristina Chavantes 

University of São Paulo, São Paulo, Brazil 

Background: Venous ulceration is one of the most severe and 

debilitating outcome of legs’ chronic venous insufficiency, making 

up 70% of all chronic lower extremity ulcers. In the USA, 600,000 

new leg ulcer cases occur yearly. The annual cost for treating 

patients’ leg ulcer is estimated at some U$25 million. Lower 

extremity venous ulcers’ symptoms include swelling, aching and


cramps. Low Level Laser Therapy (LLLT) has been employed to 

assist several wound healing process, helping successfully the 

anti-inflammatory and analgesic effects. The aim of this study was 

to evaluate LLLT applied onto venous ulceration and its 

correlation with pH. 

Study: A.S., 63 years, presented chronic venous ulcer, edema and 

pain in the right leg for 3 years. Without success with 

conventional treatment, patient underwent to LLLT (? ¼ 685 nm, 

DE ¼ 8 J/cm 2 , P ¼ 30 mW, T ¼ 11 seconds), punctually, around 

the ulcer, initially, 2 /week and afterwards 1 /s.e.m., in which 

pH was measured before and after laser. Since first LLLT 

application, patient described pain reduction, besides changes in 

pH level inside the ulcer. Also, this procedure may aid to 

determine bacteria and fungi infection intralesion. 

Results: Leg ulcers are a huge problem for both patients and 

health service resources, attacking people of different ages that it 

is associated with socioeconomical problems, like absence from 

work. pH alteration onto the skin irradiated by LLLT signals to be 

a relevant parameter to the dosimetry. The effective treatment 

using LLLT in diminished edema, wound size, besides analgesia 

affects patient’s quality of life. We could identify these alterations 

and the correlations with pH changes, inclining lesion normality. 

Conclusion: These findings support the continued use of LLLT in 

clinical practice for this type of ulceration, and promote awareness 

for its use as an adjunctive therapy life. Thus, LLLT denoted to be 

safe and exceptionally valuable tool with cost-effectiveness. 

#249 

1,927 NM FRACTIONAL THULIUM FIBER LASER 

FOR THE TREATMENT OF NON-FACIAL 

PHOTODAMAGE: A PILOT STUDY 

Kristel Polder, April Harrison, 

Leigh Ellen Eubanks, Suzanne Bruce 

University of Texas Houston; Suzanne Bruce and Associates, 

Houston, TX 

Background: A 1,927 nm wavelength was recently added to the 

1,550 nm erbium-doped fiber laser. This wavelength possesses a 

higher absorption coefficient for water as compared to the 

1,550 nm, conferring an increased ability to target epidermal 

processes. This study evaluates the efficacy and safety of a novel 

1,927 nm fractional thulium fiber laser in the treatment of nonfacial 

photodamage. 

Study: Nine patients with moderate to severe non-facial 

photodamage underwent three laser treatments (3- to 4-week 

intervals) at pulse energies of 10–20 mJ and 30–55% surface area 

coverage (4–8 passes) with a 1,927 nm thulium fiber laser. 

Treatment areas represented in this study included the dorsal 

hands, bilateral circumferential forearms, neck, and chest. 

Clinical improvement of treatment areas was evaluated by a 

blinded assessor using randomized photos at 1-month follow-up 

with a quartile grading scale (0–4). Patients also completed a 

satisfaction questionnaire. 

Results: Nine patients with a total of 12 treatment areas 

completed three treatments and the 1-month follow-up visit. At 

follow-up, a blinded assessor rated mean improvement in 

photodamage as 3.25 1.0 and lentigines as 3.33 0.9 on a scale 

of 0–4 (0¼ none, 1 ¼ 1–25%, 2 ¼ 26–50%, 3 ¼ 51–75%, and 

4 ¼ 76–100% improvement). Eight of 12 treatment areas 

demonstrated at least 51–75% improvement in overall 

photodamage. Patients rated the mean level of improvement in 

sun freckling as 2.71 0.8 and overall improvement in sun 

damage as 2.0 0.9. Skin responses observed after treatment 

were moderate erythema, mild edema, itching, and 

desquamation. No scarring or post-inflammatory hyper- or 

hypopigmentation was observed. 

Conclusion: The 1,927 nm fractional thulium fiber laser is a safe, 

effective treatment for non-facial photodamage. 

#250 

FRACTIONAL CO2 LASER IN THE COMBINED 

TREATMENT OF PAPULOPUSTULAR ACNE 

VULGARIS 

Julia Pryaslova, Anastasia Tolstaya, 

Mikhail Golikov, Ksenia Krechko 

Ekaterinburg, Russia 

Background: Acne is a common skin disease that dramatically 

reduces the quality of life. Despite the wide range of treatment 

modalities, the problem remains actual. The use of laser- and 

light-based options has increased dramatically in recent years. 

Fractional lasers are commonly used for acne scars treatment, so 

we wanted to check its effectiveness in treatment of inflammatory 

acne. 

Study: Twenty-one patients 16–43 years old (mean 30 3) with 

inflammatory facial acne mild–moderate severity and/or acne 

scars were enrolled in the study. Treatment included 1.3 0.2 

(1–4) sessions of fractional CO2 laser (SmartXide) ablation at 1– 

1.5 months intervals in combination with systemic antiviral and 

topical antibiotic therapy. Mean treatments fluence was 3.3 0.5 

(0.8–7.5) J/cm 2 . During post-partum period were applied an 

antiseptic solution, antibacterial agents, wound healing cream, as 

well as recommending the use of photoprotection with SPF ¼ 30. 

Clinical photographs were obtained at baseline and after each 

treatment, improvements were rated on a five-point scale 

(0—unchanged; 1—weak; 2—good; 3—very good; 4—excellent). 

Results: There was a cumulative therapeutic effect, with 

objective and subjective significant reduction of skin oil, the 

number of inflammatory elements, the relief smoothing, the 

improvements of atrophic scars, lightening pigments and 

stagnant inflammatory spots. Treatment-related pain was well 

tolerated, and adverse effects were limited to transient erythema 

and edema at treatment sites and 1 case of streptostaphylodermia. 

Investigator and subject assessments show positive results in 81% 

patients and good–excellent results in 57% patients. 

Conclusion: Fractional CO2 ablation can be used to treat 

inflammatory acne and scars mild–moderate severity, but we 

need to develop appropriate protocols to increase the effectiveness 

of the treatment. 

#251 

EVALUATION OF EFFICACY OF Q-SWITCHED 

ND:YAG LASER FOR TATTOO REMOVAL IN 

INDIAN PATIENTS 

Srikantha Rathi, Niteen Dhepe, Ashok Naik 

Dr. Dhepe’s Skin City, Solapur, India 

Background: There are many studies on type I to type IV skin in 

regard to tattoo removal. There are few studies assessing the 

efficacy of laser for tattoo removal in type IV–VI skin. Moreover 

there are not many studies from India. In view of this we aim to 

study the efficacy of Q-switched Nd:YAG laser for treatment of 

tattoos by using two different energy settings and to study the side 

effects of the treatment.

Study: Institutional based prospective study conducted on 24 

patients with tattoo from July 2009 to August 2010. Body tattoo 

was divided into two equal units, one unit received 700 mJ/pulse 

and other received 900 mJ/pulse. Bindi tattoo patients were 

treated alternately with 700 and 900 mJ/pulse. Total number of 

tattoos included in study was 40. Spot size of 3 mm at a 

wavelength of 1,064 nm and frequency of 2 Hz was used. During 

the procedure cooling was done using Cryo5. Three sittings were 

given at 6 weeks interval and follow-up period was for 9–12 

months after the third sitting. Percentage of clearance of tattoo 

was evaluated by two blinded physicians using visual analogue 

scale at the end of the treatment. The occurrence of adverse events 

was assessed and graded accordingly. 

Results: There was more than 75% clearance in 85% of patients. 

There was no statistically significant difference in clearance of 

tattoos and adverse events using 700 or 900 mJ/pulse. Transient 

hyperpigmentation was present in 52.5% of tattoos which 

improved over the period. There was higher incidence of scarring 

and depression in forehead tattoos as compared to body tattoos. 

Hypopigmentation was not seen in present study. 

Conclusion: Using higher fluences good tattoo clearance could be 

achieved in 95% of patients. Hyperpigmentation was seen more 

frequently with higher fluences and use of cooling which was 

transient. Scarring and depression were more common in 

forehead tattoos. 

#252 


PRELIMINARY RESULTS OF A CLINICAL TRIAL 

USING A NOVEL INTRALESIONAL FRACTIONAL 

RADIOFREQUENCY DEVICE FOR DEEP DERMAL 

HEATING OF FACIAL SKIN 

Nark-Kyoung Rho, Jeong-Yeop Lee, Soohong Kim, 

Kyung-Ae Jang, Seok-Beom Park 

Leaders Aesthetic Laser & Cosmetic Surgery Center, Seoul, Korea 

Background: The objective of this preliminary study was to 

evaluate the clinical efficacy and safety of a novel intralesional 

fractional radiofrequency device for deep dermal heating. 

Study: The device used for the study was equipped with a 

treatment tip of 25 non-insulated radiofrequency insertion 

needles in 1 cm 2 . The range of needle penetration depth was from 

0.5 to 3.5 mm in 0.1 mm increment. Histologic study using porcine 

skin and human fresh cadaver skin was performed before clinical 

trial. Standard treatment protocol was 0.8–3.0 mm of penetration 

depth, 7–9 level of radiofrequency energy (arbitrary scale), 100– 

200 milliseconds of pulse duration, depending on the treatment 

area. Before treatment, topical anesthetic cream was applied for 

30 minutes. Thirty Korean subjects were treated and evaluated 1 

day, 7 days and 1 month, and 2 months after the procedure. 

Results: The treatment was well-tolerated in all subjects. 

Immediate post-treatment erythema and edema were evident in 

all subjects; however, these resolved spontaneously within an 

hour. Minimal microcrusts in a fractional pattern, mainly on the 

lateral cheek area, developed 1–2 days after treatment and 

spontaneously resolved after 7–8 days. At the 1-month follow-up, 

clinical improvement was seen regarding the skin tone and 

pigmentation (95%), prominent facial pores (89%), fine winkles 

(76%), midface laxity (70%), mentolabial folds (62%), and 

nasolabial folds (57%). After 3 months, mild improvement of acne 

scarring was noticed in some subjects. Interestingly, facial 

flushing and rosacea improved in three subjects. No serious side 

effects were noticed. 

Conclusion: According to the preliminary study, intralesional 

deep dermal heating by fractional radiofrequency was found to be 

effective and safe treatment for the facial rejuvenation in 

Koreans. 

#253 

TREATMENT OF PORT WINE STAIN USING A NEW 

OPTIMIZED PULSED LIGHT HANDPIECE 

E. Victor Ross, Emily Yu 

Scripps Clinic, San Diego, CA 

Background: Pulsed dye lasers (PDL) have been preferred for 

port wine stain (PWS) treatments. Approximately 20% of PWS, 

however, are poor responders. Intense pulsed-light devices are 

increasingly popular because of their versatility. This study 

evaluates PWS treatments with a new optimized pulsed light 

(OPL) device. 

Study: This study was performed under IRB approval. No PWS 

had prior light-based treatments. Thus far, four female and one 

male (mean age 38) have been enrolled. Extra-facial PWS received 

up to four treatments with the OPL (MaxG TM , Palomar Medical 

Technologies, Inc., Burlington, MA) approximately 1 month apart. 

Using the OPL, 3, 5, and 10 milliseconds pulse widths were 

applied over three respective regions of the PWS at the highest 

fluence without epidermal side effects. The OPL provided a 

spectral range of 500–670 and 870–1,200 nm and fluences 20– 

40 J/cm 2 . Another area of each PWS was treated with a PDL 

(VBeam 1 , Candela Corporation, Wayland, MA) at 1.5– 

3 milliseconds, and 6.0–8.5 J/cm 2 . Photographs were taken and 

improvement was assessed clinically at each treatment. A 

reflectance spectrophotometer measured hemoglobin and melanin 

levels and tracked PWS clearance. 

Results: Most patients underwent three to four treatments; one 

patient relocated after two. Purpura, edema, blanching, and 

erythema were commonly observed immediately post 3 and 

5 milliseconds OPL pulses and post 1.5 and 3 milliseconds PDL 

pulses. Patients had overall fair (26–50%) improvement after one 

treatment and good (51–75%) to excellent (76%–99%) 

improvement after three or four treatments. The 3 and 

5 milliseconds pulses demonstrated lower purpura thresholds (24 

and 28 J/cm 2 respectively) with improved clearance per 

treatment. However, hemosiderin deposition was also noted at 

purpuric sites. Reflectance device hemoglobin levels correlated 

with PWS clearance. 

Conclusion: The new optimized light handpiece is effective in the 

treatment of PWS. Immediate response and subsequent 

lightening post-OPL was comparable to that post-PDL. Longer 

follow-ups will clarify the role of purpura in PWS clearance. 

#254 

CLINICAL APPLICATIONS OF LOW LEVEL 

LASERS IN A DENTAL PRACTICE 

Gerry Ross 

General Practice, Tottenham, Canada 

Background: I have been using low level lasers in my dental 

practice since 1993 and the have proven to be an extremely 

valuable tool in delivering high quality low pain dentistry. I will 

outline their uses in restorative dentistry, implants, orthodontics, 

facial pain, soft tissue lesions, endodontics’ nerve regeneration 

and neuropathic pain.


Study: The devices illustrated will be both red and infra-red 

lasers and LEDs. 

#255 

IS SKIN TIGHTENING AN ADDED ADVANTAGE TO 

LASER LIPOLYSIS AS COMPARED TO 

CONVENTIONAL SUCTION ASSISTED 

LIPOSUCTION? A CONTROLLED STUDY 

Kenneth Rothaus 

New York Presbyterian Hospital Weill Cornell, New York, NY 

Background: The purpose of this study is to determine in a 

prospective controlled fashion using an IRB approved protocol if in 

fact there are any additional skin tightening benefits during laser 

lipolysis compared to conventional liposuction. 

Study: A 24 W 924/975 nm laser (Palomar Medical Technologies) 

was used to perform laser lipolysis on the posterior aspect of the 

upper extremity for correction of the ‘‘bat wing’’ deformity on nine 

patients. The contralateral extremity served as the control and 

underwent conventional liposuction. Treatments were performed 

in an accredited office based surgical facility using local tumescent 

anesthesia. Laser energies were delivered until an internal 

temperature of 45 and 508C measured using an internal probe was 

achieved. Following the laser lipolysis, the patients underwent 

traditional liposuction using 2.5-mm cobra cannulae. The controls 

sides underwent traditional liposuction alone. All patients were 

followed for up to 24 weeks. Skin tightening was measured as 

change in diameter of the abducted upper extremity measured 

using a commercial web-based program (ImageStore, Portola 

Valley, California). Patient questionnaires were concurrently 

taken at 72 hours, 4 and 12 weeks to assess pain, morbidity, skin 

contour changes and overall satisfaction. 

Results: The lasered extremities experienced greater skin 

tightening (3.77%) than the controls (0.28%). This was significant 

using a paired T-test (P < 0.04). There were no complications. 

Patients had minimal bruising that was resolved within 7–10 

days. Patient discomfort was also minimal. Patient questionnaires 

demonstrated increased satisfaction and skin contour changes as 

well as decreased pain and morbidity on the lasered side as 

compared with the controls. These findings were consistent with 

investigator assessment. 

Conclusion: Upper extremities treated with laser-assisted 

liposuction using a 924/975 nm laser device demonstrated 

statistically greater skin tightening than those treated with 

traditional liposuction alone with no increase in complications or 

patient morbidity and increased patient satisfaction. 

#256 

POLARIZED PHOTOGRAPHY OF THE SKIN 

Claudia Sá Guimarães 

Rio de Janeiro, Brazil 

Background: It is proposed that clinical examination is 

accompanied by photographs with circular polarizing filter that 

enhances skin pigmentation and vascularization as a way to 

improve the assessment of these patients. Through the use the 

circular polarizing filter it is possible to register the presence of 

hemoglobin and melanin in the skin, which are not observable to 

the naked eye. The development of photographic equipment with 

more powerful CCD (15 MP) for the prosumer machines, enabled 

the recording of details of the skin independent of its natural color. 

The luminance increased with the use of torches flash provides 

illumination similar to daylight (55,000 K), as well as the use of 

technical lighting with light sources applied to 458, improves the 

quality of the pictures with the representation of colors faithfully, 

and permitted the use of circular polarizing filter attached to 

digital camera and exposure compensation with increasing 

aperture. 

Study: A group of 30 volunteers selected at random were 

photographed with digital camera Canon T1i, with 60 mm and 

100 mm macro lens, and circular polarizing filter (Hoya Pro1) and 

lighting of torches flash applied at an angle of 458. The light was 

measured with a digital photometer for calculating the aperture 

(f) and shutter speed. 

Results: Digital photography with polarized filter has proved to 

be a biased method of clinical evaluation improved more than 

the examination with naked eye, as it enables the observation of 

the colors red and brown skin, allowing the observation of 

cutaneous vascular and variations of the melanin pigment in all 

patients. 

Conclusion: The use of polarized light in the dermatological 

examination and photographs is not new. However, with the 

improvement of photographic equipment and photographic 

technique (respecting focal length, proper lighting, good focus on 

the object photographed and the use of circular polarizing filter) it 

is possible a faithful record of the moment of the dermatological 

examination and aid in the detection of skin pigments. The 

method is simple, fast and low cost. 

#257 

AN ANATOMICALLY-BASED ALGORITHM FOR 

CELLULITE TREATMENT WITH A 1,440 NM 

PULSED LASER FOR LIPOLYSIS, SUBCISION OF 

FIBROUS SEPTAE AND DERMAL THICKENING 

AND ELASTICITY 

Gordon Sasaki, Barry DiBernardo 

Cynosure, Pasadena, CA; Cynosure Montclair, NJ 

Background: Cellulite, characterized by alterations to the 

cutaneous surface, pseudo-herniations of fat and septal dimpling, 

especially to the buttocks and thighs, represents a common 

unsightly condition. Cellulite’s definition, etiology, and anatomy 

are subjects of continued debate and, currently, challenges 

consistent effective treatment. (1) Evaluate the safety, efficacy 

and duration of a pulsed 1,440 nm laser for subdermal lipolysis, 

release of septal bands, and thermal salutary effects on dermal 

structures. (2) Evaluate improvements in skin elasticity and 

thickness. (3) Evaluate physicians and subjects satisfaction by 

questionnaires. 

Study: Healthy female subjects (n ¼ 50; average age 41 

7.3 years; average BMI 27.5 6.2) with Grade II–III (Modified 

Muller Nuremberger Scale) cellulite on their thighs were 

enrolled in a prospective, IDE-approved study conducted in two 

plastic surgery offices, each treating 25 subjects. Subjects were 

treated in a single session with a 1,440 nm pulsed Nd:YAG laser. 

A measured amount of energy was delivered through a 1,000 mm 

side-firing fiber to create localized damage in order to disrupt 

fat cells, subcise septae, and heat the dermal/fat junction to 

damage fat and stimulate collagen production within the 

tumesced mapped areas. At baseline, 2, 3 and 6 months, 

treatment efficacy was assessed by (1) high-resolution 

standardized digital photography graded by evaluators, (2) skin 

elasticity by DermaLab Elasticity module, and (3) skin 

thickness with a 20-MHz high frequency ultrasound DermaScan 

probe.

Results: High improvement by subjective physician evaluation 

(5.3–5.4/6.0) and subject evaluation (5.1–5.2/6) were observed 

throughout the 6-month evaluation period with minimal severe 

adverse events or side effects. Skin elasticity increased at 77% of 

treatment sites (63/82 legs) at 2 months, 74% of treatment sites 

(62/84 legs) at 3 months, and 73% of treatment sites (48/66 legs) at 

6 months. The average skin elasticity index increase for all 

treatment sites was 25%, at both 2 and 3 months, and 32% at 6 

months (P-value < 0.01), compared to baseline values. Skin 

thickness increased in 100% of treatment sites at 2 months (86 

legs), 3 months (90 legs) and 6 months (73 legs). The average skin 

thickness for all treatment sites was 15% at 2 months, 19% at 3 

months, and 22% at 6 months (P-value < 0.01), compared to 

baseline values. 

Conclusion: A single anatomically based treatment with a 

1,440 nm pulsed Nd:YAG laser improves the appearance of 

Grade II–III thigh cellulite for at least 6 months with 

minimal side effects, associated with statistically significant 

positive changes in skin elasticity and dermal thickness. 

Additional studies are recommended to further refine the 

technique. 

#258 


#259 

FLUENCE DEPENDENCY OF THE 400 NM 

ABLATION RATES OF SUPRA AND SUBGINGIVAL 

DENTAL CALCULUS 

Joshua Schoenly, Wolf Seka, Peter Rechmann 

Laboratory for Laser Energetics, University of Rochester, 

Rochester, NY; School of Dentistry, University of California at San 

Francisco, San Francisco, CA 

Background: Near-UV laser-ablation rates of supra- and 

subgingival dental calculus are measured as a function of incident 

fluence. 

Study: A frequency-doubled Ti:sapphire laser (400 nm 

wavelength, 10-Hz repetition rate, 60-nanosecond pulse 

duration) was used to irradiate 20 human teeth in vitro with 

supra- and subgingival calculus at fluences between 1.5 and 

8 J/cm 2 . All teeth were irradiated with a 300-mm diameter, 

10th-order super-Gaussian beam at an 858 irradiation angle 

relative to the tooth surface. The depth and volume of calculus 

craters were measured using laser triangulation and monitored 

using light microscopy with a flashing blue light-emitting diode 

(LED). Removal rates were obtained by irradiation in five-pulse 

increments using a shutter control in the laser cavity. 

Results: At each irradiation site, the removal rate of subgingival 

calculus tends to be linear, whereas the removal rate of 

supragingival calculus is more uncertain and often decreases as 

the crater deepens even at higher fluence. Linear trends are seen 

in depth-removal rates as a function of incident fluence for 

supra- and subgingival calculus with slopes of 1.6 and 2.1 (mm/ 

pulse)/(J/cm 2 ), respectively. Volume removal rates of supra- and 

subgingival calculus show a linear, but more uncertain, fluence 

dependence of 1.6 10 3 and 3.5 10 3 (mm 3 /pulse)/(J/cm 2 ), 

respectively. Fitting these data to an ablation blowoff model result 

in an average linear absorption coefficient and fluence ablation 

threshold of 1.4 10 3 cm 1 and 1.7 J/cm 2 , respectively, for 

calculus. 

Conclusion: The removal rates of supra- and subgingival 

calculus, on average, linearly increase with the incident fluence. 

At each fluence, ablation rates of subgingival calculus more 

consistently exhibit linear depth and volume removal compared to 

those of supragingival calculus. 

LASER HAIR REMOVAL FOR DIVERSE 

POPULATION WITH A MULTIPLEX DUAL 

WAVELENGTH DEVICE 

Emil Tanghetti 

Center for Dermatology and Laser Surgery, Sacramento, CA 

Background: Single wavelength devices for hair removal have 

established a track record for safety and efficacy. The ethnic 

make-up and skin types are often dramatically varied in the 

United States. The practitioner is often forced to choose between 

fixed laser wavelengths for hair removal that are not optimized for 

the individual skin type—for example a 755 nm Alexandrite or 

1,064 nm Nd:YAG. A device that allows a tailored combination of 

the two sources depending on the patient skin type and the 

physician’s clinical observations during treatment would allow 

customized treatment with improved safety, efficacy and patient 

comfort. 

Study: Ten female subjects with skin types III–V and aged 20–49 

years presented with unwanted axilla hair. Four treatment areas 

were defined per person (two treatment areas per axilla). Each 

area was treated with one of eight different fluence combinations 

using the Elite MPX dual wavelength laser. The Elite MPX is 

capable of sequentially emitting energy at two wavelengths 755 

and 1,064 nm within the same pulse envelope. The user is able to 

change the wavelength order. Fluence combinations included; 

100% Alex, 25% Alex followed or preceded by 75% Nd:YAG, 50% 

Alex followed or preceded by 50% Nd:YAG, 75% Alex followed or 

preceded by 25% Nd:YAG, and 100%Nd:YAG. Fluence 

combinations were kept consistent within each treatment area 

relative to baseline and were performed at 4- to 6-week intervals. 

Patients were treated post operatively with standard care. 

Follow-up visits were scheduled at 3 and 6 months post last 

treatment. 

Results: All 10 patients tolerated the treatment well. There were 

no major complications and no injuries. All of the fluence 

combinations showed excellent hair clearance at 6 months 

following the last treatment. The 100% Nd:YAG achieved slightly 

lower clearance (77%) than the dual wavelength combinations and 

the 100%Alex (82–89%). Single wavelength treatment with the 

Nd:YAG laser was rated as more painful than treatment with the 

Alexandrite laser. Dual wavelength treatments with equivalent 

fluence were rated as equal or more painful when the Nd:YAG 

pulse preceded the Alexandite pulse. 

Conclusion: The dual wavelength Elite MPX allows for 

customized wavelength combinations depending on the patient’s 

skin type and the physician’s observations. The laser shows 

promising results for improved patient comfort while maintaining 

high level of safety and efficacy. 

#260 

EVALUATION OF ER:YAG LASER GINGIVAL 

TREATMENT USING LASER DOPPLER 

FLOWMETRY 

Carmen Todea, Dorin Dodenciu, Cosmin Balabuc, 

Laura Filip, Mariana Miron, Diana Lungeanu 

University of Medicine and Pharmacy of Timisoara, Timisoara, 

Romania 

Background: This study was performed in order to investigate 

the outcome of Er:YAG laser gingivectomy in comparison with the 

conventional treatment. Laser Doppler Flowmetry was used for 

healing process evaluation.


#262 

Study: This study was conducted on 18 patients with gingival 

hyperplasia, randomly divided into two study groups, group I 

(laser) and group II (conventional). The laser device used in group 

I was represented by an Er:YAG laser (2,940 nm, LP, VLP, 140– 

250 mJ, 10–20 Hz). In group II, the gingivectomy was performed 

with a microsurgical scalpel. Gingival microcirculation was 

recorded using two Laser Doppler Flowmetry channels available 

for simultaneous measurements of two sites, before, 1 week after 

treatment, 1 and 6 months post-treatment. All collected data were 

processed and analyzed statistically. 

Results: The collected data showed significant increase of 

gingival blood flow 1 week after treatment as compared to the 

baseline (P < 0.005). After subsequent examinations, the gingival 

blood flow was similar to the baseline (P > 0.005). Moreover, in 

group I, the blood was similar to the baseline at 15 days and at 30 

in group II (P < 0.005). 

Conclusion: Under the study conditions, laser-assisted 

treatment proved to be more effective than conventional 

approach. The results of this study demonstrated that Laser 

Doppler Flowmetry can be useful in the management of healing 

process. 

#261 

ROOT CANAL MICROLEAKAGE INVESTIGATION 

AFTER ER:YAG LASER-ASSISTED TREATMENT 

Cosmin Balabuc, Laura Filip, Aurel Raduta, 

Cosmin Locovei, Carmen Todea 

University of Medicine and Pharmacy of Timisoara; 

Politehnica University of Timisoara, Timisoara, Romania 

Background: In endodontics, the quality of the root canal filling 

is the result of the root canal cleaning and shaping, leading to the 

prevention of leakage. The aim of this study was to investigate 

using Scanning Electron Microscopy the effect of Er:YAG laser 

irradiation of the root canal in reducing the microleakage. 

Study: Twenty-four extracted teeth with one straight root canal, 

closed apices and extracted for periodontal reasons were used in 

this study. The crowns were removed by transversal sectioning 

and the roots were submitted to biomechanical treatment. After 

the biomechanical treatment, the teeth were divided randomly 

into two study groups, group I (laser) and group II (conventional— 

control), each of 12 teeth. The teeth from group I received laser 

irradiation of the root canal. The laser device used was 

represented by an Er:YAG laser (VSP, 40–80 mJ, 20 Hz). The 

teeth from group II received only conventional biomechanical 

treatment. Then, all the root canals were dried with paper points 

and filled with root canal sealer in conjuction with gutta-percha 

points using lateral condensation and vertical compactation 

techniques. Then, the roots were embedded in acrylic resin using 

specially designed conformators and 5 mm sections were 

performed from apical to coronal direction of the root. The voids 

inside the root canals were quantified and the measurements were 

analyzed statistically. 

Results: The investigation evidenced the presence of voids inside 

the root canal, microleakage areas being detected between the 

root canal sealer and the dentine root canal wall, but also at the 

gutta-percha – sealer interface. Most of the defects were noticed 

in the group were only conventional biomechanical preparation of 

root canal was performed. 

Conclusion: The results of this study demonstrated a reduction 

of microleakage in the apical area when using Er:YAG laser 

irradiation in combination with the conventional biomechanical 

root canal preparation. 

MELASMA TREATMENT WITH A COMBINATION 

OF TOPICAL CREAMS AND PULSED CO2 

FRACTIONAL ABLATIVE RESURFACING 

Mario Trelles, Mariano Velez 

Instituto Medico Vilafortuny, Cambrils, Spain 

Background: Melasma is difficult entity to treat and, in general, 

antipigment cream is the treatment of choice but with inconstant 

results. Fractional lasers have been proposed as a useful 

treatment. This presentation reports on treatment with topical 

creams combined with a pulsed CO2 ablative fractional 

resurfacing. 

Study: Twenty-two females, suffering from melasma, treated 

with an antipigment cream program following pulsed CO2 

ablative fractional resurfacing with a follow-up of 2 years, are 

presented. CO2 laser fixed pulse width, high power, low frequency 

non-sequential pulses were used first. Then, an antipigment 

cream at low dosage to be used regularly every day and once the 

skin was free of scabs. Patients, mean age was 36 years with skin 

types II–IV. Subjective patient and clinician assessments 

according to melasma severity index scores (MASI) were made at 

baseline and at 1, 2, 6, 12 and 24 months. The satisfaction index 

(SI) and overall efficacy was also calculated. 

Results: All 22 patients completed controls. The overall efficacy 

was of 90% at all assessments, with no necessity of increasing 

cream regimen of repeating laser resurfacing. MASI scores were 

clear statistically and favorably significant (P < 0.001). 

Conclusion: Pulsed fractional CO2 laser and topical cream 

regimen obtained evident well-maintained results when combined 

for melasma treatment, and it is most favorable in cases of dermal 

location of pigment. 

#263 

HISTOPATHOLOGY AND 

IMMUNOHISTOCHEMISTRY OF CUTANEOUS 

LUPUS ERYTHEMATOSUS AFTER PULSED DYE 

LASER TREATMENT 

Teresa Truchuelo, Pablo Boixeda, Carmen Moreno, 

María Luisa Zamorano, Javier Alcántara, 

Pedro Jaén 

Ramón y Cajal Hospital, Madrid, Spain 

Background: Cutaneous lupus erythematosus (CLE) is an 

autoimmune heterogeneous disorder with a wide range of skin 

manifestations. Current treatment options include topical and 

systemic approaches. Physical and surgical therapies including 

cryotherapy, dermabrasion, and laser treatment have also been 

tried. Few controlled prospective studies have been performed 

with pulsed dye laser (PDL). Based on previous experience of our 

group which supported the efficacy of PDL treatment in CLE, we 

decided to study the histological changes induced by PDL. To 

determine the efficacy of PDL in cutaneous lupus erythematosus 

(CLE) lesions and the histological and immunohistochemical 

changes. 

Study: A prospective study was performed on nine patients with 

histologically confirmed CLE (six chronic discoid CLE, two 

tumidus CLE and one subacute CLE) who were treated with PDL 

(595 nm, fluence 11 J/cm 2 , spot-size 7 mm, single pulse of 

2 milliseconds). Biopsies were taken before, immediately after 

and 4 weeks after treatment and they were stained with 

hematoxylin–eosin and with commercially available antibodies 

to the following endothelial cell adhesion molecules (ECAM):

ICAM-1 and VCAM-1. Clinical and histological results were 

evaluated by three observers. 

Results: Evaluation after PDL treatment showed a significant 

reduction of the dermal lymphocytic infiltrate in 6/9 patients 

(66.66%) as well as an important reduction of the basal damage in 

6/7 patients (85.71%). Other epidermal changes improved in 4/6 

patients (66.66%). Mucin deposition persisted only in two 

patients. ICAM and VCAM expression was reduced in 7/7 patients 

(100%) and 5/6 patients (83.33%) (P < 0.05). Clinical 

improvement was present in 8/9 patients (88.88%) without side 

effects. 

Conclusion: PDL therapy is an effective treatment for CLE. 

The selective destruction of vessels and the immunomodulatory 

effect could be the main mechanisms of action. Downregulation 

of ECAMs could also have influence on the treatment 

response. 

#264 


#265 

EFFICACY OF A NOVEL NON-HYDROQUINONE 

FORMULATION IN THE TREATMENT OF 

MELASMA: A REFLECTANCE CONFOCAL 

MICROSCOPE STUDY 

Katerina Tsilika, Jean-Luc Levy, Hee-Yang Kang, 

Luc Duteil, Abdallah Khemis, Thierry Passeron, 

Jean-Paul Ortonne, Philippe Bahadoran 

CHU of Nice, Nice, France; Center of Dermatological Lasers, 

Marseille, France; Suwon, Korea 

Background: Melasma is a frequent and disabling pigmentary 

disorder. Available treatments are still unsatisfactory. 

Reflectance confocal microscopy (RCM) is a new imaging 

technique that detects pigment changes at a cellular level. In this 

study, we evaluated the clinical efficacy and tolerance of a novel 

non-hydroquinone formulation, Dermamelan 1 (Mesoestetic, 

Barcelona, Spain), in the treatment of melasma, and we used 

RCM to monitor pigment changes at the cellular level. 

Study: Ten subjects with Fitzpatrick skin types II–IV and facial 

melasma were recruited for this open label study. Patients applied 

Dermamelan 1 (azelaic acid, kojic acid, alpha arbutin, glycirriza 

glabra extract and ascorbic acid) once daily during 12 weeks. Each 

visit (week 0, week 4, week 8, week 12, week 12 þ 4) included 

clinical examination, MASI score, standard and UV-light 

photographs and RCM examination. Adverse events were also 

assessed. RCM images of the epidermis and superficial dermis 

were acquired by means of a Vivascope 1500 microscope (Lucid, 

Inc., Rochester, NY, USA). 

Results: Before treatment the mean MASI score was 22. RCM 

detected hyperpigmented keratinocytes in all lesions, activated 

melanocytes in 2/10 lesions, and dermal melanophages in 2/10 

lesions. After completion of treatment, the MASI decreased to 11 

(P ¼ 0.008). The decrease of MASI was reached after 1 month of 

treatment and was maintained until 1 month after the end of it. 

These results were confirmed by standard and UV-light 

photographs. In parallel to clinical improvement, RCM showed a 

statistically significant decrease of hyperpigmented keratinocytes 

(P ¼ 0.02). Noticingly, patients with dermal melanophages on 

RCM at baseline had only a limited response and melanophages 

persisted on RCM follow-up. Mild irritation was the only adverse 

event observed. 

Conclusion: In this pilot study of Dermamelan 1 in melasma, we 

observed a good outcome in most patients. We also demonstrated 

the interest of RCM to monitor and possibly predict treatment 

efficacy of a novel depigmenting agent in melasma. 

CO2 LASER RESURFACING: A 15-YEAR 

EXPERIENCE 

Samir Undavia, Russell Kridel 

University of Texas Health Science Center, Houston, TX 

Background: To review our experience with CO2 laser 

resurfacing in patients with fine rhytids and other cutaneous 

textural problems, poorly healed scars, and actinic-related skin 

conditions. 

Study: A retrospective chart review of all patients who 

underwent CO2 laser resurfacing by the senior author from 1995 

to 2010. Adjunctive procedures do not exclude patients from the 

study. 

Intervention: Ultrapulse 5000C Computer Pattern Generated 

Carbon Dioxide Laser with a CPG (computer generated hand 

piece) (Coherent Laser Corporation, Palo Alto, CA) and later the 

upgraded model, the Encore Plus Carbon Dioxide Laser with CPG 

and later fractionated hand pieces (Lumenis Corporation, which 

purchased Coherent Corporation). 

Main Outcome Measure(s): Indications, treatment protocols, 

follow-up care, patient demographics and skin types, mean followup 

time, adjunctive procedures, complications, timing of 

complications, treatment of complications, setting of treatments, 

patients satisfaction surveys, and grading of pre- and long-term 

post-treatment photographs by a panel of blinded facial plastic 

surgery reviewers using a standardized facial rhytids scale will be 

reported. 

#266 

A NOVEL THERAPY FOR EFFECTIVE CELLULITE 

TREATMENT IN WOMEN 

Elizabeth VanderVeer, Carrie Anderson 


Background: Cellulite, a common disorder on the buttocks and 

thighs of women, is caused by the herniation of subcutaneous fat 

within fibrous connective tissue. Cellulite is difficult to treat and 

most FDA-approved devices lack significant efficacy. This study 

assessed a six-treatment protocol for the treatment of cellulite 

over three weeks using a novel Acoustic Wave Technology (AWT) 

Device. The study evaluated whether this novel technology was 

safe; tolerable by the patient; and effective with long-lasting 

results. 

Study: A total of five adult women received treatment to their 

bilateral buttock and posterior thigh region. The average patient 

age was 46 with an average BMI of 22. Patients did not alter their 

lifestyle and maintained their normal daily activities without any 

side effects or downtime. Six 30-minute treatments were 

administered to the treatment area using AWT via a hand piece 

with a 15 mm applicator tip. Ultrasound gel was used to apply 

2,000 Acoustic Wave ‘‘pulses’’ in a circular motion to each 

20 20 cm 2 area. An average total of 8,000 pulses were 

administered per patient per-treatment session. The delivery 

frequency (Hz) and energy level (Bar) were increased as tolerated 

during each session until the maximum therapeutic ‘‘dose’’ of 

4 Bar and 18 Hz could be achieved. 

Results: All five patients completed treatment. Photographic 

assessment and cellulite grade was assigned to each patient by 

two blinded observers before treatment and at 4 and 12 weeks 

post-treatment protocol. No adverse events were reported. 

Treatment was described as uncomfortable, but tolerable by all 

patients. Significant improvement was noted with an average of


one grade decrease in the severity of cellulite, as assessed by 

photography by the blinded observers. 

Conclusion: This study demonstrates AWT as an effective and 

well-tolerated treatment for cellulite in pre-menopausal and low- 

BMI women. More studies are warranted to investigate this novel 

approach to an age-old problem. 

#267 

BOTULINUM TOXIN A FOR THE EFFECTIVE 

TREATMENT OF TMJ AND BRUXISM 

Elizabeth VanderVeer, Dianna Burget 


Background: Temperomandibular Joint Disorder (‘‘TMJ’’) and 

Repetitive grinding of the teeth (‘‘Bruxism’’) cause a significant 

amount of pain, distress, and alteration of daily activities for those 

who suffer from these disorders. Over 10 million people in the US 

experience TMJ and/or Bruxism, and 90% of all patients are 

women. These problems take a heavy financial toll (time loss; 

repeated dental work; poor sleep, etc.), and there are often comorbidities 

seen such as depression or fibromyalgia. Botulinum 

toxin A is a known potent muscle relaxer. The purpose of this 

study was to observe the in vivo response to injecting the masseter 

muscle the TMJ with botulinum toxin A. 

Study: Three female patients with severe ‘‘TMJ’’ and/or 

‘‘Bruxism’’ were selected to receive botulinum toxin A into their 

masseter muscles for a total of five treatments at 6-week intervals 

to see if any improvement could be observed in their symptoms. 

Fifty units of botulinum toxin A were injected in a total of ten sites 

(five per side). The injections were restricted to the masseter 

muscle. 

Results: All patients reported a significant improvement in their 

symptoms within 1 week after treatment. All three patients 

experienced some degree of relief at first, with the full 

symptomatology returning at approximately 4 weeks after 

injection. However, after repeated treatments, not only did the 

symptoms continue to improve, but each time, they were 

significantly milder in nature. After the completion of five 

treatments over 30 weeks, all patients were able to extend their 

time between treatments to nearly 12 weeks. None of the women 

needed a nighttime dental appliance or required dental work 

during the period of this study, and all three women rated the 

improvements in their symptoms as ‘‘exceptional.’’ 

Conclusion: From this small study, it appears that TMJ and 

Bruxism symptoms can be effectively treated with botulinum 

toxin A. 

#268 

TREATMENT OF POST-INFLAMMATORY 

HYPERPIGMENTATION WITH 1,927 NM THULIUM 

FRACTIONAL LASER 

Jill Waibel, Dan Wasserman, Elizabeth Houshmand, 

Emily Tierney 

Miami Dermatology and Laser Institute, Miami, FL; 

Total Skin and Beauty Dermatology Center, Birmingham, AL; 

Wright State University, Dayton, OH; 

South Shore Skin Center, Cohasset & Plymouth, MA 

Background: Cutaneous hyperpigmentation is created when 

melanocytes produce excessive melanin resulting in either 

epidermal or dermal melanosis. Hyperpigmentation caused by 

irritation or inflammation is known as post-inflammatory 

hyperpigmentation (PIH). PIH is usually transient in nature, 

however, it may last for several months and is often poorly 

tolerated by patients. The treatment of PIH may be a difficult and 

prolonged process that often takes 6–12 months to achieve the 

desired results of depigmentation. Most conventional treatment 

options potentially improve epidermal hypermelanosis, however, 

dermal hypermelanosis is more challenging. Laser therapy may 

be a proposed treatment since fractional lasers are able to 

penetrate to the depths of dermal pigment. The 1,927 nm nonablative 

fractional thulium laser reaches depths between 150 and 

250 mm and thus treats superficial conditions such as 

pigmentation. This study examined efficacy and safety of 

1,927 nm laser in improving PIH. 

Study: Ten patients of Fitzpatrick types I–IV with various 

etiologies of both acute and long-standing hyperpigmentation 

were enrolled in a prospective study to examine efficacy of 

1,927 nm fractional laser on PIH. Subjects received one or 

two treatments at 20 mJ, and coverages from 25% to 65%. 

Three blinded investigators evaluated photographs taken at 

baseline and 1 month after the final laser treatment. 

Scores were assigned using a quintile improvement scoring 

system. 

Results: Patients tolerated the procedures well with minimal 

edema, erythema and desquamation. No severe adverse events 

were noted. The level of pigmentation improvement showed a 

mean investigator score of 4.2/5.0. Forty percent of the subjects 

received very significant (75–100%) improvement of 

hyperpigmentation and 30% of subjects received marked (51– 

75%) improvement of hyperpigmentation. 

Conclusion: The 1,927 nm non-ablative fractional laser can 

penetrate to depths to target both epidermal and dermal 

hyperpigmentation and can effectively and safely improve acute 

and chronic post-inflammatory hyperpigmentation in minimal 

treatment sessions. 

#269 

CLINICAL RESEARCH STUDY TO EVALUATE THE 

EFFECTS OF PROTOTYPE DENTIFRICES ON 

SOFT-TISSUE ARCHITECTURE 

Joseph Youssef, Steven Duong, Travis Tucker, 

Jun Zhang, Kathryn Osann, Petra Wilder-Smith 



Background: Dry mouth can be caused by a plethora of factors 

such as dehydration and side effects of certain medications. 

Therefore, the aim of this project is to investigate the potential of 

non-invasive in vivo Optical Coherence Tomography (OCT) 

imaging to determine the response of patients with clinically 

diagnosed severe dry mouth (xerostomia), to the use of a dry 

mouth dentifrice versus a placebo. 

Study: This project was a double-blind, crossover, placebocontrolled 

study in six subjects diagnosed with severe xerostomia. 

Two products were tested, with one dentifrice as the active dry 

mouth treatment and the other a placebo. Baseline clinical exam 

and OCT imaging were recorded before the subjects used the first 

dentifrice (Product A) for 15 days. After a 7-day wash out period 

using regular Colgate toothpaste, another 15-day period using the 

second supplied dentifrice (Product B) occurred. Standard 

toothbrushes and floss were provided to the subjects; however, no 

other form of oral healthcare was permitted. OCT imaging and 

clinical exams, dry mouth questionnaires, and photographs were 

acquired at 5-day intervals.

Results: OCT images showed a partial reversal of xerostomiainduced 

mucosal thinning by Product A. Characteristic, 

quantifiable, simple optical measures of mucosal rehydration by 

Product A were identified and validated using backscattering data 

extracted from OCT images. Standard dry mouth questionnaires 

and tongue blade adhesion determinations were not able to track 

oral response to dry mouth treatments with any degree of 

usefulness. 

Conclusion: This study demonstrated that in vivo OCT imaging 

(which requires < 1 second per scan) can detect and measure oral 

epithelial response to dry mouth treatments in patients diagnosed 

with severe xerostomia. Using a simple fiber optic probe, images 

are produced instantly and the procedure is very well tolerated by 

patients. 

#49 


TREATMENT OF INFANTILE HEMANGIOMAS 

WITH THE 595 NM PULSED DYE LASER USING 

DIFFERENT PULSE WIDTHS IN AN ASIAN 

POPULATION 

Yong-Kwang Tay 

Changi General Hospital, Singapore, Singapore 

Background: The pulsed dye laser (PDL) is effective in the 

treatment of hemangiomas. Treatment parameters with varying 

fluences (low to high) and varying pulse durations (short to long) 

have been used, however optimal parameters are unknown. The 

aim was to examine the efficacy and safety of the 595 nm PDL for 

the treatment of infantile hemangiomas using short (1.5– 

3 milliseconds) versus long (10 milliseconds) pulse durations and 

high fluences. 

Study: Records were reviewed for all patients with infantile 

hemangiomas treated with the 595 nm PDL (V-Beam 1 , Candela) 

alone from January 2003 to December 2007. Cases with missing 

data and those who defaulted follow-up were excluded. The end 

point was complete or near complete clearance of the 

hemangioma. Most hemangiomas were treated without 

anesthesia, with EMLA cream applied only to larger lesions. For 

the short pulse duration group (1.5–3 milliseconds), n ¼ 15 

patients, the following parameters were used: 7 mm spot size, 

fluence 10–13.5 J/cm 2 (mean 11.2 J/cm 2 ) and dynamic cooling 

device (DCD) spray duration of 50 milliseconds (ms) and delay of 

30 milliseconds. For the long pulse duration group 

(10 milliseconds), n ¼ 8 patients, the following parameters were 

used: 7 mm spot size, fluence 10.5–14.5 J/cm 2 (mean 12 J/cm 2 ) and 

DCD spray duration of 40 milliseconds and delay of 

20 milliseconds. The areas were treated with non-overlapping 

pulses. Post-treatment purpura was seen in the short pulse 

duration group and minimal or no purpura in the long pulse 

duration group. 

Results: Twenty-three patients, 19 girls and 4 boys (Fitzpatrick 

skin type III–VI) met the study criteria. The age at the start of 

treatment ranged from 21 2 months to 19 months (mean 6.5 

months). Twenty-one hemangiomas were situated on the face, one 

on the neck and one on the left labia majora. Twenty-one 

hemangiomas were in the proliferative phase and two were in the 

stable phase when treatment was started. Ten children had 

superficial hemangiomas and 13 had mixed hemangiomas 

(presence of a subcutaneous component). The number of 

treatments needed to achieve complete or almost complete 

resolution of the hemangioma for the short pulse duration group 

ranged from 3 to 14 (mean, 8 treatments, median 7 treatments) 

and for the long pulse duration group 4–14 treatments (mean 9, 

median 7 treatments). For both groups, more treatments were 

needed to achieve clearance of mixed hemangiomas, compared to 

superficial hemangiomas (on average, 4–5 treatments more). 

Erythema, edema and purpura lasted for about a week for the 

short pulse duration group versus 2 days for the long pulse 

duration group. Two patients had one episode of blistering each 

using 1.5 milliseconds pulse duration which resolved 

spontaneously without sequelae versus none for the 

10 milliseconds pulse duration group. For the short pulse duration 

group, hyperpigmentation was noted in two patients (13%), 

hypopigmentation in three patients (20%), and mild textural 

changes in two patients (13%). For the long pulse duration group, 

hyperpigmentation was noted in one patient (12.5%), 

hypopigmentation in one patient (12.5%), and mild textural 

change in one patient (12.5%). There was no ulceration or 

hypertrophic scarring noted in both groups. 

Conclusion: Both short and long pulse durations using 

moderately high fluences are equally effective in the treatment of 

infantile hemangiomas. Treatments were well tolerated and side 

effects mild. Shorter pulse durations (1.5–3 milliseconds) had a 

slightly higher incidence of side effects compared to longer pulse 

durations (10 milliseconds) in these patients with darker 

phototypes. Hemangiomas are tumors with relatively larger 

diameter blood vessels compared to port-wine stains and this 

provides the basis for the use of longer pulse durations. 

Limitations were the retrospective nature and the small sample 

size of the study. Larger prospective studies are needed to 

determine the optimal parameters for the treatment of infantile 

hemangiomas. 

NURSING/ALLIED HEALTH 

#280 

TREATMENT OF SUBCUTANEOUS FAT USING A 

NOVEL NON-INVASIVE COOLING DEVICE—COOL 

SCULPTING TM BY ZELTIQ TM 

Holly Bryan, Tina Alster, Elizabeth Tanzi 

Washington Institute of Dermatologic Laser Surgery, Washington, 

DC 

Background: To outline a nursing guide and provide an 

updated discussion of our experience using a novel non-invasive 

cooling device for the treatment of subcutaneous fat by inducing 

fat cell apoptosis through a process called Cryolipolysis TM . 

Study: Understand the theory behind Cryolipolysis TM ; Review 

proper patient selection and patient expectations; importance of 

clinical photography; outline the treatment protocol; review 

expected post-operative side effects; outline timing of expected 

clinical results; review procedure set-up, application of device, and 

intraoperative patient care. 

Conclusion: This FDA approved non-invasive cooling device is a 

safe and effective method for the treatment of subcutaneous fat 

resulting in volume loss with minimal transient side effects. 

Measurable fat reduction was obtained in most patients on 

abdomen, back and flank regions. Side effects are limited to 

transient erythema, purpura, edema, and reduced sensation at 

the treatment site.


#281 

EDUCATION AND TRAINING IN THE USE OF 

COSMETIC LASER AND INTENSE PULSED LIGHT 

Trudy Fleming 

Fleming Institute, Melbourne, Australia 

Background: Training in the use of cosmetic laser and light 

devices has traditionally been offered mainly by manufacturers 

and product retailers in most countries. Now, however, there are 

also courses offered by schools and institutes in many countries. 

Some industry associations also offer training now. What is 

involved with this range of training? What sort of recognized 

qualification is offered, if any? Is any of the training on offer 

government accredited within that state or country? How much 

time is involved with the training? Is it sufficient, valid, current 

and subject appropriate? How do school courses compare to what 

the manufacturers offer? Who are the trainers and what 

qualifications do they hold? Who are the trainees? 

Study: The study involves on-site visits and interviews with 

various training organizations, manufacturers and retailers of 

laser/light devices along with detailed questionnaires to be filled 

in at these visits. Questionnaires are also sent out to businesses 

and organizations offering training that I cannot visit personally. 

Information gained gives in-depth insight on the various aspects 

and methods of the training offered. 

Results: The research has commenced in Australia but will 

include visits to UK sites in December and all information 

collected will be collated and comparisons made. 

Conclusion: Cosmetic laser and IPL training varies from a 

matter of hours to more substantial weeks or months. Training is 

offered on-site at the clients’ business premises, at manufacturers 

and retailers sites and in various government and private 

colleges. With such a variety of forms of laser and light device 

training available, the expertise developed by the user also varies 

widely. Currently there is no standardization of training within 

this industry, would it really be so hard to put some international 

minimum standards in place? 

#282 

DEVELOPMENT OF COMBINATION THERAPY 

STRATEGIES 

Patricia A. Owens, James Brazil, Sharon Olson 

Olympic Dermatology and Laser Clinic, Olympia, WA 

Background: In the treatment of photoaging skin, attention is 

directed towards the improvement of facial rhytids, vascular 

lesions, hyperpigmentation, skin laxity and volume loss. The 

benefits of combination therapies have been noted in recent 

clinical articles for global improvement. Our approach to 

maximize patient outcomes has been to offer a RESTOR program 

that combines different protocols utilizing lasers, radiofrequency, 

IPL, liposuction, facial fillers and onabotulinum toxin A. 

Study: A retrospective study over 1 year has examined three 

different types of protocols that have been identified in literature 

to produce beneficial outcomes. Protocols involve a consultation 

and assessment process, followed by the treatment series, followup 

with patient evaluation. Care has been taken to select the 

appropriate protocol(s) to address the patient’s goals and their 

static and dynamic changes from photoaging. 

Results: Twelve months of patient data completing the RESTOR 

program will be reported. Three different programs were 

primarily utilized; RF monopolar tightening device/liposuction, 

RF monopolar tightening device/IPL FotoFacials, and RF 

monopolar tightening device/1,550 nm non-ablative fractional 

resurfacing. Recovery and post-treatment side effects were 

minimal and without incident. Patients were also offered a 

package of facial fillers and/or onabotulinum toxin A to 

compliment their outcomes. Improvement was noted in facial 

contouring, laxity, pigmentation, vascularity and skin texture 

dependent on each specific protocol. A synergistic effect of 

combination therapies has been noted over individual treatment 

outcome. 

Conclusion: Combination therapies are enticing to patients and 

have proven to be complimentary in their rejuvenation effects. 

The RESTOR program demonstrates a successful option for 

patients in order to enhance their outcomes and overall 

satisfaction. 

#283 

EVALUATION OF THE THULIUM FIBER 

1,927 NM WAVELENGTH FOR OFF-FACE 

TREATMENT OF PHOTODAMAGED SKIN WITH 

ACTINIC LESIONS 

Rebecca Sprague, Suzanne Kilmer 

Laser & Skin Surgery Center of Northern California, Sacramento, 

CA 

Background: This study evaluates the safety and efficacy of the 

1,927 nm fractional laser for off-face treatment of actinic damage. 

The 1,927 nm wavelength’s water absorption characteristics and 

optimized dosimetry targets superficial dermis. Primary endpoint 

of the study is overall improvement in the appearance of actinic 

damage and reduction of lesions. 

Study: Eleven subjects (43–65 years old) Fitzpatrick skin types 

I–III with photodamage and actinic lesions on the chest, forearms 

and hands received a series of up to three treatments with the 

1,927 nm laser spaced at 2- to 4-week intervals. Subjects were 

treated at an energy level of 10 mJ with coverage of 40–55%. Skin 

responses and clinical assessment of improvement in the actinic 

damage, lesions and pigmentation were performed by the 

investigator and subjects at 1, 3 and 6 months after the final 

treatment. Improvement was scored using a 0–4 improvement 

scale (0 ¼ none, 1 ¼ mild, 2 ¼ moderate, 3 ¼ marked, 4 ¼ very 

significant). Photos were taken at each treatment and study visit. 

Results: Data were collected for all subjects 3 months after final 

treatment and for 10 of 11 subjects 6 months after final treatment, 

one subject lost to follow-up. Treatments resulted in an 86% mean 

reduction of off-face actinic lesions from baseline to 6 months after 

final treatment. Investigator assessment demonstrated mild-tomoderate 

improvement scores at 3 and 6 months for photodamage/ 

actinic lesions, pigmentation. Subjective scoring was higher for 

photodamage/actinic lesions and pigmentation demonstrating 

moderate improvements. At 6 months, 89% observed at least a 

noticeable improvement in skin texture and all subjects surveyed 

reported improvement in skin tone. Procedures were welltolerated 

with minimal edema or erythema. No serious adverse 

events were reported. 

Conclusion: The 1,927 nm thulium wavelength is a safe and 

effective treatment for reduction of actinic keratoses and 

improving photodamaged skin on non-facial areas. No serious 

adverse effects were noted and subject satisfaction with efficacy 

was high.

American Society for Laser Medicine and Surgery Abstracts 83

84 American Society for Laser Medicine and Surgery Abstracts
























Cutaneous Laser Surgery Session 

LATE-BREAKING ABSTRACTS 

TREATMENT OF BURN SCAR DEFORMITIES IN FITZPATRICK SKIN TYPES IV-V WITH NON-ABLATIVE 

FRACTIONAL PHOTOTHERMOLYSIS: A REPORT OF 7 CASES 

Sean Boutros, Houston Plastic & Craniofacial Surgery, Houston, TX 

Background: The objective of this study was to determine optimal treatment parameters utilizing non-ablative 

fractional photothermolysis for the treatment of burn scars in patients with Fitzpatrick skin types (FST) IV-V. Patients 

were evaluated for improvement at variable follow up intervals. Study: nine patients (4 female, 5 male), FST IV-V, 

with burn scarring of the face were treated with a 1550-nm fractionated Erbium-doped fiber laser. Patients 

underwent 4-8 treatments at a minimum of 6-8 week intervals (8 passes per treatment session) at energy fluences 

ranging from 60-70 mJ and treatment levels ranging from 5-8, which corresponds to surface area coverage of % 

(0.58-3.70 total kJ; average 2.06 kJ). All patients were started on a topical bleaching cream at their initial treatment 

visit and continued use in between and after laser treatments. Patients were evaluated for improvement in the 

clinical appearance of burn scar before each treatment and at a follow-up visit after the final treatment. Results: 

100% of patients had improvement in the appearance of the burn scars. After a minimum of 4 treatments, 4 

patients (44.4%) had excellent results rated by an independent dermatologist. 4 patients (44.4%) had good results 

as rated by an independent dermatologist. 1 patient had mild improvement as rated by an independent 

dermatologist. Improvement in appearance continued throughout treatment and further treatments yielded 

improved results in all cases. Conclusion: Our results indicate that fractional photothermolysis with the 1550-nm 

erbium-doped fiber laser is a safe and effective treatment option for burn deformities in patients with FST IV-V. 

A RANDOMIZED, BLINDED CLINICAL STUDY OF A MICROWAVE DEVICE FOR TREATMENT OF AXILLARY 

HYPERHIDROSIS 

Suzanne Kilmer, William Coleman III, Larry Fan, Dee Anna Glaser, Michael Kaminer, Robert Nossa, Stacy Smith, 

Laser & Skin Surgery Center of Northern CA, Sacramento, CA; Coleman Center for Cosmetic Dermatologic 

Surgery, Metairie, LA; Bay Area Center for Plastic Surgery, Oakland, CA; St Louis University, St Louis, MO; 

SkinCare Physicians, Chestnut Hill, MA; The Dermatology Group of Northern New Jersey, Verona, NJ; UCSD 

Division of Dermatology Cardiff 

Background: Current treatment options for axillary hyperhidrosis (excessive underarm sweating) are limited either 

by duration of effect or efficacy. A novel procedure using an early generation microwave-energy device was 

tested.Study: A multi-center, randomized, sham-controlled study involving 120 adult subjects with primary axillary 

hyperhidrosis was conducted. Subjects were required to have a Hyperhidrosis Disease Severity Scale (HDSS) 

score of 3 or 4 and baseline gravimetric readings greater than 50 mg (5 minutes). Subjects were randomized to the 

treatment group (n=81) or sham group (n=39) and were treated with the microwave device in one to three sessions. 

Follow-up was 6 months for sham group and 12 months for treatment group. Responders were defined as subjects 

reporting a reduction to an HDSS score of 1 or 2. Results: Demographics: mean age 32.8 years; 58% female; 84% 

Caucasian. Efficacy results for the treatment group were 89% at 30-days; 74% at 3-months; 67% at 6-months and 

69% at the 9- and 12-month visits. Sham group results were 54% at 30-days, and 44% for 3- and 6-months. For all 

time points, the efficacy for the treatment group was statistically significantly greater than for the sham group 

(p

and randomized to receive up to four treatments approximately one month apart with OPL (MaxG Optimized Light 

Handpiece, Palomar, Burlington, MA). OPL was used with a spectral range of 500-670 and 870-1200nm, pulse 

duration of 3, 5 or 10msec, and fluence range of 20-40 J/cm 2 

. One small area of the PWS was treated with PDL 

(VBeam, Candela, Wayland, MA) at 595nm, 1.5-3ms, and 6.0-8.5 J/cm 2 

for comparison. Clinical photographs were 

taken before and after each treatment, and improvement of the PWS was assessed clinically. A reflectance-based 

device was used to objectively measure hemoglobin and melanin levels to track PWS clearance in comparison to 

adjacent normal skin. Results: Five patients with PWS on the trunk or extremity were enrolled in the study. Most 

patients underwent four treatment sessions. One patient only received two treatment sessions due to relocation. 

Majority of the patients had fair (26-50%) improvement of PWS after one treatment. Good (51-75%) to excellent 

(76%-99%) improvement of PWS vascularity was achieved in patients four treatments with various pulse durations 

(3, 5, and 10msec). Areas treated with the lower pulse duration (3 msec) showed the greatest improvement based 

on reflectometer readings. However, in two cases, post-inflammatory hyperpigmentation compromised the clinical 

vascular clearance. Pain associated with OPL treatment was mild to moderate, and only one patient required 

numbing cream prior to the treatment. Erythema and edema were commonly observed post OPL treatment 

regardless of settings. However, purpura, blanching, and hyperpigmentation were observed with the short pulse 

duration (3 msec) and high fluence settings. Conclusion: A new optimized light handpiece is effective in the 

treatment of PWS. Lightening of PWS with OPL is comparable to PDL. Shorter pulses achieved slightly better 

clearance, but with greater risk of post-inflammatory hyperpigmentation. 

1064NM QS Nd:YAG LASER AND 1550NM ERBIUM-DOPED FRACTIONATED FIBER LASER FOR THE 

TREATMENT OF NEVUS OF OTA IN FITZPATRICK SKIN TYPE IV 

Irene Vergilis-Kalner, Paul Friedman, Jennifer Landau, Megan Moody, Leonard Goldberg, Denise Marquez, Derm 

Surgery Associates, Houston, TX 

Background: Nevus of Ota, or oculodermal melanocytosis, typically presents as a blue-black, brown, or gray 

macule on the face along the distribution of the ophthalmic or maxillary branches of the trigeminal nerve. It is a 

congenital lesion that is present at birth in the majority of cases; otherwise, it tends to appear in the teen 

years. Treatment options for these nevi include the use of bleaching creams, cryotherapy, surgery, and lasers, with 

varying degrees of success being reported. Lasers have recently been designated the most effective treatment 

modality for this condition. Most commonly, Q-switched (QS) lasers have been used, including the Q-switched 

ruby (QSRL), Q-switched neodymium-doped yttrium aluminum garnet (QS Nd:YAG), and Q-switched alexandrite 

(QSAL) lasers. The Q-switched mechanism is advantageous over other options in that it allows for the laser to be 

used at higher energies over a shorter pulse duration, which limits nonspecific thermal damage and 

scarring. More recently, a fractionated 1550-nm erbium-doped fiber laser was reported to effectively treat one 

patient with nevus of Ota. We report the successful treatment of a nevus of Ota in two patients with Fitzpatrick Skin 

Type IV utilizing serial therapy with a 1064-nm QS Nd:YAG and a 1550-nm fractionated Erbium-doped fiber laser. 

Study: In case 1, patient received over the period of 2 years a total of 9 treatments with the 1064-nm QS 

Nd:YAG (Medlite®, HOYA ConBio®, Fremont CA). Response to treatment was observed to plateau 6 months 

after the final QS Nd:YAG session. Consequently, it was decided to utilize nonablative fractional technology. The 

patient subsequently underwent 4 treatments with the 1550-nm fractionated erbium-doped fiber laser (Fraxel 

re:store, Solta Medical, Haywood, CA) conducted at an average treatment interval of 2 months. In case 2, 

patient underwent 2 treatments with the 1064-nm QS Nd:YAG laser (Medlite®, HOYA ConBio®, Fremont CA). 

Due to the minimal response to treatment, it was decided to utilize a sequential approach with the 1064-nm QS 

Nd:YAG laser followed immediately on the same day by a treatment session with the 1550-nm fractionated erbium 

doped fiber laser (Fraxel re:store, Solta Medical, Haywood, CA). A total of ten treatment sessions were 

conducted at an average treatment interval of 2 months. Results: In case 1, 85% improvement was noted after 

the series of treatments with the1064-nm QS Nd:YAG, and >95% improvement was achieved after additional 

treatment sessions with the 1550-nm fractionated Erbium-doped fiber laser. At the12-month follow-up after the 

final laser treatment session, greater than 95% improvement in the nevus of Ota was seen without any visible 

evidence of recurrence. In case 2, significant improvement was noted after 6 sequential treatment sessions with 

the1064-nm QS Nd:YAG followed immediately by treatment with the 1550-nm fractionated Erbium-doped fiber 

laser; complete clearance was noted after a total of 10 sessions. At an 11-month follow-up after the final laser 

treatment session, we noted that complete clearance in the Nevus of Ota was maintained without any visible 

evidence of recurrence. Conclusion: These cases exemplify the utilization of a serial therapy treatment approach 

to accomplish clearance of the nevi of Ota using both the 1064-nm QS Nd:YAG laser and the1550-nm fractionated 

erbium-doped fiber laser in patients with FST IV. In the first case, after observing no further response 6 months 

after the final treatment with 1064-nm QS Nd:YAG, we decided to see if fractionated laser technology would yield 

further improvement in our patient’s condition. And in the second case, we treated the patient sequentially with both 

lasers on the same day. In both cases, the combination turned out to be an ideal treatment regimen considering that 

it targets pigment by two different, yet seemingly synergistic mechanisms. The 1064-nm QS Nd:YAG laser functions 

by selective photothermolysis of melanin, which results in injury to epidermal and dermal melanosomes. Fractional 

photothermolysis is believed to function by a “melanin shuttle” mechanism, which results in the elimination of

melanin pigment from the skin with other photocoagulation debris through microscopic treatment zones (MTZs) 

created by the laser. Because nevus of Ota is a dermal lesion, specifically localized to the papillary and upper 

portion of the reticular dermis, treatment options need to allow adequate dermal penetration. Both of the lasers used 

in these patients have settings that, when adjusted accordingly, ensure sufficient depth to target the pigment 

characteristic of this lesion. Consequently, this combination therapy approach adds to the currently available 

options for successful and safe laser treatment of nevus of Ota in FST IV. Further long-term, prospective studies 

with a more expansive study population are indicated to better understand the efficacy of this serial therapy for the 

treatment of nevi of Ota and to determine optimal treatment settings. 

SUCCESSFUL TREATMENT OF FACIAL MELASMA WITH A COMBINATION OF MICROMDERMABRASION 

AND Q-SWITCHED Nd:YAG LASER TREATMENT 

Arielle Kauvar, New York Laser & Skin Care, New York, NY 

Background: Melasma is a common, disfiguring problem in women that is often refractory to various treatment 

modalities, and long term remissions are difficult to achieve. The purpose of this study was to assess the safety and 

effectiveness of a procedure combining microdermabrasion and Q-Switched (QS) Nd: YAG laser treatment. Study: 

This was an observational study of 27 female subjects, photoypes (II-V), who were referred for treatment of 

mixed-type melasma refractory to previous therapies. Treatment consisted of a microdermabrasion, immediately 

followed by low fluence QS Nd: YAG laser treatment. Repeat treatment was performed at 4 week intervals. 

Beginning 2 days after each laser treatment, the subjects used a topical skin care regimen consisting of 

hydroquinone, tretinoin and a broad spectrum sunscreen. Standardized digital photographs were obtained before 

each treatment session, and at the follow up visits. Grading was assessed by blinded comparison of standardized 

pre- and post-treatment digital images, using a quartile grading system. Adverse effects were recorded at each visit. 

Follow up was obtained at 3 to 12 months after the last treatment. Results: The treatment was deemed painless by 

all subjects and required no anesthesia. The average number of treatment sessions was 2.6. Of the 27 subjects, 

22 (81%) had greater than 75% clearance of melasma, with 11 (40%) of the subjects achieving >95% clearance of 

their pigmented patches. The majority of patients showed greater than 50% clearance of their melasma 1 month 

after the first treatment session. Only one subject demonstrated less than 25% clearance after one treatment. Side 

effects were limited to mild post-treatment erythema, which developed after the microdermabrasion, and lasted 

approximately 30-60 minutes. Four subjects noted temporary exacerbation of their melasma after inadvertent sun 

exposure, but this resolved within several weeks of resuming the hydroquinone and tretinoin skin care regime. 

Conclusion: The combination of a microdermabrasion and low fluence QS:YAG application is a simple, 

non-invasive procedure with minimal risk and no recovery time. Subject compliance with skin care was excellent, 

probably due to the dramatic improvement they observed within 4 weeks. The combination of a 

microdermabrasion and low fluence QS Nd:YAG laser appears to produce consistent improvement in melasma in 

all skin phototypes, in just 2-3 treatment sessions, with remissions lasting at least 6 months. 

PULSE STACKING WITH A 1450-NM LASER CAN INCREASE DEPTH OF TREATMENT 

Arisa Ortiz, William Lewis, R. Rox Anderson, University of California Irvine, Irvine, CA; Wellman Center for 


Background: Mid-infrared (1320, 1450nm) lasers, absorbed by water, are used to treat a variety of dermal 

conditions, but depth of treatment is a limitation. Thermal injury is typically achieved at dermal depths ranging from 

150 to 400 microns, while maintaining epidermal preservation with a dynamic cooling device (DCD). In theory, pulse 

stacking might be used to increase the depth of treatment depending on the balance between laser-induced skin 

heating and cryogen-induced skin cooling. We tested this hypothesis by examining the pattern of thermal injury for 

stacked pulses at different DCD cryogen spray durations. Study: Ex vivo porcine skin was irradiated with a 1450nm 

laser at a fluence of 14 J/cm 2 

, a frequency of 1 Hz, and a 6 mm spot size. A variable number of stacked pulses were 

delivered at DCD cryogen spray durations ranging from 0 to 85 milliseconds. Biopsies taken immediately after 

irradiation were stained grossly with nitroblue tetrazolium chloride (NBTC). Digital photography was used to 

evaluate the depth and pattern of dermal necrosis, and preservation of epidermal viability. Results: The number 

of stacked pulses necessary to achieve dermal necrosis increased with increasing cryogen spray duration. Near the 

threshold for dermal necrosis, epidermis was preserved. The depth of dermal injury increased with pulse stacking 

up to approximately 1 mm. Conclusion: We show the ability to control the depth of dermal treatment by a 1450-nm 

laser without epidermal injury by adjusting DCD settings and the number of pulses stacked. Clinical studies are 

warranted to explore the possibility of pulse stacking with the 1450-nm laser as a treatment for deep dermal 

processes. 

Experimental and Translational Medicine Session 

CHARACTERIZING VARIABILITY IN RAMAN SPECTRA OF BENIGN LESIONS TOWARDS CANCER 

DETECTION IN SKIN 

Isaac Pence, Chetan Patil, Elizabeth Vargis, Darrell Ellis, Anita Mahadevan-Jansen, Alex Walsh, Matthew Keller,

Harish Krishnamoorthi, Jonathan Cayce, Constantine Paras, Alex Makowski, Xiaohong Bi, Mark Mackanos, Duco 

Jansen, Vanderbilt University, Nashville, TN; Lockheed-Martin Aculight, Bothel, WA 

Background: Clinical diagnosis of malignant and benign skin lesions is often difficult because of the subjective 

nature of visual inspection and the potential for sampling error in biopsy. Raman Spectroscopy has demonstrated 

the potential to perform non-invasive classification of skin lesions; however, the high level of physiological and 

anatomical variability in benign skin can complicate optical diagnosis. A thorough understanding of benign lesion’s 

variability both between patients and within a single patient may lead to improved diagnostic outcomes. Study: 

Here, we present a fiber-optic probe-based 785nm Raman Spectroscopy study of 164 patients with benign lesions, 

which included seborrheic keratosis, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, dysplastic 

nevus, and congenital nevus. Measurements were made of both the lesions and adjacent or contralateral normal 

skin. Diagnosis of the lesions was performed by dermatologists through visual inspection of patients prior to data 

collection. Results: We report an analysis of the spectral variability of normal skin and common benign lesions. 

Through a pairwise analysis, Raman Spectroscopy shows the ability to detect the presence of malignancy as well 

as the potential to discriminate between benign tissue classes. Conclusion: Characterization of these classes of 

skin is a critical first step in the formation of a non-malignant spectral database that will serve as the basis for future 

comparisons with malignant lesions. 

INTRAVITAL IMAGING OF ABNORMAL VASCULATURE IN PRENEOPLASTIC ORAL MUCOSA BY 

TWO-PHOTON LUMINESCENCE OF GOLD NANORODS 

Saam Motamedi, Tuya Shilagard, Kert Edward, Luke Koong, Suimin Qui, Gracie Vargas, University of Texas 

Medical Branch, Galveston, TX 

Background: Gold nanorods (GNRs) exhibit very bright two-photon luminescence (TPL) signals that have been 

shown to be many times brighter than traditional fluorophores, They are of great interest as contrast agents for in 

vivo optical imaging, such as in cancer, due to their ability to be excited with extremely low incident powers and 

potential for enabling large imaging depths by intravital two-photon microscopy. The objective of the study was to 

evaluate their use for visualizing abnormal microvasculature of oral precancerous lesions. Study: GNRs were 

delivered i.v. into hamsters with DMBA-induced carcinogenesis on the buccal pouch. Intravital imaging by TPL was 

performed immediately and 24 hours following injection on lesion sites first identified visually or by reflectance 

imaging. Following the 24 hour timepoint, biopsies of imaged sites were obtained and processed for histological 

staining by hemotoxylin and eosin. TPL images and 3D reconstructions were analyzed for vessel features, such as 

tortuosity and blood vessel counts; histological sections were graded by a pathologist and counted for blood 

vessels. Results: Low incident powers used for TPL of GNRs allowed for 3D visualization of lesion 

microvasculature in vivo without confounding background autofluorescence. Intravital imaging within minutes of 

intravenous delivery revealed an abnormal 3-dimensional vessel structure of dysplastic lesions, which were highly 

dense and tortuous compared to vessels in normal oral mucosa, and revealed GNRs diffusely distributed 

throughout lesion space after 24 hours. Conclusion: This investigation suggests that GNRs can function as 

high-contrast imaging agents for visualization of in vivo features of carcinogenesis. 

IN VIVO TUMOR-TARGETING OF GOLD NANOPARTICLES: EFFECT OF PARTICLE TYPE AND DOSING 

STRATEGY 

Priyaveena Puvanakrishnan, Jaesook Park, Parameshwaran Diagaradjane, Glenn Goodrich, Jon Schwartz, Sunil 

Krishnan, James Tunnell, The University of Texas at Austin, Austin, TX; MD Anderson Cancer Center, Houston, TX; 

Nanospectra Biosciences, Houston, TX 

Background: Gold nanoparticles (GNP) have gained significant interest as nanovectors for combined imaging and 

photothermal therapy of tumors. Delivered systemically, GNP’s preferentially accumulate at the tumor site via the 

enhanced permeability and retention effect, and when irradiated with sufficient NIR light, produce sufficient heat to 

treat tumor tissue. The efficacy of this process strongly depends on the targeting ability of the GNPs, which is a 

function of the particle’s geometric properties (e.g. size and shape) and dosing strategy (e.g. number and amount of 

injections). The purpose of this study was to investigate the effect of GNP type and dosing strategy on in vivo tumor 

targeting. Specifically, we investigated the tumor-targeting efficiency of pegylated gold nanoshells (GNS) and gold 

nanorods (GNR) for single and multiple, fractionated dosing. Study: We used Swiss nu/nu mice with a 

subcutaneous tumor xenograft model that received intravenous administration for a single and a fractionated dose 

of GNS and GNR. We determined the GNP distribution and accumulation pattern within tumors using near-infrared 

narrow-band imaging (NBI) and two-photon microscopy. We performed Neutron Activation Analysis (NAA) to 

quantify the gold present in the tumor and liver. Results: NBI and two-photon microscopy of tumor xenografts 

demonstrated a highly heterogeneous distribution of GNP within the tumor with higher accumulation at the cortex. 

GNPs were observed in unique patterns surrounding the perivascular region. NAA results showed that the smaller 

GNRs accumulated in higher concentrations in the tumor compared to the larger GNSs. We observed a significant 

increase of GNS and GNR accumulation in liver for higher doses. However, multiple doses increased GNS only 

slightly with no increase for GNR. Conclusion: These results suggest a significant effect of particle type on tumor 

targeting ability; however, the effect of multiple doses on increasing particle accumulation appears minimal.

CAN A FRACTIONAL LASER ASSIST TRANSDERMAL ABSORPTION OF LIDOCAINE IN AN IN VIVO ANIMAL 

MODEL? 

Georgette Ori, Spencer Brown, Jeffrey Kenkel, UT Southwestern Medical Center, Dallas, TX 

Background and objectives: It is thought that the pretreatment of skin with a laser enhances transdermal delivery 

of drugs. Several studies have looked at the effects ex vivo. The aim of this study is to demonstrate in vivo firstly 

that laser can enhance transdermal penetration of a drug and secondly that this can be manipulated by altering the 

laser settings. Study Design, Methods/Materials: 3 pigs were included in this IACUC approved study. On day 

0, a 400cm 2 area on the abdomen was marked and 5g of LMX4 (Ferndale laboratories) was applied under 

occlusion. Blood was drawn at time 0, 60, 90, 120, 180 and 240 minutes and biopsies taken for histology. On day 

7, the Er:YAG laser (2490nm, Profile, Sciton) was used at 500µm, 250µm and 50µm ablative depth, 22% density to 

pretreat a 400cm 2 area on the abdomen. 5g of LMX4 was applied immediately with occlusion for 60 mins, and then 

removed. Blood was drawn at time 0, 60, 90, 120, 180 and 240 minutes. The serum was extracted and analyzed 

for lidocaine levels and its metabolite monoethyglycinide (MEGX). Results: Serum levels of lidocaine and MEGX 

were undetectable in untreated skin. Following laser treatment levels of both lidocaine and MEGX were 

detectable. Peak levels of lidocaine were significantly higher (p=0.02) at 250µm (0.59mg/L), compared to 500µm 

(0.29mg/L) and 50 µm (0.31mg/L). Peak levels of MEGX were significantly higher (p

Laser has proven to be a safe new option in severe Rhinophyma treatment with outstanding effectiveness. 

924nm, 975nm LASER DEVICE: NEW APPROACH TO TREAT CELLULITE 

Rafael Nunes, Francisco Leite, Daniella Nunes, Luciana Camara, Ana Paula Martins, Monica Souza, Guilherme 

Nunes, Slim Clinique Laser Center and Bonsucesso Dermatology Hospital, Rio De Janeiro, Brazil 

Background: Body Sculpting and improvement of Cellulites has been the objective of several procedures. 

Traditional liposuction, Subcision and other invasive procedures can produce contour deformities, hematoma and 

pigmentary problems as a complication. 924nm, 975nm laser device represents a new option of treatment for 

Cellulites. Study: 10 subjects, female, 27-49 years old, with cellulites III to IV grade in gluteous and buttocks areas 

was submitted to a 1 treatment with 924nm, 975nm laser device. Results: The combination of 2 wave lengths 

(924nm, 975nm) in a laser lipolysis device allowed the correction of the contour deformity and the cellulites with no 

adverse effect. Subject referred high level of satisfaction. Conclusion: Laser lipolysis device with 924nm, 975nm 

wave lengths showed to be an efficient and safe technique for the treatment of cellulites. 

COMBINED ABLATIVE FRACTIONAL RADIOFREQUENCY AND ULTRASOUND IN SKIN REFINING 

Maria Angelo-Khattar, Aesthetic Clinic, Dubai, United Arab Emerites 

Background: Ablative Fractional Resurfacing is currently recognized as one of the most effective means of skin 

refining. The vast majority of studies on fractional ablation are based upon the Erbium Yag and the Carbon-Dioxide 

lasers. This study examines the clinical efficacy and safety of application of a novel fractional ablative system 

comprising two different technologies; Fractional Radiofrequency for the creation of micro-channels in the skin and 

Ultrasound for post ablation dermo-cosmeceutical delivery. Study: Twenty-five subjects with skin textural changes 

underwent an average of two treatments sessions with the novel device and photographs were taken before and six 

months after the last session. Initially, the radiofrequency applicator was used at a power setting of 45 to 60 

watts, which resulted in the creation of plasma energy and consequently the fractional resurfacing of the skin. This 

was followed by an infusion of a transdermal solution through the perforations using acoustic pressure, delivered by 

the Ultrasound applicator, known as the Impact mode. The Transdermal solution consisted of a combination of 

Vitamin C , Alpha Lipoic acid, Zinc, Silica and Manganese. Results: Treatment of skin ageing changes such as 

wrinkles and open pores as well as post acne atrophic scarring, yielded very satisfying results. A fortuitous finding 

was that patients with Melasma had a very long-term remission of their condition. There was a high satisfaction 

level of satisfaction from all patients treated. Conclusion: The novel combination treatment strategy of Ablative 

Fractional Radiofrequency and Impact Ultrasound provides an attractive alternative to standard lasers. 

THE NEW FASHION VECTORIAL WAY TO IMPROVE FAT REMODELING AND SCULPING THE FACE USING 

NON INVASIVE IN MOTION SELECTIVE ULTRASOUND (ACCENT ULTRAFACE): 12 MONTHS OF FOLLOW 

UP 

Elaine Marques, Almeida Guilherme, Almeida Leticia, Rachel Queiroz, Hospital Sirio Libanes, Sao Paulo, Brazil 

Background: Since the early days, the search for the perfect body has been sought. In a country like Brazil 

where the sun shines most of the year, the cult of the body is a fact. The demand for a nonsurgical, noninvasive 

treatment of located fat has inspired some manufactures to invest in a new age of sophisticated devices and 

treatment therapies to repair the skin and improve contours. The aim of this paper is to present a new vectorial 

fashion way to improve of fat remodeling and sculping the face using the combination of non invasive in motion 

selective ultrasound (ACCENT ULTRAFACE, Alma Lasers Ltd, Israel). Study: 45 patients with located fat on the 

submental and malar areas were treated (age 21 to 74). The sessions with Ultra were separated by 14 days apart 

in a total of 3 treatments using the same parameters of 8 minutes and level 3 on submental and 4 minutes and level 

5 each malar part. Each patient´s face cleaned and marked with cirurgical marker in 3 specific points (submental 

and malars). A coat of vaseline was spread evenly over the areas. After the procedure the areas were cleaned d 

dried. Results were evalueted by standard and three-dimension photography (VECTRA 3D, Canfield) before and 

after treatments (0 day, 6 weeks, and 12 months). Both patient and physician investigator evaluated the treatment 

using a grading scale of improvement ranging from I (no), II (less than 25%), III (26-50%), IV (51-75%), and V 

(76-100%). Only grades IV and V were considered satisfactory. Results: The mode of propagation of mechanical 

waves generated are called shear waves. The shear waves histological damages the membrane of fat cells, 

repeatedly stretch and relax the adipocytes and causes disruption of that, damaging also the septa of the fat layer 

with no epidermal and dermal damage. The mean patients rate of satisfaction with a grade IV and V was 80%. 

No side effects were related to the treatment. Conclusion: The treatment sessions with non invasive selective 

ultrasound produce fat remodeling and sculping the face with efficiency and safety. Based on these good results, 

others protocols should be encouraged in view of the results are maintained over time. 

STRIAE IMPROVEMENT WITH A NOVEL APPROACH BY SUBLATIVE REJUVENATION: A PRELIMINARY 

REPORT WITH OBJECTIVE MEASUREMENT 

Maurice Adatto, Boris Vaynberg, Ruthie Amir, Hanit Brenner-Lavie, Guido Mariotto, Roman Kantor, Skinpulse Laser 

Center Geneva, Switzerland; Syneron Medical, Yokneam, Israel; Miravex Limited, Dublin, Ireland 

Background: Striae distensae, or stretch marks, are linear scars in the dermis which arise from rapid stretching of

the skin over weakened connective tissue. 95% of women are affected by this phenomenon either during puberty or 

pregnancy. Although being not considered as a disease, striae can affect psychologically. In this study, we are 

looking at the efficiency of a new ablative fractionated bipolar radiofrequency, in terms of improvement of the global 

aspect of striae, not only in depth but also in width. Study: Eight patients received one treatment per month over 4 

to 6 months in the areas where the striae were more prominent (abdomen, buttocks, thighs). This new device has 

the ability to place the heat energy within the dermis, with a minimal epidermal impact. All patients were treated with 

the 144 pin tip at energies varying between 30 to 36 mJ/pin, with one or two passes. Results were evaluated by 

clinical pictures and patient self evaluation at 1 month post last treatment. Three patients have been assessed 

prior and after treatment with the Antera 3D, a novel 3D camera system, capable of objectively measuring the 

global improvement of the depth of striae. Results: All patients have seen a visible improvement after the first or 

second treatment. As the study is still ongoing, the final results will be given at the meeting. Treatments were 

performed without any anesthesia and post operative care consisted in the application of a moisturizing cream, 

twice a day, for 3 days. Conclusion: The application of this new ablative fractionated bipolar radiofrequency for 

improvement of striae seems promising. This preliminary study performed with this device suggests a similar 

mechanism of action on collagen as in facial treatments for acne scar improvement and wrinkle reduction. 

REJUVENATION OF THE NECK WITH THE E-MATRIX FRACTIONAL RADIOFREQUENCY DEVICE 

Sylvie Angel, Jean-Michel Mazer, Paris, France 

Background: Rejuvenation of the neck is a challenge. Lasers procedures proved disappointing in their efficacy with 

remodelling lasers or in their safety, especially for the risk of scarring, with fractional CO2 lasers. The E-Matrix is a 

radiofrequency system by which fractional RF energy is delivered to the skin with low epidermal disruption and high 

dermal impact. Study: 20 female patients were treated for rejuvenation of the neck (age 57.00±6.94, phototype II 

to IV). 3 treatments were performed at 1 month interval, using a 64 electrode tip and energy levels from 40 to 44 mJ 

per electrode. A topical anesthesia was applied 1 hour before each session. Standardized photographs were taken 

before and 1 month after each treatment. The evaluation of wrinkles and elastosis was rated according to the 

Fitzpatrick-Goldmann classification (average of 2 investigators’s judgment). The pain level during treatment as well 

as the patient's and the practitioner's satisfaction were evaluated on visual analogical scales from 0 to 10. 

Results: The percentage of patients who gained at least one class in the Fitzpatrick-Goldmann classification was 

the following, 1 month after treatment 1, 2 and 3 respectively: Wrinkles: 15% (NS); 74% (p

Wounds were treated using PCRB and photoradiated or photoradiated alone. Composite dressing-treated wounds 

received 1cm x1cm PCRB wafers, applied by excising Tegaderm TM 

overlying the ulcer, placing PCRB over the 

wound and covering the wound with Tegaderm TM 

. Wounds were irradiated at 450nm (350mW, 1cm spot diameter, 

15min) using a diode laser 10min after dressing placement daily (0, 1, 2, or 3 treatments). Control wounds received 

neither PCRB nor photoradiation. Wounds were cultured daily. Animals were euthanized on day 7 and quantitative 

bacterial counts (CFU/g tissue) were determined. Results: PCRB plus photoradiation resulted in statistically 

significant 2-3 log reduction in bacterial counts (p

Presidential Greeting - American Society for Laser Medicine and ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?